0	"A process is an entity that exists in time by occurring or happening, has temporal parts and always involves and depends on some entity during the time it occurs." []	\N	process	\N	\N	EFO	"A process is an entity that exists in time by occurring or happening, has temporal parts and always involves and depends on some entity during the time it occurs." []	EFO	65140	BFO:0000007	\N	process	BFO:0000007
0	"A disposition is an entity that essentially causes a specific process or transformation in an entity in which it inheres, under specific circumstances and in conjunction with the laws of nature. For example, the disposition of vegetables to decay when not refrigerated, the disposition of blood to coagulate, the disposition of a patient with a weakened immune system to contract disease." []	\N	disposition	\N	\N	EFO	"A disposition is an entity that essentially causes a specific process or transformation in an entity in which it inheres, under specific circumstances and in conjunction with the laws of nature. For example, the disposition of vegetables to decay when not refrigerated, the disposition of blood to coagulate, the disposition of a patient with a weakened immune system to contract disease." []	EFO	65141	BFO:0000016	\N	disposition	BFO:0000016
0	"A quality is an entity that describes some aspect which is intrinsic to that particular object and is dependent on or more material entities in which it inheres in or is borne by. Example the color of a tomato, the ambient temperature of air, the circumference of a waist, the shape of a nose, the mass of a piece of gold, the weight of a chimpanzee" []	\N	quality	\N	\N	EFO	"A quality is an entity that describes some aspect which is intrinsic to that particular object and is dependent on or more material entities in which it inheres in or is borne by. Example the color of a tomato, the ambient temperature of air, the circumference of a waist, the shape of a nose, the mass of a piece of gold, the weight of a chimpanzee" []	EFO	65142	BFO:0000019	\N	quality	BFO:0000019
0	"An experimental factor which is a property or characteristic of some other entity.  For example, the mouse has the colour white." []	\N	material property	\N	\N	EFO	"An experimental factor which is a property or characteristic of some other entity.  For example, the mouse has the colour white." []	EFO	65143	BFO:0000020	\N	material property	BFO:0000020
0	"A role is an entity which is borne in a material entity in some kinds of natural, social or institutional contexts, but which is not essential to the fundamental definition of that material entity (i.e. the material entity exists with or without the role).  For example, the role of a person as a surgeon, the role of an artificial heart in pumping blood, the role of a chemical compound in an experiment, the role of a drug in the treatment of a disease." []	\N	role	\N	\N	EFO	"A role is an entity which is borne in a material entity in some kinds of natural, social or institutional contexts, but which is not essential to the fundamental definition of that material entity (i.e. the material entity exists with or without the role).  For example, the role of a person as a surgeon, the role of an artificial heart in pumping blood, the role of a chemical compound in an experiment, the role of a drug in the treatment of a disease." []	EFO	65144	BFO:0000023	\N	role	BFO:0000023
0	"A site is an entity which consists of a characteristic spatial shape in relation to some arrangement of other material entities." []	\N	site	\N	\N	EFO	"A site is an entity which consists of a characteristic spatial shape in relation to some arrangement of other material entities." []	EFO	65145	BFO:0000029	\N	site	BFO:0000029
0	"A function is an entity which is an essentially end-directed activity of a material entity in virtue of that entity being a specific kind of entity in the kind or kinds of contexts that it is made for.  For example," []	\N	function	\N	\N	EFO	"A function is an entity which is an essentially end-directed activity of a material entity in virtue of that entity being a specific kind of entity in the kind or kinds of contexts that it is made for.  For example," []	EFO	65146	BFO:0000034	\N	function	BFO:0000034
0	"A material entity is an entity that exists in full during the length of time of its existence, persists through this time while maintaining its identity and has no temporal parts. For example a heart, a human, a fly, a microarray." []	\N	material entity	\N	\N	EFO	"A material entity is an entity that exists in full during the length of time of its existence, persists through this time while maintaining its identity and has no temporal parts. For example a heart, a human, a fly, a microarray." []	EFO	65147	BFO:0000040	\N	material entity	BFO:0000040
0	"This gene is involved in cell adhesion, differentiation, division and stress response." []	\N	ciprofloxacin	\N	\N	EFO	"This gene is involved in cell adhesion, differentiation, division and stress response." []	EFO	65148	CHEBI:100241	\N	ciprofloxacin	CHEBI:100241
0	"\\"A synthetic fluoroquinolone with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.\\" []" []	\N	norfloxacin	\N	\N	EFO	"\\"A synthetic fluoroquinolone with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.\\" []" []	EFO	65149	CHEBI:100246	\N	norfloxacin	CHEBI:100246
0	"" []	\N	warfarin	\N	\N	EFO	"" []	EFO	65150	CHEBI:10033	\N	warfarin	CHEBI:10033
0	"" []	\N	diltiazem	\N	\N	EFO	"" []	EFO	65151	CHEBI:101278	\N	diltiazem	CHEBI:101278
0	"A radiolabelled urea molecule used to diagnose stomach ulcers caused by Heliobacter pylori. In the presence of H. pylori, urea C-13 is metabolized by urease to produce ammonia and radioactive carbon dioxide at the interface between the gastric epithelium and lumen. The radioactive carbon dioxide is absorbed in the blood and is detected when exhaled in the breath." []	\N	2-nitrofluorene	\N	\N	EFO	"A radiolabelled urea molecule used to diagnose stomach ulcers caused by Heliobacter pylori. In the presence of H. pylori, urea C-13 is metabolized by urease to produce ammonia and radioactive carbon dioxide at the interface between the gastric epithelium and lumen. The radioactive carbon dioxide is absorbed in the blood and is detected when exhaled in the breath." []	EFO	65152	CHEBI:1224	\N	2-nitrofluorene	CHEBI:1224
0	"" []	\N	cefalotin	\N	\N	EFO	"" []	EFO	65153	CHEBI:124991	\N	cefalotin	CHEBI:124991
0	"" []	\N	vitamin A	\N	\N	EFO	"" []	EFO	65154	CHEBI:12777	\N	vitamin A	CHEBI:12777
0	"A tetrachlorobiphenyl that has formula C12H6Cl4." []	\N	3,3',4,4'-tetrachlorobiphenyl	\N	\N	EFO	"A tetrachlorobiphenyl that has formula C12H6Cl4." []	EFO	65155	CHEBI:1367	\N	3,3',4,4'-tetrachlorobiphenyl	CHEBI:1367
0	"The determination of the amount of complement C4 present in a sample." []	\N	acetoacetate	\N	\N	EFO	"The determination of the amount of complement C4 present in a sample." []	EFO	65156	CHEBI:13705	\N	acetoacetate	CHEBI:13705
0	"A selenium oxoanion that has formula O4Se." []	\N	selenate	\N	\N	EFO	"A selenium oxoanion that has formula O4Se." []	EFO	65157	CHEBI:15075	\N	selenate	CHEBI:15075
0	"" []	\N	acetaldehyde	\N	\N	EFO	"" []	EFO	65158	CHEBI:15343	\N	acetaldehyde	CHEBI:15343
0	"A propanone that has formula C3H6O." []	\N	acetone	\N	\N	EFO	"A propanone that has formula C3H6O." []	EFO	65159	CHEBI:15347	\N	acetone	CHEBI:15347
0	"" []	\N	acetylsalicylic acid	\N	\N	EFO	"" []	EFO	65160	CHEBI:15365	\N	acetylsalicylic acid	CHEBI:15365
0	"A simple carboxylic acid containing two carbons; the active ingredient in vinegar. The building block of natural fatty acids which, unlike them, does not occur in natural triglycerides. Reported to suppress accumulation of body fat and liver lipids in mice." []	\N	acetic acid	\N	\N	EFO	"A simple carboxylic acid containing two carbons; the active ingredient in vinegar. The building block of natural fatty acids which, unlike them, does not occur in natural triglycerides. Reported to suppress accumulation of body fat and liver lipids in mice." []	EFO	65161	CHEBI:15366	\N	acetic acid	CHEBI:15366
0	"" []	\N	all-trans-retinoic acid	\N	\N	EFO	"" []	EFO	65162	CHEBI:15367	\N	all-trans-retinoic acid	CHEBI:15367
0	"" []	\N	endothelin-1	\N	\N	EFO	"" []	EFO	65163	CHEBI:153671	\N	endothelin-1	CHEBI:153671
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	acrolein	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65164	CHEBI:15368	\N	acrolein	CHEBI:15368
0	"" []	\N	5,6,7,8-tetrahydrobiopterin	\N	\N	EFO	"" []	EFO	65165	CHEBI:15372	\N	5,6,7,8-tetrahydrobiopterin	CHEBI:15372
0	"An inorganic hydroxy compound that has formula H2O." []	\N	water	\N	\N	EFO	"An inorganic hydroxy compound that has formula H2O." []	EFO	65166	CHEBI:15377	\N	water	CHEBI:15377
0	"An elemental molecule that has formula O2." []	\N	oxygen	\N	\N	EFO	"An elemental molecule that has formula O2." []	EFO	65167	CHEBI:15379	\N	oxygen	CHEBI:15379
0	"" []	\N	S-adenosyl-L-methionine	\N	\N	EFO	"" []	EFO	65168	CHEBI:15414	\N	S-adenosyl-L-methionine	CHEBI:15414
0	"" []	\N	prostaglandin E2	\N	\N	EFO	"" []	EFO	65169	CHEBI:15551	\N	prostaglandin E2	CHEBI:15551
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	(15Z)-12-oxophyto-10,15-dienoic acid	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65170	CHEBI:15560	\N	(15Z)-12-oxophyto-10,15-dienoic acid	CHEBI:15560
0	"An organic heterooctacyclic compound that has formula C28H26N4O3." []	\N	staurosporine	\N	\N	EFO	"An organic heterooctacyclic compound that has formula C28H26N4O3." []	EFO	65171	CHEBI:15738	\N	staurosporine	CHEBI:15738
0	"A straight-chain, sixteen-carbon, saturated long-chain fatty acid." []	\N	Hexadecanoic acid	\N	\N	EFO	"A straight-chain, sixteen-carbon, saturated long-chain fatty acid." []	EFO	65172	CHEBI:15756	\N	Hexadecanoic acid	CHEBI:15756
0	"" []	\N	dichloromethane	\N	\N	EFO	"" []	EFO	65173	CHEBI:15767	\N	dichloromethane	CHEBI:15767
0	"" []	\N	arachidonic acid	\N	\N	EFO	"" []	EFO	65174	CHEBI:15843	\N	arachidonic acid	CHEBI:15843
0	"A phenol that has formula C6H6O." []	\N	phenol	\N	\N	EFO	"A phenol that has formula C6H6O." []	EFO	65175	CHEBI:15882	\N	phenol	CHEBI:15882
0	"" []	\N	methyl (-)-jasmonate	\N	\N	EFO	"" []	EFO	65176	CHEBI:15929	\N	methyl (-)-jasmonate	CHEBI:15929
0	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	\N	atrazine	\N	\N	EFO	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	EFO	65177	CHEBI:15930	\N	atrazine	CHEBI:15930
0	"" []	\N	nicotinic acid	\N	\N	EFO	"" []	EFO	65178	CHEBI:15940	\N	nicotinic acid	CHEBI:15940
0	"" []	\N	biotin	\N	\N	EFO	"" []	EFO	65179	CHEBI:15956	\N	biotin	CHEBI:15956
0	"" []	\N	sn-glycerol 3-phosphate	\N	\N	EFO	"" []	EFO	65180	CHEBI:15978	\N	sn-glycerol 3-phosphate	CHEBI:15978
0	"" []	\N	phosphatidylethanolamine	\N	\N	EFO	"" []	EFO	65181	CHEBI:16038	\N	phosphatidylethanolamine	CHEBI:16038
0	"The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils." []	\N	cholesterol	\N	\N	EFO	"The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils." []	EFO	65182	CHEBI:16113	\N	cholesterol	CHEBI:16113
0	"An ethanol that has formula C2H6O." []	\N	ethanol	\N	\N	EFO	"An ethanol that has formula C2H6O." []	EFO	65183	CHEBI:16236	\N	ethanol	CHEBI:16236
0	"A pentahydroxyflavone that has formula C15H10O7." []	\N	quercetin	\N	\N	EFO	"A pentahydroxyflavone that has formula C15H10O7." []	EFO	65184	CHEBI:16243	\N	quercetin	CHEBI:16243
0	"" []	\N	phospholipid	\N	\N	EFO	"" []	EFO	65185	CHEBI:16247	\N	phospholipid	CHEBI:16247
0	"" []	\N	chitosan	\N	\N	EFO	"" []	EFO	65186	CHEBI:16261	\N	chitosan	CHEBI:16261
0	"An androgen that has formula C19H30O2." []	\N	17beta-hydroxy-5alpha-androstan-3-one	\N	\N	EFO	"An androgen that has formula C19H30O2." []	EFO	65187	CHEBI:16330	\N	17beta-hydroxy-5alpha-androstan-3-one	CHEBI:16330
0	"" []	\N	hyaluronan	\N	\N	EFO	"" []	EFO	65188	CHEBI:16336	\N	hyaluronan	CHEBI:16336
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	3-nitropropionic acid	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65189	CHEBI:16348	\N	3-nitropropionic acid	CHEBI:16348
0	"A steroidal bile acid derived from cholesterol." []	\N	cholic acid	\N	\N	EFO	"A steroidal bile acid derived from cholesterol." []	EFO	65190	CHEBI:16359	\N	cholic acid	CHEBI:16359
0	"An aconitate(3-) that has formula C6H3O6." []	\N	cis-aconitate(3-)	\N	\N	EFO	"An aconitate(3-) that has formula C6H3O6." []	EFO	65191	CHEBI:16383	\N	cis-aconitate(3-)	CHEBI:16383
0	"" []	\N	indole-3-acetic acid	\N	\N	EFO	"" []	EFO	65192	CHEBI:16411	\N	indole-3-acetic acid	CHEBI:16411
0	"Natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria)." []	\N	lipopolysaccharide	\N	\N	EFO	"Natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria)." []	EFO	65193	CHEBI:16412	\N	lipopolysaccharide	CHEBI:16412
0	"An alpha-amino acid that has formula C3H7NO2." []	\N	alanine	\N	\N	EFO	"An alpha-amino acid that has formula C3H7NO2." []	EFO	65194	CHEBI:16449	\N	alanine	CHEBI:16449
0	"" []	\N	17beta-estradiol	\N	\N	EFO	"" []	EFO	65195	CHEBI:16469	\N	17beta-estradiol	CHEBI:16469
0	"" []	\N	naphthalene	\N	\N	EFO	"" []	EFO	65196	CHEBI:16482	\N	naphthalene	CHEBI:16482
0	"A zeatin that has formula C10H13N5O." []	\N	trans-zeatin	\N	\N	EFO	"A zeatin that has formula C10H13N5O." []	EFO	65197	CHEBI:16522	\N	trans-zeatin	CHEBI:16522
0	"The R-enantiomer of serine." []	\N	D-serine	\N	\N	EFO	"The R-enantiomer of serine." []	EFO	65198	CHEBI:16523	\N	D-serine	CHEBI:16523
0	"Encoded by human CYP8B1 Gene (Cytochrome P450 Family), 501-aa 58-kDa Cytochrome P450 8B1 is a liver endoplasmic reticulum membrane P450 heme-thiolate monooxygenase involved in bile acid synthesis that catalyzes conversion of 7 alpha-hydroxy-4-cholesten-3-one into 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one. The balance between these steroids determines the relative amount of cholic and chenodeoxycholic acids secreted in the bile that affect cholesterol solubility. CYP8B1 has broad substrate specificity including 7-alpha-hydroxylated C27 steroids. P450 enzymes catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. (NCI)" []	\N	20-hydroxyecdysone	\N	\N	EFO	"Encoded by human CYP8B1 Gene (Cytochrome P450 Family), 501-aa 58-kDa Cytochrome P450 8B1 is a liver endoplasmic reticulum membrane P450 heme-thiolate monooxygenase involved in bile acid synthesis that catalyzes conversion of 7 alpha-hydroxy-4-cholesten-3-one into 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one. The balance between these steroids determines the relative amount of cholic and chenodeoxycholic acids secreted in the bile that affect cholesterol solubility. CYP8B1 has broad substrate specificity including 7-alpha-hydroxylated C27 steroids. P450 enzymes catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. (NCI)" []	EFO	65199	CHEBI:16587	\N	20-hydroxyecdysone	CHEBI:16587
0	"A chloroethene that has formula C2HCl3." []	\N	trichloroethylene	\N	\N	EFO	"A chloroethene that has formula C2HCl3." []	EFO	65200	CHEBI:16602	\N	trichloroethylene	CHEBI:16602
0	"" []	\N	allyl alcohol	\N	\N	EFO	"" []	EFO	65201	CHEBI:16605	\N	allyl alcohol	CHEBI:16605
0	"An ecdysteroid that has formula C27H44O6." []	\N	ecdysone	\N	\N	EFO	"An ecdysteroid that has formula C27H44O6." []	EFO	65202	CHEBI:16688	\N	ecdysone	CHEBI:16688
0	"The sixth of the seven cervical vertebrae." []	\N	benzene	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65203	CHEBI:16716	\N	benzene	CHEBI:16716
0	"The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes." []	\N	cinnamaldehyde	\N	\N	EFO	"The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes." []	EFO	65204	CHEBI:16731	\N	cinnamaldehyde	CHEBI:16731
0	"" []	\N	creatinine	\N	\N	EFO	"" []	EFO	65205	CHEBI:16737	\N	creatinine	CHEBI:16737
0	"The sixth of the seven cervical vertebrae." []	\N	2,4-dichlorophenol	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65206	CHEBI:16738	\N	2,4-dichlorophenol	CHEBI:16738
0	"Human C5 wild-type allele is located within 9q33-q34 and is approximately 98 kb in length. This allele, which encodes complement C5 protein, is involved in the complement system, inflammatory responses, and histamine release." []	\N	orotic acid	\N	\N	EFO	"Human C5 wild-type allele is located within 9q33-q34 and is approximately 98 kb in length. This allele, which encodes complement C5 protein, is involved in the complement system, inflammatory responses, and histamine release." []	EFO	65207	CHEBI:16742	\N	orotic acid	CHEBI:16742
0	"" []	\N	scopolamine	\N	\N	EFO	"" []	EFO	65208	CHEBI:16794	\N	scopolamine	CHEBI:16794
0	"" []	\N	dehydroepiandrosterone sulfate	\N	\N	EFO	"" []	EFO	65209	CHEBI:16814	\N	dehydroepiandrosterone sulfate	CHEBI:16814
0	"The simplest aldehyde." []	\N	formaldehyde	\N	\N	EFO	"The simplest aldehyde." []	EFO	65210	CHEBI:16842	\N	formaldehyde	CHEBI:16842
0	"The D-enantiomer of mannitol." []	\N	D-mannitol	\N	\N	EFO	"The D-enantiomer of mannitol." []	EFO	65211	CHEBI:16899	\N	D-mannitol	CHEBI:16899
0	"" []	\N	salicylic acid	\N	\N	EFO	"" []	EFO	65212	CHEBI:16914	\N	salicylic acid	CHEBI:16914
0	"A glycine derivative that has formula C4H9N3O2." []	\N	creatine	\N	\N	EFO	"A glycine derivative that has formula C4H9N3O2." []	EFO	65213	CHEBI:16919	\N	creatine	CHEBI:16919
0	"The sixth of the seven cervical vertebrae." []	\N	benzene-1,2,4-triol	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65214	CHEBI:16979	\N	benzene-1,2,4-triol	CHEBI:16979
0	"" []	\N	bilirubin	\N	\N	EFO	"" []	EFO	65215	CHEBI:16990	\N	bilirubin	CHEBI:16990
0	"High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms." []	\N	DNA	\N	\N	EFO	"High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms." []	EFO	65216	CHEBI:16991	\N	DNA	CHEBI:16991
0	"Cholesterol esterified at the 3-hydroxy group." []	\N	cholesterol ester	\N	\N	EFO	"Cholesterol esterified at the 3-hydroxy group." []	EFO	65217	CHEBI:17002	\N	cholesterol ester	CHEBI:17002
0	"A steroid hormone that has formula C21H30O2." []	\N	progesterone	\N	\N	EFO	"A steroid hormone that has formula C21H30O2." []	EFO	65218	CHEBI:17026	\N	progesterone	CHEBI:17026
0	"An aminoglycan that has formula (C8H13NO5)n." []	\N	chitin	\N	\N	EFO	"An aminoglycan that has formula (C8H13NO5)n." []	EFO	65219	CHEBI:17029	\N	chitin	CHEBI:17029
0	"" []	\N	glycoprotein	\N	\N	EFO	"" []	EFO	65220	CHEBI:17089	\N	glycoprotein	CHEBI:17089
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	methyl glyoxal	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65221	CHEBI:17158	\N	methyl glyoxal	CHEBI:17158
0	"" []	\N	17alpha-estradiol	\N	\N	EFO	"" []	EFO	65222	CHEBI:17160	\N	17alpha-estradiol	CHEBI:17160
0	"" []	\N	L-proline	\N	\N	EFO	"" []	EFO	65223	CHEBI:17203	\N	L-proline	CHEBI:17203
0	"A monoterpene that has formula C10H16." []	\N	myrcene	\N	\N	EFO	"A monoterpene that has formula C10H16." []	EFO	65224	CHEBI:17221	\N	myrcene	CHEBI:17221
0	"" []	\N	homocysteine	\N	\N	EFO	"" []	EFO	65225	CHEBI:17230	\N	homocysteine	CHEBI:17230
0	"" []	\N	mono(2-ethylhexyl) phthalate	\N	\N	EFO	"" []	EFO	65226	CHEBI:17243	\N	mono(2-ethylhexyl) phthalate	CHEBI:17243
0	"A carbon oxide that has formula CO." []	\N	carbon monoxide	\N	\N	EFO	"A carbon oxide that has formula CO." []	EFO	65227	CHEBI:17245	\N	carbon monoxide	CHEBI:17245
0	"A morphinane alkaloid that has formula C17H19NO3." []	\N	morphine	\N	\N	EFO	"A morphinane alkaloid that has formula C17H19NO3." []	EFO	65228	CHEBI:17303	\N	morphine	CHEBI:17303
0	"" []	\N	phytol	\N	\N	EFO	"" []	EFO	65229	CHEBI:17327	\N	phytol	CHEBI:17327
0	"Unlike testosterone, which is a flat molecule, its 8-isomer has a folded conformation." []	\N	testosterone	\N	\N	EFO	"Unlike testosterone, which is a flat molecule, its 8-isomer has a folded conformation." []	EFO	65230	CHEBI:17347	\N	testosterone	CHEBI:17347
0	"\\"An ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2.\\" []" []	\N	2-acetylaminofluorene	\N	\N	EFO	"\\"An ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2.\\" []" []	EFO	65231	CHEBI:17356	\N	2-acetylaminofluorene	CHEBI:17356
0	"The simplest member of the quinoline class of compounds, comprising a benzene ring ortho fused to C-2 and C-3 of a pyridine ring." []	\N	quinoline	\N	\N	EFO	"The simplest member of the quinoline class of compounds, comprising a benzene ring ortho fused to C-2 and C-3 of a pyridine ring." []	EFO	65232	CHEBI:17362	\N	quinoline	CHEBI:17362
0	"" []	\N	L-cysteine	\N	\N	EFO	"" []	EFO	65233	CHEBI:17561	\N	L-cysteine	CHEBI:17561
0	"A nitrogen oxoanion that has formula NO3." []	\N	nitrate	\N	\N	EFO	"A nitrogen oxoanion that has formula NO3." []	EFO	65234	CHEBI:17632	\N	nitrate	CHEBI:17632
0	"" []	\N	sphingomyelin	\N	\N	EFO	"" []	EFO	65235	CHEBI:17636	\N	sphingomyelin	CHEBI:17636
0	"Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the \\"stress hormone\\" as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses" []	\N	cortisol	\N	\N	EFO	"Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the \\"stress hormone\\" as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses" []	EFO	65236	CHEBI:17650	\N	cortisol	CHEBI:17650
0	"A dichloro-substituted acetamide containing a nitrobenzene ring, an amide bond and two alcohol functions." []	\N	chloramphenicol	\N	\N	EFO	"A dichloro-substituted acetamide containing a nitrobenzene ring, an amide bond and two alcohol functions." []	EFO	65237	CHEBI:17698	\N	chloramphenicol	CHEBI:17698
0	"" []	\N	N,N-dimethylformamide	\N	\N	EFO	"" []	EFO	65238	CHEBI:17741	\N	N,N-dimethylformamide	CHEBI:17741
0	"The bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid." []	\N	diethylhexyl phthalate	\N	\N	EFO	"The bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid." []	EFO	65239	CHEBI:17747	\N	diethylhexyl phthalate	CHEBI:17747
0	"" []	\N	ceramide	\N	\N	EFO	"" []	EFO	65240	CHEBI:17761	\N	ceramide	CHEBI:17761
0	"The simplest aliphatic alcohol, comprising a methyl and an alcohol group." []	\N	methanol	\N	\N	EFO	"The simplest aliphatic alcohol, comprising a methyl and an alcohol group." []	EFO	65241	CHEBI:17790	\N	methanol	CHEBI:17790
0	"Encoded by human CYP8B1 Gene (Cytochrome P450 Family), 501-aa 58-kDa Cytochrome P450 8B1 is a liver endoplasmic reticulum membrane P450 heme-thiolate monooxygenase involved in bile acid synthesis that catalyzes conversion of 7 alpha-hydroxy-4-cholesten-3-one into 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one. The balance between these steroids determines the relative amount of cholic and chenodeoxycholic acids secreted in the bile that affect cholesterol solubility. CYP8B1 has broad substrate specificity including 7-alpha-hydroxylated C27 steroids. P450 enzymes catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. (NCI)" []	\N	calcitriol	\N	\N	EFO	"Encoded by human CYP8B1 Gene (Cytochrome P450 Family), 501-aa 58-kDa Cytochrome P450 8B1 is a liver endoplasmic reticulum membrane P450 heme-thiolate monooxygenase involved in bile acid synthesis that catalyzes conversion of 7 alpha-hydroxy-4-cholesten-3-one into 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one. The balance between these steroids determines the relative amount of cholic and chenodeoxycholic acids secreted in the bile that affect cholesterol solubility. CYP8B1 has broad substrate specificity including 7-alpha-hydroxylated C27 steroids. P450 enzymes catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. (NCI)" []	EFO	65242	CHEBI:17823	\N	calcitriol	CHEBI:17823
0	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	\N	gentamicin	\N	\N	EFO	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	EFO	65243	CHEBI:17833	\N	gentamicin	CHEBI:17833
0	"" []	\N	triglyceride	\N	\N	EFO	"" []	EFO	65244	CHEBI:17855	\N	triglyceride	CHEBI:17855
0	"A diatomic molecule containing covalently bonded hydrogen and chlorine atoms." []	\N	hydrochloric acid	\N	\N	EFO	"A diatomic molecule containing covalently bonded hydrogen and chlorine atoms." []	EFO	65245	CHEBI:17883	\N	hydrochloric acid	CHEBI:17883
0	"A D-glucopyranose that has formula C6H12O6." []	\N	alpha-D-glucose	\N	\N	EFO	"A D-glucopyranose that has formula C6H12O6." []	EFO	65246	CHEBI:17925	\N	alpha-D-glucose	CHEBI:17925
0	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	\N	asymmetric dimethylarginine	\N	\N	EFO	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	EFO	65247	CHEBI:17929	\N	asymmetric dimethylarginine	CHEBI:17929
0	"An aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome." []	\N	puromycin	\N	\N	EFO	"An aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome." []	EFO	65248	CHEBI:17939	\N	puromycin	CHEBI:17939
0	"" []	\N	butyrate	\N	\N	EFO	"" []	EFO	65249	CHEBI:17968	\N	butyrate	CHEBI:17968
0	"A glycosyl glycoside that has formula C12H22O11." []	\N	sucrose	\N	\N	EFO	"A glycosyl glycoside that has formula C12H22O11." []	EFO	65250	CHEBI:17992	\N	sucrose	CHEBI:17992
0	"" []	\N	L-glutamine	\N	\N	EFO	"" []	EFO	65251	CHEBI:18050	\N	L-glutamine	CHEBI:18050
0	"The determination of the amount of complement C4 present in a sample." []	\N	1-aminocyclopropane-1-carboxylic acid	\N	\N	EFO	"The determination of the amount of complement C4 present in a sample." []	EFO	65252	CHEBI:18053	\N	1-aminocyclopropane-1-carboxylic acid	CHEBI:18053
0	"" []	\N	oxamic acid	\N	\N	EFO	"" []	EFO	65253	CHEBI:18058	\N	oxamic acid	CHEBI:18058
0	"A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)" []	\N	lipid	\N	\N	EFO	"A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)" []	EFO	65254	CHEBI:18059	\N	lipid	CHEBI:18059
0	"An alpha-tocopherol that has formula C29H50O2." []	\N	(+)-alpha-tocopherol	\N	\N	EFO	"An alpha-tocopherol that has formula C29H50O2." []	EFO	65255	CHEBI:18145	\N	(+)-alpha-tocopherol	CHEBI:18145
0	"An alkene that has formula C2H4." []	\N	ethene	\N	\N	EFO	"An alkene that has formula C2H4." []	EFO	65256	CHEBI:18153	\N	ethene	CHEBI:18153
0	"" []	\N	polysaccharide	\N	\N	EFO	"" []	EFO	65257	CHEBI:18154	\N	polysaccharide	CHEBI:18154
0	"A tocopherol that has formula C28H48O2." []	\N	gamma-tocopherol	\N	\N	EFO	"A tocopherol that has formula C28H48O2." []	EFO	65258	CHEBI:18185	\N	gamma-tocopherol	CHEBI:18185
0	"" []	\N	tyrosine	\N	\N	EFO	"" []	EFO	65259	CHEBI:18186	\N	tyrosine	CHEBI:18186
0	"" []	\N	benzylpenicillin	\N	\N	EFO	"" []	EFO	65260	CHEBI:18208	\N	benzylpenicillin	CHEBI:18208
0	"A selenium oxoanion that has formula O3Se." []	\N	selenite(2-)	\N	\N	EFO	"A selenium oxoanion that has formula O3Se." []	EFO	65261	CHEBI:18212	\N	selenite(2-)	CHEBI:18212
0	"An isoflavone that has formula C15H10O2." []	\N	isoflavone	\N	\N	EFO	"An isoflavone that has formula C15H10O2." []	EFO	65262	CHEBI:18220	\N	isoflavone	CHEBI:18220
0	"An aldopentose, found in the embryos of most edible plants and used in medicine to test for malabsorption by administration in water to the patient." []	\N	xylose	\N	\N	EFO	"An aldopentose, found in the embryos of most edible plants and used in medicine to test for malabsorption by administration in water to the patient." []	EFO	65263	CHEBI:18222	\N	xylose	CHEBI:18222
0	"" []	\N	dopamine	\N	\N	EFO	"" []	EFO	65264	CHEBI:18243	\N	dopamine	CHEBI:18243
0	"An iron group element that has formula Fe." []	\N	iron	\N	\N	EFO	"An iron group element that has formula Fe." []	EFO	65265	CHEBI:18248	\N	iron	CHEBI:18248
0	"" []	\N	3,3',5-triiodo-L-thyronine	\N	\N	EFO	"" []	EFO	65266	CHEBI:18258	\N	3,3',5-triiodo-L-thyronine	CHEBI:18258
0	"An oxo monocarboxylic acid that has formula C12H18O3." []	\N	jasmonic acid	\N	\N	EFO	"An oxo monocarboxylic acid that has formula C12H18O3." []	EFO	65267	CHEBI:18292	\N	jasmonic acid	CHEBI:18292
0	"The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol." []	\N	1,4-dithiothreitol	\N	\N	EFO	"The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol." []	EFO	65268	CHEBI:18320	\N	1,4-dithiothreitol	CHEBI:18320
0	"" []	\N	5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide	\N	\N	EFO	"" []	EFO	65269	CHEBI:18406	\N	5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide	CHEBI:18406
0	"A sulfur oxide that has formula O2S." []	\N	sulphur dioxide	\N	\N	EFO	"A sulfur oxide that has formula O2S." []	EFO	65270	CHEBI:18422	\N	sulphur dioxide	CHEBI:18422
0	"The 5-fluoro derivative of uridine." []	\N	5-fluorouridine	\N	\N	EFO	"The 5-fluoro derivative of uridine." []	EFO	65271	CHEBI:185922	\N	5-fluorouridine	CHEBI:185922
0	"A pyrrolidine alkaloid that has formula C10H14N2." []	\N	nicotine	\N	\N	EFO	"A pyrrolidine alkaloid that has formula C10H14N2." []	EFO	65272	CHEBI:18723	\N	nicotine	CHEBI:18723
0	"" []	\N	3-dehydroteasterone	\N	\N	EFO	"" []	EFO	65273	CHEBI:20000	\N	3-dehydroteasterone	CHEBI:20000
0	"A N-glycosyl-1,3,5-triazine that has formula C8H12N4O5." []	\N	5-azacytidine	\N	\N	EFO	"A N-glycosyl-1,3,5-triazine that has formula C8H12N4O5." []	EFO	65274	CHEBI:2038	\N	5-azacytidine	CHEBI:2038
0	"" []	\N	3-dehydro-6-deoxoteasterone	\N	\N	EFO	"" []	EFO	65275	CHEBI:20710	\N	3-dehydro-6-deoxoteasterone	CHEBI:20710
0	"" []	\N	6-deoxocastasterone	\N	\N	EFO	"" []	EFO	65276	CHEBI:20712	\N	6-deoxocastasterone	CHEBI:20712
0	"" []	\N	6-deoxycathasterone	\N	\N	EFO	"" []	EFO	65277	CHEBI:20714	\N	6-deoxycathasterone	CHEBI:20714
0	"" []	\N	6-deoxotyphasterol	\N	\N	EFO	"" []	EFO	65278	CHEBI:20717	\N	6-deoxotyphasterol	CHEBI:20717
0	"" []	\N	N-methyl-N'-nitro-N-nitrosoguanidine	\N	\N	EFO	"" []	EFO	65279	CHEBI:21759	\N	N-methyl-N'-nitro-N-nitrosoguanidine	CHEBI:21759
0	"An apo carotenoid sesquiterpenoid that has formula C15H20O4." []	\N	abscisic acid	\N	\N	EFO	"An apo carotenoid sesquiterpenoid that has formula C15H20O4." []	EFO	65280	CHEBI:22152	\N	abscisic acid	CHEBI:22152
0	"Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases." []	\N	alkylating agent role	\N	\N	EFO	"Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases." []	EFO	65281	CHEBI:22333	\N	alkylating agent role	CHEBI:22333
0	"" []	\N	alpha-tocopherol	\N	\N	EFO	"" []	EFO	65282	CHEBI:22470	\N	alpha-tocopherol	CHEBI:22470
0	"Substance produced by, and obtained from, certain living cells (especially bacteria, yeasts and moulds), or an equivalent synthetic substance, which is biostatic or biocidal at low concentrations to some other form of life, especially pathogenic or noxious organisms." []	\N	antibiotic	\N	\N	EFO	"Substance produced by, and obtained from, certain living cells (especially bacteria, yeasts and moulds), or an equivalent synthetic substance, which is biostatic or biocidal at low concentrations to some other form of life, especially pathogenic or noxious organisms." []	EFO	65283	CHEBI:22582	\N	antibiotic	CHEBI:22582
0	"A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison." []	\N	antimycin A	\N	\N	EFO	"A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison." []	EFO	65284	CHEBI:22584	\N	antimycin A	CHEBI:22584
0	"A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides." []	\N	antioxidant	\N	\N	EFO	"A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides." []	EFO	65285	CHEBI:22586	\N	antioxidant	CHEBI:22586
0	"" []	\N	antiviral	\N	\N	EFO	"" []	EFO	65286	CHEBI:22587	\N	antiviral	CHEBI:22587
0	"Any of a group of compounds, both naturally occurring and synthetic, that regulate aspects of plant growth (from Greek alphaupsilonxialphanuomega, \\"to grow\\")." []	\N	auxin	\N	\N	EFO	"Any of a group of compounds, both naturally occurring and synthetic, that regulate aspects of plant growth (from Greek alphaupsilonxialphanuomega, \\"to grow\\")." []	EFO	65287	CHEBI:22676	\N	auxin	CHEBI:22676
0	"" []	\N	benzenetriols	\N	\N	EFO	"" []	EFO	65288	CHEBI:22707	\N	benzenetriols	CHEBI:22707
0	"" []	\N	benzodiazepine	\N	\N	EFO	"" []	EFO	65289	CHEBI:22720	\N	benzodiazepine	CHEBI:22720
0	"" []	\N	bleomycin	\N	\N	EFO	"" []	EFO	65290	CHEBI:22907	\N	bleomycin	CHEBI:22907
0	"An insecticide compound naturally occurring in plants." []	\N	phytogenic insecticide	\N	\N	EFO	"An insecticide compound naturally occurring in plants." []	EFO	65291	CHEBI:22917	\N	phytogenic insecticide	CHEBI:22917
0	"" []	\N	cadmium compounds	\N	\N	EFO	"" []	EFO	65292	CHEBI:22978	\N	cadmium compounds	CHEBI:22978
0	"" []	\N	calcium	\N	\N	EFO	"" []	EFO	65293	CHEBI:22984	\N	calcium	CHEBI:22984
0	"" []	\N	carbohydrate	\N	\N	EFO	"" []	EFO	65294	CHEBI:23008	\N	carbohydrate	CHEBI:23008
0	"" []	\N	castasterone	\N	\N	EFO	"" []	EFO	65295	CHEBI:23051	\N	castasterone	CHEBI:23051
0	"" []	\N	cathasterone	\N	\N	EFO	"" []	EFO	65296	CHEBI:23057	\N	cathasterone	CHEBI:23057
0	"" []	\N	coenzyme	\N	\N	EFO	"" []	EFO	65297	CHEBI:23354	\N	coenzyme	CHEBI:23354
0	"A carbotricyclic compound that has formula C22H25NO6." []	\N	colchicine	\N	\N	EFO	"A carbotricyclic compound that has formula C22H25NO6." []	EFO	65298	CHEBI:23359	\N	colchicine	CHEBI:23359
0	"" []	\N	compatible osmolytes role	\N	\N	EFO	"" []	EFO	65299	CHEBI:23366	\N	compatible osmolytes role	CHEBI:23366
0	"" []	\N	AACOCF3	\N	\N	EFO	"" []	EFO	65300	CHEBI:2341	\N	AACOCF3	CHEBI:2341
0	"" []	\N	cytochalasin B	\N	\N	EFO	"" []	EFO	65301	CHEBI:23527	\N	cytochalasin B	CHEBI:23527
0	"" []	\N	cytokinins	\N	\N	EFO	"" []	EFO	65302	CHEBI:23530	\N	cytokinins	CHEBI:23530
0	"" []	\N	abacavir	\N	\N	EFO	"" []	EFO	65303	CHEBI:2360	\N	abacavir	CHEBI:2360
0	"The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold." []	\N	(+)-abscisic acid	\N	\N	EFO	"The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold." []	EFO	65304	CHEBI:2365	\N	(+)-abscisic acid	CHEBI:2365
0	"" []	\N	acarbose	\N	\N	EFO	"" []	EFO	65305	CHEBI:2376	\N	acarbose	CHEBI:2376
0	"Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances." []	\N	drug	\N	\N	EFO	"Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances." []	EFO	65306	CHEBI:23888	\N	drug	CHEBI:23888
0	"A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction." []	\N	enzyme inhibitor	\N	\N	EFO	"A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction." []	EFO	65307	CHEBI:23924	\N	enzyme inhibitor	CHEBI:23924
0	"A steroid hormone that has formula C18H24O2." []	\N	estradiol	\N	\N	EFO	"A steroid hormone that has formula C18H24O2." []	EFO	65308	CHEBI:23965	\N	estradiol	CHEBI:23965
0	"A urea compound having ethyl and nitroso substituents in the 1-position." []	\N	ethyl nitrosourea	\N	\N	EFO	"A urea compound having ethyl and nitroso substituents in the 1-position." []	EFO	65309	CHEBI:23995	\N	ethyl nitrosourea	CHEBI:23995
0	"A substance used to destroy fungal pests." []	\N	fungicide	\N	\N	EFO	"A substance used to destroy fungal pests." []	EFO	65310	CHEBI:24127	\N	fungicide	CHEBI:24127
0	"A role played by the molecular entity or part thereof within a biological context." []	\N	biological role	\N	\N	EFO	"A role played by the molecular entity or part thereof within a biological context." []	EFO	65311	CHEBI:24432	\N	biological role	CHEBI:24432
0	"A 2-aminopurine that has formula C8H11N5O3." []	\N	acyclovir	\N	\N	EFO	"A 2-aminopurine that has formula C8H11N5O3." []	EFO	65312	CHEBI:2453	\N	acyclovir	CHEBI:2453
0	"" []	\N	organic heterocyclic compound	\N	\N	EFO	"" []	EFO	65313	CHEBI:24532	\N	organic heterocyclic compound	CHEBI:24532
0	"An endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function." []	\N	hormone	\N	\N	EFO	"An endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function." []	EFO	65314	CHEBI:24621	\N	hormone	CHEBI:24621
0	"A weak, unstable acid with formula HOCl, which is the active form of chlorine in water." []	\N	hypochlorous acid	\N	\N	EFO	"A weak, unstable acid with formula HOCl, which is the active form of chlorine in water." []	EFO	65315	CHEBI:24757	\N	hypochlorous acid	CHEBI:24757
0	"A substance used to destroy pests of the class Insecta." []	\N	insecticide	\N	\N	EFO	"A substance used to destroy pests of the class Insecta." []	EFO	65316	CHEBI:24852	\N	insecticide	CHEBI:24852
0	"" []	\N	jasmonic acids	\N	\N	EFO	"" []	EFO	65317	CHEBI:24937	\N	jasmonic acids	CHEBI:24937
0	"A carbon group element that has formula Pb." []	\N	lead	\N	\N	EFO	"A carbon group element that has formula Pb." []	EFO	65318	CHEBI:25016	\N	lead	CHEBI:25016
0	"This gene is involved in cell adhesion, differentiation, division and stress response." []	\N	aflatoxin B1	\N	\N	EFO	"This gene is involved in cell adhesion, differentiation, division and stress response." []	EFO	65319	CHEBI:2504	\N	aflatoxin B1	CHEBI:2504
0	"Any of two trienoic essential fatty acids; a nutrient essential to the formation of prostaglandins. Also used in making paints and synthetic resins." []	\N	linoleic acids	\N	\N	EFO	"Any of two trienoic essential fatty acids; a nutrient essential to the formation of prostaglandins. Also used in making paints and synthetic resins." []	EFO	65320	CHEBI:25048	\N	linoleic acids	CHEBI:25048
0	"" []	\N	lysine	\N	\N	EFO	"" []	EFO	65321	CHEBI:25094	\N	lysine	CHEBI:25094
0	"" []	\N	magnesium	\N	\N	EFO	"" []	EFO	65322	CHEBI:25107	\N	magnesium	CHEBI:25107
0	"A polysaccharide that has formula (C12H18O9)n." []	\N	agarose	\N	\N	EFO	"A polysaccharide that has formula (C12H18O9)n." []	EFO	65323	CHEBI:2511	\N	agarose	CHEBI:2511
0	"Any intermediate or product resulting from metabolism." []	\N	metabolite role	\N	\N	EFO	"Any intermediate or product resulting from metabolism." []	EFO	65324	CHEBI:25212	\N	metabolite role	CHEBI:25212
0	"" []	\N	mevalonate	\N	\N	EFO	"" []	EFO	65325	CHEBI:25350	\N	mevalonate	CHEBI:25350
0	"" []	\N	mitochondrial respiratory-chain inhibitor	\N	\N	EFO	"" []	EFO	65326	CHEBI:25355	\N	mitochondrial respiratory-chain inhibitor	CHEBI:25355
0	"An ethyl sulfide that has formula C4H8Cl2S." []	\N	bis(2-chloroethyl) sulfide	\N	\N	EFO	"An ethyl sulfide that has formula C4H8Cl2S." []	EFO	65327	CHEBI:25434	\N	bis(2-chloroethyl) sulfide	CHEBI:25434
0	"An agent that increases the frequency of spontanenous mutation, usually by interacting directly with DNA and causing it damage, including base substitution." []	\N	mutagen	\N	\N	EFO	"An agent that increases the frequency of spontanenous mutation, usually by interacting directly with DNA and causing it damage, including base substitution." []	EFO	65328	CHEBI:25435	\N	mutagen	CHEBI:25435
0	"A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke." []	\N	7,12-dimethylbenz(a)anthracene	\N	\N	EFO	"A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke." []	EFO	65329	CHEBI:254496	\N	7,12-dimethylbenz(a)anthracene	CHEBI:254496
0	"A 2,4'-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2'-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase." []	\N	myxothiazol	\N	\N	EFO	"A 2,4'-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2'-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase." []	EFO	65330	CHEBI:25461	\N	myxothiazol	CHEBI:25461
0	"The oxime carbamate resulting from the addition of 2-methyl-2-(methylsulfanyl)propanaldoxime to methyl isocyanate. A member of the class of oxime carbamate insecticides, aldicarb is a mixture of E and Z isomers; it is not known which isomer is more active." []	\N	aldicarb	\N	\N	EFO	"The oxime carbamate resulting from the addition of 2-methyl-2-(methylsulfanyl)propanaldoxime to methyl isocyanate. A member of the class of oxime carbamate insecticides, aldicarb is a mixture of E and Z isomers; it is not known which isomer is more active." []	EFO	65331	CHEBI:2555	\N	aldicarb	CHEBI:2555
0	"" []	\N	nitrogen atom	\N	\N	EFO	"" []	EFO	65332	CHEBI:25555	\N	nitrogen atom	CHEBI:25555
0	"" []	\N	alendronic acid	\N	\N	EFO	"" []	EFO	65333	CHEBI:2567	\N	alendronic acid	CHEBI:2567
0	"" []	\N	oligomycin	\N	\N	EFO	"" []	EFO	65334	CHEBI:25675	\N	oligomycin	CHEBI:25675
0	"" []	\N	organochlorine pesticides	\N	\N	EFO	"" []	EFO	65335	CHEBI:25705	\N	organochlorine pesticides	CHEBI:25705
0	"A triatomic oxygen that has formula O3." []	\N	ozone	\N	\N	EFO	"A triatomic oxygen that has formula O3." []	EFO	65336	CHEBI:25812	\N	ozone	CHEBI:25812
0	"Salts and esters of phosphoric and oligophosphoric acids and their chalcogen analogues. In inorganic chemistry, the term is also used to describe anionic coordination entities with phosphorus as central atom." []	\N	phosphate	\N	\N	EFO	"Salts and esters of phosphoric and oligophosphoric acids and their chalcogen analogues. In inorganic chemistry, the term is also used to describe anionic coordination entities with phosphorus as central atom." []	EFO	65337	CHEBI:26020	\N	phosphate	CHEBI:26020
0	"An endogenous molecular entity that results in a colour of an organism as the consequence of the selective absorption of light." []	\N	pigment	\N	\N	EFO	"An endogenous molecular entity that results in a colour of an organism as the consequence of the selective absorption of light." []	EFO	65338	CHEBI:26130	\N	pigment	CHEBI:26130
0	"A chemical, natural or artificial, that can affect the rate of growth of a plant." []	\N	plant growth regulator	\N	\N	EFO	"A chemical, natural or artificial, that can affect the rate of growth of a plant." []	EFO	65339	CHEBI:26155	\N	plant growth regulator	CHEBI:26155
0	"" []	\N	phytohormone	\N	\N	EFO	"" []	EFO	65340	CHEBI:26158	\N	phytohormone	CHEBI:26158
0	"An alpha-D-glucoside that has formula C22H43N5O13." []	\N	amikacin	\N	\N	EFO	"An alpha-D-glucoside that has formula C22H43N5O13." []	EFO	65341	CHEBI:2637	\N	amikacin	CHEBI:2637
0	"A retinoid that has formula C20H28O2." []	\N	retinoic acid	\N	\N	EFO	"A retinoid that has formula C20H28O2." []	EFO	65342	CHEBI:26536	\N	retinoic acid	CHEBI:26536
0	"" []	\N	amiodarone	\N	\N	EFO	"" []	EFO	65343	CHEBI:2663	\N	amiodarone	CHEBI:2663
0	"A tricyclic antidepressant that has formula C20H23N." []	\N	amitriptyline	\N	\N	EFO	"A tricyclic antidepressant that has formula C20H23N." []	EFO	65344	CHEBI:2666	\N	amitriptyline	CHEBI:2666
0	"\\"A cholate salt that has formula C24H39NaO5.\\" []" []	\N	sodium cholate	\N	\N	EFO	"\\"A cholate salt that has formula C24H39NaO5.\\" []" []	EFO	65345	CHEBI:26711	\N	sodium cholate	CHEBI:26711
0	"A penicillin that has formula C16H19N3O5S." []	\N	amoxicillin	\N	\N	EFO	"A penicillin that has formula C16H19N3O5S." []	EFO	65346	CHEBI:2676	\N	amoxicillin	CHEBI:2676
0	"Steroid hormones produced by the GONADS. They stimulate reproductive organs, germ cell maturation, and the secondary sex characteristics in the males and the females. The major sex steroid hormones include ESTRADIOL; PROGESTERONE; and TESTOSTERONE." []	\N	steroid hormone	\N	\N	EFO	"Steroid hormones produced by the GONADS. They stimulate reproductive organs, germ cell maturation, and the secondary sex characteristics in the males and the females. The major sex steroid hormones include ESTRADIOL; PROGESTERONE; and TESTOSTERONE." []	EFO	65347	CHEBI:26764	\N	steroid hormone	CHEBI:26764
0	"A macrolide antibiotic used to treat potentially life-threatening fungal infections." []	\N	amphotericin B	\N	\N	EFO	"A macrolide antibiotic used to treat potentially life-threatening fungal infections." []	EFO	65348	CHEBI:2682	\N	amphotericin B	CHEBI:2682
0	"" []	\N	teasterone	\N	\N	EFO	"" []	EFO	65349	CHEBI:26863	\N	teasterone	CHEBI:26863
0	"Poisonous substance produced by a biological organism such as a microbe, animal or plant." []	\N	toxin	\N	\N	EFO	"Poisonous substance produced by a biological organism such as a microbe, animal or plant." []	EFO	65350	CHEBI:27026	\N	toxin	CHEBI:27026
0	"" []	\N	micronutrient	\N	\N	EFO	"" []	EFO	65351	CHEBI:27027	\N	micronutrient	CHEBI:27027
0	"A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position." []	\N	anastrozole	\N	\N	EFO	"A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position." []	EFO	65352	CHEBI:2704	\N	anastrozole	CHEBI:2704
0	"" []	\N	typhasterol	\N	\N	EFO	"" []	EFO	65353	CHEBI:27173	\N	typhasterol	CHEBI:27173
0	"" []	\N	uric acid	\N	\N	EFO	"" []	EFO	65354	CHEBI:27226	\N	uric acid	CHEBI:27226
0	"Vitamin D is a group of fat-soluble prohormones, which can be obtained from sun exposure, food and supplements. Vitamin D is biologically inactive and converted to the biologically active calcicitriol via double hydroxilation in the body." []	\N	Vitamin D	\N	\N	EFO	"Vitamin D is a group of fat-soluble prohormones, which can be obtained from sun exposure, food and supplements. Vitamin D is biologically inactive and converted to the biologically active calcicitriol via double hydroxilation in the body." []	EFO	65355	CHEBI:27300	\N	Vitamin D	CHEBI:27300
0	"A zinc group element that has formula Zn." []	\N	Zinc	\N	\N	EFO	"A zinc group element that has formula Zn." []	EFO	65356	CHEBI:27363	\N	Zinc	CHEBI:27363
0	"" []	\N	tetrachloromethane	\N	\N	EFO	"" []	EFO	65357	CHEBI:27385	\N	tetrachloromethane	CHEBI:27385
0	"" []	\N	kinetin	\N	\N	EFO	"" []	EFO	65358	CHEBI:27407	\N	kinetin	CHEBI:27407
0	"" []	\N	methyltestosterone	\N	\N	EFO	"" []	EFO	65359	CHEBI:27436	\N	methyltestosterone	CHEBI:27436
0	"" []	\N	folic acid	\N	\N	EFO	"" []	EFO	65360	CHEBI:27470	\N	folic acid	CHEBI:27470
0	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	\N	mitomycin C	\N	\N	EFO	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	EFO	65361	CHEBI:27504	\N	mitomycin C	CHEBI:27504
0	"" []	\N	oxirane	\N	\N	EFO	"" []	EFO	65362	CHEBI:27561	\N	oxirane	CHEBI:27561
0	"A pnictogen that has formula As." []	\N	arsenic	\N	\N	EFO	"A pnictogen that has formula As." []	EFO	65363	CHEBI:27563	\N	arsenic	CHEBI:27563
0	"A chalcogen that has formula Se." []	\N	selenium	\N	\N	EFO	"A chalcogen that has formula Se." []	EFO	65364	CHEBI:27568	\N	selenium	CHEBI:27568
0	"A carbon group element that has formula Si." []	\N	silicon	\N	\N	EFO	"A carbon group element that has formula Si." []	EFO	65365	CHEBI:27573	\N	silicon	CHEBI:27573
0	"A pregnane-based steroidal hormone produced by the outer-section (zona glomerulosa) of the adrenal cortex in the adrenal gland, and acts on the distal tubules and collecting ducts of the kidney to cause the conservation of sodium, secretion of potassium, increased water retention, and increased blood pressure. The overall effect of aldosterone is to increase reabsorption of ions and water in the kidney." []	\N	aldosterone	\N	\N	EFO	"A pregnane-based steroidal hormone produced by the outer-section (zona glomerulosa) of the adrenal cortex in the adrenal gland, and acts on the distal tubules and collecting ducts of the kidney to cause the conservation of sodium, secretion of potassium, increased water retention, and increased blood pressure. The overall effect of aldosterone is to increase reabsorption of ions and water in the kidney." []	EFO	65366	CHEBI:27584	\N	aldosterone	CHEBI:27584
0	"A carbon group element atom that has formula C." []	\N	carbon	\N	\N	EFO	"A carbon group element atom that has formula C." []	EFO	65367	CHEBI:27594	\N	carbon	CHEBI:27594
0	"" []	\N	monensin A	\N	\N	EFO	"" []	EFO	65368	CHEBI:27617	\N	monensin A	CHEBI:27617
0	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	\N	cycloheximide	\N	\N	EFO	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	EFO	65369	CHEBI:27641	\N	cycloheximide	CHEBI:27641
0	"A pyranoindolizinoquinoline that has formula C20H16N2O4." []	\N	camptothecin	\N	\N	EFO	"A pyranoindolizinoquinoline that has formula C20H16N2O4." []	EFO	65370	CHEBI:27656	\N	camptothecin	CHEBI:27656
0	"" []	\N	aphidicolin	\N	\N	EFO	"" []	EFO	65371	CHEBI:2766	\N	aphidicolin	CHEBI:2766
0	"An actinomycin that has formula C62H86N12O16." []	\N	actinomycin D	\N	\N	EFO	"An actinomycin that has formula C62H86N12O16." []	EFO	65372	CHEBI:27666	\N	actinomycin D	CHEBI:27666
0	"" []	\N	acetazolamide	\N	\N	EFO	"" []	EFO	65373	CHEBI:27690	\N	acetazolamide	CHEBI:27690
0	"A vanadium group element that has formula V." []	\N	Vanadium	\N	\N	EFO	"A vanadium group element that has formula V." []	EFO	65374	CHEBI:27698	\N	Vanadium	CHEBI:27698
0	"A trimethylxanthine that has formula C8H10N4O2." []	\N	caffeine	\N	\N	EFO	"A trimethylxanthine that has formula C8H10N4O2." []	EFO	65375	CHEBI:27732	\N	caffeine	CHEBI:27732
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	glyphosate	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65376	CHEBI:27744	\N	glyphosate	CHEBI:27744
0	"" []	\N	griseofulvin	\N	\N	EFO	"" []	EFO	65377	CHEBI:27779	\N	griseofulvin	CHEBI:27779
0	"A surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions." []	\N	detergent role	\N	\N	EFO	"A surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions." []	EFO	65378	CHEBI:27780	\N	detergent role	CHEBI:27780
0	"A stilbenol that has formula C14H12O3." []	\N	resveratrol	\N	\N	EFO	"A stilbenol that has formula C14H12O3." []	EFO	65379	CHEBI:27881	\N	resveratrol	CHEBI:27881
0	"" []	\N	cisplatin	\N	\N	EFO	"" []	EFO	65380	CHEBI:27899	\N	cisplatin	CHEBI:27899
0	"A monounsaturated very long-chain fatty acid with a 22-carbon backbone and a single double bond originating from the  9th position from the methyl end, with the double bond in the trans- configuration." []	\N	tetracycline	\N	\N	EFO	"A monounsaturated very long-chain fatty acid with a 22-carbon backbone and a single double bond originating from the  9th position from the methyl end, with the double bond in the trans- configuration." []	EFO	65381	CHEBI:27902	\N	tetracycline	CHEBI:27902
0	"An alkaloid obtained from leaves of the South American shrub Erythroxylon coca." []	\N	cocaine	\N	\N	EFO	"An alkaloid obtained from leaves of the South American shrub Erythroxylon coca." []	EFO	65382	CHEBI:27958	\N	cocaine	CHEBI:27958
0	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	\N	3-methylbenzyl alcohol	\N	\N	EFO	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	EFO	65383	CHEBI:27995	\N	3-methylbenzyl alcohol	CHEBI:27995
0	"An urea that has formula C12H18N2O3S." []	\N	tolbutamide	\N	\N	EFO	"An urea that has formula C12H18N2O3S." []	EFO	65384	CHEBI:27999	\N	tolbutamide	CHEBI:27999
0	"The tooth, teeth, or implant that supports a fixed bridge or removable prosthesis." []	\N	vancomycin	\N	\N	EFO	"The tooth, teeth, or implant that supports a fixed bridge or removable prosthesis." []	EFO	65385	CHEBI:28001	\N	vancomycin	CHEBI:28001
0	"" []	\N	phenylalanine	\N	\N	EFO	"" []	EFO	65386	CHEBI:28044	\N	phenylalanine	CHEBI:28044
0	"A chromium group element that has formula Cr." []	\N	chromium	\N	\N	EFO	"A chromium group element that has formula Cr." []	EFO	65387	CHEBI:28073	\N	chromium	CHEBI:28073
0	"A N-iminopiperazine that has formula C43H58N4O12." []	\N	rifampicin	\N	\N	EFO	"A N-iminopiperazine that has formula C43H58N4O12." []	EFO	65388	CHEBI:28077	\N	rifampicin	CHEBI:28077
0	"A phytoestrogenic isoflavone with antioxidant properties." []	\N	genistein	\N	\N	EFO	"A phytoestrogenic isoflavone with antioxidant properties." []	EFO	65389	CHEBI:28088	\N	genistein	CHEBI:28088
0	"" []	\N	2,3,7,8-tetrachlorodibenzodioxine	\N	\N	EFO	"" []	EFO	65390	CHEBI:28119	\N	2,3,7,8-tetrachlorodibenzodioxine	CHEBI:28119
0	"" []	\N	docosahexaenoic acid	\N	\N	EFO	"" []	EFO	65391	CHEBI:28125	\N	docosahexaenoic acid	CHEBI:28125
0	"A 14alpha-hydroxy steroid that has formula C27H44O6." []	\N	ponasterone A	\N	\N	EFO	"A 14alpha-hydroxy steroid that has formula C27H44O6." []	EFO	65392	CHEBI:28135	\N	ponasterone A	CHEBI:28135
0	"" []	\N	theophylline	\N	\N	EFO	"" []	EFO	65393	CHEBI:28177	\N	theophylline	CHEBI:28177
0	"A chromenone that has formula C23H22O6." []	\N	rotenone	\N	\N	EFO	"A chromenone that has formula C23H22O6." []	EFO	65394	CHEBI:28201	\N	rotenone	CHEBI:28201
0	"A chlorine molecular entity that has formula CH3ClHg." []	\N	methyl mercuric(II) chloride	\N	\N	EFO	"A chlorine molecular entity that has formula CH3ClHg." []	EFO	65395	CHEBI:28216	\N	methyl mercuric(II) chloride	CHEBI:28216
0	"" []	\N	dichloroacetate	\N	\N	EFO	"" []	EFO	65396	CHEBI:28240	\N	dichloroacetate	CHEBI:28240
0	"" []	\N	papaverine	\N	\N	EFO	"" []	EFO	65397	CHEBI:28241	\N	papaverine	CHEBI:28241
0	"" []	\N	aristolochic acid	\N	\N	EFO	"" []	EFO	65398	CHEBI:2825	\N	aristolochic acid	CHEBI:2825
0	"" []	\N	dimethyl sulfoxide	\N	\N	EFO	"" []	EFO	65399	CHEBI:28262	\N	dimethyl sulfoxide	CHEBI:28262
0	"A brassinosteroid that has formula C28H48O6." []	\N	brassinolide	\N	\N	EFO	"A brassinosteroid that has formula C28H48O6." []	EFO	65400	CHEBI:28277	\N	brassinolide	CHEBI:28277
0	"" []	\N	oligomycin A	\N	\N	EFO	"" []	EFO	65401	CHEBI:28285	\N	oligomycin A	CHEBI:28285
0	"An alpha-amino acid that has formula C5H10N2O3." []	\N	glutamine	\N	\N	EFO	"An alpha-amino acid that has formula C5H10N2O3." []	EFO	65402	CHEBI:28300	\N	glutamine	CHEBI:28300
0	"An icosapentaenoic acid that has formula C20H30O2." []	\N	all-cis-icosa-5,8,11,14,17-pentaenoic acid	\N	\N	EFO	"An icosapentaenoic acid that has formula C20H30O2." []	EFO	65403	CHEBI:28364	\N	all-cis-icosa-5,8,11,14,17-pentaenoic acid	CHEBI:28364
0	"" []	\N	novobiocin	\N	\N	EFO	"" []	EFO	65404	CHEBI:28368	\N	novobiocin	CHEBI:28368
0	"A vinca alkaloid that has formula C46H56N4O10." []	\N	vincristine	\N	\N	EFO	"A vinca alkaloid that has formula C46H56N4O10." []	EFO	65405	CHEBI:28445	\N	vincristine	CHEBI:28445
0	"" []	\N	ajmaline	\N	\N	EFO	"" []	EFO	65406	CHEBI:28462	\N	ajmaline	CHEBI:28462
0	"" []	\N	1,2-dibromoethane	\N	\N	EFO	"" []	EFO	65407	CHEBI:28534	\N	1,2-dibromoethane	CHEBI:28534
0	"" []	\N	piperazine	\N	\N	EFO	"" []	EFO	65408	CHEBI:28568	\N	piperazine	CHEBI:28568
0	"" []	\N	quinidine	\N	\N	EFO	"" []	EFO	65409	CHEBI:28593	\N	quinidine	CHEBI:28593
0	"" []	\N	1,4-dichlorobenzene	\N	\N	EFO	"" []	EFO	65410	CHEBI:28618	\N	1,4-dichlorobenzene	CHEBI:28618
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	acrylamide	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65411	CHEBI:28619	\N	acrylamide	CHEBI:28619
0	"A teichoic acid which is covalently bound to a lipid." []	\N	lipoteichoic Acid	\N	\N	EFO	"A teichoic acid which is covalently bound to a lipid." []	EFO	65412	CHEBI:28640	\N	lipoteichoic Acid	CHEBI:28640
0	"" []	\N	phosphorus	\N	\N	EFO	"" []	EFO	65413	CHEBI:28659	\N	phosphorus	CHEBI:28659
0	"A leukotriene that has formula C25H40N2O6S." []	\N	leukotriene D4	\N	\N	EFO	"A leukotriene that has formula C25H40N2O6S." []	EFO	65414	CHEBI:28666	\N	leukotriene D4	CHEBI:28666
0	"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis." []	\N	cytarabine	\N	\N	EFO	"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis." []	EFO	65415	CHEBI:28680	\N	cytarabine	CHEBI:28680
0	"An androgen that has formula C19H28O2." []	\N	dehydroepiandrosterone	\N	\N	EFO	"An androgen that has formula C19H28O2." []	EFO	65416	CHEBI:28689	\N	dehydroepiandrosterone	CHEBI:28689
0	"A copper group element that has formula Cu." []	\N	copper	\N	\N	EFO	"A copper group element that has formula Cu." []	EFO	65417	CHEBI:28694	\N	copper	CHEBI:28694
0	"A deoxy hexoside that has formula C27H29NO11." []	\N	doxorubicin	\N	\N	EFO	"A deoxy hexoside that has formula C27H29NO11." []	EFO	65418	CHEBI:28748	\N	doxorubicin	CHEBI:28748
0	"" []	\N	serotonin	\N	\N	EFO	"" []	EFO	65419	CHEBI:28790	\N	serotonin	CHEBI:28790
0	"" []	\N	coumarin	\N	\N	EFO	"" []	EFO	65420	CHEBI:28794	\N	coumarin	CHEBI:28794
0	"" []	\N	phytosterol	\N	\N	EFO	"" []	EFO	65421	CHEBI:28824	\N	phytosterol	CHEBI:28824
0	"" []	\N	gibberellin A3	\N	\N	EFO	"" []	EFO	65422	CHEBI:28833	\N	gibberellin A3	CHEBI:28833
0	"" []	\N	5-amino-1-(5-phospho-D-ribosyl)imidazole	\N	\N	EFO	"" []	EFO	65423	CHEBI:28843	\N	5-amino-1-(5-phospho-D-ribosyl)imidazole	CHEBI:28843
0	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	\N	(2,4-dichlorophenoxy)acetic acid	\N	\N	EFO	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	EFO	65424	CHEBI:28854	\N	(2,4-dichlorophenoxy)acetic acid	CHEBI:28854
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	tobramycin	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65425	CHEBI:28864	\N	tobramycin	CHEBI:28864
0	"The determination of the amount of complement C4 present in a sample." []	\N	butan-1-ol	\N	\N	EFO	"The determination of the amount of complement C4 present in a sample." []	EFO	65426	CHEBI:28885	\N	butan-1-ol	CHEBI:28885
0	"The sixth of the seven cervical vertebrae." []	\N	3-aminophenol	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65427	CHEBI:28924	\N	3-aminophenol	CHEBI:28924
0	"A vitamin D that has formula C27H44O." []	\N	calciol	\N	\N	EFO	"A vitamin D that has formula C27H44O." []	EFO	65428	CHEBI:28940	\N	calciol	CHEBI:28940
0	"A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group." []	\N	ampicillin	\N	\N	EFO	"A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group." []	EFO	65429	CHEBI:28971	\N	ampicillin	CHEBI:28971
0	"A boron group element that has formula Al." []	\N	aluminium	\N	\N	EFO	"A boron group element that has formula Al." []	EFO	65430	CHEBI:28984	\N	aluminium	CHEBI:28984
0	"A cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side groups." []	\N	ceftriaxone	\N	\N	EFO	"A cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side groups." []	EFO	65431	CHEBI:29007	\N	ceftriaxone	CHEBI:29007
0	"" []	\N	N-benzyladenine	\N	\N	EFO	"" []	EFO	65432	CHEBI:29022	\N	N-benzyladenine	CHEBI:29022
0	"The L- enatiomer of ascorbic acid and conjugate acid of L-ascorbate; an essential nutrient and antioxidant with possible anticancer role, especially with intravenous administration. A cofactor in several enzymatic reactions of living organisms, it is linked with effective wound healing and  prevention or treatment of scurvy and gout. Also known as vitamin C, it is believed to boost the immune system. Humans alone of the primates require exogenous sources of daily vitamin C." []	\N	L-ascorbic acid	\N	\N	EFO	"The L- enatiomer of ascorbic acid and conjugate acid of L-ascorbate; an essential nutrient and antioxidant with possible anticancer role, especially with intravenous administration. A cofactor in several enzymatic reactions of living organisms, it is linked with effective wound healing and  prevention or treatment of scurvy and gout. Also known as vitamin C, it is believed to boost the immune system. Humans alone of the primates require exogenous sources of daily vitamin C." []	EFO	65433	CHEBI:29073	\N	L-ascorbic acid	CHEBI:29073
0	"" []	\N	phosgene	\N	\N	EFO	"" []	EFO	65434	CHEBI:29365	\N	phosgene	CHEBI:29365
0	"" []	\N	dioxygen(2+)	\N	\N	EFO	"" []	EFO	65435	CHEBI:29371	\N	dioxygen(2+)	CHEBI:29371
0	"" []	\N	azathioprine	\N	\N	EFO	"" []	EFO	65436	CHEBI:2948	\N	azathioprine	CHEBI:2948
0	"A chromosome band present on 10q" []	\N	azithromycin	\N	\N	EFO	"A chromosome band present on 10q" []	EFO	65437	CHEBI:2955	\N	azithromycin	CHEBI:2955
0	"" []	\N	neocarzinostatin chromophore	\N	\N	EFO	"" []	EFO	65438	CHEBI:29655	\N	neocarzinostatin chromophore	CHEBI:29655
0	"" []	\N	sodium metaarsenite	\N	\N	EFO	"" []	EFO	65439	CHEBI:29678	\N	sodium metaarsenite	CHEBI:29678
0	"" []	\N	thiostrepton	\N	\N	EFO	"" []	EFO	65440	CHEBI:29693	\N	thiostrepton	CHEBI:29693
0	"The glycosyloxyflavone which is the 7-O-glucuronide of baicalein." []	\N	baicalin	\N	\N	EFO	"The glycosyloxyflavone which is the 7-O-glucuronide of baicalein." []	EFO	65441	CHEBI:2981	\N	baicalin	CHEBI:2981
0	"An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings." []	\N	benzo(a)pyrene	\N	\N	EFO	"An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings." []	EFO	65442	CHEBI:29865	\N	benzo(a)pyrene	CHEBI:29865
0	"An arsenite ion that has formula AsO3." []	\N	arsenite(3-)	\N	\N	EFO	"An arsenite ion that has formula AsO3." []	EFO	65443	CHEBI:29866	\N	arsenite(3-)	CHEBI:29866
0	"" []	\N	divanadium pentaoxide	\N	\N	EFO	"" []	EFO	65444	CHEBI:30045	\N	divanadium pentaoxide	CHEBI:30045
0	"The conjugate base of acetic acid." []	\N	acetate	\N	\N	EFO	"The conjugate base of acetic acid." []	EFO	65445	CHEBI:30089	\N	acetate	CHEBI:30089
0	"An aluminium coordination entity that has formula AlCl3." []	\N	aluminium trichloride	\N	\N	EFO	"An aluminium coordination entity that has formula AlCl3." []	EFO	65446	CHEBI:30114	\N	aluminium trichloride	CHEBI:30114
0	"" []	\N	lithium atom	\N	\N	EFO	"" []	EFO	65447	CHEBI:30145	\N	lithium atom	CHEBI:30145
0	"A radiolabelled urea molecule used to diagnose stomach ulcers caused by Heliobacter pylori. In the presence of H. pylori, urea C-14 is metabolized by urease to produce ammonia and radioactive carbon dioxide at the interface between the gastric epithelium and lumen. The radioactive carbon dioxide is absorbed in the blood and is detected when exhaled in the breath." []	\N	benomyl	\N	\N	EFO	"A radiolabelled urea molecule used to diagnose stomach ulcers caused by Heliobacter pylori. In the presence of H. pylori, urea C-14 is metabolized by urease to produce ammonia and radioactive carbon dioxide at the interface between the gastric epithelium and lumen. The radioactive carbon dioxide is absorbed in the blood and is detected when exhaled in the breath." []	EFO	65448	CHEBI:3015	\N	benomyl	CHEBI:3015
0	"" []	\N	benzbromarone	\N	\N	EFO	"" []	EFO	65449	CHEBI:3023	\N	benzbromarone	CHEBI:3023
0	"" []	\N	antimony(0)	\N	\N	EFO	"" []	EFO	65450	CHEBI:30304	\N	antimony(0)	CHEBI:30304
0	"A bipyridine that has formula C10H8N2." []	\N	2,2'-bipyridine	\N	\N	EFO	"A bipyridine that has formula C10H8N2." []	EFO	65451	CHEBI:30351	\N	2,2'-bipyridine	CHEBI:30351
0	"An epoxide that has formula C20H14O3." []	\N	benzo(a)pyrene diolepoxide 1	\N	\N	EFO	"An epoxide that has formula C20H14O3." []	EFO	65452	CHEBI:30614	\N	benzo(a)pyrene diolepoxide 1	CHEBI:30614
0	"" []	\N	diarsenic trioxide	\N	\N	EFO	"" []	EFO	65453	CHEBI:30621	\N	diarsenic trioxide	CHEBI:30621
0	"" []	\N	thyroxine	\N	\N	EFO	"" []	EFO	65454	CHEBI:30660	\N	thyroxine	CHEBI:30660
0	"A 1,2-glycol compound produced via reaction of ethylene oxide with water." []	\N	ethylene glycol	\N	\N	EFO	"A 1,2-glycol compound produced via reaction of ethylene oxide with water." []	EFO	65455	CHEBI:30742	\N	ethylene glycol	CHEBI:30742
0	"Human CXCL10 wild-type allele is located within 4q21 and is approximately 2 kb in length. This allele, which encodes small inducible cytokine B10 protein, plays a role in both immune cell migration and in the modulation of adhesion molecule expression." []	\N	benzoic acid	\N	\N	EFO	"Human CXCL10 wild-type allele is located within 4q21 and is approximately 2 kb in length. This allele, which encodes small inducible cytokine B10 protein, plays a role in both immune cell migration and in the modulation of adhesion molecule expression." []	EFO	65456	CHEBI:30746	\N	benzoic acid	CHEBI:30746
0	"An amide that has formula C18H14F4N2O4S." []	\N	bicalutamide	\N	\N	EFO	"An amide that has formula C18H14F4N2O4S." []	EFO	65457	CHEBI:3090	\N	bicalutamide	CHEBI:3090
0	"Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species." []	\N	bicuculline	\N	\N	EFO	"Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species." []	EFO	65458	CHEBI:3092	\N	bicuculline	CHEBI:3092
0	"\\"A hydrate that has formula C34H38Cl2N2O5.\\" []" []	\N	apomorphine hydrochloride	\N	\N	EFO	"\\"A hydrate that has formula C34H38Cl2N2O5.\\" []" []	EFO	65459	CHEBI:31228	\N	apomorphine hydrochloride	CHEBI:31228
0	"A platinum coordination entity that has formula C6H12N2O4Pt." []	\N	carboplatin	\N	\N	EFO	"A platinum coordination entity that has formula C6H12N2O4Pt." []	EFO	65460	CHEBI:31355	\N	carboplatin	CHEBI:31355
0	"A bleomycin that has formula C55H84N17O21S3." []	\N	bleomycin A2	\N	\N	EFO	"A bleomycin that has formula C55H84N17O21S3." []	EFO	65461	CHEBI:3139	\N	bleomycin A2	CHEBI:3139
0	"" []	\N	fasudil hydrochloride	\N	\N	EFO	"" []	EFO	65462	CHEBI:31593	\N	fasudil hydrochloride	CHEBI:31593
0	"" []	\N	ferric ammonium citrate	\N	\N	EFO	"" []	EFO	65463	CHEBI:31604	\N	ferric ammonium citrate	CHEBI:31604
0	"A 3-hydroxy steroid that has formula C32H47F5O3S." []	\N	fulvestrant	\N	\N	EFO	"A 3-hydroxy steroid that has formula C32H47F5O3S." []	EFO	65464	CHEBI:31638	\N	fulvestrant	CHEBI:31638
0	"" []	\N	imatinib methanesulfonate	\N	\N	EFO	"" []	EFO	65465	CHEBI:31690	\N	imatinib methanesulfonate	CHEBI:31690
0	"A pyrrolidinemonocarboxylic acid that has formula C10H15NO4." []	\N	kainic acid	\N	\N	EFO	"A pyrrolidinemonocarboxylic acid that has formula C10H15NO4." []	EFO	65466	CHEBI:31746	\N	kainic acid	CHEBI:31746
0	"" []	\N	bromobenzene	\N	\N	EFO	"" []	EFO	65467	CHEBI:3179	\N	bromobenzene	CHEBI:3179
0	"Human CD82 wild-type allele is located in the vicinity of 11p11.2 and is approximately 54 kb in length. This allele, which encodes CD82 antigen Immunoprotein, is involved in metastasis suppression." []	\N	bromocriptine methanesulfonate	\N	\N	EFO	"Human CD82 wild-type allele is located in the vicinity of 11p11.2 and is approximately 54 kb in length. This allele, which encodes CD82 antigen Immunoprotein, is involved in metastasis suppression." []	EFO	65468	CHEBI:3182	\N	bromocriptine methanesulfonate	CHEBI:3182
0	"An aspartic acid derivative having an N-methyl substituent and D-configuration." []	\N	N-methyl-D-aspartic acid	\N	\N	EFO	"An aspartic acid derivative having an N-methyl substituent and D-configuration." []	EFO	65469	CHEBI:31882	\N	N-methyl-D-aspartic acid	CHEBI:31882
0	"" []	\N	nemonapride	\N	\N	EFO	"" []	EFO	65470	CHEBI:31899	\N	nemonapride	CHEBI:31899
0	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	\N	oxaliplatin	\N	\N	EFO	"Homeobox protein Hox-C6 (235 aa, ~27 kDa) is encoded by the human HOXC6 gene. This protein plays a role in transcription and embryonic development." []	EFO	65471	CHEBI:31941	\N	oxaliplatin	CHEBI:31941
0	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	\N	phenol red	\N	\N	EFO	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	EFO	65472	CHEBI:31991	\N	phenol red	CHEBI:31991
0	"A metal bromide salt with a K(+) counterion." []	\N	potassium bromide	\N	\N	EFO	"A metal bromide salt with a K(+) counterion." []	EFO	65473	CHEBI:32030	\N	potassium bromide	CHEBI:32030
0	"" []	\N	propylparaben	\N	\N	EFO	"" []	EFO	65474	CHEBI:32063	\N	propylparaben	CHEBI:32063
0	"" []	\N	sapropterin dihydrochloride	\N	\N	EFO	"" []	EFO	65475	CHEBI:32120	\N	sapropterin dihydrochloride	CHEBI:32120
0	"" []	\N	sodium hydroxide	\N	\N	EFO	"" []	EFO	65476	CHEBI:32145	\N	sodium hydroxide	CHEBI:32145
0	"" []	\N	sulpiride	\N	\N	EFO	"" []	EFO	65477	CHEBI:32168	\N	sulpiride	CHEBI:32168
0	"" []	\N	butein	\N	\N	EFO	"" []	EFO	65478	CHEBI:3237	\N	butein	CHEBI:3237
0	"" []	\N	thioacetamide	\N	\N	EFO	"" []	EFO	65479	CHEBI:32497	\N	thioacetamide	CHEBI:32497
0	"" []	\N	pirinixic acid	\N	\N	EFO	"" []	EFO	65480	CHEBI:32509	\N	pirinixic acid	CHEBI:32509
0	"A hydroxyaldehyde that has formula C9H16O2." []	\N	4-hydroxy-2-nonenal	\N	\N	EFO	"A hydroxyaldehyde that has formula C9H16O2." []	EFO	65481	CHEBI:32585	\N	4-hydroxy-2-nonenal	CHEBI:32585
0	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	\N	piperonylbutoxide	\N	\N	EFO	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	EFO	65482	CHEBI:32687	\N	piperonylbutoxide	CHEBI:32687
0	"A nitrosamine that has formula C10H13N3O2." []	\N	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	\N	\N	EFO	"A nitrosamine that has formula C10H13N3O2." []	EFO	65483	CHEBI:32692	\N	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	CHEBI:32692
0	"" []	\N	gibberellin A4	\N	\N	EFO	"" []	EFO	65484	CHEBI:32902	\N	gibberellin A4	CHEBI:32902
0	"A naphthylacetic acid that has formula C12H10O2." []	\N	1-naphthylacetic acid	\N	\N	EFO	"A naphthylacetic acid that has formula C12H10O2." []	EFO	65485	CHEBI:32918	\N	1-naphthylacetic acid	CHEBI:32918
0	"An ortho- and peri-fused polycyclic arene that has formula C16H10." []	\N	fluroanthene	\N	\N	EFO	"An ortho- and peri-fused polycyclic arene that has formula C16H10." []	EFO	65486	CHEBI:33083	\N	fluroanthene	CHEBI:33083
0	"A member of the 4-nitrotoluenes that has formula C7H7NO2." []	\N	P-nitrotoluene	\N	\N	EFO	"A member of the 4-nitrotoluenes that has formula C7H7NO2." []	EFO	65487	CHEBI:33097	\N	P-nitrotoluene	CHEBI:33097
0	"A nitrotoluene that has formula C7H7NO2." []	\N	O-nitrotoluene	\N	\N	EFO	"A nitrotoluene that has formula C7H7NO2." []	EFO	65488	CHEBI:33098	\N	O-nitrotoluene	CHEBI:33098
0	"A member of the aluminium hydroxides that has formula H3AlO3." []	\N	aluminium hydroxide	\N	\N	EFO	"A member of the aluminium hydroxides that has formula H3AlO3." []	EFO	65489	CHEBI:33130	\N	aluminium hydroxide	CHEBI:33130
0	"" []	\N	vanadyl sulfate	\N	\N	EFO	"" []	EFO	65490	CHEBI:33146	\N	vanadyl sulfate	CHEBI:33146
0	"" []	\N	calicheamicin gamma1(I)	\N	\N	EFO	"" []	EFO	65491	CHEBI:3319	\N	calicheamicin gamma1(I)	CHEBI:3319
0	"A bisphenol that has formula C15H16O2." []	\N	bisphenol A	\N	\N	EFO	"A bisphenol that has formula C15H16O2." []	EFO	65492	CHEBI:33216	\N	bisphenol A	CHEBI:33216
0	"An organic substance that is distributed in foodstuffs, is distinct from the main organic components of food (protein, carbohydrate and fat) and is needed for the normal nutrition of the organism in question. The term \\"vitamines\\" (from vita + amines) was coined in 1912 by Casimir Funk, who believed that these compounds were amines." []	\N	vitamin	\N	\N	EFO	"An organic substance that is distributed in foodstuffs, is distinct from the main organic components of food (protein, carbohydrate and fat) and is needed for the normal nutrition of the organism in question. The term \\"vitamines\\" (from vita + amines) was coined in 1912 by Casimir Funk, who believed that these compounds were amines." []	EFO	65493	CHEBI:33229	\N	vitamin	CHEBI:33229
0	"" []	\N	element	\N	\N	EFO	"" []	EFO	65494	CHEBI:33250	\N	element	CHEBI:33250
0	"The food provided to the organism (e.g., chow, fertilizer, DEMM 10%FBS, etc.)." []	\N	nutrient	\N	\N	EFO	"The food provided to the organism (e.g., chow, fertilizer, DEMM 10%FBS, etc.)." []	EFO	65495	CHEBI:33284	\N	nutrient	CHEBI:33284
0	"An agrochemical is a substance that is used in agriculture or horticulture." []	\N	agrochemical role	\N	\N	EFO	"An agrochemical is a substance that is used in agriculture or horticulture." []	EFO	65496	CHEBI:33286	\N	agrochemical role	CHEBI:33286
0	"" []	\N	fertilizer	\N	\N	EFO	"" []	EFO	65497	CHEBI:33287	\N	fertilizer	CHEBI:33287
0	"A chromosome band present on 10p" []	\N	candesartan	\N	\N	EFO	"A chromosome band present on 10p" []	EFO	65498	CHEBI:3347	\N	candesartan	CHEBI:3347
0	"A catecholamine that has formula C9H13NO3." []	\N	adrenaline	\N	\N	EFO	"A catecholamine that has formula C9H13NO3." []	EFO	65499	CHEBI:33568	\N	adrenaline	CHEBI:33568
0	"RNA is a chemical compound which are naturally occurring polyribonucleotides." []	\N	RNA	\N	\N	EFO	"RNA is a chemical compound which are naturally occurring polyribonucleotides." []	EFO	65500	CHEBI:33697	\N	RNA	CHEBI:33697
0	"An RNA molecule that transfers the coding information for protein synthesis from the chromosomes to the ribosomes mRNA is formed from a DNA template by transcription. It may be a copy of a single gene or of several adjacent genes (polycistronic mRNA). On the ribosome, the sequence is converted into the programmed amino acid sequence through translation." []	\N	messenger RNA	\N	\N	EFO	"An RNA molecule that transfers the coding information for protein synthesis from the chromosomes to the ribosomes mRNA is formed from a DNA template by transcription. It may be a copy of a single gene or of several adjacent genes (polycistronic mRNA). On the ribosome, the sequence is converted into the programmed amino acid sequence through translation." []	EFO	65501	CHEBI:33699	\N	messenger RNA	CHEBI:33699
0	"" []	\N	amino acid	\N	\N	EFO	"" []	EFO	65502	CHEBI:33709	\N	amino acid	CHEBI:33709
0	"" []	\N	captopril	\N	\N	EFO	"" []	EFO	65503	CHEBI:3380	\N	captopril	CHEBI:3380
0	"An iminostilbene derivative with a carbamoyl group at the azepine nitrogen, used as an anticonvulsant." []	\N	carbamazepine	\N	\N	EFO	"An iminostilbene derivative with a carbamoyl group at the azepine nitrogen, used as an anticonvulsant." []	EFO	65504	CHEBI:3387	\N	carbamazepine	CHEBI:3387
0	"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)" []	\N	carbaryl	\N	\N	EFO	"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)" []	EFO	65505	CHEBI:3390	\N	carbaryl	CHEBI:3390
0	"The (9R,13R)-diastereomer of 12-oxophytodienoic acid." []	\N	(9R,13R)-12-oxo-phytodienoic acid	\N	\N	EFO	"The (9R,13R)-diastereomer of 12-oxophytodienoic acid." []	EFO	65506	CHEBI:34005	\N	(9R,13R)-12-oxo-phytodienoic acid	CHEBI:34005
0	"" []	\N	16-ketoestradiol	\N	\N	EFO	"" []	EFO	65507	CHEBI:34165	\N	16-ketoestradiol	CHEBI:34165
0	"" []	\N	carvacrol	\N	\N	EFO	"" []	EFO	65508	CHEBI:3440	\N	carvacrol	CHEBI:3440
0	"" []	\N	4-nonylphenol	\N	\N	EFO	"" []	EFO	65509	CHEBI:34440	\N	4-nonylphenol	CHEBI:34440
0	"An organochlorine acaricide that has formula C9H11Cl3NO3PS." []	\N	chlorpyrifos	\N	\N	EFO	"An organochlorine acaricide that has formula C9H11Cl3NO3PS." []	EFO	65510	CHEBI:34631	\N	chlorpyrifos	CHEBI:34631
0	"" []	\N	clofibric acid	\N	\N	EFO	"" []	EFO	65511	CHEBI:34648	\N	clofibric acid	CHEBI:34648
0	"" []	\N	diazinon	\N	\N	EFO	"" []	EFO	65512	CHEBI:34682	\N	diazinon	CHEBI:34682
0	"The dibutyl ester of benzene-1,2-dicarboxylic acid." []	\N	dibutyl phthalate	\N	\N	EFO	"The dibutyl ester of benzene-1,2-dicarboxylic acid." []	EFO	65513	CHEBI:34687	\N	dibutyl phthalate	CHEBI:34687
0	"A 3-isobutyl-1-methylxanthine that has formula C10H14N4O2." []	\N	3-isobutyl-1-methyl-7H-xanthine	\N	\N	EFO	"A 3-isobutyl-1-methylxanthine that has formula C10H14N4O2." []	EFO	65514	CHEBI:34795	\N	3-isobutyl-1-methyl-7H-xanthine	CHEBI:34795
0	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	\N	methoprene	\N	\N	EFO	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	EFO	65515	CHEBI:34839	\N	methoprene	CHEBI:34839
0	"" []	\N	N-nitrosodiethylamine	\N	\N	EFO	"" []	EFO	65516	CHEBI:34873	\N	N-nitrosodiethylamine	CHEBI:34873
0	"A thiophene that has formula C14H11N3O3S." []	\N	nocodazole	\N	\N	EFO	"A thiophene that has formula C14H11N3O3S." []	EFO	65517	CHEBI:34892	\N	nocodazole	CHEBI:34892
0	"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)" []	\N	paraquat	\N	\N	EFO	"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)" []	EFO	65518	CHEBI:34905	\N	paraquat	CHEBI:34905
0	"" []	\N	pentachloronitrobenzene	\N	\N	EFO	"" []	EFO	65519	CHEBI:34908	\N	pentachloronitrobenzene	CHEBI:34908
0	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	\N	permethrin	\N	\N	EFO	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	EFO	65520	CHEBI:34911	\N	permethrin	CHEBI:34911
0	"" []	\N	sulmazole	\N	\N	EFO	"" []	EFO	65521	CHEBI:34988	\N	sulmazole	CHEBI:34988
0	"A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain." []	\N	cefuroxime	\N	\N	EFO	"A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain." []	EFO	65522	CHEBI:3515	\N	cefuroxime	CHEBI:3515
0	"A metal sulfate compound having zinc(2+) as the counterion." []	\N	zinc sulfate	\N	\N	EFO	"A metal sulfate compound having zinc(2+) as the counterion." []	EFO	65523	CHEBI:35176	\N	zinc sulfate	CHEBI:35176
0	"A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces." []	\N	surfactant role	\N	\N	EFO	"A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces." []	EFO	65524	CHEBI:35195	\N	surfactant role	CHEBI:35195
0	"An apratoxin that has formula C45H69N5O8S." []	\N	apratoxin A	\N	\N	EFO	"An apratoxin that has formula C45H69N5O8S." []	EFO	65525	CHEBI:35212	\N	apratoxin A	CHEBI:35212
0	"" []	\N	plant growth retardant	\N	\N	EFO	"" []	EFO	65526	CHEBI:35219	\N	plant growth retardant	CHEBI:35219
0	"Substance, structurally similar to a metabolite, which competes with it or replaces it, and so prevents or reduces its normal utilization." []	\N	antimetabolite role	\N	\N	EFO	"Substance, structurally similar to a metabolite, which competes with it or replaces it, and so prevents or reduces its normal utilization." []	EFO	65527	CHEBI:35221	\N	antimetabolite role	CHEBI:35221
0	"A substance that diminishes the rate of a chemical reaction." []	\N	inhibitor role	\N	\N	EFO	"A substance that diminishes the rate of a chemical reaction." []	EFO	65528	CHEBI:35222	\N	inhibitor role	CHEBI:35222
0	"A benzofuran that has formula C8H6O." []	\N	1-benzofuran	\N	\N	EFO	"A benzofuran that has formula C8H6O." []	EFO	65529	CHEBI:35260	\N	1-benzofuran	CHEBI:35260
0	"Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids." []	\N	steroid	\N	\N	EFO	"Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids." []	EFO	65530	CHEBI:35341	\N	steroid	CHEBI:35341
0	"A substance used in the treatment or control of nematode infestations." []	\N	antinematodal drug	\N	\N	EFO	"A substance used in the treatment or control of nematode infestations." []	EFO	65531	CHEBI:35444	\N	antinematodal drug	CHEBI:35444
0	"" []	\N	polychlorinated biphenyls	\N	\N	EFO	"" []	EFO	65532	CHEBI:35446	\N	polychlorinated biphenyls	CHEBI:35446
0	"" []	\N	1-naphthyl isothiocyanate	\N	\N	EFO	"" []	EFO	65533	CHEBI:35455	\N	1-naphthyl isothiocyanate	CHEBI:35455
0	"" []	\N	angiotensin-converting enzyme inhibitor	\N	\N	EFO	"" []	EFO	65534	CHEBI:35457	\N	angiotensin-converting enzyme inhibitor	CHEBI:35457
0	"" []	\N	antidepressant	\N	\N	EFO	"" []	EFO	65535	CHEBI:35469	\N	antidepressant	CHEBI:35469
0	"A substance that reduces or suppresses inflammation." []	\N	anti-inflammatory drug	\N	\N	EFO	"A substance that reduces or suppresses inflammation." []	EFO	65536	CHEBI:35472	\N	anti-inflammatory drug	CHEBI:35472
0	"An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins." []	\N	non-steroidal anti-inflammatory drug	\N	\N	EFO	"An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins." []	EFO	65537	CHEBI:35475	\N	non-steroidal anti-inflammatory drug	CHEBI:35475
0	"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect." []	\N	antipsychotic drug	\N	\N	EFO	"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect." []	EFO	65538	CHEBI:35476	\N	antipsychotic drug	CHEBI:35476
0	"Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders." []	\N	antimanic drug	\N	\N	EFO	"Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders." []	EFO	65539	CHEBI:35477	\N	antimanic drug	CHEBI:35477
0	"A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors." []	\N	non-narcotic analgesic	\N	\N	EFO	"A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors." []	EFO	65540	CHEBI:35481	\N	non-narcotic analgesic	CHEBI:35481
0	"A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever." []	\N	antipyretic	\N	\N	EFO	"A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever." []	EFO	65541	CHEBI:35493	\N	antipyretic	CHEBI:35493
0	"An agent that selectively binds to and activates beta-adrenergic receptors." []	\N	beta-adrenergic agonist	\N	\N	EFO	"An agent that selectively binds to and activates beta-adrenergic receptors." []	EFO	65542	CHEBI:35522	\N	beta-adrenergic agonist	CHEBI:35522
0	"A drug which lowers the blood glucose level." []	\N	hypoglycemic drug	\N	\N	EFO	"A drug which lowers the blood glucose level." []	EFO	65543	CHEBI:35526	\N	hypoglycemic drug	CHEBI:35526
0	"A compound or agent that combines with cyclooxygenases and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes." []	\N	cyclooxygenase inhibitor	\N	\N	EFO	"A compound or agent that combines with cyclooxygenases and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes." []	EFO	65544	CHEBI:35544	\N	cyclooxygenase inhibitor	CHEBI:35544
0	"" []	\N	perfluorodecanoic acid	\N	\N	EFO	"" []	EFO	65545	CHEBI:35546	\N	perfluorodecanoic acid	CHEBI:35546
0	"" []	\N	perhexiline	\N	\N	EFO	"" []	EFO	65546	CHEBI:35553	\N	perhexiline	CHEBI:35553
0	"A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume." []	\N	cardiovascular drug	\N	\N	EFO	"A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume." []	EFO	65547	CHEBI:35554	\N	cardiovascular drug	CHEBI:35554
0	"" []	\N	furan	\N	\N	EFO	"" []	EFO	65548	CHEBI:35559	\N	furan	CHEBI:35559
0	"" []	\N	alpha-adrenergic agonist	\N	\N	EFO	"" []	EFO	65549	CHEBI:35569	\N	alpha-adrenergic agonist	CHEBI:35569
0	"A nitrile that has formula C22H31NO2." []	\N	pregnenolone 16alpha-carbonitrile	\N	\N	EFO	"A nitrile that has formula C22H31NO2." []	EFO	65550	CHEBI:35591	\N	pregnenolone 16alpha-carbonitrile	CHEBI:35591
0	"" []	\N	isoxazole	\N	\N	EFO	"" []	EFO	65551	CHEBI:35595	\N	isoxazole	CHEBI:35595
0	"A substance that inhibits or prevents the proliferation of neoplasms." []	\N	antineoplastic agent	\N	\N	EFO	"A substance that inhibits or prevents the proliferation of neoplasms." []	EFO	65552	CHEBI:35610	\N	antineoplastic agent	CHEBI:35610
0	"A drug used to cause dilation of the blood vessels." []	\N	vasodilator agent	\N	\N	EFO	"A drug used to cause dilation of the blood vessels." []	EFO	65553	CHEBI:35620	\N	vasodilator agent	CHEBI:35620
0	"A drug used to prevent seizures or reduce their severity." []	\N	anticonvulsant	\N	\N	EFO	"A drug used to prevent seizures or reduce their severity." []	EFO	65554	CHEBI:35623	\N	anticonvulsant	CHEBI:35623
0	"Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin." []	\N	adrenergic uptake inhibitor	\N	\N	EFO	"Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin." []	EFO	65555	CHEBI:35640	\N	adrenergic uptake inhibitor	CHEBI:35640
0	"" []	\N	thiopurines	\N	\N	EFO	"" []	EFO	65556	CHEBI:35666	\N	thiopurines	CHEBI:35666
0	"A substance used to treat hyperlipidemia (an excess of lipids in the blood)." []	\N	antilipemic drug	\N	\N	EFO	"A substance used to treat hyperlipidemia (an excess of lipids in the blood)." []	EFO	65557	CHEBI:35679	\N	antilipemic drug	CHEBI:35679
0	"foreign\\"; bios \\"life" []	\N	xenobiotic	\N	\N	EFO	"foreign\\"; bios \\"life" []	EFO	65558	CHEBI:35703	\N	xenobiotic	CHEBI:35703
0	"An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response." []	\N	immunosuppressive agent	\N	\N	EFO	"An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response." []	EFO	65559	CHEBI:35705	\N	immunosuppressive agent	CHEBI:35705
0	"A drug used to induce drowsiness or sleep or to reduce psychological excitement or anxiety." []	\N	sedative drug	\N	\N	EFO	"A drug used to induce drowsiness or sleep or to reduce psychological excitement or anxiety." []	EFO	65560	CHEBI:35717	\N	sedative drug	CHEBI:35717
0	"A substance that destroys fungi by suppressing their ability to grow or reproduce. Antifungal drugs differ from industrial fungicides in that they defend against fungi present in human or animal tissues." []	\N	antifungal drug	\N	\N	EFO	"A substance that destroys fungi by suppressing their ability to grow or reproduce. Antifungal drugs differ from industrial fungicides in that they defend against fungi present in human or animal tissues." []	EFO	65561	CHEBI:35718	\N	antifungal drug	CHEBI:35718
0	"" []	\N	N-nitrosodimethylamine	\N	\N	EFO	"" []	EFO	65562	CHEBI:35807	\N	N-nitrosodimethylamine	CHEBI:35807
0	"A substance used to lower plasma cholesterol levels." []	\N	anticholesteremic drug	\N	\N	EFO	"A substance used to lower plasma cholesterol levels." []	EFO	65563	CHEBI:35821	\N	anticholesteremic drug	CHEBI:35821
0	"A drug used to treat rheumatoid arthritis." []	\N	antirheumatic drug	\N	\N	EFO	"A drug used to treat rheumatoid arthritis." []	EFO	65564	CHEBI:35842	\N	antirheumatic drug	CHEBI:35842
0	"" []	\N	antibacterial drug	\N	\N	EFO	"" []	EFO	65565	CHEBI:36047	\N	antibacterial drug	CHEBI:36047
0	"A protein is an (also known as polypeptides) organic compound made of amino acids arranged in a linear chain and folded into a globular form." []	\N	protein	\N	\N	EFO	"A protein is an (also known as polypeptides) organic compound made of amino acids arranged in a linear chain and folded into a globular form." []	EFO	65566	CHEBI:36080	\N	protein	CHEBI:36080
0	"A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge." []	\N	chlorhexidine	\N	\N	EFO	"A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge." []	EFO	65567	CHEBI:3614	\N	chlorhexidine	CHEBI:3614
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	chloroquine	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65568	CHEBI:3638	\N	chloroquine	CHEBI:3638
0	"A strontium salt that has formula Cl2Sr." []	\N	strontium chloride	\N	\N	EFO	"A strontium salt that has formula Cl2Sr." []	EFO	65569	CHEBI:36383	\N	strontium chloride	CHEBI:36383
0	"" []	\N	chlorpromazine	\N	\N	EFO	"" []	EFO	65570	CHEBI:3647	\N	chlorpromazine	CHEBI:3647
0	"" []	\N	chlorpropamide	\N	\N	EFO	"" []	EFO	65571	CHEBI:3650	\N	chlorpropamide	CHEBI:3650
0	"A sapphyrin that has formula C24H17N5." []	\N	sapphyrin	\N	\N	EFO	"A sapphyrin that has formula C24H17N5." []	EFO	65572	CHEBI:36779	\N	sapphyrin	CHEBI:36779
0	"" []	\N	campestanol	\N	\N	EFO	"" []	EFO	65573	CHEBI:36799	\N	campestanol	CHEBI:36799
0	"" []	\N	cimetidine	\N	\N	EFO	"" []	EFO	65574	CHEBI:3699	\N	cimetidine	CHEBI:3699
0	"" []	\N	citalopram	\N	\N	EFO	"" []	EFO	65575	CHEBI:3723	\N	citalopram	CHEBI:3723
0	"A heterodetic cyclic peptide that has formula C39H54N10O14S." []	\N	alpha-amanitin	\N	\N	EFO	"A heterodetic cyclic peptide that has formula C39H54N10O14S." []	EFO	65576	CHEBI:37415	\N	alpha-amanitin	CHEBI:37415
0	"A S-glycosyl compound that has formula C18H33ClN2O5S." []	\N	clindamycin	\N	\N	EFO	"A S-glycosyl compound that has formula C18H33ClN2O5S." []	EFO	65577	CHEBI:3745	\N	clindamycin	CHEBI:3745
0	"" []	\N	clofibrate	\N	\N	EFO	"" []	EFO	65578	CHEBI:3750	\N	clofibrate	CHEBI:3750
0	"Commonly employed in biomedical research to activate the signal transduction enzyme protein kinase." []	\N	phorbol 13-acetate 12-myristate	\N	\N	EFO	"Commonly employed in biomedical research to activate the signal transduction enzyme protein kinase." []	EFO	65579	CHEBI:37537	\N	phorbol 13-acetate 12-myristate	CHEBI:37537
0	"" []	\N	clomipramine hydrochloride	\N	\N	EFO	"" []	EFO	65580	CHEBI:3755	\N	clomipramine hydrochloride	CHEBI:3755
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	sphingosine 1-phosphate	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65581	CHEBI:37550	\N	sphingosine 1-phosphate	CHEBI:37550
0	"A molecular entity consisting of two or more chemical elements." []	\N	chemical compound	\N	\N	EFO	"A molecular entity consisting of two or more chemical elements." []	EFO	65582	CHEBI:37577	\N	chemical compound	CHEBI:37577
0	"An imidazole that has formula C22H17ClN2." []	\N	clotrimazole	\N	\N	EFO	"An imidazole that has formula C22H17ClN2." []	EFO	65583	CHEBI:3764	\N	clotrimazole	CHEBI:3764
0	"" []	\N	clozapine	\N	\N	EFO	"" []	EFO	65584	CHEBI:3766	\N	clozapine	CHEBI:3766
0	"\\"A beta-D-glucan in which the glucose units are connected by (1->3) linkages.\\" []" []	\N	(1->3)-beta-D-glucan	\N	\N	EFO	"\\"A beta-D-glucan in which the glucose units are connected by (1->3) linkages.\\" []" []	EFO	65585	CHEBI:37671	\N	(1->3)-beta-D-glucan	CHEBI:37671
0	"" []	\N	mannose	\N	\N	EFO	"" []	EFO	65586	CHEBI:37684	\N	mannose	CHEBI:37684
0	"An agent that inhibits protein kinases." []	\N	protein kinase inhibitor	\N	\N	EFO	"An agent that inhibits protein kinases." []	EFO	65587	CHEBI:37699	\N	protein kinase inhibitor	CHEBI:37699
0	"" []	\N	protein kinase C inhibitor	\N	\N	EFO	"" []	EFO	65588	CHEBI:37700	\N	protein kinase C inhibitor	CHEBI:37700
0	"" []	\N	cholinesterase inhibitor	\N	\N	EFO	"" []	EFO	65589	CHEBI:37733	\N	cholinesterase inhibitor	CHEBI:37733
0	"" []	\N	iodoform	\N	\N	EFO	"" []	EFO	65590	CHEBI:37758	\N	iodoform	CHEBI:37758
0	"A hormone that specifically regulates growth." []	\N	growth hormone	\N	\N	EFO	"A hormone that specifically regulates growth." []	EFO	65591	CHEBI:37845	\N	growth hormone	CHEBI:37845
0	"" []	\N	plant growth hormone	\N	\N	EFO	"" []	EFO	65592	CHEBI:37848	\N	plant growth hormone	CHEBI:37848
0	"An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists." []	\N	adrenergic antagonist	\N	\N	EFO	"An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists." []	EFO	65593	CHEBI:37887	\N	adrenergic antagonist	CHEBI:37887
0	"An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma." []	\N	alpha-adrenergic antagonist	\N	\N	EFO	"An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma." []	EFO	65594	CHEBI:37890	\N	alpha-adrenergic antagonist	CHEBI:37890
0	"" []	\N	phenothiazine antipsychotic drug	\N	\N	EFO	"" []	EFO	65595	CHEBI:37930	\N	phenothiazine antipsychotic drug	CHEBI:37930
0	"Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists." []	\N	histamine antagonist	\N	\N	EFO	"Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists." []	EFO	65596	CHEBI:37956	\N	histamine antagonist	CHEBI:37956
0	"" []	\N	dye role	\N	\N	EFO	"" []	EFO	65597	CHEBI:37960	\N	dye role	CHEBI:37960
0	"" []	\N	Cy3 dye	\N	\N	EFO	"" []	EFO	65598	CHEBI:37987	\N	Cy3 dye	CHEBI:37987
0	"" []	\N	Cy5 dye	\N	\N	EFO	"" []	EFO	65599	CHEBI:37989	\N	Cy5 dye	CHEBI:37989
0	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	\N	methyltrienolone	\N	\N	EFO	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	EFO	65600	CHEBI:379896	\N	methyltrienolone	CHEBI:379896
0	"A triazole that has formula C15H18ClN3O." []	\N	uniconazole-P	\N	\N	EFO	"A triazole that has formula C15H18ClN3O." []	EFO	65601	CHEBI:38000	\N	uniconazole-P	CHEBI:38000
0	"" []	\N	antimalarial	\N	\N	EFO	"" []	EFO	65602	CHEBI:38068	\N	antimalarial	CHEBI:38068
0	"" []	\N	anti-arrhythmia drug	\N	\N	EFO	"" []	EFO	65603	CHEBI:38070	\N	anti-arrhythmia drug	CHEBI:38070
0	"A drug that has a strengthening effect on the heart or that can increase cardiac output." []	\N	cardiotonic drug	\N	\N	EFO	"A drug that has a strengthening effect on the heart or that can increase cardiac output." []	EFO	65604	CHEBI:38147	\N	cardiotonic drug	CHEBI:38147
0	"A bromate salt that has formula BrKO3." []	\N	potassium bromate	\N	\N	EFO	"A bromate salt that has formula BrKO3." []	EFO	65605	CHEBI:38211	\N	potassium bromate	CHEBI:38211
0	"One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools." []	\N	calcium channel blocker	\N	\N	EFO	"One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools." []	EFO	65606	CHEBI:38215	\N	calcium channel blocker	CHEBI:38215
0	"Any substance that inhibits the enzyme acetylcholinesterase from breaking down acetylcholine into choline and acetic acid." []	\N	acetylcholinesterase inhibitor	\N	\N	EFO	"Any substance that inhibits the enzyme acetylcholinesterase from breaking down acetylcholine into choline and acetic acid." []	EFO	65607	CHEBI:38462	\N	acetylcholinesterase inhibitor	CHEBI:38462
0	"A nitrile that has formula C2H3N." []	\N	acetonitrile	\N	\N	EFO	"A nitrile that has formula C2H3N." []	EFO	65608	CHEBI:38472	\N	acetonitrile	CHEBI:38472
0	"" []	\N	mitochondrial NADH:ubiquinone reductase inhibitor	\N	\N	EFO	"" []	EFO	65609	CHEBI:38498	\N	mitochondrial NADH:ubiquinone reductase inhibitor	CHEBI:38498
0	"" []	\N	rosuvastatin	\N	\N	EFO	"" []	EFO	65610	CHEBI:38545	\N	rosuvastatin	CHEBI:38545
0	"" []	\N	cytochrome P450	\N	\N	EFO	"" []	EFO	65611	CHEBI:38559	\N	cytochrome P450	CHEBI:38559
0	"A quinazoline that has formula C20H22N2O." []	\N	fenazaquin	\N	\N	EFO	"A quinazoline that has formula C20H22N2O." []	EFO	65612	CHEBI:38593	\N	fenazaquin	CHEBI:38593
0	"" []	\N	tyrosine kinase inhibitor	\N	\N	EFO	"" []	EFO	65613	CHEBI:38637	\N	tyrosine kinase inhibitor	CHEBI:38637
0	"An organothiophosphate insecticide that has formula C11H12NO4PS2." []	\N	phosmet	\N	\N	EFO	"An organothiophosphate insecticide that has formula C11H12NO4PS2." []	EFO	65614	CHEBI:38786	\N	phosmet	CHEBI:38786
0	"A surfactant with an uncharged hydrophilic headgroup." []	\N	non ionic surfactant role	\N	\N	EFO	"A surfactant with an uncharged hydrophilic headgroup." []	EFO	65615	CHEBI:38828	\N	non ionic surfactant role	CHEBI:38828
0	"" []	\N	tetrafluoroethene	\N	\N	EFO	"" []	EFO	65616	CHEBI:38866	\N	tetrafluoroethene	CHEBI:38866
0	"" []	\N	inhalation anaesthetic	\N	\N	EFO	"" []	EFO	65617	CHEBI:38870	\N	inhalation anaesthetic	CHEBI:38870
0	"" []	\N	intravenous anaesthetic	\N	\N	EFO	"" []	EFO	65618	CHEBI:38877	\N	intravenous anaesthetic	CHEBI:38877
0	"A polypeptide hormone produced and secreted by the pituitary gland comprising 39 amino acid residues coupled in a linear sequence. The N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). It is used in the treatment of certain neurological disorders such as infantile spasms and multiple sclerosis, and diagnostically to investigate adrenocortical insufficiency." []	\N	adrenocorticotropic hormone	\N	\N	EFO	"A polypeptide hormone produced and secreted by the pituitary gland comprising 39 amino acid residues coupled in a linear sequence. The N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). It is used in the treatment of certain neurological disorders such as infantile spasms and multiple sclerosis, and diagnostically to investigate adrenocortical insufficiency." []	EFO	65619	CHEBI:3892	\N	adrenocorticotropic hormone	CHEBI:3892
0	"A pyrrole that has formula C22H27FN4O2." []	\N	sunitinib	\N	\N	EFO	"A pyrrole that has formula C22H27FN4O2." []	EFO	65620	CHEBI:38940	\N	sunitinib	CHEBI:38940
0	"" []	\N	low-density lipoprotein	\N	\N	EFO	"" []	EFO	65621	CHEBI:39026	\N	low-density lipoprotein	CHEBI:39026
0	"" []	\N	pyrethroid ester insecticide	\N	\N	EFO	"" []	EFO	65622	CHEBI:39116	\N	pyrethroid ester insecticide	CHEBI:39116
0	"" []	\N	(E)-clothianidin	\N	\N	EFO	"" []	EFO	65623	CHEBI:39177	\N	(E)-clothianidin	CHEBI:39177
0	"Mixture of 80% avermectin B1a and 20% avermectin B1b." []	\N	abamectin	\N	\N	EFO	"Mixture of 80% avermectin B1a and 20% avermectin B1b." []	EFO	65624	CHEBI:39214	\N	abamectin	CHEBI:39214
0	"" []	\N	dibenzothiazepine	\N	\N	EFO	"" []	EFO	65625	CHEBI:39268	\N	dibenzothiazepine	CHEBI:39268
0	"" []	\N	dinitrophenol	\N	\N	EFO	"" []	EFO	65626	CHEBI:39352	\N	dinitrophenol	CHEBI:39352
0	"This gene is involved in cell adhesion, differentiation, division and stress response." []	\N	lufenuron	\N	\N	EFO	"This gene is involved in cell adhesion, differentiation, division and stress response." []	EFO	65627	CHEBI:39384	\N	lufenuron	CHEBI:39384
0	"Human CD82 wild-type allele is located in the vicinity of 11p11.2 and is approximately 54 kb in length. This allele, which encodes CD82 antigen Immunoprotein, is involved in metastasis suppression." []	\N	atorvastatin	\N	\N	EFO	"Human CD82 wild-type allele is located in the vicinity of 11p11.2 and is approximately 54 kb in length. This allele, which encodes CD82 antigen Immunoprotein, is involved in metastasis suppression." []	EFO	65628	CHEBI:39548	\N	atorvastatin	CHEBI:39548
0	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	\N	curcumin	\N	\N	EFO	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	EFO	65629	CHEBI:3962	\N	curcumin	CHEBI:3962
0	"" []	\N	valproic acid	\N	\N	EFO	"" []	EFO	65630	CHEBI:39867	\N	valproic acid	CHEBI:39867
0	"" []	\N	cyclophosphamide hydrate	\N	\N	EFO	"" []	EFO	65631	CHEBI:4026	\N	cyclophosphamide hydrate	CHEBI:4026
0	"Human CXCL10 wild-type allele is located within 4q21 and is approximately 2 kb in length. This allele, which encodes small inducible cytokine B10 protein, plays a role in both immune cell migration and in the modulation of adhesion molecule expression." []	\N	cyclophosphamide	\N	\N	EFO	"Human CXCL10 wild-type allele is located within 4q21 and is approximately 2 kb in length. This allele, which encodes small inducible cytokine B10 protein, plays a role in both immune cell migration and in the modulation of adhesion molecule expression." []	EFO	65632	CHEBI:4027	\N	cyclophosphamide	CHEBI:4027
0	"" []	\N	allopurinol	\N	\N	EFO	"" []	EFO	65633	CHEBI:40279	\N	allopurinol	CHEBI:40279
0	"" []	\N	cyfluthrin	\N	\N	EFO	"" []	EFO	65634	CHEBI:4034	\N	cyfluthrin	CHEBI:4034
0	"" []	\N	azoxystrobin	\N	\N	EFO	"" []	EFO	65635	CHEBI:40909	\N	azoxystrobin	CHEBI:40909
0	"A pyrazole that has formula C17H14F3N3O2S." []	\N	celecoxib	\N	\N	EFO	"A pyrazole that has formula C17H14F3N3O2S." []	EFO	65636	CHEBI:41423	\N	celecoxib	CHEBI:41423
0	"" []	\N	4-phenylbutyric acid	\N	\N	EFO	"" []	EFO	65637	CHEBI:41500	\N	4-phenylbutyric acid	CHEBI:41500
0	"" []	\N	tamoxifen	\N	\N	EFO	"" []	EFO	65638	CHEBI:41774	\N	tamoxifen	CHEBI:41774
0	"A fluorinated steroid that has formula C22H29FO5." []	\N	dexamethasone	\N	\N	EFO	"A fluorinated steroid that has formula C22H29FO5." []	EFO	65639	CHEBI:41879	\N	dexamethasone	CHEBI:41879
0	"An estrogen that has formula C18H20O2." []	\N	diethylstilbestrol	\N	\N	EFO	"An estrogen that has formula C18H20O2." []	EFO	65640	CHEBI:41922	\N	diethylstilbestrol	CHEBI:41922
0	"The sixth of the seven cervical vertebrae." []	\N	2,4-dinitrophenol	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65641	CHEBI:42017	\N	2,4-dinitrophenol	CHEBI:42017
0	"" []	\N	(R)-lactic acid	\N	\N	EFO	"" []	EFO	65642	CHEBI:42111	\N	(R)-lactic acid	CHEBI:42111
0	"" []	\N	ethylenediaminetetraacetic acid	\N	\N	EFO	"" []	EFO	65643	CHEBI:42191	\N	ethylenediaminetetraacetic acid	CHEBI:42191
0	"" []	\N	forskolin	\N	\N	EFO	"" []	EFO	65644	CHEBI:42471	\N	forskolin	CHEBI:42471
0	"A member of the flavones that has formula C15H10O2." []	\N	flavone	\N	\N	EFO	"A member of the flavones that has formula C15H10O2." []	EFO	65645	CHEBI:42491	\N	flavone	CHEBI:42491
0	"" []	\N	3-(5-fluorouracil-1-yl)-L-alanine	\N	\N	EFO	"" []	EFO	65646	CHEBI:42549	\N	3-(5-fluorouracil-1-yl)-L-alanine	CHEBI:42549
0	"A tetrahydroxyflavone that has formula C15H10O6." []	\N	fisetin	\N	\N	EFO	"A tetrahydroxyflavone that has formula C15H10O6." []	EFO	65647	CHEBI:42567	\N	fisetin	CHEBI:42567
0	"" []	\N	4-hydroxyphenyl retinamide	\N	\N	EFO	"" []	EFO	65648	CHEBI:42588	\N	4-hydroxyphenyl retinamide	CHEBI:42588
0	"" []	\N	flufenamic acid	\N	\N	EFO	"" []	EFO	65649	CHEBI:42638	\N	flufenamic acid	CHEBI:42638
0	"" []	\N	3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine	\N	\N	EFO	"" []	EFO	65650	CHEBI:42839	\N	3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine	CHEBI:42839
0	"" []	\N	danazol	\N	\N	EFO	"" []	EFO	65651	CHEBI:4315	\N	danazol	CHEBI:4315
0	"" []	\N	dantrolene	\N	\N	EFO	"" []	EFO	65652	CHEBI:4317	\N	dantrolene	CHEBI:4317
0	"" []	\N	dexibuprofen	\N	\N	EFO	"" []	EFO	65653	CHEBI:43415	\N	dexibuprofen	CHEBI:43415
0	"" []	\N	desferrioxamine B	\N	\N	EFO	"" []	EFO	65654	CHEBI:4356	\N	desferrioxamine B	CHEBI:4356
0	"A dipeptide that has formula C21H31N3O5." []	\N	lisinopril	\N	\N	EFO	"A dipeptide that has formula C21H31N3O5." []	EFO	65655	CHEBI:43755	\N	lisinopril	CHEBI:43755
0	"" []	\N	(S)-alpha-methyl-4-carboxyphenylglycine	\N	\N	EFO	"" []	EFO	65656	CHEBI:43876	\N	(S)-alpha-methyl-4-carboxyphenylglycine	CHEBI:43876
0	"" []	\N	(-)-demecolcine	\N	\N	EFO	"" []	EFO	65657	CHEBI:4393	\N	(-)-demecolcine	CHEBI:4393
0	"A pteridine that has formula C20H22N8O5." []	\N	methotrexate	\N	\N	EFO	"A pteridine that has formula C20H22N8O5." []	EFO	65658	CHEBI:44185	\N	methotrexate	CHEBI:44185
0	"" []	\N	nimesulide	\N	\N	EFO	"" []	EFO	65659	CHEBI:44445	\N	nimesulide	CHEBI:44445
0	"\\"An octadeca-10,12-dienoic acid having 10-trans,12-cis-configuration.\\" []" []	\N	10-trans,12-cis-octadecadienoic acid	\N	\N	EFO	"\\"An octadeca-10,12-dienoic acid having 10-trans,12-cis-configuration.\\" []" []	EFO	65660	CHEBI:44526	\N	10-trans,12-cis-octadecadienoic acid	CHEBI:44526
0	"" []	\N	afimoxifene	\N	\N	EFO	"" []	EFO	65661	CHEBI:44616	\N	afimoxifene	CHEBI:44616
0	"A phenol that has formula C12H18O." []	\N	propofol	\N	\N	EFO	"A phenol that has formula C12H18O." []	EFO	65662	CHEBI:44915	\N	propofol	CHEBI:44915
0	"A phenanthroline that has formula C12H8N2." []	\N	1,10-phenanthroline	\N	\N	EFO	"A phenanthroline that has formula C12H8N2." []	EFO	65663	CHEBI:44975	\N	1,10-phenanthroline	CHEBI:44975
0	"" []	\N	pentamidine	\N	\N	EFO	"" []	EFO	65664	CHEBI:45081	\N	pentamidine	CHEBI:45081
0	"The sodium salt of diclofenac." []	\N	diclofenac sodium	\N	\N	EFO	"The sodium salt of diclofenac." []	EFO	65665	CHEBI:4509	\N	diclofenac sodium	CHEBI:4509
0	"" []	\N	praziquantel	\N	\N	EFO	"" []	EFO	65666	CHEBI:45267	\N	praziquantel	CHEBI:45267
0	"A N-methylpiperazine that has formula C29H31N7O." []	\N	imatinib	\N	\N	EFO	"A N-methylpiperazine that has formula C29H31N7O." []	EFO	65667	CHEBI:45783	\N	imatinib	CHEBI:45783
0	"" []	\N	paclitaxel	\N	\N	EFO	"" []	EFO	65668	CHEBI:45863	\N	paclitaxel	CHEBI:45863
0	"" []	\N	trifluoperazine	\N	\N	EFO	"" []	EFO	65669	CHEBI:45951	\N	trifluoperazine	CHEBI:45951
0	"\\"An aromatic amine that has formula C13H14N2.\\" []" []	\N	tacrine	\N	\N	EFO	"\\"An aromatic amine that has formula C13H14N2.\\" []" []	EFO	65670	CHEBI:45980	\N	tacrine	CHEBI:45980
0	"" []	\N	2,4,6-trinitrotoluene	\N	\N	EFO	"" []	EFO	65671	CHEBI:46053	\N	2,4,6-trinitrotoluene	CHEBI:46053
0	"A triazole that has formula C13H12F2N6O." []	\N	fluconazole	\N	\N	EFO	"A triazole that has formula C13H12F2N6O." []	EFO	65672	CHEBI:46081	\N	fluconazole	CHEBI:46081
0	"" []	\N	paracetamol	\N	\N	EFO	"" []	EFO	65673	CHEBI:46195	\N	paracetamol	CHEBI:46195
0	"" []	\N	5-fluorouracil	\N	\N	EFO	"" []	EFO	65674	CHEBI:46345	\N	5-fluorouracil	CHEBI:46345
0	"" []	\N	zardaverine	\N	\N	EFO	"" []	EFO	65675	CHEBI:46548	\N	zardaverine	CHEBI:46548
0	"" []	\N	disopyramide	\N	\N	EFO	"" []	EFO	65676	CHEBI:4657	\N	disopyramide	CHEBI:4657
0	"" []	\N	disulfiram	\N	\N	EFO	"" []	EFO	65677	CHEBI:4659	\N	disulfiram	CHEBI:4659
0	"Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements." []	\N	asbestos	\N	\N	EFO	"Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements." []	EFO	65678	CHEBI:46661	\N	asbestos	CHEBI:46661
0	"A polymer composed of repeating ethyleneoxy units." []	\N	polyethylene glycol	\N	\N	EFO	"A polymer composed of repeating ethyleneoxy units." []	EFO	65679	CHEBI:46793	\N	polyethylene glycol	CHEBI:46793
0	"" []	\N	polidocanol	\N	\N	EFO	"" []	EFO	65680	CHEBI:46859	\N	polidocanol	CHEBI:46859
0	"A diacyl lipopeptide that has formula C65H126N10O12S." []	\N	S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys	\N	\N	EFO	"A diacyl lipopeptide that has formula C65H126N10O12S." []	EFO	65681	CHEBI:46889	\N	S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys	CHEBI:46889
0	"The determination of the amount of complement C4 present in a sample." []	\N	1-4-dioxane	\N	\N	EFO	"The determination of the amount of complement C4 present in a sample." []	EFO	65682	CHEBI:47032	\N	1-4-dioxane	CHEBI:47032
0	"A non-steroidal anti-inflammatory drug (NSAID), administered primarily as its sodium salt." []	\N	diclofenac	\N	\N	EFO	"A non-steroidal anti-inflammatory drug (NSAID), administered primarily as its sodium salt." []	EFO	65683	CHEBI:47381	\N	diclofenac	CHEBI:47381
0	"A cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side groups." []	\N	cefazolin	\N	\N	EFO	"A cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side groups." []	EFO	65684	CHEBI:474053	\N	cefazolin	CHEBI:474053
0	"A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall." []	\N	caspofungin	\N	\N	EFO	"A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall." []	EFO	65685	CHEBI:474180	\N	caspofungin	CHEBI:474180
0	"" []	\N	furosemide	\N	\N	EFO	"" []	EFO	65686	CHEBI:47426	\N	furosemide	CHEBI:47426
0	"" []	\N	imipramine	\N	\N	EFO	"" []	EFO	65687	CHEBI:47499	\N	imipramine	CHEBI:47499
0	"" []	\N	cis-ketoconazole	\N	\N	EFO	"" []	EFO	65688	CHEBI:47519	\N	cis-ketoconazole	CHEBI:47519
0	"" []	\N	bezafibrate	\N	\N	EFO	"" []	EFO	65689	CHEBI:47612	\N	bezafibrate	CHEBI:47612
0	"Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol." []	\N	HDL cholesterol	\N	\N	EFO	"Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol." []	EFO	65690	CHEBI:47775	\N	HDL cholesterol	CHEBI:47775
0	"" []	\N	clomipramine	\N	\N	EFO	"" []	EFO	65691	CHEBI:47780	\N	clomipramine	CHEBI:47780
0	"" []	\N	dibenzazepines	\N	\N	EFO	"" []	EFO	65692	CHEBI:47804	\N	dibenzazepines	CHEBI:47804
0	"A sulfoxide that has formula C6H11NOS2." []	\N	sulforaphane	\N	\N	EFO	"A sulfoxide that has formula C6H11NOS2." []	EFO	65693	CHEBI:47807	\N	sulforaphane	CHEBI:47807
0	"" []	\N	enalapril	\N	\N	EFO	"" []	EFO	65694	CHEBI:4784	\N	enalapril	CHEBI:4784
0	"" []	\N	HC toxin	\N	\N	EFO	"" []	EFO	65695	CHEBI:48028	\N	HC toxin	CHEBI:48028
0	"" []	\N	epigallocatechin gallate	\N	\N	EFO	"" []	EFO	65696	CHEBI:4806	\N	epigallocatechin gallate	CHEBI:4806
0	"" []	\N	antiseptic drug	\N	\N	EFO	"" []	EFO	65697	CHEBI:48218	\N	antiseptic drug	CHEBI:48218
0	"" []	\N	trichlorofluoromethane	\N	\N	EFO	"" []	EFO	65698	CHEBI:48236	\N	trichlorofluoromethane	CHEBI:48236
0	"" []	\N	serotonergic drug	\N	\N	EFO	"" []	EFO	65699	CHEBI:48278	\N	serotonergic drug	CHEBI:48278
0	"Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists." []	\N	serotonergic antagonist	\N	\N	EFO	"Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists." []	EFO	65700	CHEBI:48279	\N	serotonergic antagonist	CHEBI:48279
0	"" []	\N	polar solvent role	\N	\N	EFO	"" []	EFO	65701	CHEBI:48354	\N	polar solvent role	CHEBI:48354
0	"" []	\N	polar aprotic solvent role	\N	\N	EFO	"" []	EFO	65702	CHEBI:48358	\N	polar aprotic solvent role	CHEBI:48358
0	"An oxazinooxazine that has formula C12H23NO2." []	\N	amphiprotic solvent role	\N	\N	EFO	"An oxazinooxazine that has formula C12H23NO2." []	EFO	65703	CHEBI:4836	\N	amphiprotic solvent role	CHEBI:4836
0	"" []	\N	but-1-ene	\N	\N	EFO	"" []	EFO	65704	CHEBI:48362	\N	but-1-ene	CHEBI:48362
0	"A biphenylyltetrazole that has formula C24H26N6O3." []	\N	olmesartan	\N	\N	EFO	"A biphenylyltetrazole that has formula C24H26N6O3." []	EFO	65705	CHEBI:48416	\N	olmesartan	CHEBI:48416
0	"" []	\N	angiotensin II	\N	\N	EFO	"" []	EFO	65706	CHEBI:48432	\N	angiotensin II	CHEBI:48432
0	"\\"A ring assembly that has formula C23H26N2O.\\" []" []	\N	roxindole	\N	\N	EFO	"\\"A ring assembly that has formula C23H26N2O.\\" []" []	EFO	65707	CHEBI:48558	\N	roxindole	CHEBI:48558
0	"A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists." []	\N	dopaminergic antagonist	\N	\N	EFO	"A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists." []	EFO	65708	CHEBI:48561	\N	dopaminergic antagonist	CHEBI:48561
0	"" []	\N	phenylbutazone	\N	\N	EFO	"" []	EFO	65709	CHEBI:48574	\N	phenylbutazone	CHEBI:48574
0	"" []	\N	ethambutol	\N	\N	EFO	"" []	EFO	65710	CHEBI:4877	\N	ethambutol	CHEBI:4877
0	"A selenite salt that has formula Na2O3Se." []	\N	sodium selenite	\N	\N	EFO	"A selenite salt that has formula Na2O3Se." []	EFO	65711	CHEBI:48843	\N	sodium selenite	CHEBI:48843
0	"" []	\N	ethionamide	\N	\N	EFO	"" []	EFO	65712	CHEBI:4885	\N	ethionamide	CHEBI:4885
0	"A benzodiazepine (sometimes colloquially \\"benzo\\"; often abbreviated \\"BZD\\") is a psychoactive drug whose core chemical structure is the fusion of a benzene ring and a diazepine ring. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and made available in 1960 by Hoffmann La Roche, which has also marketed diazepam (Valium) since 1963.[1]" []	\N	benzothiadiazole	\N	\N	EFO	"A benzodiazepine (sometimes colloquially \\"benzo\\"; often abbreviated \\"BZD\\") is a psychoactive drug whose core chemical structure is the fusion of a benzene ring and a diazepine ring. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and made available in 1960 by Hoffmann La Roche, which has also marketed diazepam (Valium) since 1963.[1]" []	EFO	65713	CHEBI:48864	\N	benzothiadiazole	CHEBI:48864
0	"Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists." []	\N	cholinergic antagonist	\N	\N	EFO	"Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists." []	EFO	65714	CHEBI:48873	\N	cholinergic antagonist	CHEBI:48873
0	"A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists." []	\N	muscarinic antagonist	\N	\N	EFO	"A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists." []	EFO	65715	CHEBI:48876	\N	muscarinic antagonist	CHEBI:48876
0	"" []	\N	17alpha-ethynylestradiol	\N	\N	EFO	"" []	EFO	65716	CHEBI:4903	\N	17alpha-ethynylestradiol	CHEBI:4903
0	"A beta-D-glucoside that has formula C29H32O13." []	\N	etoposide	\N	\N	EFO	"A beta-D-glucoside that has formula C29H32O13." []	EFO	65717	CHEBI:4911	\N	etoposide	CHEBI:4911
0	"A guaiacol with an allyl chain substituted para to the hydroxy group." []	\N	eugenol	\N	\N	EFO	"A guaiacol with an allyl chain substituted para to the hydroxy group." []	EFO	65718	CHEBI:4917	\N	eugenol	CHEBI:4917
0	"A radiotracer consisting of choline labeled with the positron-emitting isotope carbon C 11 with potential imaging use. Upon administration, C-11 choline incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, an enzyme frequently upregulated in human tumors, yielding phosphoryl C-11 choline. In turn, phosphoryl C-11 choline is integrated into phospholipids in the cell membrane as part of phosphatidylcholine. As the proliferation of cancer cells is much higher than normal cells, tumor cells exhibit an increased rate of C-11 choline uptake and incorporation, allowing tunor imaging with positron emission tomography (PET)." []	\N	methyleugenol	\N	\N	EFO	"A radiotracer consisting of choline labeled with the positron-emitting isotope carbon C 11 with potential imaging use. Upon administration, C-11 choline incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, an enzyme frequently upregulated in human tumors, yielding phosphoryl C-11 choline. In turn, phosphoryl C-11 choline is integrated into phospholipids in the cell membrane as part of phosphatidylcholine. As the proliferation of cancer cells is much higher than normal cells, tumor cells exhibit an increased rate of C-11 choline uptake and incorporation, allowing tunor imaging with positron emission tomography (PET)." []	EFO	65719	CHEBI:4918	\N	methyleugenol	CHEBI:4918
0	"" []	\N	phosphatidylcholine	\N	\N	EFO	"" []	EFO	65720	CHEBI:49183	\N	phosphatidylcholine	CHEBI:49183
0	"A N-(2-hydroxyethyl)piperazine that has formula C22H26ClN7O2S." []	\N	dasatinib	\N	\N	EFO	"A N-(2-hydroxyethyl)piperazine that has formula C22H26ClN7O2S." []	EFO	65721	CHEBI:49375	\N	dasatinib	CHEBI:49375
0	"Androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group.a selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer." []	\N	exemestane	\N	\N	EFO	"Androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group.a selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer." []	EFO	65722	CHEBI:4953	\N	exemestane	CHEBI:4953
0	"Chloride of copper in which the metal is in the +2 oxidation state." []	\N	copper(II) chloride	\N	\N	EFO	"Chloride of copper in which the metal is in the +2 oxidation state." []	EFO	65723	CHEBI:49553	\N	copper(II) chloride	CHEBI:49553
0	"A 1,4-benzodiazepinone that has formula C16H13ClN2O." []	\N	diazepam	\N	\N	EFO	"A 1,4-benzodiazepinone that has formula C16H13ClN2O." []	EFO	65724	CHEBI:49575	\N	diazepam	CHEBI:49575
0	"A quinazoline that has formula C29H26ClFN4O4S." []	\N	lapatinib	\N	\N	EFO	"A quinazoline that has formula C29H26ClFN4O4S." []	EFO	65725	CHEBI:49603	\N	lapatinib	CHEBI:49603
0	"" []	\N	indomethacin	\N	\N	EFO	"" []	EFO	65726	CHEBI:49662	\N	indomethacin	CHEBI:49662
0	"A quinazoline that has formula C22H24ClFN4O3." []	\N	gefitinib	\N	\N	EFO	"A quinazoline that has formula C22H24ClFN4O3." []	EFO	65727	CHEBI:49668	\N	gefitinib	CHEBI:49668
0	"A methylmercury compound that has formula CH3Hg." []	\N	methylmercury	\N	\N	EFO	"A methylmercury compound that has formula CH3Hg." []	EFO	65728	CHEBI:49747	\N	methylmercury	CHEBI:49747
0	"" []	\N	famotidine	\N	\N	EFO	"" []	EFO	65729	CHEBI:4975	\N	famotidine	CHEBI:4975
0	"" []	\N	tetraethylenepentamine	\N	\N	EFO	"" []	EFO	65730	CHEBI:49798	\N	tetraethylenepentamine	CHEBI:49798
0	"\\"The complex formed between iron(III) and citrate.\\" []" []	\N	iron(III) dicitrate	\N	\N	EFO	"\\"The complex formed between iron(III) and citrate.\\" []" []	EFO	65731	CHEBI:4991	\N	iron(III) dicitrate	CHEBI:4991
0	"\\"A chlorobenzophenone that has formula C20H21ClO4.\\" []" []	\N	fenofibrate	\N	\N	EFO	"\\"A chlorobenzophenone that has formula C20H21ClO4.\\" []" []	EFO	65732	CHEBI:5001	\N	fenofibrate	CHEBI:5001
0	"\\"A benzazepine that has formula C16H16ClNO3.\\" []" []	\N	fenoldopam	\N	\N	EFO	"\\"A benzazepine that has formula C16H16ClNO3.\\" []" []	EFO	65733	CHEBI:5002	\N	fenoldopam	CHEBI:5002
0	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	\N	imidazole	\N	\N	EFO	"This gene plays a regulatory role in the complement pathway, which is comprised of a complex proteolytic cascade." []	EFO	65734	CHEBI:50059	\N	imidazole	CHEBI:50059
0	"A glutathione derivative that has formula C10H16N4O7S." []	\N	S-nitrosoglutathione	\N	\N	EFO	"A glutathione derivative that has formula C10H16N4O7S." []	EFO	65735	CHEBI:50091	\N	S-nitrosoglutathione	CHEBI:50091
0	"" []	\N	bucladesine	\N	\N	EFO	"" []	EFO	65736	CHEBI:50095	\N	bucladesine	CHEBI:50095
0	"An agent that binds to and activates excitatory amino acid receptors." []	\N	excitatory amino acid agonist	\N	\N	EFO	"An agent that binds to and activates excitatory amino acid receptors." []	EFO	65737	CHEBI:50103	\N	excitatory amino acid agonist	CHEBI:50103
0	"Any hormone that is responsible for controlling sexual characteristics and reproductive function." []	\N	sex hormone	\N	\N	EFO	"Any hormone that is responsible for controlling sexual characteristics and reproductive function." []	EFO	65738	CHEBI:50112	\N	sex hormone	CHEBI:50112
0	"A steroid hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors." []	\N	androgen	\N	\N	EFO	"A steroid hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors." []	EFO	65739	CHEBI:50113	\N	androgen	CHEBI:50113
0	"Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds." []	\N	estrogen	\N	\N	EFO	"Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds." []	EFO	65740	CHEBI:50114	\N	estrogen	CHEBI:50114
0	"" []	\N	rosiglitazone	\N	\N	EFO	"" []	EFO	65741	CHEBI:50122	\N	rosiglitazone	CHEBI:50122
0	"" []	\N	5-aza-2'-deoxycytidine	\N	\N	EFO	"" []	EFO	65742	CHEBI:50131	\N	5-aza-2'-deoxycytidine	CHEBI:50131
0	"An indazole that has formula C15H10Cl2N2O2." []	\N	1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid	\N	\N	EFO	"An indazole that has formula C15H10Cl2N2O2." []	EFO	65743	CHEBI:50138	\N	1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid	CHEBI:50138
0	"An organic sodium salt that has formula C3H3NaO3." []	\N	sodium pyruvate	\N	\N	EFO	"An organic sodium salt that has formula C3H3NaO3." []	EFO	65744	CHEBI:50144	\N	sodium pyruvate	CHEBI:50144
0	"A morpholine that has formula C20H33NO." []	\N	fenpropimorph	\N	\N	EFO	"A morpholine that has formula C20H33NO." []	EFO	65745	CHEBI:50148	\N	fenpropimorph	CHEBI:50148
0	"" []	\N	1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane	\N	\N	EFO	"" []	EFO	65746	CHEBI:50154	\N	1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane	CHEBI:50154
0	"A steroid acid anion that has formula C22H29O4." []	\N	canrenoate	\N	\N	EFO	"A steroid acid anion that has formula C22H29O4." []	EFO	65747	CHEBI:50159	\N	canrenoate	CHEBI:50159
0	"A metallotexaphyrin that has formula C52H72GdN5O14." []	\N	motexafin gadolinium	\N	\N	EFO	"A metallotexaphyrin that has formula C52H72GdN5O14." []	EFO	65748	CHEBI:50161	\N	motexafin gadolinium	CHEBI:50161
0	"A drug used to treat or prevent skin disorders or for the routine care of skin." []	\N	dermatologic drug	\N	\N	EFO	"A drug used to treat or prevent skin disorders or for the routine care of skin." []	EFO	65749	CHEBI:50177	\N	dermatologic drug	CHEBI:50177
0	"A razoxane that has formula C11H16N4O4." []	\N	(+)-dexrazoxane	\N	\N	EFO	"A razoxane that has formula C11H16N4O4." []	EFO	65750	CHEBI:50223	\N	(+)-dexrazoxane	CHEBI:50223
0	"An agent that prevents blood clotting." []	\N	anticoagulant	\N	\N	EFO	"An agent that prevents blood clotting." []	EFO	65751	CHEBI:50249	\N	anticoagulant	CHEBI:50249
0	"A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug." []	\N	prodrug role	\N	\N	EFO	"A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug." []	EFO	65752	CHEBI:50266	\N	prodrug role	CHEBI:50266
0	"An inhibitor of bacterial enzymes of the DNA topoisomerases, Type I class that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA." []	\N	topoisomerase I inhibitor	\N	\N	EFO	"An inhibitor of bacterial enzymes of the DNA topoisomerases, Type I class that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA." []	EFO	65753	CHEBI:50276	\N	topoisomerase I inhibitor	CHEBI:50276
0	"A labdane diterpenoid that has formula C22H34O5." []	\N	1,9-dideoxyforskolin	\N	\N	EFO	"A labdane diterpenoid that has formula C22H34O5." []	EFO	65754	CHEBI:50295	\N	1,9-dideoxyforskolin	CHEBI:50295
0	"A parasympatholytic agent is a substance or activity that reduces the activity of the parasympathetic nervous system.[1] (The parasympathetic nervous system is often colloquially described as the \\"Feed and Breed\\" or \\"Rest and Digest\\" portion of the autonomic nervous system. The parasympathetic nervous system becomes strongly engaged during or after a meal and during times when the body is at rest.)\\nThe term parasympatholytic typically refers to the effect of a drug, although some poisons act to block the parasympathetic nervous system as well. Most drugs with parasympatholytic properties are anticholinergics." []	\N	parasympatholytic	\N	\N	EFO	"A parasympatholytic agent is a substance or activity that reduces the activity of the parasympathetic nervous system.[1] (The parasympathetic nervous system is often colloquially described as the \\"Feed and Breed\\" or \\"Rest and Digest\\" portion of the autonomic nervous system. The parasympathetic nervous system becomes strongly engaged during or after a meal and during times when the body is at rest.)\\nThe term parasympatholytic typically refers to the effect of a drug, although some poisons act to block the parasympathetic nervous system as well. Most drugs with parasympatholytic properties are anticholinergics." []	EFO	65755	CHEBI:50370	\N	parasympatholytic	CHEBI:50370
0	"A heme b that has formula C34H32ClFeN4O4." []	\N	hemin	\N	\N	EFO	"A heme b that has formula C34H32ClFeN4O4." []	EFO	65756	CHEBI:50385	\N	hemin	CHEBI:50385
0	"" []	\N	phospholipase A2 inhibitor	\N	\N	EFO	"" []	EFO	65757	CHEBI:50469	\N	phospholipase A2 inhibitor	CHEBI:50469
0	"Compound that increase urine volume by increasing the amount of osmotically active solute in the urine. It also increases the osmolarity of plasma." []	\N	osmotic diuretic	\N	\N	EFO	"Compound that increase urine volume by increasing the amount of osmotically active solute in the urine. It also increases the osmolarity of plasma." []	EFO	65758	CHEBI:50504	\N	osmotic diuretic	CHEBI:50504
0	"Substance that sweeten food, beverages, medications, etc." []	\N	sweetening agent role	\N	\N	EFO	"Substance that sweeten food, beverages, medications, etc." []	EFO	65759	CHEBI:50505	\N	sweetening agent role	CHEBI:50505
0	"Drug used to cause constriction of the blood vessels." []	\N	vasoconstrictor agent	\N	\N	EFO	"Drug used to cause constriction of the blood vessels." []	EFO	65760	CHEBI:50514	\N	vasoconstrictor agent	CHEBI:50514
0	"" []	\N	arsenic oxide	\N	\N	EFO	"" []	EFO	65761	CHEBI:50527	\N	arsenic oxide	CHEBI:50527
0	"A cyclooxygenase inhibitor with specificity for cyclooxygenase 2." []	\N	cyclooxygenase 2 inhibitor	\N	\N	EFO	"A cyclooxygenase inhibitor with specificity for cyclooxygenase 2." []	EFO	65762	CHEBI:50629	\N	cyclooxygenase 2 inhibitor	CHEBI:50629
0	"A cyclooxygenase inhibitor with specificity for cyclooxygenase 1." []	\N	cyclooxygenase 1 inhibitor	\N	\N	EFO	"A cyclooxygenase inhibitor with specificity for cyclooxygenase 1." []	EFO	65763	CHEBI:50630	\N	cyclooxygenase 1 inhibitor	CHEBI:50630
0	"An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat metabolic bone diseases." []	\N	bone density conservation agent	\N	\N	EFO	"An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat metabolic bone diseases." []	EFO	65764	CHEBI:50646	\N	bone density conservation agent	CHEBI:50646
0	"" []	\N	9-cis-retinoic acid	\N	\N	EFO	"" []	EFO	65765	CHEBI:50648	\N	9-cis-retinoic acid	CHEBI:50648
0	"" []	\N	mercaptopurine	\N	\N	EFO	"" []	EFO	65766	CHEBI:50667	\N	mercaptopurine	CHEBI:50667
0	"" []	\N	methimazole	\N	\N	EFO	"" []	EFO	65767	CHEBI:50673	\N	methimazole	CHEBI:50673
0	"" []	\N	folic acid reductase inhibitor	\N	\N	EFO	"" []	EFO	65768	CHEBI:50683	\N	folic acid reductase inhibitor	CHEBI:50683
0	"" []	\N	minocycline	\N	\N	EFO	"" []	EFO	65769	CHEBI:50694	\N	minocycline	CHEBI:50694
0	"A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance." []	\N	nutraceutical	\N	\N	EFO	"A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance." []	EFO	65770	CHEBI:50733	\N	nutraceutical	CHEBI:50733
0	"A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure." []	\N	estrogen receptor modulator	\N	\N	EFO	"A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure." []	EFO	65771	CHEBI:50739	\N	estrogen receptor modulator	CHEBI:50739
0	"An inhibitor of DNA topoisomerase II, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands." []	\N	topoisomerase II inhibitor	\N	\N	EFO	"An inhibitor of DNA topoisomerase II, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands." []	EFO	65772	CHEBI:50750	\N	topoisomerase II inhibitor	CHEBI:50750
0	"" []	\N	aromatase inhibitor	\N	\N	EFO	"" []	EFO	65773	CHEBI:50790	\N	aromatase inhibitor	CHEBI:50790
0	"An antagonist at the estrogen receptor." []	\N	estrogen receptor antagonist role	\N	\N	EFO	"An antagonist at the estrogen receptor." []	EFO	65774	CHEBI:50792	\N	estrogen receptor antagonist role	CHEBI:50792
0	"A pyridazinone that has formula C12H9ClF3N3O." []	\N	norflurazon	\N	\N	EFO	"A pyridazinone that has formula C12H9ClF3N3O." []	EFO	65775	CHEBI:50842	\N	norflurazon	CHEBI:50842
0	"Tetracycline in which the 5beta-hydrogen is replaced by a hydroxy group, while the 6alpha-hydroxy group is replaced by hydrogen. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), and adult periodontitis." []	\N	doxycycline	\N	\N	EFO	"Tetracycline in which the 5beta-hydrogen is replaced by a hydroxy group, while the 6alpha-hydroxy group is replaced by hydrogen. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), and adult periodontitis." []	EFO	65776	CHEBI:50845	\N	doxycycline	CHEBI:50845
0	"" []	\N	antiatherogenic agent	\N	\N	EFO	"" []	EFO	65777	CHEBI:50855	\N	antiatherogenic agent	CHEBI:50855
0	"A naphthalene that has formula C31H33N3O11." []	\N	azinomycin B	\N	\N	EFO	"A naphthalene that has formula C31H33N3O11." []	EFO	65778	CHEBI:50862	\N	azinomycin B	CHEBI:50862
0	"An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma)." []	\N	insulin-sensitizing drug	\N	\N	EFO	"An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma)." []	EFO	65779	CHEBI:50864	\N	insulin-sensitizing drug	CHEBI:50864
0	"A 1,2-dithiole that has formula C3H2S3." []	\N	3H-1,2-dithiole-3-thione	\N	\N	EFO	"A 1,2-dithiole that has formula C3H2S3." []	EFO	65780	CHEBI:50866	\N	3H-1,2-dithiole-3-thione	CHEBI:50866
0	"A ring assembly that has formula C13H14Cl2O3." []	\N	ciprofibrate	\N	\N	EFO	"A ring assembly that has formula C13H14Cl2O3." []	EFO	65781	CHEBI:50867	\N	ciprofibrate	CHEBI:50867
0	"A mineralocorticoid that has formula C21H29FO5." []	\N	fludrocortisone	\N	\N	EFO	"A mineralocorticoid that has formula C21H29FO5." []	EFO	65782	CHEBI:50885	\N	fludrocortisone	CHEBI:50885
0	"A role played by a chemical compound in the onset of allergic reaction and interacting with molecular pathways involved in allergy." []	\N	allergenic agent	\N	\N	EFO	"A role played by a chemical compound in the onset of allergic reaction and interacting with molecular pathways involved in allergy." []	EFO	65783	CHEBI:50904	\N	allergenic agent	CHEBI:50904
0	"A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centers (the vomiting center and the chemoreceptive trigger zone) or affect the peripheral receptors." []	\N	antiemetic	\N	\N	EFO	"A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centers (the vomiting center and the chemoreceptive trigger zone) or affect the peripheral receptors." []	EFO	65784	CHEBI:50919	\N	antiemetic	CHEBI:50919
0	"" []	\N	flucloxacillin	\N	\N	EFO	"" []	EFO	65785	CHEBI:5098	\N	flucloxacillin	CHEBI:5098
0	"A drug that binds to and activates dopamine receptors." []	\N	dopamine agonist	\N	\N	EFO	"A drug that binds to and activates dopamine receptors." []	EFO	65786	CHEBI:51065	\N	dopamine agonist	CHEBI:51065
0	"A role played by the molecular entity or part thereof within a chemical context." []	\N	chemical role	\N	\N	EFO	"A role played by the molecular entity or part thereof within a chemical context." []	EFO	65787	CHEBI:51086	\N	chemical role	CHEBI:51086
0	"\\"A benzenoid aromatic compound that has formula C17H18F3NO.\\" []" []	\N	fluoxetine	\N	\N	EFO	"\\"A benzenoid aromatic compound that has formula C17H18F3NO.\\" []" []	EFO	65788	CHEBI:5118	\N	fluoxetine	CHEBI:5118
0	"" []	\N	fluphenazine	\N	\N	EFO	"" []	EFO	65789	CHEBI:5123	\N	fluphenazine	CHEBI:5123
0	"" []	\N	flutamide	\N	\N	EFO	"" []	EFO	65790	CHEBI:5132	\N	flutamide	CHEBI:5132
0	"" []	\N	polyamide	\N	\N	EFO	"" []	EFO	65791	CHEBI:51953	\N	polyamide	CHEBI:51953
0	"" []	\N	chlorphenamine	\N	\N	EFO	"" []	EFO	65792	CHEBI:52010	\N	chlorphenamine	CHEBI:52010
0	"An organofluorine compound that has formula C28H22F3N7O." []	\N	nilotinib	\N	\N	EFO	"An organofluorine compound that has formula C28H22F3N7O." []	EFO	65793	CHEBI:52172	\N	nilotinib	CHEBI:52172
0	"An organic heteropentacyclic compound that has formula C23H24O8 and has biological role specific, covalent inhibitor of phosphoinositide 3-kinases (PI3Ks)." []	\N	wortmannin	\N	\N	EFO	"An organic heteropentacyclic compound that has formula C23H24O8 and has biological role specific, covalent inhibitor of phosphoinositide 3-kinases (PI3Ks)." []	EFO	65794	CHEBI:52289	\N	wortmannin	CHEBI:52289
0	"" []	\N	N-acylethanolamine	\N	\N	EFO	"" []	EFO	65795	CHEBI:52640	\N	N-acylethanolamine	CHEBI:52640
0	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	\N	bortezomib	\N	\N	EFO	"Human USP6 wild-type allele is located within 17p13 and is approximately 47 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 6 protein, is involved in protein binding and the cleavage of free ubiquitin chains. The USP6 gene is overexpressed in a specific osseous neoplasm termed an aneurysmal bone cyst." []	EFO	65796	CHEBI:52717	\N	bortezomib	CHEBI:52717
0	"" []	\N	gemfibrozil	\N	\N	EFO	"" []	EFO	65797	CHEBI:5296	\N	gemfibrozil	CHEBI:5296
0	"A mycotoxin, which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis." []	\N	cytochalasin D	\N	\N	EFO	"A mycotoxin, which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis." []	EFO	65798	CHEBI:529996	\N	cytochalasin D	CHEBI:529996
0	"Amyloid beta (Aβ or Abeta) is a peptide of 36–43 amino acids that is processed from the Amyloid precursor protein. While it is most commonly known in association with Alzheimer's disease, it does not exist specifically to cause disease. Evidence has been found that Aβ has multiple non-disease activities.[1]" []	\N	beta amyloid	\N	\N	EFO	"Amyloid beta (Aβ or Abeta) is a peptide of 36–43 amino acids that is processed from the Amyloid precursor protein. While it is most commonly known in association with Alzheimer's disease, it does not exist specifically to cause disease. Evidence has been found that Aβ has multiple non-disease activities.[1]" []	EFO	65799	CHEBI:53002	\N	beta amyloid	CHEBI:53002
0	"" []	\N	naphthalene-1,5-diamine	\N	\N	EFO	"" []	EFO	65800	CHEBI:53003	\N	naphthalene-1,5-diamine	CHEBI:53003
0	"A fluorobenzene compound with two nitro substituents in the 2- and 4-positions." []	\N	1-fluoro-2,4-dinitrobenzene	\N	\N	EFO	"A fluorobenzene compound with two nitro substituents in the 2- and 4-positions." []	EFO	65801	CHEBI:53049	\N	1-fluoro-2,4-dinitrobenzene	CHEBI:53049
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	Bandrowski's base	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65802	CHEBI:53109	\N	Bandrowski's base	CHEBI:53109
0	"" []	\N	4,5-dianilinophthalimide	\N	\N	EFO	"" []	EFO	65803	CHEBI:53110	\N	4,5-dianilinophthalimide	CHEBI:53110
0	"Caffeine substituted at its 8-position by an (E)-3-chlorostyryl group." []	\N	8-(3-chlorostyryl) caffeine	\N	\N	EFO	"Caffeine substituted at its 8-position by an (E)-3-chlorostyryl group." []	EFO	65804	CHEBI:53115	\N	8-(3-chlorostyryl) caffeine	CHEBI:53115
0	"" []	\N	pristane	\N	\N	EFO	"" []	EFO	65805	CHEBI:53181	\N	pristane	CHEBI:53181
0	"A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 and a single terminal is capped by a dodecanoyl group." []	\N	polysorbate 20	\N	\N	EFO	"A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 and a single terminal is capped by a dodecanoyl group." []	EFO	65806	CHEBI:53424	\N	polysorbate 20	CHEBI:53424
0	"" []	\N	polysorbate 60	\N	\N	EFO	"" []	EFO	65807	CHEBI:53425	\N	polysorbate 60	CHEBI:53425
0	"" []	\N	calcineurin	\N	\N	EFO	"" []	EFO	65808	CHEBI:53439	\N	calcineurin	CHEBI:53439
0	"" []	\N	potassium dichromate	\N	\N	EFO	"" []	EFO	65809	CHEBI:53444	\N	potassium dichromate	CHEBI:53444
0	"A (1->4)-beta-D-glucan compound formed by methylating cellulose through exposure to NaOH/CH3Cl." []	\N	methyl cellulose	\N	\N	EFO	"A (1->4)-beta-D-glucan compound formed by methylating cellulose through exposure to NaOH/CH3Cl." []	EFO	65810	CHEBI:53448	\N	methyl cellulose	CHEBI:53448
0	"" []	\N	N-(1-naphthyl)ethylenediamine dihydrochloride	\N	\N	EFO	"" []	EFO	65811	CHEBI:53452	\N	N-(1-naphthyl)ethylenediamine dihydrochloride	CHEBI:53452
0	"" []	\N	neuropeptide S	\N	\N	EFO	"" []	EFO	65812	CHEBI:53461	\N	neuropeptide S	CHEBI:53461
0	"" []	\N	nickel chloride hexahydrate	\N	\N	EFO	"" []	EFO	65813	CHEBI:53542	\N	nickel chloride hexahydrate	CHEBI:53542
0	"" []	\N	acenocoumarol	\N	\N	EFO	"" []	EFO	65814	CHEBI:53766	\N	acenocoumarol	CHEBI:53766
0	"" []	\N	antispasmodic	\N	\N	EFO	"" []	EFO	65815	CHEBI:53784	\N	antispasmodic	CHEBI:53784
0	"" []	\N	glucosamine	\N	\N	EFO	"" []	EFO	65816	CHEBI:5417	\N	glucosamine	CHEBI:5417
0	"" []	\N	glyburide	\N	\N	EFO	"" []	EFO	65817	CHEBI:5441	\N	glyburide	CHEBI:5441
0	"" []	\N	camphorsulfonic acid	\N	\N	EFO	"" []	EFO	65818	CHEBI:55379	\N	camphorsulfonic acid	CHEBI:55379
0	"" []	\N	radicicol	\N	\N	EFO	"" []	EFO	65819	CHEBI:556075	\N	radicicol	CHEBI:556075
0	"A hydroxypiperidine that has formula C21H23ClFNO2." []	\N	haloperidol	\N	\N	EFO	"A hydroxypiperidine that has formula C21H23ClFNO2." []	EFO	65820	CHEBI:5613	\N	haloperidol	CHEBI:5613
0	"A haloalkane that has formula C2HBrClF3." []	\N	halothane	\N	\N	EFO	"A haloalkane that has formula C2HBrClF3." []	EFO	65821	CHEBI:5615	\N	halothane	CHEBI:5615
0	"The sixth of the seven cervical vertebrae." []	\N	hexachlorobenzene	\N	\N	EFO	"The sixth of the seven cervical vertebrae." []	EFO	65822	CHEBI:5692	\N	hexachlorobenzene	CHEBI:5692
0	"" []	\N	hydroxyzine	\N	\N	EFO	"" []	EFO	65823	CHEBI:5818	\N	hydroxyzine	CHEBI:5818
0	"" []	\N	felodipine	\N	\N	EFO	"" []	EFO	65824	CHEBI:585948	\N	felodipine	CHEBI:585948
0	"" []	\N	imidacloprid	\N	\N	EFO	"" []	EFO	65825	CHEBI:5870	\N	imidacloprid	CHEBI:5870
0	"\\"The monohydrate of (+)-catechin.\\" []" []	\N	(+)-catechin monohydrate	\N	\N	EFO	"\\"The monohydrate of (+)-catechin.\\" []" []	EFO	65826	CHEBI:58994	\N	(+)-catechin monohydrate	CHEBI:58994
0	"A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction." []	\N	caerulein	\N	\N	EFO	"A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction." []	EFO	65827	CHEBI:59219	\N	caerulein	CHEBI:59219
0	"" []	\N	insulin	\N	\N	EFO	"" []	EFO	65828	CHEBI:5931	\N	insulin	CHEBI:5931
0	"" []	\N	DNA synthesis inhibitor	\N	\N	EFO	"" []	EFO	65829	CHEBI:59517	\N	DNA synthesis inhibitor	CHEBI:59517
0	"The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate." []	\N	cyproheptadine hydrochloride	\N	\N	EFO	"The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate." []	EFO	65830	CHEBI:59695	\N	cyproheptadine hydrochloride	CHEBI:59695
0	"An organofluorine compound that has formula C3H2ClF5O." []	\N	isoflurane	\N	\N	EFO	"An organofluorine compound that has formula C3H2ClF5O." []	EFO	65831	CHEBI:6015	\N	isoflurane	CHEBI:6015
0	"" []	\N	oxidised LDL	\N	\N	EFO	"" []	EFO	65832	CHEBI:60151	\N	oxidised LDL	CHEBI:60151
0	"" []	\N	isoniazide	\N	\N	EFO	"" []	EFO	65833	CHEBI:6030	\N	isoniazide	CHEBI:6030
0	"A retinoic acid that has formula C20H28O2." []	\N	isotretinoin	\N	\N	EFO	"A retinoic acid that has formula C20H28O2." []	EFO	65834	CHEBI:6067	\N	isotretinoin	CHEBI:6067
0	"" []	\N	ivermectin	\N	\N	EFO	"" []	EFO	65835	CHEBI:6078	\N	ivermectin	CHEBI:6078
0	"" []	\N	lysobisphosphatidic acid	\N	\N	EFO	"" []	EFO	65836	CHEBI:60815	\N	lysobisphosphatidic acid	CHEBI:60815
0	"" []	\N	tacrolimus hydrate	\N	\N	EFO	"" []	EFO	65837	CHEBI:61057	\N	tacrolimus hydrate	CHEBI:61057
0	"" []	\N	alpha-methyl-L-dopa	\N	\N	EFO	"" []	EFO	65838	CHEBI:61058	\N	alpha-methyl-L-dopa	CHEBI:61058
0	"\\"A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.\\" []" []	\N	scopolamine methobromide	\N	\N	EFO	"\\"A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.\\" []" []	EFO	65839	CHEBI:61276	\N	scopolamine methobromide	CHEBI:61276
0	"" []	\N	(S)-azetidine-2-carboxylic acid	\N	\N	EFO	"" []	EFO	65840	CHEBI:6198	\N	(S)-azetidine-2-carboxylic acid	CHEBI:6198
0	"" []	\N	oligogalacturonide	\N	\N	EFO	"" []	EFO	65841	CHEBI:62533	\N	oligogalacturonide	CHEBI:62533
0	"\\"An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.\\" []" []	\N	ammonium sulfate	\N	\N	EFO	"\\"An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.\\" []" []	EFO	65842	CHEBI:62946	\N	ammonium sulfate	CHEBI:62946
0	"\\"The ammonium salt of phosphoric acid (molar ratio 1:1).\\" []" []	\N	ammonium phosphate	\N	\N	EFO	"\\"The ammonium salt of phosphoric acid (molar ratio 1:1).\\" []" []	EFO	65843	CHEBI:62982	\N	ammonium phosphate	CHEBI:62982
0	"\\"The ammonium salt of nitric acid.\\" []" []	\N	ammonium nitrate	\N	\N	EFO	"\\"The ammonium salt of nitric acid.\\" []" []	EFO	65844	CHEBI:63038	\N	ammonium nitrate	CHEBI:63038
0	"\\"The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.\\" []" []	\N	caesium chloride	\N	\N	EFO	"\\"The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.\\" []" []	EFO	65845	CHEBI:63039	\N	caesium chloride	CHEBI:63039
0	"" []	\N	potassium nitrate	\N	\N	EFO	"" []	EFO	65846	CHEBI:63043	\N	potassium nitrate	CHEBI:63043
0	"" []	\N	phase-transfer catalyst role	\N	\N	EFO	"" []	EFO	65847	CHEBI:63060	\N	phase-transfer catalyst role	CHEBI:63060
0	"" []	\N	labetalol	\N	\N	EFO	"" []	EFO	65848	CHEBI:6343	\N	labetalol	CHEBI:6343
0	"A substance capable of undergoing rapid and highly exothermic decomposition." []	\N	explosive role	\N	\N	EFO	"A substance capable of undergoing rapid and highly exothermic decomposition." []	EFO	65849	CHEBI:63490	\N	explosive role	CHEBI:63490
0	"\\"A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. Antiviral agent; once incorporated into DNA, 2F-ara-ATP (its metabolite) functions as a DNA chain terminator\\" []" []	\N	fludarabine phosphate	\N	\N	EFO	"\\"A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. Antiviral agent; once incorporated into DNA, 2F-ara-ATP (its metabolite) functions as a DNA chain terminator\\" []" []	EFO	65850	CHEBI:63599	\N	fludarabine phosphate	CHEBI:63599
0	"\\"A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.\\" []" []	\N	mefloquine	\N	\N	EFO	"\\"A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.\\" []" []	EFO	65851	CHEBI:63609	\N	mefloquine	CHEBI:63609
0	"" []	\N	nevirapine	\N	\N	EFO	"" []	EFO	65852	CHEBI:63613	\N	nevirapine	CHEBI:63613
0	"" []	\N	topiramate	\N	\N	EFO	"" []	EFO	65853	CHEBI:63631	\N	topiramate	CHEBI:63631
0	"\\"A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.\\" []" []	\N	topotecan	\N	\N	EFO	"\\"A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.\\" []" []	EFO	65854	CHEBI:63632	\N	topotecan	CHEBI:63632
0	"" []	\N	iloprost	\N	\N	EFO	"" []	EFO	65855	CHEBI:63916	\N	iloprost	CHEBI:63916
0	"" []	\N	symphytine oxide	\N	\N	EFO	"" []	EFO	65856	CHEBI:63917	\N	symphytine oxide	CHEBI:63917
0	"" []	\N	artesunate	\N	\N	EFO	"" []	EFO	65857	CHEBI:63918	\N	artesunate	CHEBI:63918
0	"" []	\N	3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol	\N	\N	EFO	"" []	EFO	65858	CHEBI:63919	\N	3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol	CHEBI:63919
0	"" []	\N	2-butoxyethanol	\N	\N	EFO	"" []	EFO	65859	CHEBI:63921	\N	2-butoxyethanol	CHEBI:63921
0	"" []	\N	riddelliine	\N	\N	EFO	"" []	EFO	65860	CHEBI:63924	\N	riddelliine	CHEBI:63924
0	"" []	\N	latanoprost free acid	\N	\N	EFO	"" []	EFO	65861	CHEBI:63925	\N	latanoprost free acid	CHEBI:63925
0	"" []	\N	cinidon ethyl	\N	\N	EFO	"" []	EFO	65862	CHEBI:63927	\N	cinidon ethyl	CHEBI:63927
0	"" []	\N	menadione sodium sulfonate	\N	\N	EFO	"" []	EFO	65863	CHEBI:63928	\N	menadione sodium sulfonate	CHEBI:63928
0	"" []	\N	Aroclor 1254	\N	\N	EFO	"" []	EFO	65864	CHEBI:63933	\N	Aroclor 1254	CHEBI:63933
0	"" []	\N	bathocuproine disulfonic acid	\N	\N	EFO	"" []	EFO	65865	CHEBI:63934	\N	bathocuproine disulfonic acid	CHEBI:63934
0	"" []	\N	cyclazosin hydrochloride	\N	\N	EFO	"" []	EFO	65866	CHEBI:63935	\N	cyclazosin hydrochloride	CHEBI:63935
0	"" []	\N	cadmium dichloride hemipentahydrate	\N	\N	EFO	"" []	EFO	65867	CHEBI:63938	\N	cadmium dichloride hemipentahydrate	CHEBI:63938
0	"" []	\N	sodium tungstate dihydrate	\N	\N	EFO	"" []	EFO	65868	CHEBI:63939	\N	sodium tungstate dihydrate	CHEBI:63939
0	"" []	\N	sodium tungstate	\N	\N	EFO	"" []	EFO	65869	CHEBI:63940	\N	sodium tungstate	CHEBI:63940
0	"" []	\N	ferrozine monosodium salt	\N	\N	EFO	"" []	EFO	65870	CHEBI:63942	\N	ferrozine monosodium salt	CHEBI:63942
0	"" []	\N	trimethyltin	\N	\N	EFO	"" []	EFO	65871	CHEBI:63948	\N	trimethyltin	CHEBI:63948
0	"" []	\N	2,3-bis(4-hydroxyphenyl)propionitrile	\N	\N	EFO	"" []	EFO	65872	CHEBI:63949	\N	2,3-bis(4-hydroxyphenyl)propionitrile	CHEBI:63949
0	"" []	\N	arsenic trichloride	\N	\N	EFO	"" []	EFO	65873	CHEBI:63952	\N	arsenic trichloride	CHEBI:63952
0	"" []	\N	ionomycin	\N	\N	EFO	"" []	EFO	65874	CHEBI:63954	\N	ionomycin	CHEBI:63954
0	"" []	\N	isoxaben	\N	\N	EFO	"" []	EFO	65875	CHEBI:63956	\N	isoxaben	CHEBI:63956
0	"" []	\N	celastrol	\N	\N	EFO	"" []	EFO	65876	CHEBI:63959	\N	celastrol	CHEBI:63959
0	"" []	\N	N(6)-acetimidoyl-L-lysine dihydrochloride	\N	\N	EFO	"" []	EFO	65877	CHEBI:63964	\N	N(6)-acetimidoyl-L-lysine dihydrochloride	CHEBI:63964
0	"" []	\N	7-chlorokynurenic acid	\N	\N	EFO	"" []	EFO	65878	CHEBI:63965	\N	7-chlorokynurenic acid	CHEBI:63965
0	"" []	\N	N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	\N	\N	EFO	"" []	EFO	65879	CHEBI:63978	\N	N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	CHEBI:63978
0	"" []	\N	N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	\N	\N	EFO	"" []	EFO	65880	CHEBI:63996	\N	N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	CHEBI:63996
0	"" []	\N	N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	\N	\N	EFO	"" []	EFO	65881	CHEBI:64002	\N	N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	CHEBI:64002
0	"" []	\N	nebivolol	\N	\N	EFO	"" []	EFO	65882	CHEBI:64022	\N	nebivolol	CHEBI:64022
0	"" []	\N	N-octylhomovanillamide	\N	\N	EFO	"" []	EFO	65883	CHEBI:64041	\N	N-octylhomovanillamide	CHEBI:64041
0	"" []	\N	3-aminobenzamide	\N	\N	EFO	"" []	EFO	65884	CHEBI:64042	\N	3-aminobenzamide	CHEBI:64042
0	"" []	\N	isoquinoline-1,5-diol	\N	\N	EFO	"" []	EFO	65885	CHEBI:64044	\N	isoquinoline-1,5-diol	CHEBI:64044
0	"" []	\N	amisulpride	\N	\N	EFO	"" []	EFO	65886	CHEBI:64045	\N	amisulpride	CHEBI:64045
0	"" []	\N	N-desmethylclozapine	\N	\N	EFO	"" []	EFO	65887	CHEBI:64050	\N	N-desmethylclozapine	CHEBI:64050
0	"" []	\N	4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate	\N	\N	EFO	"" []	EFO	65888	CHEBI:64053	\N	4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate	CHEBI:64053
0	"" []	\N	3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride	\N	\N	EFO	"" []	EFO	65889	CHEBI:64057	\N	3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride	CHEBI:64057
0	"" []	\N	CGP 78608 hydrochloride	\N	\N	EFO	"" []	EFO	65890	CHEBI:64065	\N	CGP 78608 hydrochloride	CHEBI:64065
0	"" []	\N	SB 224289 hydrochloride	\N	\N	EFO	"" []	EFO	65891	CHEBI:64067	\N	SB 224289 hydrochloride	CHEBI:64067
0	"" []	\N	exendin-4	\N	\N	EFO	"" []	EFO	65892	CHEBI:64073	\N	exendin-4	CHEBI:64073
0	"" []	\N	(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride	\N	\N	EFO	"" []	EFO	65893	CHEBI:64078	\N	(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride	CHEBI:64078
0	"" []	\N	RS 39604 hydrochloride	\N	\N	EFO	"" []	EFO	65894	CHEBI:64081	\N	RS 39604 hydrochloride	CHEBI:64081
0	"" []	\N	vanoxerine dihydrochloride	\N	\N	EFO	"" []	EFO	65895	CHEBI:64086	\N	vanoxerine dihydrochloride	CHEBI:64086
0	"" []	\N	1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	\N	\N	EFO	"" []	EFO	65896	CHEBI:64091	\N	1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	CHEBI:64091
0	"" []	\N	N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine	\N	\N	EFO	"" []	EFO	65897	CHEBI:64098	\N	N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine	CHEBI:64098
0	"" []	\N	4-fluoro-N-\\\\\\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\\\\\\}benzamide hydrochloride	\N	\N	EFO	"" []	EFO	65898	CHEBI:64099	\N	4-fluoro-N-\\\\\\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\\\\\\}benzamide hydrochloride	CHEBI:64099
0	"" []	\N	sodium butyrate	\N	\N	EFO	"" []	EFO	65899	CHEBI:64103	\N	sodium butyrate	CHEBI:64103
0	"" []	\N	sodium 8-bromo-3',5'-cyclic GMP	\N	\N	EFO	"" []	EFO	65900	CHEBI:64104	\N	sodium 8-bromo-3',5'-cyclic GMP	CHEBI:64104
0	"" []	\N	4,4',4''-(4-propylpyrazole-1,3,5-triyl)trisphenol	\N	\N	EFO	"" []	EFO	65901	CHEBI:64110	\N	4,4',4''-(4-propylpyrazole-1,3,5-triyl)trisphenol	CHEBI:64110
0	"" []	\N	GR 127935 hydrochloride	\N	\N	EFO	"" []	EFO	65902	CHEBI:64111	\N	GR 127935 hydrochloride	CHEBI:64111
0	"" []	\N	(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride	\N	\N	EFO	"" []	EFO	65903	CHEBI:64115	\N	(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride	CHEBI:64115
0	"" []	\N	(S)-(-)-sulpiride	\N	\N	EFO	"" []	EFO	65904	CHEBI:64119	\N	(S)-(-)-sulpiride	CHEBI:64119
0	"" []	\N	NAN 190 hydrobromide	\N	\N	EFO	"" []	EFO	65905	CHEBI:64123	\N	NAN 190 hydrobromide	CHEBI:64123
0	"" []	\N	2-\\\\\\{[(2E)-3-iodoprop-2-en-1-yl](propyl)amino\\\\\\}tetralin-7-ol maleate	\N	\N	EFO	"" []	EFO	65906	CHEBI:64134	\N	2-\\\\\\{[(2E)-3-iodoprop-2-en-1-yl](propyl)amino\\\\\\}tetralin-7-ol maleate	CHEBI:64134
0	"" []	\N	(2R,3S)-EHNA hydrochloride	\N	\N	EFO	"" []	EFO	65907	CHEBI:64139	\N	(2R,3S)-EHNA hydrochloride	CHEBI:64139
0	"" []	\N	tropanyl 3,5-dimethylbenzoate	\N	\N	EFO	"" []	EFO	65908	CHEBI:64142	\N	tropanyl 3,5-dimethylbenzoate	CHEBI:64142
0	"" []	\N	depudecin	\N	\N	EFO	"" []	EFO	65909	CHEBI:64143	\N	depudecin	CHEBI:64143
0	"" []	\N	1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine maleate	\N	\N	EFO	"" []	EFO	65910	CHEBI:64144	\N	1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine maleate	CHEBI:64144
0	"" []	\N	5-nonyloxytryptamine oxalate	\N	\N	EFO	"" []	EFO	65911	CHEBI:64147	\N	5-nonyloxytryptamine oxalate	CHEBI:64147
0	"" []	\N	imetit dihydrobromide	\N	\N	EFO	"" []	EFO	65912	CHEBI:64151	\N	imetit dihydrobromide	CHEBI:64151
0	"" []	\N	tanespimycin	\N	\N	EFO	"" []	EFO	65913	CHEBI:64153	\N	tanespimycin	CHEBI:64153
0	"" []	\N	2-methyl-6-(phenylethynyl)pyridine hydrochloride	\N	\N	EFO	"" []	EFO	65914	CHEBI:64158	\N	2-methyl-6-(phenylethynyl)pyridine hydrochloride	CHEBI:64158
0	"" []	\N	N-methylquipazine dimaleate	\N	\N	EFO	"" []	EFO	65915	CHEBI:64162	\N	N-methylquipazine dimaleate	CHEBI:64162
0	"" []	\N	diquat	\N	\N	EFO	"" []	EFO	65916	CHEBI:64163	\N	diquat	CHEBI:64163
0	"" []	\N	clobenpropit dihydrobromide	\N	\N	EFO	"" []	EFO	65917	CHEBI:64165	\N	clobenpropit dihydrobromide	CHEBI:64165
0	"" []	\N	benserazide	\N	\N	EFO	"" []	EFO	65918	CHEBI:64187	\N	benserazide	CHEBI:64187
0	"" []	\N	nafadotride	\N	\N	EFO	"" []	EFO	65919	CHEBI:64191	\N	nafadotride	CHEBI:64191
0	"" []	\N	paroxetine maleate	\N	\N	EFO	"" []	EFO	65920	CHEBI:64194	\N	paroxetine maleate	CHEBI:64194
0	"" []	\N	ritanserin	\N	\N	EFO	"" []	EFO	65921	CHEBI:64195	\N	ritanserin	CHEBI:64195
0	"" []	\N	dimercaprol	\N	\N	EFO	"" []	EFO	65922	CHEBI:64198	\N	dimercaprol	CHEBI:64198
0	"" []	\N	carmoxirole hydrochloride	\N	\N	EFO	"" []	EFO	65923	CHEBI:64199	\N	carmoxirole hydrochloride	CHEBI:64199
0	"" []	\N	methiothepin maleate	\N	\N	EFO	"" []	EFO	65924	CHEBI:64202	\N	methiothepin maleate	CHEBI:64202
0	"" []	\N	bromochloroacetic acid	\N	\N	EFO	"" []	EFO	65925	CHEBI:64206	\N	bromochloroacetic acid	CHEBI:64206
0	"" []	\N	spiramide	\N	\N	EFO	"" []	EFO	65926	CHEBI:64207	\N	spiramide	CHEBI:64207
0	"" []	\N	(2Z,3Z)-bis\\\\\\{amino[(2-aminophenyl)sulfanyl]methylidene\\\\\\}butanedinitrile	\N	\N	EFO	"" []	EFO	65927	CHEBI:64208	\N	(2Z,3Z)-bis\\\\\\{amino[(2-aminophenyl)sulfanyl]methylidene\\\\\\}butanedinitrile	CHEBI:64208
0	"" []	\N	4-\\\\\\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\\\\\\}benzoic acid	\N	\N	EFO	"" []	EFO	65928	CHEBI:64210	\N	4-\\\\\\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\\\\\\}benzoic acid	CHEBI:64210
0	"" []	\N	8-bromo-3',5'-cyclic AMP	\N	\N	EFO	"" []	EFO	65929	CHEBI:64211	\N	8-bromo-3',5'-cyclic AMP	CHEBI:64211
0	"" []	\N	sulindac sulfone	\N	\N	EFO	"" []	EFO	65930	CHEBI:64212	\N	sulindac sulfone	CHEBI:64212
0	"" []	\N	cantharidin	\N	\N	EFO	"" []	EFO	65931	CHEBI:64213	\N	cantharidin	CHEBI:64213
0	"" []	\N	2,3-dimethoxynaphthalene-1,4-dione	\N	\N	EFO	"" []	EFO	65932	CHEBI:64215	\N	2,3-dimethoxynaphthalene-1,4-dione	CHEBI:64215
0	"" []	\N	metergoline	\N	\N	EFO	"" []	EFO	65933	CHEBI:64216	\N	metergoline	CHEBI:64216
0	"" []	\N	ciglitazone	\N	\N	EFO	"" []	EFO	65934	CHEBI:64227	\N	ciglitazone	CHEBI:64227
0	"" []	\N	levetiracetam	\N	\N	EFO	"" []	EFO	65935	CHEBI:6437	\N	levetiracetam	CHEBI:6437
0	"" []	\N	lincomycin	\N	\N	EFO	"" []	EFO	65936	CHEBI:6472	\N	lincomycin	CHEBI:6472
0	"A lipoxin that has formula C20H32O5." []	\N	lipoxin A4	\N	\N	EFO	"A lipoxin that has formula C20H32O5." []	EFO	65937	CHEBI:6498	\N	lipoxin A4	CHEBI:6498
0	"A chromone substituted with a phenyl group at position 8 and a morpholine group at position 2." []	\N	LY294002	\N	\N	EFO	"A chromone substituted with a phenyl group at position 8 and a morpholine group at position 2." []	EFO	65938	CHEBI:65329	\N	LY294002	CHEBI:65329
0	"A monounsaturated very long-chain fatty acid with a 22-carbon backbone and a single double bond originating from the  9th position from the methyl end, with the double bond in the trans- configuration." []	\N	losartan	\N	\N	EFO	"A monounsaturated very long-chain fatty acid with a 22-carbon backbone and a single double bond originating from the  9th position from the methyl end, with the double bond in the trans- configuration." []	EFO	65939	CHEBI:6541	\N	losartan	CHEBI:6541
0	"" []	\N	loxtidine	\N	\N	EFO	"" []	EFO	65940	CHEBI:6550	\N	loxtidine	CHEBI:6550
0	"" []	\N	malathion	\N	\N	EFO	"" []	EFO	65941	CHEBI:6651	\N	malathion	CHEBI:6651
0	"" []	\N	mesalamine	\N	\N	EFO	"" []	EFO	65942	CHEBI:6775	\N	mesalamine	CHEBI:6775
0	"A guanidine that has formula C4H11N5." []	\N	metformin	\N	\N	EFO	"A guanidine that has formula C4H11N5." []	EFO	65943	CHEBI:6801	\N	metformin	CHEBI:6801
0	"" []	\N	methamphetamine	\N	\N	EFO	"" []	EFO	65944	CHEBI:6809	\N	methamphetamine	CHEBI:6809
0	"An ethylenediamine derivative that has formula C14H19N3S." []	\N	methapyrilene	\N	\N	EFO	"An ethylenediamine derivative that has formula C14H19N3S." []	EFO	65945	CHEBI:6820	\N	methapyrilene	CHEBI:6820
0	"An organochlorine insecticide that has formula C16H15Cl3O2." []	\N	methoxychlor	\N	\N	EFO	"An organochlorine insecticide that has formula C16H15Cl3O2." []	EFO	65946	CHEBI:6842	\N	methoxychlor	CHEBI:6842
0	"" []	\N	6alpha-methylprednisolone	\N	\N	EFO	"" []	EFO	65947	CHEBI:6888	\N	6alpha-methylprednisolone	CHEBI:6888
0	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	\N	metoprolol	\N	\N	EFO	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	EFO	65948	CHEBI:6904	\N	metoprolol	CHEBI:6904
0	"" []	\N	alpha-methyl-L-tyrosine	\N	\N	EFO	"" []	EFO	65949	CHEBI:6912	\N	alpha-methyl-L-tyrosine	CHEBI:6912
0	"" []	\N	mexiletine	\N	\N	EFO	"" []	EFO	65950	CHEBI:6916	\N	mexiletine	CHEBI:6916
0	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	\N	miconazole	\N	\N	EFO	"Expressed in keratinocytes by human FABP5 Gene (FABP Family), highly conserved 135-aa 15-kDa cytoplasmic Fatty Acid Binding Protein 5 binds long-chain fatty acids with high specificity, and other hydrophobic ligands. Likely involved in fatty acid uptake, transport, or metabolism and in keratinocyte differentiation, FABP5 has highest affinity for C18 chain lengths and decreasing affinity for decreasing chain lengths or chains with double bonds. (NCI)" []	EFO	65951	CHEBI:6923	\N	miconazole	CHEBI:6923
0	"" []	\N	monocrotaline	\N	\N	EFO	"" []	EFO	65952	CHEBI:6980	\N	monocrotaline	CHEBI:6980
0	"" []	\N	myoglobin	\N	\N	EFO	"" []	EFO	65953	CHEBI:7044	\N	myoglobin	CHEBI:7044
0	"A formamide compound having an N-methyl substituent." []	\N	N-methylformamide	\N	\N	EFO	"A formamide compound having an N-methyl substituent." []	EFO	65954	CHEBI:7438	\N	N-methylformamide	CHEBI:7438
0	"" []	\N	nandrolone	\N	\N	EFO	"" []	EFO	65955	CHEBI:7466	\N	nandrolone	CHEBI:7466
0	"" []	\N	naproxen	\N	\N	EFO	"" []	EFO	65956	CHEBI:7476	\N	naproxen	CHEBI:7476
0	"A dihydropyridine that has formula C17H18N2O6." []	\N	nifedipine	\N	\N	EFO	"A dihydropyridine that has formula C17H18N2O6." []	EFO	65957	CHEBI:7565	\N	nifedipine	CHEBI:7565
0	"" []	\N	nimodipine	\N	\N	EFO	"" []	EFO	65958	CHEBI:7575	\N	nimodipine	CHEBI:7575
0	"" []	\N	nitrofurantoin	\N	\N	EFO	"" []	EFO	65959	CHEBI:7591	\N	nitrofurantoin	CHEBI:7591
0	"A phenylalanine derivative that has formula C20H18ClNO6." []	\N	ochratoxin A	\N	\N	EFO	"A phenylalanine derivative that has formula C20H18ClNO6." []	EFO	65960	CHEBI:7719	\N	ochratoxin A	CHEBI:7719
0	"A benzodiazepine that has formula C17H20N4S." []	\N	olanzapine	\N	\N	EFO	"A benzodiazepine that has formula C17H20N4S." []	EFO	65961	CHEBI:7735	\N	olanzapine	CHEBI:7735
0	"" []	\N	omeprazole	\N	\N	EFO	"" []	EFO	65962	CHEBI:7772	\N	omeprazole	CHEBI:7772
0	"A cyclohexenecarboxylate ester that has formula C16H28N2O4." []	\N	oseltamivir	\N	\N	EFO	"A cyclohexenecarboxylate ester that has formula C16H28N2O4." []	EFO	65963	CHEBI:7798	\N	oseltamivir	CHEBI:7798
0	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	\N	oxazepam	\N	\N	EFO	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	EFO	65964	CHEBI:7823	\N	oxazepam	CHEBI:7823
0	"" []	\N	paroxetine	\N	\N	EFO	"" []	EFO	65965	CHEBI:7936	\N	paroxetine	CHEBI:7936
0	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	\N	parthenolide	\N	\N	EFO	"Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse." []	EFO	65966	CHEBI:7939	\N	parthenolide	CHEBI:7939
0	"" []	\N	D-penicillamine	\N	\N	EFO	"" []	EFO	65967	CHEBI:7959	\N	D-penicillamine	CHEBI:7959
0	"" []	\N	pergolide mesylate	\N	\N	EFO	"" []	EFO	65968	CHEBI:8021	\N	pergolide mesylate	CHEBI:8021
0	"" []	\N	perphenazine	\N	\N	EFO	"" []	EFO	65969	CHEBI:8028	\N	perphenazine	CHEBI:8028
0	"" []	\N	phenacetin	\N	\N	EFO	"" []	EFO	65970	CHEBI:8050	\N	phenacetin	CHEBI:8050
0	"Barbituric acid substituted at C-5 by ethyl and phenyl groups." []	\N	phenobarbital	\N	\N	EFO	"Barbituric acid substituted at C-5 by ethyl and phenyl groups." []	EFO	65971	CHEBI:8069	\N	phenobarbital	CHEBI:8069
0	"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis." []	\N	phenylephrine	\N	\N	EFO	"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis." []	EFO	65972	CHEBI:8093	\N	phenylephrine	CHEBI:8093
0	"" []	\N	phenytoin	\N	\N	EFO	"" []	EFO	65973	CHEBI:8107	\N	phenytoin	CHEBI:8107
0	"An aliphatic alcohol (with nine carbon atoms and two hydroxyl groups at positions 1 and 9) used in chemical synthesis and biomedical research.  1,9-Nonanediol suppresses glycine currents in neurons; glycine is a major inhibitory neurotransmitter in the mature mammalian central nervous system. (NCI04)" []	\N	pimozide	\N	\N	EFO	"An aliphatic alcohol (with nine carbon atoms and two hydroxyl groups at positions 1 and 9) used in chemical synthesis and biomedical research.  1,9-Nonanediol suppresses glycine currents in neurons; glycine is a major inhibitory neurotransmitter in the mature mammalian central nervous system. (NCI04)" []	EFO	65974	CHEBI:8212	\N	pimozide	CHEBI:8212
0	"A thiazolidenedione that has formula C19H20N2O3S." []	\N	pioglitazone	\N	\N	EFO	"A thiazolidenedione that has formula C19H20N2O3S." []	EFO	65975	CHEBI:8228	\N	pioglitazone	CHEBI:8228
0	"" []	\N	prazosin	\N	\N	EFO	"" []	EFO	65976	CHEBI:8364	\N	prazosin	CHEBI:8364
0	"A glucocorticoid that has formula C21H28O5." []	\N	prednisolone	\N	\N	EFO	"A glucocorticoid that has formula C21H28O5." []	EFO	65977	CHEBI:8378	\N	prednisolone	CHEBI:8378
0	"" []	\N	prochlorperazine	\N	\N	EFO	"" []	EFO	65978	CHEBI:8435	\N	prochlorperazine	CHEBI:8435
0	"" []	\N	promethazine	\N	\N	EFO	"" []	EFO	65979	CHEBI:8461	\N	promethazine	CHEBI:8461
0	"" []	\N	6-propyl-2-thiouracil	\N	\N	EFO	"" []	EFO	65980	CHEBI:8502	\N	6-propyl-2-thiouracil	CHEBI:8502
0	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	\N	quetiapine	\N	\N	EFO	"Human TBL1XR1 wild-type allele is located in the vicinity of 3q26.32 and is approximately 186 kb in length. This allele, which encodes F-box-like/WD repeat-containing protein TBL1XR1, plays a role in activation of transcription. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia." []	EFO	65981	CHEBI:8707	\N	quetiapine	CHEBI:8707
0	"A benzothiophene that has formula C28H27NO4S." []	\N	raloxifene	\N	\N	EFO	"A benzothiophene that has formula C28H27NO4S." []	EFO	65982	CHEBI:8772	\N	raloxifene	CHEBI:8772
0	"" []	\N	ranitidine	\N	\N	EFO	"" []	EFO	65983	CHEBI:8776	\N	ranitidine	CHEBI:8776
0	"" []	\N	risperidone	\N	\N	EFO	"" []	EFO	65984	CHEBI:8871	\N	risperidone	CHEBI:8871
0	"A sulfone that has formula C17H14O4S." []	\N	rofecoxib	\N	\N	EFO	"A sulfone that has formula C17H14O4S." []	EFO	65985	CHEBI:8887	\N	rofecoxib	CHEBI:8887
0	"" []	\N	salmeterol	\N	\N	EFO	"" []	EFO	65986	CHEBI:9011	\N	salmeterol	CHEBI:9011
0	"" []	\N	sertraline hydrochloride	\N	\N	EFO	"" []	EFO	65987	CHEBI:9124	\N	sertraline hydrochloride	CHEBI:9124
0	"An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups." []	\N	sevoflurane	\N	\N	EFO	"An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups." []	EFO	65988	CHEBI:9130	\N	sevoflurane	CHEBI:9130
0	"Simvastatin (INN) ( /ˈsɪmvəstætɨn/) is a hypolipidemic drug used to control elevated cholesterol, or hypercholesterolemia. It is a member of the statin class of pharmaceuticals." []	\N	simvastatin	\N	\N	EFO	"Simvastatin (INN) ( /ˈsɪmvəstætɨn/) is a hypolipidemic drug used to control elevated cholesterol, or hypercholesterolemia. It is a member of the statin class of pharmaceuticals." []	EFO	65989	CHEBI:9150	\N	simvastatin	CHEBI:9150
0	"" []	\N	rapamycin	\N	\N	EFO	"" []	EFO	65990	CHEBI:9168	\N	rapamycin	CHEBI:9168
0	"An antibiotic that is produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals." []	\N	streptozotocin	\N	\N	EFO	"An antibiotic that is produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals." []	EFO	65991	CHEBI:9288	\N	streptozotocin	CHEBI:9288
0	"" []	\N	sulfasalazine	\N	\N	EFO	"" []	EFO	65992	CHEBI:9334	\N	sulfasalazine	CHEBI:9334
0	"A sulfoxide that has formula C20H17FO3S." []	\N	sulindac	\N	\N	EFO	"A sulfoxide that has formula C20H17FO3S." []	EFO	65993	CHEBI:9352	\N	sulindac	CHEBI:9352
0	"" []	\N	tetrabenazine	\N	\N	EFO	"" []	EFO	65994	CHEBI:9467	\N	tetrabenazine	CHEBI:9467
0	"" []	\N	thalidomide	\N	\N	EFO	"" []	EFO	65995	CHEBI:9513	\N	thalidomide	CHEBI:9513
0	"An involuntary muscular contraction involving a muscle of the abdomen or of a hollow organ within the abdomen." []	\N	thapsigargin	\N	\N	EFO	"An involuntary muscular contraction involving a muscle of the abdomen or of a hollow organ within the abdomen." []	EFO	65996	CHEBI:9516	\N	thapsigargin	CHEBI:9516
0	"A phenothiazine that has formula C21H26N2S2." []	\N	thioridazine	\N	\N	EFO	"A phenothiazine that has formula C21H26N2S2." []	EFO	65997	CHEBI:9566	\N	thioridazine	CHEBI:9566
0	"" []	\N	ticlopidine	\N	\N	EFO	"" []	EFO	65998	CHEBI:9588	\N	ticlopidine	CHEBI:9588
0	"" []	\N	tomatidine	\N	\N	EFO	"" []	EFO	65999	CHEBI:9629	\N	tomatidine	CHEBI:9629
0	"" []	\N	tomatine	\N	\N	EFO	"" []	EFO	66000	CHEBI:9630	\N	tomatine	CHEBI:9630
0	"" []	\N	triazolam	\N	\N	EFO	"" []	EFO	66001	CHEBI:9674	\N	triazolam	CHEBI:9674
0	"" []	\N	tribenuron methyl	\N	\N	EFO	"" []	EFO	66002	CHEBI:9678	\N	tribenuron methyl	CHEBI:9678
0	"A chromane that has formula C24H27NO5S." []	\N	troglitazone	\N	\N	EFO	"A chromane that has formula C24H27NO5S." []	EFO	66003	CHEBI:9753	\N	troglitazone	CHEBI:9753
0	"The sodium salt of valproic acid." []	\N	sodium valproate	\N	\N	EFO	"The sodium salt of valproic acid." []	EFO	66004	CHEBI:9925	\N	sodium valproate	CHEBI:9925
0	"\\"An L-type calcium channel blocker of the phenylalkylamine class.\\" []" []	\N	verapamil	\N	\N	EFO	"\\"An L-type calcium channel blocker of the phenylalkylamine class.\\" []" []	EFO	66005	CHEBI:9948	\N	verapamil	CHEBI:9948
0	"A cell line cell that is expected to be capable of an unlimited number of divisions, and is thus able to support indefinite growth/propagation in vitro as part of a immortal cell line." []	\N	immortal cell line cell	\N	\N	EFO	"A cell line cell that is expected to be capable of an unlimited number of divisions, and is thus able to support indefinite growth/propagation in vitro as part of a immortal cell line." []	EFO	66006	CL:0000002	\N	immortal cell line cell	CL:0000002
0	"A cell found in the embryo before the formation of all the gem layers is complete." []	\N	early embryonic cell	\N	\N	EFO	"A cell found in the embryo before the formation of all the gem layers is complete." []	EFO	66007	CL:0000007	\N	early embryonic cell	CL:0000007
0	"" []	\N	male germ cell	\N	\N	EFO	"" []	EFO	66008	CL:0000015	\N	male germ cell	CL:0000015
0	"Definitive germ cell of the male sex." []	\N	sperm	\N	\N	EFO	"Definitive germ cell of the male sex." []	EFO	66009	CL:0000019	\N	sperm	CL:0000019
0	"A female germ cell that has entered meiosis." []	\N	oocyte	\N	\N	EFO	"A female germ cell that has entered meiosis." []	EFO	66010	CL:0000023	\N	oocyte	CL:0000023
0	"A female gamete where meiosis has progressed to metaphase II and is able to participate in fertilization." []	\N	plant egg	\N	\N	EFO	"A female gamete where meiosis has progressed to metaphase II and is able to participate in fertilization." []	EFO	66011	CL:0000025	\N	plant egg	CL:0000025
0	"A relatively undifferentiated cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells." []	\N	stem cell	\N	\N	EFO	"A relatively undifferentiated cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells." []	EFO	66012	CL:0000034	\N	stem cell	CL:0000034
0	"A stem cell from which all cells of the lymphoid and myeloid lineages develop, including blood cells and cells of the immune system. Hematopoietic stem cells lack cell markers of effector cells (lin-negative). Lin-negative is defined by lacking one or more of the following cell surface markers: CD2, CD3 epsilon, CD4,CD5,CD8 alpha chain, CD14, CD19, CD20, integrin alpha-M, neural cell adhesion molecule 1, lymphocyte antigen 6G, lymphocyte antigen 76." []	\N	hematopoietic stem cell	\N	\N	EFO	"A stem cell from which all cells of the lymphoid and myeloid lineages develop, including blood cells and cells of the immune system. Hematopoietic stem cells lack cell markers of effector cells (lin-negative). Lin-negative is defined by lacking one or more of the following cell surface markers: CD2, CD3 epsilon, CD4,CD5,CD8 alpha chain, CD14, CD19, CD20, integrin alpha-M, neural cell adhesion molecule 1, lymphocyte antigen 6G, lymphocyte antigen 76." []	EFO	66013	CL:0000037	\N	hematopoietic stem cell	CL:0000037
0	"A progenitor cell committed to the erythroid lineage. This cell is ter119-positive but lacks expression of other hematopoietic lineage markers (lin-negative)." []	\N	erythroid progenitor cell	\N	\N	EFO	"A progenitor cell committed to the erythroid lineage. This cell is ter119-positive but lacks expression of other hematopoietic lineage markers (lin-negative)." []	EFO	66014	CL:0000038	\N	erythroid progenitor cell	CL:0000038
0	"" []	\N	monoblast	\N	\N	EFO	"" []	EFO	66015	CL:0000040	\N	monoblast	CL:0000040
0	"" []	\N	mature eosinophil	\N	\N	EFO	"" []	EFO	66016	CL:0000041	\N	mature eosinophil	CL:0000041
0	"" []	\N	neutrophilic myeloblast	\N	\N	EFO	"" []	EFO	66017	CL:0000042	\N	neutrophilic myeloblast	CL:0000042
0	"" []	\N	mature basophil	\N	\N	EFO	"" []	EFO	66018	CL:0000043	\N	mature basophil	CL:0000043
0	"Neural stem cell is characterized as an undifferentiated cell that originates from the neuroectoderm and has  the capacity both to perpetually self-renew without differentiating and to generate multiple types of lineage-restricted progenitors." []	\N	neuronal stem cell	\N	\N	EFO	"Neural stem cell is characterized as an undifferentiated cell that originates from the neuroectoderm and has  the capacity both to perpetually self-renew without differentiating and to generate multiple types of lineage-restricted progenitors." []	EFO	66019	CL:0000047	\N	neuronal stem cell	CL:0000047
0	"A stem cell that can give rise to multiple lineages of cells." []	\N	multipotent stem cell	\N	\N	EFO	"A stem cell that can give rise to multiple lineages of cells." []	EFO	66020	CL:0000048	\N	multipotent stem cell	CL:0000048
0	"" []	\N	common myeloid progenitor	\N	\N	EFO	"" []	EFO	66021	CL:0000049	\N	common myeloid progenitor	CL:0000049
0	"" []	\N	megakaryocyte-erythroid progenitor cell	\N	\N	EFO	"" []	EFO	66022	CL:0000050	\N	megakaryocyte-erythroid progenitor cell	CL:0000050
0	"" []	\N	common lymphoid progenitor	\N	\N	EFO	"" []	EFO	66023	CL:0000051	\N	common lymphoid progenitor	CL:0000051
0	"A precursor cell with a limited number of potential fates." []	\N	blast cell	\N	\N	EFO	"A precursor cell with a limited number of potential fates." []	EFO	66024	CL:0000055	\N	blast cell	CL:0000055
0	"An embryonic cell that becomes a cell of muscle fiber." []	\N	myoblast	\N	\N	EFO	"An embryonic cell that becomes a cell of muscle fiber." []	EFO	66025	CL:0000056	\N	myoblast	CL:0000056
0	"A large, flat, oval cell found in connective tissue and responsible for the formation of fibers." []	\N	fibroblast	\N	\N	EFO	"A large, flat, oval cell found in connective tissue and responsible for the formation of fibers." []	EFO	66026	CL:0000057	\N	fibroblast	CL:0000057
0	"A bone-forming cell which secretes an extracellular matrix. Hydroxyapatite crystals are then deposited into the matrix to form bone." []	\N	osteoblast	\N	\N	EFO	"A bone-forming cell which secretes an extracellular matrix. Hydroxyapatite crystals are then deposited into the matrix to form bone." []	EFO	66027	CL:0000062	\N	osteoblast	CL:0000062
0	"Cell that line the inner and outer surfaces of the body by forming cellular layers (epithelium) or masses (MSH)." []	\N	epithelial cell	\N	\N	EFO	"Cell that line the inner and outer surfaces of the body by forming cellular layers (epithelium) or masses (MSH)." []	EFO	66028	CL:0000066	\N	epithelial cell	CL:0000066
0	"The endothelial cells that line the vasculature." []	\N	blood vessel endothelial cell	\N	\N	EFO	"The endothelial cells that line the vasculature." []	EFO	66029	CL:0000071	\N	blood vessel endothelial cell	CL:0000071
0	"A flattened epithelial cell of mesenchymal origin that lines the serous cavity." []	\N	mesothelial cell	\N	\N	EFO	"A flattened epithelial cell of mesenchymal origin that lines the serous cavity." []	EFO	66030	CL:0000077	\N	mesothelial cell	CL:0000077
0	"A cell which moves among different tissues of the body, via blood, lymph, or other medium." []	\N	circulating cell	\N	\N	EFO	"A cell which moves among different tissues of the body, via blood, lymph, or other medium." []	EFO	66031	CL:0000080	\N	circulating cell	CL:0000080
0	"A cell found predominately in the blood." []	\N	blood cell	\N	\N	EFO	"A cell found predominately in the blood." []	EFO	66032	CL:0000081	\N	blood cell	CL:0000081
0	"Cells of the pancreas that secrete digestive enzymes, the archetypal secretory cell upon which much of the early work on the sequence of events in the secretory process was done." []	\N	exocrine pancreas cell	\N	\N	EFO	"Cells of the pancreas that secrete digestive enzymes, the archetypal secretory cell upon which much of the early work on the sequence of events in the secretory process was done." []	EFO	66033	CL:0000083	\N	exocrine pancreas cell	CL:0000083
0	"A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex." []	\N	T cell	\N	\N	EFO	"A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex." []	EFO	66034	CL:0000084	\N	T cell	CL:0000084
0	"" []	\N	Kupffer cell	\N	\N	EFO	"" []	EFO	66035	CL:0000091	\N	Kupffer cell	CL:0000091
0	"" []	\N	osteoclast	\N	\N	EFO	"" []	EFO	66036	CL:0000092	\N	osteoclast	CL:0000092
0	"A polymorphonuclear white blood cell with granule-containing cytoplasm.nIn humans the granulocytes are also classified as polymorphonuclear leucocytes and are subdivided according to the staining properties of the granules into eosinophils, basophils  and neutrophils, some invertebrate blood cells are also referred to, not very helpfully, as granulocytes." []	\N	granulocyte	\N	\N	EFO	"A polymorphonuclear white blood cell with granule-containing cytoplasm.nIn humans the granulocytes are also classified as polymorphonuclear leucocytes and are subdivided according to the staining properties of the granules into eosinophils, basophils  and neutrophils, some invertebrate blood cells are also referred to, not very helpfully, as granulocytes." []	EFO	66037	CL:0000094	\N	granulocyte	CL:0000094
0	"" []	\N	mature neutrophil	\N	\N	EFO	"" []	EFO	66038	CL:0000096	\N	mature neutrophil	CL:0000096
0	"" []	\N	mast cell	\N	\N	EFO	"" []	EFO	66039	CL:0000097	\N	mast cell	CL:0000097
0	"Most generally any neuron which is not motor or sensory. Interneurons may also refer to neurons whose axons remain within a particular brain region as contrasted with projection neurons which have axons projecting to other brain regions." []	\N	interneuron	\N	\N	EFO	"Most generally any neuron which is not motor or sensory. Interneurons may also refer to neurons whose axons remain within a particular brain region as contrasted with projection neurons which have axons projecting to other brain regions." []	EFO	66040	CL:0000099	\N	interneuron	CL:0000099
0	"Neurons which activate muscle cells (MSH)." []	\N	motor neuron	\N	\N	EFO	"Neurons which activate muscle cells (MSH)." []	EFO	66041	CL:0000100	\N	motor neuron	CL:0000100
0	"Any neuron having a sensory function; an afferent neuron conveying sensory impulses." []	\N	sensory neuron	\N	\N	EFO	"Any neuron having a sensory function; an afferent neuron conveying sensory impulses." []	EFO	66042	CL:0000101	\N	sensory neuron	CL:0000101
0	"A neuron that is part of nerve found outside the central nervous system." []	\N	somatic nervous system	\N	\N	EFO	"A neuron that is part of nerve found outside the central nervous system." []	EFO	66043	CL:0000111	\N	somatic nervous system	CL:0000111
0	"" []	\N	columnar neuron	\N	\N	EFO	"" []	EFO	66044	CL:0000112	\N	columnar neuron	CL:0000112
0	"The main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart." []	\N	endothelial cell	\N	\N	EFO	"The main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart." []	EFO	66045	CL:0000115	\N	endothelial cell	CL:0000115
0	"The delicate network of branched cells and fibers that supports the tissue of the central nervous system." []	\N	glial cell	\N	\N	EFO	"The delicate network of branched cells and fibers that supports the tissue of the central nervous system." []	EFO	66046	CL:0000125	\N	glial cell	CL:0000125
0	"cells) are irregularly shaped with many long processes, including those with \\"end feet\\" which form the glial (limiting) membrane and directly and indirectly contribute to the blood-brain barrier. They regulate the extracellular ionic and chemical environment, and" []	\N	astrocyte	\N	\N	EFO	"cells) are irregularly shaped with many long processes, including those with \\"end feet\\" which form the glial (limiting) membrane and directly and indirectly contribute to the blood-brain barrier. They regulate the extracellular ionic and chemical environment, and" []	EFO	66047	CL:0000127	\N	astrocyte	CL:0000127
0	"A class of large neuroglial (macroglial) cells in the central nervous system. Oligodendroglia may be called interfascicular, perivascular, or perineuronal (not the same as satellite cells, perineuronal of ganglia) according to their location. They form the insulating myelin sheath of axons in the central nervous system (MSH)." []	\N	oligodendrocyte	\N	\N	EFO	"A class of large neuroglial (macroglial) cells in the central nervous system. Oligodendroglia may be called interfascicular, perivascular, or perineuronal (not the same as satellite cells, perineuronal of ganglia) according to their location. They form the insulating myelin sheath of axons in the central nervous system (MSH)." []	EFO	66048	CL:0000128	\N	oligodendrocyte	CL:0000128
0	"The small, non-neural, interstitial cells of mesodermal origin that form part of the supporting structure of the central nervous system. They are of various forms and may have slender branched processes. They are migratory and act as phagocytes to waste products of nerve tissue." []	\N	microglial cell	\N	\N	EFO	"The small, non-neural, interstitial cells of mesodermal origin that form part of the supporting structure of the central nervous system. They are of various forms and may have slender branched processes. They are migratory and act as phagocytes to waste products of nerve tissue." []	EFO	66049	CL:0000129	\N	microglial cell	CL:0000129
0	"A fat-storing cell found mostly in the abdominal cavity and subcutaneous tissue of mammals. Fat is usually stored in the form of tryglycerides." []	\N	fat cell	\N	\N	EFO	"A fat-storing cell found mostly in the abdominal cavity and subcutaneous tissue of mammals. Fat is usually stored in the form of tryglycerides." []	EFO	66050	CL:0000136	\N	fat cell	CL:0000136
0	"Polymorphic cell that form cartilage." []	\N	chondrocyte	\N	\N	EFO	"Polymorphic cell that form cartilage." []	EFO	66051	CL:0000138	\N	chondrocyte	CL:0000138
0	"An epidermal cell that produces melanin." []	\N	melanocyte	\N	\N	EFO	"An epidermal cell that produces melanin." []	EFO	66052	CL:0000148	\N	melanocyte	CL:0000148
0	"A cell that specializes in controlled release of one or more substances." []	\N	secretory cell	\N	\N	EFO	"A cell that specializes in controlled release of one or more substances." []	EFO	66053	CL:0000151	\N	secretory cell	CL:0000151
0	"A large, oval stomach epithelial cell with a central nucleus; source of gastric acid. Secretes HCl." []	\N	parietal cell	\N	\N	EFO	"A large, oval stomach epithelial cell with a central nucleus; source of gastric acid. Secretes HCl." []	EFO	66054	CL:0000162	\N	parietal cell	CL:0000162
0	"Neuroendocrine cells are cells that receive neuronal input (neurotransmitters released by nerve cells) and, as a consequence of this input, release message molecules (hormones) to the blood. In this way they bring about and integration between the nervous system and the endocrine system, a process known as neuroendocrine integration. An example of a neuroendocrine cell is the cell of the adrenal medulla (innermost part of the adrenal gland) which releases adrenalin to the blood. The adrenal medullary cells are controlled by the sympathetic division of the autonomic nervous system. These cells are modified postganglionic neurons. Autonomic nerve fibers lead directly to them from the central nervous system. The major center of neuroendocrine integration in the body is found in the hypothalamus and the pituitary gland. Here hypothalamic neurosecretory cells release factors to the blood. Some of these these factors, release at the median eminence, control the secretion of pituitary hormones, while others (the hormones oxytocin and vasopressin) are released directly to the peripheral circulation." []	\N	neuroendocrine cell	\N	\N	EFO	"Neuroendocrine cells are cells that receive neuronal input (neurotransmitters released by nerve cells) and, as a consequence of this input, release message molecules (hormones) to the blood. In this way they bring about and integration between the nervous system and the endocrine system, a process known as neuroendocrine integration. An example of a neuroendocrine cell is the cell of the adrenal medulla (innermost part of the adrenal gland) which releases adrenalin to the blood. The adrenal medullary cells are controlled by the sympathetic division of the autonomic nervous system. These cells are modified postganglionic neurons. Autonomic nerve fibers lead directly to them from the central nervous system. The major center of neuroendocrine integration in the body is found in the hypothalamus and the pituitary gland. Here hypothalamic neurosecretory cells release factors to the blood. Some of these these factors, release at the median eminence, control the secretion of pituitary hormones, while others (the hormones oxytocin and vasopressin) are released directly to the peripheral circulation." []	EFO	66055	CL:0000165	\N	neuroendocrine cell	CL:0000165
0	"A cell that composes the bulk of the islets of Langerhans and secretes insulin." []	\N	beta cell	\N	\N	EFO	"A cell that composes the bulk of the islets of Langerhans and secretes insulin." []	EFO	66056	CL:0000168	\N	beta cell	CL:0000168
0	"A type of enteocrine cell found in the periphery of the islets of Langerhans that secretes glucagon." []	\N	alpha cell	\N	\N	EFO	"A type of enteocrine cell found in the periphery of the islets of Langerhans that secretes glucagon." []	EFO	66057	CL:0000171	\N	alpha cell	CL:0000171
0	"A Leydig cell is a testosterone-secreting cell in the interstitial area, between the seminiferous tubules, in the testis." []	\N	Leydig cell	\N	\N	EFO	"A Leydig cell is a testosterone-secreting cell in the interstitial area, between the seminiferous tubules, in the testis." []	EFO	66058	CL:0000178	\N	Leydig cell	CL:0000178
0	"The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated." []	\N	hepatocyte	\N	\N	EFO	"The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated." []	EFO	66059	CL:0000182	\N	hepatocyte	CL:0000182
0	"Mature contractile cells, commonly known as myocytes, that form one of three kinds of muscle. The three types of muscle cells are skeletal (muscle fibers), cardiac (myocytes, cardiac), and smooth (myocytes, smooth muscle). They are derived from embryonic (precursor) muscle cells called myoblasts (MSH)." []	\N	muscle cell	\N	\N	EFO	"Mature contractile cells, commonly known as myocytes, that form one of three kinds of muscle. The three types of muscle cells are skeletal (muscle fibers), cardiac (myocytes, cardiac), and smooth (myocytes, smooth muscle). They are derived from embryonic (precursor) muscle cells called myoblasts (MSH)." []	EFO	66060	CL:0000187	\N	muscle cell	CL:0000187
0	"Non-striated, elongated, spindle-shaped cells found lining the digestive tract, uterus, and blood vessels. They are derived from specialized myoblasts (myoblasts, smooth muscle) (MSH)." []	\N	smooth muscle cell	\N	\N	EFO	"Non-striated, elongated, spindle-shaped cells found lining the digestive tract, uterus, and blood vessels. They are derived from specialized myoblasts (myoblasts, smooth muscle) (MSH)." []	EFO	66061	CL:0000192	\N	smooth muscle cell	CL:0000192
0	"A mechanoreceptor cell located in the organ of Corti that is sensitive to auditory stimuli and in the vestibular apparatus that is sensitive to movement of the head. In each case the accessory sensory structures are arranged so that appropriate stimuli cause movement of the hair-like projections (stereocilia and kinocilia) which relay the information centrally in the nervous system." []	\N	cochlear hair cell	\N	\N	EFO	"A mechanoreceptor cell located in the organ of Corti that is sensitive to auditory stimuli and in the vestibular apparatus that is sensitive to movement of the head. In each case the accessory sensory structures are arranged so that appropriate stimuli cause movement of the hair-like projections (stereocilia and kinocilia) which relay the information centrally in the nervous system." []	EFO	66062	CL:0000202	\N	cochlear hair cell	CL:0000202
0	"\\nA cell whose function is determined by the generation or the reception of an electric signal.\\n" []	\N	electrically active cell	\N	\N	cell	"\\nA cell whose function is determined by the generation or the reception of an electric signal.\\n" []	EFO	66063	CL:0000211	\N	electrically active cell	CL:0000211
0	"A supporting cell projecting inward from the basement membrane of seminiferous tubules. They surround and nourish the developing male germ cells and secrete androgen binding protein. Their tight junctions with the spermatogonia and spermatocytes provide a blood-testis barrier." []	\N	Sertoli cell	\N	\N	EFO	"A supporting cell projecting inward from the basement membrane of seminiferous tubules. They surround and nourish the developing male germ cells and secrete androgen binding protein. Their tight junctions with the spermatogonia and spermatocytes provide a blood-testis barrier." []	EFO	66064	CL:0000216	\N	Sertoli cell	CL:0000216
0	"A neuroglial cell of the peripheral nervous system which forms the insulating myelin sheaths of peripheral axons." []	\N	Schwann cell	\N	\N	EFO	"A neuroglial cell of the peripheral nervous system which forms the insulating myelin sheaths of peripheral axons." []	EFO	66065	CL:0000218	\N	Schwann cell	CL:0000218
0	"A cell of the middle germ layer of the embryo." []	\N	mesodermal cell	\N	\N	EFO	"A cell of the middle germ layer of the embryo." []	EFO	66066	CL:0000222	\N	mesodermal cell	CL:0000222
0	"Any of the hemoglobin-containing cells that carry oxygen to the tissues and are responsible for the red color of vertebrate blood." []	\N	erythrocyte	\N	\N	EFO	"Any of the hemoglobin-containing cells that carry oxygen to the tissues and are responsible for the red color of vertebrate blood." []	EFO	66067	CL:0000232	\N	erythrocyte	CL:0000232
0	"A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation." []	\N	platelet	\N	\N	EFO	"A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation." []	EFO	66068	CL:0000233	\N	platelet	CL:0000233
0	"Relatively long-lived phagocytic cell of mammalian tissues, derived from blood monocyte. Macrophages from different sites have distinctly different properties. Main types are peritoneal and alveolar macrophages, tissue macrophages (histiocytes), Kuppfer cells of the liver, and osteoclasts. In response to foreign materials may become stimulated or activated. Macrophages play an important role in killing of some bacteria, protozoa, and tumour cells, release substances that stimulate other cells of the immune system, and are involved in antigen presentation. May further differentiate within chronic inflammatory lesions to epithelioid cells or may fuse to form foreign body giant cells or Langhans' giant cells." []	\N	macrophage	\N	\N	EFO	"Relatively long-lived phagocytic cell of mammalian tissues, derived from blood monocyte. Macrophages from different sites have distinctly different properties. Main types are peritoneal and alveolar macrophages, tissue macrophages (histiocytes), Kuppfer cells of the liver, and osteoclasts. In response to foreign materials may become stimulated or activated. Macrophages play an important role in killing of some bacteria, protozoa, and tumour cells, release substances that stimulate other cells of the immune system, and are involved in antigen presentation. May further differentiate within chronic inflammatory lesions to epithelioid cells or may fuse to form foreign body giant cells or Langhans' giant cells." []	EFO	66069	CL:0000235	\N	macrophage	CL:0000235
0	"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins." []	\N	B cell	\N	\N	EFO	"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins." []	EFO	66070	CL:0000236	\N	B cell	CL:0000236
0	"A haploid (1n) spore developing into a female gametophyte in heterosporous plants." []	\N	megaspore	\N	\N	EFO	"A haploid (1n) spore developing into a female gametophyte in heterosporous plants." []	EFO	66071	CL:0000250	\N	megaspore	CL:0000250
0	"The structure into which a haploid microspore develops; contains a halpoid tube nucleus and two haploid sperm nuclei at maturity." []	\N	microspore	\N	\N	EFO	"The structure into which a haploid microspore develops; contains a halpoid tube nucleus and two haploid sperm nuclei at maturity." []	EFO	66072	CL:0000252	\N	microspore	CL:0000252
0	"A cell of a filament of a fungal mycelium." []	\N	hyphal cell	\N	\N	cell	"A cell of a filament of a fungal mycelium." []	EFO	66073	CL:0000286	\N	hyphal cell	CL:0000286
0	"One of a pair of cells flanking the stomatal pore and causing the opening and closing of the pore by changes in turgor." []	\N	guard cell	\N	\N	EFO	"One of a pair of cells flanking the stomatal pore and causing the opening and closing of the pore by changes in turgor." []	EFO	66074	CL:0000292	\N	guard cell	CL:0000292
0	"Skin cell, of the keratinized layer of epidermis: its characteristic intermediate filament protein is cytokeratin.nA cell of the stratum spinosum of the epidermis." []	\N	keratinocyte	\N	\N	EFO	"Skin cell, of the keratinized layer of epidermis: its characteristic intermediate filament protein is cytokeratin.nA cell of the stratum spinosum of the epidermis." []	EFO	66075	CL:0000312	\N	keratinocyte	CL:0000312
0	"A cell of the strip of specialized ectoderm flanking each side of the embryonal neural plate, which after the closure of the neural tube, forms a column of isolated cells along the dorsal aspect of the neural tube. Most of the cranial and all of the spinal sensory ganglion cells arise by differentiation of neural crest cells." []	\N	neural crest cell	\N	\N	EFO	"A cell of the strip of specialized ectoderm flanking each side of the embryonal neural plate, which after the closure of the neural tube, forms a column of isolated cells along the dorsal aspect of the neural tube. Most of the cranial and all of the spinal sensory ganglion cells arise by differentiation of neural crest cells." []	EFO	66076	CL:0000333	\N	neural crest cell	CL:0000333
0	"Either of a pair of complex endocrine organs near the anterior medial border of the kidney consisting of a mesodermal cortex that produces glucocorticoid, mineralocorticoid, and androgenic hormones and an ectodermal medulla that produces epinephrine and norepinephrine." []	\N	adrenal gland	\N	\N	EFO	"Either of a pair of complex endocrine organs near the anterior medial border of the kidney consisting of a mesodermal cortex that produces glucocorticoid, mineralocorticoid, and androgenic hormones and an ectodermal medulla that produces epinephrine and norepinephrine." []	EFO	66077	CL:0000336	\N	adrenal gland	CL:0000336
0	"An embryonic cell that develops into a nerve cell or neuron." []	\N	neuroblast (sensu Vertebrata)	\N	\N	EFO	"An embryonic cell that develops into a nerve cell or neuron." []	EFO	66078	CL:0000337	\N	neuroblast (sensu Vertebrata)	CL:0000337
0	"A specialized mesenchymal cell that resides in the dermal papilla located at the bottom of hair follicles. This cell plays a pivotal roles in hair formation, growth, and cycling." []	\N	hair follicle dermal papilla cell	\N	\N	EFO	"A specialized mesenchymal cell that resides in the dermal papilla located at the bottom of hair follicles. This cell plays a pivotal roles in hair formation, growth, and cycling." []	EFO	66079	CL:0000346	\N	hair follicle dermal papilla cell	CL:0000346
0	"A cell which is part of an extraembryonic structure associated with an embryo and derived from the zygote from which it develops, but which does not contribute to the embryo proper or to structures that are part of the same organism after embryogenesis." []	\N	extraembryonic cell	\N	\N	EFO	"A cell which is part of an extraembryonic structure associated with an embryo and derived from the zygote from which it develops, but which does not contribute to the embryo proper or to structures that are part of the same organism after embryogenesis." []	EFO	66080	CL:0000349	\N	extraembryonic cell	CL:0000349
0	"A cell lining the outside of the blastocyst. After binding to the endometrium, trophoblast cells develop into two distinct layers, an inner layer of mononuclear cytotrophoblast cells and an outer layer of continuous multinuclear cytoplasm, the syncytiotrophoblast cells, which form the early fetal-maternal interface." []	\N	trophoblast cell	\N	\N	EFO	"A cell lining the outside of the blastocyst. After binding to the endometrium, trophoblast cells develop into two distinct layers, an inner layer of mononuclear cytotrophoblast cells and an outer layer of continuous multinuclear cytoplasm, the syncytiotrophoblast cells, which form the early fetal-maternal interface." []	EFO	66081	CL:0000351	\N	trophoblast cell	CL:0000351
0	"A cell of the outer layer of a blastula that gives rise to the ectoderm after gastrulation." []	\N	epiblast cell	\N	\N	EFO	"A cell of the outer layer of a blastula that gives rise to the ectoderm after gastrulation." []	EFO	66082	CL:0000352	\N	epiblast cell	CL:0000352
0	"An epithelial cell of the integument (the outer layer of an organism)." []	\N	epidermal cell	\N	\N	EFO	"An epithelial cell of the integument (the outer layer of an organism)." []	EFO	66083	CL:0000362	\N	epidermal cell	CL:0000362
0	"The stage at which a diploid cell is produced by the fusion of sperm cell nucleus and egg cell." []	\N	zygote	\N	\N	EFO	"The stage at which a diploid cell is produced by the fusion of sperm cell nucleus and egg cell." []	EFO	66084	CL:0000365	\N	zygote	CL:0000365
0	"The cell protoplasm after removal of the cell wall." []	\N	protoplast	\N	\N	EFO	"The cell protoplasm after removal of the cell wall." []	EFO	66085	CL:0000371	\N	protoplast	CL:0000371
0	"" []	\N	ligament cell	\N	\N	EFO	"" []	EFO	66086	CL:0000384	\N	ligament cell	CL:0000384
0	"" []	\N	prohemocyte (sensu Nematoda and Protostomia)	\N	\N	EFO	"" []	EFO	66087	CL:0000385	\N	prohemocyte (sensu Nematoda and Protostomia)	CL:0000385
0	"A blood cell especially of an invertebrate animal." []	\N	hemocyte	\N	\N	EFO	"A blood cell especially of an invertebrate animal." []	EFO	66088	CL:0000387	\N	hemocyte	CL:0000387
0	"Tissue which consists of fibroblasts, osteocytes or chondrocytes and intercellular matrix produced by these cells. Examples: bone (tissue), dense regular elastic tissue, areolar tissue, neuroglia, adipose tissue." []	\N	connective tissue	\N	\N	EFO	"Tissue which consists of fibroblasts, osteocytes or chondrocytes and intercellular matrix produced by these cells. Examples: bone (tissue), dense regular elastic tissue, areolar tissue, neuroglia, adipose tissue." []	EFO	66089	CL:0000388	\N	connective tissue	CL:0000388
0	"" []	\N	blood cell (sensu Nematoda and Protostomia)	\N	\N	EFO	"" []	EFO	66090	CL:0000390	\N	blood cell (sensu Nematoda and Protostomia)	CL:0000390
0	"A cell that is slightly larger than the plasmatocytes and is distinguished by containing large crystalline inclusions that are not membrane bound (Brehelin, 1982)." []	\N	crystal cell	\N	\N	EFO	"A cell that is slightly larger than the plasmatocytes and is distinguished by containing large crystalline inclusions that are not membrane bound (Brehelin, 1982)." []	EFO	66091	CL:0000392	\N	crystal cell	CL:0000392
0	"A cell whose nucleus has two haploid genomes." []	\N	diploid cell	\N	\N	cell	"A cell whose nucleus has two haploid genomes." []	EFO	66092	CL:0000415	\N	diploid cell	CL:0000415
0	"\\nA free floating cell, including amebocytes and eleocytes, in the coelom of certain animals, especially annelids.\\n" []	\N	coelomocyte	\N	\N	cell	"\\nA free floating cell, including amebocytes and eleocytes, in the coelom of certain animals, especially annelids.\\n" []	EFO	66093	CL:0000421	\N	coelomocyte	CL:0000421
0	"A cell with extensive dendritic processes found in the B cell areas (primary follicles and germinal centers) of lymphoid tissue. They are unrelated to the dendritic cell associated with T cells. Follicular dendritic cells have Fc receptors and C3b receptors, but unlike other dendritic cells, they do not process or present antigen in a way that allows recognition by T cells. Instead, they hold antigen in the form of immune complexes on their surfaces for long periods and can present antigen to B cells during an immune response." []	\N	follicular dendritic cell	\N	\N	cell	"A cell with extensive dendritic processes found in the B cell areas (primary follicles and germinal centers) of lymphoid tissue. They are unrelated to the dendritic cell associated with T cells. Follicular dendritic cells have Fc receptors and C3b receptors, but unlike other dendritic cells, they do not process or present antigen in a way that allows recognition by T cells. Instead, they hold antigen in the form of immune complexes on their surfaces for long periods and can present antigen to B cells during an immune response." []	EFO	66094	CL:0000442	\N	follicular dendritic cell	CL:0000442
0	"Any of usually four small endocrine glands that are adjacent to or embedded in the thyroid gland and produce parathyroid hormone." []	\N	parathyroid	\N	\N	EFO	"Any of usually four small endocrine glands that are adjacent to or embedded in the thyroid gland and produce parathyroid hormone." []	EFO	66095	CL:0000446	\N	parathyroid	CL:0000446
0	"A cell from the thermogenic form of adipose tissue found in newborns of many species, including humans, and in hibernating mammals. Brown fat is capable of rapid liberation of energy and seems to be important in the maintenance of body temperature immediately after birth and upon waking from hibernation." []	\N	brown fat cell	\N	\N	EFO	"A cell from the thermogenic form of adipose tissue found in newborns of many species, including humans, and in hibernating mammals. Brown fat is capable of rapid liberation of energy and seems to be important in the maintenance of body temperature immediately after birth and upon waking from hibernation." []	EFO	66096	CL:0000449	\N	brown fat cell	CL:0000449
0	"Large, stellate fibroblast found along the network of collagen fibers of the reticulum of the spleen; synthesize the matrix components of the reticulum." []	\N	dendritic cell	\N	\N	EFO	"Large, stellate fibroblast found along the network of collagen fibers of the reticulum of the spleen; synthesize the matrix components of the reticulum." []	EFO	66097	CL:0000451	\N	dendritic cell	CL:0000451
0	"" []	\N	Langerhans cell	\N	\N	EFO	"" []	EFO	66098	CL:0000453	\N	Langerhans cell	CL:0000453
0	"" []	\N	follicle cell	\N	\N	EFO	"" []	EFO	66099	CL:0000477	\N	follicle cell	CL:0000477
0	"" []	\N	connective tissue type mast cell	\N	\N	EFO	"" []	EFO	66100	CL:0000484	\N	connective tissue type mast cell	CL:0000484
0	"" []	\N	mucosal type mast cell	\N	\N	EFO	"" []	EFO	66101	CL:0000485	\N	mucosal type mast cell	CL:0000485
0	"" []	\N	CD4-positive helper T cell	\N	\N	EFO	"" []	EFO	66102	CL:0000492	\N	CD4-positive helper T cell	CL:0000492
0	"A connective tissue cell of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere." []	\N	stromal cell	\N	\N	EFO	"A connective tissue cell of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere." []	EFO	66103	CL:0000499	\N	stromal cell	CL:0000499
0	"A supporting cell for the developing female gamete in the ovary of mammals. They develop from the coelomic epithelial cells of the gonadal ridge. Granulosa cells form a single layer around the mammalian oocyte in the primordial ovarian follicle and advance to form a multilayered cumulus oophorus surrounding the ovum in the Graafian follicle. The major functions of granulosa cells include the production of steroids and LH receptors." []	\N	granulosa cell	\N	\N	EFO	"A supporting cell for the developing female gamete in the ovary of mammals. They develop from the coelomic epithelial cells of the gonadal ridge. Granulosa cells form a single layer around the mammalian oocyte in the primordial ovarian follicle and advance to form a multilayered cumulus oophorus surrounding the ovum in the Graafian follicle. The major functions of granulosa cells include the production of steroids and LH receptors." []	EFO	66104	CL:0000501	\N	granulosa cell	CL:0000501
0	"A precursor cell destined to differentiate into smooth muscle myocytes." []	\N	smooth muscle myoblast	\N	\N	EFO	"A precursor cell destined to differentiate into smooth muscle myocytes." []	EFO	66105	CL:0000514	\N	smooth muscle myoblast	CL:0000514
0	"A myoblast that differentiates into skeletal muscle fibers." []	\N	skeletal muscle myoblast	\N	\N	EFO	"A myoblast that differentiates into skeletal muscle fibers." []	EFO	66106	CL:0000515	\N	skeletal muscle myoblast	CL:0000515
0	"" []	\N	prokaryotic cell	\N	\N	cell	"" []	EFO	66107	CL:0000520	\N	prokaryotic cell	CL:0000520
0	"" []	\N	fungal cell	\N	\N	cell	"" []	EFO	66108	CL:0000521	\N	fungal cell	CL:0000521
0	"A cell from the outer syncytial layer of the trophoblast of an early mammalian embryo. It It secretes hCG in order to maintain progesterone secretion and sustain a pregnancy." []	\N	syncytiotrophoblast cell	\N	\N	EFO	"A cell from the outer syncytial layer of the trophoblast of an early mammalian embryo. It It secretes hCG in order to maintain progesterone secretion and sustain a pregnancy." []	EFO	66109	CL:0000525	\N	syncytiotrophoblast cell	CL:0000525
0	"The basic cellular units of nervous tissue. Neurons are polarized cells with defined regions consisting of the cell body, an axon, and dendrites, although some types of neurons lack axons or dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system." []	\N	neuron	\N	\N	EFO	"The basic cellular units of nervous tissue. Neurons are polarized cells with defined regions consisting of the cell body, an axon, and dendrites, although some types of neurons lack axons or dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system." []	EFO	66110	CL:0000540	\N	neuron	CL:0000540
0	"Any of the colorless weakly motile cells originating from stem cells and differentiating in lymphoid tissue (as of the thymus or bone marrow) that are the typical cellular elements of lymph, include the cellular mediators of immunity, and constitute 20 to 30 percent of the white blood cells of normal human blood." []	\N	lymphocyte	\N	\N	EFO	"Any of the colorless weakly motile cells originating from stem cells and differentiating in lymphoid tissue (as of the thymus or bone marrow) that are the typical cellular elements of lymph, include the cellular mediators of immunity, and constitute 20 to 30 percent of the white blood cells of normal human blood." []	EFO	66111	CL:0000542	\N	lymphocyte	CL:0000542
0	"" []	\N	T-helper 1 cell	\N	\N	EFO	"" []	EFO	66112	CL:0000545	\N	T-helper 1 cell	CL:0000545
0	"" []	\N	T-helper 2 cell	\N	\N	EFO	"" []	EFO	66113	CL:0000546	\N	T-helper 2 cell	CL:0000546
0	"An immature, nucleated erythrocyte occupying the stage of erythropoeisis that follows formation of erythroid progenitor cells. This cell is CD71-positive, has both a nucleus and a nucleolus, and lacks hematopoeitic lineage markers." []	\N	proerythroblast	\N	\N	EFO	"An immature, nucleated erythrocyte occupying the stage of erythropoeisis that follows formation of erythroid progenitor cells. This cell is CD71-positive, has both a nucleus and a nucleolus, and lacks hematopoeitic lineage markers." []	EFO	66114	CL:0000547	\N	proerythroblast	CL:0000547
0	"A nucleated immature erythrocyte, having cytoplasm generally similar to that of the earlier proerythroblast but sometimes even more basophilic, and usually regular in outline. The nucleus is still relatively large, but the chromatin strands are thicker and more deeply staining, giving a coarser appearance; the nucleoli have disappeared. This cell is CD71-positive and lacks hematopoeitic lineage markers." []	\N	basophilic erythroblast	\N	\N	EFO	"A nucleated immature erythrocyte, having cytoplasm generally similar to that of the earlier proerythroblast but sometimes even more basophilic, and usually regular in outline. The nucleus is still relatively large, but the chromatin strands are thicker and more deeply staining, giving a coarser appearance; the nucleoli have disappeared. This cell is CD71-positive and lacks hematopoeitic lineage markers." []	EFO	66115	CL:0000549	\N	basophilic erythroblast	CL:0000549
0	"" []	\N	polychromatophilic erythroblast	\N	\N	EFO	"" []	EFO	66116	CL:0000550	\N	polychromatophilic erythroblast	CL:0000550
0	"" []	\N	orthochromatic erythroblast	\N	\N	EFO	"" []	EFO	66117	CL:0000552	\N	orthochromatic erythroblast	CL:0000552
0	"The earliest cytologically identifiable precursor in the thrombocytic series. This cell is capable of endomitosis and lacks expression of hematopoieitic lineage markers (lin-negative)." []	\N	megakaryocyte progenitor cell	\N	\N	EFO	"The earliest cytologically identifiable precursor in the thrombocytic series. This cell is capable of endomitosis and lacks expression of hematopoieitic lineage markers (lin-negative)." []	EFO	66118	CL:0000553	\N	megakaryocyte progenitor cell	CL:0000553
0	"A large cell that has a lobulated nucleus, is found especially in the bone marrow, and is the source of blood platelets." []	\N	megakaryocyte	\N	\N	EFO	"A large cell that has a lobulated nucleus, is found especially in the bone marrow, and is the source of blood platelets." []	EFO	66119	CL:0000556	\N	megakaryocyte	CL:0000556
0	"A progenitor cell that has plasma membrane part CD123, CD34, and CD45RA, lacks plasma membrane part CD19 and CD3, and is committed to the granulocyte and monocyte lineages." []	\N	granulocyte monocyte progenitor cell	\N	\N	EFO	"A progenitor cell that has plasma membrane part CD123, CD34, and CD45RA, lacks plasma membrane part CD19 and CD3, and is committed to the granulocyte and monocyte lineages." []	EFO	66120	CL:0000557	\N	granulocyte monocyte progenitor cell	CL:0000557
0	"An immature erythrocyte that changes the protein composition of its plasma membrane by exosome formation and extrusion. The types of protein removed differ between species though removal of the transferrin receptor is apparent in mammals and birds." []	\N	reticulocyte	\N	\N	EFO	"An immature erythrocyte that changes the protein composition of its plasma membrane by exosome formation and extrusion. The types of protein removed differ between species though removal of the transferrin receptor is apparent in mammals and birds." []	EFO	66121	CL:0000558	\N	reticulocyte	CL:0000558
0	"" []	\N	promonocyte	\N	\N	EFO	"" []	EFO	66122	CL:0000559	\N	promonocyte	CL:0000559
0	"" []	\N	band form neutrophil	\N	\N	EFO	"" []	EFO	66123	CL:0000560	\N	band form neutrophil	CL:0000560
0	"" []	\N	nucleate erythrocyte	\N	\N	EFO	"" []	EFO	66124	CL:0000562	\N	nucleate erythrocyte	CL:0000562
0	"" []	\N	neutrophilic promyelocyte	\N	\N	EFO	"" []	EFO	66125	CL:0000564	\N	neutrophilic promyelocyte	CL:0000564
0	"Myeloid mononuclear recirculating leukocyte that can act as a precursor of tissue macrophages, osteoclasts and some populations of tissue dendritic cells." []	\N	monocyte	\N	\N	EFO	"Myeloid mononuclear recirculating leukocyte that can act as a precursor of tissue macrophages, osteoclasts and some populations of tissue dendritic cells." []	EFO	66126	CL:0000576	\N	monocyte	CL:0000576
0	"A follicle cell that migrates from the anterior pole of the egg chamber, between the nurse cells, to the anterior of the oocyte where they participate in formation of the micropyle. About 6-10 border cells per egg chamber migrate as a tightly associated cluster." []	\N	border follicle cell	\N	\N	EFO	"A follicle cell that migrates from the anterior pole of the egg chamber, between the nurse cells, to the anterior of the oocyte where they participate in formation of the micropyle. About 6-10 border cells per egg chamber migrate as a tightly associated cluster." []	EFO	66127	CL:0000579	\N	border follicle cell	CL:0000579
0	"" []	\N	neutrophilic myelocyte	\N	\N	EFO	"" []	EFO	66128	CL:0000580	\N	neutrophilic myelocyte	CL:0000580
0	"" []	\N	peritoneal macrophage	\N	\N	EFO	"" []	EFO	66129	CL:0000581	\N	peritoneal macrophage	CL:0000581
0	"" []	\N	neutrophilic metamyelocyte	\N	\N	EFO	"" []	EFO	66130	CL:0000582	\N	neutrophilic metamyelocyte	CL:0000582
0	"" []	\N	alveolar macrophage	\N	\N	EFO	"" []	EFO	66131	CL:0000583	\N	alveolar macrophage	CL:0000583
0	"The reproductive cell in multicellular organisms." []	\N	germ cell	\N	\N	EFO	"The reproductive cell in multicellular organisms." []	EFO	66132	CL:0000586	\N	germ cell	CL:0000586
0	"" []	\N	odontoclast	\N	\N	EFO	"" []	EFO	66133	CL:0000588	\N	odontoclast	CL:0000588
0	"" []	\N	enucleate erythrocyte	\N	\N	EFO	"" []	EFO	66134	CL:0000595	\N	enucleate erythrocyte	CL:0000595
0	"A projection neuron in the cerebral cortex and the hippocampus. Pyramidal cells have a pyramid-shaped soma with the apex and an apical dendrite pointed toward the pial surface and other dendrites and an axon emerging from the base. The axons may have local collaterals but also project outside their cortical region." []	\N	pyramidal cell	\N	\N	cell	"A projection neuron in the cerebral cortex and the hippocampus. Pyramidal cells have a pyramid-shaped soma with the apex and an apical dendrite pointed toward the pial surface and other dendrites and an axon emerging from the base. The axons may have local collaterals but also project outside their cortical region." []	EFO	66135	CL:0000598	\N	pyramidal cell	CL:0000598
0	"\\nAn asexual, nonmotile spore formed by higher fungi; conidia are usually made from the side or tip of specialized sporogenous cells and do not form by progressive cleavage of the cytoplasm.\\n" []	\N	conidium	\N	\N	cell	"\\nAn asexual, nonmotile spore formed by higher fungi; conidia are usually made from the side or tip of specialized sporogenous cells and do not form by progressive cleavage of the cytoplasm.\\n" []	EFO	66136	CL:0000599	\N	conidium	CL:0000599
0	"A cell found in seeded plants." []	\N	plant cell	\N	\N	EFO	"A cell found in seeded plants." []	EFO	66137	CL:0000610	\N	plant cell	CL:0000610
0	"" []	\N	eosinophil progenitor cell	\N	\N	EFO	"" []	EFO	66138	CL:0000611	\N	eosinophil progenitor cell	CL:0000611
0	"" []	\N	eosinophilic myelocyte	\N	\N	EFO	"" []	EFO	66139	CL:0000612	\N	eosinophilic myelocyte	CL:0000612
0	"" []	\N	basophil progenitor cell	\N	\N	EFO	"" []	EFO	66140	CL:0000613	\N	basophil progenitor cell	CL:0000613
0	"" []	\N	basophilic myelocyte	\N	\N	EFO	"" []	EFO	66141	CL:0000614	\N	basophilic myelocyte	CL:0000614
0	"A neuron that uses GABA as a vesicular neurotransmitter" []	\N	GABAergic neuron	\N	\N	EFO	"A neuron that uses GABA as a vesicular neurotransmitter" []	EFO	66142	CL:0000617	\N	GABAergic neuron	CL:0000617
0	"A secretory cell that is grouped together with other cells of the same type to form grape shaped clusters known as acini (singular acinus)." []	\N	acinar cell	\N	\N	EFO	"A secretory cell that is grouped together with other cells of the same type to form grape shaped clusters known as acini (singular acinus)." []	EFO	66143	CL:0000622	\N	acinar cell	CL:0000622
0	"A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells." []	\N	natural killer cell	\N	\N	EFO	"A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells." []	EFO	66144	CL:0000623	\N	natural killer cell	CL:0000623
0	"" []	\N	CD4-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66145	CL:0000624	\N	CD4-positive, alpha-beta T cell	CL:0000624
0	"" []	\N	CD8-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66146	CL:0000625	\N	CD8-positive, alpha-beta T cell	CL:0000625
0	"\\nA cell that can perform photosynthesis, in which carbohydrates are synthesized from carbon dioxide and water, using light as the energy source.\\n" []	\N	photosynthetic cell	\N	\N	cell	"\\nA cell that can perform photosynthesis, in which carbohydrates are synthesized from carbon dioxide and water, using light as the energy source.\\n" []	EFO	66147	CL:0000628	\N	photosynthetic cell	CL:0000628
0	"\\nA cell that is found in the perisinusoidal space of the liver that is capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components that can contribute to liver fibrosis. This activated state has a myofibroblast-like phenotype, though it's not clear in the literature if this is terminally differentiated. This cell type comprises approximately 8-15% of total cells in the liver.\\n" []	\N	hepatic stellate cell	\N	\N	cell	"\\nA cell that is found in the perisinusoidal space of the liver that is capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components that can contribute to liver fibrosis. This activated state has a myofibroblast-like phenotype, though it's not clear in the literature if this is terminally differentiated. This cell type comprises approximately 8-15% of total cells in the liver.\\n" []	EFO	66148	CL:0000632	\N	hepatic stellate cell	CL:0000632
0	"Undifferentiated; mitotic stem cell for other epithelial cell types; rounded or elliptical with little cytoplasm and few organelles; contain cytokeratin intermediate filament." []	\N	basal cell	\N	\N	EFO	"Undifferentiated; mitotic stem cell for other epithelial cell types; rounded or elliptical with little cytoplasm and few organelles; contain cytokeratin intermediate filament." []	EFO	66149	CL:0000646	\N	basal cell	CL:0000646
0	"" []	\N	multinucleated giant cell	\N	\N	EFO	"" []	EFO	66150	CL:0000647	\N	multinucleated giant cell	CL:0000647
0	"An elongated, contractile cell found wrapped about precapillary arterioles outside the basement membrane. They are relatively undifferentiated and may become fibroblasts, macrophages, or smooth muscle cells." []	\N	pericyte	\N	\N	EFO	"An elongated, contractile cell found wrapped about precapillary arterioles outside the basement membrane. They are relatively undifferentiated and may become fibroblasts, macrophages, or smooth muscle cells." []	EFO	66151	CL:0000669	\N	pericyte	CL:0000669
0	"A primordial germ cell is a diploid germ cell precursors that transiently exist in the embryo before they enter into close association with the somatic cells of the gonad and become irreversibly committed as germ cells." []	\N	primordial germ cell	\N	\N	EFO	"A primordial germ cell is a diploid germ cell precursors that transiently exist in the embryo before they enter into close association with the somatic cells of the gonad and become irreversibly committed as germ cells." []	EFO	66152	CL:0000670	\N	primordial germ cell	CL:0000670
0	"" []	\N	glutamatergic neuron	\N	\N	EFO	"" []	EFO	66153	CL:0000679	\N	glutamatergic neuron	CL:0000679
0	"A neuron that releases dopamine as a neurotransmitter." []	\N	dopaminergic neuron	\N	\N	EFO	"A neuron that releases dopamine as a neurotransmitter." []	EFO	66154	CL:0000700	\N	dopaminergic neuron	CL:0000700
0	"\\nCumulus cell is a specialized granulosa cell that surrounds and nourishes the oocyte. This cell-type surrounds the fully-grown oocyte to form a cumulus-oocyte complex (abbr. COC). The terms cumulus oophorus cells, cumulus granulosa cells, cumulus oophorous granulosa cells, granulosa-cumulus cells are used to make a distinction between this cell and the other functionally different subpopulation of granulosa cells at the wall of the Graafian follicle.\\n" []	\N	cumulus cell	\N	\N	cell	"\\nCumulus cell is a specialized granulosa cell that surrounds and nourishes the oocyte. This cell-type surrounds the fully-grown oocyte to form a cumulus-oocyte complex (abbr. COC). The terms cumulus oophorus cells, cumulus granulosa cells, cumulus oophorous granulosa cells, granulosa-cumulus cells are used to make a distinction between this cell and the other functionally different subpopulation of granulosa cells at the wall of the Graafian follicle.\\n" []	EFO	66155	CL:0000711	\N	cumulus cell	CL:0000711
0	"Any of the blood cells that are colorless, lack hemoglobin, contain a nucleus, and include the lymphocytes, monocytes, neutrophils, eosinophils, and basophils." []	\N	leukocyte	\N	\N	EFO	"Any of the blood cells that are colorless, lack hemoglobin, contain a nucleus, and include the lymphocytes, monocytes, neutrophils, eosinophils, and basophils." []	EFO	66156	CL:0000738	\N	leukocyte	CL:0000738
0	"Striated muscle cells found in the heart. They are derived from cardiac myoblasts (myoblasts, cardiac (MSH)." []	\N	cardiac myocyte	\N	\N	EFO	"Striated muscle cells found in the heart. They are derived from cardiac myoblasts (myoblasts, cardiac (MSH)." []	EFO	66157	CL:0000746	\N	cardiac myocyte	CL:0000746
0	"" []	\N	nucleated thrombocyte	\N	\N	EFO	"" []	EFO	66158	CL:0000762	\N	nucleated thrombocyte	CL:0000762
0	"Any of the immature blood cells that develop in the bone marrow, such as those involved in hematopoiesis." []	\N	myeloid cell	\N	\N	EFO	"Any of the immature blood cells that develop in the bone marrow, such as those involved in hematopoiesis." []	EFO	66159	CL:0000763	\N	myeloid cell	CL:0000763
0	"A immature or mature cell in the lineage leading to and including erythrocytes." []	\N	erythroid lineage cell	\N	\N	EFO	"A immature or mature cell in the lineage leading to and including erythrocytes." []	EFO	66160	CL:0000764	\N	erythroid lineage cell	CL:0000764
0	"A nucleated precursor of an erythrocyte." []	\N	erythroblast	\N	\N	EFO	"A nucleated precursor of an erythrocyte." []	EFO	66161	CL:0000765	\N	erythroblast	CL:0000765
0	"" []	\N	myeloid leukocyte	\N	\N	EFO	"" []	EFO	66162	CL:0000766	\N	myeloid leukocyte	CL:0000766
0	"Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes." []	\N	basophil	\N	\N	EFO	"Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes." []	EFO	66163	CL:0000767	\N	basophil	CL:0000767
0	"" []	\N	immature basophil	\N	\N	EFO	"" []	EFO	66164	CL:0000768	\N	immature basophil	CL:0000768
0	"" []	\N	basophilic metamyelocyte	\N	\N	EFO	"" []	EFO	66165	CL:0000769	\N	basophilic metamyelocyte	CL:0000769
0	"" []	\N	band form basophil	\N	\N	EFO	"" []	EFO	66166	CL:0000770	\N	band form basophil	CL:0000770
0	"Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin." []	\N	eosinophil	\N	\N	EFO	"Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin." []	EFO	66167	CL:0000771	\N	eosinophil	CL:0000771
0	"" []	\N	immature eosinophil	\N	\N	EFO	"" []	EFO	66168	CL:0000772	\N	immature eosinophil	CL:0000772
0	"" []	\N	eosinophilic metamyelocyte	\N	\N	EFO	"" []	EFO	66169	CL:0000773	\N	eosinophilic metamyelocyte	CL:0000773
0	"" []	\N	band form eosinophil	\N	\N	EFO	"" []	EFO	66170	CL:0000774	\N	band form eosinophil	CL:0000774
0	"Any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes." []	\N	neutrophil	\N	\N	EFO	"Any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes." []	EFO	66171	CL:0000775	\N	neutrophil	CL:0000775
0	"" []	\N	immature neutrophil	\N	\N	EFO	"" []	EFO	66172	CL:0000776	\N	immature neutrophil	CL:0000776
0	"A tissue-resident macrophage of the renal glomerular mesangium." []	\N	mesangial phagocyte	\N	\N	EFO	"A tissue-resident macrophage of the renal glomerular mesangium." []	EFO	66173	CL:0000777	\N	mesangial phagocyte	CL:0000777
0	"" []	\N	mononuclear osteoclast	\N	\N	EFO	"" []	EFO	66174	CL:0000778	\N	mononuclear osteoclast	CL:0000778
0	"" []	\N	multinuclear osteoclast	\N	\N	EFO	"" []	EFO	66175	CL:0000779	\N	multinuclear osteoclast	CL:0000779
0	"" []	\N	multinuclear odontoclast	\N	\N	EFO	"" []	EFO	66176	CL:0000780	\N	multinuclear odontoclast	CL:0000780
0	"" []	\N	mononuclear odontoclast	\N	\N	EFO	"" []	EFO	66177	CL:0000781	\N	mononuclear odontoclast	CL:0000781
0	"" []	\N	myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66178	CL:0000782	\N	myeloid dendritic cell	CL:0000782
0	"A dendritic cell type of distinct morphology, localization, and surface marker expression from other dendritic cell types and associated with early stage immune responses, particularly the release of physiologically abundant amounts of type I interferons in response to infection." []	\N	plasmacytoid dendritic cell	\N	\N	EFO	"A dendritic cell type of distinct morphology, localization, and surface marker expression from other dendritic cell types and associated with early stage immune responses, particularly the release of physiologically abundant amounts of type I interferons in response to infection." []	EFO	66179	CL:0000784	\N	plasmacytoid dendritic cell	CL:0000784
0	"A B cell that is mature, having left the bone marrow. Initially, these cells are IgM-positive and IgD-positive, and they can be activated by antigen." []	\N	mature B cell	\N	\N	EFO	"A B cell that is mature, having left the bone marrow. Initially, these cells are IgM-positive and IgD-positive, and they can be activated by antigen." []	EFO	66180	CL:0000785	\N	mature B cell	CL:0000785
0	"A terminally differentiated, post-mitotic, antibody secreting cell of the B cell lineage with the phenotype CD138-positive, surface immunonoglobulin-negative, and MHC Class II-negative. Plasma cells are oval or round with extensive rough endoplasmic reticulum, a well-developed Golgi apparatus, and a round nucleus having a characteristic cartwheel heterochromatin pattern and are devoted to producing large amounts of immunoglobulin." []	\N	plasma cell	\N	\N	EFO	"A terminally differentiated, post-mitotic, antibody secreting cell of the B cell lineage with the phenotype CD138-positive, surface immunonoglobulin-negative, and MHC Class II-negative. Plasma cells are oval or round with extensive rough endoplasmic reticulum, a well-developed Golgi apparatus, and a round nucleus having a characteristic cartwheel heterochromatin pattern and are devoted to producing large amounts of immunoglobulin." []	EFO	66181	CL:0000786	\N	plasma cell	CL:0000786
0	"" []	\N	memory B cell	\N	\N	EFO	"" []	EFO	66182	CL:0000787	\N	memory B cell	CL:0000787
0	"" []	\N	naive B cell	\N	\N	EFO	"" []	EFO	66183	CL:0000788	\N	naive B cell	CL:0000788
0	"" []	\N	alpha-beta T cell	\N	\N	EFO	"" []	EFO	66184	CL:0000789	\N	alpha-beta T cell	CL:0000789
0	"" []	\N	immature alpha-beta T cell	\N	\N	EFO	"" []	EFO	66185	CL:0000790	\N	immature alpha-beta T cell	CL:0000790
0	"" []	\N	mature alpha-beta T cell	\N	\N	EFO	"" []	EFO	66186	CL:0000791	\N	mature alpha-beta T cell	CL:0000791
0	"" []	\N	CD4-positive, CD25-positive, alpha-beta regulatory T cell	\N	\N	EFO	"" []	EFO	66187	CL:0000792	\N	CD4-positive, CD25-positive, alpha-beta regulatory T cell	CL:0000792
0	"" []	\N	CD4-positive, alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66188	CL:0000793	\N	CD4-positive, alpha-beta intraepithelial T cell	CL:0000793
0	"" []	\N	CD8-positive, alpha-beta cytotoxic T cell	\N	\N	EFO	"" []	EFO	66189	CL:0000794	\N	CD8-positive, alpha-beta cytotoxic T cell	CL:0000794
0	"" []	\N	CD8-positive, alpha-beta regulatory T cell	\N	\N	EFO	"" []	EFO	66190	CL:0000795	\N	CD8-positive, alpha-beta regulatory T cell	CL:0000795
0	"" []	\N	CD8-alpha-beta-positive, alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66191	CL:0000796	\N	CD8-alpha-beta-positive, alpha-beta intraepithelial T cell	CL:0000796
0	"" []	\N	alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66192	CL:0000797	\N	alpha-beta intraepithelial T cell	CL:0000797
0	"" []	\N	gamma-delta T cell	\N	\N	EFO	"" []	EFO	66193	CL:0000798	\N	gamma-delta T cell	CL:0000798
0	"" []	\N	immature gamma-delta T cell	\N	\N	EFO	"" []	EFO	66194	CL:0000799	\N	immature gamma-delta T cell	CL:0000799
0	"" []	\N	mature gamma-delta T cell	\N	\N	EFO	"" []	EFO	66195	CL:0000800	\N	mature gamma-delta T cell	CL:0000800
0	"" []	\N	gamma-delta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66196	CL:0000801	\N	gamma-delta intraepithelial T cell	CL:0000801
0	"" []	\N	CD8-alpha alpha positive, gamma-delta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66197	CL:0000802	\N	CD8-alpha alpha positive, gamma-delta intraepithelial T cell	CL:0000802
0	"" []	\N	CD4-negative CD8-negative gamma-delta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66198	CL:0000803	\N	CD4-negative CD8-negative gamma-delta intraepithelial T cell	CL:0000803
0	"" []	\N	immature single positive thymocyte	\N	\N	EFO	"" []	EFO	66199	CL:0000805	\N	immature single positive thymocyte	CL:0000805
0	"" []	\N	DN2 thymocyte	\N	\N	EFO	"" []	EFO	66200	CL:0000806	\N	DN2 thymocyte	CL:0000806
0	"" []	\N	DN3 thymocyte	\N	\N	EFO	"" []	EFO	66201	CL:0000807	\N	DN3 thymocyte	CL:0000807
0	"" []	\N	DN4 thymocyte	\N	\N	EFO	"" []	EFO	66202	CL:0000808	\N	DN4 thymocyte	CL:0000808
0	"A thymocyte expressing the alpha-beta T cell receptor complex as well as both the CD4 and CD8 coreceptors." []	\N	double-positive, alpha-beta thymocyte	\N	\N	EFO	"A thymocyte expressing the alpha-beta T cell receptor complex as well as both the CD4 and CD8 coreceptors." []	EFO	66203	CL:0000809	\N	double-positive, alpha-beta thymocyte	CL:0000809
0	"" []	\N	CD4-positive, alpha-beta thymocyte	\N	\N	EFO	"" []	EFO	66204	CL:0000810	\N	CD4-positive, alpha-beta thymocyte	CL:0000810
0	"" []	\N	CD8-positive, alpha-beta thymocyte	\N	\N	EFO	"" []	EFO	66205	CL:0000811	\N	CD8-positive, alpha-beta thymocyte	CL:0000811
0	"A T-cell that bears receptors for a specific foreign antigen encountered during a prior infection or vaccination. After an infection or a vaccination, some of the T-cells that participated in the response remain as memory T-cells, which can rapidly mobilize and clone themselves should the same antigen be re-encountered during a second infection at a later time." []	\N	memory T cell	\N	\N	EFO	"A T-cell that bears receptors for a specific foreign antigen encountered during a prior infection or vaccination. After an infection or a vaccination, some of the T-cells that participated in the response remain as memory T-cells, which can rapidly mobilize and clone themselves should the same antigen be re-encountered during a second infection at a later time." []	EFO	66206	CL:0000813	\N	memory T cell	CL:0000813
0	"" []	\N	mature NK T cell	\N	\N	EFO	"" []	EFO	66207	CL:0000814	\N	mature NK T cell	CL:0000814
0	"A T cell which regulates overall immune responses as well as the responses of other T cell subsets through direct cell-cell contact and cytokine release." []	\N	regulatory T cell	\N	\N	EFO	"A T cell which regulates overall immune responses as well as the responses of other T cell subsets through direct cell-cell contact and cytokine release." []	EFO	66208	CL:0000815	\N	regulatory T cell	CL:0000815
0	"An immature B cell is a precursor B cell that has the phenotype surface IgM-positive and surface IgD-negative, and have not undergone class immunoglobulin class switching or peripheral encounter with antigen and activation." []	\N	immature B cell	\N	\N	EFO	"An immature B cell is a precursor B cell that has the phenotype surface IgM-positive and surface IgD-negative, and have not undergone class immunoglobulin class switching or peripheral encounter with antigen and activation." []	EFO	66209	CL:0000816	\N	immature B cell	CL:0000816
0	"A precursor B cell is a B cell with the phenotype CD10-positive." []	\N	precursor B cell	\N	\N	EFO	"A precursor B cell is a B cell with the phenotype CD10-positive." []	EFO	66210	CL:0000817	\N	precursor B cell	CL:0000817
0	"" []	\N	transitional stage B cell	\N	\N	EFO	"" []	EFO	66211	CL:0000818	\N	transitional stage B cell	CL:0000818
0	"" []	\N	B-1 B cell	\N	\N	EFO	"" []	EFO	66212	CL:0000819	\N	B-1 B cell	CL:0000819
0	"" []	\N	B-1a B cell	\N	\N	EFO	"" []	EFO	66213	CL:0000820	\N	B-1a B cell	CL:0000820
0	"" []	\N	B-1b B cell	\N	\N	EFO	"" []	EFO	66214	CL:0000821	\N	B-1b B cell	CL:0000821
0	"A conventional B cell subject to antigenic stimulation and dependent on T cell help and with a distinct surface marker expression pattern from B-1 B cells. These cells are CD43-negative." []	\N	B-2 B cell	\N	\N	EFO	"A conventional B cell subject to antigenic stimulation and dependent on T cell help and with a distinct surface marker expression pattern from B-1 B cells. These cells are CD43-negative." []	EFO	66215	CL:0000822	\N	B-2 B cell	CL:0000822
0	"" []	\N	immature natural killer cell	\N	\N	EFO	"" []	EFO	66216	CL:0000823	\N	immature natural killer cell	CL:0000823
0	"" []	\N	mature natural killer cell	\N	\N	EFO	"" []	EFO	66217	CL:0000824	\N	mature natural killer cell	CL:0000824
0	"" []	\N	pro-NK cell	\N	\N	EFO	"" []	EFO	66218	CL:0000825	\N	pro-NK cell	CL:0000825
0	"" []	\N	pro-B cell	\N	\N	EFO	"" []	EFO	66219	CL:0000826	\N	pro-B cell	CL:0000826
0	"" []	\N	pro-T cell	\N	\N	EFO	"" []	EFO	66220	CL:0000827	\N	pro-T cell	CL:0000827
0	"" []	\N	thromboblast	\N	\N	EFO	"" []	EFO	66221	CL:0000828	\N	thromboblast	CL:0000828
0	"" []	\N	basophilic myeloblast	\N	\N	EFO	"" []	EFO	66222	CL:0000829	\N	basophilic myeloblast	CL:0000829
0	"" []	\N	basophilic promyelocyte	\N	\N	EFO	"" []	EFO	66223	CL:0000830	\N	basophilic promyelocyte	CL:0000830
0	"" []	\N	mast cell progenitor	\N	\N	EFO	"" []	EFO	66224	CL:0000831	\N	mast cell progenitor	CL:0000831
0	"" []	\N	eosinophilic myeloblast	\N	\N	EFO	"" []	EFO	66225	CL:0000832	\N	eosinophilic myeloblast	CL:0000832
0	"" []	\N	eosinophilic promyelocyte	\N	\N	EFO	"" []	EFO	66226	CL:0000833	\N	eosinophilic promyelocyte	CL:0000833
0	"" []	\N	neutrophil progenitor cell	\N	\N	EFO	"" []	EFO	66227	CL:0000834	\N	neutrophil progenitor cell	CL:0000834
0	"" []	\N	myeloblast	\N	\N	EFO	"" []	EFO	66228	CL:0000835	\N	myeloblast	CL:0000835
0	"" []	\N	promyelocyte	\N	\N	EFO	"" []	EFO	66229	CL:0000836	\N	promyelocyte	CL:0000836
0	"A progenitor cell of any hematopoietic lineage, potentially multipotent." []	\N	hematopoietic multipotent progenitor cell	\N	\N	EFO	"A progenitor cell of any hematopoietic lineage, potentially multipotent." []	EFO	66230	CL:0000837	\N	hematopoietic multipotent progenitor cell	CL:0000837
0	"" []	\N	lymphoid lineage restricted progenitor cell	\N	\N	EFO	"" []	EFO	66231	CL:0000838	\N	lymphoid lineage restricted progenitor cell	CL:0000838
0	"A progenitor cell restricted to the myeloid lineage." []	\N	myeloid lineage restricted progenitor cell	\N	\N	EFO	"A progenitor cell restricted to the myeloid lineage." []	EFO	66232	CL:0000839	\N	myeloid lineage restricted progenitor cell	CL:0000839
0	"" []	\N	immature conventional dendritic cell	\N	\N	EFO	"" []	EFO	66233	CL:0000840	\N	immature conventional dendritic cell	CL:0000840
0	"" []	\N	mature conventional dendritic cell	\N	\N	EFO	"" []	EFO	66234	CL:0000841	\N	mature conventional dendritic cell	CL:0000841
0	"A leukocyte with a single non-segmented nucleus in the mature form." []	\N	mononuclear cell	\N	\N	EFO	"A leukocyte with a single non-segmented nucleus in the mature form." []	EFO	66235	CL:0000842	\N	mononuclear cell	CL:0000842
0	"" []	\N	follicular B cell	\N	\N	EFO	"" []	EFO	66236	CL:0000843	\N	follicular B cell	CL:0000843
0	"" []	\N	germinal center B cell	\N	\N	EFO	"" []	EFO	66237	CL:0000844	\N	germinal center B cell	CL:0000844
0	"" []	\N	marginal zone B cell	\N	\N	EFO	"" []	EFO	66238	CL:0000845	\N	marginal zone B cell	CL:0000845
0	"" []	\N	classical monocyte	\N	\N	EFO	"" []	EFO	66239	CL:0000860	\N	classical monocyte	CL:0000860
0	"" []	\N	elicited macrophage	\N	\N	EFO	"" []	EFO	66240	CL:0000861	\N	elicited macrophage	CL:0000861
0	"" []	\N	suppressor macrophage	\N	\N	EFO	"" []	EFO	66241	CL:0000862	\N	suppressor macrophage	CL:0000862
0	"" []	\N	inflammatory macrophage	\N	\N	EFO	"" []	EFO	66242	CL:0000863	\N	inflammatory macrophage	CL:0000863
0	"" []	\N	tissue-resident macrophage	\N	\N	EFO	"" []	EFO	66243	CL:0000864	\N	tissue-resident macrophage	CL:0000864
0	"" []	\N	gastrointestinal tract (lamina propria) macrophage	\N	\N	EFO	"" []	EFO	66244	CL:0000865	\N	gastrointestinal tract (lamina propria) macrophage	CL:0000865
0	"" []	\N	thymic macrophage	\N	\N	EFO	"" []	EFO	66245	CL:0000866	\N	thymic macrophage	CL:0000866
0	"" []	\N	secondary lymphoid organ macrophage	\N	\N	EFO	"" []	EFO	66246	CL:0000867	\N	secondary lymphoid organ macrophage	CL:0000867
0	"" []	\N	lymph node macrophage	\N	\N	EFO	"" []	EFO	66247	CL:0000868	\N	lymph node macrophage	CL:0000868
0	"" []	\N	tonsillar macrophage	\N	\N	EFO	"" []	EFO	66248	CL:0000869	\N	tonsillar macrophage	CL:0000869
0	"" []	\N	Peyer's patch macrophage	\N	\N	EFO	"" []	EFO	66249	CL:0000870	\N	Peyer's patch macrophage	CL:0000870
0	"" []	\N	splenic macrophage	\N	\N	EFO	"" []	EFO	66250	CL:0000871	\N	splenic macrophage	CL:0000871
0	"" []	\N	splenic marginal zone macrophage	\N	\N	EFO	"" []	EFO	66251	CL:0000872	\N	splenic marginal zone macrophage	CL:0000872
0	"" []	\N	splenic metallophillic macrophage	\N	\N	EFO	"" []	EFO	66252	CL:0000873	\N	splenic metallophillic macrophage	CL:0000873
0	"" []	\N	splenic red pulp macrophage	\N	\N	EFO	"" []	EFO	66253	CL:0000874	\N	splenic red pulp macrophage	CL:0000874
0	"" []	\N	non-classical monocyte	\N	\N	EFO	"" []	EFO	66254	CL:0000875	\N	non-classical monocyte	CL:0000875
0	"" []	\N	splenic white pulp macrophage	\N	\N	EFO	"" []	EFO	66255	CL:0000876	\N	splenic white pulp macrophage	CL:0000876
0	"" []	\N	splenic tingible body macrophage	\N	\N	EFO	"" []	EFO	66256	CL:0000877	\N	splenic tingible body macrophage	CL:0000877
0	"" []	\N	central nervous system macrophage	\N	\N	EFO	"" []	EFO	66257	CL:0000878	\N	central nervous system macrophage	CL:0000878
0	"" []	\N	meningeal macrophage	\N	\N	EFO	"" []	EFO	66258	CL:0000879	\N	meningeal macrophage	CL:0000879
0	"" []	\N	choroid-plexus macrophage	\N	\N	EFO	"" []	EFO	66259	CL:0000880	\N	choroid-plexus macrophage	CL:0000880
0	"" []	\N	perivascular macrophage	\N	\N	EFO	"" []	EFO	66260	CL:0000881	\N	perivascular macrophage	CL:0000881
0	"" []	\N	thymic medullary macrophage	\N	\N	EFO	"" []	EFO	66261	CL:0000882	\N	thymic medullary macrophage	CL:0000882
0	"" []	\N	thymic cortical macrophage	\N	\N	EFO	"" []	EFO	66262	CL:0000883	\N	thymic cortical macrophage	CL:0000883
0	"" []	\N	mucosa-associated lymphoid tissue macrophage	\N	\N	EFO	"" []	EFO	66263	CL:0000884	\N	mucosa-associated lymphoid tissue macrophage	CL:0000884
0	"" []	\N	gut-associated lymphoid tissue macrophage	\N	\N	EFO	"" []	EFO	66264	CL:0000885	\N	gut-associated lymphoid tissue macrophage	CL:0000885
0	"" []	\N	nasal and broncial associated lymphoid tissue macrophage	\N	\N	EFO	"" []	EFO	66265	CL:0000886	\N	nasal and broncial associated lymphoid tissue macrophage	CL:0000886
0	"" []	\N	lymph node subcapsular sinus macrophage	\N	\N	EFO	"" []	EFO	66266	CL:0000887	\N	lymph node subcapsular sinus macrophage	CL:0000887
0	"" []	\N	lymph node tingible body macrophage	\N	\N	EFO	"" []	EFO	66267	CL:0000888	\N	lymph node tingible body macrophage	CL:0000888
0	"" []	\N	myeloid suppressor cell	\N	\N	EFO	"" []	EFO	66268	CL:0000889	\N	myeloid suppressor cell	CL:0000889
0	"" []	\N	alternatively activated macrophage	\N	\N	EFO	"" []	EFO	66269	CL:0000890	\N	alternatively activated macrophage	CL:0000890
0	"An immature T cell located in the thymus." []	\N	thymocyte	\N	\N	EFO	"An immature T cell located in the thymus." []	EFO	66270	CL:0000893	\N	thymocyte	CL:0000893
0	"" []	\N	DN1 thymic pro-T cell	\N	\N	EFO	"" []	EFO	66271	CL:0000894	\N	DN1 thymic pro-T cell	CL:0000894
0	"" []	\N	naive thymus-derived CD4-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66272	CL:0000895	\N	naive thymus-derived CD4-positive, alpha-beta T cell	CL:0000895
0	"" []	\N	activated CD4-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66273	CL:0000896	\N	activated CD4-positive, alpha-beta T cell	CL:0000896
0	"" []	\N	CD4-positive, alpha-beta memory T cell	\N	\N	EFO	"" []	EFO	66274	CL:0000897	\N	CD4-positive, alpha-beta memory T cell	CL:0000897
0	"" []	\N	naive T cell	\N	\N	EFO	"" []	EFO	66275	CL:0000898	\N	naive T cell	CL:0000898
0	"" []	\N	T-helper 17 cell	\N	\N	EFO	"" []	EFO	66276	CL:0000899	\N	T-helper 17 cell	CL:0000899
0	"" []	\N	naive thymus-derived CD8-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66277	CL:0000900	\N	naive thymus-derived CD8-positive, alpha-beta T cell	CL:0000900
0	"" []	\N	Tr1 cell	\N	\N	EFO	"" []	EFO	66278	CL:0000901	\N	Tr1 cell	CL:0000901
0	"" []	\N	induced T-regulatory cell	\N	\N	EFO	"" []	EFO	66279	CL:0000902	\N	induced T-regulatory cell	CL:0000902
0	"" []	\N	natural T-regulatory cell	\N	\N	EFO	"" []	EFO	66280	CL:0000903	\N	natural T-regulatory cell	CL:0000903
0	"" []	\N	central memory CD4-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66281	CL:0000904	\N	central memory CD4-positive, alpha-beta T cell	CL:0000904
0	"" []	\N	effector memory CD4-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66282	CL:0000905	\N	effector memory CD4-positive, alpha-beta T cell	CL:0000905
0	"" []	\N	activated CD8-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66283	CL:0000906	\N	activated CD8-positive, alpha-beta T cell	CL:0000906
0	"" []	\N	central memory CD8 positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66284	CL:0000907	\N	central memory CD8 positive, alpha-beta T cell	CL:0000907
0	"" []	\N	CD8-positive, alpha-beta cytokine secreting effector T cell	\N	\N	EFO	"" []	EFO	66285	CL:0000908	\N	CD8-positive, alpha-beta cytokine secreting effector T cell	CL:0000908
0	"" []	\N	CD8-positive, alpha-beta memory T cell	\N	\N	EFO	"" []	EFO	66286	CL:0000909	\N	CD8-positive, alpha-beta memory T cell	CL:0000909
0	"" []	\N	cytotoxic T cell	\N	\N	EFO	"" []	EFO	66287	CL:0000910	\N	cytotoxic T cell	CL:0000910
0	"" []	\N	effector T cell	\N	\N	EFO	"" []	EFO	66288	CL:0000911	\N	effector T cell	CL:0000911
0	"" []	\N	helper T cell	\N	\N	EFO	"" []	EFO	66289	CL:0000912	\N	helper T cell	CL:0000912
0	"" []	\N	effector memory CD8-positive, alpha-beta T cell	\N	\N	EFO	"" []	EFO	66290	CL:0000913	\N	effector memory CD8-positive, alpha-beta T cell	CL:0000913
0	"" []	\N	immature NK T cell	\N	\N	EFO	"" []	EFO	66291	CL:0000914	\N	immature NK T cell	CL:0000914
0	"" []	\N	CD8-alpha-alpha-positive, alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66292	CL:0000915	\N	CD8-alpha-alpha-positive, alpha-beta intraepithelial T cell	CL:0000915
0	"" []	\N	dendritic epidermal T cell	\N	\N	EFO	"" []	EFO	66293	CL:0000916	\N	dendritic epidermal T cell	CL:0000916
0	"" []	\N	Tc1 cell	\N	\N	EFO	"" []	EFO	66294	CL:0000917	\N	Tc1 cell	CL:0000917
0	"" []	\N	Tc2 cell	\N	\N	EFO	"" []	EFO	66295	CL:0000918	\N	Tc2 cell	CL:0000918
0	"" []	\N	CD8-positive, CD25-positive, alpha-beta regulatory T cell	\N	\N	EFO	"" []	EFO	66296	CL:0000919	\N	CD8-positive, CD25-positive, alpha-beta regulatory T cell	CL:0000919
0	"" []	\N	CD8-positive, CD28-negative, alpha-beta regulatory T cell	\N	\N	EFO	"" []	EFO	66297	CL:0000920	\N	CD8-positive, CD28-negative, alpha-beta regulatory T cell	CL:0000920
0	"" []	\N	type I NK T cell	\N	\N	EFO	"" []	EFO	66298	CL:0000921	\N	type I NK T cell	CL:0000921
0	"" []	\N	type II NK T cell	\N	\N	EFO	"" []	EFO	66299	CL:0000922	\N	type II NK T cell	CL:0000922
0	"" []	\N	CD4-positive type I NK T cell	\N	\N	EFO	"" []	EFO	66300	CL:0000923	\N	CD4-positive type I NK T cell	CL:0000923
0	"" []	\N	CD4-negative, CD8-negative type I NK T cell	\N	\N	EFO	"" []	EFO	66301	CL:0000924	\N	CD4-negative, CD8-negative type I NK T cell	CL:0000924
0	"" []	\N	activated CD4-positive type I NK T cell	\N	\N	EFO	"" []	EFO	66302	CL:0000925	\N	activated CD4-positive type I NK T cell	CL:0000925
0	"" []	\N	CD4-positive type I NK T cell secreting interferon-gamma	\N	\N	EFO	"" []	EFO	66303	CL:0000926	\N	CD4-positive type I NK T cell secreting interferon-gamma	CL:0000926
0	"" []	\N	CD4-positive type I NK T cell secreting interleukin-4	\N	\N	EFO	"" []	EFO	66304	CL:0000927	\N	CD4-positive type I NK T cell secreting interleukin-4	CL:0000927
0	"" []	\N	activated CD4-negative, CD8-negative type I NK T cell	\N	\N	EFO	"" []	EFO	66305	CL:0000928	\N	activated CD4-negative, CD8-negative type I NK T cell	CL:0000928
0	"" []	\N	CD4-negative, CD8-negative type I NK T cell secreting interferon-gamma	\N	\N	EFO	"" []	EFO	66306	CL:0000929	\N	CD4-negative, CD8-negative type I NK T cell secreting interferon-gamma	CL:0000929
0	"" []	\N	CD4-negative, CD8-negative type I NK T cell secreting interleukin-4	\N	\N	EFO	"" []	EFO	66307	CL:0000930	\N	CD4-negative, CD8-negative type I NK T cell secreting interleukin-4	CL:0000930
0	"" []	\N	activated type II NK T cell	\N	\N	EFO	"" []	EFO	66308	CL:0000931	\N	activated type II NK T cell	CL:0000931
0	"" []	\N	type II NK T cell secreting interferon-gamma	\N	\N	EFO	"" []	EFO	66309	CL:0000932	\N	type II NK T cell secreting interferon-gamma	CL:0000932
0	"" []	\N	type II NK T cell secreting interleukin-4	\N	\N	EFO	"" []	EFO	66310	CL:0000933	\N	type II NK T cell secreting interleukin-4	CL:0000933
0	"" []	\N	CD4-positive, alpha-beta cytotoxic T cell	\N	\N	EFO	"" []	EFO	66311	CL:0000934	\N	CD4-positive, alpha-beta cytotoxic T cell	CL:0000934
0	"" []	\N	CD4-negative, CD8-negative, alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66312	CL:0000935	\N	CD4-negative, CD8-negative, alpha-beta intraepithelial T cell	CL:0000935
0	"" []	\N	early lymphoid progenitor	\N	\N	EFO	"" []	EFO	66313	CL:0000936	\N	early lymphoid progenitor	CL:0000936
0	"" []	\N	pre-natural killer cell	\N	\N	EFO	"" []	EFO	66314	CL:0000937	\N	pre-natural killer cell	CL:0000937
0	"" []	\N	CD56-bright cytokine secreting natural killer cell	\N	\N	EFO	"" []	EFO	66315	CL:0000938	\N	CD56-bright cytokine secreting natural killer cell	CL:0000938
0	"" []	\N	cytotoxic CD56-dim natural killer cell	\N	\N	EFO	"" []	EFO	66316	CL:0000939	\N	cytotoxic CD56-dim natural killer cell	CL:0000939
0	"" []	\N	mucosal invariant T cell	\N	\N	EFO	"" []	EFO	66317	CL:0000940	\N	mucosal invariant T cell	CL:0000940
0	"" []	\N	thymic conventional dendritic cell	\N	\N	EFO	"" []	EFO	66318	CL:0000941	\N	thymic conventional dendritic cell	CL:0000941
0	"" []	\N	thymic plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66319	CL:0000942	\N	thymic plasmacytoid dendritic cell	CL:0000942
0	"" []	\N	Be1 Cell	\N	\N	EFO	"" []	EFO	66320	CL:0000943	\N	Be1 Cell	CL:0000943
0	"" []	\N	Be2 cell	\N	\N	EFO	"" []	EFO	66321	CL:0000944	\N	Be2 cell	CL:0000944
0	"" []	\N	lymphocyte of B lineage	\N	\N	EFO	"" []	EFO	66322	CL:0000945	\N	lymphocyte of B lineage	CL:0000945
0	"" []	\N	antibody secreting cell	\N	\N	EFO	"" []	EFO	66323	CL:0000946	\N	antibody secreting cell	CL:0000946
0	"" []	\N	IgE plasma cell	\N	\N	EFO	"" []	EFO	66324	CL:0000947	\N	IgE plasma cell	CL:0000947
0	"" []	\N	IgE memory B cell	\N	\N	EFO	"" []	EFO	66325	CL:0000948	\N	IgE memory B cell	CL:0000948
0	"" []	\N	IgD plasmablast	\N	\N	EFO	"" []	EFO	66326	CL:0000949	\N	IgD plasmablast	CL:0000949
0	"" []	\N	IgE plasmablast	\N	\N	EFO	"" []	EFO	66327	CL:0000950	\N	IgE plasmablast	CL:0000950
0	"" []	\N	IgE short lived plasma cell	\N	\N	EFO	"" []	EFO	66328	CL:0000951	\N	IgE short lived plasma cell	CL:0000951
0	"" []	\N	preBCR-positive large pre-B-II cell	\N	\N	EFO	"" []	EFO	66329	CL:0000952	\N	preBCR-positive large pre-B-II cell	CL:0000952
0	"" []	\N	preBCR-negative large pre-B-II cell	\N	\N	EFO	"" []	EFO	66330	CL:0000953	\N	preBCR-negative large pre-B-II cell	CL:0000953
0	"" []	\N	small pre-B-II cell	\N	\N	EFO	"" []	EFO	66331	CL:0000954	\N	small pre-B-II cell	CL:0000954
0	"" []	\N	pre-B-II cell	\N	\N	EFO	"" []	EFO	66332	CL:0000955	\N	pre-B-II cell	CL:0000955
0	"" []	\N	pre-B-I cell	\N	\N	EFO	"" []	EFO	66333	CL:0000956	\N	pre-B-I cell	CL:0000956
0	"" []	\N	large pre-B-II cell	\N	\N	EFO	"" []	EFO	66334	CL:0000957	\N	large pre-B-II cell	CL:0000957
0	"" []	\N	T1 B cell	\N	\N	EFO	"" []	EFO	66335	CL:0000958	\N	T1 B cell	CL:0000958
0	"" []	\N	T2 B cell	\N	\N	EFO	"" []	EFO	66336	CL:0000959	\N	T2 B cell	CL:0000959
0	"" []	\N	T3 B cell	\N	\N	EFO	"" []	EFO	66337	CL:0000960	\N	T3 B cell	CL:0000960
0	"" []	\N	Bm1 B cell	\N	\N	EFO	"" []	EFO	66338	CL:0000961	\N	Bm1 B cell	CL:0000961
0	"" []	\N	Bm2 B cell	\N	\N	EFO	"" []	EFO	66339	CL:0000962	\N	Bm2 B cell	CL:0000962
0	"" []	\N	Bm3-delta B cell	\N	\N	EFO	"" []	EFO	66340	CL:0000963	\N	Bm3-delta B cell	CL:0000963
0	"" []	\N	Bm2' B cell	\N	\N	EFO	"" []	EFO	66341	CL:0000964	\N	Bm2' B cell	CL:0000964
0	"" []	\N	Bm3 B cell	\N	\N	EFO	"" []	EFO	66342	CL:0000965	\N	Bm3 B cell	CL:0000965
0	"" []	\N	Bm4 B cell	\N	\N	EFO	"" []	EFO	66343	CL:0000966	\N	Bm4 B cell	CL:0000966
0	"" []	\N	Bm5 B cell	\N	\N	EFO	"" []	EFO	66344	CL:0000967	\N	Bm5 B cell	CL:0000967
0	"" []	\N	Be cell	\N	\N	EFO	"" []	EFO	66345	CL:0000968	\N	Be cell	CL:0000968
0	"" []	\N	regulatory B cell	\N	\N	EFO	"" []	EFO	66346	CL:0000969	\N	regulatory B cell	CL:0000969
0	"" []	\N	unswitched memory B cell	\N	\N	EFO	"" []	EFO	66347	CL:0000970	\N	unswitched memory B cell	CL:0000970
0	"" []	\N	IgM memory B cell	\N	\N	EFO	"" []	EFO	66348	CL:0000971	\N	IgM memory B cell	CL:0000971
0	"" []	\N	class switched memory B cell	\N	\N	EFO	"" []	EFO	66349	CL:0000972	\N	class switched memory B cell	CL:0000972
0	"" []	\N	IgA memory B cell	\N	\N	EFO	"" []	EFO	66350	CL:0000973	\N	IgA memory B cell	CL:0000973
0	"" []	\N	long lived plasma cell	\N	\N	EFO	"" []	EFO	66351	CL:0000974	\N	long lived plasma cell	CL:0000974
0	"" []	\N	short lived plasma cell	\N	\N	EFO	"" []	EFO	66352	CL:0000975	\N	short lived plasma cell	CL:0000975
0	"" []	\N	IgA short lived plasma cell	\N	\N	EFO	"" []	EFO	66353	CL:0000976	\N	IgA short lived plasma cell	CL:0000976
0	"" []	\N	IgG short lived plasma cell	\N	\N	EFO	"" []	EFO	66354	CL:0000977	\N	IgG short lived plasma cell	CL:0000977
0	"" []	\N	IgM short lived plasma cell	\N	\N	EFO	"" []	EFO	66355	CL:0000978	\N	IgM short lived plasma cell	CL:0000978
0	"" []	\N	IgG memory B cell	\N	\N	EFO	"" []	EFO	66356	CL:0000979	\N	IgG memory B cell	CL:0000979
0	"" []	\N	plasmablast	\N	\N	EFO	"" []	EFO	66357	CL:0000980	\N	plasmablast	CL:0000980
0	"" []	\N	double negative memory B cell	\N	\N	EFO	"" []	EFO	66358	CL:0000981	\N	double negative memory B cell	CL:0000981
0	"" []	\N	IgG plasmablast	\N	\N	EFO	"" []	EFO	66359	CL:0000982	\N	IgG plasmablast	CL:0000982
0	"" []	\N	IgM plasmablast	\N	\N	EFO	"" []	EFO	66360	CL:0000983	\N	IgM plasmablast	CL:0000983
0	"" []	\N	IgA plasmablast	\N	\N	EFO	"" []	EFO	66361	CL:0000984	\N	IgA plasmablast	CL:0000984
0	"" []	\N	IgG plasma cell	\N	\N	EFO	"" []	EFO	66362	CL:0000985	\N	IgG plasma cell	CL:0000985
0	"" []	\N	IgM plasma cell	\N	\N	EFO	"" []	EFO	66363	CL:0000986	\N	IgM plasma cell	CL:0000986
0	"" []	\N	IgA plasma cell	\N	\N	EFO	"" []	EFO	66364	CL:0000987	\N	IgA plasma cell	CL:0000987
0	"A cell of a hematopoietic lineage." []	\N	hematopoietic cell	\N	\N	EFO	"A cell of a hematopoietic lineage." []	EFO	66365	CL:0000988	\N	hematopoietic cell	CL:0000988
0	"" []	\N	CD11c-low plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66366	CL:0000989	\N	CD11c-low plasmacytoid dendritic cell	CL:0000989
0	"" []	\N	conventional dendritic cell	\N	\N	EFO	"" []	EFO	66367	CL:0000990	\N	conventional dendritic cell	CL:0000990
0	"" []	\N	CD11c-negative plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66368	CL:0000991	\N	CD11c-negative plasmacytoid dendritic cell	CL:0000991
0	"" []	\N	immature CD11c-low plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66369	CL:0000992	\N	immature CD11c-low plasmacytoid dendritic cell	CL:0000992
0	"" []	\N	mature CD11c-low plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66370	CL:0000993	\N	mature CD11c-low plasmacytoid dendritic cell	CL:0000993
0	"" []	\N	immature CD11c-negative plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66371	CL:0000994	\N	immature CD11c-negative plasmacytoid dendritic cell	CL:0000994
0	"" []	\N	CD34-positive, CD38-positive common myeloid progenitor OR CD34-positive, CD38-positive common lymphoid progenitor	\N	\N	EFO	"" []	EFO	66372	CL:0000995	\N	CD34-positive, CD38-positive common myeloid progenitor OR CD34-positive, CD38-positive common lymphoid progenitor	CL:0000995
0	"" []	\N	mature CD11c-negative plasmacytoid dendritic cell	\N	\N	EFO	"" []	EFO	66373	CL:0000996	\N	mature CD11c-negative plasmacytoid dendritic cell	CL:0000996
0	"" []	\N	immature CD8_alpha-negative CD11b-positive dendritic cell	\N	\N	EFO	"" []	EFO	66374	CL:0000997	\N	immature CD8_alpha-negative CD11b-positive dendritic cell	CL:0000997
0	"" []	\N	CD8_alpha-negative CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66375	CL:0000998	\N	CD8_alpha-negative CD11b-negative dendritic cell	CL:0000998
0	"" []	\N	CD4-positive CD11b-positive dendritic cell	\N	\N	EFO	"" []	EFO	66376	CL:0000999	\N	CD4-positive CD11b-positive dendritic cell	CL:0000999
0	"" []	\N	CD8_alpha-positive CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66377	CL:0001000	\N	CD8_alpha-positive CD11b-negative dendritic cell	CL:0001000
0	"" []	\N	immature CD8_alpha-negative CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66378	CL:0001001	\N	immature CD8_alpha-negative CD11b-negative dendritic cell	CL:0001001
0	"" []	\N	mature CD8_alpha-negative CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66379	CL:0001002	\N	mature CD8_alpha-negative CD11b-negative dendritic cell	CL:0001002
0	"" []	\N	mature CD8_alpha-negative CD11b-positive dendritic cell	\N	\N	EFO	"" []	EFO	66380	CL:0001003	\N	mature CD8_alpha-negative CD11b-positive dendritic cell	CL:0001003
0	"" []	\N	immature CD8_alpha-positive CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66381	CL:0001004	\N	immature CD8_alpha-positive CD11b-negative dendritic cell	CL:0001004
0	"" []	\N	mature CD8_alpha-positive CD11b-negative dendritic cell	\N	\N	EFO	"" []	EFO	66382	CL:0001005	\N	mature CD8_alpha-positive CD11b-negative dendritic cell	CL:0001005
0	"" []	\N	dermal dendritic cell	\N	\N	EFO	"" []	EFO	66383	CL:0001006	\N	dermal dendritic cell	CL:0001006
0	"" []	\N	interstitial dendritic cell	\N	\N	EFO	"" []	EFO	66384	CL:0001007	\N	interstitial dendritic cell	CL:0001007
0	"" []	\N	Kit and Sca1-positive hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66385	CL:0001008	\N	Kit and Sca1-positive hematopoietic stem cell	CL:0001008
0	"" []	\N	immature dermal dendritic cell	\N	\N	EFO	"" []	EFO	66386	CL:0001009	\N	immature dermal dendritic cell	CL:0001009
0	"" []	\N	mature dermal dendritic cell	\N	\N	EFO	"" []	EFO	66387	CL:0001010	\N	mature dermal dendritic cell	CL:0001010
0	"" []	\N	immature interstitial dendritic cell	\N	\N	EFO	"" []	EFO	66388	CL:0001011	\N	immature interstitial dendritic cell	CL:0001011
0	"" []	\N	CD7-negative lymphoid progenitor OR granulocyte monocyte progenitor	\N	\N	EFO	"" []	EFO	66389	CL:0001012	\N	CD7-negative lymphoid progenitor OR granulocyte monocyte progenitor	CL:0001012
0	"" []	\N	mature interstitial dendritic cell	\N	\N	EFO	"" []	EFO	66390	CL:0001013	\N	mature interstitial dendritic cell	CL:0001013
0	"" []	\N	CD1a-positive Langerhans cell	\N	\N	EFO	"" []	EFO	66391	CL:0001014	\N	CD1a-positive Langerhans cell	CL:0001014
0	"" []	\N	CD8_alpha-low Langerhans cell	\N	\N	EFO	"" []	EFO	66392	CL:0001015	\N	CD8_alpha-low Langerhans cell	CL:0001015
0	"" []	\N	immature CD1a-positive Langerhans cell	\N	\N	EFO	"" []	EFO	66393	CL:0001016	\N	immature CD1a-positive Langerhans cell	CL:0001016
0	"" []	\N	mature CD1a-positive Langerhans cell	\N	\N	EFO	"" []	EFO	66394	CL:0001017	\N	mature CD1a-positive Langerhans cell	CL:0001017
0	"" []	\N	immature CD8_alpha-low Langerhans cell	\N	\N	EFO	"" []	EFO	66395	CL:0001018	\N	immature CD8_alpha-low Langerhans cell	CL:0001018
0	"" []	\N	CD115-positive monocyte OR common dendritic progenitor	\N	\N	EFO	"" []	EFO	66396	CL:0001019	\N	CD115-positive monocyte OR common dendritic progenitor	CL:0001019
0	"" []	\N	mature CD8_alpha-low Langerhans cell	\N	\N	EFO	"" []	EFO	66397	CL:0001020	\N	mature CD8_alpha-low Langerhans cell	CL:0001020
0	"" []	\N	CD34-positive, CD38-positive common lymphoid progenitor	\N	\N	EFO	"" []	EFO	66398	CL:0001021	\N	CD34-positive, CD38-positive common lymphoid progenitor	CL:0001021
0	"" []	\N	CD115-positive monocyte	\N	\N	EFO	"" []	EFO	66399	CL:0001022	\N	CD115-positive monocyte	CL:0001022
0	"" []	\N	Kit-positive, CD34-positive common myeloid progenitor	\N	\N	EFO	"" []	EFO	66400	CL:0001023	\N	Kit-positive, CD34-positive common myeloid progenitor	CL:0001023
0	"" []	\N	CD34-positive, CD38-negative hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66401	CL:0001024	\N	CD34-positive, CD38-negative hematopoietic stem cell	CL:0001024
0	"" []	\N	Kit-positive, Sca1-positive common lymphoid progenitor	\N	\N	EFO	"" []	EFO	66402	CL:0001025	\N	Kit-positive, Sca1-positive common lymphoid progenitor	CL:0001025
0	"" []	\N	CD34-positive, CD38-positive common myeloid progenitor	\N	\N	EFO	"" []	EFO	66403	CL:0001026	\N	CD34-positive, CD38-positive common myeloid progenitor	CL:0001026
0	"" []	\N	CD7-negative lymphoid progenitor cell	\N	\N	EFO	"" []	EFO	66404	CL:0001027	\N	CD7-negative lymphoid progenitor cell	CL:0001027
0	"" []	\N	CD7-positive lymphoid progenitor cell	\N	\N	EFO	"" []	EFO	66405	CL:0001028	\N	CD7-positive lymphoid progenitor cell	CL:0001028
0	"" []	\N	common dendritic progenitor	\N	\N	EFO	"" []	EFO	66406	CL:0001029	\N	common dendritic progenitor	CL:0001029
0	"" []	\N	CD117-positive common myeloid progenitor OR CD217-positive common lymphoid progenitor	\N	\N	EFO	"" []	EFO	66407	CL:0001030	\N	CD117-positive common myeloid progenitor OR CD217-positive common lymphoid progenitor	CL:0001030
0	"" []	\N	Kit-positive erythroid progenitor cell	\N	\N	EFO	"" []	EFO	66408	CL:0002000	\N	Kit-positive erythroid progenitor cell	CL:0002000
0	"" []	\N	CD34-positive, CD38-positive granulocyte monocyte progenitor	\N	\N	EFO	"" []	EFO	66409	CL:0002001	\N	CD34-positive, CD38-positive granulocyte monocyte progenitor	CL:0002001
0	"" []	\N	Kit-positive granulocyte monocyte progenitor	\N	\N	EFO	"" []	EFO	66410	CL:0002002	\N	Kit-positive granulocyte monocyte progenitor	CL:0002002
0	"" []	\N	CD34-positive, GlyA-negative erythroid progenitor cell	\N	\N	EFO	"" []	EFO	66411	CL:0002003	\N	CD34-positive, GlyA-negative erythroid progenitor cell	CL:0002003
0	"" []	\N	CD34-negative, GlyA-negative proerythroblast	\N	\N	EFO	"" []	EFO	66412	CL:0002004	\N	CD34-negative, GlyA-negative proerythroblast	CL:0002004
0	"" []	\N	CD34-positive, CD38-positive megakaryocyte erythroid progenitor cell	\N	\N	EFO	"" []	EFO	66413	CL:0002005	\N	CD34-positive, CD38-positive megakaryocyte erythroid progenitor cell	CL:0002005
0	"" []	\N	Kit-positive, CD34-negative megakaryocyte erythroid progenitor cell	\N	\N	EFO	"" []	EFO	66414	CL:0002006	\N	Kit-positive, CD34-negative megakaryocyte erythroid progenitor cell	CL:0002006
0	"" []	\N	Kit-low, CD34-positive eosinophil progenitor cell	\N	\N	EFO	"" []	EFO	66415	CL:0002007	\N	Kit-low, CD34-positive eosinophil progenitor cell	CL:0002007
0	"" []	\N	CD34-positive, CD38-positive eosinophil progenitor cell	\N	\N	EFO	"" []	EFO	66416	CL:0002008	\N	CD34-positive, CD38-positive eosinophil progenitor cell	CL:0002008
0	"" []	\N	macrophage dendritic cell progenitor	\N	\N	EFO	"" []	EFO	66417	CL:0002009	\N	macrophage dendritic cell progenitor	CL:0002009
0	"" []	\N	pre-conventional dendritic cell	\N	\N	EFO	"" []	EFO	66418	CL:0002010	\N	pre-conventional dendritic cell	CL:0002010
0	"" []	\N	Kit-positive macrophage dendritic cell progenitor	\N	\N	EFO	"" []	EFO	66419	CL:0002011	\N	Kit-positive macrophage dendritic cell progenitor	CL:0002011
0	"" []	\N	Kit-low proerythroblast	\N	\N	EFO	"" []	EFO	66420	CL:0002012	\N	Kit-low proerythroblast	CL:0002012
0	"" []	\N	GlyA-positive basophillic erythroblast	\N	\N	EFO	"" []	EFO	66421	CL:0002013	\N	GlyA-positive basophillic erythroblast	CL:0002013
0	"" []	\N	Kit-negative, Ly-76 high basophilic erythroblast	\N	\N	EFO	"" []	EFO	66422	CL:0002014	\N	Kit-negative, Ly-76 high basophilic erythroblast	CL:0002014
0	"" []	\N	Kit-negative, Ly-76 high polychromatophilic erythroblast	\N	\N	EFO	"" []	EFO	66423	CL:0002015	\N	Kit-negative, Ly-76 high polychromatophilic erythroblast	CL:0002015
0	"" []	\N	CD71-low, GlyA-positive polychromatic erythroblast	\N	\N	EFO	"" []	EFO	66424	CL:0002016	\N	CD71-low, GlyA-positive polychromatic erythroblast	CL:0002016
0	"" []	\N	Kit-negative, Ly-76 high orthochromatophilic erythroblasts	\N	\N	EFO	"" []	EFO	66425	CL:0002017	\N	Kit-negative, Ly-76 high orthochromatophilic erythroblasts	CL:0002017
0	"" []	\N	CD71-negative, GlyA-positive orthochromatic erythroblast	\N	\N	EFO	"" []	EFO	66426	CL:0002018	\N	CD71-negative, GlyA-positive orthochromatic erythroblast	CL:0002018
0	"" []	\N	Ly-76 high reticulocyte	\N	\N	EFO	"" []	EFO	66427	CL:0002019	\N	Ly-76 high reticulocyte	CL:0002019
0	"" []	\N	GlyA-positive reticulocytes	\N	\N	EFO	"" []	EFO	66428	CL:0002020	\N	GlyA-positive reticulocytes	CL:0002020
0	"" []	\N	GlyA-positive erythrocyte	\N	\N	EFO	"" []	EFO	66429	CL:0002021	\N	GlyA-positive erythrocyte	CL:0002021
0	"" []	\N	Ly-76 high positive erythrocyte	\N	\N	EFO	"" []	EFO	66430	CL:0002022	\N	Ly-76 high positive erythrocyte	CL:0002022
0	"" []	\N	CD34-positive, CD41-positive, CD42-positive megakaryocyte progenitor cell	\N	\N	EFO	"" []	EFO	66431	CL:0002023	\N	CD34-positive, CD41-positive, CD42-positive megakaryocyte progenitor cell	CL:0002023
0	"" []	\N	Kit-positive megakaryocyte progenitor cell	\N	\N	EFO	"" []	EFO	66432	CL:0002024	\N	Kit-positive megakaryocyte progenitor cell	CL:0002024
0	"" []	\N	CD34-positive, CD41-positive, CD42-negative megakaryocyte progenitor cell	\N	\N	EFO	"" []	EFO	66433	CL:0002025	\N	CD34-positive, CD41-positive, CD42-negative megakaryocyte progenitor cell	CL:0002025
0	"" []	\N	CD34-negative, CD41-positive, CD42-positive megakaryocyte cell	\N	\N	EFO	"" []	EFO	66434	CL:0002026	\N	CD34-negative, CD41-positive, CD42-positive megakaryocyte cell	CL:0002026
0	"" []	\N	CD9-positive, CD41-positive megakaryocyte cell	\N	\N	EFO	"" []	EFO	66435	CL:0002027	\N	CD9-positive, CD41-positive megakaryocyte cell	CL:0002027
0	"" []	\N	basophil mast progenitor cell	\N	\N	EFO	"" []	EFO	66436	CL:0002028	\N	basophil mast progenitor cell	CL:0002028
0	"" []	\N	Fc-epsilon RIalpha-low mast cell progenitor	\N	\N	EFO	"" []	EFO	66437	CL:0002029	\N	Fc-epsilon RIalpha-low mast cell progenitor	CL:0002029
0	"" []	\N	Fc-epsilon RIalpha-high basophil progenitor cell	\N	\N	EFO	"" []	EFO	66438	CL:0002030	\N	Fc-epsilon RIalpha-high basophil progenitor cell	CL:0002030
0	"" []	\N	hematopoietic lineage restricted progenitor cell	\N	\N	EFO	"" []	EFO	66439	CL:0002031	\N	hematopoietic lineage restricted progenitor cell	CL:0002031
0	"" []	\N	hematopoietic oligopotent progenitor cell	\N	\N	EFO	"" []	EFO	66440	CL:0002032	\N	hematopoietic oligopotent progenitor cell	CL:0002032
0	"" []	\N	short term hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66441	CL:0002033	\N	short term hematopoietic stem cell	CL:0002033
0	"" []	\N	long term hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66442	CL:0002034	\N	long term hematopoietic stem cell	CL:0002034
0	"" []	\N	Slamf1-negative multipotent progenitor cell	\N	\N	EFO	"" []	EFO	66443	CL:0002035	\N	Slamf1-negative multipotent progenitor cell	CL:0002035
0	"" []	\N	Slamf1-positive multipotent progenitor cell	\N	\N	EFO	"" []	EFO	66444	CL:0002036	\N	Slamf1-positive multipotent progenitor cell	CL:0002036
0	"" []	\N	CD2-positive, CD5-positive, CD44-positive alpha-beta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66445	CL:0002037	\N	CD2-positive, CD5-positive, CD44-positive alpha-beta intraepithelial T cell	CL:0002037
0	"" []	\N	T follicular helper cell	\N	\N	EFO	"" []	EFO	66446	CL:0002038	\N	T follicular helper cell	CL:0002038
0	"" []	\N	immature NK T cell stage I	\N	\N	EFO	"" []	EFO	66447	CL:0002039	\N	immature NK T cell stage I	CL:0002039
0	"" []	\N	immature NK T cell stage II	\N	\N	EFO	"" []	EFO	66448	CL:0002040	\N	immature NK T cell stage II	CL:0002040
0	"" []	\N	immature NK T cell stage III	\N	\N	EFO	"" []	EFO	66449	CL:0002041	\N	immature NK T cell stage III	CL:0002041
0	"" []	\N	immature NK T cell stage IV	\N	\N	EFO	"" []	EFO	66450	CL:0002042	\N	immature NK T cell stage IV	CL:0002042
0	"" []	\N	CD34-positive, CD38-negative multipotent progenitor cell	\N	\N	EFO	"" []	EFO	66451	CL:0002043	\N	CD34-positive, CD38-negative multipotent progenitor cell	CL:0002043
0	"" []	\N	Kit-positive, integrin beta7-high basophil mast progenitor cell	\N	\N	EFO	"" []	EFO	66452	CL:0002044	\N	Kit-positive, integrin beta7-high basophil mast progenitor cell	CL:0002044
0	"" []	\N	Fraction A pre-pro B cell	\N	\N	EFO	"" []	EFO	66453	CL:0002045	\N	Fraction A pre-pro B cell	CL:0002045
0	"" []	\N	Early pro-B cell	\N	\N	EFO	"" []	EFO	66454	CL:0002046	\N	Early pro-B cell	CL:0002046
0	"" []	\N	Fraction B precursor B cell	\N	\N	EFO	"" []	EFO	66455	CL:0002047	\N	Fraction B precursor B cell	CL:0002047
0	"" []	\N	late pro-B cell	\N	\N	EFO	"" []	EFO	66456	CL:0002048	\N	late pro-B cell	CL:0002048
0	"" []	\N	Fraction C precursor B cell	\N	\N	EFO	"" []	EFO	66457	CL:0002049	\N	Fraction C precursor B cell	CL:0002049
0	"" []	\N	Fraction C' precursor B cell	\N	\N	EFO	"" []	EFO	66458	CL:0002050	\N	Fraction C' precursor B cell	CL:0002050
0	"" []	\N	CD38-high pre-BCR positive cell	\N	\N	EFO	"" []	EFO	66459	CL:0002051	\N	CD38-high pre-BCR positive cell	CL:0002051
0	"" []	\N	Fraction D precursor B cell	\N	\N	EFO	"" []	EFO	66460	CL:0002052	\N	Fraction D precursor B cell	CL:0002052
0	"" []	\N	CD22-positive, CD38-low small pre-B cell	\N	\N	EFO	"" []	EFO	66461	CL:0002053	\N	CD22-positive, CD38-low small pre-B cell	CL:0002053
0	"" []	\N	Fraction E immature B cell	\N	\N	EFO	"" []	EFO	66462	CL:0002054	\N	Fraction E immature B cell	CL:0002054
0	"" []	\N	CD38-negative immature B cell	\N	\N	EFO	"" []	EFO	66463	CL:0002055	\N	CD38-negative immature B cell	CL:0002055
0	"" []	\N	Fraction F mature B cell	\N	\N	EFO	"" []	EFO	66464	CL:0002056	\N	Fraction F mature B cell	CL:0002056
0	"" []	\N	CD14-positive, CD16-negative classical monocyte	\N	\N	EFO	"" []	EFO	66465	CL:0002057	\N	CD14-positive, CD16-negative classical monocyte	CL:0002057
0	"" []	\N	Gr1-low non-classical monocyte	\N	\N	EFO	"" []	EFO	66466	CL:0002058	\N	Gr1-low non-classical monocyte	CL:0002058
0	"" []	\N	CD8alpha-positive thymic conventional dendritic cell	\N	\N	EFO	"" []	EFO	66467	CL:0002059	\N	CD8alpha-positive thymic conventional dendritic cell	CL:0002059
0	"" []	\N	melanophage	\N	\N	EFO	"" []	EFO	66468	CL:0002060	\N	melanophage	CL:0002060
0	"" []	\N	T-helper 9 cell	\N	\N	EFO	"" []	EFO	66469	CL:0002061	\N	T-helper 9 cell	CL:0002061
0	"" []	\N	nongranular leukocyte	\N	\N	EFO	"" []	EFO	66470	CL:0002087	\N	nongranular leukocyte	CL:0002087
0	"" []	\N	nuocyte	\N	\N	EFO	"" []	EFO	66471	CL:0002089	\N	nuocyte	CL:0002089
0	"" []	\N	CD38-positive naive B cell	\N	\N	EFO	"" []	EFO	66472	CL:0002101	\N	CD38-positive naive B cell	CL:0002101
0	"" []	\N	CD38-negative naive B cell	\N	\N	EFO	"" []	EFO	66473	CL:0002102	\N	CD38-negative naive B cell	CL:0002102
0	"" []	\N	IgG-positive double negative memory B cell	\N	\N	EFO	"" []	EFO	66474	CL:0002103	\N	IgG-positive double negative memory B cell	CL:0002103
0	"" []	\N	IgG-negative double negative memory B cell	\N	\N	EFO	"" []	EFO	66475	CL:0002104	\N	IgG-negative double negative memory B cell	CL:0002104
0	"" []	\N	CD38-positive IgG memory B cell	\N	\N	EFO	"" []	EFO	66476	CL:0002105	\N	CD38-positive IgG memory B cell	CL:0002105
0	"" []	\N	IgD-positive CD38-positive IgG memory B cell	\N	\N	EFO	"" []	EFO	66477	CL:0002106	\N	IgD-positive CD38-positive IgG memory B cell	CL:0002106
0	"" []	\N	IgD-negative CD38-positive IgG memory B cell	\N	\N	EFO	"" []	EFO	66478	CL:0002107	\N	IgD-negative CD38-positive IgG memory B cell	CL:0002107
0	"" []	\N	CD38-negative IgG memory B cell	\N	\N	EFO	"" []	EFO	66479	CL:0002108	\N	CD38-negative IgG memory B cell	CL:0002108
0	"" []	\N	B220-positive CD38-positive naive B cell	\N	\N	EFO	"" []	EFO	66480	CL:0002109	\N	B220-positive CD38-positive naive B cell	CL:0002109
0	"" []	\N	B220-low CD38-positive naive B cell	\N	\N	EFO	"" []	EFO	66481	CL:0002110	\N	B220-low CD38-positive naive B cell	CL:0002110
0	"" []	\N	CD38-negative unswitched memory B cell	\N	\N	EFO	"" []	EFO	66482	CL:0002111	\N	CD38-negative unswitched memory B cell	CL:0002111
0	"" []	\N	B220-positive CD38-negative unswitched memory B cell	\N	\N	EFO	"" []	EFO	66483	CL:0002112	\N	B220-positive CD38-negative unswitched memory B cell	CL:0002112
0	"" []	\N	B220-low CD38-negative unswitched memory B cell	\N	\N	EFO	"" []	EFO	66484	CL:0002113	\N	B220-low CD38-negative unswitched memory B cell	CL:0002113
0	"" []	\N	CD38-positive unswitched memory B cell	\N	\N	EFO	"" []	EFO	66485	CL:0002114	\N	CD38-positive unswitched memory B cell	CL:0002114
0	"" []	\N	B220-positive CD38-positive unswitched memory B cell	\N	\N	EFO	"" []	EFO	66486	CL:0002115	\N	B220-positive CD38-positive unswitched memory B cell	CL:0002115
0	"" []	\N	B220-low CD38-positive unswitched memory B cell	\N	\N	EFO	"" []	EFO	66487	CL:0002116	\N	B220-low CD38-positive unswitched memory B cell	CL:0002116
0	"" []	\N	IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66488	CL:0002117	\N	IgG-negative class switched memory B cell	CL:0002117
0	"" []	\N	CD38-negative IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66489	CL:0002118	\N	CD38-negative IgG-negative class switched memory B cell	CL:0002118
0	"" []	\N	CD38-positive IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66490	CL:0002119	\N	CD38-positive IgG-negative class switched memory B cell	CL:0002119
0	"" []	\N	CD24-positive CD38-negative IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66491	CL:0002120	\N	CD24-positive CD38-negative IgG-negative class switched memory B cell	CL:0002120
0	"" []	\N	CD24-negative CD38-negative IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66492	CL:0002121	\N	CD24-negative CD38-negative IgG-negative class switched memory B cell	CL:0002121
0	"" []	\N	B220-positive CD38-positive IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66493	CL:0002122	\N	B220-positive CD38-positive IgG-negative class switched memory B cell	CL:0002122
0	"" []	\N	B220-low CD38-positive IgG-negative class switched memory B cell	\N	\N	EFO	"" []	EFO	66494	CL:0002123	\N	B220-low CD38-positive IgG-negative class switched memory B cell	CL:0002123
0	"" []	\N	CD27-positive gamma-delta T cell	\N	\N	EFO	"" []	EFO	66495	CL:0002124	\N	CD27-positive gamma-delta T cell	CL:0002124
0	"" []	\N	CD27-negative gamma-delta T cell	\N	\N	EFO	"" []	EFO	66496	CL:0002125	\N	CD27-negative gamma-delta T cell	CL:0002125
0	"" []	\N	CD25-positive, CD27-positive immature gamma-delta T cell	\N	\N	EFO	"" []	EFO	66497	CL:0002126	\N	CD25-positive, CD27-positive immature gamma-delta T cell	CL:0002126
0	"" []	\N	innate effector T cell	\N	\N	EFO	"" []	EFO	66498	CL:0002127	\N	innate effector T cell	CL:0002127
0	"" []	\N	Tc17 cell	\N	\N	EFO	"" []	EFO	66499	CL:0002128	\N	Tc17 cell	CL:0002128
0	"An endothelial cell found in capillaries." []	\N	capillary endothelial cell	\N	\N	cell	"An endothelial cell found in capillaries." []	EFO	66500	CL:0002144	\N	capillary endothelial cell	CL:0002144
0	"" []	\N	epitheloid cell	\N	\N	EFO	"" []	EFO	66501	CL:0002150	\N	epitheloid cell	CL:0002150
0	"" []	\N	late promyelocyte	\N	\N	EFO	"" []	EFO	66502	CL:0002151	\N	late promyelocyte	CL:0002151
0	"" []	\N	early promyelocyte	\N	\N	EFO	"" []	EFO	66503	CL:0002154	\N	early promyelocyte	CL:0002154
0	"" []	\N	echinocyte	\N	\N	EFO	"" []	EFO	66504	CL:0002155	\N	echinocyte	CL:0002155
0	"" []	\N	granulocytopoietic cell	\N	\N	EFO	"" []	EFO	66505	CL:0002191	\N	granulocytopoietic cell	CL:0002191
0	"" []	\N	metamyelocyte	\N	\N	EFO	"" []	EFO	66506	CL:0002192	\N	metamyelocyte	CL:0002192
0	"A cell type that is the first of the maturation stages of the granulocytic leukocytes normally found in the bone marrow. Granules are seen in the cytoplasm. The nuclear material of the myelocyte is denser than that of the myeloblast but lacks a definable membrane. The cell is flat and contains increasing numbers of granules as maturation progresses." []	\N	myelocyte	\N	\N	EFO	"A cell type that is the first of the maturation stages of the granulocytic leukocytes normally found in the bone marrow. Granules are seen in the cytoplasm. The nuclear material of the myelocyte is denser than that of the myeloblast but lacks a definable membrane. The cell is flat and contains increasing numbers of granules as maturation progresses." []	EFO	66507	CL:0002193	\N	myelocyte	CL:0002193
0	"" []	\N	monopoietic cell	\N	\N	EFO	"" []	EFO	66508	CL:0002194	\N	monopoietic cell	CL:0002194
0	"A trophoblast that leaves the placenta and invades the endometrium and myometrium. This cell type is crucial in increasing blood flow to the fetus." []	\N	intermediate trophoblast cell	\N	\N	EFO	"A trophoblast that leaves the placenta and invades the endometrium and myometrium. This cell type is crucial in increasing blood flow to the fetus." []	EFO	66509	CL:0002217	\N	intermediate trophoblast cell	CL:0002217
0	"" []	\N	immature dendritic epithelial T cell precursor	\N	\N	EFO	"" []	EFO	66510	CL:0002218	\N	immature dendritic epithelial T cell precursor	CL:0002218
0	"An epithelial cell of the prostate." []	\N	epithelial cell of prostate	\N	\N	cell	"An epithelial cell of the prostate." []	EFO	66511	CL:0002231	\N	epithelial cell of prostate	CL:0002231
0	"" []	\N	peripheral blood stem cell	\N	\N	EFO	"" []	EFO	66512	CL:0002246	\N	peripheral blood stem cell	CL:0002246
0	"" []	\N	pleural macrophage	\N	\N	EFO	"" []	EFO	66513	CL:0002247	\N	pleural macrophage	CL:0002247
0	"An epithelial cell of the large intestine." []	\N	epithelial cell of large intestine	\N	\N	cell	"An epithelial cell of the large intestine." []	EFO	66514	CL:0002253	\N	epithelial cell of large intestine	CL:0002253
0	"" []	\N	periperhal blood mesothelial cell	\N	\N	EFO	"" []	EFO	66515	CL:0002318	\N	periperhal blood mesothelial cell	CL:0002318
0	"" []	\N	neural cell	\N	\N	EFO	"" []	EFO	66516	CL:0002319	\N	neural cell	CL:0002319
0	"A cell of the embryo." []	\N	embryonic cell	\N	\N	EFO	"A cell of the embryo." []	EFO	66517	CL:0002321	\N	embryonic cell	CL:0002321
0	"Totipotent cell cultured from early embryo. Have the advantage that following modification in vitrothey can be used to produce chimeric embryos and thus transgenic animals." []	\N	embryonic stem cell	\N	\N	EFO	"Totipotent cell cultured from early embryo. Have the advantage that following modification in vitrothey can be used to produce chimeric embryos and thus transgenic animals." []	EFO	66518	CL:0002322	\N	embryonic stem cell	CL:0002322
0	"An epithelial cell of the mammary gland." []	\N	mammary epithelial cell	\N	\N	cell	"An epithelial cell of the mammary gland." []	EFO	66519	CL:0002327	\N	mammary epithelial cell	CL:0002327
0	"An undifferentiated fibroblast that can be stimulated to form a fat cell." []	\N	preadipocyte	\N	\N	EFO	"An undifferentiated fibroblast that can be stimulated to form a fat cell." []	EFO	66520	CL:0002334	\N	preadipocyte	CL:0002334
0	"" []	\N	CD56-positive, CD161-positive immature natural killer cell	\N	\N	EFO	"" []	EFO	66521	CL:0002338	\N	CD56-positive, CD161-positive immature natural killer cell	CL:0002338
0	"A circulating endothelial cell of the phenotype CD146-positive, CD105-positive, CD45-negative. This cell type is indicative of recent vascular damage." []	\N	circulating endothelial cell	\N	\N	cell	"A circulating endothelial cell of the phenotype CD146-positive, CD105-positive, CD45-negative. This cell type is indicative of recent vascular damage." []	EFO	66522	CL:0002342	\N	circulating endothelial cell	CL:0002342
0	"" []	\N	decidual natural killer cell	\N	\N	EFO	"" []	EFO	66523	CL:0002343	\N	decidual natural killer cell	CL:0002343
0	"" []	\N	CD56-negative, CD161-positive immature natural killer cell	\N	\N	EFO	"" []	EFO	66524	CL:0002344	\N	CD56-negative, CD161-positive immature natural killer cell	CL:0002344
0	"" []	\N	CD27-low, CD11b-low immature natural killer cell	\N	\N	EFO	"" []	EFO	66525	CL:0002345	\N	CD27-low, CD11b-low immature natural killer cell	CL:0002345
0	"" []	\N	Dx5-negative, NK1.1-positive immature natural killer cell	\N	\N	EFO	"" []	EFO	66526	CL:0002346	\N	Dx5-negative, NK1.1-positive immature natural killer cell	CL:0002346
0	"" []	\N	CD27-high, CD11b-high natural killer cell	\N	\N	EFO	"" []	EFO	66527	CL:0002347	\N	CD27-high, CD11b-high natural killer cell	CL:0002347
0	"" []	\N	CD27-low, CD11b-high natural killer cell	\N	\N	EFO	"" []	EFO	66528	CL:0002348	\N	CD27-low, CD11b-high natural killer cell	CL:0002348
0	"" []	\N	CD27-high, CD11b-low natural killer cell	\N	\N	EFO	"" []	EFO	66529	CL:0002349	\N	CD27-high, CD11b-low natural killer cell	CL:0002349
0	"A multi-fate stem cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1." []	\N	progenitor cell of endocrine pancreas	\N	\N	EFO	"A multi-fate stem cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1." []	EFO	66530	CL:0002351	\N	progenitor cell of endocrine pancreas	CL:0002351
0	"" []	\N	gestational hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66531	CL:0002352	\N	gestational hematopoietic stem cell	CL:0002352
0	"A hematopoietic stem cell that resides in the fetal liver. In mice, this cell type is first observed at E10.5. This cell type is MHC-positive, HSA-positive, AA4.1-positive, CD45-positive, Sca-1 positive, CD150-positive, CD48-negative and CD244-negative." []	\N	fetal liver hematopoietic progenitor cell	\N	\N	EFO	"A hematopoietic stem cell that resides in the fetal liver. In mice, this cell type is first observed at E10.5. This cell type is MHC-positive, HSA-positive, AA4.1-positive, CD45-positive, Sca-1 positive, CD150-positive, CD48-negative and CD244-negative." []	EFO	66532	CL:0002353	\N	fetal liver hematopoietic progenitor cell	CL:0002353
0	"" []	\N	yolk sac hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66533	CL:0002354	\N	yolk sac hematopoietic stem cell	CL:0002354
0	"" []	\N	primitive red blood cell	\N	\N	EFO	"" []	EFO	66534	CL:0002355	\N	primitive red blood cell	CL:0002355
0	"" []	\N	primitive reticulocyte	\N	\N	EFO	"" []	EFO	66535	CL:0002356	\N	primitive reticulocyte	CL:0002356
0	"" []	\N	fetal derived definitive erythrocyte	\N	\N	EFO	"" []	EFO	66536	CL:0002357	\N	fetal derived definitive erythrocyte	CL:0002357
0	"" []	\N	pyrenocyte	\N	\N	EFO	"" []	EFO	66537	CL:0002358	\N	pyrenocyte	CL:0002358
0	"" []	\N	placental hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66538	CL:0002359	\N	placental hematopoietic stem cell	CL:0002359
0	"" []	\N	AGM hematopoietic stem cell	\N	\N	EFO	"" []	EFO	66539	CL:0002360	\N	AGM hematopoietic stem cell	CL:0002360
0	"" []	\N	primitive erythroid progenitor	\N	\N	EFO	"" []	EFO	66540	CL:0002361	\N	primitive erythroid progenitor	CL:0002361
0	"A keratocyte is a specialized fibroblast residing in the stroma that has a flattened, dendritic cell located between the lamellae with a large flattened nucleus and lengthy processes which communicate with neighboring cells. This corneal layer, representing about 85-90% of corneal thickness, is built up from highly regular collagenous lamellae and extracellular matrix components. Keratocytes play the major role in keeping it transparent, healing its wounds, and synthesizing its components.  This cell type secretes collagen I, V, VI, and keratin sulfate." []	\N	keratocyte	\N	\N	EFO	"A keratocyte is a specialized fibroblast residing in the stroma that has a flattened, dendritic cell located between the lamellae with a large flattened nucleus and lengthy processes which communicate with neighboring cells. This corneal layer, representing about 85-90% of corneal thickness, is built up from highly regular collagenous lamellae and extracellular matrix components. Keratocytes play the major role in keeping it transparent, healing its wounds, and synthesizing its components.  This cell type secretes collagen I, V, VI, and keratin sulfate." []	EFO	66541	CL:0002363	\N	keratocyte	CL:0002363
0	"An epithelial cell of the medullary thymus. This cell type  expresses a diverse range of tissue-specific antigens. This promiscuous gene expression is a cell-autonomous property of medullary epithelial cells and is maintained during the entire period of thymic T cell output." []	\N	medullary thymic epithelial cell	\N	\N	EFO	"An epithelial cell of the medullary thymus. This cell type  expresses a diverse range of tissue-specific antigens. This promiscuous gene expression is a cell-autonomous property of medullary epithelial cells and is maintained during the entire period of thymic T cell output." []	EFO	66542	CL:0002365	\N	medullary thymic epithelial cell	CL:0002365
0	"Epithelium of the respiratory portion of the bronchial tree." []	\N	airway epithelial cell	\N	\N	EFO	"Epithelium of the respiratory portion of the bronchial tree." []	EFO	66543	CL:0002368	\N	airway epithelial cell	CL:0002368
0	"One of the cells of the body that compose the tissues, organs, and parts of that individual other than the germ cells." []	\N	somatic cell	\N	\N	EFO	"One of the cells of the body that compose the tissues, organs, and parts of that individual other than the germ cells." []	EFO	66544	CL:0002371	\N	somatic cell	CL:0002371
0	"" []	\N	immature Vgamma2-positive fetal thymocyte	\N	\N	EFO	"" []	EFO	66545	CL:0002378	\N	immature Vgamma2-positive fetal thymocyte	CL:0002378
0	"" []	\N	intermediate monocyte	\N	\N	EFO	"" []	EFO	66546	CL:0002393	\N	intermediate monocyte	CL:0002393
0	"" []	\N	CD141-positive myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66547	CL:0002394	\N	CD141-positive myeloid dendritic cell	CL:0002394
0	"" []	\N	Gr1-high classical monocyte	\N	\N	EFO	"" []	EFO	66548	CL:0002395	\N	Gr1-high classical monocyte	CL:0002395
0	"" []	\N	CD14-low, CD16-positive monocyte	\N	\N	EFO	"" []	EFO	66549	CL:0002396	\N	CD14-low, CD16-positive monocyte	CL:0002396
0	"" []	\N	CD14-positive, CD16-positive monocyte	\N	\N	EFO	"" []	EFO	66550	CL:0002397	\N	CD14-positive, CD16-positive monocyte	CL:0002397
0	"" []	\N	Gr1-positive, CD43-positive monocyte	\N	\N	EFO	"" []	EFO	66551	CL:0002398	\N	Gr1-positive, CD43-positive monocyte	CL:0002398
0	"" []	\N	CD1c-positive myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66552	CL:0002399	\N	CD1c-positive myeloid dendritic cell	CL:0002399
0	"" []	\N	Fraction B/C precursor B cell	\N	\N	EFO	"" []	EFO	66553	CL:0002400	\N	Fraction B/C precursor B cell	CL:0002400
0	"" []	\N	mature dendritic epithelial T cell precursor	\N	\N	EFO	"" []	EFO	66554	CL:0002401	\N	mature dendritic epithelial T cell precursor	CL:0002401
0	"" []	\N	Peyer's patch B cell	\N	\N	EFO	"" []	EFO	66555	CL:0002402	\N	Peyer's patch B cell	CL:0002402
0	"" []	\N	mature Vgamma2-positive fetal thymocyte	\N	\N	EFO	"" []	EFO	66556	CL:0002403	\N	mature Vgamma2-positive fetal thymocyte	CL:0002403
0	"" []	\N	fetal thymocyte	\N	\N	EFO	"" []	EFO	66557	CL:0002404	\N	fetal thymocyte	CL:0002404
0	"" []	\N	gamma-delta thymocyte	\N	\N	EFO	"" []	EFO	66558	CL:0002405	\N	gamma-delta thymocyte	CL:0002405
0	"" []	\N	immature Vgamma2-positive thymocyte	\N	\N	EFO	"" []	EFO	66559	CL:0002406	\N	immature Vgamma2-positive thymocyte	CL:0002406
0	"" []	\N	mature Vgamma2-positive thymocyte	\N	\N	EFO	"" []	EFO	66560	CL:0002407	\N	mature Vgamma2-positive thymocyte	CL:0002407
0	"" []	\N	immature Vgamma2-negative thymocyte	\N	\N	EFO	"" []	EFO	66561	CL:0002408	\N	immature Vgamma2-negative thymocyte	CL:0002408
0	"" []	\N	mature Vgamma2-negative thymocyte	\N	\N	EFO	"" []	EFO	66562	CL:0002409	\N	mature Vgamma2-negative thymocyte	CL:0002409
0	"" []	\N	Vgamma1.1-positive, Vdelta6.3-negative thymocyte	\N	\N	EFO	"" []	EFO	66563	CL:0002411	\N	Vgamma1.1-positive, Vdelta6.3-negative thymocyte	CL:0002411
0	"" []	\N	Vgamma1.1-positive, Vdelta6.3-positive thymocyte	\N	\N	EFO	"" []	EFO	66564	CL:0002412	\N	Vgamma1.1-positive, Vdelta6.3-positive thymocyte	CL:0002412
0	"" []	\N	mature Vgamma1.1-positive, Vdelta6.3-negative thymocyte	\N	\N	EFO	"" []	EFO	66565	CL:0002413	\N	mature Vgamma1.1-positive, Vdelta6.3-negative thymocyte	CL:0002413
0	"" []	\N	immature Vgamma1.1-positive, Vdelta6.3-negative thymocyte	\N	\N	EFO	"" []	EFO	66566	CL:0002414	\N	immature Vgamma1.1-positive, Vdelta6.3-negative thymocyte	CL:0002414
0	"" []	\N	immature Vgamma1.1-positive, Vdelta6.3-positive thymocyte	\N	\N	EFO	"" []	EFO	66567	CL:0002415	\N	immature Vgamma1.1-positive, Vdelta6.3-positive thymocyte	CL:0002415
0	"" []	\N	mature Vgamma1.1-positive, Vdelta6.3-positive thymocyte	\N	\N	EFO	"" []	EFO	66568	CL:0002416	\N	mature Vgamma1.1-positive, Vdelta6.3-positive thymocyte	CL:0002416
0	"" []	\N	primitive erythroid lineage cell	\N	\N	EFO	"" []	EFO	66569	CL:0002417	\N	primitive erythroid lineage cell	CL:0002417
0	"" []	\N	mature T cell	\N	\N	EFO	"" []	EFO	66570	CL:0002419	\N	mature T cell	CL:0002419
0	"" []	\N	immature T cell	\N	\N	EFO	"" []	EFO	66571	CL:0002420	\N	immature T cell	CL:0002420
0	"" []	\N	nucleated reticulocyte	\N	\N	EFO	"" []	EFO	66572	CL:0002421	\N	nucleated reticulocyte	CL:0002421
0	"" []	\N	enucleated reticulocyte	\N	\N	EFO	"" []	EFO	66573	CL:0002422	\N	enucleated reticulocyte	CL:0002422
0	"" []	\N	DN2a thymocyte	\N	\N	EFO	"" []	EFO	66574	CL:0002423	\N	DN2a thymocyte	CL:0002423
0	"" []	\N	DN2b thymocyte	\N	\N	EFO	"" []	EFO	66575	CL:0002424	\N	DN2b thymocyte	CL:0002424
0	"" []	\N	early T lineage precursor	\N	\N	EFO	"" []	EFO	66576	CL:0002425	\N	early T lineage precursor	CL:0002425
0	"" []	\N	CD11b-positive, CD27-positive natural killer cell	\N	\N	EFO	"" []	EFO	66577	CL:0002426	\N	CD11b-positive, CD27-positive natural killer cell	CL:0002426
0	"" []	\N	resting double-positive thymocyte	\N	\N	EFO	"" []	EFO	66578	CL:0002427	\N	resting double-positive thymocyte	CL:0002427
0	"" []	\N	double-positive blast	\N	\N	EFO	"" []	EFO	66579	CL:0002428	\N	double-positive blast	CL:0002428
0	"" []	\N	CD69-positive double-positive thymocyte	\N	\N	EFO	"" []	EFO	66580	CL:0002429	\N	CD69-positive double-positive thymocyte	CL:0002429
0	"" []	\N	CD4-intermediate, CD8-positive double-positive thymocyte	\N	\N	EFO	"" []	EFO	66581	CL:0002430	\N	CD4-intermediate, CD8-positive double-positive thymocyte	CL:0002430
0	"" []	\N	CD4-positive, CD8-intermediate double-positive thymocyte	\N	\N	EFO	"" []	EFO	66582	CL:0002431	\N	CD4-positive, CD8-intermediate double-positive thymocyte	CL:0002431
0	"" []	\N	CD24-positive, CD4 single-positive thymocyte	\N	\N	EFO	"" []	EFO	66583	CL:0002432	\N	CD24-positive, CD4 single-positive thymocyte	CL:0002432
0	"" []	\N	CD69-positive, CD4-positive single-positive thymocyte	\N	\N	EFO	"" []	EFO	66584	CL:0002433	\N	CD69-positive, CD4-positive single-positive thymocyte	CL:0002433
0	"" []	\N	CD24-positive, CD8 single-positive thymocyte	\N	\N	EFO	"" []	EFO	66585	CL:0002434	\N	CD24-positive, CD8 single-positive thymocyte	CL:0002434
0	"" []	\N	CD69-positive, CD8-positive single-positive thymocyte	\N	\N	EFO	"" []	EFO	66586	CL:0002435	\N	CD69-positive, CD8-positive single-positive thymocyte	CL:0002435
0	"" []	\N	mature CD4 single-positive thymocyte	\N	\N	EFO	"" []	EFO	66587	CL:0002436	\N	mature CD4 single-positive thymocyte	CL:0002436
0	"" []	\N	mature CD8 single-positive thymocyte	\N	\N	EFO	"" []	EFO	66588	CL:0002437	\N	mature CD8 single-positive thymocyte	CL:0002437
0	"" []	\N	NK1.1-positive natural killer cell	\N	\N	EFO	"" []	EFO	66589	CL:0002438	\N	NK1.1-positive natural killer cell	CL:0002438
0	"" []	\N	NKGA2-positive natural killer cell	\N	\N	EFO	"" []	EFO	66590	CL:0002439	\N	NKGA2-positive natural killer cell	CL:0002439
0	"" []	\N	Ly49D-positive natural killer cell	\N	\N	EFO	"" []	EFO	66591	CL:0002440	\N	Ly49D-positive natural killer cell	CL:0002440
0	"" []	\N	CD94-positive natural killer cell	\N	\N	EFO	"" []	EFO	66592	CL:0002441	\N	CD94-positive natural killer cell	CL:0002441
0	"" []	\N	CD94-negative, Ly49CI-negative natural killer cell	\N	\N	EFO	"" []	EFO	66593	CL:0002442	\N	CD94-negative, Ly49CI-negative natural killer cell	CL:0002442
0	"" []	\N	Ly49CI-positive natural killer cell	\N	\N	EFO	"" []	EFO	66594	CL:0002443	\N	Ly49CI-positive natural killer cell	CL:0002443
0	"" []	\N	Ly49H-positive natural killer cell	\N	\N	EFO	"" []	EFO	66595	CL:0002444	\N	Ly49H-positive natural killer cell	CL:0002444
0	"" []	\N	Ly49D-negative natural killer cell	\N	\N	EFO	"" []	EFO	66596	CL:0002445	\N	Ly49D-negative natural killer cell	CL:0002445
0	"" []	\N	Ly49CI-negative natural killer cell	\N	\N	EFO	"" []	EFO	66597	CL:0002446	\N	Ly49CI-negative natural killer cell	CL:0002446
0	"" []	\N	CD94-negative natural killer cell	\N	\N	EFO	"" []	EFO	66598	CL:0002447	\N	CD94-negative natural killer cell	CL:0002447
0	"" []	\N	Ly49H-negative natural killer cell	\N	\N	EFO	"" []	EFO	66599	CL:0002448	\N	Ly49H-negative natural killer cell	CL:0002448
0	"" []	\N	CD94-positive Ly49CI-positive natural killer cell	\N	\N	EFO	"" []	EFO	66600	CL:0002449	\N	CD94-positive Ly49CI-positive natural killer cell	CL:0002449
0	"" []	\N	Cd4-negative, CD8_alpha-negative, CD11b-positive dendritic cell	\N	\N	EFO	"" []	EFO	66601	CL:0002454	\N	Cd4-negative, CD8_alpha-negative, CD11b-positive dendritic cell	CL:0002454
0	"" []	\N	CD8_alpha-negative plasmactyoid dendritic cell	\N	\N	EFO	"" []	EFO	66602	CL:0002455	\N	CD8_alpha-negative plasmactyoid dendritic cell	CL:0002455
0	"" []	\N	CD8_alpha-positive plasmactyoid dendritic cell	\N	\N	EFO	"" []	EFO	66603	CL:0002456	\N	CD8_alpha-positive plasmactyoid dendritic cell	CL:0002456
0	"" []	\N	epidermal Langerhans cell	\N	\N	EFO	"" []	EFO	66604	CL:0002457	\N	epidermal Langerhans cell	CL:0002457
0	"" []	\N	langerin-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66605	CL:0002458	\N	langerin-positive dermal dendritic cell	CL:0002458
0	"" []	\N	langerin-negative dermal  dendritic cell	\N	\N	EFO	"" []	EFO	66606	CL:0002459	\N	langerin-negative dermal  dendritic cell	CL:0002459
0	"" []	\N	CD8alpha-negative thymic conventional dendritic cell	\N	\N	EFO	"" []	EFO	66607	CL:0002460	\N	CD8alpha-negative thymic conventional dendritic cell	CL:0002460
0	"" []	\N	CD103-positive dendritic cell	\N	\N	EFO	"" []	EFO	66608	CL:0002461	\N	CD103-positive dendritic cell	CL:0002461
0	"" []	\N	adipose dendritic cell	\N	\N	EFO	"" []	EFO	66609	CL:0002462	\N	adipose dendritic cell	CL:0002462
0	"" []	\N	SIRPa-positive adipose dendritic cell	\N	\N	EFO	"" []	EFO	66610	CL:0002463	\N	SIRPa-positive adipose dendritic cell	CL:0002463
0	"" []	\N	SIRPa-negative adipose dendritic cell	\N	\N	EFO	"" []	EFO	66611	CL:0002464	\N	SIRPa-negative adipose dendritic cell	CL:0002464
0	"" []	\N	CD11b-positive dendritic cell	\N	\N	EFO	"" []	EFO	66612	CL:0002465	\N	CD11b-positive dendritic cell	CL:0002465
0	"" []	\N	small intestine serosal dendritic cell	\N	\N	EFO	"" []	EFO	66613	CL:0002466	\N	small intestine serosal dendritic cell	CL:0002466
0	"" []	\N	Gr1-high myeloid suppressor cell	\N	\N	EFO	"" []	EFO	66614	CL:0002467	\N	Gr1-high myeloid suppressor cell	CL:0002467
0	"" []	\N	Gr1-low myeloid suppressor cell	\N	\N	EFO	"" []	EFO	66615	CL:0002468	\N	Gr1-low myeloid suppressor cell	CL:0002468
0	"" []	\N	MHC-II-negative classical monocyte	\N	\N	EFO	"" []	EFO	66616	CL:0002469	\N	MHC-II-negative classical monocyte	CL:0002469
0	"" []	\N	MHC-II-positive classical monocyte	\N	\N	EFO	"" []	EFO	66617	CL:0002470	\N	MHC-II-positive classical monocyte	CL:0002470
0	"" []	\N	MHC-II-negative non-classical monocyte	\N	\N	EFO	"" []	EFO	66618	CL:0002471	\N	MHC-II-negative non-classical monocyte	CL:0002471
0	"" []	\N	MHC-II-low non-classical monocyte	\N	\N	EFO	"" []	EFO	66619	CL:0002472	\N	MHC-II-low non-classical monocyte	CL:0002472
0	"" []	\N	MHC-II-high non-classical monocyte	\N	\N	EFO	"" []	EFO	66620	CL:0002473	\N	MHC-II-high non-classical monocyte	CL:0002473
0	"" []	\N	lymphoid MHC-II-negative classical monocyte	\N	\N	EFO	"" []	EFO	66621	CL:0002474	\N	lymphoid MHC-II-negative classical monocyte	CL:0002474
0	"" []	\N	lymphoid MHC-II-negative non-classical monocyte	\N	\N	EFO	"" []	EFO	66622	CL:0002475	\N	lymphoid MHC-II-negative non-classical monocyte	CL:0002475
0	"" []	\N	bone marrow macrophage	\N	\N	EFO	"" []	EFO	66623	CL:0002476	\N	bone marrow macrophage	CL:0002476
0	"" []	\N	adipose macrophage	\N	\N	EFO	"" []	EFO	66624	CL:0002477	\N	adipose macrophage	CL:0002477
0	"" []	\N	F4/80-negative adipose macrophage	\N	\N	EFO	"" []	EFO	66625	CL:0002478	\N	F4/80-negative adipose macrophage	CL:0002478
0	"" []	\N	F4/80-positive adipose macrophage	\N	\N	EFO	"" []	EFO	66626	CL:0002479	\N	F4/80-positive adipose macrophage	CL:0002479
0	"" []	\N	double negative thymocyte	\N	\N	EFO	"" []	EFO	66627	CL:0002489	\N	double negative thymocyte	CL:0002489
0	"" []	\N	intraepithelial lymphocyte	\N	\N	EFO	"" []	EFO	66628	CL:0002496	\N	intraepithelial lymphocyte	CL:0002496
0	"" []	\N	liver CD103-negative dendritic cell	\N	\N	EFO	"" []	EFO	66629	CL:0002505	\N	liver CD103-negative dendritic cell	CL:0002505
0	"" []	\N	liver CD103-positive dendritic cell	\N	\N	EFO	"" []	EFO	66630	CL:0002506	\N	liver CD103-positive dendritic cell	CL:0002506
0	"" []	\N	langerin-positive lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66631	CL:0002507	\N	langerin-positive lymph node dendritic cell	CL:0002507
0	"" []	\N	langerin-negative, CD103-negative lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66632	CL:0002508	\N	langerin-negative, CD103-negative lymph node dendritic cell	CL:0002508
0	"" []	\N	CD103-positive, langerin-positive lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66633	CL:0002509	\N	CD103-positive, langerin-positive lymph node dendritic cell	CL:0002509
0	"" []	\N	CD103-negative, langerin-positive lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66634	CL:0002510	\N	CD103-negative, langerin-positive lymph node dendritic cell	CL:0002510
0	"" []	\N	CD11b-low, CD103-negative, langerin-negative lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66635	CL:0002511	\N	CD11b-low, CD103-negative, langerin-negative lymph node dendritic cell	CL:0002511
0	"" []	\N	CD11b-high, CD103-negative, langerin-negative lymph node dendritic cell	\N	\N	EFO	"" []	EFO	66636	CL:0002512	\N	CD11b-high, CD103-negative, langerin-negative lymph node dendritic cell	CL:0002512
0	"" []	\N	Vgamma5-positive CD8alpha alpha positive gamma-delta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66637	CL:0002513	\N	Vgamma5-positive CD8alpha alpha positive gamma-delta intraepithelial T cell	CL:0002513
0	"" []	\N	Vgamma5-negative CD8alpha alpha positive gamma-delta intraepithelial T cell	\N	\N	EFO	"" []	EFO	66638	CL:0002514	\N	Vgamma5-negative CD8alpha alpha positive gamma-delta intraepithelial T cell	CL:0002514
0	"" []	\N	CD14-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66639	CL:0002526	\N	CD14-positive dermal dendritic cell	CL:0002526
0	"" []	\N	immature CD14-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66640	CL:0002527	\N	immature CD14-positive dermal dendritic cell	CL:0002527
0	"" []	\N	mature CD14-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66641	CL:0002528	\N	mature CD14-positive dermal dendritic cell	CL:0002528
0	"" []	\N	CD1a-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66642	CL:0002529	\N	CD1a-positive dermal dendritic cell	CL:0002529
0	"" []	\N	immature CD1a-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66643	CL:0002530	\N	immature CD1a-positive dermal dendritic cell	CL:0002530
0	"" []	\N	mature CD1a-positive dermal dendritic cell	\N	\N	EFO	"" []	EFO	66644	CL:0002531	\N	mature CD1a-positive dermal dendritic cell	CL:0002531
0	"" []	\N	CD16-positive myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66645	CL:0002532	\N	CD16-positive myeloid dendritic cell	CL:0002532
0	"" []	\N	immature CD16-positive myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66646	CL:0002533	\N	immature CD16-positive myeloid dendritic cell	CL:0002533
0	"" []	\N	mature CD16-positive myeloid dendritic cell	\N	\N	EFO	"" []	EFO	66647	CL:0002534	\N	mature CD16-positive myeloid dendritic cell	CL:0002534
0	"A fibroblast that is part of lung" []	\N	lung fibroblast	\N	\N	EFO	"A fibroblast that is part of lung" []	EFO	66648	CL:0002553	\N	lung fibroblast	CL:0002553
0	"A smooth muscle cell of the uterus." []	\N	uterine smooth muscle cell	\N	\N	cell	"A smooth muscle cell of the uterus." []	EFO	66649	CL:0002601	\N	uterine smooth muscle cell	CL:0002601
0	"A neuron of the hippocampus." []	\N	hippocampal neuron	\N	\N	EFO	"A neuron of the hippocampus." []	EFO	66650	CL:0002608	\N	hippocampal neuron	CL:0002608
0	"A fat cell that is part of the breast." []	\N	adipocyte of breast	\N	\N	EFO	"A fat cell that is part of the breast." []	EFO	66651	CL:0002617	\N	adipocyte of breast	CL:0002617
0	"Any cell in the retina, the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates." []	\N	retinal cell	\N	\N	EFO	"Any cell in the retina, the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates." []	EFO	66652	CL:0009004	\N	retinal cell	CL:0009004
0	"" []	\N	kidney cell	\N	\N	cell	"" []	EFO	66653	CL:1000497	\N	kidney cell	CL:1000497
0	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	\N	GM08388 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	EFO	66654	CLO:0010521	\N	GM08388 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0010521
0	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	\N	GM08390 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	EFO	66655	CLO:0010523	\N	GM08390 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0010523
0	"APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM08398 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	66656	CLO:0010526	\N	GM08398 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0010526
0	"ATAXIA-TELANGIECTASIA; AT ATAXIA-TELANGIECTASIA MUTATED GENE; ATM" []	\N	GM08436 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT ATAXIA-TELANGIECTASIA MUTATED GENE; ATM" []	EFO	66657	CLO:0010557	\N	GM08436 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0010557
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM08931 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66658	CLO:0011234	\N	GM08931 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011234
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM08930 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66659	CLO:0011235	\N	GM08930 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011235
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM08928 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66660	CLO:0011237	\N	GM08928 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011237
0	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	\N	GM09585 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT" []	EFO	66661	CLO:0011391	\N	GM09585 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011391
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM09583 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66662	CLO:0011394	\N	GM09583 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011394
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM09581 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66663	CLO:0011436	\N	GM09581 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011436
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM09579 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66664	CLO:0011438	\N	GM09579 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0011438
0	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	\N	ND03432 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	EFO	66665	CLO:0012496	\N	ND03432 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0012496
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17289 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66666	CLO:0013077	\N	GM17289 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013077
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17288 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66667	CLO:0013080	\N	GM17288 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013080
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17287 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66668	CLO:0013082	\N	GM17287 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013082
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17286 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66669	CLO:0013086	\N	GM17286 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013086
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17285 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66670	CLO:0013090	\N	GM17285 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013090
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17284 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66671	CLO:0013092	\N	GM17284 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013092
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17282 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66672	CLO:0013094	\N	GM17282 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013094
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17283 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66673	CLO:0013095	\N	GM17283 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013095
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	\N	GM17280 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	EFO	66674	CLO:0013096	\N	GM17280 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013096
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200" []	\N	GM17281 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200" []	EFO	66675	CLO:0013097	\N	GM17281 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013097
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17296 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66676	CLO:0013124	\N	GM17296 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013124
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17295 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66677	CLO:0013127	\N	GM17295 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013127
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17291 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66678	CLO:0013135	\N	GM17291 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013135
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17292 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66679	CLO:0013136	\N	GM17292 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013136
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17293 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66680	CLO:0013137	\N	GM17293 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013137
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17294 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66681	CLO:0013138	\N	GM17294 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013138
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17290 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66682	CLO:0013140	\N	GM17290 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013140
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17265 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66683	CLO:0013163	\N	GM17265 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013163
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17264 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66684	CLO:0013168	\N	GM17264 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013168
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17263 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66685	CLO:0013169	\N	GM17263 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013169
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17262 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66686	CLO:0013173	\N	GM17262 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013173
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17269 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66687	CLO:0013176	\N	GM17269 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013176
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66688	CLO:0013177	\N	GM17268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013177
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17267 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66689	CLO:0013179	\N	GM17267 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013179
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17266 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66690	CLO:0013181	\N	GM17266 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013181
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17260 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66691	CLO:0013182	\N	GM17260 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013182
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17261 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66692	CLO:0013183	\N	GM17261 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013183
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17274 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66693	CLO:0013193	\N	GM17274 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013193
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17273 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66694	CLO:0013197	\N	GM17273 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013197
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17276 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66695	CLO:0013199	\N	GM17276 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013199
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17275 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66696	CLO:0013202	\N	GM17275 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013202
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17278 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66697	CLO:0013204	\N	GM17278 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013204
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17277 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66698	CLO:0013208	\N	GM17277 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013208
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17279 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66699	CLO:0013210	\N	GM17279 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013210
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17270 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66700	CLO:0013212	\N	GM17270 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013212
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17271 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66701	CLO:0013213	\N	GM17271 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013213
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17272 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66702	CLO:0013214	\N	GM17272 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013214
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17180 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66703	CLO:0013751	\N	GM17180 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013751
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17184 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66704	CLO:0013752	\N	GM17184 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013752
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17183 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66705	CLO:0013753	\N	GM17183 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013753
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17182 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66706	CLO:0013754	\N	GM17182 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013754
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17181 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66707	CLO:0013755	\N	GM17181 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013755
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17187 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66708	CLO:0013775	\N	GM17187 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013775
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17188 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66709	CLO:0013777	\N	GM17188 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013777
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17185 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66710	CLO:0013781	\N	GM17185 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013781
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17186 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66711	CLO:0013784	\N	GM17186 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013784
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17189 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66712	CLO:0013790	\N	GM17189 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013790
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17191 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66713	CLO:0013793	\N	GM17191 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013793
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17190 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66714	CLO:0013794	\N	GM17190 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013794
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17193 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66715	CLO:0013795	\N	GM17193 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013795
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17192 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66716	CLO:0013796	\N	GM17192 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013796
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17195 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66717	CLO:0013797	\N	GM17195 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013797
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17194 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66718	CLO:0013798	\N	GM17194 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013798
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17196 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66719	CLO:0013816	\N	GM17196 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013816
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17197 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66720	CLO:0013818	\N	GM17197 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013818
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17198 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66721	CLO:0013823	\N	GM17198 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013823
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17199 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66722	CLO:0013826	\N	GM17199 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013826
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17206 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66723	CLO:0013833	\N	GM17206 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013833
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17205 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66724	CLO:0013834	\N	GM17205 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013834
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17204 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66725	CLO:0013835	\N	GM17204 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013835
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17203 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66726	CLO:0013836	\N	GM17203 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013836
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17202 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66727	CLO:0013837	\N	GM17202 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013837
0	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17201 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66728	CLO:0013839	\N	GM17201 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013839
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17200 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66729	CLO:0013840	\N	GM17200 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013840
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17209 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66730	CLO:0013875	\N	GM17209 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013875
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17207 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66731	CLO:0013881	\N	GM17207 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013881
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17208 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66732	CLO:0013884	\N	GM17208 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013884
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17215 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66733	CLO:0013885	\N	GM17215 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013885
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17214 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66734	CLO:0013886	\N	GM17214 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013886
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17217 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66735	CLO:0013887	\N	GM17217 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013887
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17216 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66736	CLO:0013888	\N	GM17216 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013888
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17211 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66737	CLO:0013890	\N	GM17211 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013890
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17210 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66738	CLO:0013891	\N	GM17210 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013891
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17213 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66739	CLO:0013893	\N	GM17213 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013893
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17212 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66740	CLO:0013895	\N	GM17212 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013895
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17218 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66741	CLO:0013921	\N	GM17218 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013921
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17219 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66742	CLO:0013924	\N	GM17219 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013924
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17140 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66743	CLO:0013935	\N	GM17140 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013935
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66744	CLO:0013936	\N	GM17144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013936
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17143 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66745	CLO:0013937	\N	GM17143 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013937
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17142 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66746	CLO:0013938	\N	GM17142 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013938
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17141 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66747	CLO:0013939	\N	GM17141 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013939
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17148 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66748	CLO:0013940	\N	GM17148 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013940
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17147 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66749	CLO:0013941	\N	GM17147 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013941
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17146 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66750	CLO:0013942	\N	GM17146 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013942
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17145 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66751	CLO:0013943	\N	GM17145 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013943
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17149 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66752	CLO:0013947	\N	GM17149 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013947
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17150 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66753	CLO:0013956	\N	GM17150 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013956
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17155 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66754	CLO:0013960	\N	GM17155 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013960
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17154 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66755	CLO:0013961	\N	GM17154 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013961
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17157 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66756	CLO:0013962	\N	GM17157 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013962
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17156 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66757	CLO:0013963	\N	GM17156 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013963
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17159 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66758	CLO:0013964	\N	GM17159 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013964
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 SNP500 PANEL" []	\N	GM17158 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 SNP500 PANEL" []	EFO	66759	CLO:0013965	\N	GM17158 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013965
0	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17161 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66760	CLO:0013982	\N	GM17161 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013982
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17162 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66761	CLO:0013983	\N	GM17162 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013983
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17160 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66762	CLO:0013984	\N	GM17160 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013984
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17168 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66763	CLO:0013987	\N	GM17168 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013987
0	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17167 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66764	CLO:0013989	\N	GM17167 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013989
0	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17166 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66765	CLO:0013990	\N	GM17166 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013990
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17165 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66766	CLO:0013993	\N	GM17165 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013993
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17164 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66767	CLO:0013994	\N	GM17164 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013994
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17163 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66768	CLO:0013996	\N	GM17163 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0013996
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17170 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66769	CLO:0014022	\N	GM17170 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014022
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17171 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66770	CLO:0014024	\N	GM17171 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014024
0	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17172 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66771	CLO:0014025	\N	GM17172 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014025
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17173 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66772	CLO:0014026	\N	GM17173 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014026
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17179 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66773	CLO:0014028	\N	GM17179 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014028
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17178 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66774	CLO:0014029	\N	GM17178 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014029
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17175 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66775	CLO:0014033	\N	GM17175 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014033
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17174 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66776	CLO:0014034	\N	GM17174 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014034
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17177 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66777	CLO:0014037	\N	GM17177 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014037
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17176 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66778	CLO:0014039	\N	GM17176 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014039
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17239 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66779	CLO:0014327	\N	GM17239 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014327
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17237 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66780	CLO:0014330	\N	GM17237 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014330
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17238 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66781	CLO:0014332	\N	GM17238 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014332
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17235 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66782	CLO:0014334	\N	GM17235 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014334
0	"CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17236 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66783	CLO:0014336	\N	GM17236 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014336
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17233 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66784	CLO:0014338	\N	GM17233 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014338
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17234 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66785	CLO:0014340	\N	GM17234 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014340
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17231 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66786	CLO:0014341	\N	GM17231 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014341
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17232 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66787	CLO:0014344	\N	GM17232 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014344
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17230 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66788	CLO:0014347	\N	GM17230 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014347
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17226 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66789	CLO:0014356	\N	GM17226 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014356
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17227 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66790	CLO:0014358	\N	GM17227 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014358
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17228 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66791	CLO:0014359	\N	GM17228 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014359
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17229 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66792	CLO:0014362	\N	GM17229 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014362
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17222 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66793	CLO:0014366	\N	GM17222 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014366
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17223 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66794	CLO:0014367	\N	GM17223 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014367
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17224 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66795	CLO:0014369	\N	GM17224 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014369
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17225 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66796	CLO:0014371	\N	GM17225 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014371
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17220 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66797	CLO:0014375	\N	GM17220 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014375
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17221 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66798	CLO:0014377	\N	GM17221 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014377
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17259 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66799	CLO:0014388	\N	GM17259 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014388
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17253 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66800	CLO:0014389	\N	GM17253 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014389
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17254 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66801	CLO:0014390	\N	GM17254 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014390
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200" []	\N	GM17251 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200" []	EFO	66802	CLO:0014391	\N	GM17251 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014391
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17252 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66803	CLO:0014392	\N	GM17252 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014392
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17257 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66804	CLO:0014393	\N	GM17257 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014393
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17258 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66805	CLO:0014394	\N	GM17258 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014394
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17255 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66806	CLO:0014395	\N	GM17255 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014395
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17256 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66807	CLO:0014396	\N	GM17256 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014396
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17250 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66808	CLO:0014397	\N	GM17250 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014397
0	"PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES" []	\N	ND02579 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES" []	EFO	66809	CLO:0014404	\N	ND02579 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014404
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17248 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66810	CLO:0014408	\N	GM17248 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014408
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17249 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66811	CLO:0014409	\N	GM17249 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014409
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17240 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66812	CLO:0014410	\N	GM17240 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014410
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17241 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66813	CLO:0014411	\N	GM17241 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014411
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17242 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66814	CLO:0014412	\N	GM17242 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014412
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17243 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66815	CLO:0014413	\N	GM17243 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014413
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17244 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66816	CLO:0014414	\N	GM17244 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014414
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	\N	GM17245 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50" []	EFO	66817	CLO:0014415	\N	GM17245 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014415
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17246 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66818	CLO:0014416	\N	GM17246 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014416
0	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	\N	GM17247 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1)" []	EFO	66819	CLO:0014417	\N	GM17247 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014417
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM02783 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	66820	CLO:0014788	\N	GM02783 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014788
0	"ANEUPLOID CHROMOSOME NUMBER - TRISOMY TRISOMY 21" []	\N	GM02767 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ANEUPLOID CHROMOSOME NUMBER - TRISOMY TRISOMY 21" []	EFO	66821	CLO:0014806	\N	GM02767 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014806
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16" []	\N	GM17109 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16" []	EFO	66822	CLO:0014887	\N	GM17109 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014887
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17108 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66823	CLO:0014889	\N	GM17108 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014889
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17102 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66824	CLO:0014896	\N	GM17102 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014896
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17103 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66825	CLO:0014898	\N	GM17103 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014898
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17104 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66826	CLO:0014900	\N	GM17104 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014900
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17105 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66827	CLO:0014901	\N	GM17105 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014901
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17106 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66828	CLO:0014902	\N	GM17106 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014902
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17107 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66829	CLO:0014903	\N	GM17107 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014903
0	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17119 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66830	CLO:0014942	\N	GM17119 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014942
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17113 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66831	CLO:0014943	\N	GM17113 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014943
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	\N	GM17114 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	EFO	66832	CLO:0014945	\N	GM17114 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014945
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	\N	GM17111 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	EFO	66833	CLO:0014947	\N	GM17111 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014947
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17112 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66834	CLO:0014948	\N	GM17112 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014948
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17117 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66835	CLO:0014950	\N	GM17117 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014950
0	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17118 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66836	CLO:0014951	\N	GM17118 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014951
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	\N	GM17115 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	EFO	66837	CLO:0014952	\N	GM17115 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014952
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17116 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66838	CLO:0014953	\N	GM17116 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014953
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	\N	GM17110 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8" []	EFO	66839	CLO:0014964	\N	GM17110 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0014964
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17132 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66840	CLO:0015081	\N	GM17132 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015081
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17133 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66841	CLO:0015082	\N	GM17133 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015082
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	\N	GM17130 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	EFO	66842	CLO:0015085	\N	GM17130 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015085
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	\N	GM17131 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	EFO	66843	CLO:0015087	\N	GM17131 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015087
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16" []	\N	GM17136 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16" []	EFO	66844	CLO:0015088	\N	GM17136 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015088
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17137 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66845	CLO:0015090	\N	GM17137 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015090
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17134 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66846	CLO:0015093	\N	GM17134 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015093
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	\N	GM17135 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24" []	EFO	66847	CLO:0015094	\N	GM17135 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015094
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17138 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66848	CLO:0015097	\N	GM17138 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015097
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17139 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66849	CLO:0015098	\N	GM17139 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015098
0	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17120 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66850	CLO:0015112	\N	GM17120 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015112
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17121 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66851	CLO:0015115	\N	GM17121 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015115
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17122 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66852	CLO:0015117	\N	GM17122 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015117
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17123 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66853	CLO:0015119	\N	GM17123 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015119
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	\N	GM17124 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50" []	EFO	66854	CLO:0015121	\N	GM17124 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015121
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17125 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66855	CLO:0015123	\N	GM17125 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015123
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17126 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66856	CLO:0015124	\N	GM17126 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015124
0	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17127 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66857	CLO:0015126	\N	GM17127 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015126
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	\N	GM17128 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100" []	EFO	66858	CLO:0015128	\N	GM17128 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015128
0	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	\N	GM17129 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	EFO	66859	CLO:0015130	\N	GM17129 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015130
0	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	\N	ND02852 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	EFO	66860	CLO:0015209	\N	ND02852 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0015209
0	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	\N	ND01737 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	EFO	66861	CLO:0016362	\N	ND01737 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016362
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17852 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66862	CLO:0016449	\N	GM17852 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016449
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17850 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66863	CLO:0016450	\N	GM17850 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016450
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17845 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66864	CLO:0016453	\N	GM17845 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016453
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17844 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66865	CLO:0016454	\N	GM17844 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016454
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17847 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66866	CLO:0016455	\N	GM17847 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016455
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17846 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66867	CLO:0016456	\N	GM17846 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016456
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17842 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66868	CLO:0016457	\N	GM17842 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016457
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17843 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66869	CLO:0016458	\N	GM17843 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016458
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17798 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66870	CLO:0016489	\N	GM17798 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016489
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17799 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66871	CLO:0016490	\N	GM17799 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016490
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17800 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66872	CLO:0016491	\N	GM17800 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016491
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17801 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66873	CLO:0016492	\N	GM17801 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016492
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17796 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66874	CLO:0016493	\N	GM17796 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016493
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17797 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66875	CLO:0016494	\N	GM17797 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016494
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17802 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66876	CLO:0016495	\N	GM17802 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016495
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17803 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66877	CLO:0016496	\N	GM17803 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016496
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17804 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66878	CLO:0016497	\N	GM17804 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016497
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17805 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66879	CLO:0016498	\N	GM17805 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016498
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17811 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66880	CLO:0016499	\N	GM17811 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016499
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17812 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66881	CLO:0016500	\N	GM17812 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016500
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17809 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66882	CLO:0016501	\N	GM17809 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016501
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17810 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66883	CLO:0016502	\N	GM17810 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016502
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17807 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66884	CLO:0016503	\N	GM17807 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016503
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17808 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66885	CLO:0016504	\N	GM17808 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016504
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17806 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66886	CLO:0016505	\N	GM17806 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016505
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17815 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66887	CLO:0016506	\N	GM17815 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016506
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17813 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66888	CLO:0016507	\N	GM17813 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016507
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17814 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66889	CLO:0016508	\N	GM17814 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016508
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17816 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66890	CLO:0016509	\N	GM17816 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016509
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17817 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66891	CLO:0016510	\N	GM17817 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016510
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17818 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66892	CLO:0016511	\N	GM17818 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016511
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17823 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66893	CLO:0016515	\N	GM17823 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016515
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17824 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66894	CLO:0016516	\N	GM17824 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016516
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17825 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66895	CLO:0016517	\N	GM17825 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016517
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17826 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66896	CLO:0016518	\N	GM17826 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016518
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17833 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66897	CLO:0016519	\N	GM17833 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016519
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17835 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66898	CLO:0016520	\N	GM17835 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016520
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17828 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66899	CLO:0016521	\N	GM17828 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016521
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17831 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66900	CLO:0016522	\N	GM17831 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016522
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17839 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66901	CLO:0016523	\N	GM17839 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016523
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17840 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66902	CLO:0016524	\N	GM17840 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016524
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17837 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66903	CLO:0016525	\N	GM17837 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016525
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17838 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66904	CLO:0016526	\N	GM17838 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016526
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17841 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66905	CLO:0016527	\N	GM17841 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016527
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17827 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66906	CLO:0016528	\N	GM17827 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016528
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17756 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66907	CLO:0016554	\N	GM17756 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016554
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17755 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66908	CLO:0016555	\N	GM17755 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016555
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17754 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66909	CLO:0016558	\N	GM17754 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016558
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17753 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66910	CLO:0016560	\N	GM17753 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016560
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17752 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66911	CLO:0016561	\N	GM17752 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016561
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17749 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66912	CLO:0016564	\N	GM17749 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016564
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17747 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66913	CLO:0016565	\N	GM17747 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016565
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17746 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66914	CLO:0016566	\N	GM17746 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016566
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17745 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66915	CLO:0016567	\N	GM17745 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016567
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17744 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66916	CLO:0016568	\N	GM17744 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016568
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17767 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66917	CLO:0016593	\N	GM17767 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016593
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17766 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66918	CLO:0016594	\N	GM17766 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016594
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17768 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66919	CLO:0016597	\N	GM17768 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016597
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17762 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66920	CLO:0016600	\N	GM17762 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016600
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17761 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66921	CLO:0016601	\N	GM17761 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016601
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17765 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66922	CLO:0016602	\N	GM17765 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016602
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17764 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66923	CLO:0016604	\N	GM17764 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016604
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	\N	GM17757 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	EFO	66924	CLO:0016606	\N	GM17757 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016606
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	\N	GM17759 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	EFO	66925	CLO:0016607	\N	GM17759 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016607
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17758 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66926	CLO:0016608	\N	GM17758 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016608
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17779 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66927	CLO:0016635	\N	GM17779 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016635
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17776 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66928	CLO:0016636	\N	GM17776 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016636
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17775 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66929	CLO:0016638	\N	GM17775 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016638
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17774 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66930	CLO:0016641	\N	GM17774 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016641
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17782 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66931	CLO:0016642	\N	GM17782 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016642
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17780 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66932	CLO:0016643	\N	GM17780 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016643
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17773 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66933	CLO:0016645	\N	GM17773 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016645
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17771 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66934	CLO:0016646	\N	GM17771 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016646
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17770 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66935	CLO:0016647	\N	GM17770 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016647
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17769 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66936	CLO:0016648	\N	GM17769 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016648
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17792 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66937	CLO:0016672	\N	GM17792 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016672
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17791 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66938	CLO:0016675	\N	GM17791 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016675
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17794 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66939	CLO:0016676	\N	GM17794 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016676
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17793 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66940	CLO:0016678	\N	GM17793 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016678
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17795 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66941	CLO:0016682	\N	GM17795 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016682
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17783 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66942	CLO:0016684	\N	GM17783 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016684
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17787 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66943	CLO:0016685	\N	GM17787 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016685
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17785 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66944	CLO:0016686	\N	GM17785 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016686
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17790 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66945	CLO:0016687	\N	GM17790 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016687
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17789 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66946	CLO:0016688	\N	GM17789 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016688
0	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 SNP500 PANEL HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 CEPH/UTAH PEDIGREE 1345" []	\N	GM07348 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 SNP500 PANEL HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 CEPH/UTAH PEDIGREE 1345" []	EFO	66947	CLO:0016951	\N	GM07348 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016951
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	\N	GM17733 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	EFO	66948	CLO:0016995	\N	GM17733 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0016995
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17741 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66949	CLO:0017020	\N	GM17741 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017020
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	\N	GM17740 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	EFO	66950	CLO:0017021	\N	GM17740 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017021
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	\N	GM17739 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24" []	EFO	66951	CLO:0017022	\N	GM17739 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017022
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17738 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66952	CLO:0017023	\N	GM17738 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017023
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17743 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66953	CLO:0017024	\N	GM17743 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017024
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	\N	GM17742 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100" []	EFO	66954	CLO:0017025	\N	GM17742 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017025
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	\N	GM17736 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	EFO	66955	CLO:0017043	\N	GM17736 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017043
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	\N	GM17737 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8" []	EFO	66956	CLO:0017044	\N	GM17737 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017044
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	\N	GM17734 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	EFO	66957	CLO:0017045	\N	GM17734 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017045
0	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	\N	GM17735 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16" []	EFO	66958	CLO:0017046	\N	GM17735 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0017046
0	"LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE" []	\N	ND06449 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE" []	EFO	66959	CLO:0018566	\N	ND06449 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0018566
0	"INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1375 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	\N	GM12264 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1375 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	EFO	66960	CLO:0019004	\N	GM12264 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0019004
0	"CEPH/UTAH PEDIGREE 1349 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	\N	GM11840 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CEPH/UTAH PEDIGREE 1349 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	EFO	66961	CLO:0020019	\N	GM11840 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0020019
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG10941 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	66962	CLO:0021459	\N	AG10941 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021459
0	"LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS" []	\N	AG11498 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS" []	EFO	66963	CLO:0021565	\N	AG11498 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021565
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG11364 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	66964	CLO:0021597	\N	AG11364 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021597
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG10049 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	66965	CLO:0021875	\N	AG10049 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021875
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG09699 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66966	CLO:0021913	\N	AG09699 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021913
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG09877 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66967	CLO:0021943	\N	AG09877 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0021943
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG13150 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66968	CLO:0022101	\N	AG13150 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022101
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG13145 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66969	CLO:0022107	\N	AG13145 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022107
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG13066 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66970	CLO:0022132	\N	AG13066 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022132
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG14446 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66971	CLO:0022320	\N	AG14446 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022320
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG11696 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	66972	CLO:0022362	\N	AG11696 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022362
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG11726 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	66973	CLO:0022371	\N	AG11726 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022371
0	"LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS" []	\N	AG11513 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS" []	EFO	66974	CLO:0022604	\N	AG11513 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0022604
0	"HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1424" []	\N	GM10845 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1424" []	EFO	66975	CLO:0023783	\N	GM10845 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0023783
0	"HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1423" []	\N	GM10842 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1423" []	EFO	66976	CLO:0023784	\N	GM10842 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0023784
0	"CEPH/UTAH PEDIGREE 1423 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	\N	GM10843 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CEPH/UTAH PEDIGREE 1423 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1" []	EFO	66977	CLO:0023785	\N	GM10843 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0023785
0	"SNP500 PANEL CEPH/UTAH PEDIGREE 1413" []	\N	GM10832 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"SNP500 PANEL CEPH/UTAH PEDIGREE 1413" []	EFO	66978	CLO:0023794	\N	GM10832 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0023794
0	"CEPH/UTAH PEDIGREE 1413 SNP500 PANEL" []	\N	GM10833 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CEPH/UTAH PEDIGREE 1413 SNP500 PANEL" []	EFO	66979	CLO:0023795	\N	GM10833 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0023795
0	"TRANSLOCATED CHROMOSOME TRISOMY 21" []	\N	GM00144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"TRANSLOCATED CHROMOSOME TRISOMY 21" []	EFO	66980	CLO:0025850	\N	GM00144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0025850
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND00259 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	66981	CLO:0026349	\N	ND00259 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0026349
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND00268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	66982	CLO:0026399	\N	ND00268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0026399
0	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15386 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66983	CLO:0026786	\N	GM15386 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0026786
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15385 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66984	CLO:0026789	\N	GM15385 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0026789
0	"ISCHEMIC STROKE NDPT081 ISCHEMIC STROKE DNA PANEL" []	\N	ND00397 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ISCHEMIC STROKE NDPT081 ISCHEMIC STROKE DNA PANEL" []	EFO	66985	CLO:0027048	\N	ND00397 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027048
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15324 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66986	CLO:0027182	\N	GM15324 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027182
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66987	CLO:0027328	\N	GM15268 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027328
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15245 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66988	CLO:0027391	\N	GM15245 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027391
0	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15242 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66989	CLO:0027447	\N	GM15242 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027447
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15236 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66990	CLO:0027467	\N	GM15236 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027467
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15227 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66991	CLO:0027473	\N	GM15227 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027473
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15223 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66992	CLO:0027483	\N	GM15223 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027483
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15224 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66993	CLO:0027484	\N	GM15224 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027484
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15226 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66994	CLO:0027486	\N	GM15226 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027486
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15221 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66995	CLO:0027487	\N	GM15221 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027487
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9" []	\N	GM15216 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9" []	EFO	66996	CLO:0027491	\N	GM15216 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027491
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15215 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66997	CLO:0027492	\N	GM15215 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027492
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15213 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66998	CLO:0027493	\N	GM15213 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0027493
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15590 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	66999	CLO:0028103	\N	GM15590 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0028103
0	"PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES" []	\N	ND01173 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES" []	EFO	67000	CLO:0028397	\N	ND01173 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0028397
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND06229 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	67001	CLO:0029036	\N	ND06229 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0029036
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND00051 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	67002	CLO:0029732	\N	ND00051 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0029732
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67003	CLO:0029916	\N	GM15144 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0029916
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND00022 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	67004	CLO:0030105	\N	ND00022 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030105
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9" []	\N	GM15029 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9" []	EFO	67005	CLO:0030305	\N	GM15029 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030305
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15038 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67006	CLO:0030309	\N	GM15038 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030309
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15036 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67007	CLO:0030311	\N	GM15036 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030311
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15061 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67008	CLO:0030324	\N	GM15061 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030324
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15056 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67009	CLO:0030328	\N	GM15056 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030328
0	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	\N	GM15072 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION" []	EFO	67010	CLO:0030337	\N	GM15072 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030337
0	"POPULATION/CONVENIENCE CONTROL" []	\N	ND00151 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"POPULATION/CONVENIENCE CONTROL" []	EFO	67011	CLO:0030688	\N	ND00151 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0030688
0	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	\N	GM14381 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	EFO	67012	CLO:0031189	\N	GM14381 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031189
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14382 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67013	CLO:0031198	\N	GM14382 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031198
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14405 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67014	CLO:0031201	\N	GM14405 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031201
0	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	\N	GM14414 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	EFO	67015	CLO:0031225	\N	GM14414 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031225
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14409 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67016	CLO:0031226	\N	GM14409 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031226
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14408 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67017	CLO:0031227	\N	GM14408 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031227
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14406 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67018	CLO:0031228	\N	GM14406 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031228
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG08904 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67019	CLO:0031232	\N	AG08904 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031232
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14439 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67020	CLO:0031234	\N	GM14439 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031234
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14433 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67021	CLO:0031236	\N	GM14433 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031236
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14432 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67022	CLO:0031238	\N	GM14432 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031238
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14417 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67023	CLO:0031239	\N	GM14417 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031239
0	"APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS" []	\N	GM14453 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS" []	EFO	67024	CLO:0031253	\N	GM14453 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031253
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14454 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67025	CLO:0031254	\N	GM14454 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031254
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14455 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67026	CLO:0031256	\N	GM14455 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031256
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14440 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67027	CLO:0031257	\N	GM14440 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031257
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14447 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67028	CLO:0031260	\N	GM14447 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031260
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14448 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67029	CLO:0031261	\N	GM14448 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031261
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14452 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67030	CLO:0031263	\N	GM14452 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031263
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14475 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67031	CLO:0031272	\N	GM14475 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031272
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14476 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67032	CLO:0031274	\N	GM14476 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031274
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14465 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67033	CLO:0031275	\N	GM14465 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031275
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14467 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67034	CLO:0031276	\N	GM14467 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031276
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14464 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67035	CLO:0031278	\N	GM14464 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031278
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14474 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67036	CLO:0031280	\N	GM14474 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031280
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14468 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67037	CLO:0031281	\N	GM14468 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031281
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14501 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67038	CLO:0031504	\N	GM14501 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031504
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14503 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67039	CLO:0031509	\N	GM14503 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031509
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14502 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67040	CLO:0031510	\N	GM14502 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031510
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14504 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67041	CLO:0031516	\N	GM14504 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031516
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14507 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67042	CLO:0031517	\N	GM14507 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031517
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14506 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67043	CLO:0031519	\N	GM14506 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031519
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14478 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67044	CLO:0031529	\N	GM14478 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031529
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14477 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67045	CLO:0031531	\N	GM14477 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031531
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14481 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67046	CLO:0031533	\N	GM14481 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031533
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14480 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67047	CLO:0031534	\N	GM14480 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031534
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14479 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67048	CLO:0031535	\N	GM14479 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031535
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14568 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67049	CLO:0031580	\N	GM14568 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031580
0	"APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS" []	\N	GM14569 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS" []	EFO	67050	CLO:0031581	\N	GM14569 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031581
0	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	\N	GM14581 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	EFO	67051	CLO:0031585	\N	GM14581 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031585
0	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	\N	GM14535 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS" []	EFO	67052	CLO:0031600	\N	GM14535 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031600
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14536 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67053	CLO:0031601	\N	GM14536 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031601
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14532 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67054	CLO:0031606	\N	GM14532 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031606
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14533 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67055	CLO:0031607	\N	GM14533 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031607
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14509 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67056	CLO:0031609	\N	GM14509 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031609
0	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14508 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67057	CLO:0031610	\N	GM14508 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031610
0	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14520 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67058	CLO:0031611	\N	GM14520 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031611
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14521 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67059	CLO:0031612	\N	GM14521 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031612
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14583 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67060	CLO:0031665	\N	GM14583 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031665
0	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	\N	GM14582 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS" []	EFO	67061	CLO:0031666	\N	GM14582 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031666
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	\N	GM14584 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS" []	EFO	67062	CLO:0031668	\N	GM14584 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031668
0	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	\N	GM14679 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE" []	EFO	67063	CLO:0031953	\N	GM14679 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0031953
0	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	\N	ND04158 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	EFO	67064	CLO:0032601	\N	ND04158 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0032601
0	"COLORECTAL CANCER, FAMILIAL" []	\N	GM13649 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"COLORECTAL CANCER, FAMILIAL" []	EFO	67065	CLO:0032713	\N	GM13649 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0032713
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM13883 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	67066	CLO:0033199	\N	GM13883 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033199
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG08048 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67067	CLO:0033570	\N	AG08048 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033570
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG08046 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67068	CLO:0033577	\N	AG08046 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033577
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM13811 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	67069	CLO:0033628	\N	GM13811 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033628
0	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	\N	ND04424 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE" []	EFO	67070	CLO:0033747	\N	ND04424 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033747
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM13995 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	67071	CLO:0033909	\N	GM13995 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0033909
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM14153 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	67072	CLO:0034375	\N	GM14153 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0034375
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG04147 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67073	CLO:0034780	\N	AG04147 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0034780
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG04351 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67074	CLO:0034796	\N	AG04351 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0034796
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG04655 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	67075	CLO:0034915	\N	AG04655 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0034915
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG05416 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67076	CLO:0035232	\N	AG05416 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0035232
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG06237 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67077	CLO:0035254	\N	AG06237 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0035254
0	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	\N	AG07307 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION" []	EFO	67078	CLO:0035579	\N	AG07307 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0035579
0	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	\N	AG07139 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA)" []	EFO	67079	CLO:0035608	\N	AG07139 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0035608
0	"TRANSLOCATED CHROMOSOME" []	\N	GM06944 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"TRANSLOCATED CHROMOSOME" []	EFO	67080	CLO:0036460	\N	GM06944 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0036460
0	"INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1340 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	\N	GM07029 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1340 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19" []	EFO	67081	CLO:0036870	\N	GM07029 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	CLO:0036870
0	"A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans." []	\N	trypanosomiasis	\N	\N	EFO	"A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans." []	EFO	67082	DOID:10113	\N	trypanosomiasis	DOID:10113
0	"A parasitic protozoa infectious disease that involves infection of the small intestine by a single-celled enteric protozoan parasite Giardia intestinalis. The symptoms include greasy and malodorous stools, diarrhea, abdominal pain, bloating, nausea, and vomiting." []	\N	giardiasis	\N	\N	EFO	"A parasitic protozoa infectious disease that involves infection of the small intestine by a single-celled enteric protozoan parasite Giardia intestinalis. The symptoms include greasy and malodorous stools, diarrhea, abdominal pain, bloating, nausea, and vomiting." []	EFO	67083	DOID:10718	\N	giardiasis	DOID:10718
0	"" []	\N	pulmonary sarcoidosis	\N	\N	EFO	"" []	EFO	67084	DOID:13406	\N	pulmonary sarcoidosis	DOID:13406
0	"A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively." []	\N	trichomoniasis	\N	\N	EFO	"A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively." []	EFO	67085	DOID:1947	\N	trichomoniasis	DOID:1947
0	"A primary bacterial infectious disease that is a sexually transmitted infection, located_in uterus, located_in fallopian tube, located_in urethra, located_in mouth, located_in throat, located_in eye or located_in anus, has_material_basis_in Neisseria gonorrhoeae, which is transmitted_by contact with the penis, vagina, mouth, or anus or transmitted_by congenitally from mother to baby during delivery. The infection has_symptom burning sensation during urination, has_symptom discharge from the penis, has_symptom increased vaginal discharge, or has_symptom vaginal bleeding between periods." []	\N	gonorrhea	\N	\N	EFO	"A primary bacterial infectious disease that is a sexually transmitted infection, located_in uterus, located_in fallopian tube, located_in urethra, located_in mouth, located_in throat, located_in eye or located_in anus, has_material_basis_in Neisseria gonorrhoeae, which is transmitted_by contact with the penis, vagina, mouth, or anus or transmitted_by congenitally from mother to baby during delivery. The infection has_symptom burning sensation during urination, has_symptom discharge from the penis, has_symptom increased vaginal discharge, or has_symptom vaginal bleeding between periods." []	EFO	67086	DOID:7551	\N	gonorrhea	DOID:7551
0	"An experimental factor in Array Express which are essentially the variable aspects of an experiment design which can be used to describe an experiment, or set of experiments, in an increasingly detailed manner. This upper level class is really used to give a root class from which applications can rely on and not be tied to upper ontology classses which do change." []	\N	Experimental Factor	\N	\N	EFO	"An experimental factor in Array Express which are essentially the variable aspects of an experiment design which can be used to describe an experiment, or set of experiments, in an increasingly detailed manner. This upper level class is really used to give a root class from which applications can rely on and not be tied to upper ontology classses which do change." []	EFO	67087	EFO:0000001	\N	Experimental Factor	EFO:0000001
0	"CS57511 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311932." []	\N	CS57511	\N	\N	EFO	"CS57511 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311932." []	EFO	67088	EFO:0000002	\N	CS57511	EFO:0000002
0	"CS57512 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311933" []	\N	CS57512	\N	\N	EFO	"CS57512 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311933" []	EFO	67089	EFO:0000003	\N	CS57512	EFO:0000003
0	"CS57515 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311936" []	\N	CS57515	\N	\N	EFO	"CS57515 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311936" []	EFO	67090	EFO:0000004	\N	CS57515	EFO:0000004
0	"CS57520 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311941" []	\N	CS57520	\N	\N	EFO	"CS57520 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311941" []	EFO	67091	EFO:0000005	\N	CS57520	EFO:0000005
0	"CS57521 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=1005152522" []	\N	CS57521	\N	\N	EFO	"CS57521 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=1005152522" []	EFO	67092	EFO:0000006	\N	CS57521	EFO:0000006
0	"CS57537 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311958" []	\N	CS57537	\N	\N	EFO	"CS57537 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311958" []	EFO	67093	EFO:0000007	\N	CS57537	EFO:0000007
0	"CS57541 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158565&type=germplasm" []	\N	CS57541	\N	\N	EFO	"CS57541 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158565&type=germplasm" []	EFO	67094	EFO:0000008	\N	CS57541	EFO:0000008
0	"CS57543 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158567&type=germplasm" []	\N	CS57543	\N	\N	EFO	"CS57543 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158567&type=germplasm" []	EFO	67095	EFO:0000009	\N	CS57543	EFO:0000009
0	"CS57544 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158568&type=germplasm" []	\N	CS57544	\N	\N	EFO	"CS57544 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158568&type=germplasm" []	EFO	67096	EFO:0000010	\N	CS57544	EFO:0000010
0	"CS57548 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158572&type=germplasm" []	\N	CS57548	\N	\N	EFO	"CS57548 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158572&type=germplasm" []	EFO	67097	EFO:0000011	\N	CS57548	EFO:0000011
0	"CS57549 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158573&type=germplasm" []	\N	CS57549	\N	\N	EFO	"CS57549 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158573&type=germplasm" []	EFO	67098	EFO:0000012	\N	CS57549	EFO:0000012
0	"CS57551 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158575&type=germplasm" []	\N	CS57551	\N	\N	EFO	"CS57551 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158575&type=germplasm" []	EFO	67099	EFO:0000013	\N	CS57551	EFO:0000013
0	"CS57556 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158580&type=germplasm" []	\N	CS57556	\N	\N	EFO	"CS57556 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158580&type=germplasm" []	EFO	67100	EFO:0000014	\N	CS57556	EFO:0000014
0	"CS57560 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158584&type=germplasm" []	\N	CS57560	\N	\N	EFO	"CS57560 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158584&type=germplasm" []	EFO	67101	EFO:0000015	\N	CS57560	EFO:0000015
0	"CS57563 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311984" []	\N	CS57563	\N	\N	EFO	"CS57563 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=stock&id=1000311984" []	EFO	67102	EFO:0000016	\N	CS57563	EFO:0000016
0	"CS57569 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158593&type=germplasm" []	\N	CS57569	\N	\N	EFO	"CS57569 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158593&type=germplasm" []	EFO	67103	EFO:0000017	\N	CS57569	EFO:0000017
0	"CS57570 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158594&type=germplasm" []	\N	CS57570	\N	\N	EFO	"CS57570 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158594&type=germplasm" []	EFO	67104	EFO:0000018	\N	CS57570	EFO:0000018
0	"CS57572 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158596&type=germplasm" []	\N	CS57572	\N	\N	EFO	"CS57572 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158596&type=germplasm" []	EFO	67105	EFO:0000019	\N	CS57572	EFO:0000019
0	"CS57580 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158604&type=germplasm" []	\N	CS57580	\N	\N	EFO	"CS57580 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158604&type=germplasm" []	EFO	67106	EFO:0000020	\N	CS57580	EFO:0000020
0	"CS57581 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158605&type=germplasm" []	\N	CS57581	\N	\N	EFO	"CS57581 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158605&type=germplasm" []	EFO	67107	EFO:0000021	\N	CS57581	EFO:0000021
0	"CS57583 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158607&type=germplasm" []	\N	CS57583	\N	\N	EFO	"CS57583 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158607&type=germplasm" []	EFO	67108	EFO:0000022	\N	CS57583	EFO:0000022
0	"CS57586 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158610&type=germplasm" []	\N	CS57586	\N	\N	EFO	"CS57586 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158610&type=germplasm" []	EFO	67109	EFO:0000023	\N	CS57586	EFO:0000023
0	"CS57587 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158611&type=germplasm" []	\N	CS57587	\N	\N	EFO	"CS57587 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158611&type=germplasm" []	EFO	67110	EFO:0000024	\N	CS57587	EFO:0000024
0	"CS57591 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158615&type=germplasm" []	\N	CS57591	\N	\N	EFO	"CS57591 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158615&type=germplasm" []	EFO	67111	EFO:0000025	\N	CS57591	EFO:0000025
0	"CS57595 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158619&type=germplasm" []	\N	CS57595	\N	\N	EFO	"CS57595 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158619&type=germplasm" []	EFO	67112	EFO:0000026	\N	CS57595	EFO:0000026
0	"CS57596 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158620&type=germplasm" []	\N	CS57596	\N	\N	EFO	"CS57596 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158620&type=germplasm" []	EFO	67113	EFO:0000027	\N	CS57596	EFO:0000027
0	"CS57598 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158622&type=germplasm" []	\N	CS57598	\N	\N	EFO	"CS57598 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158622&type=germplasm" []	EFO	67114	EFO:0000028	\N	CS57598	EFO:0000028
0	"CS57601 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158625&type=germplasm" []	\N	CS57601	\N	\N	EFO	"CS57601 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158625&type=germplasm" []	EFO	67115	EFO:0000029	\N	CS57601	EFO:0000029
0	"CS57603 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158627&type=germplasm" []	\N	CS57603	\N	\N	EFO	"CS57603 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158627&type=germplasm" []	EFO	67116	EFO:0000030	\N	CS57603	EFO:0000030
0	"CS57606 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158630&type=germplasm" []	\N	CS57606	\N	\N	EFO	"CS57606 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158630&type=germplasm" []	EFO	67117	EFO:0000031	\N	CS57606	EFO:0000031
0	"CS57610 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158634&type=germplasm" []	\N	CS57610	\N	\N	EFO	"CS57610 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158634&type=germplasm" []	EFO	67118	EFO:0000032	\N	CS57610	EFO:0000032
0	"CS57615 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158639&type=germplasm" []	\N	CS57615	\N	\N	EFO	"CS57615 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158639&type=germplasm" []	EFO	67119	EFO:0000033	\N	CS57615	EFO:0000033
0	"CS57616 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158640&type=germplasm" []	\N	CS57616	\N	\N	EFO	"CS57616 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158640&type=germplasm" []	EFO	67120	EFO:0000034	\N	CS57616	EFO:0000034
0	"CS57618 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158642&type=germplasm" []	\N	CS57618	\N	\N	EFO	"CS57618 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158642&type=germplasm" []	EFO	67121	EFO:0000035	\N	CS57618	EFO:0000035
0	"CS57619 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158643&type=germplasm" []	\N	CS57619	\N	\N	EFO	"CS57619 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158643&type=germplasm" []	EFO	67122	EFO:0000036	\N	CS57619	EFO:0000036
0	"CS57620 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158644&type=germplasm" []	\N	CS57620	\N	\N	EFO	"CS57620 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158644&type=germplasm" []	EFO	67123	EFO:0000037	\N	CS57620	EFO:0000037
0	"CS57621 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158645&type=germplasm" []	\N	CS57621	\N	\N	EFO	"CS57621 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158645&type=germplasm" []	EFO	67124	EFO:0000038	\N	CS57621	EFO:0000038
0	"CS57622 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158646&type=germplasm" []	\N	CS57622	\N	\N	EFO	"CS57622 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158646&type=germplasm" []	EFO	67125	EFO:0000039	\N	CS57622	EFO:0000039
0	"CS57624 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158648&type=germplasm" []	\N	CS57624	\N	\N	EFO	"CS57624 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158648&type=germplasm" []	EFO	67126	EFO:0000040	\N	CS57624	EFO:0000040
0	"CS57625 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158649&type=germplasm" []	\N	CS57625	\N	\N	EFO	"CS57625 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158649&type=germplasm" []	EFO	67127	EFO:0000041	\N	CS57625	EFO:0000041
0	"CS57626 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158650&type=germplasm" []	\N	CS57626	\N	\N	EFO	"CS57626 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158650&type=germplasm" []	EFO	67128	EFO:0000042	\N	CS57626	EFO:0000042
0	"CS57627 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158651&type=germplasm" []	\N	CS57627	\N	\N	EFO	"CS57627 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158651&type=germplasm" []	EFO	67129	EFO:0000043	\N	CS57627	EFO:0000043
0	"CS57628 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158652&type=germplasm" []	\N	CS57628	\N	\N	EFO	"CS57628 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158652&type=germplasm" []	EFO	67130	EFO:0000044	\N	CS57628	EFO:0000044
0	"CS57629 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158653&type=germplasm" []	\N	CS57629	\N	\N	EFO	"CS57629 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158653&type=germplasm" []	EFO	67131	EFO:0000045	\N	CS57629	EFO:0000045
0	"CS57630 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158654&type=germplasm" []	\N	CS57630	\N	\N	EFO	"CS57630 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158654&type=germplasm" []	EFO	67132	EFO:0000046	\N	CS57630	EFO:0000046
0	"CS57631 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158655&type=germplasm" []	\N	CS57631	\N	\N	EFO	"CS57631 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158655&type=germplasm" []	EFO	67133	EFO:0000047	\N	CS57631	EFO:0000047
0	"CS57637 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158661&type=germplasm" []	\N	CS57637	\N	\N	EFO	"CS57637 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158661&type=germplasm" []	EFO	67134	EFO:0000048	\N	CS57637	EFO:0000048
0	"CS57641 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158665&type=germplasm" []	\N	CS57641	\N	\N	EFO	"CS57641 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158665&type=germplasm" []	EFO	67135	EFO:0000049	\N	CS57641	EFO:0000049
0	"CS57644 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158668&type=germplasm" []	\N	CS57644	\N	\N	EFO	"CS57644 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158668&type=germplasm" []	EFO	67136	EFO:0000050	\N	CS57644	EFO:0000050
0	"CS57646 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158670&type=germplasm" []	\N	CS57646	\N	\N	EFO	"CS57646 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158670&type=germplasm" []	EFO	67137	EFO:0000051	\N	CS57646	EFO:0000051
0	"CS57648 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158672&type=germplasm" []	\N	CS57648	\N	\N	EFO	"CS57648 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158672&type=germplasm" []	EFO	67138	EFO:0000052	\N	CS57648	EFO:0000052
0	"CS57655 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158679&type=germplasm" []	\N	CS57655	\N	\N	EFO	"CS57655 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158679&type=germplasm" []	EFO	67139	EFO:0000053	\N	CS57655	EFO:0000053
0	"CS57658 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158682&type=germplasm" []	\N	CS57658	\N	\N	EFO	"CS57658 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158682&type=germplasm" []	EFO	67140	EFO:0000054	\N	CS57658	EFO:0000054
0	"CS57660 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158684&type=germplasm" []	\N	CS57660	\N	\N	EFO	"CS57660 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158684&type=germplasm" []	EFO	67141	EFO:0000055	\N	CS57660	EFO:0000055
0	"CS57663 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158687&type=germplasm" []	\N	CS57663	\N	\N	EFO	"CS57663 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158687&type=germplasm" []	EFO	67142	EFO:0000056	\N	CS57663	EFO:0000056
0	"CS57664 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158688&type=germplasm" []	\N	CS57664	\N	\N	EFO	"CS57664 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158688&type=germplasm" []	EFO	67143	EFO:0000057	\N	CS57664	EFO:0000057
0	"CS57664 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158690&type=germplasm" []	\N	CS57666	\N	\N	EFO	"CS57664 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158690&type=germplasm" []	EFO	67144	EFO:0000058	\N	CS57666	EFO:0000058
0	"CS57671 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158695&type=germplasm" []	\N	CS57671	\N	\N	EFO	"CS57671 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158695&type=germplasm" []	EFO	67145	EFO:0000059	\N	CS57671	EFO:0000059
0	"CS57677 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158695&type=germplasm" []	\N	CS57677	\N	\N	EFO	"CS57677 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158695&type=germplasm" []	EFO	67146	EFO:0000060	\N	CS57677	EFO:0000060
0	"CS57691 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158715&type=germplasm" []	\N	CS57691	\N	\N	EFO	"CS57691 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158715&type=germplasm" []	EFO	67147	EFO:0000061	\N	CS57691	EFO:0000061
0	"CS57692 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158716&type=germplasm" []	\N	CS57692	\N	\N	EFO	"CS57692 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158716&type=germplasm" []	EFO	67148	EFO:0000062	\N	CS57692	EFO:0000062
0	"CS57699 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158723&type=germplasm" []	\N	CS57699	\N	\N	EFO	"CS57699 is an Arabidopsis thaliana strain as described in TAIR  http://www.arabidopsis.org/servlets/TairObject?id=1005158723&type=germplasm" []	EFO	67149	EFO:0000063	\N	CS57699	EFO:0000063
0	"CS57701 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158725&type=germplasm" []	\N	CS57701	\N	\N	EFO	"CS57701 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158725&type=germplasm" []	EFO	67150	EFO:0000064	\N	CS57701	EFO:0000064
0	"CS57704 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158728&type=germplasm" []	\N	CS57704	\N	\N	EFO	"CS57704 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158728&type=germplasm" []	EFO	67151	EFO:0000065	\N	CS57704	EFO:0000065
0	"CS57705 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158729&type=germplasm" []	\N	CS57705	\N	\N	EFO	"CS57705 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158729&type=germplasm" []	EFO	67152	EFO:0000066	\N	CS57705	EFO:0000066
0	"CS57706 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158730&type=germplasm" []	\N	CS57706	\N	\N	EFO	"CS57706 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158730&type=germplasm" []	EFO	67153	EFO:0000067	\N	CS57706	EFO:0000067
0	"CS57709 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158733&type=germplasm" []	\N	CS57709	\N	\N	EFO	"CS57709 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158733&type=germplasm" []	EFO	67154	EFO:0000068	\N	CS57709	EFO:0000068
0	"CS57710 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158734&type=germplasm" []	\N	CS57710	\N	\N	EFO	"CS57710 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158734&type=germplasm" []	EFO	67155	EFO:0000069	\N	CS57710	EFO:0000069
0	"CS57714 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158738&type=germplasm" []	\N	CS57714	\N	\N	EFO	"CS57714 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158738&type=germplasm" []	EFO	67156	EFO:0000070	\N	CS57714	EFO:0000070
0	"CS57715 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158739&type=germplasm" []	\N	CS57715	\N	\N	EFO	"CS57715 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158739&type=germplasm" []	EFO	67157	EFO:0000071	\N	CS57715	EFO:0000071
0	"CS57716 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158740&type=germplasm" []	\N	CS57716	\N	\N	EFO	"CS57716 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158740&type=germplasm" []	EFO	67158	EFO:0000072	\N	CS57716	EFO:0000072
0	"CS57717 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158741&type=germplasm" []	\N	CS57717	\N	\N	EFO	"CS57717 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158741&type=germplasm" []	EFO	67159	EFO:0000073	\N	CS57717	EFO:0000073
0	"CS57719 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158743&type=germplasm" []	\N	CS57719	\N	\N	EFO	"CS57719 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158743&type=germplasm" []	EFO	67160	EFO:0000074	\N	CS57719	EFO:0000074
0	"CS57722 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158746&type=germplasm" []	\N	CS57722	\N	\N	EFO	"CS57722 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158746&type=germplasm" []	EFO	67161	EFO:0000075	\N	CS57722	EFO:0000075
0	"CS57727 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158751&type=germplasm" []	\N	CS57727	\N	\N	EFO	"CS57727 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158751&type=germplasm" []	EFO	67162	EFO:0000076	\N	CS57727	EFO:0000076
0	"CS57731 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158755&type=germplasm" []	\N	CS57731	\N	\N	EFO	"CS57731 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158755&type=germplasm" []	EFO	67163	EFO:0000077	\N	CS57731	EFO:0000077
0	"CS57732 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158756&type=germplasm" []	\N	CS57732	\N	\N	EFO	"CS57732 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158756&type=germplasm" []	EFO	67164	EFO:0000078	\N	CS57732	EFO:0000078
0	"CS57733 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158757&type=germplasm" []	\N	CS57733	\N	\N	EFO	"CS57733 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158757&type=germplasm" []	EFO	67165	EFO:0000079	\N	CS57733	EFO:0000079
0	"CS57735 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158759&type=germplasm" []	\N	CS57735	\N	\N	EFO	"CS57735 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158759&type=germplasm" []	EFO	67166	EFO:0000080	\N	CS57735	EFO:0000080
0	"CS57737 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158761&type=germplasm" []	\N	CS57737	\N	\N	EFO	"CS57737 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158761&type=germplasm" []	EFO	67167	EFO:0000081	\N	CS57737	EFO:0000081
0	"CS57740 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158764&type=germplasm" []	\N	CS57740	\N	\N	EFO	"CS57740 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158764&type=germplasm" []	EFO	67168	EFO:0000082	\N	CS57740	EFO:0000082
0	"CS57742 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158766&type=germplasm" []	\N	CS57742	\N	\N	EFO	"CS57742 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158766&type=germplasm" []	EFO	67169	EFO:0000083	\N	CS57742	EFO:0000083
0	"CS57743 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158767&type=germplasm" []	\N	CS57743	\N	\N	EFO	"CS57743 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158767&type=germplasm" []	EFO	67170	EFO:0000084	\N	CS57743	EFO:0000084
0	"CS57750 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158774&type=germplasm" []	\N	CS57750	\N	\N	EFO	"CS57750 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158774&type=germplasm" []	EFO	67171	EFO:0000085	\N	CS57750	EFO:0000085
0	"CS57751 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158775&type=germplasm" []	\N	CS57751	\N	\N	EFO	"CS57751 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158775&type=germplasm" []	EFO	67172	EFO:0000086	\N	CS57751	EFO:0000086
0	"CS57752 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158776&type=germplasm" []	\N	CS57752	\N	\N	EFO	"CS57752 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158776&type=germplasm" []	EFO	67173	EFO:0000087	\N	CS57752	EFO:0000087
0	"CS57753 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158777&type=germplasm" []	\N	CS57753	\N	\N	EFO	"CS57753 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158777&type=germplasm" []	EFO	67174	EFO:0000088	\N	CS57753	EFO:0000088
0	"CS57758 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158782&type=germplasm" []	\N	CS57758	\N	\N	EFO	"CS57758 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158782&type=germplasm" []	EFO	67175	EFO:0000089	\N	CS57758	EFO:0000089
0	"CS57769 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158793&type=germplasm" []	\N	CS57769	\N	\N	EFO	"CS57769 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158793&type=germplasm" []	EFO	67176	EFO:0000090	\N	CS57769	EFO:0000090
0	"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called precursor B lymphoblastic leukemia (B-cell acute lymphoblastic leukemia).  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) -- 2003" []	\N	B-cell acute lymphoblastic leukemia	\N	\N	EFO	"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called precursor B lymphoblastic leukemia (B-cell acute lymphoblastic leukemia).  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) -- 2003" []	EFO	67177	EFO:0000094	\N	B-cell acute lymphoblastic leukemia	EFO:0000094
0	"A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease." []	\N	chronic lymphocytic leukemia	\N	\N	EFO	"A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease." []	EFO	67178	EFO:0000095	\N	chronic lymphocytic leukemia	EFO:0000095
0	"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003" []	\N	neoplasm of mature B-cells	\N	\N	EFO	"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003" []	EFO	67179	EFO:0000096	\N	neoplasm of mature B-cells	EFO:0000096
0	"" []	\N	BY4741	\N	\N	EFO	"" []	EFO	67180	EFO:0000098	\N	BY4741	EFO:0000098
0	"" []	\N	BY5251	\N	\N	EFO	"" []	EFO	67181	EFO:0000100	\N	BY5251	EFO:0000100
0	"CS57770 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158794&type=germplasm" []	\N	CS57770	\N	\N	EFO	"CS57770 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158794&type=germplasm" []	EFO	67182	EFO:0000111	\N	CS57770	EFO:0000111
0	"CS57771 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158795&type=germplasm" []	\N	CS57771	\N	\N	EFO	"CS57771 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158795&type=germplasm" []	EFO	67183	EFO:0000112	\N	CS57771	EFO:0000112
0	"CS57776 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158800&type=germplasm" []	\N	CS57776	\N	\N	EFO	"CS57776 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158800&type=germplasm" []	EFO	67184	EFO:0000113	\N	CS57776	EFO:0000113
0	"CS57777 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158801&type=germplasm" []	\N	CS57777	\N	\N	EFO	"CS57777 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158801&type=germplasm" []	EFO	67185	EFO:0000114	\N	CS57777	EFO:0000114
0	"CS57778 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158802&type=germplasm" []	\N	CS57778	\N	\N	EFO	"CS57778 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158802&type=germplasm" []	EFO	67186	EFO:0000115	\N	CS57778	EFO:0000115
0	"CS57779 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158803&type=germplasm" []	\N	CS57779	\N	\N	EFO	"CS57779 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158803&type=germplasm" []	EFO	67187	EFO:0000116	\N	CS57779	EFO:0000116
0	"CS57783 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158807&type=germplasm" []	\N	CS57783	\N	\N	EFO	"CS57783 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158807&type=germplasm" []	EFO	67188	EFO:0000117	\N	CS57783	EFO:0000117
0	"CS57785 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158809&type=germplasm" []	\N	CS57785	\N	\N	EFO	"CS57785 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158809&type=germplasm" []	EFO	67189	EFO:0000118	\N	CS57785	EFO:0000118
0	"CS57789 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158813&type=germplasm" []	\N	CS57789	\N	\N	EFO	"CS57789 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158813&type=germplasm" []	EFO	67190	EFO:0000119	\N	CS57789	EFO:0000119
0	"CS57790 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158814&type=germplasm" []	\N	CS57790	\N	\N	EFO	"CS57790 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158814&type=germplasm" []	EFO	67191	EFO:0000120	\N	CS57790	EFO:0000120
0	"CS57801 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158825&type=germplasm" []	\N	CS57801	\N	\N	EFO	"CS57801 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158825&type=germplasm" []	EFO	67192	EFO:0000121	\N	CS57801	EFO:0000121
0	"CS57803 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158827&type=germplasm" []	\N	CS57803	\N	\N	EFO	"CS57803 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158827&type=germplasm" []	EFO	67193	EFO:0000122	\N	CS57803	EFO:0000122
0	"CS57807 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158831&type=germplasm" []	\N	CS57807	\N	\N	EFO	"CS57807 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158831&type=germplasm" []	EFO	67194	EFO:0000123	\N	CS57807	EFO:0000123
0	"CS57810 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158834&type=germplasm" []	\N	CS57810	\N	\N	EFO	"CS57810 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158834&type=germplasm" []	EFO	67195	EFO:0000124	\N	CS57810	EFO:0000124
0	"CS57811 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158835&type=germplasm" []	\N	CS57811	\N	\N	EFO	"CS57811 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158835&type=germplasm" []	EFO	67196	EFO:0000125	\N	CS57811	EFO:0000125
0	"CS57812 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158836&type=germplasm" []	\N	CS57812	\N	\N	EFO	"CS57812 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158836&type=germplasm" []	EFO	67197	EFO:0000126	\N	CS57812	EFO:0000126
0	"CS57813 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158837&type=germplasm" []	\N	CS57813	\N	\N	EFO	"CS57813 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158837&type=germplasm" []	EFO	67198	EFO:0000127	\N	CS57813	EFO:0000127
0	"CS57816 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158840&type=germplasm" []	\N	CS57816	\N	\N	EFO	"CS57816 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158840&type=germplasm" []	EFO	67199	EFO:0000128	\N	CS57816	EFO:0000128
0	"CS57820 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158844&type=germplasm" []	\N	CS57820	\N	\N	EFO	"CS57820 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158844&type=germplasm" []	EFO	67200	EFO:0000129	\N	CS57820	EFO:0000129
0	"CS57822 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158846&type=germplasm" []	\N	CS57822	\N	\N	EFO	"CS57822 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158846&type=germplasm" []	EFO	67201	EFO:0000130	\N	CS57822	EFO:0000130
0	"CS57823 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158847&type=germplasm" []	\N	CS57823	\N	\N	EFO	"CS57823 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158847&type=germplasm" []	EFO	67202	EFO:0000131	\N	CS57823	EFO:0000131
0	"CS57824  is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158848&type=germplasm" []	\N	CS57824	\N	\N	EFO	"CS57824  is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158848&type=germplasm" []	EFO	67203	EFO:0000132	\N	CS57824	EFO:0000132
0	"CS57825 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158849&type=germplasm" []	\N	CS57825	\N	\N	EFO	"CS57825 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158849&type=germplasm" []	EFO	67204	EFO:0000133	\N	CS57825	EFO:0000133
0	"CS57826 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158850&type=germplasm" []	\N	CS57826	\N	\N	EFO	"CS57826 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158850&type=germplasm" []	EFO	67205	EFO:0000134	\N	CS57826	EFO:0000134
0	"CS57827 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158851&type=germplasm" []	\N	CS57827	\N	\N	EFO	"CS57827 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158851&type=germplasm" []	EFO	67206	EFO:0000135	\N	CS57827	EFO:0000135
0	"CS57828 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158852&type=germplasm" []	\N	CS57828	\N	\N	EFO	"CS57828 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158852&type=germplasm" []	EFO	67207	EFO:0000136	\N	CS57828	EFO:0000136
0	"CS57834 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158858&type=germplasm" []	\N	CS57834	\N	\N	EFO	"CS57834 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158858&type=germplasm" []	EFO	67208	EFO:0000137	\N	CS57834	EFO:0000137
0	"CS57835 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158859&type=germplasm" []	\N	CS57835	\N	\N	EFO	"CS57835 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158859&type=germplasm" []	EFO	67209	EFO:0000138	\N	CS57835	EFO:0000138
0	"CS57836 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158860&type=germplasm" []	\N	CS57836	\N	\N	EFO	"CS57836 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158860&type=germplasm" []	EFO	67210	EFO:0000139	\N	CS57836	EFO:0000139
0	"CS57840 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158864&type=germplasm" []	\N	CS57840	\N	\N	EFO	"CS57840 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158864&type=germplasm" []	EFO	67211	EFO:0000140	\N	CS57840	EFO:0000140
0	"CS57842 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158866&type=germplasm" []	\N	CS57842	\N	\N	EFO	"CS57842 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158866&type=germplasm" []	EFO	67212	EFO:0000141	\N	CS57842	EFO:0000141
0	"CS57843 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158867&type=germplasm" []	\N	CS57843	\N	\N	EFO	"CS57843 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158867&type=germplasm" []	EFO	67213	EFO:0000142	\N	CS57843	EFO:0000142
0	"CS57847 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158871&type=germplasm" []	\N	CS57847	\N	\N	EFO	"CS57847 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158871&type=germplasm" []	EFO	67214	EFO:0000143	\N	CS57847	EFO:0000143
0	"CS57848 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158872&type=germplasm" []	\N	CS57848	\N	\N	EFO	"CS57848 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158872&type=germplasm" []	EFO	67215	EFO:0000144	\N	CS57848	EFO:0000144
0	"CS57850 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158874&type=germplasm" []	\N	CS57850	\N	\N	EFO	"CS57850 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158874&type=germplasm" []	EFO	67216	EFO:0000145	\N	CS57850	EFO:0000145
0	"CS57854 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158878&type=germplasm" []	\N	CS57854	\N	\N	EFO	"CS57854 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158878&type=germplasm" []	EFO	67217	EFO:0000146	\N	CS57854	EFO:0000146
0	"CS57858 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158882&type=germplasm" []	\N	CS57858	\N	\N	EFO	"CS57858 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158882&type=germplasm" []	EFO	67218	EFO:0000147	\N	CS57858	EFO:0000147
0	"CS57859 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158883&type=germplasm" []	\N	CS57859	\N	\N	EFO	"CS57859 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158883&type=germplasm" []	EFO	67219	EFO:0000148	\N	CS57859	EFO:0000148
0	"CS57867 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158891&type=germplasm" []	\N	CS57867	\N	\N	EFO	"CS57867 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158891&type=germplasm" []	EFO	67220	EFO:0000149	\N	CS57867	EFO:0000149
0	"CS57870 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158894&type=germplasm" []	\N	CS57870	\N	\N	EFO	"CS57870 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158894&type=germplasm" []	EFO	67221	EFO:0000150	\N	CS57870	EFO:0000150
0	"CS57871 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158895&type=germplasm" []	\N	CS57871	\N	\N	EFO	"CS57871 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158895&type=germplasm" []	EFO	67222	EFO:0000151	\N	CS57871	EFO:0000151
0	"CS57873 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158897&type=germplasm" []	\N	CS57873	\N	\N	EFO	"CS57873 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158897&type=germplasm" []	EFO	67223	EFO:0000152	\N	CS57873	EFO:0000152
0	"CS57874 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158898&type=germplasm" []	\N	CS57874	\N	\N	EFO	"CS57874 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158898&type=germplasm" []	EFO	67224	EFO:0000153	\N	CS57874	EFO:0000153
0	"CS57875 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158899&type=germplasm" []	\N	CS57875	\N	\N	EFO	"CS57875 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158899&type=germplasm" []	EFO	67225	EFO:0000154	\N	CS57875	EFO:0000154
0	"CS57876 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158900&type=germplasm" []	\N	CS57876	\N	\N	EFO	"CS57876 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158900&type=germplasm" []	EFO	67226	EFO:0000155	\N	CS57876	EFO:0000155
0	"CS57883 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158907&type=germplasm" []	\N	CS57883	\N	\N	EFO	"CS57883 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158907&type=germplasm" []	EFO	67227	EFO:0000156	\N	CS57883	EFO:0000156
0	"CS57884 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158908&type=germplasm" []	\N	CS57884	\N	\N	EFO	"CS57884 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158908&type=germplasm" []	EFO	67228	EFO:0000157	\N	CS57884	EFO:0000157
0	"CS57886 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158910&type=germplasm" []	\N	CS57886	\N	\N	EFO	"CS57886 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158910&type=germplasm" []	EFO	67229	EFO:0000158	\N	CS57886	EFO:0000158
0	"CS57890 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158914&type=germplasm" []	\N	CS57890	\N	\N	EFO	"CS57890 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158914&type=germplasm" []	EFO	67230	EFO:0000159	\N	CS57890	EFO:0000159
0	"CS57896 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158920&type=germplasm" []	\N	CS57896	\N	\N	EFO	"CS57896 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158920&type=germplasm" []	EFO	67231	EFO:0000160	\N	CS57896	EFO:0000160
0	"CS57901 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158925&type=germplasm" []	\N	CS57901	\N	\N	EFO	"CS57901 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158925&type=germplasm" []	EFO	67232	EFO:0000161	\N	CS57901	EFO:0000161
0	"CS57904 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158928&type=germplasm" []	\N	CS57904	\N	\N	EFO	"CS57904 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158928&type=germplasm" []	EFO	67233	EFO:0000162	\N	CS57904	EFO:0000162
0	"CS57905 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158929&type=germplasm" []	\N	CS57905	\N	\N	EFO	"CS57905 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158929&type=germplasm" []	EFO	67234	EFO:0000163	\N	CS57905	EFO:0000163
0	"CS57908 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158932&type=germplasm" []	\N	CS57908	\N	\N	EFO	"CS57908 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005158932&type=germplasm" []	EFO	67235	EFO:0000164	\N	CS57908	EFO:0000164
0	"CS57923 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005164919&type=germplasm" []	\N	CS57923	\N	\N	EFO	"CS57923 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005164919&type=germplasm" []	EFO	67236	EFO:0000165	\N	CS57923	EFO:0000165
0	"CS57924 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005164920&type=germplasm" []	\N	CS57924	\N	\N	EFO	"CS57924 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=1005164920&type=germplasm" []	EFO	67237	EFO:0000166	\N	CS57924	EFO:0000166
0	"CS8581 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=4473197&type=germplasm" []	\N	CS8581	\N	\N	EFO	"CS8581 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?id=4473197&type=germplasm" []	EFO	67238	EFO:0000167	\N	CS8581	EFO:0000167
0	"A multilayer of deep cells of fairly uniform thickness that forms during early epiboly (at dome stage; upon conversion of the blastodisc to the blastoderm); during gastrulation the DEL (deep cell layer) gives rise to the epiblast and hypoblast." []	\N	DEL cells	\N	\N	EFO	"A multilayer of deep cells of fairly uniform thickness that forms during early epiboly (at dome stage; upon conversion of the blastodisc to the blastoderm); during gastrulation the DEL (deep cell layer) gives rise to the epiblast and hypoblast." []	EFO	67239	EFO:0000170	\N	DEL cells	EFO:0000170
0	"A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells.  Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor.  Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities.  These tumors may occur in the soft tissues or the bones.  Pain and the presence of a mass are the most common clinical symptoms. -- 2004" []	\N	Ewing sarcoma	\N	\N	EFO	"A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells.  Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor.  Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities.  These tumors may occur in the soft tissues or the bones.  Pain and the presence of a mass are the most common clinical symptoms. -- 2004" []	EFO	67240	EFO:0000174	\N	Ewing sarcoma	EFO:0000174
0	"FUM1 is a yeast strain as described in http://www.genedb.org/genedb/Search?organism=cerevisiae&name=YPL262W&isid=true" []	\N	FUM1	\N	\N	EFO	"FUM1 is a yeast strain as described in http://www.genedb.org/genedb/Search?organism=cerevisiae&name=YPL262W&isid=true" []	EFO	67241	EFO:0000175	\N	FUM1	EFO:0000175
0	"Fisher344 is a rat strain as described in http://www.ratmap.org/ShowStrainDetails.html?strain=72" []	\N	Fischer 344	\N	\N	EFO	"Fisher344 is a rat strain as described in http://www.ratmap.org/ShowStrainDetails.html?strain=72" []	EFO	67242	EFO:0000176	\N	Fischer 344	EFO:0000176
0	"" []	\N	gastric carcinoma	\N	\N	EFO	"" []	EFO	67243	EFO:0000178	\N	gastric carcinoma	EFO:0000178
0	"Goto-Kakizaki is a rat strain as described in http://www.taconic.com/wmspage.cfm?parm1=757" []	\N	Goto-Kakizaki	\N	\N	EFO	"Goto-Kakizaki is a rat strain as described in http://www.taconic.com/wmspage.cfm?parm1=757" []	EFO	67244	EFO:0000179	\N	Goto-Kakizaki	EFO:0000179
0	"The type species of lentivirus and the etiologic agent of acquired immunodeficiency syndrome (AIDS). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte." []	\N	HIV-1 infection	\N	\N	EFO	"The type species of lentivirus and the etiologic agent of acquired immunodeficiency syndrome (AIDS). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte." []	EFO	67245	EFO:0000180	\N	HIV-1 infection	EFO:0000180
0	"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands." []	\N	head and neck squamous cell carcinoma	\N	\N	EFO	"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands." []	EFO	67246	EFO:0000181	\N	head and neck squamous cell carcinoma	EFO:0000181
0	"Tumors or cancer of the LIVER." []	\N	hepatocellular carcinoma	\N	\N	EFO	"Tumors or cancer of the LIVER." []	EFO	67247	EFO:0000182	\N	hepatocellular carcinoma	EFO:0000182
0	"A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen." []	\N	Hodgkins lymphoma	\N	\N	EFO	"A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen." []	EFO	67248	EFO:0000183	\N	Hodgkins lymphoma	EFO:0000183
0	"The most common type of invasive breast carcinoma, accounting for approximately 70% of breast carcinomas.  The gross appearance is usually typical with an irregular stellate outline.  Microscopically, randomly arranged epithelial elements are seen.  When large sheets of malignant cells are present, necrosis may be seen.  With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma.  The in situ component is nearly always ductal but occasionally may be lobular or both." []	\N	invasive ductal carcinoma	\N	\N	EFO	"The most common type of invasive breast carcinoma, accounting for approximately 70% of breast carcinomas.  The gross appearance is usually typical with an irregular stellate outline.  Microscopically, randomly arranged epithelial elements are seen.  When large sheets of malignant cells are present, necrosis may be seen.  With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma.  The in situ component is nearly always ductal but occasionally may be lobular or both." []	EFO	67249	EFO:0000186	\N	invasive ductal carcinoma	EFO:0000186
0	"A multicentric, malignant neoplastic vascular proliferation characterized by bluish-red cutaneous nodules, usually on the legs, toes, or feet, that slowly increase in size and number and spread to more proximal sites. The tumors have endothelium-lined channels and vascular spaces mixed with aggregates of spindle-shaped cells; they may remain confined to skin and subcutaneous tissue, but widespread visceral involvement may occur." []	\N	Kaposi's sarcoma cell	\N	\N	EFO	"A multicentric, malignant neoplastic vascular proliferation characterized by bluish-red cutaneous nodules, usually on the legs, toes, or feet, that slowly increase in size and number and spread to more proximal sites. The tumors have endothelium-lined channels and vascular spaces mixed with aggregates of spindle-shaped cells; they may remain confined to skin and subcutaneous tissue, but widespread visceral involvement may occur." []	EFO	67250	EFO:0000187	\N	Kaposi's sarcoma cell	EFO:0000187
0	"" []	\N	MALT lymphoma	\N	\N	EFO	"" []	EFO	67251	EFO:0000191	\N	MALT lymphoma	EFO:0000191
0	"A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)" []	\N	metabolic syndrome	\N	\N	EFO	"A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)" []	EFO	67252	EFO:0000195	\N	metabolic syndrome	EFO:0000195
0	"" []	\N	metastatic prostate cancer	\N	\N	EFO	"" []	EFO	67253	EFO:0000196	\N	metastatic prostate cancer	EFO:0000196
0	"" []	\N	mucinous carcinoma	\N	\N	EFO	"" []	EFO	67254	EFO:0000197	\N	mucinous carcinoma	EFO:0000197
0	"Myelodysplastic syndromes are a class of syndromes which involve ineffective production (or dysplasia) of the myeloid class of blood cells." []	\N	myelodysplastic syndrome	\N	\N	EFO	"Myelodysplastic syndromes are a class of syndromes which involve ineffective production (or dysplasia) of the myeloid class of blood cells." []	EFO	67255	EFO:0000198	\N	myelodysplastic syndrome	EFO:0000198
0	"" []	\N	oral squamous cell carcinoma	\N	\N	EFO	"" []	EFO	67256	EFO:0000199	\N	oral squamous cell carcinoma	EFO:0000199
0	"" []	\N	plasma cell neoplasm	\N	\N	EFO	"" []	EFO	67257	EFO:0000200	\N	plasma cell neoplasm	EFO:0000200
0	"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases." []	\N	monoclonal gammopathy	\N	\N	EFO	"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases." []	EFO	67258	EFO:0000203	\N	monoclonal gammopathy	EFO:0000203
0	"" []	\N	stage I endometrioid carcinoma	\N	\N	EFO	"" []	EFO	67259	EFO:0000205	\N	stage I endometrioid carcinoma	EFO:0000205
0	"" []	\N	stage II endometrioid carcinoma	\N	\N	EFO	"" []	EFO	67260	EFO:0000206	\N	stage II endometrioid carcinoma	EFO:0000206
0	"This type of acute lymphoblastic leukemia comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)" []	\N	T-cell acute lymphoblastic leukemia	\N	\N	EFO	"This type of acute lymphoblastic leukemia comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)" []	EFO	67261	EFO:0000209	\N	T-cell acute lymphoblastic leukemia	EFO:0000209
0	"" []	\N	unspecified peripheral T-cell lymphoma	\N	\N	EFO	"" []	EFO	67262	EFO:0000211	\N	unspecified peripheral T-cell lymphoma	EFO:0000211
0	"The skin or integument surrounding the abdomen." []	\N	abdominal skin	\N	\N	EFO	"The skin or integument surrounding the abdomen." []	EFO	67263	EFO:0000214	\N	abdominal skin	EFO:0000214
0	"A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)" []	\N	acinar cell carcinoma	\N	\N	EFO	"A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)" []	EFO	67264	EFO:0000216	\N	acinar cell carcinoma	EFO:0000216
0	"Inflammation of the stomach." []	\N	active gastritis	\N	\N	EFO	"Inflammation of the stomach." []	EFO	67265	EFO:0000217	\N	active gastritis	EFO:0000217
0	"" []	\N	acute erythroleukemia	\N	\N	EFO	"" []	EFO	67266	EFO:0000218	\N	acute erythroleukemia	EFO:0000218
0	"When the disease process is confined to a mass lesion with no or minimal evidence of blood and less than 25% marrow involvement, the diagnosis is lymphoblastic lymphoma; with blood and greater than 25% marrow involvement, ALL is the appropriate term." []	\N	acute lymphoblastic leukemia	\N	\N	EFO	"When the disease process is confined to a mass lesion with no or minimal evidence of blood and less than 25% marrow involvement, the diagnosis is lymphoblastic lymphoma; with blood and greater than 25% marrow involvement, ALL is the appropriate term." []	EFO	67267	EFO:0000220	\N	acute lymphoblastic leukemia	EFO:0000220
0	"An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES." []	\N	acute monocytic leukemia	\N	\N	EFO	"An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES." []	EFO	67268	EFO:0000221	\N	acute monocytic leukemia	EFO:0000221
0	"Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES." []	\N	acute myeloid leukemia	\N	\N	EFO	"Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES." []	EFO	67269	EFO:0000222	\N	acute myeloid leukemia	EFO:0000222
0	"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  Patients typically present with anemia, thrombocytopenia, fever and fatigue.  This type of leukemia frequently responds to aggressive therapy.  (WHO, 2001) -- 2003" []	\N	acute myelomonocytic leukemia	\N	\N	EFO	"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  Patients typically present with anemia, thrombocytopenia, fever and fatigue.  This type of leukemia frequently responds to aggressive therapy.  (WHO, 2001) -- 2003" []	EFO	67270	EFO:0000223	\N	acute myelomonocytic leukemia	EFO:0000223
0	"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)" []	\N	acute promyelocytic leukemia	\N	\N	EFO	"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)" []	EFO	67271	EFO:0000224	\N	acute promyelocytic leukemia	EFO:0000224
0	"" []	\N	acute quadriplegic myopathy	\N	\N	EFO	"" []	EFO	67272	EFO:0000225	\N	acute quadriplegic myopathy	EFO:0000225
0	"" []	\N	adaxial cells	\N	\N	EFO	"" []	EFO	67273	EFO:0000226	\N	adaxial cells	EFO:0000226
0	"A type of carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures." []	\N	adenocarcinoma	\N	\N	EFO	"A type of carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures." []	EFO	67274	EFO:0000228	\N	adenocarcinoma	EFO:0000228
0	"Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)" []	\N	adenoid cystic carcinoma	\N	\N	EFO	"Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)" []	EFO	67275	EFO:0000231	\N	adenoid cystic carcinoma	EFO:0000231
0	"A neoplasm arising from the epithelium. It may be encapsulated or non-encapsulated but non-invasive. The neoplastic epithelial cells may or may not display cellular atypia or dysplasia. In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ. Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract." []	\N	adenoma	\N	\N	EFO	"A neoplasm arising from the epithelium. It may be encapsulated or non-encapsulated but non-invasive. The neoplastic epithelial cells may or may not display cellular atypia or dysplasia. In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ. Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract." []	EFO	67276	EFO:0000232	\N	adenoma	EFO:0000232
0	"An aggressive carcinoma with a poor prognosis characterized by a presence of both malignant squamous cells and glandular cells." []	\N	adenosquamous lung carcinoma	\N	\N	EFO	"An aggressive carcinoma with a poor prognosis characterized by a presence of both malignant squamous cells and glandular cells." []	EFO	67277	EFO:0000233	\N	adenosquamous lung carcinoma	EFO:0000233
0	"A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines.  It arises from the chromaffin cells of the adrenal medulla.  Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present." []	\N	adrenal gland pheochromocytoma	\N	\N	EFO	"A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines.  It arises from the chromaffin cells of the adrenal medulla.  Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present." []	EFO	67278	EFO:0000239	\N	adrenal gland pheochromocytoma	EFO:0000239
0	"." []	\N	adult eye primordium	\N	\N	EFO	"." []	EFO	67279	EFO:0000240	\N	adult eye primordium	EFO:0000240
0	"" []	\N	adult foregut precursor	\N	\N	EFO	"" []	EFO	67280	EFO:0000241	\N	adult foregut precursor	EFO:0000241
0	"" []	\N	adult hindgut precursor	\N	\N	EFO	"" []	EFO	67281	EFO:0000242	\N	adult hindgut precursor	EFO:0000242
0	"" []	\N	adult midgut precursor	\N	\N	EFO	"" []	EFO	67282	EFO:0000244	\N	adult midgut precursor	EFO:0000244
0	"" []	\N	adult muscle precursor primordium	\N	\N	EFO	"" []	EFO	67283	EFO:0000245	\N	adult muscle precursor primordium	EFO:0000245
0	"A temporal measurement of the time period elapsed since an identifiable point in the life cycle of an organism. If a developmental stage is specified, the identifiable point would be the beginning of that stage. Otherwise the identifiable point must be specified such as planting (e.g. 3 days post planting)." []	\N	age	\N	\N	EFO	"A temporal measurement of the time period elapsed since an identifiable point in the life cycle of an organism. If a developmental stage is specified, the identifiable point would be the beginning of that stage. Otherwise the identifiable point must be specified such as planting (e.g. 3 days post planting)." []	EFO	67284	EFO:0000246	\N	age	EFO:0000246
0	"Alveolar" []	\N	alveolar rhabdomyosarcoma	\N	\N	EFO	"Alveolar" []	EFO	67285	EFO:0000248	\N	alveolar rhabdomyosarcoma	EFO:0000248
0	"A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language." []	\N	Alzheimer's disease	\N	\N	EFO	"A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language." []	EFO	67286	EFO:0000249	\N	Alzheimer's disease	EFO:0000249
0	"" []	\N	amnioserosa anlage in statu nascendi	\N	\N	EFO	"" []	EFO	67287	EFO:0000251	\N	amnioserosa anlage in statu nascendi	EFO:0000251
0	"An autosomal dominant inherited form of amyloidosis." []	\N	amyotrophic lateral sclerosis	\N	\N	EFO	"An autosomal dominant inherited form of amyloidosis." []	EFO	67288	EFO:0000253	\N	amyotrophic lateral sclerosis	EFO:0000253
0	"" []	\N	anal pad specific anlage	\N	\N	EFO	"" []	EFO	67289	EFO:0000254	\N	anal pad specific anlage	EFO:0000254
0	"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes.  It occurs in the middle aged and elderly, with an equal incidence in males and females.  The clinical course is typically aggressive.  (WHO, 2001)" []	\N	angioimmunoblastic T-cell lymphoma	\N	\N	EFO	"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes.  It occurs in the middle aged and elderly, with an equal incidence in males and females.  The clinical course is typically aggressive.  (WHO, 2001)" []	EFO	67290	EFO:0000255	\N	angioimmunoblastic T-cell lymphoma	EFO:0000255
0	"\\"anlagen in statu nascendi\\" are domains that do not yet coincide 1:1 with a later organ. Anlagen in statu nascendi are typically defined for the early blastoderm by the expression domains of genes which, in the late blastoderm or later, are expressed in specific anlagen, but initially come on in larger domains." []	\N	anlage in statu nascendi	\N	\N	EFO	"\\"anlagen in statu nascendi\\" are domains that do not yet coincide 1:1 with a later organ. Anlagen in statu nascendi are typically defined for the early blastoderm by the expression domains of genes which, in the late blastoderm or later, are expressed in specific anlagen, but initially come on in larger domains." []	EFO	67291	EFO:0000256	\N	anlage in statu nascendi	EFO:0000256
0	"." []	\N	antennal primordium1	\N	\N	EFO	"." []	EFO	67292	EFO:0000257	\N	antennal primordium1	EFO:0000257
0	"" []	\N	antennal primordium2	\N	\N	EFO	"" []	EFO	67293	EFO:0000258	\N	antennal primordium2	EFO:0000258
0	"" []	\N	anterior endoderm anlage	\N	\N	EFO	"" []	EFO	67294	EFO:0000259	\N	anterior endoderm anlage	EFO:0000259
0	"" []	\N	anterior endoderm anlage in statu nascendi	\N	\N	EFO	"" []	EFO	67295	EFO:0000260	\N	anterior endoderm anlage in statu nascendi	EFO:0000260
0	"" []	\N	anterior endoderm primordium	\N	\N	EFO	"" []	EFO	67296	EFO:0000261	\N	anterior endoderm primordium	EFO:0000261
0	"" []	\N	anterior midgut primordium	\N	\N	EFO	"" []	EFO	67297	EFO:0000262	\N	anterior midgut primordium	EFO:0000262
0	"" []	\N	anterior spiracle specific anlage	\N	\N	EFO	"" []	EFO	67298	EFO:0000263	\N	anterior spiracle specific anlage	EFO:0000263
0	"An antibody function (or antigen binding function) is an infection-fighting protein molecule in blood or secretory fluids that tags, neutralizes, and helps destroy pathogenic microorganisms such as bacteria, viruses and toxins." []	\N	antibody	\N	\N	EFO	"An antibody function (or antigen binding function) is an infection-fighting protein molecule in blood or secretory fluids that tags, neutralizes, and helps destroy pathogenic microorganisms such as bacteria, viruses and toxins." []	EFO	67299	EFO:0000264	\N	antibody	EFO:0000264
0	"Aortic valve stenosis is a aortic valve disease caused by the incomplete opening of the aortic valve. The aortic valve controls the direction of blood flow from the left ventricle to the aorta. When in good working order, the aortic valve does not impede the flow of blood between these two spaces. Under some circumstances, the aortic valve becomes narrower than normal, impeding the flow of blood. This is known as aortic valve stenosis, or aortic stenosis, often abbreviated AS." []	\N	aortic stenosis	\N	\N	EFO	"Aortic valve stenosis is a aortic valve disease caused by the incomplete opening of the aortic valve. The aortic valve controls the direction of blood flow from the left ventricle to the aorta. When in good working order, the aortic valve does not impede the flow of blood between these two spaces. Under some circumstances, the aortic valve becomes narrower than normal, impeding the flow of blood. This is known as aortic valve stenosis, or aortic stenosis, often abbreviated AS." []	EFO	67300	EFO:0000266	\N	aortic stenosis	EFO:0000266
0	"A group of cells at the tip of the stem and root that give rise by cell division to the primary tissues and are ultimately responsible for the structural organization of the entire primary plant body." []	\N	apical meristem	\N	\N	EFO	"A group of cells at the tip of the stem and root that give rise by cell division to the primary tissues and are ultimately responsible for the structural organization of the entire primary plant body." []	EFO	67301	EFO:0000267	\N	apical meristem	EFO:0000267
0	"" []	\N	apoptotic amnioserosa	\N	\N	EFO	"" []	EFO	67302	EFO:0000268	\N	apoptotic amnioserosa	EFO:0000268
0	"An instrument design which describes the design of the array." []	\N	array design	\N	\N	EFO	"An instrument design which describes the design of the array." []	EFO	67303	EFO:0000269	\N	array design	EFO:0000269
0	"Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory." []	\N	asthma	\N	\N	EFO	"Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory." []	EFO	67304	EFO:0000270	\N	asthma	EFO:0000270
0	"Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)" []	\N	astrocytoma	\N	\N	EFO	"Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)" []	EFO	67305	EFO:0000272	\N	astrocytoma	EFO:0000272
0	"The atmospheric conditions used to culture or grow an organism." []	\N	atmosphere	\N	\N	EFO	"The atmospheric conditions used to culture or grow an organism." []	EFO	67306	EFO:0000273	\N	atmosphere	EFO:0000273
0	"A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema." []	\N	atopic eczema	\N	\N	EFO	"A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema." []	EFO	67307	EFO:0000274	\N	atopic eczema	EFO:0000274
0	"Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation." []	\N	atrial fibrillation	\N	\N	EFO	"Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation." []	EFO	67308	EFO:0000275	\N	atrial fibrillation	EFO:0000275
0	"INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis." []	\N	pancreatitis	\N	\N	EFO	"INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis." []	EFO	67309	EFO:0000278	\N	pancreatitis	EFO:0000278
0	"A condition of suboptimal concentration of SPERMATOZOA in the ejaculated SEMEN to ensure successful FERTILIZATION of an OVUM. In humans, oligospermia is defined as a sperm count below 20 million per milliliter semen." []	\N	azoospermia	\N	\N	EFO	"A condition of suboptimal concentration of SPERMATOZOA in the ejaculated SEMEN to ensure successful FERTILIZATION of an OVUM. In humans, oligospermia is defined as a sperm count below 20 million per milliliter semen." []	EFO	67310	EFO:0000279	\N	azoospermia	EFO:0000279
0	"A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus." []	\N	Barrett's esophagus	\N	\N	EFO	"A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus." []	EFO	67311	EFO:0000280	\N	Barrett's esophagus	EFO:0000280
0	"basal breast tumor is a high grade, triple-negative breast tumor, i.e. they express no estrogen receptor, progesterone receptor nor Her2/neu proteins." []	\N	basal-like carcinoma	\N	\N	EFO	"basal breast tumor is a high grade, triple-negative breast tumor, i.e. they express no estrogen receptor, progesterone receptor nor Her2/neu proteins." []	EFO	67312	EFO:0000281	\N	basal-like carcinoma	EFO:0000281
0	"A treatment applied to a sample where some behaviour is expected as a result e.g. avoidance" []	\N	behavioral stimulus	\N	\N	EFO	"A treatment applied to a sample where some behaviour is expected as a result e.g. avoidance" []	EFO	67313	EFO:0000283	\N	behavioral stimulus	EFO:0000283
0	"Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both." []	\N	benign prostatic hyperplasia	\N	\N	EFO	"Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both." []	EFO	67314	EFO:0000284	\N	benign prostatic hyperplasia	EFO:0000284
0	"A biopsy number is an information entity about the numerical label given to a partciular biopsy obtained." []	\N	biopsy number	\N	\N	EFO	"A biopsy number is an information entity about the numerical label given to a partciular biopsy obtained." []	EFO	67315	EFO:0000287	\N	biopsy number	EFO:0000287
0	"The physical site from which tissue has been removed from a living organism. Does not imply any statistical significance, i.e. that it is a statistically representative sample of the whole." []	\N	biopsy site	\N	\N	EFO	"The physical site from which tissue has been removed from a living organism. Does not imply any statistical significance, i.e. that it is a statistically representative sample of the whole." []	EFO	67316	EFO:0000288	\N	biopsy site	EFO:0000288
0	"A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence." []	\N	bipolar disorder	\N	\N	EFO	"A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence." []	EFO	67317	EFO:0000289	\N	bipolar disorder	EFO:0000289
0	"Bladder carcinoma is a carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas." []	\N	bladder carcinoma	\N	\N	EFO	"Bladder carcinoma is a carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas." []	EFO	67318	EFO:0000292	\N	bladder carcinoma	EFO:0000292
0	"" []	\N	bladder mucosa	\N	\N	EFO	"" []	EFO	67319	EFO:0000293	\N	bladder mucosa	EFO:0000293
0	"An abnormal growth, i.e. tumor, located in the bladder." []	\N	bladder tumor	\N	\N	EFO	"An abnormal growth, i.e. tumor, located in the bladder." []	EFO	67320	EFO:0000294	\N	bladder tumor	EFO:0000294
0	"The hard form of connective tissue that constitutes the majority of the skeleton of most vertebrates; it consists of an organic component (the cells and matrix) and an inorganic, or mineral, component; the matrix contains a framework of collagenous fibers and is impregnated with the mineral component, chiefly calcium phosphate (85 per cent) and calcium carbonate (10 per cent), which imparts the quality of rigidity to bone." []	\N	bone	\N	\N	EFO	"The hard form of connective tissue that constitutes the majority of the skeleton of most vertebrates; it consists of an organic component (the cells and matrix) and an inorganic, or mineral, component; the matrix contains a framework of collagenous fibers and is impregnated with the mineral component, chiefly calcium phosphate (85 per cent) and calcium carbonate (10 per cent), which imparts the quality of rigidity to bone." []	EFO	67321	EFO:0000298	\N	bone	EFO:0000298
0	"DOID:3458" []	\N	breast adenocarcinoma	\N	\N	EFO	"DOID:3458" []	EFO	67322	EFO:0000304	\N	breast adenocarcinoma	EFO:0000304
0	"Tumors or cancer of the human BREAST." []	\N	breast carcinoma	\N	\N	EFO	"Tumors or cancer of the human BREAST." []	EFO	67323	EFO:0000305	\N	breast carcinoma	EFO:0000305
0	"" []	\N	breast tumor luminal	\N	\N	EFO	"" []	EFO	67324	EFO:0000306	\N	breast tumor luminal	EFO:0000306
0	"" []	\N	bronchial epithelium	\N	\N	EFO	"" []	EFO	67325	EFO:0000307	\N	bronchial epithelium	EFO:0000307
0	"A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion." []	\N	bronchoalveolar adenocarcinoma	\N	\N	EFO	"A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion." []	EFO	67326	EFO:0000308	\N	bronchoalveolar adenocarcinoma	EFO:0000308
0	"A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative." []	\N	Burkitts lymphoma	\N	\N	EFO	"A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative." []	EFO	67327	EFO:0000309	\N	Burkitts lymphoma	EFO:0000309
0	"A malignant neoplasm in which new abnormal tissue grow by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease." []	\N	cancer	\N	\N	EFO	"A malignant neoplasm in which new abnormal tissue grow by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease." []	EFO	67328	EFO:0000311	\N	cancer	EFO:0000311
0	"Location of cancer, primary or metastatic" []	\N	cancer site	\N	\N	EFO	"Location of cancer, primary or metastatic" []	EFO	67329	EFO:0000312	\N	cancer site	EFO:0000312
0	"A type of malignant cancer that arises from epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases." []	\N	carcinoma	\N	\N	EFO	"A type of malignant cancer that arises from epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases." []	EFO	67330	EFO:0000313	\N	carcinoma	EFO:0000313
0	"" []	\N	cardiac mesoderm primordium	\N	\N	EFO	"" []	EFO	67331	EFO:0000315	\N	cardiac mesoderm primordium	EFO:0000315
0	"A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS)." []	\N	cardiomyopathy	\N	\N	EFO	"A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS)." []	EFO	67332	EFO:0000318	\N	cardiomyopathy	EFO:0000318
0	"Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM." []	\N	cardiovascular disease	\N	\N	EFO	"Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM." []	EFO	67333	EFO:0000319	\N	cardiovascular disease	EFO:0000319
0	"A cell line is a population of cells cultured in vitro that are descended through one or more generations (and possible sub-cultures) from a single primary culture which was originally derived from part of an organism." []	\N	cell line	\N	\N	EFO	"A cell line is a population of cells cultured in vitro that are descended through one or more generations (and possible sub-cultures) from a single primary culture which was originally derived from part of an organism." []	EFO	67334	EFO:0000322	\N	cell line	EFO:0000322
0	"An attribute of a cell e.g. CD8+" []	\N	cell property	\N	\N	EFO	"An attribute of a cell e.g. CD8+" []	EFO	67335	EFO:0000323	\N	cell property	EFO:0000323
0	"A cell type is a distinct morphological or functional form of cell.  Examples are epithelial, glial etc." []	\N	cell type	\N	\N	EFO	"A cell type is a distinct morphological or functional form of cell.  Examples are epithelial, glial etc." []	EFO	67336	EFO:0000324	\N	cell type	EFO:0000324
0	"The act of alteration or modification of a cell e.g. RNAi" []	\N	cellular modification	\N	\N	EFO	"The act of alteration or modification of a cell e.g. RNAi" []	EFO	67337	EFO:0000325	\N	cellular modification	EFO:0000325
0	"Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas ( ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas ( OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle (MeSH)." []	\N	central nervous system cancer	\N	\N	EFO	"Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas ( ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas ( OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle (MeSH)." []	EFO	67338	EFO:0000326	\N	central nervous system cancer	EFO:0000326
0	"" []	\N	childhood acute myeloid leukemia	\N	\N	EFO	"" []	EFO	67339	EFO:0000330	\N	childhood acute myeloid leukemia	EFO:0000330
0	"A usually benign tumor composed of cells which arise from chondroblasts or their precursors and which tend to differentiate into cartilage cells. It occurs primarily in the epiphyses of adolescents. It is relatively rare and represents less than 2% of all primary bone tumors. The peak incidence is in the second decade of life; it is about twice as common in males as in females. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1846)" []	\N	chondroblastoma	\N	\N	EFO	"A usually benign tumor composed of cells which arise from chondroblasts or their precursors and which tend to differentiate into cartilage cells. It occurs primarily in the epiphyses of adolescents. It is relatively rare and represents less than 2% of all primary bone tumors. The peak incidence is in the second decade of life; it is about twice as common in males as in females. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1846)" []	EFO	67340	EFO:0000331	\N	chondroblastoma	EFO:0000331
0	"An uncommon benign neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain." []	\N	chondromyxoid fibroma	\N	\N	EFO	"An uncommon benign neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain." []	EFO	67341	EFO:0000332	\N	chondromyxoid fibroma	EFO:0000332
0	"A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)" []	\N	chondrosarcoma	\N	\N	EFO	"A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)" []	EFO	67342	EFO:0000333	\N	chondrosarcoma	EFO:0000333
0	"Chromophobe adenocarcinoma is a renal cell carcinoma described as the third most common type of renal cell carcinoma. The cancerous cells are similar with the clear cells, they appear pale when viewed under microscope, but there are larger and display different features than clear cells. This type of cancer rarely metastasizes, and the tumors can be successfully removed with surgery." []	\N	chromophobe renal cell carcinoma	\N	\N	EFO	"Chromophobe adenocarcinoma is a renal cell carcinoma described as the third most common type of renal cell carcinoma. The cancerous cells are similar with the clear cells, they appear pale when viewed under microscope, but there are larger and display different features than clear cells. This type of cancer rarely metastasizes, and the tumors can be successfully removed with surgery." []	EFO	67343	EFO:0000335	\N	chromophobe renal cell carcinoma	EFO:0000335
0	"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material." []	\N	chromosomal aberration	\N	\N	EFO	"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material." []	EFO	67344	EFO:0000336	\N	chromosomal aberration	EFO:0000336
0	"A stomach disease that is an inflammation of the lining of the stomach." []	\N	chronic gastritis	\N	\N	EFO	"A stomach disease that is an inflammation of the lining of the stomach." []	EFO	67345	EFO:0000337	\N	chronic gastritis	EFO:0000337
0	"Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS." []	\N	chronic myelogenous leukemia	\N	\N	EFO	"Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS." []	EFO	67346	EFO:0000339	\N	chronic myelogenous leukemia	EFO:0000339
0	"A group of disorders affecting the bronchi and the lung parenchyma. It is characterized by chronic and irreversible obstruction of the airflow. It includes chronic bronchitis and pulmonary emphysema." []	\N	chronic obstructive pulmonary disease	\N	\N	EFO	"A group of disorders affecting the bronchi and the lung parenchyma. It is characterized by chronic and irreversible obstruction of the airflow. It includes chronic bronchitis and pulmonary emphysema." []	EFO	67347	EFO:0000341	\N	chronic obstructive pulmonary disease	EFO:0000341
0	"INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse." []	\N	chronic pancreatitis	\N	\N	EFO	"INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse." []	EFO	67348	EFO:0000342	\N	chronic pancreatitis	EFO:0000342
0	"Primordium of the circular visceral muscle of the trunk. Becomes distinct from the rest of the trunk mesoderm by stage 11 when two distinct layers of trunk mesoderm are apparent, the inner of which is the circular visceral muscle primordium. By stage 12, these cells form a palisade consisting of a dorsal row an a ventral row of tightly packed cells. These cells adhere to the anterior and posterior midgut rudiments as they extend. During dorsal closure they spread out to encircle the midgut." []	\N	circular visceral mesoderm primordium	\N	\N	EFO	"Primordium of the circular visceral muscle of the trunk. Becomes distinct from the rest of the trunk mesoderm by stage 11 when two distinct layers of trunk mesoderm are apparent, the inner of which is the circular visceral muscle primordium. By stage 12, these cells form a palisade consisting of a dorsal row an a ventral row of tightly packed cells. These cells adhere to the anterior and posterior midgut rudiments as they extend. During dorsal closure they spread out to encircle the midgut." []	EFO	67349	EFO:0000344	\N	circular visceral mesoderm primordium	EFO:0000344
0	"" []	\N	circular visceral muscle fibers	\N	\N	EFO	"" []	EFO	67350	EFO:0000345	\N	circular visceral muscle fibers	EFO:0000345
0	"An extrapolation into the future of data into a class with specified label." []	\N	classifier prediction	\N	\N	EFO	"An extrapolation into the future of data into a class with specified label." []	EFO	67351	EFO:0000347	\N	classifier prediction	EFO:0000347
0	"An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)" []	\N	clear cell adenocarcinoma	\N	\N	EFO	"An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)" []	EFO	67352	EFO:0000348	\N	clear cell adenocarcinoma	EFO:0000348
0	"Clear cell carcinoma of kidney is a renal cell carcinoma described as the most common type of renal cell carcinoma. The cancerous cells appear very pale or clear when examined under microscope. This cancer can be effectively treated with surgery if the tumor is confined to the kidney." []	\N	clear cell renal carcinoma	\N	\N	EFO	"Clear cell carcinoma of kidney is a renal cell carcinoma described as the most common type of renal cell carcinoma. The cancerous cells appear very pale or clear when examined under microscope. This cancer can be effectively treated with surgery if the tumor is confined to the kidney." []	EFO	67353	EFO:0000349	\N	clear cell renal carcinoma	EFO:0000349
0	"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. This type of sarcoma frequently metastasizes to the bones." []	\N	clear cell sarcoma of the kidney	\N	\N	EFO	"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. This type of sarcoma frequently metastasizes to the bones." []	EFO	67354	EFO:0000350	\N	clear cell sarcoma of the kidney	EFO:0000350
0	"Is an information entity about the material's (i.e., the patient's) medical record as background information relevant to the experiment." []	\N	clinical history	\N	\N	EFO	"Is an information entity about the material's (i.e., the patient's) medical record as background information relevant to the experiment." []	EFO	67355	EFO:0000352	\N	clinical history	EFO:0000352
0	"A clinical treatment is a treatment of some organism designed to have some clinical effect, for example the treatment of a disease E.g. radiotherapy" []	\N	clinical treatment protocol	\N	\N	EFO	"A clinical treatment is a treatment of some organism designed to have some clinical effect, for example the treatment of a disease E.g. radiotherapy" []	EFO	67356	EFO:0000355	\N	clinical treatment protocol	EFO:0000355
0	"" []	\N	clypeo-labral primordium	\N	\N	EFO	"" []	EFO	67357	EFO:0000356	\N	clypeo-labral primordium	EFO:0000356
0	"An invasive adenocarcinoma of the colon characterized by the presence of pools of extracellular mucin.  Malignant glandular epithelial cells are present in the mucin collections.  Mucin constitutes more than 50% of the lesion." []	\N	colon mucinous adenocarcinoma	\N	\N	EFO	"An invasive adenocarcinoma of the colon characterized by the presence of pools of extracellular mucin.  Malignant glandular epithelial cells are present in the mucin collections.  Mucin constitutes more than 50% of the lesion." []	EFO	67358	EFO:0000364	\N	colon mucinous adenocarcinoma	EFO:0000364
0	"Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI." []	\N	colorectal adenocarcinoma	\N	\N	EFO	"Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI." []	EFO	67359	EFO:0000365	\N	colorectal adenocarcinoma	EFO:0000365
0	"A congenic strain in which the donor allele transferred to the host strain background is a minor histocompatibility gene." []	\N	minor histocompatibility congenic strain	\N	\N	EFO	"A congenic strain in which the donor allele transferred to the host strain background is a minor histocompatibility gene." []	EFO	67360	EFO:0000368	\N	minor histocompatibility congenic strain	EFO:0000368
0	"A treatment process in which a chemical compound is administered to the subject under investigation." []	\N	compound based treatment	\N	\N	EFO	"A treatment process in which a chemical compound is administered to the subject under investigation." []	EFO	67361	EFO:0000369	\N	compound based treatment	EFO:0000369
0	"A genetic modification introduced by treatment of an individual by chemical mutagenesis, e.g. by use of ENU" []	\N	chemically induced mutation	\N	\N	EFO	"A genetic modification introduced by treatment of an individual by chemical mutagenesis, e.g. by use of ENU" []	EFO	67362	EFO:0000370	\N	chemically induced mutation	EFO:0000370
0	"Heart failure involving the RIGHT VENTRICLE." []	\N	congestive heart failure	\N	\N	EFO	"Heart failure involving the RIGHT VENTRICLE." []	EFO	67363	EFO:0000373	\N	congestive heart failure	EFO:0000373
0	"An array design in which a reporter that could be hybridized to an exogenously added nucleic acid or protein (spike) before or during hybridization is used as a control for data processing." []	\N	array control spike calibration	\N	\N	EFO	"An array design in which a reporter that could be hybridized to an exogenously added nucleic acid or protein (spike) before or during hybridization is used as a control for data processing." []	EFO	67364	EFO:0000375	\N	array control spike calibration	EFO:0000375
0	"Thickening and loss of elasticity of the CORONARY ARTERIES, leading to progressive arterial insufficiency (CORONARY DISEASE)." []	\N	coronary artery disease	\N	\N	EFO	"Thickening and loss of elasticity of the CORONARY ARTERIES, leading to progressive arterial insufficiency (CORONARY DISEASE)." []	EFO	67365	EFO:0000378	\N	coronary artery disease	EFO:0000378
0	"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ." []	\N	corpus uteri	\N	\N	EFO	"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ." []	EFO	67366	EFO:0000382	\N	corpus uteri	EFO:0000382
0	"A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients." []	\N	Crohn's disease	\N	\N	EFO	"A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients." []	EFO	67367	EFO:0000384	\N	Crohn's disease	EFO:0000384
0	"" []	\N	crystal cell specific anlage	\N	\N	EFO	"" []	EFO	67368	EFO:0000386	\N	crystal cell specific anlage	EFO:0000386
0	"The measure of movement of electrical charges in a conductor measured in milliamperes." []	\N	electrical current	\N	\N	EFO	"The measure of movement of electrical charges in a conductor measured in milliamperes." []	EFO	67369	EFO:0000388	\N	electrical current	EFO:0000388
0	"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma." []	\N	cutaneous melanoma	\N	\N	EFO	"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma." []	EFO	67370	EFO:0000389	\N	cutaneous melanoma	EFO:0000389
0	"A measurement of physical damage, e.g. by a caterpillar on a plant leaf" []	\N	damage intensity	\N	\N	EFO	"A measurement of physical damage, e.g. by a caterpillar on a plant leaf" []	EFO	67371	EFO:0000391	\N	damage intensity	EFO:0000391
0	"" []	\N	Robertsonian translocation	\N	\N	EFO	"" []	EFO	67372	EFO:0000393	\N	Robertsonian translocation	EFO:0000393
0	"An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor." []	\N	dedifferentiated chondrosarcoma	\N	\N	EFO	"An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor." []	EFO	67373	EFO:0000394	\N	dedifferentiated chondrosarcoma	EFO:0000394
0	"A description of the method used to deliver e.g. a compound or solution for treatment." []	\N	delivery method	\N	\N	EFO	"A description of the method used to deliver e.g. a compound or solution for treatment." []	EFO	67374	EFO:0000395	\N	delivery method	EFO:0000395
0	"A dermal neurofibroma is a neurofibroma that occurs in situ of the skin." []	\N	dermal neurofibroma	\N	\N	EFO	"A dermal neurofibroma is a neurofibroma that occurs in situ of the skin." []	EFO	67375	EFO:0000397	\N	dermal neurofibroma	EFO:0000397
0	"A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)" []	\N	dermatomyositis	\N	\N	EFO	"A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)" []	EFO	67376	EFO:0000398	\N	dermatomyositis	EFO:0000398
0	"A developmental stage is spatiotemporal region encompassing some part of the life cycle of an organism, e.g. blastula stage" []	\N	developmental stage	\N	\N	EFO	"A developmental stage is spatiotemporal region encompassing some part of the life cycle of an organism, e.g. blastula stage" []	EFO	67377	EFO:0000399	\N	developmental stage	EFO:0000399
0	"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization." []	\N	diabetes mellitus	\N	\N	EFO	"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization." []	EFO	67378	EFO:0000400	\N	diabetes mellitus	EFO:0000400
0	"Diabetic nephropathy (sometimes called Kimmelstiel-Wilson syndrome) is a peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)" []	\N	diabetic nephropathy	\N	\N	EFO	"Diabetic nephropathy (sometimes called Kimmelstiel-Wilson syndrome) is a peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)" []	EFO	67379	EFO:0000401	\N	diabetic nephropathy	EFO:0000401
0	"An adenocarcinoma arising from the stomach.  Microscopically, it is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma.  Many cells contain mucin droplets, producing a signet-ring configuration." []	\N	diffuse gastric adenocarcinoma	\N	\N	EFO	"An adenocarcinoma arising from the stomach.  Microscopically, it is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma.  Many cells contain mucin droplets, producing a signet-ring configuration." []	EFO	67380	EFO:0000402	\N	diffuse gastric adenocarcinoma	EFO:0000402
0	"Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation." []	\N	diffuse large B-cell lymphoma	\N	\N	EFO	"Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation." []	EFO	67381	EFO:0000403	\N	diffuse large B-cell lymphoma	EFO:0000403
0	"A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability." []	\N	diffuse scleroderma	\N	\N	EFO	"A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability." []	EFO	67382	EFO:0000404	\N	diffuse scleroderma	EFO:0000404
0	"Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM." []	\N	digestive system disease	\N	\N	EFO	"Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM." []	EFO	67383	EFO:0000405	\N	digestive system disease	EFO:0000405
0	"decreased function of the heart associated with cardiac enlargement and congestive heart failure" []	\N	dilated cardiomyopathy	\N	\N	EFO	"decreased function of the heart associated with cardiac enlargement and congestive heart failure" []	EFO	67384	EFO:0000407	\N	dilated cardiomyopathy	EFO:0000407
0	"A disease is a disposition that describes states of disease associated with a particular sample and/or organism." []	\N	disease	\N	\N	EFO	"A disease is a disposition that describes states of disease associated with a particular sample and/or organism." []	EFO	67385	EFO:0000408	\N	disease	EFO:0000408
0	"A temporal measurement of the period after successful treatment in which there is no appearance of the symptoms or effects of the disease." []	\N	disease free survival	\N	\N	EFO	"A temporal measurement of the period after successful treatment in which there is no appearance of the symptoms or effects of the disease." []	EFO	67386	EFO:0000409	\N	disease free survival	EFO:0000409
0	"The stage or progression of a disease in an organism. Includes pathological staging of cancers and other disease progression. E.g. Dukes C stage describing colon cancer" []	\N	disease staging	\N	\N	EFO	"The stage or progression of a disease in an organism. Includes pathological staging of cancers and other disease progression. E.g. Dukes C stage describing colon cancer" []	EFO	67387	EFO:0000410	\N	disease staging	EFO:0000410
0	"Is a temporal measure from a defined start point e.g. diagnosis, or treatment of the period to appearance of a distant metastasis. A distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes. Also known as distant cancer." []	\N	distant metastasis free survival	\N	\N	EFO	"Is a temporal measure from a defined start point e.g. diagnosis, or treatment of the period to appearance of a distant metastasis. A distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes. Also known as distant cancer." []	EFO	67388	EFO:0000412	\N	distant metastasis free survival	EFO:0000412
0	"" []	\N	dorsal apodeme specific anlage	\N	\N	EFO	"" []	EFO	67389	EFO:0000413	\N	dorsal apodeme specific anlage	EFO:0000413
0	"" []	\N	dorsal ectoderm anlage in statu nascendi	\N	\N	EFO	"" []	EFO	67390	EFO:0000415	\N	dorsal ectoderm anlage in statu nascendi	EFO:0000415
0	"" []	\N	dorsal ectoderm primordium	\N	\N	EFO	"" []	EFO	67391	EFO:0000416	\N	dorsal ectoderm primordium	EFO:0000416
0	"" []	\N	dorsal epidermis primordium	\N	\N	EFO	"" []	EFO	67392	EFO:0000417	\N	dorsal epidermis primordium	EFO:0000417
0	"" []	\N	dorsal histoblast nest abdominal	\N	\N	EFO	"" []	EFO	67393	EFO:0000418	\N	dorsal histoblast nest abdominal	EFO:0000418
0	"" []	\N	dorsal imaginal precursor	\N	\N	EFO	"" []	EFO	67394	EFO:0000419	\N	dorsal imaginal precursor	EFO:0000419
0	"Dorsal imaginal disc of the metathorax. Precursor of structure of the adult dorsal metathorax including the haltere." []	\N	dorsal metathoracic disc	\N	\N	EFO	"Dorsal imaginal disc of the metathorax. Precursor of structure of the adult dorsal metathorax including the haltere." []	EFO	67395	EFO:0000421	\N	dorsal metathoracic disc	EFO:0000421
0	"" []	\N	dorsal pharyngeal muscle primordium	\N	\N	EFO	"" []	EFO	67396	EFO:0000422	\N	dorsal pharyngeal muscle primordium	EFO:0000422
0	"" []	\N	dorsal prothoracic pharyngeal muscle	\N	\N	EFO	"" []	EFO	67397	EFO:0000423	\N	dorsal prothoracic pharyngeal muscle	EFO:0000423
0	"" []	\N	dorsal ridge	\N	\N	EFO	"" []	EFO	67398	EFO:0000424	\N	dorsal ridge	EFO:0000424
0	"" []	\N	dorsal trunk specific anlage	\N	\N	EFO	"" []	EFO	67399	EFO:0000426	\N	dorsal trunk specific anlage	EFO:0000426
0	"" []	\N	dorsomedial neurosecretory cell	\N	\N	EFO	"" []	EFO	67400	EFO:0000427	\N	dorsomedial neurosecretory cell	EFO:0000427
0	"The total quantity or strength of a substance administered at one time." []	\N	dose	\N	\N	EFO	"The total quantity or strength of a substance administered at one time." []	EFO	67401	EFO:0000428	\N	dose	EFO:0000428
0	"A carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast.  Ductal carcinomas account for about two thirds of all breast cancers.  Two types of ductal carcinomas have been described: Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma, not otherwise specified.  The latter often spreads to the axillary lymph nodes and other anatomic sites.  The two forms of ductal carcinoma often coexist." []	\N	ductal adenocarcinoma	\N	\N	EFO	"A carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast.  Ductal carcinomas account for about two thirds of all breast cancers.  Two types of ductal carcinomas have been described: Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma, not otherwise specified.  The latter often spreads to the axillary lymph nodes and other anatomic sites.  The two forms of ductal carcinoma often coexist." []	EFO	67402	EFO:0000430	\N	ductal adenocarcinoma	EFO:0000430
0	"DOID:8791" []	\N	ductal carcinoma in situ	\N	\N	EFO	"DOID:8791" []	EFO	67403	EFO:0000432	\N	ductal carcinoma in situ	EFO:0000432
0	"A temporal measurement of the time between two specified points." []	\N	duration	\N	\N	EFO	"A temporal measurement of the time between two specified points." []	EFO	67404	EFO:0000433	\N	duration	EFO:0000433
0	"A biotype resulting from selection in a particular habitat, e.g. the A. thaliana Ecotype Ler" []	\N	ecotype	\N	\N	EFO	"A biotype resulting from selection in a particular habitat, e.g. the A. thaliana Ecotype Ler" []	EFO	67405	EFO:0000434	\N	ecotype	EFO:0000434
0	"" []	\N	ectoderm anlage in statu nascendi	\N	\N	EFO	"" []	EFO	67406	EFO:0000435	\N	ectoderm anlage in statu nascendi	EFO:0000435
0	"The early developmental stage that, through embryological development, ultimately becomes an adult individual. In plants, that portion of a seed that will form the growing seedling following germination; it has a radicle, apical meristem, and embryonic leaf or leaves." []	\N	plant embryo	\N	\N	EFO	"The early developmental stage that, through embryological development, ultimately becomes an adult individual. In plants, that portion of a seed that will form the growing seedling following germination; it has a radicle, apical meristem, and embryonic leaf or leaves." []	EFO	67407	EFO:0000436	\N	plant embryo	EFO:0000436
0	"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.  There are three histologic types, spindle cell, botryoid and anaplastic." []	\N	embryonal rhabdomyosarcoma	\N	\N	EFO	"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.  There are three histologic types, spindle cell, botryoid and anaplastic." []	EFO	67408	EFO:0000437	\N	embryonal rhabdomyosarcoma	EFO:0000437
0	"" []	\N	embryonic anal pad	\N	\N	EFO	"" []	EFO	67409	EFO:0000438	\N	embryonic anal pad	EFO:0000438
0	"" []	\N	embryonic antennal sense organ	\N	\N	EFO	"" []	EFO	67410	EFO:0000439	\N	embryonic antennal sense organ	EFO:0000439
0	"Brain of the embryo." []	\N	embryonic brain	\N	\N	EFO	"Brain of the embryo." []	EFO	67411	EFO:0000440	\N	embryonic brain	EFO:0000440
0	"" []	\N	embryonic central brain	\N	\N	EFO	"" []	EFO	67412	EFO:0000441	\N	embryonic central brain	EFO:0000441
0	"" []	\N	embryonic central brain glia	\N	\N	EFO	"" []	EFO	67413	EFO:0000442	\N	embryonic central brain glia	EFO:0000442
0	"The development of the mushroom body proceeds as follows: Axonogenesis of embryonic Kenyon cells starts late in embryonic stage 14. The axons from these cells extend towards the lateral proto-cerebral tract (LTP). During stage 16, a second set of kenyon cell fibres form a second tract, closely apposed to the first.  By late stage 16, both tracts extend anteriorly beyond the LTP to form the distal part of the peduncle. These tracts make a sharp medial turn close to the boundary with the deutocerebrum to form the medial lobe. By late stage 17 the dorsal lobe has emerged as a collateral outgrowth from the point where these tracts bend. Finally, the calyx forms near to the end of embryogenesis." []	\N	embryonic central brain mushroom body	\N	\N	EFO	"The development of the mushroom body proceeds as follows: Axonogenesis of embryonic Kenyon cells starts late in embryonic stage 14. The axons from these cells extend towards the lateral proto-cerebral tract (LTP). During stage 16, a second set of kenyon cell fibres form a second tract, closely apposed to the first.  By late stage 16, both tracts extend anteriorly beyond the LTP to form the distal part of the peduncle. These tracts make a sharp medial turn close to the boundary with the deutocerebrum to form the medial lobe. By late stage 17 the dorsal lobe has emerged as a collateral outgrowth from the point where these tracts bend. Finally, the calyx forms near to the end of embryogenesis." []	EFO	67414	EFO:0000443	\N	embryonic central brain mushroom body	EFO:0000443
0	"" []	\N	embryonic central brain neuron	\N	\N	EFO	"" []	EFO	67415	EFO:0000444	\N	embryonic central brain neuron	EFO:0000444
0	"" []	\N	embryonic central brain pars intercerebralis	\N	\N	EFO	"" []	EFO	67416	EFO:0000445	\N	embryonic central brain pars intercerebralis	EFO:0000445
0	"" []	\N	embryonic central brain surface glia	\N	\N	EFO	"" []	EFO	67417	EFO:0000446	\N	embryonic central brain surface glia	EFO:0000446
0	"" []	\N	embryonic central nervous system	\N	\N	EFO	"" []	EFO	67418	EFO:0000447	\N	embryonic central nervous system	EFO:0000447
0	"A component of the embryonic/larval ring gland composed of a cluster of about 10 cells that sit medially on top of the aorta." []	\N	embryonic corpus allatum	\N	\N	EFO	"A component of the embryonic/larval ring gland composed of a cluster of about 10 cells that sit medially on top of the aorta." []	EFO	67419	EFO:0000448	\N	embryonic corpus allatum	EFO:0000448
0	"The corpora cardiaca precursor first appear during stage 10 as two pairs of head mesoderm cells between the roof of the stomodeum and the inner surface of the brain primordium. Between stages 11 and 15, these cells migrate posteriorly, gradually increasing in number. During stage 15, they fuse with the precursors of the corpus allatum from the gnathal mesoderm to form the ring gland." []	\N	embryonic corpus cardiacum	\N	\N	EFO	"The corpora cardiaca precursor first appear during stage 10 as two pairs of head mesoderm cells between the roof of the stomodeum and the inner surface of the brain primordium. Between stages 11 and 15, these cells migrate posteriorly, gradually increasing in number. During stage 15, they fuse with the precursors of the corpus allatum from the gnathal mesoderm to form the ring gland." []	EFO	67420	EFO:0000449	\N	embryonic corpus cardiacum	EFO:0000449
0	"" []	\N	embryonic cuprophilic cell	\N	\N	EFO	"" []	EFO	67421	EFO:0000450	\N	embryonic cuprophilic cell	EFO:0000450
0	"" []	\N	embryonic dorsal apodeme	\N	\N	EFO	"" []	EFO	67422	EFO:0000451	\N	embryonic dorsal apodeme	EFO:0000451
0	"" []	\N	embryonic dorsal epidermis	\N	\N	EFO	"" []	EFO	67423	EFO:0000452	\N	embryonic dorsal epidermis	EFO:0000452
0	"" []	\N	embryonic epipharynx	\N	\N	EFO	"" []	EFO	67424	EFO:0000453	\N	embryonic epipharynx	EFO:0000453
0	"" []	\N	embryonic esophageal ganglion	\N	\N	EFO	"" []	EFO	67425	EFO:0000454	\N	embryonic esophageal ganglion	EFO:0000454
0	"" []	\N	embryonic esophagus	\N	\N	EFO	"" []	EFO	67426	EFO:0000455	\N	embryonic esophagus	EFO:0000455
0	"" []	\N	embryonic foregut	\N	\N	EFO	"" []	EFO	67427	EFO:0000456	\N	embryonic foregut	EFO:0000456
0	"" []	\N	embryonic foregut sensory structure	\N	\N	EFO	"" []	EFO	67428	EFO:0000457	\N	embryonic foregut sensory structure	EFO:0000457
0	"" []	\N	embryonic frontal ganglion	\N	\N	EFO	"" []	EFO	67429	EFO:0000458	\N	embryonic frontal ganglion	EFO:0000458
0	"Any ganglion mother cell (FBbt:00005149) that is part of some embryo (FBbt:00000052)." []	\N	embryonic ganglion mother cell	\N	\N	EFO	"Any ganglion mother cell (FBbt:00005149) that is part of some embryo (FBbt:00000052)." []	EFO	67430	EFO:0000459	\N	embryonic ganglion mother cell	EFO:0000459
0	"Primordium of the gastric caecum of the larva. There are four of these per midgut. They first become apparent as evaginations at the anterior end of the fused midgut primordium during stage 16." []	\N	embryonic gastric caecum	\N	\N	EFO	"Primordium of the gastric caecum of the larva. There are four of these per midgut. They first become apparent as evaginations at the anterior end of the fused midgut primordium during stage 16." []	EFO	67431	EFO:0000460	\N	embryonic gastric caecum	EFO:0000460
0	"A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing." []	\N	emphysema	\N	\N	EFO	"A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing." []	EFO	67432	EFO:0000464	\N	emphysema	EFO:0000464
0	"Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening." []	\N	endocarditis	\N	\N	EFO	"Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening." []	EFO	67433	EFO:0000465	\N	endocarditis	EFO:0000465
0	"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament." []	\N	endometrioid carcinoma	\N	\N	EFO	"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament." []	EFO	67434	EFO:0000466	\N	endometrioid carcinoma	EFO:0000466
0	"The external elements and conditions which surround, influence, and affect the life and development of an organism or population." []	\N	environmental factor	\N	\N	EFO	"The external elements and conditions which surround, influence, and affect the life and development of an organism or population." []	EFO	67435	EFO:0000469	\N	environmental factor	EFO:0000469
0	"Environmental stress is a treatment where some aspect of the environment is perturbed in order to stress the organism or culture, e.g. change in temperature, change in watering regime" []	\N	environmental stress	\N	\N	EFO	"Environmental stress is a treatment where some aspect of the environment is perturbed in order to stress the organism or culture, e.g. change in temperature, change in watering regime" []	EFO	67436	EFO:0000470	\N	environmental stress	EFO:0000470
0	"" []	\N	epigenetic factor	\N	\N	EFO	"" []	EFO	67437	EFO:0000472	\N	epigenetic factor	EFO:0000472
0	"Epigenetic status describes the imprinting state of a sample. E.g. Loss of imprinting occurs in some tumour cells" []	\N	epigenetic status	\N	\N	EFO	"Epigenetic status describes the imprinting state of a sample. E.g. Loss of imprinting occurs in some tumour cells" []	EFO	67438	EFO:0000473	\N	epigenetic status	EFO:0000473
0	"A disorder characterized by recurrent seizures" []	\N	epilepsy	\N	\N	EFO	"A disorder characterized by recurrent seizures" []	EFO	67439	EFO:0000474	\N	epilepsy	EFO:0000474
0	"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor." []	\N	esophageal adenocarcinoma	\N	\N	EFO	"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor." []	EFO	67440	EFO:0000478	\N	esophageal adenocarcinoma	EFO:0000478
0	"A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets." []	\N	essential thrombocythemia	\N	\N	EFO	"A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets." []	EFO	67441	EFO:0000479	\N	essential thrombocythemia	EFO:0000479
0	"An event that has caused the permanent cessation of all vital functions; the end of life. Can be applied to a whole organism or to a part of an organism." []	\N	event death	\N	\N	EFO	"An event that has caused the permanent cessation of all vital functions; the end of life. Can be applied to a whole organism or to a part of an organism." []	EFO	67442	EFO:0000480	\N	event death	EFO:0000480
0	"Is the survival of a subject (or group of subjects) measured from the date of diagnosis until  locoregional or systemic recurrence,  second malignancy, or death from any cause or disease progression or relapse, institution of new unplanned anticancer treatment, or death from any cause." []	\N	event free survival time	\N	\N	EFO	"Is the survival of a subject (or group of subjects) measured from the date of diagnosis until  locoregional or systemic recurrence,  second malignancy, or death from any cause or disease progression or relapse, institution of new unplanned anticancer treatment, or death from any cause." []	EFO	67443	EFO:0000482	\N	event free survival time	EFO:0000482
0	"Activity that requires physical or mental exertion, especially when performed to develop or maintain fitness." []	\N	exercise	\N	\N	EFO	"Activity that requires physical or mental exertion, especially when performed to develop or maintain fitness." []	EFO	67444	EFO:0000483	\N	exercise	EFO:0000483
0	"The act of subjecting someone or something to an influencing experience. E.g. exposure to cigarette smoke" []	\N	exposure	\N	\N	EFO	"The act of subjecting someone or something to an influencing experience. E.g. exposure to cigarette smoke" []	EFO	67445	EFO:0000487	\N	exposure	EFO:0000487
0	"Use of spiked in controls in a measurement of the spiked in external/internal ratio" []	\N	external control ratio	\N	\N	EFO	"Use of spiked in controls in a measurement of the spiked in external/internal ratio" []	EFO	67446	EFO:0000488	\N	external control ratio	EFO:0000488
0	"A benign or malignant sympathetic paraganglioma arising from paraganglia outside the adrenal gland.  Clinical symptoms are related to secretion of catecholamines.  Representative examples include the superior and inferior paraaortic and bladder paragangliomas." []	\N	extra-adrenal sympathetic paraganglioma	\N	\N	EFO	"A benign or malignant sympathetic paraganglioma arising from paraganglia outside the adrenal gland.  Clinical symptoms are related to secretion of catecholamines.  Representative examples include the superior and inferior paraaortic and bladder paragangliomas." []	EFO	67447	EFO:0000489	\N	extra-adrenal sympathetic paraganglioma	EFO:0000489
0	"The procedure used to obtain something from a mixture or compound by chemical or physical or mechanical means, e.g. DNA/RNA extraction" []	\N	extraction protocol	\N	\N	EFO	"The procedure used to obtain something from a mixture or compound by chemical or physical or mechanical means, e.g. DNA/RNA extraction" []	EFO	67448	EFO:0000490	\N	extraction protocol	EFO:0000490
0	"Family history is a form of clinicaly history specifically about relevant aspects of genetic preconditions or family member's clinical history." []	\N	family history	\N	\N	EFO	"Family history is a form of clinicaly history specifically about relevant aspects of genetic preconditions or family member's clinical history." []	EFO	67449	EFO:0000493	\N	family history	EFO:0000493
0	"The process of obtaining quantifiable values from the scanned image of the array. Exact synonyms: image analysis, image quantification" []	\N	feature extraction	\N	\N	EFO	"The process of obtaining quantifiable values from the scanned image of the array. Exact synonyms: image analysis, image quantification" []	EFO	67450	EFO:0000494	\N	feature extraction	EFO:0000494
0	"" []	\N	fetal growth restriction	\N	\N	EFO	"" []	EFO	67451	EFO:0000495	\N	fetal growth restriction	EFO:0000495
0	"A poorly circumscribed neoplasm arising from the soft tissues. It is characterized by the presence of spindle-shaped fibroblasts and an infiltrative growth pattern." []	\N	fibromatosis	\N	\N	EFO	"A poorly circumscribed neoplasm arising from the soft tissues. It is characterized by the presence of spindle-shaped fibroblasts and an infiltrative growth pattern." []	EFO	67452	EFO:0000497	\N	fibromatosis	EFO:0000497
0	"A benign epithelial tumor with a glandular organization." []	\N	follicular thyroid adenoma	\N	\N	EFO	"A benign epithelial tumor with a glandular organization." []	EFO	67453	EFO:0000499	\N	follicular thyroid adenoma	EFO:0000499
0	"A benign neuroblastic tumor of the sympathetic nervous system that occurs in childhood. Ganglioneuroma typically arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. Common presenting features include a palpable abdominal mass, hepatomegaly, and a thoracic mass detected on routine chest X-ray." []	\N	ganglioneuroma	\N	\N	EFO	"A benign neuroblastic tumor of the sympathetic nervous system that occurs in childhood. Ganglioneuroma typically arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. Common presenting features include a palpable abdominal mass, hepatomegaly, and a thoracic mass detected on routine chest X-ray." []	EFO	67454	EFO:0000500	\N	ganglioneuroma	EFO:0000500
0	"An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)" []	\N	follicular thyroid carcinoma	\N	\N	EFO	"An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)" []	EFO	67455	EFO:0000501	\N	follicular thyroid carcinoma	EFO:0000501
0	"A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular." []	\N	ganglioneuroblastoma	\N	\N	EFO	"A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular." []	EFO	67456	EFO:0000502	\N	ganglioneuroblastoma	EFO:0000502
0	"curative" []	\N	gastric adenocarcinoma	\N	\N	EFO	"curative" []	EFO	67457	EFO:0000503	\N	gastric adenocarcinoma	EFO:0000503
0	"An adenocarcinoma of the stomach arising on a background of intestinal metaplasia.  Microscopically, it is characterized by a glandular pattern and it closely resembles a colonic adenocarcinoma.  Grossly, it tends to be nodular, polypoid or ulcerated." []	\N	gastric intestinal type adenocarcinoma	\N	\N	EFO	"An adenocarcinoma of the stomach arising on a background of intestinal metaplasia.  Microscopically, it is characterized by a glandular pattern and it closely resembles a colonic adenocarcinoma.  Grossly, it tends to be nodular, polypoid or ulcerated." []	EFO	67458	EFO:0000504	\N	gastric intestinal type adenocarcinoma	EFO:0000504
0	"" []	\N	gene knock out	\N	\N	EFO	"" []	EFO	67459	EFO:0000506	\N	gene knock out	EFO:0000506
0	"The number of cell passages if the organism or organism part that is cultured is unicellular or a cell culture; otherwise the number of generations." []	\N	generation	\N	\N	EFO	"The number of cell passages if the organism or organism part that is cultured is unicellular or a cell culture; otherwise the number of generations." []	EFO	67460	EFO:0000507	\N	generation	EFO:0000507
0	"A genetic disorder is a disorder in which an abnormality, i.e. mutation, of a gene or gene has occurred resulting in a diseased state. Note, this not imply that the disorder is hereditary since genetic mutations can occur during life time and are not always directly inherited or presented in parents (although they can be)." []	\N	genetic disorder	\N	\N	EFO	"A genetic disorder is a disorder in which an abnormality, i.e. mutation, of a gene or gene has occurred resulting in a diseased state. Note, this not imply that the disorder is hereditary since genetic mutations can occur during life time and are not always directly inherited or presented in parents (although they can be)." []	EFO	67461	EFO:0000508	\N	genetic disorder	EFO:0000508
0	"A genetic modification of the genome of  an organism which may occur naturally by spontaneous mutation, or be introduced by some experimental means. Examples of genetic modification include specification of a transgene or the gene knocked-out or details of transient transfection." []	\N	genetic modification	\N	\N	EFO	"A genetic modification of the genome of  an organism which may occur naturally by spontaneous mutation, or be introduced by some experimental means. Examples of genetic modification include specification of a transgene or the gene knocked-out or details of transient transfection." []	EFO	67462	EFO:0000510	\N	genetic modification	EFO:0000510
0	"Genetic traits are small inherited parts of the phenotype of an organism" []	\N	genetic trait	\N	\N	EFO	"Genetic traits are small inherited parts of the phenotype of an organism" []	EFO	67463	EFO:0000511	\N	genetic trait	EFO:0000511
0	"" []	\N	reproductive system disease	\N	\N	EFO	"" []	EFO	67464	EFO:0000512	\N	reproductive system disease	EFO:0000512
0	"The total sum of the genetic information of an organism that is known and relevant to the experiment being performed, including chromosomal, plasmid, viral or other genetic material which has been introduced into the organism either prior to or during the experiment." []	\N	genotype	\N	\N	EFO	"The total sum of the genetic information of an organism that is known and relevant to the experiment being performed, including chromosomal, plasmid, viral or other genetic material which has been introduced into the organism either prior to or during the experiment." []	EFO	67465	EFO:0000513	\N	genotype	EFO:0000513
0	"Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS." []	\N	germ cell tumor	\N	\N	EFO	"Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS." []	EFO	67466	EFO:0000514	\N	germ cell tumor	EFO:0000514
0	"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor." []	\N	glaucoma	\N	\N	EFO	"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor." []	EFO	67467	EFO:0000516	\N	glaucoma	EFO:0000516
0	"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)" []	\N	glioblastoma multiforme	\N	\N	EFO	"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)" []	EFO	67468	EFO:0000519	\N	glioblastoma multiforme	EFO:0000519
0	"A role that a material entity can play which enables particular conditions used to grow organisms or parts of the organism. This includes isolated environments such as cultures and open environments such as field studies." []	\N	growth condition	\N	\N	EFO	"A role that a material entity can play which enables particular conditions used to grow organisms or parts of the organism. This includes isolated environments such as cultures and open environments such as field studies." []	EFO	67469	EFO:0000523	\N	growth condition	EFO:0000523
0	"The name of the pathology diagnosed in the organism from which the biomaterial was derived. The disease state is normal if no disease has been diagnosed.  E.g Acute Lymphocytic Leukemia" []	\N	head disease	\N	\N	EFO	"The name of the pathology diagnosed in the organism from which the biomaterial was derived. The disease state is normal if no disease has been diagnosed.  E.g Acute Lymphocytic Leukemia" []	EFO	67470	EFO:0000524	\N	head disease	EFO:0000524
0	"A part of the brain consisting of a three layered cortex located in the forebrain bordering the medial surface of the lateral ventricle. The term hippocampus is often used synonymously with hippocampal formation which consists of the hippocampus proper or Cornu Ammonis, the dentate gyrus and the subiculum." []	\N	hippocampus	\N	\N	EFO	"A part of the brain consisting of a three layered cortex located in the forebrain bordering the medial surface of the lateral ventricle. The term hippocampus is often used synonymously with hippocampal formation which consists of the hippocampus proper or Cornu Ammonis, the dentate gyrus and the subiculum." []	EFO	67471	EFO:0000530	\N	hippocampus	EFO:0000530
0	"An animal or plant or part thereof that nourishes and supports a parasite either in a lab or natural environment." []	\N	host	\N	\N	EFO	"An animal or plant or part thereof that nourishes and supports a parasite either in a lab or natural environment." []	EFO	67472	EFO:0000532	\N	host	EFO:0000532
0	"The pressure exerted by a liquid as a result of its potential energy, ignoring its kinetic energy." []	\N	hydrostatic pressure	\N	\N	EFO	"The pressure exerted by a liquid as a result of its potential energy, ignoring its kinetic energy." []	EFO	67473	EFO:0000534	\N	hydrostatic pressure	EFO:0000534
0	"Abnormally high BLOOD GLUCOSE level." []	\N	hyperglycemia	\N	\N	EFO	"Abnormally high BLOOD GLUCOSE level." []	EFO	67474	EFO:0000535	\N	hyperglycemia	EFO:0000535
0	"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement." []	\N	hyperplasia	\N	\N	EFO	"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement." []	EFO	67475	EFO:0000536	\N	hyperplasia	EFO:0000536
0	"Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more." []	\N	hypertension	\N	\N	EFO	"Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more." []	EFO	67476	EFO:0000537	\N	hypertension	EFO:0000537
0	"A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY)." []	\N	hypertrophic cardiomyopathy	\N	\N	EFO	"A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY)." []	EFO	67477	EFO:0000538	\N	hypertrophic cardiomyopathy	EFO:0000538
0	"A group of non-neoplastic and neoplastic disorders resulting from the deregulation and/or deficiency of immune system functions.  It includes autoimmune disorders (e.g., lupus erythematosus, dermatomyositis, rheumatoid arthritis), congenital and acquired immunodeficiency syndromes including the acquired immune deficiency syndrome (AIDS), and neoplasms (e.g., lymphomas and malignancies secondary to transplantation.)" []	\N	immune system disease	\N	\N	EFO	"A group of non-neoplastic and neoplastic disorders resulting from the deregulation and/or deficiency of immune system functions.  It includes autoimmune disorders (e.g., lupus erythematosus, dermatomyositis, rheumatoid arthritis), congenital and acquired immunodeficiency syndromes including the acquired immune deficiency syndrome (AIDS), and neoplasms (e.g., lymphomas and malignancies secondary to transplantation.)" []	EFO	67478	EFO:0000540	\N	immune system disease	EFO:0000540
0	"The precipitate antibody bound target molecules generated when precipitating an antigen out of a solution during the process of immunoprecipitation." []	\N	immunoprecipitate	\N	\N	EFO	"The precipitate antibody bound target molecules generated when precipitating an antigen out of a solution during the process of immunoprecipitation." []	EFO	67479	EFO:0000541	\N	immunoprecipitate	EFO:0000541
0	"An individual used a specimen in an experiment, from which a material sample was derived." []	\N	individual	\N	\N	EFO	"An individual used a specimen in an experiment, from which a material sample was derived." []	EFO	67480	EFO:0000542	\N	individual	EFO:0000542
0	"The state of being infected such as from the introduction of a foreign agent such as serum, vaccine, antigenic substance or organism." []	\N	infection	\N	\N	EFO	"The state of being infected such as from the introduction of a foreign agent such as serum, vaccine, antigenic substance or organism." []	EFO	67481	EFO:0000544	\N	infection	EFO:0000544
0	"Inability to reproduce after a specified period of unprotected intercourse. Reproductive sterility is permanent infertility." []	\N	infertility	\N	\N	EFO	"Inability to reproduce after a specified period of unprotected intercourse. Reproductive sterility is permanent infertility." []	EFO	67482	EFO:0000545	\N	infertility	EFO:0000545
0	"Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity." []	\N	injury	\N	\N	EFO	"Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity." []	EFO	67483	EFO:0000546	\N	injury	EFO:0000546
0	"An instrument is a device which provides a mechanical or electronic function." []	\N	instrument	\N	\N	EFO	"An instrument is a device which provides a mechanical or electronic function." []	EFO	67484	EFO:0000548	\N	instrument	EFO:0000548
0	"A usually benign, well circumscribed neoplasm arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin." []	\N	insulinoma	\N	\N	EFO	"A usually benign, well circumscribed neoplasm arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin." []	EFO	67485	EFO:0000549	\N	insulinoma	EFO:0000549
0	"Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces." []	\N	intracranial hemorrhage NOS	\N	\N	EFO	"Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces." []	EFO	67486	EFO:0000551	\N	intracranial hemorrhage NOS	EFO:0000551
0	"An invasive ductal breast carcinoma associated with a lobular carcinomatous component. The lobular carcinomatous component may be in situ or invasive." []	\N	invasive ductal and lobular carcinoma	\N	\N	EFO	"An invasive ductal breast carcinoma associated with a lobular carcinomatous component. The lobular carcinomatous component may be in situ or invasive." []	EFO	67487	EFO:0000552	\N	invasive ductal and lobular carcinoma	EFO:0000552
0	"An infiltrating lobular adenocarcinoma.  The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma.  The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures." []	\N	invasive lobular carcinoma	\N	\N	EFO	"An infiltrating lobular adenocarcinoma.  The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma.  The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures." []	EFO	67488	EFO:0000553	\N	invasive lobular carcinoma	EFO:0000553
0	"The process of treating a material with radiation" []	\N	irradiate	\N	\N	EFO	"The process of treating a material with radiation" []	EFO	67489	EFO:0000554	\N	irradiate	EFO:0000554
0	"A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause." []	\N	irritable bowel syndrome	\N	\N	EFO	"A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause." []	EFO	67490	EFO:0000555	\N	irritable bowel syndrome	EFO:0000555
0	"A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION." []	\N	ischemia	\N	\N	EFO	"A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION." []	EFO	67491	EFO:0000556	\N	ischemia	EFO:0000556
0	"A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)" []	\N	juvenile dermatomyositis	\N	\N	EFO	"A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)" []	EFO	67492	EFO:0000557	\N	juvenile dermatomyositis	EFO:0000557
0	"A sarcoma that is caused by human herpesvirus 8 (HHV8), which is also called Kaposi's sarcoma-associated herpesvirus (KSHV)." []	\N	Kaposi's sarcoma	\N	\N	EFO	"A sarcoma that is caused by human herpesvirus 8 (HHV8), which is also called Kaposi's sarcoma-associated herpesvirus (KSHV)." []	EFO	67493	EFO:0000558	\N	Kaposi's sarcoma	EFO:0000558
0	"Squamous cell carcinomas with morphologically prominent production of keratin." []	\N	keratinizing squamous cell carcinoma	\N	\N	EFO	"Squamous cell carcinomas with morphologically prominent production of keratin." []	EFO	67494	EFO:0000559	\N	keratinizing squamous cell carcinoma	EFO:0000559
0	"Knock in expression is a process in which a gene is replaced by an altered version of the same gene using homologous recombination resulting in a gain of function." []	\N	knock in expression	\N	\N	EFO	"Knock in expression is a process in which a gene is replaced by an altered version of the same gene using homologous recombination resulting in a gain of function." []	EFO	67495	EFO:0000561	\N	knock in expression	EFO:0000561
0	"The process of marking a material in some way for experimental purposes. E.g. the labelling of  a nucleic acid with biotin in a microarray experiment" []	\N	labelling	\N	\N	EFO	"The process of marking a material in some way for experimental purposes. E.g. the labelling of  a nucleic acid with biotin in a microarray experiment" []	EFO	67496	EFO:0000562	\N	labelling	EFO:0000562
0	"A usually aggressive carcinoma composed of large malignant cells which display neuroendocrine characteristics. It is characterized by the presence of high mitotic activity and necrotic changes. The vast majority of cases are positive for neuron-specific enolase. Representative examples include lung, breast, cervical, and thymic neuroendocrine carcinomas." []	\N	large cell neuroendocrine carcinoma	\N	\N	EFO	"A usually aggressive carcinoma composed of large malignant cells which display neuroendocrine characteristics. It is characterized by the presence of high mitotic activity and necrotic changes. The vast majority of cases are positive for neuron-specific enolase. Representative examples include lung, breast, cervical, and thymic neuroendocrine carcinomas." []	EFO	67497	EFO:0000563	\N	large cell neuroendocrine carcinoma	EFO:0000563
0	"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas." []	\N	leiomyosarcoma	\N	\N	EFO	"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas." []	EFO	67498	EFO:0000564	\N	leiomyosarcoma	EFO:0000564
0	"A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)" []	\N	leukemia	\N	\N	EFO	"A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)" []	EFO	67499	EFO:0000565	\N	leukemia	EFO:0000565
0	"The photoperiod and type (e.g., natural, restricted wavelength) of light exposure." []	\N	light	\N	\N	EFO	"The photoperiod and type (e.g., natural, restricted wavelength) of light exposure." []	EFO	67500	EFO:0000568	\N	light	EFO:0000568
0	"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors." []	\N	liposarcoma	\N	\N	EFO	"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors." []	EFO	67501	EFO:0000569	\N	liposarcoma	EFO:0000569
0	"A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor." []	\N	lung adenocarcinoma	\N	\N	EFO	"A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor." []	EFO	67502	EFO:0000571	\N	lung adenocarcinoma	EFO:0000571
0	"Often referred to as a blast cell. Unlike other usages of the suffix -blast a lymphoblast is a further differentiation of a lymphocyte, T- or B-, occasioned by an antigenic stimulus. The lymphoblast usually develops by enlargement of a lymphocyte, active re-entry to the S phase of the cell cycle, mitogenesis and production of much m-RNA and ribosomes." []	\N	lymphoblast	\N	\N	EFO	"Often referred to as a blast cell. Unlike other usages of the suffix -blast a lymphoblast is a further differentiation of a lymphocyte, T- or B-, occasioned by an antigenic stimulus. The lymphoblast usually develops by enlargement of a lymphocyte, active re-entry to the S phase of the cell cycle, mitogenesis and production of much m-RNA and ribosomes." []	EFO	67503	EFO:0000572	\N	lymphoblast	EFO:0000572
0	"Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease." []	\N	lymphoma	\N	\N	EFO	"Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease." []	EFO	67504	EFO:0000574	\N	lymphoma	EFO:0000574
0	"The physical state or matrix used to provide nutrients to the organism (e.g., liquid, agar, soil)." []	\N	media	\N	\N	EFO	"The physical state or matrix used to provide nutrients to the organism (e.g., liquid, agar, soil)." []	EFO	67505	EFO:0000579	\N	media	EFO:0000579
0	"An infiltrating breast carcinoma with a relatively favorable prognosis.  It is an uncommon carcinoma, accounting for fewer than 1% of all infiltrating breast carcinomas.  It is well circumscribed, with soft cut surface and often of considerable size.  Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells.  The malignant cells are round with abundant cytoplasm and vesicular nuclei.  The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate.  Glandular or tubular structures are absent." []	\N	medullary breast carcinoma	\N	\N	EFO	"An infiltrating breast carcinoma with a relatively favorable prognosis.  It is an uncommon carcinoma, accounting for fewer than 1% of all infiltrating breast carcinomas.  It is well circumscribed, with soft cut surface and often of considerable size.  Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells.  The malignant cells are round with abundant cytoplasm and vesicular nuclei.  The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate.  Glandular or tubular structures are absent." []	EFO	67506	EFO:0000580	\N	medullary breast carcinoma	EFO:0000580
0	"Meningitis is a nervous system infectious disease characterized as an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells. Meningitis is a diffuse infection caused by a variety of different agents." []	\N	meningitis infection	\N	\N	EFO	"Meningitis is a nervous system infectious disease characterized as an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells. Meningitis is a diffuse infection caused by a variety of different agents." []	EFO	67507	EFO:0000584	\N	meningitis infection	EFO:0000584
0	"" []	\N	mesenchymal stem cell	\N	\N	EFO	"" []	EFO	67508	EFO:0000586	\N	mesenchymal stem cell	EFO:0000586
0	"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos." []	\N	mesothelioma	\N	\N	EFO	"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos." []	EFO	67509	EFO:0000588	\N	mesothelioma	EFO:0000588
0	"Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)" []	\N	metabolic disease	\N	\N	EFO	"Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)" []	EFO	67510	EFO:0000589	\N	metabolic disease	EFO:0000589
0	"A synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only." []	\N	monophasic synovial sarcoma	\N	\N	EFO	"A synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only." []	EFO	67511	EFO:0000595	\N	monophasic synovial sarcoma	EFO:0000595
0	"129 is a mouse strain as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	\N	129 mouse strain	\N	\N	EFO	"129 is a mouse strain as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	EFO	67512	EFO:0000597	\N	129 mouse strain	EFO:0000597
0	"129S6 is a substrain of the mouse strain 129 as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	\N	129S6	\N	\N	EFO	"129S6 is a substrain of the mouse strain 129 as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	EFO	67513	EFO:0000598	\N	129S6	EFO:0000598
0	"129/Sv is a substrain of the mouse strain 129 as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	\N	129/Sv	\N	\N	EFO	"129/Sv is a substrain of the mouse strain 129 as described in Jackson Laboratory http://www.informatics.jax.org/mgihome/nomen/strain_129.shtml" []	EFO	67514	EFO:0000599	\N	129/Sv	EFO:0000599
0	"129X1/SvJ is a substrain of the mouse strain 129 as described in Jackson Laboratory http://jaxmice.jax.org/strain/000691.html  Note this strain was formerly called 129X1" []	\N	129X1/SvJ	\N	\N	EFO	"129X1/SvJ is a substrain of the mouse strain 129 as described in Jackson Laboratory http://jaxmice.jax.org/strain/000691.html  Note this strain was formerly called 129X1" []	EFO	67515	EFO:0000600	\N	129X1/SvJ	EFO:0000600
0	"129xC57BL/6 is a substrain of the mouse strain 129 as described in article PUBMED ID 15015938" []	\N	129xC57BL/6	\N	\N	EFO	"129xC57BL/6 is a substrain of the mouse strain 129 as described in article PUBMED ID 15015938" []	EFO	67516	EFO:0000601	\N	129xC57BL/6	EFO:0000601
0	"BALB/c is a mouse strain of albion mice." []	\N	BALB/c	\N	\N	EFO	"BALB/c is a mouse strain of albion mice." []	EFO	67517	EFO:0000602	\N	BALB/c	EFO:0000602
0	"BALB is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/001026.html" []	\N	BALB/cByJ	\N	\N	EFO	"BALB is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/001026.html" []	EFO	67518	EFO:0000603	\N	BALB/cByJ	EFO:0000603
0	"C57BL/10 is a mouse strain as described in Jackson Laboratory http://www.informatics.jax.org/searches/reference.cgi?7550" []	\N	C57BL/10	\N	\N	EFO	"C57BL/10 is a mouse strain as described in Jackson Laboratory http://www.informatics.jax.org/searches/reference.cgi?7550" []	EFO	67519	EFO:0000604	\N	C57BL/10	EFO:0000604
0	"C57BL/6J is a mouse strain as described in Jackson Laboratory http://phenome.jax.org/db/q?rtn=strains/details&strainid=7" []	\N	C57BL/6J	\N	\N	EFO	"C57BL/6J is a mouse strain as described in Jackson Laboratory http://phenome.jax.org/db/q?rtn=strains/details&strainid=7" []	EFO	67520	EFO:0000606	\N	C57BL/6J	EFO:0000606
0	"NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION)." []	\N	myocardial infarction	\N	\N	EFO	"NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION)." []	EFO	67521	EFO:0000612	\N	myocardial infarction	EFO:0000612
0	"The most common type of liposarcoma.  It is composed of round to oval mesenchymal cells, small signet ring lipoblasts, and a rich network of capillaries in a myxoid stroma." []	\N	myxoid liposarcoma	\N	\N	EFO	"The most common type of liposarcoma.  It is composed of round to oval mesenchymal cells, small signet ring lipoblasts, and a rich network of capillaries in a myxoid stroma." []	EFO	67522	EFO:0000613	\N	myxoid liposarcoma	EFO:0000613
0	"A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)" []	\N	narcolepsy	\N	\N	EFO	"A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)" []	EFO	67523	EFO:0000614	\N	narcolepsy	EFO:0000614
0	"A benign or malignant tissue growth resulting from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias." []	\N	neoplasm	\N	\N	EFO	"A benign or malignant tissue growth resulting from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias." []	EFO	67524	EFO:0000616	\N	neoplasm	EFO:0000616
0	"" []	\N	nervous system disease	\N	\N	EFO	"" []	EFO	67525	EFO:0000618	\N	nervous system disease	EFO:0000618
0	"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation." []	\N	neuroblastoma	\N	\N	EFO	"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation." []	EFO	67526	EFO:0000621	\N	neuroblastoma	EFO:0000621
0	"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors." []	\N	neurofibroma	\N	\N	EFO	"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors." []	EFO	67527	EFO:0000622	\N	neurofibroma	EFO:0000622
0	"" []	\N	nevus	\N	\N	EFO	"" []	EFO	67528	EFO:0000625	\N	nevus	EFO:0000625
0	"The scalar number of injections administered to a material or organism." []	\N	number of injections	\N	\N	EFO	"The scalar number of injections administered to a material or organism." []	EFO	67529	EFO:0000627	\N	number of injections	EFO:0000627
0	"The act of regarding attentively and studying facts and occurrences, gathering data through analyzing, measuring, and drawing conclusions" []	\N	observational design	\N	\N	EFO	"The act of regarding attentively and studying facts and occurrences, gathering data through analyzing, measuring, and drawing conclusions" []	EFO	67530	EFO:0000629	\N	observational design	EFO:0000629
0	"A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)" []	\N	oligoastrocytoma	\N	\N	EFO	"A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)" []	EFO	67531	EFO:0000630	\N	oligoastrocytoma	EFO:0000630
0	"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO.)" []	\N	oligodendroglioma	\N	\N	EFO	"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO.)" []	EFO	67532	EFO:0000632	\N	oligodendroglioma	EFO:0000632
0	"A measurement of the effects of different investigators, laboratories, or organizations on experimental results are studied." []	\N	operator variation	\N	\N	EFO	"A measurement of the effects of different investigators, laboratories, or organizations on experimental results are studied." []	EFO	67533	EFO:0000633	\N	operator variation	EFO:0000633
0	"The part of organism's anatomy or substance arising from an organism from which the biomaterial was derived, excludes cells. E.g. tissue, organ, system, sperm, blood or body location (arm)." []	\N	organism part	\N	\N	EFO	"The part of organism's anatomy or substance arising from an organism from which the biomaterial was derived, excludes cells. E.g. tissue, organ, system, sperm, blood or body location (arm)." []	EFO	67534	EFO:0000635	\N	organism part	EFO:0000635
0	"A usually aggressive malignant bone-forming mesenchymal tumor, predominantly affecting adolescents and young adults.  It usually involves bones and less frequently extraosseous sites.  It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus).  Pain with or without a palpable mass is the most frequent clinical symptom.  It may spread to other anatomic sites, particularly the lungs." []	\N	osteosarcoma	\N	\N	EFO	"A usually aggressive malignant bone-forming mesenchymal tumor, predominantly affecting adolescents and young adults.  It usually involves bones and less frequently extraosseous sites.  It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus).  Pain with or without a palpable mass is the most frequent clinical symptom.  It may spread to other anatomic sites, particularly the lungs." []	EFO	67535	EFO:0000637	\N	osteosarcoma	EFO:0000637
0	"A measurement of the survival rate for a group of individuals suffering from a disease." []	\N	overall survival	\N	\N	EFO	"A measurement of the survival rate for a group of individuals suffering from a disease." []	EFO	67536	EFO:0000638	\N	overall survival	EFO:0000638
0	"An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface." []	\N	papillary cystadenocarcinoma	\N	\N	EFO	"An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface." []	EFO	67537	EFO:0000639	\N	papillary cystadenocarcinoma	EFO:0000639
0	"Papillary renal cell carcinoma is a renal cell carcinoma characterized as the second most common type of renal cell carcinoma. The cancerous cells form some projections in a finger shape, called papillae, in the tumor. This type of cancer is more common among African Americans and has a good prognosis if treated with surgery in its early stages." []	\N	papillary renal cell carcinoma	\N	\N	EFO	"Papillary renal cell carcinoma is a renal cell carcinoma characterized as the second most common type of renal cell carcinoma. The cancerous cells form some projections in a finger shape, called papillae, in the tumor. This type of cancer is more common among African Americans and has a good prognosis if treated with surgery in its early stages." []	EFO	67538	EFO:0000640	\N	papillary renal cell carcinoma	EFO:0000640
0	"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  It is linked to radiation exposure and is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound, and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.  Depending on the size and spread of the disease, surgical options include lobectomy, and partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation." []	\N	papillary thyroid carcinoma	\N	\N	EFO	"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  It is linked to radiation exposure and is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound, and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.  Depending on the size and spread of the disease, surgical options include lobectomy, and partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation." []	EFO	67539	EFO:0000641	\N	papillary thyroid carcinoma	EFO:0000641
0	"A biological agent that causes disease or illness to its host" []	\N	pathogen	\N	\N	EFO	"A biological agent that causes disease or illness to its host" []	EFO	67540	EFO:0000643	\N	pathogen	EFO:0000643
0	"Tests and results for pathogens infecting organism from which the biosource is derived" []	\N	pathogen test	\N	\N	EFO	"Tests and results for pathogens infecting organism from which the biosource is derived" []	EFO	67541	EFO:0000644	\N	pathogen test	EFO:0000644
0	"An individual who does some experimental process." []	\N	experiment performer	\N	\N	EFO	"An individual who does some experimental process." []	EFO	67542	EFO:0000647	\N	experiment performer	EFO:0000647
0	"" []	\N	period of infection	\N	\N	EFO	"" []	EFO	67543	EFO:0000648	\N	period of infection	EFO:0000648
0	"Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)" []	\N	periodontitis	\N	\N	EFO	"Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)" []	EFO	67544	EFO:0000649	\N	periodontitis	EFO:0000649
0	"A respiratory system infectious disease that is caused by bacteria of the genus Bordetella characterized by a prolonged, high-pitched, deeply indrawn breath (whoop). The bacterium Bordetella pertussis causes a highly contagious form of whooping cough, and a milder disease is caused by Bordetella parapertussis." []	\N	whooping cough	\N	\N	EFO	"A respiratory system infectious disease that is caused by bacteria of the genus Bordetella characterized by a prolonged, high-pitched, deeply indrawn breath (whoop). The bacterium Bordetella pertussis causes a highly contagious form of whooping cough, and a milder disease is caused by Bordetella parapertussis." []	EFO	67545	EFO:0000650	\N	whooping cough	EFO:0000650
0	"The observable form taken by some character (or group of characters) in an individual or an organism, excluding pathology and disease.  The detectable outward manifestations of a specific genotype." []	\N	phenotype	\N	\N	EFO	"The observable form taken by some character (or group of characters) in an individual or an organism, excluding pathology and disease.  The detectable outward manifestations of a specific genotype." []	EFO	67546	EFO:0000651	\N	phenotype	EFO:0000651
0	"A type of connective tissue neoplasm typically arising from intralobular stroma of the breast. It is characterized by the rapid enlargement of an asymmetric firm mobile mass. Histologically, its leaf-like stromal clefts are lined by EPITHELIAL CELLS. Rare phyllodes tumor of the prostate is also known." []	\N	phyllodes tumor	\N	\N	EFO	"A type of connective tissue neoplasm typically arising from intralobular stroma of the breast. It is characterized by the rapid enlargement of an asymmetric firm mobile mass. Histologically, its leaf-like stromal clefts are lined by EPITHELIAL CELLS. Rare phyllodes tumor of the prostate is also known." []	EFO	67547	EFO:0000653	\N	phyllodes tumor	EFO:0000653
0	"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO.)" []	\N	plexiform neurofibroma	\N	\N	EFO	"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO.)" []	EFO	67548	EFO:0000658	\N	plexiform neurofibroma	EFO:0000658
0	"The number of single sets of chromosomes in the cell or an organism e.g., haploid, diploid, triploid, etc." []	\N	ploidy	\N	\N	EFO	"The number of single sets of chromosomes in the cell or an organism e.g., haploid, diploid, triploid, etc." []	EFO	67549	EFO:0000659	\N	ploidy	EFO:0000659
0	"A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading." []	\N	polycystic ovary syndrome	\N	\N	EFO	"A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading." []	EFO	67550	EFO:0000660	\N	polycystic ovary syndrome	EFO:0000660
0	"Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base." []	\N	polyp	\N	\N	EFO	"Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base." []	EFO	67551	EFO:0000662	\N	polyp	EFO:0000662
0	"A mix of specimens from multiple individuals." []	\N	pool	\N	\N	EFO	"A mix of specimens from multiple individuals." []	EFO	67552	EFO:0000663	\N	pool	EFO:0000663
0	"Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS." []	\N	portal hypertension	\N	\N	EFO	"Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS." []	EFO	67553	EFO:0000666	\N	portal hypertension	EFO:0000666
0	"A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria." []	\N	preeclampsia	\N	\N	EFO	"A pregnancy induced hypertensive state that occurs after 20 weeks of gestation characterized by an increase in blood pressure, along with body swelling and proteinuria." []	EFO	67554	EFO:0000668	\N	preeclampsia	EFO:0000668
0	"A population in which a grouping of subjects in some study grouped on the basis of the probable outcome of some disease e.g. by gene expression, by physiological indicators etc" []	\N	prognostic subgroup	\N	\N	EFO	"A population in which a grouping of subjects in some study grouped on the basis of the probable outcome of some disease e.g. by gene expression, by physiological indicators etc" []	EFO	67555	EFO:0000672	\N	prognostic subgroup	EFO:0000672
0	"Tumors or cancer of the PROSTATE." []	\N	prostate adenocarcinoma	\N	\N	EFO	"Tumors or cancer of the PROSTATE." []	EFO	67556	EFO:0000673	\N	prostate adenocarcinoma	EFO:0000673
0	"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis." []	\N	psoriasis	\N	\N	EFO	"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis." []	EFO	67557	EFO:0000676	\N	psoriasis	EFO:0000676
0	"Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function (MeSH)." []	\N	mental or behavioural disorder	\N	\N	EFO	"Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function (MeSH)." []	EFO	67558	EFO:0000677	\N	mental or behavioural disorder	EFO:0000677
0	"An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)" []	\N	pterygium	\N	\N	EFO	"An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)" []	EFO	67559	EFO:0000678	\N	pterygium	EFO:0000678
0	"A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma." []	\N	renal cell carcinoma	\N	\N	EFO	"A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma." []	EFO	67560	EFO:0000681	\N	renal cell carcinoma	EFO:0000681
0	"A role played by a a biological sample in the context of a microarray experiment where the intent is that biological or technical variation is measured." []	\N	replicate	\N	\N	EFO	"A role played by a a biological sample in the context of a microarray experiment where the intent is that biological or technical variation is measured." []	EFO	67561	EFO:0000683	\N	replicate	EFO:0000683
0	"A body system disease that occurs in different organs functioning in respiration and consisting especially of the nose, nasal passages, nasopharynx, larynx, trachea, bronchi, and lungs." []	\N	respiratory system disease	\N	\N	EFO	"A body system disease that occurs in different organs functioning in respiration and consisting especially of the nose, nasal passages, nasopharynx, larynx, trachea, bronchi, and lungs." []	EFO	67562	EFO:0000684	\N	respiratory system disease	EFO:0000684
0	"Rheumatoid arthritis is a rheumatologic disorder described as an autoimmune disease that is usually a chronic disease and is characterized especially by pain, stiffness, inflammation, swelling, and sometimes destruction of joints." []	\N	rheumatoid arthritis	\N	\N	EFO	"Rheumatoid arthritis is a rheumatologic disorder described as an autoimmune disease that is usually a chronic disease and is characterized especially by pain, stiffness, inflammation, swelling, and sometimes destruction of joints." []	EFO	67563	EFO:0000685	\N	rheumatoid arthritis	EFO:0000685
0	"The probability that an event will occur generally with unfavorable outcome." []	\N	risk status	\N	\N	EFO	"The probability that an event will occur generally with unfavorable outcome." []	EFO	67564	EFO:0000686	\N	risk status	EFO:0000686
0	"A site from which a sample, i.e. a statistically representative of the whole, is extracted from the whole. e.g. a liver sample" []	\N	sampling site	\N	\N	EFO	"A site from which a sample, i.e. a statistically representative of the whole, is extracted from the whole. e.g. a liver sample" []	EFO	67565	EFO:0000688	\N	sampling site	EFO:0000688
0	"" []	\N	sampling time	\N	\N	EFO	"" []	EFO	67566	EFO:0000689	\N	sampling time	EFO:0000689
0	"Type of cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue." []	\N	sarcoma	\N	\N	EFO	"Type of cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue." []	EFO	67567	EFO:0000691	\N	sarcoma	EFO:0000691
0	"A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior." []	\N	schizophrenia	\N	\N	EFO	"A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior." []	EFO	67568	EFO:0000692	\N	schizophrenia	EFO:0000692
0	"A tumor of the peripheral nervous system composed of neoplastic Schwann cells.  The vast majority of schwannomas follow a benign clinical course.  Only rare cases associated with a malignant clinical course have been reported." []	\N	schwannoma	\N	\N	EFO	"A tumor of the peripheral nervous system composed of neoplastic Schwann cells.  The vast majority of schwannomas follow a benign clinical course.  Only rare cases associated with a malignant clinical course have been reported." []	EFO	67569	EFO:0000693	\N	schwannoma	EFO:0000693
0	"Severe acute respiratory syndrome is a respiratory tract infection described as a severe respiratory illness that is transmitted especially by contact with infectious material (as respiratory droplets or body fluids), is caused by a single-stranded RNA virus of the genus Coronavirus (SARS-CoV), is characterized by fever, headache, body aches, a dry cough, and hypoxia and usually by pneumonia." []	\N	severe acute respiratory syndrome	\N	\N	EFO	"Severe acute respiratory syndrome is a respiratory tract infection described as a severe respiratory illness that is transmitted especially by contact with infectious material (as respiratory droplets or body fluids), is caused by a single-stranded RNA virus of the genus Coronavirus (SARS-CoV), is characterized by fever, headache, body aches, a dry cough, and hypoxia and usually by pneumonia." []	EFO	67570	EFO:0000694	\N	severe acute respiratory syndrome	EFO:0000694
0	"The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female." []	\N	sex	\N	\N	EFO	"The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female." []	EFO	67571	EFO:0000695	\N	sex	EFO:0000695
0	"A process whereby a stress state is applied parallel or tangential to a face of the material." []	\N	shear stressing	\N	\N	EFO	"A process whereby a stress state is applied parallel or tangential to a face of the material." []	EFO	67572	EFO:0000696	\N	shear stressing	EFO:0000696
0	"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland." []	\N	signet ring cell carcinoma	\N	\N	EFO	"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland." []	EFO	67573	EFO:0000698	\N	signet ring cell carcinoma	EFO:0000698
0	"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis." []	\N	Sjogren syndrome	\N	\N	EFO	"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis." []	EFO	67574	EFO:0000699	\N	Sjogren syndrome	EFO:0000699
0	"An organ that constitutes the external surface of the body.  It consists of the epidermis, dermis, and skin appendages." []	\N	integumental cell	\N	\N	EFO	"An organ that constitutes the external surface of the body.  It consists of the epidermis, dermis, and skin appendages." []	EFO	67575	EFO:0000700	\N	integumental cell	EFO:0000700
0	"Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs." []	\N	skin disease	\N	\N	EFO	"Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs." []	EFO	67576	EFO:0000701	\N	skin disease	EFO:0000701
0	"An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)" []	\N	small cell lung carcinoma	\N	\N	EFO	"An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)" []	EFO	67577	EFO:0000702	\N	small cell lung carcinoma	EFO:0000702
0	"A sarcoma that is composed of spindle cells with a rich vascular network." []	\N	spindle cell tumor	\N	\N	EFO	"A sarcoma that is composed of spindle cells with a rich vascular network." []	EFO	67578	EFO:0000705	\N	spindle cell tumor	EFO:0000705
0	"Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others." []	\N	spondyloarthropathy	\N	\N	EFO	"Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others." []	EFO	67579	EFO:0000706	\N	spondyloarthropathy	EFO:0000706
0	"A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)" []	\N	squamous cell carcinoma	\N	\N	EFO	"A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)" []	EFO	67580	EFO:0000707	\N	squamous cell carcinoma	EFO:0000707
0	"A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma." []	\N	squamous cell lung carcinoma	\N	\N	EFO	"A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma." []	EFO	67581	EFO:0000708	\N	squamous cell lung carcinoma	EFO:0000708
0	"Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis." []	\N	stroke	\N	\N	EFO	"Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis." []	EFO	67582	EFO:0000712	\N	stroke	EFO:0000712
0	"Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status." []	\N	subarachnoid hemorrhage	\N	\N	EFO	"Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status." []	EFO	67583	EFO:0000713	\N	subarachnoid hemorrhage	EFO:0000713
0	"Time of survival is an information entity which is about the length of time a material entity has survived after some adverse event, such as infection from a disease." []	\N	survival time	\N	\N	EFO	"Time of survival is an information entity which is about the length of time a material entity has survived after some adverse event, such as infection from a disease." []	EFO	67584	EFO:0000714	\N	survival time	EFO:0000714
0	"The probabilty of continuance of life or existence especially under adverse conditions; Probably need a parent survival metric or similar" []	\N	survival probability	\N	\N	EFO	"The probabilty of continuance of life or existence especially under adverse conditions; Probably need a parent survival metric or similar" []	EFO	67585	EFO:0000715	\N	survival probability	EFO:0000715
0	"A scleroderma that is characterized by fibrosis (or hardening) of the skin and major organs, as well as vascular alterations, and autoantibodies." []	\N	systemic scleroderma	\N	\N	EFO	"A scleroderma that is characterized by fibrosis (or hardening) of the skin and major organs, as well as vascular alterations, and autoantibodies." []	EFO	67586	EFO:0000717	\N	systemic scleroderma	EFO:0000717
0	"The temperature that a material is exposed to." []	\N	exposure temperature	\N	\N	EFO	"The temperature that a material is exposed to." []	EFO	67587	EFO:0000718	\N	exposure temperature	EFO:0000718
0	"A temporal entity is an entity that has temporal parts and that happens, unfolds or develops through time. An occurrent is something which exists over time, rather than existing completely at many times" []	\N	temporal measurement	\N	\N	EFO	"A temporal entity is an entity that has temporal parts and that happens, unfolds or develops through time. An occurrent is something which exists over time, rather than existing completely at many times" []	EFO	67588	EFO:0000719	\N	temporal measurement	EFO:0000719
0	"The recorded value of the outcome of some test." []	\N	test result	\N	\N	EFO	"The recorded value of the outcome of some test." []	EFO	67589	EFO:0000720	\N	test result	EFO:0000720
0	"" []	\N	time	\N	\N	EFO	"" []	EFO	67590	EFO:0000721	\N	time	EFO:0000721
0	"Time point at which a sample or observation is made or taken from a biomaterial as measured from some reference point." []	\N	timepoint	\N	\N	EFO	"Time point at which a sample or observation is made or taken from a biomaterial as measured from some reference point." []	EFO	67591	EFO:0000724	\N	timepoint	EFO:0000724
0	"The process of bringing about genetic alteration of any cell or organism by a variety of means including recombinant DNA technology, viruses, chemical mutagens and X-rays." []	\N	transfection	\N	\N	EFO	"The process of bringing about genetic alteration of any cell or organism by a variety of means including recombinant DNA technology, viruses, chemical mutagens and X-rays." []	EFO	67592	EFO:0000726	\N	transfection	EFO:0000726
0	"A process in which the act is intended to modify or alter some other material entity," []	\N	treatment	\N	\N	EFO	"A process in which the act is intended to modify or alter some other material entity," []	EFO	67593	EFO:0000727	\N	treatment	EFO:0000727
0	"Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN." []	\N	ulcerative colitis	\N	\N	EFO	"Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN." []	EFO	67594	EFO:0000729	\N	ulcerative colitis	EFO:0000729
0	"A rare malignant tumor of the liver, the incidence of which is highest in children between 6 and 10 years of age." []	\N	undifferentiated sarcoma	\N	\N	EFO	"A rare malignant tumor of the liver, the incidence of which is highest in children between 6 and 10 years of age." []	EFO	67595	EFO:0000730	\N	undifferentiated sarcoma	EFO:0000730
0	"An uncommon benign neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain." []	\N	uterine fibroid	\N	\N	EFO	"An uncommon benign neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain." []	EFO	67596	EFO:0000731	\N	uterine fibroid	EFO:0000731
0	"A carrier or inert medium used as a solvent (or diluent) in which some compound is formulated and or administered." []	\N	vehicle role	\N	\N	EFO	"A carrier or inert medium used as a solvent (or diluent) in which some compound is formulated and or administered." []	EFO	67597	EFO:0000732	\N	vehicle role	EFO:0000732
0	"A nutritional condition produced by a deficiency of VITAMIN B 12 in the diet, characterized by megaloblastic anemia. Since vitamin B 12 is not present in plants, humans have obtained their supply from animal products, from multivitamin supplements in the form of pills, and as additives to food preparations. A wide variety of neuropsychiatric abnormalities is also seen in vitamin B 12 deficiency and appears to be due to an undefined defect involving myelin synthesis. (From Cecil Textbook of Medicine, 19th ed, p848)" []	\N	vitamin B12 deficiency	\N	\N	EFO	"A nutritional condition produced by a deficiency of VITAMIN B 12 in the diet, characterized by megaloblastic anemia. Since vitamin B 12 is not present in plants, humans have obtained their supply from animal products, from multivitamin supplements in the form of pills, and as additives to food preparations. A wide variety of neuropsychiatric abnormalities is also seen in vitamin B 12 deficiency and appears to be due to an undefined defect involving myelin synthesis. (From Cecil Textbook of Medicine, 19th ed, p848)" []	EFO	67598	EFO:0000734	\N	vitamin B12 deficiency	EFO:0000734
0	"The process of applying a solvent (e.g. water) or some solution (e.g. SSC/SDS) to a BioMaterial or an array to remove impurities or unwanted compounds." []	\N	washing	\N	\N	EFO	"The process of applying a solvent (e.g. water) or some solution (e.g. SSC/SDS) to a BioMaterial or an array to remove impurities or unwanted compounds." []	EFO	67599	EFO:0000735	\N	washing	EFO:0000735
0	"A locally aggressive malignant neoplasm composed of mature adipocytes showing cell size variation and nuclear atypia.  It is often associated with the presence of hyperchromatic multinucleated stromal cells, and varying numbers of lipoblasts. There are three histologic subtypes, sclerosing, inflammatory, and spindle cell liposarcoma.  These tumors do not usually metastasize unless they undergo dedifferentiation." []	\N	well-differentiated liposarcoma	\N	\N	EFO	"A locally aggressive malignant neoplasm composed of mature adipocytes showing cell size variation and nuclear atypia.  It is often associated with the presence of hyperchromatic multinucleated stromal cells, and varying numbers of lipoblasts. There are three histologic subtypes, sclerosing, inflammatory, and spindle cell liposarcoma.  These tumors do not usually metastasize unless they undergo dedifferentiation." []	EFO	67600	EFO:0000736	\N	well-differentiated liposarcoma	EFO:0000736
0	"" []	\N	well-differentiated sarcoma	\N	\N	EFO	"" []	EFO	67601	EFO:0000737	\N	well-differentiated sarcoma	EFO:0000737
0	"An assay where proteins in a sample are detected, quantified or otherwise analysed, e.g. antibody profiling" []	\N	proteomic profiling	\N	\N	EFO	"An assay where proteins in a sample are detected, quantified or otherwise analysed, e.g. antibody profiling" []	EFO	67602	EFO:0000746	\N	proteomic profiling	EFO:0000746
0	"An assay where an antigen array is used (antigens deposited on the array) to detect, quantify or otherwise analyse antibodies in solution." []	\N	antigen profiling	\N	\N	EFO	"An assay where an antigen array is used (antigens deposited on the array) to detect, quantify or otherwise analyse antibodies in solution." []	EFO	67603	EFO:0000747	\N	antigen profiling	EFO:0000747
0	"An experiment where chromatin immunoprecipitation (ChIP) is used in combination with microarray technology." []	\N	ChIP-Chip	\N	\N	EFO	"An experiment where chromatin immunoprecipitation (ChIP) is used in combination with microarray technology." []	EFO	67604	EFO:0000748	\N	ChIP-Chip	EFO:0000748
0	"An assay in which changes in DNA sequence copy number are analysed using a microarray. For example the analysis of LOH in tumor cells vs a non diseased sample or the comparison of clinical isolated of disease causing bacteria." []	\N	comparative genomic hybridization by array	\N	\N	EFO	"An assay in which changes in DNA sequence copy number are analysed using a microarray. For example the analysis of LOH in tumor cells vs a non diseased sample or the comparison of clinical isolated of disease causing bacteria." []	EFO	67605	EFO:0000749	\N	comparative genomic hybridization by array	EFO:0000749
0	"An assay in which variation in the genome is analysed" []	\N	genotyping	\N	\N	EFO	"An assay in which variation in the genome is analysed" []	EFO	67606	EFO:0000750	\N	genotyping	EFO:0000750
0	"An assay in which the methylation state is determined and is compared between samples." []	\N	methylation profiling	\N	\N	EFO	"An assay in which the methylation state is determined and is compared between samples." []	EFO	67607	EFO:0000751	\N	methylation profiling	EFO:0000751
0	"An assay in which one or more metabolites are analysed." []	\N	metabolomic profiling	\N	\N	EFO	"An assay in which one or more metabolites are analysed." []	EFO	67608	EFO:0000752	\N	metabolomic profiling	EFO:0000752
0	"An assay in which a microRNA array is used to analyse the microRNA component of the transcriptome." []	\N	microRNA profiling by array	\N	\N	EFO	"An assay in which a microRNA array is used to analyse the microRNA component of the transcriptome." []	EFO	67609	EFO:0000753	\N	microRNA profiling by array	EFO:0000753
0	"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain." []	\N	melanoma	\N	\N	EFO	"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain." []	EFO	67610	EFO:0000756	\N	melanoma	EFO:0000756
0	"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue." []	\N	lipoma	\N	\N	EFO	"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue." []	EFO	67611	EFO:0000759	\N	lipoma	EFO:0000759
0	"Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category." []	\N	malignant peripheral nerve sheath tumor	\N	\N	EFO	"Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category." []	EFO	67612	EFO:0000760	\N	malignant peripheral nerve sheath tumor	EFO:0000760
0	"The state of the organism when it functions optimally without evidence of disease." []	\N	normal	\N	\N	EFO	"The state of the organism when it functions optimally without evidence of disease." []	EFO	67613	EFO:0000761	\N	normal	EFO:0000761
0	"A benign epithelial neoplasm arising from the hepatocytes. Grossly, it appears as a soft, round mass which often contains areas of hemorrhage and necrosis. Morphologically, the neoplastic cells resemble normal hepatocytes and form plates separated by sinusoids. Most patients have a history of contraceptive or anabolic steroids use." []	\N	hepatocellular adenoma	\N	\N	EFO	"A benign epithelial neoplasm arising from the hepatocytes. Grossly, it appears as a soft, round mass which often contains areas of hemorrhage and necrosis. Morphologically, the neoplastic cells resemble normal hepatocytes and form plates separated by sinusoids. Most patients have a history of contraceptive or anabolic steroids use." []	EFO	67614	EFO:0000762	\N	hepatocellular adenoma	EFO:0000762
0	"A viral disease is a disease factor that is caused primarily by the infection or otherise hosting of a virus." []	\N	viral disease	\N	\N	EFO	"A viral disease is a disease factor that is caused primarily by the infection or otherise hosting of a virus." []	EFO	67615	EFO:0000763	\N	viral disease	EFO:0000763
0	"Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS)." []	\N	HIV infection	\N	\N	EFO	"Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS)." []	EFO	67616	EFO:0000764	\N	HIV infection	EFO:0000764
0	"An HIV infectious disease that is a characterized cytologically by a reduction in the numbers of CD4-bearing helper T cells to 20 percent or less of normal thereby rendering the subject highly vulnerable to life-threatening conditions (as Pneumocystis carinii pneumonia) and to some that become life threatening (as Kaposi's sarcoma) and that is caused by infection with HIV commonly transmitted in infected blood especially during illicit intravenous drug use and in bodily secretions (as semen) during sexual intercourse." []	\N	AIDS	\N	\N	EFO	"An HIV infectious disease that is a characterized cytologically by a reduction in the numbers of CD4-bearing helper T cells to 20 percent or less of normal thereby rendering the subject highly vulnerable to life-threatening conditions (as Pneumocystis carinii pneumonia) and to some that become life threatening (as Kaposi's sarcoma) and that is caused by infection with HIV commonly transmitted in infected blood especially during illicit intravenous drug use and in bodily secretions (as semen) during sexual intercourse." []	EFO	67617	EFO:0000765	\N	AIDS	EFO:0000765
0	"A disease of the heart muscle or myocardium proper whose cause is unknown." []	\N	idiopathic cardiomyopathy	\N	\N	EFO	"A disease of the heart muscle or myocardium proper whose cause is unknown." []	EFO	67618	EFO:0000767	\N	idiopathic cardiomyopathy	EFO:0000767
0	"Chronic and progressive fibrosis of the lung parenchyma of unknown cause." []	\N	idiopathic pulmonary fibrosis	\N	\N	EFO	"Chronic and progressive fibrosis of the lung parenchyma of unknown cause." []	EFO	67619	EFO:0000768	\N	idiopathic pulmonary fibrosis	EFO:0000768
0	"Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY)." []	\N	Epstein-Barr virus infection	\N	\N	EFO	"Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY)." []	EFO	67620	EFO:0000769	\N	Epstein-Barr virus infection	EFO:0000769
0	"" []	\N	malignant pleural mesothelioma	\N	\N	EFO	"" []	EFO	67621	EFO:0000770	\N	malignant pleural mesothelioma	EFO:0000770
0	"A bacterial disease is a disease factor that is caused primarily by bacteria." []	\N	bacterial disease	\N	\N	EFO	"A bacterial disease is a disease factor that is caused primarily by bacteria." []	EFO	67622	EFO:0000771	\N	bacterial disease	EFO:0000771
0	"Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE." []	\N	pneumococcal infection	\N	\N	EFO	"Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE." []	EFO	67623	EFO:0000772	\N	pneumococcal infection	EFO:0000772
0	"A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic (i.e., related to an identified disease process or lesion). (From Adams et al., Principles of Neurology, 6th ed, p321)" []	\N	temporal lobe epilepsy	\N	\N	EFO	"A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic (i.e., related to an identified disease process or lesion). (From Adams et al., Principles of Neurology, 6th ed, p321)" []	EFO	67624	EFO:0000773	\N	temporal lobe epilepsy	EFO:0000773
0	"A chronic systemic infection by a gram-positive bacterium, Tropheryma whippelii, mainly affecting the SMALL INTESTINE but also the JOINTS; CARDIOVASCULAR SYSTEM; and the CENTRAL NERVOUS SYSTEM. The disease is characterized by fat deposits in the INTESTINAL MUCOSA and LYMPH NODES, malabsorption, DIARRHEA with fatty stools, MALNUTRITION, and ARTHRITIS." []	\N	Whipple's disease	\N	\N	EFO	"A chronic systemic infection by a gram-positive bacterium, Tropheryma whippelii, mainly affecting the SMALL INTESTINE but also the JOINTS; CARDIOVASCULAR SYSTEM; and the CENTRAL NERVOUS SYSTEM. The disease is characterized by fat deposits in the INTESTINAL MUCOSA and LYMPH NODES, malabsorption, DIARRHEA with fatty stools, MALNUTRITION, and ARTHRITIS." []	EFO	67625	EFO:0000775	\N	Whipple's disease	EFO:0000775
0	"Aeromonas hydrophila infection is a bacterial disease caused by infection from the Aeromonas hydrophila bacteria." []	\N	Aeromonas hydrophila infection	\N	\N	EFO	"Aeromonas hydrophila infection is a bacterial disease caused by infection from the Aeromonas hydrophila bacteria." []	EFO	67626	EFO:0000776	\N	Aeromonas hydrophila infection	EFO:0000776
0	"" []	\N	human granulocytic anaplasmosis	\N	\N	EFO	"" []	EFO	67627	EFO:0000777	\N	human granulocytic anaplasmosis	EFO:0000777
0	"A primary Bacillaceae infectious disease that results_in infection located_in skin, located_in lung lymph nodes or located_in gastrointestinal tract, has_agent Bacillus anthracis, transmitted_by contact with infected animals or animal products, transmitted_by airborne spores or transmitted_by ingestion of undercooked meat from infected animals and has_symptom skin ulcer, has_symptom nausea, has_symptom poor appetite, has_symptom bloody diarrhea, has_symptom fever or has_symptom shortness of breath." []	\N	anthrax infection	\N	\N	EFO	"A primary Bacillaceae infectious disease that results_in infection located_in skin, located_in lung lymph nodes or located_in gastrointestinal tract, has_agent Bacillus anthracis, transmitted_by contact with infected animals or animal products, transmitted_by airborne spores or transmitted_by ingestion of undercooked meat from infected animals and has_symptom skin ulcer, has_symptom nausea, has_symptom poor appetite, has_symptom bloody diarrhea, has_symptom fever or has_symptom shortness of breath." []	EFO	67628	EFO:0000778	\N	anthrax infection	EFO:0000778
0	"" []	\N	Drosophila C virus infection	\N	\N	EFO	"" []	EFO	67629	EFO:0000779	\N	Drosophila C virus infection	EFO:0000779
0	"" []	\N	Enterococcus faecalis infection	\N	\N	EFO	"" []	EFO	67630	EFO:0000780	\N	Enterococcus faecalis infection	EFO:0000780
0	"" []	\N	Pectobacterium carotovorum infection	\N	\N	EFO	"" []	EFO	67631	EFO:0000781	\N	Pectobacterium carotovorum infection	EFO:0000781
0	"" []	\N	Hibiscus chlorotic ringspot virus infection	\N	\N	EFO	"" []	EFO	67632	EFO:0000782	\N	Hibiscus chlorotic ringspot virus infection	EFO:0000782
0	"Inflammation of a muscle or muscle tissue." []	\N	myositis	\N	\N	EFO	"Inflammation of a muscle or muscle tissue." []	EFO	67633	EFO:0000783	\N	myositis	EFO:0000783
0	"" []	\N	anatomy basic component	\N	\N	EFO	"" []	EFO	67634	EFO:0000786	\N	anatomy basic component	EFO:0000786
0	"" []	\N	animal component	\N	\N	EFO	"" []	EFO	67635	EFO:0000787	\N	animal component	EFO:0000787
0	"" []	\N	fungal component	\N	\N	EFO	"" []	EFO	67636	EFO:0000788	\N	fungal component	EFO:0000788
0	"" []	\N	plant component	\N	\N	EFO	"" []	EFO	67637	EFO:0000789	\N	plant component	EFO:0000789
0	"The larval cranium exclusive of the dorsal apotome." []	\N	craniofacial tissue	\N	\N	EFO	"The larval cranium exclusive of the dorsal apotome." []	EFO	67638	EFO:0000792	\N	craniofacial tissue	EFO:0000792
0	"Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells." []	\N	animal developmental tissue	\N	\N	EFO	"Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells." []	EFO	67639	EFO:0000795	\N	animal developmental tissue	EFO:0000795
0	"" []	\N	animal fluid	\N	\N	EFO	"" []	EFO	67640	EFO:0000796	\N	animal fluid	EFO:0000796
0	"" []	\N	haemopoietic system	\N	\N	EFO	"" []	EFO	67641	EFO:0000798	\N	haemopoietic system	EFO:0000798
0	"" []	\N	renal system	\N	\N	EFO	"" []	EFO	67642	EFO:0000803	\N	renal system	EFO:0000803
0	"Anatomical structure, which is a subdivision of a cardinal body part; it may exclude bones; is demarcated from other subdivisions of the same cardinal body part by anatomical surfaces or lines or topographical references; together with other contiguous subdivisions of the same cardinal body part, it constitutes a cardinal body part. Examples: thorax, perineum, back of neck, forearm, hand, phalanx, nose, auricle of ear, scrotum." []	\N	animal body part	\N	\N	EFO	"Anatomical structure, which is a subdivision of a cardinal body part; it may exclude bones; is demarcated from other subdivisions of the same cardinal body part by anatomical surfaces or lines or topographical references; together with other contiguous subdivisions of the same cardinal body part, it constitutes a cardinal body part. Examples: thorax, perineum, back of neck, forearm, hand, phalanx, nose, auricle of ear, scrotum." []	EFO	67643	EFO:0000808	\N	animal body part	EFO:0000808
0	"" []	\N	animal reproductive system	\N	\N	EFO	"" []	EFO	67644	EFO:0000809	\N	animal reproductive system	EFO:0000809
0	"Collective term for the masses and sheets of adipose tissue that are distributed throughout the organism's body." []	\N	fat body sensu invertebrata	\N	\N	EFO	"Collective term for the masses and sheets of adipose tissue that are distributed throughout the organism's body." []	EFO	67645	EFO:0000810	\N	fat body sensu invertebrata	EFO:0000810
0	"An adipose tissue associated with the amphibiian gonad" []	\N	fat body sensu amphibia	\N	\N	EFO	"An adipose tissue associated with the amphibiian gonad" []	EFO	67646	EFO:0000811	\N	fat body sensu amphibia	EFO:0000811
0	"A mammalian heat-producing tissue occurring especially in human newborns and in hibernators." []	\N	brown fat	\N	\N	EFO	"A mammalian heat-producing tissue occurring especially in human newborns and in hibernators." []	EFO	67647	EFO:0000812	\N	brown fat	EFO:0000812
0	"" []	\N	white fat	\N	\N	EFO	"" []	EFO	67648	EFO:0000813	\N	white fat	EFO:0000813
0	"The two principal arteries supplying the structures of the head and neck. They ascend in the neck, one on each side, and at the level of the upper border of the thyroid cartilage, each divides into two branches, the external (CAROTID ARTERY, EXTERNAL) and internal (CAROTID ARTERY, INTERNAL) carotid arteries." []	\N	carotid artery	\N	\N	EFO	"The two principal arteries supplying the structures of the head and neck. They ascend in the neck, one on each side, and at the level of the upper border of the thyroid cartilage, each divides into two branches, the external (CAROTID ARTERY, EXTERNAL) and internal (CAROTID ARTERY, INTERNAL) carotid arteries." []	EFO	67649	EFO:0000818	\N	carotid artery	EFO:0000818
0	"The organ of hearing." []	\N	ear	\N	\N	EFO	"The organ of hearing." []	EFO	67650	EFO:0000826	\N	ear	EFO:0000826
0	"Any sense organ (FBbt:00005155) that has function 'detection of chemical stimulus involved in sensory perception (GO:0050907)'." []	\N	nose structure	\N	\N	EFO	"Any sense organ (FBbt:00005155) that has function 'detection of chemical stimulus involved in sensory perception (GO:0050907)'." []	EFO	67651	EFO:0000828	\N	nose structure	EFO:0000828
0	"Any sense organ (FBbt:00005155) that has function 'detection of chemical stimulus involved in sensory perception of taste (GO:0050912)'." []	\N	taste system	\N	\N	EFO	"Any sense organ (FBbt:00005155) that has function 'detection of chemical stimulus involved in sensory perception of taste (GO:0050912)'." []	EFO	67652	EFO:0000830	\N	taste system	EFO:0000830
0	"The part of the vertebrate alimentary canal between the cavity of the mouth and the esophagus.nThe pharynx of Nematodes is an efficient pump and forces food into the intestines." []	\N	pharynx structure	\N	\N	EFO	"The part of the vertebrate alimentary canal between the cavity of the mouth and the esophagus.nThe pharynx of Nematodes is an efficient pump and forces food into the intestines." []	EFO	67653	EFO:0000836	\N	pharynx structure	EFO:0000836
0	"Organ with a cavity which consist of dentine and enamel. Examples: incisor, molar." []	\N	tooth	\N	\N	EFO	"Organ with a cavity which consist of dentine and enamel. Examples: incisor, molar." []	EFO	67654	EFO:0000839	\N	tooth	EFO:0000839
0	"Organ with organ cavity which is continuous proximally with the cecum and distally terminates in the tip of the appendix. Examples: There is only one appendix." []	\N	appendix	\N	\N	EFO	"Organ with organ cavity which is continuous proximally with the cecum and distally terminates in the tip of the appendix. Examples: There is only one appendix." []	EFO	67655	EFO:0000849	\N	appendix	EFO:0000849
0	"Any of the three membranes that envelop the brain and spinal cord." []	\N	meninges	\N	\N	EFO	"Any of the three membranes that envelop the brain and spinal cord." []	EFO	67656	EFO:0000867	\N	meninges	EFO:0000867
0	"" []	\N	lymphatic system	\N	\N	EFO	"" []	EFO	67657	EFO:0000870	\N	lymphatic system	EFO:0000870
0	"Surface structure involved in locomotion." []	\N	fin	\N	\N	EFO	"Surface structure involved in locomotion." []	EFO	67658	EFO:0000875	\N	fin	EFO:0000875
0	"The generic name for hand, paw, foot etc" []	\N	autopod	\N	\N	EFO	"The generic name for hand, paw, foot etc" []	EFO	67659	EFO:0000877	\N	autopod	EFO:0000877
0	"The walking appendages of each segment of the ventral adult external thorax." []	\N	invertebrate limb	\N	\N	EFO	"The walking appendages of each segment of the ventral adult external thorax." []	EFO	67660	EFO:0000884	\N	invertebrate limb	EFO:0000884
0	"Visceral muscle of the adult." []	\N	smooth muscle	\N	\N	EFO	"Visceral muscle of the adult." []	EFO	67661	EFO:0000889	\N	smooth muscle	EFO:0000889
0	"Any of a number of aggregations of neurons, glial cells and their processes, surrounded by a glial cell and connective tissue sheath (plural: ganglia)." []	\N	invertebrate ganglion	\N	\N	EFO	"Any of a number of aggregations of neurons, glial cells and their processes, surrounded by a glial cell and connective tissue sheath (plural: ganglia)." []	EFO	67662	EFO:0000890	\N	invertebrate ganglion	EFO:0000890
0	"" []	\N	pharyngeal nervous system	\N	\N	EFO	"" []	EFO	67663	EFO:0000897	\N	pharyngeal nervous system	EFO:0000897
0	"Ganglion which is located in the trunk." []	\N	body ganglion	\N	\N	EFO	"Ganglion which is located in the trunk." []	EFO	67664	EFO:0000901	\N	body ganglion	EFO:0000901
0	"The dorsal part of the midbrain including the corpora quadrigemina." []	\N	tectum	\N	\N	EFO	"The dorsal part of the midbrain including the corpora quadrigemina." []	EFO	67665	EFO:0000920	\N	tectum	EFO:0000920
0	"Subdivision of the midbrain lying anterior to the tectum and posterior to the substantia nigra and cerebral peduncle." []	\N	tegmentum	\N	\N	EFO	"Subdivision of the midbrain lying anterior to the tectum and posterior to the substantia nigra and cerebral peduncle." []	EFO	67666	EFO:0000921	\N	tegmentum	EFO:0000921
0	"Compound organ that consists of gill filaments, gill lamellae, gill rakers and pharyngeal arches 3-7. The gills are responsible for primary gas exchange between the blood and the surrounding water." []	\N	gill	\N	\N	EFO	"Compound organ that consists of gill filaments, gill lamellae, gill rakers and pharyngeal arches 3-7. The gills are responsible for primary gas exchange between the blood and the surrounding water." []	EFO	67667	EFO:0000933	\N	gill	EFO:0000933
0	"The mostly slit-like opening on the body surface of the insects through which air is taken into the respiratory system." []	\N	spiracle	\N	\N	EFO	"The mostly slit-like opening on the body surface of the insects through which air is taken into the respiratory system." []	EFO	67668	EFO:0000936	\N	spiracle	EFO:0000936
0	"A sensillum with a long, unicellular, setiform outgrowth that is strongly chitinized." []	\N	sensory bristle	\N	\N	EFO	"A sensillum with a long, unicellular, setiform outgrowth that is strongly chitinized." []	EFO	67669	EFO:0000938	\N	sensory bristle	EFO:0000938
0	"Defined by Snodgrass as \\"a simple sense organ, or one of the structural units of a compound sense organ,\\" and by Schneider as \\"a specialized area of the integument, consisting of formative cells, the sensory nerve cells, and, in some cases, auxiliary cells\\"." []	\N	sensillum	\N	\N	EFO	"Defined by Snodgrass as \\"a simple sense organ, or one of the structural units of a compound sense organ,\\" and by Schneider as \\"a specialized area of the integument, consisting of formative cells, the sensory nerve cells, and, in some cases, auxiliary cells\\"." []	EFO	67670	EFO:0000939	\N	sensillum	EFO:0000939
0	"The post-cranial structural components forming the long axis of the vertebrate body; usually consists of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins." []	\N	axial skeleton structure	\N	\N	EFO	"The post-cranial structural components forming the long axis of the vertebrate body; usually consists of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins." []	EFO	67671	EFO:0000942	\N	axial skeleton structure	EFO:0000942
0	"The outer non-living layer of the integumentary system derived from the epidermis." []	\N	exoskeleton	\N	\N	EFO	"The outer non-living layer of the integumentary system derived from the epidermis." []	EFO	67672	EFO:0000944	\N	exoskeleton	EFO:0000944
0	"Subdivision of free upper limb, which is the proximal segment of an upper limb and links the free upper limb to the trunk; it is demarcated by the plane of the surface of the glenoid fossa from the free upper limb; together with the free upper limb, it constitutes the upper limb. Examples: There are only two instances, right and left pectoral girdles." []	\N	pectoral girdle	\N	\N	EFO	"Subdivision of free upper limb, which is the proximal segment of an upper limb and links the free upper limb to the trunk; it is demarcated by the plane of the surface of the glenoid fossa from the free upper limb; together with the free upper limb, it constitutes the upper limb. Examples: There are only two instances, right and left pectoral girdles." []	EFO	67673	EFO:0000946	\N	pectoral girdle	EFO:0000946
0	"Subdivision of free lower limb, which is the proximal segment of a lower limb and links the free lower limb to the trunk; it is demarcated by the plane of the surface of the acetabular fossa from the free lower limb; together with the free lower limb, it constitutes the lower limb. Examples: There are only two instances, right and left pelvic girdles." []	\N	pelvic girdle	\N	\N	EFO	"Subdivision of free lower limb, which is the proximal segment of a lower limb and links the free lower limb to the trunk; it is demarcated by the plane of the surface of the acetabular fossa from the free lower limb; together with the free lower limb, it constitutes the lower limb. Examples: There are only two instances, right and left pelvic girdles." []	EFO	67674	EFO:0000947	\N	pelvic girdle	EFO:0000947
0	"The point of contact between elements of an animal skeleton with the parts that surround and support it." []	\N	joint	\N	\N	EFO	"The point of contact between elements of an animal skeleton with the parts that surround and support it." []	EFO	67675	EFO:0000948	\N	joint	EFO:0000948
0	"Portion of tissue which is connective tissue composed of collagen and/or elastin fibers and chondrocytes. Cartilage is avascular and provides both skeletal functions and a framework upon which bone is deposited." []	\N	cartilage	\N	\N	EFO	"Portion of tissue which is connective tissue composed of collagen and/or elastin fibers and chondrocytes. Cartilage is avascular and provides both skeletal functions and a framework upon which bone is deposited." []	EFO	67676	EFO:0000949	\N	cartilage	EFO:0000949
0	"" []	\N	median fin skeleton	\N	\N	EFO	"" []	EFO	67677	EFO:0000950	\N	median fin skeleton	EFO:0000950
0	"Skeletal system that consists of the paired fins (pectoral or pelvic fins)." []	\N	paired fin skeleton	\N	\N	EFO	"Skeletal system that consists of the paired fins (pectoral or pelvic fins)." []	EFO	67678	EFO:0000951	\N	paired fin skeleton	EFO:0000951
0	"1: A slender threadlike outgrowth of the epidermis of an animal; especially: one of the usually pigmented filaments that form the characteristic coat of a mammal.n2: The hairy covering of an animal or a body part; especially: the coating of hairs on a human head." []	\N	hair	\N	\N	EFO	"1: A slender threadlike outgrowth of the epidermis of an animal; especially: one of the usually pigmented filaments that form the characteristic coat of a mammal.n2: The hairy covering of an animal or a body part; especially: the coating of hairs on a human head." []	EFO	67679	EFO:0000958	\N	hair	EFO:0000958
0	"One of the repeated divisions of the whole organism." []	\N	adult segment	\N	\N	EFO	"One of the repeated divisions of the whole organism." []	EFO	67680	EFO:0000961	\N	adult segment	EFO:0000961
0	"The integument of an animal (as a fur-bearing mammal or a bird) separated from the body usually with its hair or feathers." []	\N	skin	\N	\N	EFO	"The integument of an animal (as a fur-bearing mammal or a bird) separated from the body usually with its hair or feathers." []	EFO	67681	EFO:0000962	\N	skin	EFO:0000962
0	"Female reproductive organ." []	\N	animal ovary	\N	\N	EFO	"Female reproductive organ." []	EFO	67682	EFO:0000973	\N	animal ovary	EFO:0000973
0	"The external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina." []	\N	vulva	\N	\N	EFO	"The external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina." []	EFO	67683	EFO:0000978	\N	vulva	EFO:0000978
0	"A constricted portion of an organ or part; especially: the narrow outer end of the uterus." []	\N	cervix	\N	\N	EFO	"A constricted portion of an organ or part; especially: the narrow outer end of the uterus." []	EFO	67684	EFO:0000979	\N	cervix	EFO:0000979
0	"The individual or generation of a plant exhibiting alternation of generations that bears sex organs." []	\N	gametophyte	\N	\N	EFO	"The individual or generation of a plant exhibiting alternation of generations that bears sex organs." []	EFO	67685	EFO:0000988	\N	gametophyte	EFO:0000988
0	"The usually underground part of a seed plant body that originates usually from the hypocotyl, functions as an organ of absorption, aeration, and food storage or as a means of anchorage and support, and differs from a stem especially in lacking nodes, buds, and leaves." []	\N	root structure	\N	\N	EFO	"The usually underground part of a seed plant body that originates usually from the hypocotyl, functions as an organ of absorption, aeration, and food storage or as a means of anchorage and support, and differs from a stem especially in lacking nodes, buds, and leaves." []	EFO	67686	EFO:0000989	\N	root structure	EFO:0000989
0	"Undifferentiated plant issue - the botanical equivalent of animal stem cells" []	\N	meristem	\N	\N	EFO	"Undifferentiated plant issue - the botanical equivalent of animal stem cells" []	EFO	67687	EFO:0000990	\N	meristem	EFO:0000990
0	"A matured ovule containing an embryo and food supply and covered by a seed coat." []	\N	seed structure	\N	\N	EFO	"A matured ovule containing an embryo and food supply and covered by a seed coat." []	EFO	67688	EFO:0000991	\N	seed structure	EFO:0000991
0	"A sending out of new growth or the growth sent out: as a stem or branch with its leaves and appendages especially when not yet mature." []	\N	shoot	\N	\N	EFO	"A sending out of new growth or the growth sent out: as a stem or branch with its leaves and appendages especially when not yet mature." []	EFO	67689	EFO:0000992	\N	shoot	EFO:0000992
0	"A lateral outgrowth from a plant stem that is typically a flattened expanded variably shaped greenish organ, constitutes a unit of the foliage, and functions primarily in food manufacture by photosynthesis." []	\N	leaf	\N	\N	EFO	"A lateral outgrowth from a plant stem that is typically a flattened expanded variably shaped greenish organ, constitutes a unit of the foliage, and functions primarily in food manufacture by photosynthesis." []	EFO	67690	EFO:0000993	\N	leaf	EFO:0000993
0	"" []	\N	plant fluid	\N	\N	EFO	"" []	EFO	67691	EFO:0000994	\N	plant fluid	EFO:0000994
0	"" []	\N	gall tissue	\N	\N	EFO	"" []	EFO	67692	EFO:0000995	\N	gall tissue	EFO:0000995
0	"The supportive and conductive tissue in plants, consisting of xylem and phloem." []	\N	vascular tissue	\N	\N	EFO	"The supportive and conductive tissue in plants, consisting of xylem and phloem." []	EFO	67693	EFO:0000996	\N	vascular tissue	EFO:0000996
0	"" []	\N	storage organ	\N	\N	EFO	"" []	EFO	67694	EFO:0000997	\N	storage organ	EFO:0000997
0	"" []	\N	plant reproductive system structure	\N	\N	EFO	"" []	EFO	67695	EFO:0000998	\N	plant reproductive system structure	EFO:0000998
0	"" []	\N	plant developmental tissue	\N	\N	EFO	"" []	EFO	67696	EFO:0000999	\N	plant developmental tissue	EFO:0000999
0	"The slender tube formed by the pollen grain that penetrates an ovule and releases the male gametes." []	\N	pollen tube	\N	\N	EFO	"The slender tube formed by the pollen grain that penetrates an ovule and releases the male gametes." []	EFO	67697	EFO:0001004	\N	pollen tube	EFO:0001004
0	"A mature male germ cell that develops from a spermatid." []	\N	plant sperm	\N	\N	EFO	"A mature male germ cell that develops from a spermatid." []	EFO	67698	EFO:0001005	\N	plant sperm	EFO:0001005
0	"a primitive plant body of gametophytes that has not differentiated into roots, stems or leaves" []	\N	thallus	\N	\N	EFO	"a primitive plant body of gametophytes that has not differentiated into roots, stems or leaves" []	EFO	67699	EFO:0001006	\N	thallus	EFO:0001006
0	"leaf of a moss or liverwort" []	\N	phyllid	\N	\N	EFO	"leaf of a moss or liverwort" []	EFO	67700	EFO:0001007	\N	phyllid	EFO:0001007
0	"A somewhat elongate usually horizontal subterranean plant stem that is often thickened by deposits of reserve food material, produces shoots above and roots below, and is distinguished from a true root in possessing buds, nodes, and usually scalelike leaves." []	\N	rhizome	\N	\N	EFO	"A somewhat elongate usually horizontal subterranean plant stem that is often thickened by deposits of reserve food material, produces shoots above and roots below, and is distinguished from a true root in possessing buds, nodes, and usually scalelike leaves." []	EFO	67701	EFO:0001008	\N	rhizome	EFO:0001008
0	"" []	\N	apical root meristem	\N	\N	EFO	"" []	EFO	67702	EFO:0001009	\N	apical root meristem	EFO:0001009
0	"" []	\N	lateral root meristem	\N	\N	EFO	"" []	EFO	67703	EFO:0001010	\N	lateral root meristem	EFO:0001010
0	"The main root of a plant, usually stouter than the lateral roots and growing straight downward from the stem." []	\N	taproot	\N	\N	EFO	"The main root of a plant, usually stouter than the lateral roots and growing straight downward from the stem." []	EFO	67704	EFO:0001011	\N	taproot	EFO:0001011
0	"A filamentous extension of an epidermal cell near the tip of a rootlet that functions in absorption of water and minerals;nSpecialized unicellular trichome found in roots." []	\N	root hair	\N	\N	EFO	"A filamentous extension of an epidermal cell near the tip of a rootlet that functions in absorption of water and minerals;nSpecialized unicellular trichome found in roots." []	EFO	67705	EFO:0001012	\N	root hair	EFO:0001012
0	"Gall-like structures on the roots of legumes that contain symbiotic nitrogen-fixing bacteria." []	\N	root nodule	\N	\N	EFO	"Gall-like structures on the roots of legumes that contain symbiotic nitrogen-fixing bacteria." []	EFO	67706	EFO:0001013	\N	root nodule	EFO:0001013
0	"A thimble-shaped group of cells found at the tip of roots; it functions to protect the meristem." []	\N	root cap	\N	\N	EFO	"A thimble-shaped group of cells found at the tip of roots; it functions to protect the meristem." []	EFO	67707	EFO:0001014	\N	root cap	EFO:0001014
0	"A short fleshy usually underground stem bearing minute scale leaves each of which bears a bud in its axil and is potentially able to produce a new plant." []	\N	tuber	\N	\N	EFO	"A short fleshy usually underground stem bearing minute scale leaves each of which bears a bud in its axil and is potentially able to produce a new plant." []	EFO	67708	EFO:0001015	\N	tuber	EFO:0001015
0	"The layer of active cells between xylem and phloem that gives rise to secondary tissues (e.g. bark)" []	\N	cambium	\N	\N	EFO	"The layer of active cells between xylem and phloem that gives rise to secondary tissues (e.g. bark)" []	EFO	67709	EFO:0001016	\N	cambium	EFO:0001016
0	"" []	\N	apical shoot meristem	\N	\N	EFO	"" []	EFO	67710	EFO:0001017	\N	apical shoot meristem	EFO:0001017
0	"" []	\N	lateral shoot meristem	\N	\N	EFO	"" []	EFO	67711	EFO:0001018	\N	lateral shoot meristem	EFO:0001018
0	"The lower part of the axis of a plant embryo or seedling." []	\N	radicle	\N	\N	EFO	"The lower part of the axis of a plant embryo or seedling." []	EFO	67712	EFO:0001019	\N	radicle	EFO:0001019
0	"A triploid nutritive tissue resulting from the fusion of a haploid sperm nucleus with the two haploid polar nuclei in the ovule of angiosperms." []	\N	endosperm	\N	\N	EFO	"A triploid nutritive tissue resulting from the fusion of a haploid sperm nucleus with the two haploid polar nuclei in the ovule of angiosperms." []	EFO	67713	EFO:0001020	\N	endosperm	EFO:0001020
0	"The outer layer of a seed that is developed from the integuments of the ovule; the testa." []	\N	seed coat	\N	\N	EFO	"The outer layer of a seed that is developed from the integuments of the ovule; the testa." []	EFO	67714	EFO:0001021	\N	seed coat	EFO:0001021
0	"A seed leaf; the first leaf formed in a seed." []	\N	cotyledon	\N	\N	EFO	"A seed leaf; the first leaf formed in a seed." []	EFO	67715	EFO:0001022	\N	cotyledon	EFO:0001022
0	"Any small part of the embryo or adult metazoon more or less resembling the bud of a plant and presumed to have potential for growth and differentiation." []	\N	bud	\N	\N	EFO	"Any small part of the embryo or adult metazoon more or less resembling the bud of a plant and presumed to have potential for growth and differentiation." []	EFO	67716	EFO:0001023	\N	bud	EFO:0001023
0	"The reproductive structure of the anthophyta or angiosperms." []	\N	flower structure	\N	\N	EFO	"The reproductive structure of the anthophyta or angiosperms." []	EFO	67717	EFO:0001024	\N	flower structure	EFO:0001024
0	"The often showy flower component attached just inside the sepals; petals are usually colorful to attract pollinators." []	\N	petal	\N	\N	EFO	"The often showy flower component attached just inside the sepals; petals are usually colorful to attract pollinators." []	EFO	67718	EFO:0001025	\N	petal	EFO:0001025
0	"One of the modified leaves comprising a calyx." []	\N	sepal	\N	\N	EFO	"One of the modified leaves comprising a calyx." []	EFO	67719	EFO:0001026	\N	sepal	EFO:0001026
0	"A division of the perianth of a flower having a virtually indistinguishable calyx and corolla, as in tulips and lilies." []	\N	tepal	\N	\N	EFO	"A division of the perianth of a flower having a virtually indistinguishable calyx and corolla, as in tulips and lilies." []	EFO	67720	EFO:0001027	\N	tepal	EFO:0001027
0	"The mature ovary or ovaries of a seed-bearing plant, together with accessory parts, containing the seeds and occurring in a wide variety of forms." []	\N	fruit	\N	\N	EFO	"The mature ovary or ovaries of a seed-bearing plant, together with accessory parts, containing the seeds and occurring in a wide variety of forms." []	EFO	67721	EFO:0001028	\N	fruit	EFO:0001028
0	"A flower cluster with a definite arrangement." []	\N	inflorescence	\N	\N	EFO	"A flower cluster with a definite arrangement." []	EFO	67722	EFO:0001029	\N	inflorescence	EFO:0001029
0	"RNAi profiling is an assay in which double stranded RNA is synthesized with a sequence complementary to a gene(s) of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway resulting in knockdown of the transcripts and providing a means to study downstream changes in gene expression." []	\N	RNAi profiling by array	\N	\N	EFO	"RNAi profiling is an assay in which double stranded RNA is synthesized with a sequence complementary to a gene(s) of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway resulting in knockdown of the transcripts and providing a means to study downstream changes in gene expression." []	EFO	67723	EFO:0001030	\N	RNAi profiling by array	EFO:0001030
0	"An assay  in which a tiling path array (where probes are arrayed covering target regions e.g. a genome or chromosome at very high density) is used to identify transcribed regions." []	\N	tiling path by array	\N	\N	EFO	"An assay  in which a tiling path array (where probes are arrayed covering target regions e.g. a genome or chromosome at very high density) is used to identify transcribed regions." []	EFO	67724	EFO:0001031	\N	tiling path by array	EFO:0001031
0	"An assay in which the transcriptome of a biological sample is analysed." []	\N	transcription profiling	\N	\N	EFO	"An assay in which the transcriptome of a biological sample is analysed." []	EFO	67725	EFO:0001032	\N	transcription profiling	EFO:0001032
0	"An assay in which surface-bound, translationally competent ribosome complexes are used to generate a translation profile for mRNA, which mRNA may be a single molecular species, or a combination of species, including complex mixtures such as those found in the set of mRNAs isolated from a cell or tissue. One or more components of the surface-bound ribosome complex may be labeled at specific positions to permit analysis of multiple or single molecules for determination of ribosomal conformational changes and translation kinetics. Translation profiles are used as the basis for comparison of an mRNA or set of mRNA species. The translation profile can be used to determine such characteristics as kinetics of initiation, kinetic of elongation, identity of the polypeptide product, and the like. Analysis of translation profiles may be used to determine differential gene expression, optimization of mRNA sequences for expression, screening drug candidates for an effect on translation." []	\N	translation profiling	\N	\N	EFO	"An assay in which surface-bound, translationally competent ribosome complexes are used to generate a translation profile for mRNA, which mRNA may be a single molecular species, or a combination of species, including complex mixtures such as those found in the set of mRNAs isolated from a cell or tissue. One or more components of the surface-bound ribosome complex may be labeled at specific positions to permit analysis of multiple or single molecules for determination of ribosomal conformational changes and translation kinetics. Translation profiles are used as the basis for comparison of an mRNA or set of mRNA species. The translation profile can be used to determine such characteristics as kinetics of initiation, kinetic of elongation, identity of the polypeptide product, and the like. Analysis of translation profiles may be used to determine differential gene expression, optimization of mRNA sequences for expression, screening drug candidates for an effect on translation." []	EFO	67726	EFO:0001033	\N	translation profiling	EFO:0001033
0	"" []	\N	male inflorescence	\N	\N	EFO	"" []	EFO	67727	EFO:0001034	\N	male inflorescence	EFO:0001034
0	"" []	\N	female inflorescence	\N	\N	EFO	"" []	EFO	67728	EFO:0001035	\N	female inflorescence	EFO:0001035
0	"" []	\N	leaf vascular tissue	\N	\N	EFO	"" []	EFO	67729	EFO:0001037	\N	leaf vascular tissue	EFO:0001037
0	"The epidermal complex consisting of two guard cells and the pore between them." []	\N	stomatal complex	\N	\N	EFO	"The epidermal complex consisting of two guard cells and the pore between them." []	EFO	67730	EFO:0001038	\N	stomatal complex	EFO:0001038
0	"" []	\N	seedhead	\N	\N	EFO	"" []	EFO	67731	EFO:0001039	\N	seedhead	EFO:0001039
0	"The main trunk of a plant; specifically: a primary plant axis that develops buds and shoots instead of roots." []	\N	stem	\N	\N	EFO	"The main trunk of a plant; specifically: a primary plant axis that develops buds and shoots instead of roots." []	EFO	67732	EFO:0001040	\N	stem	EFO:0001040
0	"The tough exterior covering of a woody root or stem; specifically: the tissues outside the cambium that include an inner layer especially of secondary phloem and an outer layer of periderm." []	\N	bark	\N	\N	EFO	"The tough exterior covering of a woody root or stem; specifically: the tissues outside the cambium that include an inner layer especially of secondary phloem and an outer layer of periderm." []	EFO	67733	EFO:0001041	\N	bark	EFO:0001041
0	"A complex tissue in the vascular system of higher plants that consists of vessels, tracheids, or both usually together with wood fibers and parenchyma cells, functions chiefly in conduction of water and dissolved minerals but also in support and food storage, and typically constitutes the woody element (as of a plant stem)." []	\N	xylem	\N	\N	EFO	"A complex tissue in the vascular system of higher plants that consists of vessels, tracheids, or both usually together with wood fibers and parenchyma cells, functions chiefly in conduction of water and dissolved minerals but also in support and food storage, and typically constitutes the woody element (as of a plant stem)." []	EFO	67734	EFO:0001042	\N	xylem	EFO:0001042
0	"" []	\N	wood parenchyma	\N	\N	EFO	"" []	EFO	67735	EFO:0001043	\N	wood parenchyma	EFO:0001043
0	"A complex tissue in the vascular system of higher plants that consists mainly of sieve tubes and elongated parenchyma cells usually with fibers and that functions in translocation and in support and storage." []	\N	phloem	\N	\N	EFO	"A complex tissue in the vascular system of higher plants that consists mainly of sieve tubes and elongated parenchyma cells usually with fibers and that functions in translocation and in support and storage." []	EFO	67736	EFO:0001044	\N	phloem	EFO:0001044
0	"The fluid between the cell wall and the plasma membrane" []	\N	apoplasm	\N	\N	EFO	"The fluid between the cell wall and the plasma membrane" []	EFO	67737	EFO:0001045	\N	apoplasm	EFO:0001045
0	"A sweet liquid that is secreted by the nectaries of a plant and is the chief raw material of honey." []	\N	nectar	\N	\N	EFO	"A sweet liquid that is secreted by the nectaries of a plant and is the chief raw material of honey." []	EFO	67738	EFO:0001046	\N	nectar	EFO:0001046
0	"" []	\N	sap	\N	\N	EFO	"" []	EFO	67739	EFO:0001047	\N	sap	EFO:0001047
0	"A resting stage of a plant (as the lily, onion, hyacinth, or tulip) that is usually formed underground and consists of a short stem base bearing one or more buds enclosed in overlapping membranous or fleshy leaves." []	\N	bulb	\N	\N	EFO	"A resting stage of a plant (as the lily, onion, hyacinth, or tulip) that is usually formed underground and consists of a short stem base bearing one or more buds enclosed in overlapping membranous or fleshy leaves." []	EFO	67740	EFO:0001048	\N	bulb	EFO:0001048
0	"A rounded thick modified underground stem base bearing membranous or scaly leaves and buds and acting as a vegetative reproductive structure." []	\N	corm	\N	\N	EFO	"A rounded thick modified underground stem base bearing membranous or scaly leaves and buds and acting as a vegetative reproductive structure." []	EFO	67741	EFO:0001049	\N	corm	EFO:0001049
0	"The floral organ that produces pollen; consisting of an anther and filament." []	\N	stamen	\N	\N	EFO	"The floral organ that produces pollen; consisting of an anther and filament." []	EFO	67742	EFO:0001050	\N	stamen	EFO:0001050
0	"The female reproductive part of a flower, consisting of stigma, style, and ovary." []	\N	carpel	\N	\N	EFO	"The female reproductive part of a flower, consisting of stigma, style, and ovary." []	EFO	67743	EFO:0001051	\N	carpel	EFO:0001051
0	"The enlarged rounded usually basal portion of the pistil or gynoecium of an angiospermous plant that bears the ovules and consists of one or more carpels." []	\N	plant ovary	\N	\N	EFO	"The enlarged rounded usually basal portion of the pistil or gynoecium of an angiospermous plant that bears the ovules and consists of one or more carpels." []	EFO	67744	EFO:0001052	\N	plant ovary	EFO:0001052
0	"The usually apical part of the pistil of a flower which receives the pollen grains and on which they germinate." []	\N	stigma	\N	\N	EFO	"The usually apical part of the pistil of a flower which receives the pollen grains and on which they germinate." []	EFO	67745	EFO:0001053	\N	stigma	EFO:0001053
0	"A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid." []	\N	leprosy	\N	\N	EFO	"A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid." []	EFO	67746	EFO:0001054	\N	leprosy	EFO:0001054
0	"A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms." []	\N	borderline leprosy	\N	\N	EFO	"A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms." []	EFO	67747	EFO:0001055	\N	borderline leprosy	EFO:0001055
0	"A principal or polar form of LEPROSY in which the skin lesions are few and are sharply demarcated. Peripheral nerve involvement is pronounced and may be severe. Unlike lepromatous leprosy (LEPROSY, LEPROMATOUS), the lepromin test is positive. Tuberculoid leprosy is rarely a source of infection to others." []	\N	tuberculoid leprosy	\N	\N	EFO	"A principal or polar form of LEPROSY in which the skin lesions are few and are sharply demarcated. Peripheral nerve involvement is pronounced and may be severe. Unlike lepromatous leprosy (LEPROSY, LEPROMATOUS), the lepromin test is positive. Tuberculoid leprosy is rarely a source of infection to others." []	EFO	67748	EFO:0001056	\N	tuberculoid leprosy	EFO:0001056
0	"A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage." []	\N	lepromatous leprosy	\N	\N	EFO	"A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage." []	EFO	67749	EFO:0001057	\N	lepromatous leprosy	EFO:0001057
0	"A sensory system disease is a disease which has as location the sensory system." []	\N	sensory system disease	\N	\N	EFO	"A sensory system disease is a disease which has as location the sensory system." []	EFO	67750	EFO:0001058	\N	sensory system disease	EFO:0001058
0	"Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)" []	\N	cataract	\N	\N	EFO	"Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)" []	EFO	67751	EFO:0001059	\N	cataract	EFO:0001059
0	"A malabsorption syndrome that is precipitated by the ingestion of GLUTEN-containing foods, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION." []	\N	celiac disease	\N	\N	EFO	"A malabsorption syndrome that is precipitated by the ingestion of GLUTEN-containing foods, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION." []	EFO	67752	EFO:0001060	\N	celiac disease	EFO:0001060
0	"Cervical carcinoma may arise from either the exocervical squamous epithelium or the endocervical glandular epithelium.  The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma." []	\N	cervical carcinoma	\N	\N	EFO	"Cervical carcinoma may arise from either the exocervical squamous epithelium or the endocervical glandular epithelium.  The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma." []	EFO	67753	EFO:0001061	\N	cervical carcinoma	EFO:0001061
0	"Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults." []	\N	cytomegalovirus infection	\N	\N	EFO	"Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults." []	EFO	67754	EFO:0001062	\N	cytomegalovirus infection	EFO:0001062
0	"An inherited or acquired condition characterized by the complete loss of the ability to hear from one or both ears." []	\N	deafness	\N	\N	EFO	"An inherited or acquired condition characterized by the complete loss of the ability to hear from one or both ears." []	EFO	67755	EFO:0001063	\N	deafness	EFO:0001063
0	"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs." []	\N	endometriosis	\N	\N	EFO	"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs." []	EFO	67756	EFO:0001065	\N	endometriosis	EFO:0001065
0	"An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)" []	\N	experimental autoimmune encephalomyelitis	\N	\N	EFO	"An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)" []	EFO	67757	EFO:0001066	\N	experimental autoimmune encephalomyelitis	EFO:0001066
0	"Infections or infestations with parasitic organisms. They are often contracted through contact with an intermediate vector, but may occur as the result of direct exposure." []	\N	parasitic Infection	\N	\N	EFO	"Infections or infestations with parasitic organisms. They are often contracted through contact with an intermediate vector, but may occur as the result of direct exposure." []	EFO	67758	EFO:0001067	\N	parasitic Infection	EFO:0001067
0	"Malaria is a parasitic disease characterized as a vector-borne arthropod infectious acute or chronic disease caused by the presence of sporozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle. Occurrance is widespread in tropical and subtropical regions, including parts of the Americas, Asia, and Africa." []	\N	malaria	\N	\N	EFO	"Malaria is a parasitic disease characterized as a vector-borne arthropod infectious acute or chronic disease caused by the presence of sporozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle. Occurrance is widespread in tropical and subtropical regions, including parts of the Americas, Asia, and Africa." []	EFO	67759	EFO:0001068	\N	malaria	EFO:0001068
0	"Disorders caused by nutritional imbalance, either overnutrition or undernutrition." []	\N	nutritional disorder	\N	\N	EFO	"Disorders caused by nutritional imbalance, either overnutrition or undernutrition." []	EFO	67760	EFO:0001069	\N	nutritional disorder	EFO:0001069
0	"A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)" []	\N	folate deficiency	\N	\N	EFO	"A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)" []	EFO	67761	EFO:0001070	\N	folate deficiency	EFO:0001070
0	"Tumors or cancer of the LUNG." []	\N	lung carcinoma	\N	\N	EFO	"Tumors or cancer of the LUNG." []	EFO	67762	EFO:0001071	\N	lung carcinoma	EFO:0001071
0	"" []	\N	memory impairment	\N	\N	EFO	"" []	EFO	67763	EFO:0001072	\N	memory impairment	EFO:0001072
0	"An eating-related disorder in which excess body fat has accumulated to such an extent that health may be negatively affected. It is commonly defined as a body mass index (weight divided by height squared) of 30 kg/m2 or higher." []	\N	obesity	\N	\N	EFO	"An eating-related disorder in which excess body fat has accumulated to such an extent that health may be negatively affected. It is commonly defined as a body mass index (weight divided by height squared) of 30 kg/m2 or higher." []	EFO	67764	EFO:0001073	\N	obesity	EFO:0001073
0	"The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2." []	\N	morbid obesity	\N	\N	EFO	"The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2." []	EFO	67765	EFO:0001074	\N	morbid obesity	EFO:0001074
0	"Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS." []	\N	ovarian carcinoma	\N	\N	EFO	"Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS." []	EFO	67766	EFO:0001075	\N	ovarian carcinoma	EFO:0001075
0	"Infections with bacteria of the genus PSEUDOMONAS." []	\N	Pseudomonas infection	\N	\N	EFO	"Infections with bacteria of the genus PSEUDOMONAS." []	EFO	67767	EFO:0001076	\N	Pseudomonas infection	EFO:0001076
0	"A Pseudomonas aeruginosa CF5 infection is a Pseudomonas infection of strain CF5." []	\N	Pseudomonas aeruginosa CF5 infection	\N	\N	EFO	"A Pseudomonas aeruginosa CF5 infection is a Pseudomonas infection of strain CF5." []	EFO	67768	EFO:0001077	\N	Pseudomonas aeruginosa CF5 infection	EFO:0001077
0	"A Pseudomonas aeruginosa PA14 infection is a Pseudomonas infection of strain PA14." []	\N	Pseudomonas aeruginosa PA14 infection	\N	\N	EFO	"A Pseudomonas aeruginosa PA14 infection is a Pseudomonas infection of strain PA14." []	EFO	67769	EFO:0001078	\N	Pseudomonas aeruginosa PA14 infection	EFO:0001078
0	"A 267b1 ki ras is a cell line.\\nA 267b1 ki ras derives from a prostate." []	\N	267B1	\N	\N	EFO	"A 267b1 ki ras is a cell line.\\nA 267b1 ki ras derives from a prostate." []	EFO	67770	EFO:0001080	\N	267B1	EFO:0001080
0	"" []	\N	267B1 Ki-ras	\N	\N	EFO	"" []	EFO	67771	EFO:0001081	\N	267B1 Ki-ras	EFO:0001081
0	"" []	\N	293T	\N	\N	EFO	"" []	EFO	67772	EFO:0001082	\N	293T	EFO:0001082
0	"" []	\N	293TsiLL	\N	\N	EFO	"" []	EFO	67773	EFO:0001083	\N	293TsiLL	EFO:0001083
0	"" []	\N	3T3-L1	\N	\N	EFO	"" []	EFO	67774	EFO:0001084	\N	3T3-L1	EFO:0001084
0	"" []	\N	600MPE	\N	\N	EFO	"" []	EFO	67775	EFO:0001085	\N	600MPE	EFO:0001085
0	"" []	\N	A549	\N	\N	EFO	"" []	EFO	67776	EFO:0001086	\N	A549	EFO:0001086
0	"" []	\N	AU565	\N	\N	EFO	"" []	EFO	67777	EFO:0001087	\N	AU565	EFO:0001087
0	"" []	\N	BEAS-2B	\N	\N	EFO	"" []	EFO	67778	EFO:0001089	\N	BEAS-2B	EFO:0001089
0	"" []	\N	BJABK3	\N	\N	EFO	"" []	EFO	67779	EFO:0001090	\N	BJABK3	EFO:0001090
0	"" []	\N	BL41K3	\N	\N	EFO	"" []	EFO	67780	EFO:0001091	\N	BL41K3	EFO:0001091
0	"A BT20 is a cell line.\\nA BT20 is all of the following: something that is bearer of a breast carcinoma, something that derives from a homo sapiens, and something that derives from an epithelial cell." []	\N	BT20	\N	\N	EFO	"A BT20 is a cell line.\\nA BT20 is all of the following: something that is bearer of a breast carcinoma, something that derives from a homo sapiens, and something that derives from an epithelial cell." []	EFO	67781	EFO:0001092	\N	BT20	EFO:0001092
0	"" []	\N	BT474	\N	\N	EFO	"" []	EFO	67782	EFO:0001093	\N	BT474	EFO:0001093
0	"" []	\N	BT483	\N	\N	EFO	"" []	EFO	67783	EFO:0001095	\N	BT483	EFO:0001095
0	"" []	\N	BT549	\N	\N	EFO	"" []	EFO	67784	EFO:0001096	\N	BT549	EFO:0001096
0	"" []	\N	C2C12	\N	\N	EFO	"" []	EFO	67785	EFO:0001098	\N	C2C12	EFO:0001098
0	"" []	\N	Caco-2	\N	\N	EFO	"" []	EFO	67786	EFO:0001099	\N	Caco-2	EFO:0001099
0	"" []	\N	CAMA1	\N	\N	EFO	"" []	EFO	67787	EFO:0001100	\N	CAMA1	EFO:0001100
0	"" []	\N	CC531	\N	\N	EFO	"" []	EFO	67788	EFO:0001101	\N	CC531	EFO:0001101
0	"" []	\N	CFT-2	\N	\N	EFO	"" []	EFO	67789	EFO:0001102	\N	CFT-2	EFO:0001102
0	"" []	\N	CSBwt-rescued fibroblasts	\N	\N	EFO	"" []	EFO	67790	EFO:0001103	\N	CSBwt-rescued fibroblasts	EFO:0001103
0	"" []	\N	GLI56	\N	\N	EFO	"" []	EFO	67791	EFO:0001104	\N	GLI56	EFO:0001104
0	"" []	\N	GLI60	\N	\N	EFO	"" []	EFO	67792	EFO:0001105	\N	GLI60	EFO:0001105
0	"" []	\N	GLI72	\N	\N	EFO	"" []	EFO	67793	EFO:0001106	\N	GLI72	EFO:0001106
0	"" []	\N	GM06985	\N	\N	EFO	"" []	EFO	67794	EFO:0001107	\N	GM06985	EFO:0001107
0	"" []	\N	GM06993	\N	\N	EFO	"" []	EFO	67795	EFO:0001108	\N	GM06993	EFO:0001108
0	"" []	\N	GM06994	\N	\N	EFO	"" []	EFO	67796	EFO:0001109	\N	GM06994	EFO:0001109
0	"" []	\N	GM07000	\N	\N	EFO	"" []	EFO	67797	EFO:0001110	\N	GM07000	EFO:0001110
0	"" []	\N	GM07022	\N	\N	EFO	"" []	EFO	67798	EFO:0001111	\N	GM07022	EFO:0001111
0	"" []	\N	GM07034	\N	\N	EFO	"" []	EFO	67799	EFO:0001112	\N	GM07034	EFO:0001112
0	"" []	\N	GM07055	\N	\N	EFO	"" []	EFO	67800	EFO:0001113	\N	GM07055	EFO:0001113
0	"" []	\N	GM07056	\N	\N	EFO	"" []	EFO	67801	EFO:0001114	\N	GM07056	EFO:0001114
0	"" []	\N	GM07345	\N	\N	EFO	"" []	EFO	67802	EFO:0001115	\N	GM07345	EFO:0001115
0	"" []	\N	GM07357	\N	\N	EFO	"" []	EFO	67803	EFO:0001116	\N	GM07357	EFO:0001116
0	"" []	\N	GM11829	\N	\N	EFO	"" []	EFO	67804	EFO:0001117	\N	GM11829	EFO:0001117
0	"" []	\N	GM11830	\N	\N	EFO	"" []	EFO	67805	EFO:0001118	\N	GM11830	EFO:0001118
0	"" []	\N	GM11831	\N	\N	EFO	"" []	EFO	67806	EFO:0001119	\N	GM11831	EFO:0001119
0	"" []	\N	GM11832	\N	\N	EFO	"" []	EFO	67807	EFO:0001120	\N	GM11832	EFO:0001120
0	"" []	\N	GM11839	\N	\N	EFO	"" []	EFO	67808	EFO:0001121	\N	GM11839	EFO:0001121
0	"" []	\N	GM11881	\N	\N	EFO	"" []	EFO	67809	EFO:0001122	\N	GM11881	EFO:0001122
0	"" []	\N	GM11882	\N	\N	EFO	"" []	EFO	67810	EFO:0001123	\N	GM11882	EFO:0001123
0	"" []	\N	GM11992	\N	\N	EFO	"" []	EFO	67811	EFO:0001124	\N	GM11992	EFO:0001124
0	"" []	\N	GM11993	\N	\N	EFO	"" []	EFO	67812	EFO:0001125	\N	GM11993	EFO:0001125
0	"" []	\N	GM11994	\N	\N	EFO	"" []	EFO	67813	EFO:0001126	\N	GM11994	EFO:0001126
0	"" []	\N	GM11995	\N	\N	EFO	"" []	EFO	67814	EFO:0001127	\N	GM11995	EFO:0001127
0	"" []	\N	GM12003	\N	\N	EFO	"" []	EFO	67815	EFO:0001128	\N	GM12003	EFO:0001128
0	"" []	\N	GM12004	\N	\N	EFO	"" []	EFO	67816	EFO:0001129	\N	GM12004	EFO:0001129
0	"" []	\N	GM12005	\N	\N	EFO	"" []	EFO	67817	EFO:0001130	\N	GM12005	EFO:0001130
0	"" []	\N	GM12006	\N	\N	EFO	"" []	EFO	67818	EFO:0001131	\N	GM12006	EFO:0001131
0	"" []	\N	GM12043	\N	\N	EFO	"" []	EFO	67819	EFO:0001132	\N	GM12043	EFO:0001132
0	"" []	\N	GM12044	\N	\N	EFO	"" []	EFO	67820	EFO:0001133	\N	GM12044	EFO:0001133
0	"" []	\N	GM12056	\N	\N	EFO	"" []	EFO	67821	EFO:0001134	\N	GM12056	EFO:0001134
0	"" []	\N	GM12057	\N	\N	EFO	"" []	EFO	67822	EFO:0001135	\N	GM12057	EFO:0001135
0	"" []	\N	GM12144	\N	\N	EFO	"" []	EFO	67823	EFO:0001136	\N	GM12144	EFO:0001136
0	"" []	\N	GM12145	\N	\N	EFO	"" []	EFO	67824	EFO:0001137	\N	GM12145	EFO:0001137
0	"" []	\N	GM12146	\N	\N	EFO	"" []	EFO	67825	EFO:0001138	\N	GM12146	EFO:0001138
0	"" []	\N	GM12154	\N	\N	EFO	"" []	EFO	67826	EFO:0001139	\N	GM12154	EFO:0001139
0	"" []	\N	GM12155	\N	\N	EFO	"" []	EFO	67827	EFO:0001140	\N	GM12155	EFO:0001140
0	"" []	\N	GM12156	\N	\N	EFO	"" []	EFO	67828	EFO:0001141	\N	GM12156	EFO:0001141
0	"" []	\N	GM12234	\N	\N	EFO	"" []	EFO	67829	EFO:0001142	\N	GM12234	EFO:0001142
0	"" []	\N	GM12236	\N	\N	EFO	"" []	EFO	67830	EFO:0001143	\N	GM12236	EFO:0001143
0	"" []	\N	GM12239	\N	\N	EFO	"" []	EFO	67831	EFO:0001144	\N	GM12239	EFO:0001144
0	"" []	\N	GM12248	\N	\N	EFO	"" []	EFO	67832	EFO:0001145	\N	GM12248	EFO:0001145
0	"" []	\N	GM12249	\N	\N	EFO	"" []	EFO	67833	EFO:0001146	\N	GM12249	EFO:0001146
0	"" []	\N	GM12716	\N	\N	EFO	"" []	EFO	67834	EFO:0001147	\N	GM12716	EFO:0001147
0	"" []	\N	GM12717	\N	\N	EFO	"" []	EFO	67835	EFO:0001148	\N	GM12717	EFO:0001148
0	"A lymphoblastoid cell line derived from CEPH/UTAH PEDIGREE 1444." []	\N	GM12750	\N	\N	EFO	"A lymphoblastoid cell line derived from CEPH/UTAH PEDIGREE 1444." []	EFO	67836	EFO:0001149	\N	GM12750	EFO:0001149
0	"" []	\N	GM12751	\N	\N	EFO	"" []	EFO	67837	EFO:0001150	\N	GM12751	EFO:0001150
0	"" []	\N	GM12760	\N	\N	EFO	"" []	EFO	67838	EFO:0001151	\N	GM12760	EFO:0001151
0	"" []	\N	GM12761	\N	\N	EFO	"" []	EFO	67839	EFO:0001152	\N	GM12761	EFO:0001152
0	"" []	\N	GM12762	\N	\N	EFO	"" []	EFO	67840	EFO:0001153	\N	GM12762	EFO:0001153
0	"" []	\N	GM12763	\N	\N	EFO	"" []	EFO	67841	EFO:0001154	\N	GM12763	EFO:0001154
0	"" []	\N	GM12812	\N	\N	EFO	"" []	EFO	67842	EFO:0001155	\N	GM12812	EFO:0001155
0	"" []	\N	GM12813	\N	\N	EFO	"" []	EFO	67843	EFO:0001156	\N	GM12813	EFO:0001156
0	"" []	\N	GM12814	\N	\N	EFO	"" []	EFO	67844	EFO:0001157	\N	GM12814	EFO:0001157
0	"" []	\N	GM12815	\N	\N	EFO	"" []	EFO	67845	EFO:0001158	\N	GM12815	EFO:0001158
0	"" []	\N	GM12872	\N	\N	EFO	"" []	EFO	67846	EFO:0001159	\N	GM12872	EFO:0001159
0	"" []	\N	GM12873	\N	\N	EFO	"" []	EFO	67847	EFO:0001160	\N	GM12873	EFO:0001160
0	"" []	\N	GM12874	\N	\N	EFO	"" []	EFO	67848	EFO:0001161	\N	GM12874	EFO:0001161
0	"" []	\N	GM12875	\N	\N	EFO	"" []	EFO	67849	EFO:0001162	\N	GM12875	EFO:0001162
0	"" []	\N	H209	\N	\N	EFO	"" []	EFO	67850	EFO:0001165	\N	H209	EFO:0001165
0	"" []	\N	H720	\N	\N	EFO	"" []	EFO	67851	EFO:0001166	\N	H720	EFO:0001166
0	"" []	\N	HBL100	\N	\N	EFO	"" []	EFO	67852	EFO:0001167	\N	HBL100	EFO:0001167
0	"A HCC1007 is a cell line.\\nA HCC1007 is all of the following: something that is bearer of a breast carcinoma, something that derives from an epithelial cell, and something that derives from a mammary gland." []	\N	HCC1007	\N	\N	EFO	"A HCC1007 is a cell line.\\nA HCC1007 is all of the following: something that is bearer of a breast carcinoma, something that derives from an epithelial cell, and something that derives from a mammary gland." []	EFO	67853	EFO:0001168	\N	HCC1007	EFO:0001168
0	"" []	\N	HCC1143	\N	\N	EFO	"" []	EFO	67854	EFO:0001169	\N	HCC1143	EFO:0001169
0	"" []	\N	HCC1187	\N	\N	EFO	"" []	EFO	67855	EFO:0001170	\N	HCC1187	EFO:0001170
0	"" []	\N	HCC1428	\N	\N	EFO	"" []	EFO	67856	EFO:0001171	\N	HCC1428	EFO:0001171
0	"" []	\N	HCC1500	\N	\N	EFO	"" []	EFO	67857	EFO:0001172	\N	HCC1500	EFO:0001172
0	"" []	\N	HCC1569	\N	\N	EFO	"" []	EFO	67858	EFO:0001173	\N	HCC1569	EFO:0001173
0	"" []	\N	HCC1937	\N	\N	EFO	"" []	EFO	67859	EFO:0001174	\N	HCC1937	EFO:0001174
0	"" []	\N	HCC1954	\N	\N	EFO	"" []	EFO	67860	EFO:0001175	\N	HCC1954	EFO:0001175
0	"" []	\N	HCC202	\N	\N	EFO	"" []	EFO	67861	EFO:0001176	\N	HCC202	EFO:0001176
0	"" []	\N	HCC2157	\N	\N	EFO	"" []	EFO	67862	EFO:0001177	\N	HCC2157	EFO:0001177
0	"" []	\N	HCC2185	\N	\N	EFO	"" []	EFO	67863	EFO:0001178	\N	HCC2185	EFO:0001178
0	"" []	\N	HCC3153	\N	\N	EFO	"" []	EFO	67864	EFO:0001179	\N	HCC3153	EFO:0001179
0	"" []	\N	HCC38	\N	\N	EFO	"" []	EFO	67865	EFO:0001180	\N	HCC38	EFO:0001180
0	"" []	\N	HCC70	\N	\N	EFO	"" []	EFO	67866	EFO:0001181	\N	HCC70	EFO:0001181
0	"" []	\N	HEK293	\N	\N	EFO	"" []	EFO	67867	EFO:0001182	\N	HEK293	EFO:0001182
0	"" []	\N	HEK-293H	\N	\N	EFO	"" []	EFO	67868	EFO:0001183	\N	HEK-293H	EFO:0001183
0	"" []	\N	HEK293T	\N	\N	EFO	"" []	EFO	67869	EFO:0001184	\N	HEK293T	EFO:0001184
0	"A HeLa is a cell line.\\nA HeLa is all of the following: something that is bearer of a cervical carcinoma, something that derives from \\na Homo sapiens, something that derives from an epithelial cell, and something that derives from a cervix." []	\N	HeLa	\N	\N	EFO	"A HeLa is a cell line.\\nA HeLa is all of the following: something that is bearer of a cervical carcinoma, something that derives from \\na Homo sapiens, something that derives from an epithelial cell, and something that derives from a cervix." []	EFO	67870	EFO:0001185	\N	HeLa	EFO:0001185
0	"" []	\N	HepaRG	\N	\N	EFO	"" []	EFO	67871	EFO:0001186	\N	HepaRG	EFO:0001186
0	"" []	\N	HepG2	\N	\N	EFO	"" []	EFO	67872	EFO:0001187	\N	HepG2	EFO:0001187
0	"" []	\N	HMEC	\N	\N	EFO	"" []	EFO	67873	EFO:0001188	\N	HMEC	EFO:0001188
0	"" []	\N	HMEC S1	\N	\N	EFO	"" []	EFO	67874	EFO:0001189	\N	HMEC S1	EFO:0001189
0	"" []	\N	HMEC184	\N	\N	EFO	"" []	EFO	67875	EFO:0001190	\N	HMEC184	EFO:0001190
0	"" []	\N	HMT3522S1	\N	\N	EFO	"" []	EFO	67876	EFO:0001191	\N	HMT3522S1	EFO:0001191
0	"" []	\N	HS578T	\N	\N	EFO	"" []	EFO	67877	EFO:0001192	\N	HS578T	EFO:0001192
0	"" []	\N	HT-29	\N	\N	EFO	"" []	EFO	67878	EFO:0001193	\N	HT-29	EFO:0001193
0	"" []	\N	IB3-1	\N	\N	EFO	"" []	EFO	67879	EFO:0001194	\N	IB3-1	EFO:0001194
0	"An IMR 32 is a cell line.\\nAn IMR 32 is both something that is bearer of a neuroblastoma, and something that derives from a \\nneuroblast sensu vertebrata." []	\N	IMR-32	\N	\N	EFO	"An IMR 32 is a cell line.\\nAn IMR 32 is both something that is bearer of a neuroblastoma, and something that derives from a \\nneuroblast sensu vertebrata." []	EFO	67880	EFO:0001195	\N	IMR-32	EFO:0001195
0	"Human Fetal Lung Fibroblast cell line" []	\N	IMR-90	\N	\N	EFO	"Human Fetal Lung Fibroblast cell line" []	EFO	67881	EFO:0001196	\N	IMR-90	EFO:0001196
0	"" []	\N	Kin-S49	\N	\N	EFO	"" []	EFO	67882	EFO:0001197	\N	Kin-S49	EFO:0001197
0	"" []	\N	L3055	\N	\N	EFO	"" []	EFO	67883	EFO:0001198	\N	L3055	EFO:0001198
0	"A LY2 is a cell line.\\nA LY2 is all of the following: something that is bearer of a breast carcinoma, something that derives from an \\nepithelial cell, and something that derives from a mammary gland." []	\N	LY2	\N	\N	EFO	"A LY2 is a cell line.\\nA LY2 is all of the following: something that is bearer of a breast carcinoma, something that derives from an \\nepithelial cell, and something that derives from a mammary gland." []	EFO	67884	EFO:0001199	\N	LY2	EFO:0001199
0	"" []	\N	MCF 10A	\N	\N	EFO	"" []	EFO	67885	EFO:0001200	\N	MCF 10A	EFO:0001200
0	"" []	\N	MCF12A	\N	\N	EFO	"" []	EFO	67886	EFO:0001202	\N	MCF12A	EFO:0001202
0	"Human breast adenocarcinoma, established from the pleural effusion of a 69-year-old caucasian woman with metastatic mammary carcinoma (after radio- and hormone therapy) in 1970; cells were described of being positive for cytoplasmic estrogen receptors and having the capability to form domes." []	\N	MCF-7	\N	\N	EFO	"Human breast adenocarcinoma, established from the pleural effusion of a 69-year-old caucasian woman with metastatic mammary carcinoma (after radio- and hormone therapy) in 1970; cells were described of being positive for cytoplasmic estrogen receptors and having the capability to form domes." []	EFO	67887	EFO:0001203	\N	MCF-7	EFO:0001203
0	"" []	\N	MDAMB134VI	\N	\N	EFO	"" []	EFO	67888	EFO:0001205	\N	MDAMB134VI	EFO:0001205
0	"" []	\N	MDAMB157	\N	\N	EFO	"" []	EFO	67889	EFO:0001206	\N	MDAMB157	EFO:0001206
0	"" []	\N	MDAMB175VII	\N	\N	EFO	"" []	EFO	67890	EFO:0001208	\N	MDAMB175VII	EFO:0001208
0	"" []	\N	MDAMB231	\N	\N	EFO	"" []	EFO	67891	EFO:0001209	\N	MDAMB231	EFO:0001209
0	"" []	\N	MDAMB361	\N	\N	EFO	"" []	EFO	67892	EFO:0001211	\N	MDAMB361	EFO:0001211
0	"" []	\N	MDAMB415	\N	\N	EFO	"" []	EFO	67893	EFO:0001212	\N	MDAMB415	EFO:0001212
0	"" []	\N	MDAMB435	\N	\N	EFO	"" []	EFO	67894	EFO:0001213	\N	MDAMB435	EFO:0001213
0	"" []	\N	MDAMB436	\N	\N	EFO	"" []	EFO	67895	EFO:0001214	\N	MDAMB436	EFO:0001214
0	"" []	\N	MDAMB453	\N	\N	EFO	"" []	EFO	67896	EFO:0001215	\N	MDAMB453	EFO:0001215
0	"" []	\N	MDAMB468	\N	\N	EFO	"" []	EFO	67897	EFO:0001216	\N	MDAMB468	EFO:0001216
0	"" []	\N	Met5A	\N	\N	EFO	"" []	EFO	67898	EFO:0001218	\N	Met5A	EFO:0001218
0	"" []	\N	MM1	\N	\N	EFO	"" []	EFO	67899	EFO:0001219	\N	MM1	EFO:0001219
0	"" []	\N	MOLT-4	\N	\N	EFO	"" []	EFO	67900	EFO:0001220	\N	MOLT-4	EFO:0001220
0	"A NCI H929 is a cell line.\\nA NCI H929 is all of the following: something that is bearer of a multiple myeloma, something that derives \\nfrom a B cell, and something that derives from a bone marrow." []	\N	NCI-H929	\N	\N	EFO	"A NCI H929 is a cell line.\\nA NCI H929 is all of the following: something that is bearer of a multiple myeloma, something that derives \\nfrom a B cell, and something that derives from a bone marrow." []	EFO	67901	EFO:0001221	\N	NCI-H929	EFO:0001221
0	"" []	\N	NIH3T3	\N	\N	EFO	"" []	EFO	67902	EFO:0001222	\N	NIH3T3	EFO:0001222
0	"" []	\N	NIH3T3-L1	\N	\N	EFO	"" []	EFO	67903	EFO:0001223	\N	NIH3T3-L1	EFO:0001223
0	"" []	\N	PAC2	\N	\N	EFO	"" []	EFO	67904	EFO:0001224	\N	PAC2	EFO:0001224
0	"" []	\N	PC12	\N	\N	EFO	"" []	EFO	67905	EFO:0001225	\N	PC12	EFO:0001225
0	"" []	\N	R18	\N	\N	EFO	"" []	EFO	67906	EFO:0001226	\N	R18	EFO:0001226
0	"" []	\N	R28	\N	\N	EFO	"" []	EFO	67907	EFO:0001227	\N	R28	EFO:0001227
0	"" []	\N	R43	\N	\N	EFO	"" []	EFO	67908	EFO:0001228	\N	R43	EFO:0001228
0	"" []	\N	R46	\N	\N	EFO	"" []	EFO	67909	EFO:0001229	\N	R46	EFO:0001229
0	"" []	\N	R8	\N	\N	EFO	"" []	EFO	67910	EFO:0001230	\N	R8	EFO:0001230
0	"" []	\N	RAW264.7	\N	\N	EFO	"" []	EFO	67911	EFO:0001231	\N	RAW264.7	EFO:0001231
0	"" []	\N	RKO	\N	\N	EFO	"" []	EFO	67912	EFO:0001232	\N	RKO	EFO:0001232
0	"Insect - fruitfly (Drosophila melanogaster) cell line, established from the late embryo of a Drosophila melanogaster (fruitfly) in 1972; originally the cells were diploid with 5-10% XY, currently the cell line has only XX cells that are now 60-80% tetraploid." []	\N	S2	\N	\N	EFO	"Insect - fruitfly (Drosophila melanogaster) cell line, established from the late embryo of a Drosophila melanogaster (fruitfly) in 1972; originally the cells were diploid with 5-10% XY, currently the cell line has only XX cells that are now 60-80% tetraploid." []	EFO	67913	EFO:0001233	\N	S2	EFO:0001233
0	"" []	\N	S49	\N	\N	EFO	"" []	EFO	67914	EFO:0001234	\N	S49	EFO:0001234
0	"A SKBR3 is a cell line.\\nA SKBR3 is all of the following: something that is bearer of a breast carcinoma, something that derives from \\nan epithelial cell, and something that derives from a mammary gland." []	\N	SKBR3	\N	\N	EFO	"A SKBR3 is a cell line.\\nA SKBR3 is all of the following: something that is bearer of a breast carcinoma, something that derives from \\nan epithelial cell, and something that derives from a mammary gland." []	EFO	67915	EFO:0001236	\N	SKBR3	EFO:0001236
0	"" []	\N	SKGT4	\N	\N	EFO	"" []	EFO	67916	EFO:0001237	\N	SKGT4	EFO:0001237
0	"" []	\N	SUM1315MO2	\N	\N	EFO	"" []	EFO	67917	EFO:0001239	\N	SUM1315MO2	EFO:0001239
0	"" []	\N	SUM149PT	\N	\N	EFO	"" []	EFO	67918	EFO:0001240	\N	SUM149PT	EFO:0001240
0	"" []	\N	SUM159PT	\N	\N	EFO	"" []	EFO	67919	EFO:0001241	\N	SUM159PT	EFO:0001241
0	"" []	\N	SUM185PE	\N	\N	EFO	"" []	EFO	67920	EFO:0001242	\N	SUM185PE	EFO:0001242
0	"" []	\N	SUM190PT	\N	\N	EFO	"" []	EFO	67921	EFO:0001243	\N	SUM190PT	EFO:0001243
0	"" []	\N	SUM225CWN	\N	\N	EFO	"" []	EFO	67922	EFO:0001244	\N	SUM225CWN	EFO:0001244
0	"" []	\N	SUM44PE	\N	\N	EFO	"" []	EFO	67923	EFO:0001245	\N	SUM44PE	EFO:0001245
0	"" []	\N	SUM52PE	\N	\N	EFO	"" []	EFO	67924	EFO:0001246	\N	SUM52PE	EFO:0001246
0	"" []	\N	T47D	\N	\N	EFO	"" []	EFO	67925	EFO:0001247	\N	T47D	EFO:0001247
0	"A TERV is a cell line.\\nA TERV derives from a kidney." []	\N	TERV	\N	\N	EFO	"A TERV is a cell line.\\nA TERV derives from a kidney." []	EFO	67926	EFO:0001249	\N	TERV	EFO:0001249
0	"" []	\N	TERV-AntiSenseB56	\N	\N	EFO	"" []	EFO	67927	EFO:0001250	\N	TERV-AntiSenseB56	EFO:0001250
0	"" []	\N	TERV-ST	\N	\N	EFO	"" []	EFO	67928	EFO:0001251	\N	TERV-ST	EFO:0001251
0	"" []	\N	TERV-ST110	\N	\N	EFO	"" []	EFO	67929	EFO:0001252	\N	TERV-ST110	EFO:0001252
0	"" []	\N	THP-1	\N	\N	EFO	"" []	EFO	67930	EFO:0001253	\N	THP-1	EFO:0001253
0	"" []	\N	U266	\N	\N	EFO	"" []	EFO	67931	EFO:0001254	\N	U266	EFO:0001254
0	"" []	\N	U373	\N	\N	EFO	"" []	EFO	67932	EFO:0001255	\N	U373	EFO:0001255
0	"" []	\N	U87	\N	\N	EFO	"" []	EFO	67933	EFO:0001256	\N	U87	EFO:0001256
0	"" []	\N	U937	\N	\N	EFO	"" []	EFO	67934	EFO:0001257	\N	U937	EFO:0001257
0	"" []	\N	UACC812	\N	\N	EFO	"" []	EFO	67935	EFO:0001258	\N	UACC812	EFO:0001258
0	"" []	\N	UBOC1	\N	\N	EFO	"" []	EFO	67936	EFO:0001259	\N	UBOC1	EFO:0001259
0	"" []	\N	WI38	\N	\N	EFO	"" []	EFO	67937	EFO:0001260	\N	WI38	EFO:0001260
0	"" []	\N	ZF4	\N	\N	EFO	"" []	EFO	67938	EFO:0001261	\N	ZF4	EFO:0001261
0	"" []	\N	ZR751	\N	\N	EFO	"" []	EFO	67939	EFO:0001262	\N	ZR751	EFO:0001262
0	"" []	\N	ZR7530	\N	\N	EFO	"" []	EFO	67940	EFO:0001263	\N	ZR7530	EFO:0001263
0	"" []	\N	ZR75B	\N	\N	EFO	"" []	EFO	67941	EFO:0001264	\N	ZR75B	EFO:0001264
0	"A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes." []	\N	female	\N	\N	EFO	"A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes." []	EFO	67942	EFO:0001265	\N	female	EFO:0001265
0	"A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes." []	\N	male	\N	\N	EFO	"A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes." []	EFO	67943	EFO:0001266	\N	male	EFO:0001266
0	"An organism having both male and female sexual characteristics and organs." []	\N	hermaphrodite	\N	\N	EFO	"An organism having both male and female sexual characteristics and organs." []	EFO	67944	EFO:0001267	\N	hermaphrodite	EFO:0001267
0	"A mating type is a biomaterial factor which describes the type of sexual reproduction through isogamy occur in eukaryotes that undergo." []	\N	mating type	\N	\N	EFO	"A mating type is a biomaterial factor which describes the type of sexual reproduction through isogamy occur in eukaryotes that undergo." []	EFO	67945	EFO:0001268	\N	mating type	EFO:0001268
0	"A S. pombe mating type determined by the mat1-Mc and mat1-Mi on the mat1 locus." []	\N	mating type h minus	\N	\N	EFO	"A S. pombe mating type determined by the mat1-Mc and mat1-Mi on the mat1 locus." []	EFO	67946	EFO:0001269	\N	mating type h minus	EFO:0001269
0	"A S. cerevisiae mating type cells that secrete a pheromone that stimulates a haploids." []	\N	mating type alpha	\N	\N	EFO	"A S. cerevisiae mating type cells that secrete a pheromone that stimulates a haploids." []	EFO	67947	EFO:0001270	\N	mating type alpha	EFO:0001270
0	"The total number of individuals inhabiting a particular region or area." []	\N	mixed sex population	\N	\N	EFO	"The total number of individuals inhabiting a particular region or area." []	EFO	67948	EFO:0001271	\N	mixed sex population	EFO:0001271
0	"A maturity quality inhering in an individual by virtue of the individual having attained sexual maturity and full growth" []	\N	adult	\N	\N	EFO	"A maturity quality inhering in an individual by virtue of the individual having attained sexual maturity and full growth" []	EFO	67949	EFO:0001272	\N	adult	EFO:0001272
0	"" []	\N	blastula 128-cell	\N	\N	EFO	"" []	EFO	67950	EFO:0001273	\N	blastula 128-cell	EFO:0001273
0	"" []	\N	blastula 1k-cell	\N	\N	EFO	"" []	EFO	67951	EFO:0001274	\N	blastula 1k-cell	EFO:0001274
0	"A S. cerevisiae mating type cells that secrete a pheromone that in alpha haploids stimulates processes that lead to mating." []	\N	mating type a	\N	\N	EFO	"A S. cerevisiae mating type cells that secrete a pheromone that in alpha haploids stimulates processes that lead to mating." []	EFO	67952	EFO:0001275	\N	mating type a	EFO:0001275
0	"" []	\N	blastula 256-cell	\N	\N	EFO	"" []	EFO	67953	EFO:0001276	\N	blastula 256-cell	EFO:0001276
0	"" []	\N	blastula 30%-epiboly	\N	\N	EFO	"" []	EFO	67954	EFO:0001277	\N	blastula 30%-epiboly	EFO:0001277
0	"" []	\N	blastula 512-cell	\N	\N	EFO	"" []	EFO	67955	EFO:0001278	\N	blastula 512-cell	EFO:0001278
0	"" []	\N	blastula dome	\N	\N	EFO	"" []	EFO	67956	EFO:0001279	\N	blastula dome	EFO:0001279
0	"" []	\N	blastula high	\N	\N	EFO	"" []	EFO	67957	EFO:0001280	\N	blastula high	EFO:0001280
0	"" []	\N	blastula oblong	\N	\N	EFO	"" []	EFO	67958	EFO:0001281	\N	blastula oblong	EFO:0001281
0	"" []	\N	blastula sphere	\N	\N	EFO	"" []	EFO	67959	EFO:0001283	\N	blastula sphere	EFO:0001283
0	"" []	\N	cleavage 16-cell	\N	\N	EFO	"" []	EFO	67960	EFO:0001284	\N	cleavage 16-cell	EFO:0001284
0	"" []	\N	cleavage 2-cell	\N	\N	EFO	"" []	EFO	67961	EFO:0001285	\N	cleavage 2-cell	EFO:0001285
0	"" []	\N	cleavage 32-cell	\N	\N	EFO	"" []	EFO	67962	EFO:0001286	\N	cleavage 32-cell	EFO:0001286
0	"" []	\N	cleavage 4-cell	\N	\N	EFO	"" []	EFO	67963	EFO:0001287	\N	cleavage 4-cell	EFO:0001287
0	"" []	\N	cleavage 64-cell	\N	\N	EFO	"" []	EFO	67964	EFO:0001288	\N	cleavage 64-cell	EFO:0001288
0	"" []	\N	cleavage 8-cell	\N	\N	EFO	"" []	EFO	67965	EFO:0001289	\N	cleavage 8-cell	EFO:0001289
0	"" []	\N	gastrula 50%-epiboly	\N	\N	EFO	"" []	EFO	67966	EFO:0001291	\N	gastrula 50%-epiboly	EFO:0001291
0	"" []	\N	gastrula 75%-epiboly	\N	\N	EFO	"" []	EFO	67967	EFO:0001292	\N	gastrula 75%-epiboly	EFO:0001292
0	"" []	\N	gastrula 90%-epiboly	\N	\N	EFO	"" []	EFO	67968	EFO:0001293	\N	gastrula 90%-epiboly	EFO:0001293
0	"" []	\N	gastrula bud	\N	\N	EFO	"" []	EFO	67969	EFO:0001294	\N	gastrula bud	EFO:0001294
0	"" []	\N	gastrula germ-ring	\N	\N	EFO	"" []	EFO	67970	EFO:0001295	\N	gastrula germ-ring	EFO:0001295
0	"" []	\N	gastrula shield	\N	\N	EFO	"" []	EFO	67971	EFO:0001297	\N	gastrula shield	EFO:0001297
0	"" []	\N	hatching stage	\N	\N	EFO	"" []	EFO	67972	EFO:0001298	\N	hatching stage	EFO:0001298
0	"" []	\N	hatching pec-fin	\N	\N	EFO	"" []	EFO	67973	EFO:0001299	\N	hatching pec-fin	EFO:0001299
0	"" []	\N	juvenile days 30-44	\N	\N	EFO	"" []	EFO	67974	EFO:0001301	\N	juvenile days 30-44	EFO:0001301
0	"" []	\N	juvenile days 45-89	\N	\N	EFO	"" []	EFO	67975	EFO:0001302	\N	juvenile days 45-89	EFO:0001302
0	"" []	\N	larval day 4	\N	\N	EFO	"" []	EFO	67976	EFO:0001304	\N	larval day 4	EFO:0001304
0	"" []	\N	larval day 5	\N	\N	EFO	"" []	EFO	67977	EFO:0001305	\N	larval day 5	EFO:0001305
0	"" []	\N	larval day 6	\N	\N	EFO	"" []	EFO	67978	EFO:0001306	\N	larval day 6	EFO:0001306
0	"" []	\N	larval day 14-20	\N	\N	EFO	"" []	EFO	67979	EFO:0001307	\N	larval day 14-20	EFO:0001307
0	"" []	\N	larval day 21-29	\N	\N	EFO	"" []	EFO	67980	EFO:0001308	\N	larval day 21-29	EFO:0001308
0	"" []	\N	larval day 7-13	\N	\N	EFO	"" []	EFO	67981	EFO:0001309	\N	larval day 7-13	EFO:0001309
0	"" []	\N	pharyngula high-pec	\N	\N	EFO	"" []	EFO	67982	EFO:0001311	\N	pharyngula high-pec	EFO:0001311
0	"" []	\N	pharyngula prim-15	\N	\N	EFO	"" []	EFO	67983	EFO:0001312	\N	pharyngula prim-15	EFO:0001312
0	"" []	\N	pharyngula prim-25	\N	\N	EFO	"" []	EFO	67984	EFO:0001313	\N	pharyngula prim-25	EFO:0001313
0	"" []	\N	pharyngula prim-5	\N	\N	EFO	"" []	EFO	67985	EFO:0001314	\N	pharyngula prim-5	EFO:0001314
0	"" []	\N	segmentation stage	\N	\N	EFO	"" []	EFO	67986	EFO:0001315	\N	segmentation stage	EFO:0001315
0	"" []	\N	segmentation 1-4 somites	\N	\N	EFO	"" []	EFO	67987	EFO:0001316	\N	segmentation 1-4 somites	EFO:0001316
0	"" []	\N	segmentation 5-9 somites	\N	\N	EFO	"" []	EFO	67988	EFO:0001317	\N	segmentation 5-9 somites	EFO:0001317
0	"" []	\N	segmentation 10-13 somites	\N	\N	EFO	"" []	EFO	67989	EFO:0001318	\N	segmentation 10-13 somites	EFO:0001318
0	"" []	\N	segmentation 14-19 somites	\N	\N	EFO	"" []	EFO	67990	EFO:0001319	\N	segmentation 14-19 somites	EFO:0001319
0	"" []	\N	segmentation 20-25 somites	\N	\N	EFO	"" []	EFO	67991	EFO:0001320	\N	segmentation 20-25 somites	EFO:0001320
0	"" []	\N	segmentation 26+ somites	\N	\N	EFO	"" []	EFO	67992	EFO:0001321	\N	segmentation 26+ somites	EFO:0001321
0	"Small but distinctive epithelial sac containing fluid, located midventrally posterior to the yolk cell or its extension, and transiently present during most of the segmentation period. Kupffer's vesicle has been compared to the mouse embryonic node." []	\N	fertilized egg stage	\N	\N	EFO	"Small but distinctive epithelial sac containing fluid, located midventrally posterior to the yolk cell or its extension, and transiently present during most of the segmentation period. Kupffer's vesicle has been compared to the mouse embryonic node." []	EFO	67993	EFO:0001322	\N	fertilized egg stage	EFO:0001322
0	"" []	\N	fetus	\N	\N	EFO	"" []	EFO	67994	EFO:0001323	\N	fetus	EFO:0001323
0	"" []	\N	Canton S	\N	\N	EFO	"" []	EFO	67995	EFO:0001325	\N	Canton S	EFO:0001325
0	"SALK_049497 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=4652085" []	\N	SALK_049497	\N	\N	EFO	"SALK_049497 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=4652085" []	EFO	67996	EFO:0001326	\N	SALK_049497	EFO:0001326
0	"A/J is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000646.html" []	\N	A/J	\N	\N	EFO	"A/J is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000646.html" []	EFO	67997	EFO:0001327	\N	A/J	EFO:0001327
0	"B6.Cg-Tg(SOD1-G93A)1Gur/J is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/004435.html" []	\N	B6.Cg-Tg(SOD1-G93A)1Gur/J	\N	\N	EFO	"B6.Cg-Tg(SOD1-G93A)1Gur/J is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/004435.html" []	EFO	67998	EFO:0001328	\N	B6.Cg-Tg(SOD1-G93A)1Gur/J	EFO:0001328
0	"C3H/HeJ is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000659.html" []	\N	C3H/HeJ	\N	\N	EFO	"C3H/HeJ is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000659.html" []	EFO	67999	EFO:0001329	\N	C3H/HeJ	EFO:0001329
0	"" []	\N	129P1/ReJ	\N	\N	EFO	"" []	EFO	68000	EFO:0001331	\N	129P1/ReJ	EFO:0001331
0	"" []	\N	129S1/SvImJ	\N	\N	EFO	"" []	EFO	68001	EFO:0001332	\N	129S1/SvImJ	EFO:0001332
0	"CBA/CaJ is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000654.html" []	\N	CBA/CaJ	\N	\N	EFO	"CBA/CaJ is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/000654.html" []	EFO	68002	EFO:0001336	\N	CBA/CaJ	EFO:0001336
0	"BDC2.5/NOD is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/004460.html" []	\N	BDC2.5/NOD	\N	\N	EFO	"BDC2.5/NOD is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/004460.html" []	EFO	68003	EFO:0001337	\N	BDC2.5/NOD	EFO:0001337
0	"TBP-71Q-16 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/008216.html" []	\N	TBP-71Q-16	\N	\N	EFO	"TBP-71Q-16 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/008216.html" []	EFO	68004	EFO:0001338	\N	TBP-71Q-16	EFO:0001338
0	"CB6F1 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/100007.html" []	\N	CB6F1	\N	\N	EFO	"CB6F1 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/100007.html" []	EFO	68005	EFO:0001339	\N	CB6F1	EFO:0001339
0	"B6C3F1 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/100010.html" []	\N	B6C3F1	\N	\N	EFO	"B6C3F1 is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/100010.html" []	EFO	68006	EFO:0001340	\N	B6C3F1	EFO:0001340
0	"TBP-105Q is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/008075.html" []	\N	TBP-105Q	\N	\N	EFO	"TBP-105Q is a mouse strain as described in Jackson Laboratory http://jaxmice.jax.org/strain/008075.html" []	EFO	68007	EFO:0001341	\N	TBP-105Q	EFO:0001341
0	"" []	\N	Wistar	\N	\N	EFO	"" []	EFO	68008	EFO:0001342	\N	Wistar	EFO:0001342
0	"" []	\N	Wistar-Furth	\N	\N	EFO	"" []	EFO	68009	EFO:0001343	\N	Wistar-Furth	EFO:0001343
0	"" []	\N	Copenhagen	\N	\N	EFO	"" []	EFO	68010	EFO:0001344	\N	Copenhagen	EFO:0001344
0	"" []	\N	Wistar-Kyoto	\N	\N	EFO	"" []	EFO	68011	EFO:0001345	\N	Wistar-Kyoto	EFO:0001345
0	"" []	\N	Syracuse High Avoidance	\N	\N	EFO	"" []	EFO	68012	EFO:0001346	\N	Syracuse High Avoidance	EFO:0001346
0	"" []	\N	Syracuse Low Avoidance	\N	\N	EFO	"" []	EFO	68013	EFO:0001347	\N	Syracuse Low Avoidance	EFO:0001347
0	"" []	\N	Okamoto-Aoki	\N	\N	EFO	"" []	EFO	68014	EFO:0001348	\N	Okamoto-Aoki	EFO:0001348
0	"" []	\N	Dahl salt-resistant	\N	\N	EFO	"" []	EFO	68015	EFO:0001349	\N	Dahl salt-resistant	EFO:0001349
0	"" []	\N	Dahl salt-sensitive	\N	\N	EFO	"" []	EFO	68016	EFO:0001350	\N	Dahl salt-sensitive	EFO:0001350
0	"" []	\N	WKY	\N	\N	EFO	"" []	EFO	68017	EFO:0001351	\N	WKY	EFO:0001351
0	"" []	\N	Sprague Dawley	\N	\N	EFO	"" []	EFO	68018	EFO:0001352	\N	Sprague Dawley	EFO:0001352
0	"" []	\N	Lewis	\N	\N	EFO	"" []	EFO	68019	EFO:0001353	\N	Lewis	EFO:0001353
0	"SALK_037727 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=4640315" []	\N	SALK_037727	\N	\N	EFO	"SALK_037727 is an Arabidopsis thaliana strain as described in TAIR http://www.arabidopsis.org/servlets/TairObject?type=germplasm&id=4640315" []	EFO	68020	EFO:0001354	\N	SALK_037727	EFO:0001354
0	"" []	\N	infant	\N	\N	EFO	"" []	EFO	68021	EFO:0001355	\N	infant	EFO:0001355
0	"Familial amyotrophic lateral sclerosis is a amyotrophic lateral sclerosis in which a family history of the disease exists." []	\N	familial amyotrophic lateral sclerosis	\N	\N	EFO	"Familial amyotrophic lateral sclerosis is a amyotrophic lateral sclerosis in which a family history of the disease exists." []	EFO	68022	EFO:0001356	\N	familial amyotrophic lateral sclerosis	EFO:0001356
0	"Sporadic amyotrophic lateral sclerosis is a amyotrophic lateral sclerosis in which there is no known cause, such as no family history." []	\N	sporadic amyotrophic lateral sclerosis	\N	\N	EFO	"Sporadic amyotrophic lateral sclerosis is a amyotrophic lateral sclerosis in which there is no known cause, such as no family history." []	EFO	68023	EFO:0001357	\N	sporadic amyotrophic lateral sclerosis	EFO:0001357
0	"An anxiety disorder precipitated by an experience of intense fear or horror while exposed to a traumatic (especially life-threatening) event. The disorder is characterized by intrusive recurring thoughts or images of the traumatic event; avoidance of anything associated with the event; a state of hyperarousal and diminished emotional responsiveness. These symptoms are present for at least one month and the disorder is usually long-term." []	\N	post-traumatic stress disorder	\N	\N	EFO	"An anxiety disorder precipitated by an experience of intense fear or horror while exposed to a traumatic (especially life-threatening) event. The disorder is characterized by intrusive recurring thoughts or images of the traumatic event; avoidance of anything associated with the event; a state of hyperarousal and diminished emotional responsiveness. These symptoms are present for at least one month and the disorder is usually long-term." []	EFO	68024	EFO:0001358	\N	post-traumatic stress disorder	EFO:0001358
0	"Diabetes mellitus characterized by insulin deficiency, sudden onset, severe hyperglycemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence." []	\N	type I diabetes mellitus	\N	\N	EFO	"Diabetes mellitus characterized by insulin deficiency, sudden onset, severe hyperglycemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence." []	EFO	68025	EFO:0001359	\N	type I diabetes mellitus	EFO:0001359
0	"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity." []	\N	type II diabetes mellitus	\N	\N	EFO	"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity." []	EFO	68026	EFO:0001360	\N	type II diabetes mellitus	EFO:0001360
0	"Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES." []	\N	pulmonary hypertension	\N	\N	EFO	"Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES." []	EFO	68027	EFO:0001361	\N	pulmonary hypertension	EFO:0001361
0	"The essential organ of hearing and equilibrium that is located in the temporal bone, is innervated by the auditory nerve, and includes the vestibule, the semicircular canals, and the cochlea." []	\N	inner ear structure	\N	\N	EFO	"The essential organ of hearing and equilibrium that is located in the temporal bone, is innervated by the auditory nerve, and includes the vestibule, the semicircular canals, and the cochlea." []	EFO	68028	EFO:0001363	\N	inner ear structure	EFO:0001363
0	"The organ, resting on the basilar membrane in the cochlear duct, that contains the special sensory receptors for hearing; it consists of neuroepithelial hair cells and several types of supporting cells, including the inner and outer pillar cells, inner and outer phalangeal cells, border cells, and Hensen's cells." []	\N	organ of corti	\N	\N	EFO	"The organ, resting on the basilar membrane in the cochlear duct, that contains the special sensory receptors for hearing; it consists of neuroepithelial hair cells and several types of supporting cells, including the inner and outer pillar cells, inner and outer phalangeal cells, border cells, and Hensen's cells." []	EFO	68029	EFO:0001364	\N	organ of corti	EFO:0001364
0	"Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms." []	\N	age-related macular degeneration	\N	\N	EFO	"Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms." []	EFO	68030	EFO:0001365	\N	age-related macular degeneration	EFO:0001365
0	"Part of the hippocampal formation forming a \\"V\\" or \\"U\\" shaped structure with the opening bounded by hippocampal area CA3. It consists of 3 layers from superficial to deep: molecular, granule cell and polymorphic or hilar layer." []	\N	dentate gyrus	\N	\N	EFO	"Part of the hippocampal formation forming a \\"V\\" or \\"U\\" shaped structure with the opening bounded by hippocampal area CA3. It consists of 3 layers from superficial to deep: molecular, granule cell and polymorphic or hilar layer." []	EFO	68031	EFO:0001366	\N	dentate gyrus	EFO:0001366
0	"An embryo is a multicellular diploid eukaryote in its earliest stage of development, from the time of first cell division until birth, hatching, or germination." []	\N	embryo stage	\N	\N	EFO	"An embryo is a multicellular diploid eukaryote in its earliest stage of development, from the time of first cell division until birth, hatching, or germination." []	EFO	68032	EFO:0001367	\N	embryo stage	EFO:0001367
0	"The post-cranial structural components forming the long axis of the vertebrate body; usually consists of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins." []	\N	vertebral column structure	\N	\N	EFO	"The post-cranial structural components forming the long axis of the vertebrate body; usually consists of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins." []	EFO	68033	EFO:0001369	\N	vertebral column structure	EFO:0001369
0	"An infant during the first month after birth." []	\N	neonate	\N	\N	EFO	"An infant during the first month after birth." []	EFO	68034	EFO:0001372	\N	neonate	EFO:0001372
0	"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes." []	\N	synovial sarcoma	\N	\N	EFO	"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes." []	EFO	68035	EFO:0001376	\N	synovial sarcoma	EFO:0001376
0	"A myeloma that is located_in the plasma cells in bone marrow." []	\N	multiple myeloma	\N	\N	EFO	"A myeloma that is located_in the plasma cells in bone marrow." []	EFO	68036	EFO:0001378	\N	multiple myeloma	EFO:0001378
0	"Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES." []	\N	endocrine system disease	\N	\N	EFO	"Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES." []	EFO	68037	EFO:0001379	\N	endocrine system disease	EFO:0001379
0	"Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions." []	\N	hypopituitarism	\N	\N	EFO	"Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions." []	EFO	68038	EFO:0001380	\N	hypopituitarism	EFO:0001380
0	"The process of sexual maturation mediated by the neuroendocrine system in mammals." []	\N	puberty	\N	\N	EFO	"The process of sexual maturation mediated by the neuroendocrine system in mammals." []	EFO	68039	EFO:0001382	\N	puberty	EFO:0001382
0	"The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes synovial fluid. (MeSH)" []	\N	synovial membrane	\N	\N	EFO	"The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes synovial fluid. (MeSH)" []	EFO	68040	EFO:0001393	\N	synovial membrane	EFO:0001393
0	"The lower region of the anterior abdominal wall located laterally to the pubic region." []	\N	inguinal region	\N	\N	EFO	"The lower region of the anterior abdominal wall located laterally to the pubic region." []	EFO	68041	EFO:0001397	\N	inguinal region	EFO:0001397
0	"" []	\N	corneal limbus	\N	\N	EFO	"" []	EFO	68042	EFO:0001403	\N	corneal limbus	EFO:0001403
0	"One of two or three twisted, curved tubules in each lobule of the testis in which spermatozoa develop." []	\N	seminiferous tubules	\N	\N	EFO	"One of two or three twisted, curved tubules in each lobule of the testis in which spermatozoa develop." []	EFO	68043	EFO:0001404	\N	seminiferous tubules	EFO:0001404
0	"" []	\N	cervical neck region	\N	\N	EFO	"" []	EFO	68044	EFO:0001408	\N	cervical neck region	EFO:0001408
0	"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb." []	\N	arm	\N	\N	EFO	"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb." []	EFO	68045	EFO:0001410	\N	arm	EFO:0001410
0	"One of the two lower extremities in humans used for locomotion and support." []	\N	leg	\N	\N	EFO	"One of the two lower extremities in humans used for locomotion and support." []	EFO	68046	EFO:0001411	\N	leg	EFO:0001411
0	"" []	\N	embryonic gonadal ridge	\N	\N	EFO	"" []	EFO	68047	EFO:0001414	\N	embryonic gonadal ridge	EFO:0001414
0	"Tumors or cancer of the UTERINE CERVIX." []	\N	cervical adenocarcinoma	\N	\N	EFO	"Tumors or cancer of the UTERINE CERVIX." []	EFO	68048	EFO:0001416	\N	cervical adenocarcinoma	EFO:0001416
0	"The presence of pathogenic microorganisms in the blood stream causing a rapidly progressing systemic reaction that may lead to shock. Symptoms include fever, chills, tachycardia, and increased respiratory rate. It is a medical emergency that requires urgent medical attention." []	\N	sepsis	\N	\N	EFO	"The presence of pathogenic microorganisms in the blood stream causing a rapidly progressing systemic reaction that may lead to shock. Symptoms include fever, chills, tachycardia, and increased respiratory rate. It is a medical emergency that requires urgent medical attention." []	EFO	68049	EFO:0001420	\N	sepsis	EFO:0001420
0	"Pathological processes of the LIVER." []	\N	liver disease	\N	\N	EFO	"Pathological processes of the LIVER." []	EFO	68050	EFO:0001421	\N	liver disease	EFO:0001421
0	"Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules." []	\N	cirrhosis of liver	\N	\N	EFO	"Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules." []	EFO	68051	EFO:0001422	\N	cirrhosis of liver	EFO:0001422
0	"A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature." []	\N	encephalomyelitis	\N	\N	EFO	"A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature." []	EFO	68052	EFO:0001423	\N	encephalomyelitis	EFO:0001423
0	"Ischemic cardiomyopathy is a cardiomyopathy in which a weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease being the most common cause." []	\N	ischemic cardiomyopathy	\N	\N	EFO	"Ischemic cardiomyopathy is a cardiomyopathy in which a weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease being the most common cause." []	EFO	68053	EFO:0001425	\N	ischemic cardiomyopathy	EFO:0001425
0	"A study type is an experimental factor describing the method of investigating particular types of research questions or solving particular types of problems, for example, a  set of protocols (which may specify how and what kinds of data will be gathered)." []	\N	study design	\N	\N	EFO	"A study type is an experimental factor describing the method of investigating particular types of research questions or solving particular types of problems, for example, a  set of protocols (which may specify how and what kinds of data will be gathered)." []	EFO	68054	EFO:0001426	\N	study design	EFO:0001426
0	"A case-control study design compares two groups of subjects: those with the disease or condition under study (cases) and a very similar group of subjects who do not have the disease or condition (controls)." []	\N	case control design	\N	\N	EFO	"A case-control study design compares two groups of subjects: those with the disease or condition under study (cases) and a very similar group of subjects who do not have the disease or condition (controls)." []	EFO	68055	EFO:0001427	\N	case control design	EFO:0001427
0	"A study in which participants are examined at only a single time for characteristics of a disease." []	\N	cross sectional design	\N	\N	EFO	"A study in which participants are examined at only a single time for characteristics of a disease." []	EFO	68056	EFO:0001428	\N	cross sectional design	EFO:0001428
0	"Research conducted on members of families, examining the affects of genetics, the environment, or twin offspring." []	\N	family based design	\N	\N	EFO	"Research conducted on members of families, examining the affects of genetics, the environment, or twin offspring." []	EFO	68057	EFO:0001429	\N	family based design	EFO:0001429
0	"Multidisciplinary study done at the population level or among the population groups, generally to find the cause, incidence or spread of the disease or to see the response to the treatment, nutrition or environment." []	\N	population based design	\N	\N	EFO	"Multidisciplinary study done at the population level or among the population groups, generally to find the cause, incidence or spread of the disease or to see the response to the treatment, nutrition or environment." []	EFO	68058	EFO:0001430	\N	population based design	EFO:0001430
0	"A twin study design is a study design in behavior genetics which aid the study of individual differences between genetically identical twins by highlighting the role of environmental and genetic causes on behavior." []	\N	twin design	\N	\N	EFO	"A twin study design is a study design in behavior genetics which aid the study of individual differences between genetically identical twins by highlighting the role of environmental and genetic causes on behavior." []	EFO	68059	EFO:0001431	\N	twin design	EFO:0001431
0	"A measurement is an information entity that is a recording of the output of a measurement such as produced by an instrument." []	\N	measurement	\N	\N	EFO	"A measurement is an information entity that is a recording of the output of a measurement such as produced by an instrument." []	EFO	68060	EFO:0001444	\N	measurement	EFO:0001444
0	"An instrument design is information in the form of a specification that describes the setup and design of an instrument." []	\N	instrument design	\N	\N	EFO	"An instrument design is information in the form of a specification that describes the setup and design of an instrument." []	EFO	68061	EFO:0001451	\N	instrument design	EFO:0001451
0	"An assay with input DNA" []	\N	DNA assay	\N	\N	EFO	"An assay with input DNA" []	EFO	68062	EFO:0001456	\N	DNA assay	EFO:0001456
0	"An assay with input RNA" []	\N	RNA assay	\N	\N	EFO	"An assay with input RNA" []	EFO	68063	EFO:0001457	\N	RNA assay	EFO:0001457
0	"An assay with input protein" []	\N	protein assay	\N	\N	EFO	"An assay with input protein" []	EFO	68064	EFO:0001458	\N	protein assay	EFO:0001458
0	"Uninfected class is a disposition in which the bearer is not known to be affected by a disease withtin the context of a study" []	\N	uninfected	\N	\N	EFO	"Uninfected class is a disposition in which the bearer is not known to be affected by a disease withtin the context of a study" []	EFO	68065	EFO:0001460	\N	uninfected	EFO:0001460
0	"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another." []	\N	control	\N	\N	EFO	"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another." []	EFO	68066	EFO:0001461	\N	control	EFO:0001461
0	"" []	\N	cancer cell line	\N	\N	EFO	"" []	EFO	68067	EFO:0001639	\N	cancer cell line	EFO:0001639
0	"" []	\N	B cell derived cell line	\N	\N	EFO	"" []	EFO	68068	EFO:0001640	\N	B cell derived cell line	EFO:0001640
0	"An epithelial cell derived cell line is defined as something that derives from an epithelial cell." []	\N	epithelial cell derived cell line	\N	\N	EFO	"An epithelial cell derived cell line is defined as something that derives from an epithelial cell." []	EFO	68069	EFO:0001641	\N	epithelial cell derived cell line	EFO:0001641
0	"Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation." []	\N	lymphoid neoplasm	\N	\N	EFO	"Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation." []	EFO	68070	EFO:0001642	\N	lymphoid neoplasm	EFO:0001642
0	"" []	\N	kidney derived cell line	\N	\N	EFO	"" []	EFO	68071	EFO:0001643	\N	kidney derived cell line	EFO:0001643
0	"The upper part of the spiral ligament of the scala media that contains numerous small blood vessels;nA layer of vascular tissue consisting of epithelial cells, mesothelial cells, and probably some neuroectoderm; it covers the outer wall of the cochlear duct and is thought to secrete the endolymph." []	\N	stria vascularis	\N	\N	EFO	"The upper part of the spiral ligament of the scala media that contains numerous small blood vessels;nA layer of vascular tissue consisting of epithelial cells, mesothelial cells, and probably some neuroectoderm; it covers the outer wall of the cochlear duct and is thought to secrete the endolymph." []	EFO	68072	EFO:0001644	\N	stria vascularis	EFO:0001644
0	"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls." []	\N	coronary heart disease	\N	\N	EFO	"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls." []	EFO	68073	EFO:0001645	\N	coronary heart disease	EFO:0001645
0	"An anatomical modifier is a quality which inheres in an organism part." []	\N	anatomical modifier	\N	\N	EFO	"An anatomical modifier is a quality which inheres in an organism part." []	EFO	68074	EFO:0001646	\N	anatomical modifier	EFO:0001646
0	"A tissue modifier is an anatomical modifier which describes some quality about a tissue." []	\N	tissue modifier	\N	\N	EFO	"A tissue modifier is an anatomical modifier which describes some quality about a tissue." []	EFO	68075	EFO:0001647	\N	tissue modifier	EFO:0001647
0	"A geometric modifier is an anatomical modifier which describes some quality about the geometric position of some organism part." []	\N	geometric modifier	\N	\N	EFO	"A geometric modifier is an anatomical modifier which describes some quality about the geometric position of some organism part." []	EFO	68076	EFO:0001648	\N	geometric modifier	EFO:0001648
0	"A placode is a tissue modifier describing the thickening of embryonic ectoderm from which a definitive structure develops. For example, the cranial placodes." []	\N	placode	\N	\N	EFO	"A placode is a tissue modifier describing the thickening of embryonic ectoderm from which a definitive structure develops. For example, the cranial placodes." []	EFO	68077	EFO:0001650	\N	placode	EFO:0001650
0	"A precursor is a tissue modifier describing a substance, cell, or cellular component from which another substance, cell, or cellular component is formed. For example, muscle precursor cell." []	\N	precursor	\N	\N	EFO	"A precursor is a tissue modifier describing a substance, cell, or cellular component from which another substance, cell, or cellular component is formed. For example, muscle precursor cell." []	EFO	68078	EFO:0001651	\N	precursor	EFO:0001651
0	"Apical is a geometric modifier describing the tip of a pyramidal or rounded structure. For example, lung apical." []	\N	apical	\N	\N	EFO	"Apical is a geometric modifier describing the tip of a pyramidal or rounded structure. For example, lung apical." []	EFO	68079	EFO:0001653	\N	apical	EFO:0001653
0	"Basal is a geometric modifier describing areas associated with the base of an organism or organism part. For example, basal ganglia." []	\N	basal	\N	\N	EFO	"Basal is a geometric modifier describing areas associated with the base of an organism or organism part. For example, basal ganglia." []	EFO	68080	EFO:0001654	\N	basal	EFO:0001654
0	"Distal is a geometric modifier describing the point furthest from the point of attachment to the body or to some point of origin. For example, distal end of femur." []	\N	distal	\N	\N	EFO	"Distal is a geometric modifier describing the point furthest from the point of attachment to the body or to some point of origin. For example, distal end of femur." []	EFO	68081	EFO:0001655	\N	distal	EFO:0001655
0	"Dorsal is a geometric modifier describing parts of an organism relating to or situated near or on the back. For example, dorsal fin." []	\N	dorsal	\N	\N	EFO	"Dorsal is a geometric modifier describing parts of an organism relating to or situated near or on the back. For example, dorsal fin." []	EFO	68082	EFO:0001656	\N	dorsal	EFO:0001656
0	"Lateral is a geometric modifier describing something which is of or pertaining to the side." []	\N	lateral	\N	\N	EFO	"Lateral is a geometric modifier describing something which is of or pertaining to the side." []	EFO	68083	EFO:0001657	\N	lateral	EFO:0001657
0	"Left is a geometric modifier describing something which is to the left of the median of an organism or organism part, for example left arm." []	\N	left	\N	\N	EFO	"Left is a geometric modifier describing something which is to the left of the median of an organism or organism part, for example left arm." []	EFO	68084	EFO:0001658	\N	left	EFO:0001658
0	"Right is a geometric modifier describing something which is to the right of the median of an organism or organism part, for example right arm." []	\N	right	\N	\N	EFO	"Right is a geometric modifier describing something which is to the right of the median of an organism or organism part, for example right arm." []	EFO	68085	EFO:0001659	\N	right	EFO:0001659
0	"Medial is a geometric modifier describing something which is pertaining to, in or toward the middle, for example medial meniscus." []	\N	medial	\N	\N	EFO	"Medial is a geometric modifier describing something which is pertaining to, in or toward the middle, for example medial meniscus." []	EFO	68086	EFO:0001660	\N	medial	EFO:0001660
0	"Proximal is a geometric modifier describing the point at which an appendage joins the body or the point nearest to some point of origin, for example proximal tibia." []	\N	proximal	\N	\N	EFO	"Proximal is a geometric modifier describing the point at which an appendage joins the body or the point nearest to some point of origin, for example proximal tibia." []	EFO	68087	EFO:0001661	\N	proximal	EFO:0001661
0	"Ventral is a geometric modifier describing parts pertaining to the front or anterior of any structure, for example ventral striatum." []	\N	ventral	\N	\N	EFO	"Ventral is a geometric modifier describing parts pertaining to the front or anterior of any structure, for example ventral striatum." []	EFO	68088	EFO:0001662	\N	ventral	EFO:0001662
0	"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002" []	\N	prostate carcinoma	\N	\N	EFO	"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002" []	EFO	68089	EFO:0001663	\N	prostate carcinoma	EFO:0001663
0	"A fold of skin that covers the glans of the penis." []	\N	foreskin	\N	\N	EFO	"A fold of skin that covers the glans of the penis." []	EFO	68090	EFO:0001664	\N	foreskin	EFO:0001664
0	"protruding sac formed by dilation of the aorta" []	\N	aortic aneurysm	\N	\N	EFO	"protruding sac formed by dilation of the aorta" []	EFO	68091	EFO:0001666	\N	aortic aneurysm	EFO:0001666
0	"" []	\N	CEM/C1	\N	\N	EFO	"" []	EFO	68092	EFO:0001667	\N	CEM/C1	EFO:0001667
0	"A viral infectious disease that has_material_basis_in human papillomaviruses, which establish productive infections only in the stratified epithelium of the skin or mucous membranes. These viruses cause warts and sometimes tumors. They are transmitted_by sexual contact." []	\N	human papilloma virus infection	\N	\N	EFO	"A viral infectious disease that has_material_basis_in human papillomaviruses, which establish productive infections only in the stratified epithelium of the skin or mucous membranes. These viruses cause warts and sometimes tumors. They are transmitted_by sexual contact." []	EFO	68093	EFO:0001668	\N	human papilloma virus infection	EFO:0001668
0	"An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system." []	\N	influenza infection	\N	\N	EFO	"An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system." []	EFO	68094	EFO:0001669	\N	influenza infection	EFO:0001669
0	"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial." []	\N	placebo	\N	\N	EFO	"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial." []	EFO	68095	EFO:0001674	\N	placebo	EFO:0001674
0	"An HIV-like virus that infects monkeys, chimpanzees, and other non-human primates. (AIDS Info HIV Glossary)" []	\N	simian immunodeficiency virus infection	\N	\N	EFO	"An HIV-like virus that infects monkeys, chimpanzees, and other non-human primates. (AIDS Info HIV Glossary)" []	EFO	68096	EFO:0001675	\N	simian immunodeficiency virus infection	EFO:0001675
0	"Size is a morphology quality which describes a material entity's physical magnitude." []	\N	size	\N	\N	EFO	"Size is a morphology quality which describes a material entity's physical magnitude." []	EFO	68097	EFO:0001695	\N	size	EFO:0001695
0	"An area is a size quality which describes the two dimensional extent of a material entity." []	\N	area	\N	\N	EFO	"An area is a size quality which describes the two dimensional extent of a material entity." []	EFO	68098	EFO:0001696	\N	area	EFO:0001696
0	"Temperature is a physical quality of the thermal energy of a system." []	\N	temperature	\N	\N	EFO	"Temperature is a physical quality of the thermal energy of a system." []	EFO	68099	EFO:0001702	\N	temperature	EFO:0001702
0	"A dervied mass unit is a derived unit which is a measure of the the amount of matter/energy of a physical object, derived from the base unit for mass." []	\N	derived mass unit	\N	\N	EFO	"A dervied mass unit is a derived unit which is a measure of the the amount of matter/energy of a physical object, derived from the base unit for mass." []	EFO	68100	EFO:0001703	\N	derived mass unit	EFO:0001703
0	"A volume is a size quality which describes the amount of 3-dimensional space an object occupies." []	\N	volume	\N	\N	EFO	"A volume is a size quality which describes the amount of 3-dimensional space an object occupies." []	EFO	68101	EFO:0001715	\N	volume	EFO:0001715
0	"A femtometer is a length unit which is equal to 1m x 10^-15." []	\N	femtometer	\N	\N	EFO	"A femtometer is a length unit which is equal to 1m x 10^-15." []	EFO	68102	EFO:0001721	\N	femtometer	EFO:0001721
0	"" []	\N	array manufacturer	\N	\N	EFO	"" []	EFO	68103	EFO:0001728	\N	array manufacturer	EFO:0001728
0	"" []	\N	biomaterial provider	\N	\N	EFO	"" []	EFO	68104	EFO:0001729	\N	biomaterial provider	EFO:0001729
0	"" []	\N	biosequence provider	\N	\N	EFO	"" []	EFO	68105	EFO:0001730	\N	biosequence provider	EFO:0001730
0	"" []	\N	consortium member	\N	\N	EFO	"" []	EFO	68106	EFO:0001731	\N	consortium member	EFO:0001731
0	"" []	\N	consultant	\N	\N	EFO	"" []	EFO	68107	EFO:0001732	\N	consultant	EFO:0001732
0	"" []	\N	curator	\N	\N	EFO	"" []	EFO	68108	EFO:0001733	\N	curator	EFO:0001733
0	"" []	\N	data analyst	\N	\N	EFO	"" []	EFO	68109	EFO:0001734	\N	data analyst	EFO:0001734
0	"" []	\N	data coder	\N	\N	EFO	"" []	EFO	68110	EFO:0001735	\N	data coder	EFO:0001735
0	"" []	\N	funder	\N	\N	EFO	"" []	EFO	68111	EFO:0001736	\N	funder	EFO:0001736
0	"" []	\N	hardware manufacturer	\N	\N	EFO	"" []	EFO	68112	EFO:0001737	\N	hardware manufacturer	EFO:0001737
0	"" []	\N	institution	\N	\N	EFO	"" []	EFO	68113	EFO:0001738	\N	institution	EFO:0001738
0	"" []	\N	investigator	\N	\N	EFO	"" []	EFO	68114	EFO:0001739	\N	investigator	EFO:0001739
0	"" []	\N	software manufacturer	\N	\N	EFO	"" []	EFO	68115	EFO:0001740	\N	software manufacturer	EFO:0001740
0	"" []	\N	submitter	\N	\N	EFO	"" []	EFO	68116	EFO:0001741	\N	submitter	EFO:0001741
0	"An information entity about the status of a publication describing the experiment." []	\N	publication status	\N	\N	EFO	"An information entity about the status of a publication describing the experiment." []	EFO	68117	EFO:0001742	\N	publication status	EFO:0001742
0	"A design in which RNA from different cell components is examined." []	\N	cell component comparison design	\N	\N	EFO	"A design in which RNA from different cell components is examined." []	EFO	68118	EFO:0001743	\N	cell component comparison design	EFO:0001743
0	"A cell cycle design study design type is one that assays events that occurs in relation to the cell cycle, which is the period between the formation of a cell, by division of its mother cell and the time when the cell itself divides to form two daughter cells." []	\N	cell cycle design	\N	\N	EFO	"A cell cycle design study design type is one that assays events that occurs in relation to the cell cycle, which is the period between the formation of a cell, by division of its mother cell and the time when the cell itself divides to form two daughter cells." []	EFO	68119	EFO:0001744	\N	cell cycle design	EFO:0001744
0	"A cell type study design experiment design type compares cells of different type for example different cell lines." []	\N	cell type comparison design	\N	\N	EFO	"A cell type study design experiment design type compares cells of different type for example different cell lines." []	EFO	68120	EFO:0001745	\N	cell type comparison design	EFO:0001745
0	"A development or differentiation study design type assays events associated with development or differentiation or moving through a life cycle. Development applies to organism(s) acquiring a mature state, and differentiation applies to cells acquiring specialized functions." []	\N	development or differentiation design	\N	\N	EFO	"A development or differentiation study design type assays events associated with development or differentiation or moving through a life cycle. Development applies to organism(s) acquiring a mature state, and differentiation applies to cells acquiring specialized functions." []	EFO	68121	EFO:0001746	\N	development or differentiation design	EFO:0001746
0	"An imprinting study design type compares differences in genetic imprinting of maternally- and paternally-inherited chromosomes (e.g., due to in vivo differences in chemical modification and/or chromatin structure)." []	\N	imprinting design	\N	\N	EFO	"An imprinting study design type compares differences in genetic imprinting of maternally- and paternally-inherited chromosomes (e.g., due to in vivo differences in chemical modification and/or chromatin structure)." []	EFO	68122	EFO:0001747	\N	imprinting design	EFO:0001747
0	"A genotype study design type compares genotype, haplotype, or other individual genetic characteristics." []	\N	genotype design	\N	\N	EFO	"A genotype study design type compares genotype, haplotype, or other individual genetic characteristics." []	EFO	68123	EFO:0001748	\N	genotype design	EFO:0001748
0	"An innate behaviour study design type in which the innate behavior of the organism is examined, e.g. path finding in bees." []	\N	innate behavior design	\N	\N	EFO	"An innate behaviour study design type in which the innate behavior of the organism is examined, e.g. path finding in bees." []	EFO	68124	EFO:0001749	\N	innate behavior design	EFO:0001749
0	"An organism part comparison study design type compares tissues, regions, organs within or between organisms." []	\N	organism part comparison design	\N	\N	EFO	"An organism part comparison study design type compares tissues, regions, organs within or between organisms." []	EFO	68125	EFO:0001750	\N	organism part comparison design	EFO:0001750
0	"A design that compares samples from live and dead organisms." []	\N	organism status design	\N	\N	EFO	"A design that compares samples from live and dead organisms." []	EFO	68126	EFO:0001751	\N	organism status design	EFO:0001751
0	"A sex study design type assays differences associated with an organism's sex, gender or mating type." []	\N	sex design	\N	\N	EFO	"A sex study design type assays differences associated with an organism's sex, gender or mating type." []	EFO	68127	EFO:0001752	\N	sex design	EFO:0001752
0	"A species study design type assays differences between distinct species." []	\N	species design	\N	\N	EFO	"A species study design type assays differences between distinct species." []	EFO	68128	EFO:0001753	\N	species design	EFO:0001753
0	"A strain or line study design type assays differences between multiple strains, cultivars, serovars, isolates, lines from organisms of a single species." []	\N	strain or line design	\N	\N	EFO	"A strain or line study design type assays differences between multiple strains, cultivars, serovars, isolates, lines from organisms of a single species." []	EFO	68129	EFO:0001754	\N	strain or line design	EFO:0001754
0	"A compound treatment study design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed." []	\N	compound treatment design	\N	\N	EFO	"A compound treatment study design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed." []	EFO	68130	EFO:0001755	\N	compound treatment design	EFO:0001755
0	"A disease state study design type in which the pathological condition of a part, organ, or system of an organism is studied. The etiology may be from infection, genetic defect, or environmental stress." []	\N	disease state design	\N	\N	EFO	"A disease state study design type in which the pathological condition of a part, organ, or system of an organism is studied. The etiology may be from infection, genetic defect, or environmental stress." []	EFO	68131	EFO:0001756	\N	disease state design	EFO:0001756
0	"A dose response study design type examines the relationship between the size of the administered dose and the extent of the response of the organism(s)." []	\N	dose response design	\N	\N	EFO	"A dose response study design type examines the relationship between the size of the administered dose and the extent of the response of the organism(s)." []	EFO	68132	EFO:0001757	\N	dose response design	EFO:0001757
0	"A genetic modification study design type is where an organism(s) has had genetic material removed, rearranged, mutagenized or added, such as knock out." []	\N	genetic modification design	\N	\N	EFO	"A genetic modification study design type is where an organism(s) has had genetic material removed, rearranged, mutagenized or added, such as knock out." []	EFO	68133	EFO:0001758	\N	genetic modification design	EFO:0001758
0	"A growth condition study design type is where some part of the growth condition is changed for the purposes of the experiment, examples of growth conditions changed are media, temperature, humidity, light, nutrients." []	\N	growth condition design	\N	\N	EFO	"A growth condition study design type is where some part of the growth condition is changed for the purposes of the experiment, examples of growth conditions changed are media, temperature, humidity, light, nutrients." []	EFO	68134	EFO:0001759	\N	growth condition design	EFO:0001759
0	"An injury study design type is where the response of an organism(s) to injury or damage is studied." []	\N	injury design	\N	\N	EFO	"An injury study design type is where the response of an organism(s) to injury or damage is studied." []	EFO	68135	EFO:0001760	\N	injury design	EFO:0001760
0	"A pathogenicity study design type is where an infective agent such as a bacterium, virus, protozoan, fungus etc. infects a host organism(s) and the infective agent is assayed." []	\N	pathogenicity design	\N	\N	EFO	"A pathogenicity study design type is where an infective agent such as a bacterium, virus, protozoan, fungus etc. infects a host organism(s) and the infective agent is assayed." []	EFO	68136	EFO:0001761	\N	pathogenicity design	EFO:0001761
0	"A stimulus or stress study design type is where the response of an organism(s) to the stress or stimulus is studied, e.g. osmotic stress, heat shock, radiation exposure, behavioral treatment etc." []	\N	stimulus or stress design	\N	\N	EFO	"A stimulus or stress study design type is where the response of an organism(s) to the stress or stimulus is studied, e.g. osmotic stress, heat shock, radiation exposure, behavioral treatment etc." []	EFO	68137	EFO:0001762	\N	stimulus or stress design	EFO:0001762
0	"An all pairs study design type is where all labeled extracts are compared to every other labeled extract." []	\N	all pairs	\N	\N	EFO	"An all pairs study design type is where all labeled extracts are compared to every other labeled extract." []	EFO	68138	EFO:0001763	\N	all pairs	EFO:0001763
0	"An experiment in which the array platform is compared, e.g. Agilent versus Affy." []	\N	array platform variation design	\N	\N	EFO	"An experiment in which the array platform is compared, e.g. Agilent versus Affy." []	EFO	68139	EFO:0001764	\N	array platform variation design	EFO:0001764
0	"A dye swap study design type where the label orientations are reversed. exact synonym: flip dye, dye flip" []	\N	dye swap design	\N	\N	EFO	"A dye swap study design type where the label orientations are reversed. exact synonym: flip dye, dye flip" []	EFO	68140	EFO:0001765	\N	dye swap design	EFO:0001765
0	"A hardware variation study design type compares different types of hardware for performance, reproducibility, accuracy and precision." []	\N	hardware variation design	\N	\N	EFO	"A hardware variation study design type compares different types of hardware for performance, reproducibility, accuracy and precision." []	EFO	68141	EFO:0001767	\N	hardware variation design	EFO:0001767
0	"A loop study design is where labeled extracts are compared in consecutive pairs. synonym: circular design." []	\N	loop design	\N	\N	EFO	"A loop study design is where labeled extracts are compared in consecutive pairs. synonym: circular design." []	EFO	68142	EFO:0001770	\N	loop design	EFO:0001770
0	"A normalization testing study design tests different normalization procedures." []	\N	normalization testing design	\N	\N	EFO	"A normalization testing study design tests different normalization procedures." []	EFO	68143	EFO:0001771	\N	normalization testing design	EFO:0001771
0	"An operator variation study design type assesses the operator performance and relation to data consistency and quality." []	\N	operator variation design	\N	\N	EFO	"An operator variation study design type assesses the operator performance and relation to data consistency and quality." []	EFO	68144	EFO:0001772	\N	operator variation design	EFO:0001772
0	"An optimization study design type is where different protocols or protocol parameters are compared." []	\N	optimization design	\N	\N	EFO	"An optimization study design type is where different protocols or protocol parameters are compared." []	EFO	68145	EFO:0001773	\N	optimization design	EFO:0001773
0	"A quality control testing study design type is where some aspect of the experiment is quality controlled for the purposes of quality assurance." []	\N	quality control testing design	\N	\N	EFO	"A quality control testing study design type is where some aspect of the experiment is quality controlled for the purposes of quality assurance." []	EFO	68146	EFO:0001774	\N	quality control testing design	EFO:0001774
0	"A reference study design type is where all samples are compared to a common reference." []	\N	reference design	\N	\N	EFO	"A reference study design type is where all samples are compared to a common reference." []	EFO	68147	EFO:0001775	\N	reference design	EFO:0001775
0	"A replicate study design type is where a series of replicates are performed to evaluate reproducibility or as a pilot study to determine the appropriate number of replicates for a subsequent experiments." []	\N	replicate design	\N	\N	EFO	"A replicate study design type is where a series of replicates are performed to evaluate reproducibility or as a pilot study to determine the appropriate number of replicates for a subsequent experiments." []	EFO	68148	EFO:0001776	\N	replicate design	EFO:0001776
0	"A self vs. self study design investigates variance and error estimates in the experimental system, and is where the same extract is compared." []	\N	self vs self design	\N	\N	EFO	"A self vs. self study design investigates variance and error estimates in the experimental system, and is where the same extract is compared." []	EFO	68149	EFO:0001777	\N	self vs self design	EFO:0001777
0	"A software variation study design type compares different types of software for performance, accuracy, precision and reproducibility." []	\N	software variation design	\N	\N	EFO	"A software variation study design type compares different types of software for performance, accuracy, precision and reproducibility." []	EFO	68150	EFO:0001778	\N	software variation design	EFO:0001778
0	"A time series study design type examines groups of assays that are related as part of a time series." []	\N	time series design	\N	\N	EFO	"A time series study design type examines groups of assays that are related as part of a time series." []	EFO	68151	EFO:0001779	\N	time series design	EFO:0001779
0	"A clinical history study design type is where the organisms clinical history of diagnosis, treatments, e.g. vaccinations, surgery etc. is studied." []	\N	clinical history design	\N	\N	EFO	"A clinical history study design type is where the organisms clinical history of diagnosis, treatments, e.g. vaccinations, surgery etc. is studied." []	EFO	68152	EFO:0001780	\N	clinical history design	EFO:0001780
0	"A RNA stability study design type examines the stability and/or decay of RNA transcripts." []	\N	RNA stability design	\N	\N	EFO	"A RNA stability study design type examines the stability and/or decay of RNA transcripts." []	EFO	68153	EFO:0001783	\N	RNA stability design	EFO:0001783
0	"A genotyping experiment design type classifies an individual or group of individuals on the basis of alleles, haplotypes, SNP's." []	\N	genotyping design	\N	\N	EFO	"A genotyping experiment design type classifies an individual or group of individuals on the basis of alleles, haplotypes, SNP's." []	EFO	68154	EFO:0001784	\N	genotyping design	EFO:0001784
0	"An operon identification experiment type is designed to identify locations and members of operons in a genome." []	\N	operon identification design	\N	\N	EFO	"An operon identification experiment type is designed to identify locations and members of operons in a genome." []	EFO	68155	EFO:0001785	\N	operon identification design	EFO:0001785
0	"A secreted protein identification design type identifies transcripts associated with a secretory pathway during translation and is used to infer which proteins are secreted or membrane bound." []	\N	secreted protein identification design	\N	\N	EFO	"A secreted protein identification design type identifies transcripts associated with a secretory pathway during translation and is used to infer which proteins are secreted or membrane bound." []	EFO	68156	EFO:0001786	\N	secreted protein identification design	EFO:0001786
0	"A translational bias is an experiment design which characterizes the association of transcripts and translation machinery." []	\N	translational bias design	\N	\N	EFO	"A translational bias is an experiment design which characterizes the association of transcripts and translation machinery." []	EFO	68157	EFO:0001787	\N	translational bias design	EFO:0001787
0	"Publication submitted to a journal for publication." []	\N	submitted	\N	\N	EFO	"Publication submitted to a journal for publication." []	EFO	68158	EFO:0001794	\N	submitted	EFO:0001794
0	"Publication in preparation before submitting to a journal." []	\N	in preparation	\N	\N	EFO	"Publication in preparation before submitting to a journal." []	EFO	68159	EFO:0001795	\N	in preparation	EFO:0001795
0	"Publication published in a journal." []	\N	published	\N	\N	EFO	"Publication published in a journal." []	EFO	68160	EFO:0001796	\N	published	EFO:0001796
0	"An ethnic group is a population whose members have a common heritage that is real or presumed such as common culture, language, religion, behaviour or biological trait." []	\N	ethnic group	\N	\N	EFO	"An ethnic group is a population whose members have a common heritage that is real or presumed such as common culture, language, religion, behaviour or biological trait." []	EFO	68161	EFO:0001799	\N	ethnic group	EFO:0001799
0	"" []	\N	hormone role	\N	\N	EFO	"" []	EFO	68162	EFO:0001824	\N	hormone role	EFO:0001824
0	"" []	\N	drug role	\N	\N	EFO	"" []	EFO	68163	EFO:0001899	\N	drug role	EFO:0001899
0	"Existing or growing in the air rather than in the ground or in water." []	\N	aerial part	\N	\N	EFO	"Existing or growing in the air rather than in the ground or in water." []	EFO	68164	EFO:0001901	\N	aerial part	EFO:0001901
0	"A thin layer of cartilage, usually hyaline, on the articular surface of bones in synovial joints." []	\N	articular cartilage	\N	\N	EFO	"A thin layer of cartilage, usually hyaline, on the articular surface of bones in synovial joints." []	EFO	68165	EFO:0001902	\N	articular cartilage	EFO:0001902
0	"" []	\N	nervous system developmental tissue	\N	\N	EFO	"" []	EFO	68166	EFO:0001903	\N	nervous system developmental tissue	EFO:0001903
0	"" []	\N	basal plate	\N	\N	EFO	"" []	EFO	68167	EFO:0001904	\N	basal plate	EFO:0001904
0	"Dorsal skin is a skin found at the dorsal area of an animal." []	\N	dorsal skin	\N	\N	EFO	"Dorsal skin is a skin found at the dorsal area of an animal." []	EFO	68168	EFO:0001907	\N	dorsal skin	EFO:0001907
0	"Caudal is a geometric modifier which indicates a position towards the tail." []	\N	caudal	\N	\N	EFO	"Caudal is a geometric modifier which indicates a position towards the tail." []	EFO	68169	EFO:0001908	\N	caudal	EFO:0001908
0	"Fin that is the most posterior median fin. It is composed of a complex of three modified centra and modified neural and hemal arches and spines." []	\N	caudal fin	\N	\N	EFO	"Fin that is the most posterior median fin. It is composed of a complex of three modified centra and modified neural and hemal arches and spines." []	EFO	68170	EFO:0001909	\N	caudal fin	EFO:0001909
0	"A brain structure developmental tissue is a nervous system developmental tissue from which mature, fully developed brain structures will emerge during growth of an organism." []	\N	brain structure developmental tissue	\N	\N	EFO	"A brain structure developmental tissue is a nervous system developmental tissue from which mature, fully developed brain structures will emerge during growth of an organism." []	EFO	68171	EFO:0001910	\N	brain structure developmental tissue	EFO:0001910
0	"" []	\N	conjunctival epithelium	\N	\N	EFO	"" []	EFO	68172	EFO:0001916	\N	conjunctival epithelium	EFO:0001916
0	"Small, bilaterally paired gland that lies behind the spermathecae and is connected to the uterus by a duct. The gland wall consists of a single layer of polygonal cells, each with a large vacuole and a minute acidophillic granule towards the gland lumen." []	\N	female accessory gland	\N	\N	EFO	"Small, bilaterally paired gland that lies behind the spermathecae and is connected to the uterus by a duct. The gland wall consists of a single layer of polygonal cells, each with a large vacuole and a minute acidophillic granule towards the gland lumen." []	EFO	68173	EFO:0001922	\N	female accessory gland	EFO:0001922
0	"A bud that will develop into a flower." []	\N	flower bud	\N	\N	EFO	"A bud that will develop into a flower." []	EFO	68174	EFO:0001924	\N	flower bud	EFO:0001924
0	"The tissue that surrounds the necks of teeth and covers the alveolar parts of the jaws; broadly: the alveolar portion of a jaw with its enveloping soft tissues." []	\N	gum	\N	\N	EFO	"The tissue that surrounds the necks of teeth and covers the alveolar parts of the jaws; broadly: the alveolar portion of a jaw with its enveloping soft tissues." []	EFO	68175	EFO:0001925	\N	gum	EFO:0001925
0	"The female reproductive organs of a flower; the pistil or pistils considered as a group." []	\N	gynoecium	\N	\N	EFO	"The female reproductive organs of a flower; the pistil or pistils considered as a group." []	EFO	68176	EFO:0001926	\N	gynoecium	EFO:0001926
0	"The fused compact cephalic plates that comprise the head, excluding the eyes, antennae and mouthparts." []	\N	head capsule	\N	\N	EFO	"The fused compact cephalic plates that comprise the head, excluding the eyes, antennae and mouthparts." []	EFO	68177	EFO:0001927	\N	head capsule	EFO:0001927
0	"The laterally projecting region of each side of the lower or posterior part of the mammalian trunk formed by the lateral parts of the pelvis and upper part of the femur together with the fleshy parts covering them." []	\N	hip	\N	\N	EFO	"The laterally projecting region of each side of the lower or posterior part of the mammalian trunk formed by the lateral parts of the pelvis and upper part of the femur together with the fleshy parts covering them." []	EFO	68178	EFO:0001929	\N	hip	EFO:0001929
0	"The inner of the two layers of the blastoderm that forms during gastrulation and give rise to the definitive mesoderm and endoderm. Kimmel et al, 1995." []	\N	hypoblast	\N	\N	EFO	"The inner of the two layers of the blastoderm that forms during gastrulation and give rise to the definitive mesoderm and endoderm. Kimmel et al, 1995." []	EFO	68179	EFO:0001930	\N	hypoblast	EFO:0001930
0	"The part of the axis of a plant embryo or seedling below the cotyledon." []	\N	hypocotyl	\N	\N	EFO	"The part of the axis of a plant embryo or seedling below the cotyledon." []	EFO	68180	EFO:0001931	\N	hypocotyl	EFO:0001931
0	"The entire dorsal mesothoracic disc (wing, notal, and pleural parts), in the larval stage of Drosophila." []	\N	wing disc	\N	\N	EFO	"The entire dorsal mesothoracic disc (wing, notal, and pleural parts), in the larval stage of Drosophila." []	EFO	68181	EFO:0001933	\N	wing disc	EFO:0001933
0	"" []	\N	blood component	\N	\N	EFO	"" []	EFO	68182	EFO:0001941	\N	blood component	EFO:0001941
0	"1: The proximal segment of the vertebrate hind limb extending from the hip to the knee and supported by a single large bone.n2: The segment of the leg immediately distal to the thigh in a bird or in a quadruped in which the true thigh is obscured." []	\N	thigh	\N	\N	EFO	"1: The proximal segment of the vertebrate hind limb extending from the hip to the knee and supported by a single large bone.n2: The segment of the leg immediately distal to the thigh in a bird or in a quadruped in which the true thigh is obscured." []	EFO	68183	EFO:0001943	\N	thigh	EFO:0001943
0	"The terminal bud (0.1 - 1.0 mm) of a plant, which consists of the apical meristem (0.05 - 0.1 mm) and the immediate surrounding leaf primordia and developing leaves and adjacent stem tissue." []	\N	shoot apex	\N	\N	EFO	"The terminal bud (0.1 - 1.0 mm) of a plant, which consists of the apical meristem (0.05 - 0.1 mm) and the immediate surrounding leaf primordia and developing leaves and adjacent stem tissue." []	EFO	68184	EFO:0001947	\N	shoot apex	EFO:0001947
0	"A shoot component is a plant component which is specifically part of a plant shoot." []	\N	shoot component	\N	\N	EFO	"A shoot component is a plant component which is specifically part of a plant shoot." []	EFO	68185	EFO:0001948	\N	shoot component	EFO:0001948
0	"A body tissue consisting of long cells that contract when stimulated and produce motion." []	\N	muscle	\N	\N	EFO	"A body tissue consisting of long cells that contract when stimulated and produce motion." []	EFO	68186	EFO:0001949	\N	muscle	EFO:0001949
0	"" []	\N	inferior parietal lobule	\N	\N	EFO	"" []	EFO	68187	EFO:0001951	\N	inferior parietal lobule	EFO:0001951
0	"" []	\N	division of carotid artery	\N	\N	EFO	"" []	EFO	68188	EFO:0001954	\N	division of carotid artery	EFO:0001954
0	"A heart component is an animal component that is part of some heart." []	\N	heart component	\N	\N	EFO	"A heart component is an animal component that is part of some heart." []	EFO	68189	EFO:0001955	\N	heart component	EFO:0001955
0	"" []	\N	joint component	\N	\N	EFO	"" []	EFO	68190	EFO:0001958	\N	joint component	EFO:0001958
0	"" []	\N	lateral root	\N	\N	EFO	"" []	EFO	68191	EFO:0001960	\N	lateral root	EFO:0001960
0	"The rostral extensions of the ventricular system of the brain consisting of two cavities, one on each side of the brain within the central regions of each cerebral hemisphere.  Cerebrospinal fluid flows from the lateral ventricles into the centrally third ventricle via the foramen of Monroe." []	\N	lateral ventricle	\N	\N	EFO	"The rostral extensions of the ventricular system of the brain consisting of two cavities, one on each side of the brain within the central regions of each cerebral hemisphere.  Cerebrospinal fluid flows from the lateral ventricles into the centrally third ventricle via the foramen of Monroe." []	EFO	68192	EFO:0001961	\N	lateral ventricle	EFO:0001961
0	"" []	\N	male accessory gland	\N	\N	EFO	"" []	EFO	68193	EFO:0001964	\N	male accessory gland	EFO:0001964
0	"" []	\N	medial collateral ligament	\N	\N	EFO	"" []	EFO	68194	EFO:0001967	\N	medial collateral ligament	EFO:0001967
0	"" []	\N	nucleus of terminal stria	\N	\N	EFO	"" []	EFO	68195	EFO:0001971	\N	nucleus of terminal stria	EFO:0001971
0	"A leaf component is a plant component which is part of a leaf." []	\N	leaf component	\N	\N	EFO	"A leaf component is a plant component which is part of a leaf." []	EFO	68196	EFO:0001983	\N	leaf component	EFO:0001983
0	"" []	\N	rosette leaf	\N	\N	EFO	"" []	EFO	68197	EFO:0001984	\N	rosette leaf	EFO:0001984
0	"" []	\N	pulmonary alveolus	\N	\N	EFO	"" []	EFO	68198	EFO:0001985	\N	pulmonary alveolus	EFO:0001985
0	"A lung structuret is a respiratory system component which is part of a lung." []	\N	lung structure	\N	\N	EFO	"A lung structuret is a respiratory system component which is part of a lung." []	EFO	68199	EFO:0001986	\N	lung structure	EFO:0001986
0	"The embryonic product of the germination of a seed; the young shoot and root axis." []	\N	seedling	\N	\N	EFO	"The embryonic product of the germination of a seed; the young shoot and root axis." []	EFO	68200	EFO:0001992	\N	seedling	EFO:0001992
0	"" []	\N	fibroblast derived cell line	\N	\N	EFO	"" []	EFO	68201	EFO:0002009	\N	fibroblast derived cell line	EFO:0002009
0	"An organization role is a role which is borne by an organization." []	\N	organization role	\N	\N	EFO	"An organization role is a role which is borne by an organization." []	EFO	68202	EFO:0002012	\N	organization role	EFO:0002012
0	"A microarray wash station is an instrument used to wash or stain microarrays." []	\N	microarray wash station	\N	\N	EFO	"A microarray wash station is an instrument used to wash or stain microarrays." []	EFO	68203	EFO:0002028	\N	microarray wash station	EFO:0002028
0	"" []	\N	software	\N	\N	EFO	"" []	EFO	68204	EFO:0002029	\N	software	EFO:0002029
0	"An Ara-C-resistant murine leukemia is a cell line.\\nA b117h, and a b140h are kinds of Ara-C-resistant murine leukemias." []	\N	Ara-C-resistant murine leukemia	\N	\N	EFO	"An Ara-C-resistant murine leukemia is a cell line.\\nA b117h, and a b140h are kinds of Ara-C-resistant murine leukemias." []	EFO	68205	EFO:0002032	\N	Ara-C-resistant murine leukemia	EFO:0002032
0	"" []	\N	Ara-C-sensitive parental cell line	\N	\N	EFO	"" []	EFO	68206	EFO:0002033	\N	Ara-C-sensitive parental cell line	EFO:0002033
0	"A GATA-1-null erythroblast is a cell line.\\nA g1e er4 is a GATA-1-null erythroblast." []	\N	G1E	\N	\N	EFO	"A GATA-1-null erythroblast is a cell line.\\nA g1e er4 is a GATA-1-null erythroblast." []	EFO	68207	EFO:0002034	\N	G1E	EFO:0002034
0	"" []	\N	murine neuroblastoma cholinergic cell line	\N	\N	EFO	"" []	EFO	68208	EFO:0002035	\N	murine neuroblastoma cholinergic cell line	EFO:0002035
0	"" []	\N	4T1	\N	\N	EFO	"" []	EFO	68209	EFO:0002037	\N	4T1	EFO:0002037
0	"" []	\N	66cl4	\N	\N	EFO	"" []	EFO	68210	EFO:0002038	\N	66cl4	EFO:0002038
0	"" []	\N	67NR	\N	\N	EFO	"" []	EFO	68211	EFO:0002039	\N	67NR	EFO:0002039
0	"A b117h is an ara c resistant murine leukemia." []	\N	B117H	\N	\N	EFO	"A b117h is an ara c resistant murine leukemia." []	EFO	68212	EFO:0002040	\N	B117H	EFO:0002040
0	"" []	\N	B117P	\N	\N	EFO	"" []	EFO	68213	EFO:0002041	\N	B117P	EFO:0002041
0	"AB140H is an Ara-C-resistant murine leukemia." []	\N	B140H	\N	\N	EFO	"AB140H is an Ara-C-resistant murine leukemia." []	EFO	68214	EFO:0002042	\N	B140H	EFO:0002042
0	"" []	\N	B140P	\N	\N	EFO	"" []	EFO	68215	EFO:0002043	\N	B140P	EFO:0002043
0	"" []	\N	BC-1	\N	\N	EFO	"" []	EFO	68216	EFO:0002044	\N	BC-1	EFO:0002044
0	"" []	\N	BC-2	\N	\N	EFO	"" []	EFO	68217	EFO:0002045	\N	BC-2	EFO:0002045
0	"" []	\N	BC-3	\N	\N	EFO	"" []	EFO	68218	EFO:0002046	\N	BC-3	EFO:0002046
0	"" []	\N	BC-5	\N	\N	EFO	"" []	EFO	68219	EFO:0002047	\N	BC-5	EFO:0002047
0	"" []	\N	BCBL-1	\N	\N	EFO	"" []	EFO	68220	EFO:0002048	\N	BCBL-1	EFO:0002048
0	"" []	\N	BCKN-1	\N	\N	EFO	"" []	EFO	68221	EFO:0002049	\N	BCKN-1	EFO:0002049
0	"" []	\N	BeWo	\N	\N	EFO	"" []	EFO	68222	EFO:0002050	\N	BeWo	EFO:0002050
0	"" []	\N	D4 glioblastoma derived primary cell line	\N	\N	EFO	"" []	EFO	68223	EFO:0002051	\N	D4 glioblastoma derived primary cell line	EFO:0002051
0	"" []	\N	EcR-RKO/KLF4	\N	\N	EFO	"" []	EFO	68224	EFO:0002052	\N	EcR-RKO/KLF4	EFO:0002052
0	"" []	\N	F9 mouse embryonal carcinoma cell line	\N	\N	EFO	"" []	EFO	68225	EFO:0002053	\N	F9 mouse embryonal carcinoma cell line	EFO:0002053
0	"" []	\N	Fu97	\N	\N	EFO	"" []	EFO	68226	EFO:0002054	\N	Fu97	EFO:0002054
0	"A g1e er4 is a GATA-1-null erythroblast." []	\N	G1E-ER4	\N	\N	EFO	"A g1e er4 is a GATA-1-null erythroblast." []	EFO	68227	EFO:0002055	\N	G1E-ER4	EFO:0002055
0	"" []	\N	HaCaT	\N	\N	EFO	"" []	EFO	68228	EFO:0002056	\N	HaCaT	EFO:0002056
0	"" []	\N	HCC1008	\N	\N	EFO	"" []	EFO	68229	EFO:0002057	\N	HCC1008	EFO:0002057
0	"" []	\N	HT1080	\N	\N	EFO	"" []	EFO	68230	EFO:0002059	\N	HT1080	EFO:0002059
0	"" []	\N	IBL4	\N	\N	EFO	"" []	EFO	68231	EFO:0002060	\N	IBL4	EFO:0002060
0	"" []	\N	ITM	\N	\N	EFO	"" []	EFO	68232	EFO:0002061	\N	ITM	EFO:0002061
0	"" []	\N	ITM-E6E7	\N	\N	EFO	"" []	EFO	68233	EFO:0002062	\N	ITM-E6E7	EFO:0002062
0	"" []	\N	ITM-E6E7-ST	\N	\N	EFO	"" []	EFO	68234	EFO:0002063	\N	ITM-E6E7-ST	EFO:0002063
0	"" []	\N	ITM-ST	\N	\N	EFO	"" []	EFO	68235	EFO:0002064	\N	ITM-ST	EFO:0002064
0	"" []	\N	ITV	\N	\N	EFO	"" []	EFO	68236	EFO:0002065	\N	ITV	EFO:0002065
0	"" []	\N	JEG3	\N	\N	EFO	"" []	EFO	68237	EFO:0002066	\N	JEG3	EFO:0002066
0	"Human chronic myeloid leukemia in blast crisis established from the pleural effusion of a 53-year-old woman with chronic myeloid leukemia (CML) in blast crisis in 1970; cells can be used as highly sensitive targets in in-vitro natural killer assays; cells produce hemoglobin; cells carry the Philadelphia chromosome with a b3-a2 fusion gene." []	\N	K562	\N	\N	EFO	"Human chronic myeloid leukemia in blast crisis established from the pleural effusion of a 53-year-old woman with chronic myeloid leukemia (CML) in blast crisis in 1970; cells can be used as highly sensitive targets in in-vitro natural killer assays; cells produce hemoglobin; cells carry the Philadelphia chromosome with a b3-a2 fusion gene." []	EFO	68238	EFO:0002067	\N	K562	EFO:0002067
0	"A Kc is a cell line.\\nA Kc derives from a drosophila melanogaster." []	\N	Kc	\N	\N	EFO	"A Kc is a cell line.\\nA Kc derives from a drosophila melanogaster." []	EFO	68239	EFO:0002068	\N	Kc	EFO:0002068
0	"A KELLY is a cell line.\\nA KELLY is all of the following: something that is bearer of a neuroblastoma, something that derives from a Homo sapiens, and something that derives from a brain." []	\N	KELLY	\N	\N	EFO	"A KELLY is a cell line.\\nA KELLY is all of the following: something that is bearer of a neuroblastoma, something that derives from a Homo sapiens, and something that derives from a brain." []	EFO	68240	EFO:0002069	\N	KELLY	EFO:0002069
0	"A Lbeta T2 is a cell line.\\nA Lbeta T2 is both something that derives from a mus musculus, and something that derives from a pituitary." []	\N	LbetaT2	\N	\N	EFO	"A Lbeta T2 is a cell line.\\nA Lbeta T2 is both something that derives from a mus musculus, and something that derives from a pituitary." []	EFO	68241	EFO:0002070	\N	LbetaT2	EFO:0002070
0	"Human prostate carcinoma, established from the left supraclavicular lymph node metastasis from a 50-year-old man with prostate carcinoma in 1977; cells were described to be androgen-sensitive." []	\N	LNCAP	\N	\N	EFO	"Human prostate carcinoma, established from the left supraclavicular lymph node metastasis from a 50-year-old man with prostate carcinoma in 1977; cells were described to be androgen-sensitive." []	EFO	68242	EFO:0002071	\N	LNCAP	EFO:0002071
0	"" []	\N	MCF-7aro	\N	\N	EFO	"" []	EFO	68243	EFO:0002072	\N	MCF-7aro	EFO:0002072
0	"" []	\N	mIMCD-3	\N	\N	EFO	"" []	EFO	68244	EFO:0002073	\N	mIMCD-3	EFO:0002073
0	"Human prostate carcinoma cell line; established from the bone marrow metastasis isolated post-mortem from a 62-year-old Caucasian man with grade IV prostate cancer, poorly differentiated adenocarcinoma, after androgen suppression therapy; described to form tumors in nude mice, to grow in soft agar, and to be unresponsive to androgen treatment." []	\N	PC-3	\N	\N	EFO	"Human prostate carcinoma cell line; established from the bone marrow metastasis isolated post-mortem from a 62-year-old Caucasian man with grade IV prostate cancer, poorly differentiated adenocarcinoma, after androgen suppression therapy; described to form tumors in nude mice, to grow in soft agar, and to be unresponsive to androgen treatment." []	EFO	68245	EFO:0002074	\N	PC-3	EFO:0002074
0	"PEL-5 is a human primary effusion lymphoma cell line" []	\N	PEL-5	\N	\N	EFO	"PEL-5 is a human primary effusion lymphoma cell line" []	EFO	68246	EFO:0002075	\N	PEL-5	EFO:0002075
0	"R1 is a mouse embryonic stem cell line." []	\N	R1	\N	\N	EFO	"R1 is a mouse embryonic stem cell line." []	EFO	68247	EFO:0002076	\N	R1	EFO:0002076
0	"Ramos cell line is an EBV-negative, HLA class 1 positive B-lymphoblastoid cell line derived from a Burkitt lymphoma" []	\N	Ramos	\N	\N	EFO	"Ramos cell line is an EBV-negative, HLA class 1 positive B-lymphoblastoid cell line derived from a Burkitt lymphoma" []	EFO	68248	EFO:0002077	\N	Ramos	EFO:0002077
0	"" []	\N	S1	\N	\N	EFO	"" []	EFO	68249	EFO:0002078	\N	S1	EFO:0002078
0	"" []	\N	SK-MEL-2	\N	\N	EFO	"" []	EFO	68250	EFO:0002079	\N	SK-MEL-2	EFO:0002079
0	"" []	\N	SKMEL5	\N	\N	EFO	"" []	EFO	68251	EFO:0002080	\N	SKMEL5	EFO:0002080
0	"" []	\N	SN56.B5.G4	\N	\N	EFO	"" []	EFO	68252	EFO:0002081	\N	SN56.B5.G4	EFO:0002081
0	"" []	\N	ssMCF7	\N	\N	EFO	"" []	EFO	68253	EFO:0002082	\N	ssMCF7	EFO:0002082
0	"" []	\N	SW480	\N	\N	EFO	"" []	EFO	68254	EFO:0002083	\N	SW480	EFO:0002083
0	"" []	\N	T84	\N	\N	EFO	"" []	EFO	68255	EFO:0002084	\N	T84	EFO:0002084
0	"Human, Caucasian, glioblastoma cell line." []	\N	T98G	\N	\N	EFO	"Human, Caucasian, glioblastoma cell line." []	EFO	68256	EFO:0002085	\N	T98G	EFO:0002085
0	"TIVE is a human cell line." []	\N	TIVE	\N	\N	EFO	"TIVE is a human cell line." []	EFO	68257	EFO:0002086	\N	TIVE	EFO:0002086
0	"" []	\N	fibrosarcoma	\N	\N	EFO	"" []	EFO	68258	EFO:0002087	\N	fibrosarcoma	EFO:0002087
0	"A technical replicate is a replicate role where the same BioSample is use e.g. the same pool of RNA used to assess technical (as opposed to biological) variation within an experiment." []	\N	technical replicate	\N	\N	EFO	"A technical replicate is a replicate role where the same BioSample is use e.g. the same pool of RNA used to assess technical (as opposed to biological) variation within an experiment." []	EFO	68259	EFO:0002090	\N	technical replicate	EFO:0002090
0	"A biological replicate is a replicate role that consists of independent biological replicates made from different individual biosamples." []	\N	biological replicate	\N	\N	EFO	"A biological replicate is a replicate role that consists of independent biological replicates made from different individual biosamples." []	EFO	68260	EFO:0002091	\N	biological replicate	EFO:0002091
0	"A dye swap replicate is a replicate role which is borne by one of a pair of replicate assays in which LabeledExtracts derived from the same BioMaterial used for both assays (e.g., a hybridization or a 2-D gel run) differ only in that the dyes used for labeling have been reversed, e.g., assay 1: A-Cy3 vs. B-Cy5, and assay 2: A-Cy5 vs. B-Cy3. The purpose of using dye-swap replicate pairs is to assess or remove dye-specific biases from the combined experimental results." []	\N	dye swap replicate	\N	\N	EFO	"A dye swap replicate is a replicate role which is borne by one of a pair of replicate assays in which LabeledExtracts derived from the same BioMaterial used for both assays (e.g., a hybridization or a 2-D gel run) differ only in that the dyes used for labeling have been reversed, e.g., assay 1: A-Cy3 vs. B-Cy5, and assay 2: A-Cy5 vs. B-Cy3. The purpose of using dye-swap replicate pairs is to assess or remove dye-specific biases from the combined experimental results." []	EFO	68261	EFO:0002092	\N	dye swap replicate	EFO:0002092
0	"" []	\N	1A2	\N	\N	EFO	"" []	EFO	68262	EFO:0002094	\N	1A2	EFO:0002094
0	"A 22rv1 is a cell line.\\nA 22rv1 is all of the following: something that is bearer of a prostate carcinoma, something that derives from a homo sapiens, and something that derives from a prostate." []	\N	22Rv1	\N	\N	EFO	"A 22rv1 is a cell line.\\nA 22rv1 is all of the following: something that is bearer of a prostate carcinoma, something that derives from a homo sapiens, and something that derives from a prostate." []	EFO	68263	EFO:0002095	\N	22Rv1	EFO:0002095
0	"" []	\N	5637	\N	\N	EFO	"" []	EFO	68264	EFO:0002096	\N	5637	EFO:0002096
0	"" []	\N	639V	\N	\N	EFO	"" []	EFO	68265	EFO:0002097	\N	639V	EFO:0002097
0	"" []	\N	647V	\N	\N	EFO	"" []	EFO	68266	EFO:0002098	\N	647V	EFO:0002098
0	"" []	\N	769P	\N	\N	EFO	"" []	EFO	68267	EFO:0002099	\N	769P	EFO:0002099
0	"An a101d is a cell line.\\nAn a101d is all of the following: something that is bearer of a melanoma, something that derives from a homo sapiens, and something that derives from a skin." []	\N	A101D	\N	\N	EFO	"An a101d is a cell line.\\nAn a101d is all of the following: something that is bearer of a melanoma, something that derives from a homo sapiens, and something that derives from a skin." []	EFO	68268	EFO:0002100	\N	A101D	EFO:0002100
0	"" []	\N	A172	\N	\N	EFO	"" []	EFO	68269	EFO:0002101	\N	A172	EFO:0002101
0	"" []	\N	A204	\N	\N	EFO	"" []	EFO	68270	EFO:0002102	\N	A204	EFO:0002102
0	"" []	\N	A375	\N	\N	EFO	"" []	EFO	68271	EFO:0002103	\N	A375	EFO:0002103
0	"" []	\N	A427	\N	\N	EFO	"" []	EFO	68272	EFO:0002104	\N	A427	EFO:0002104
0	"" []	\N	A498	\N	\N	EFO	"" []	EFO	68273	EFO:0002105	\N	A498	EFO:0002105
0	"" []	\N	A673	\N	\N	EFO	"" []	EFO	68274	EFO:0002106	\N	A673	EFO:0002106
0	"" []	\N	A7	\N	\N	EFO	"" []	EFO	68275	EFO:0002107	\N	A7	EFO:0002107
0	"" []	\N	ACHN	\N	\N	EFO	"" []	EFO	68276	EFO:0002108	\N	ACHN	EFO:0002108
0	"" []	\N	AGS	\N	\N	EFO	"" []	EFO	68277	EFO:0002109	\N	AGS	EFO:0002109
0	"" []	\N	AN3CA	\N	\N	EFO	"" []	EFO	68278	EFO:0002110	\N	AN3CA	EFO:0002110
0	"An arh77 is a cell line.\\nAn arh77 is both something that is bearer of a plasma cell neoplasm, and something that derives from a lymphatic system." []	\N	ARH77	\N	\N	EFO	"An arh77 is a cell line.\\nAn arh77 is both something that is bearer of a plasma cell neoplasm, and something that derives from a lymphatic system." []	EFO	68279	EFO:0002111	\N	ARH77	EFO:0002111
0	"" []	\N	AsPC1	\N	\N	EFO	"" []	EFO	68280	EFO:0002112	\N	AsPC1	EFO:0002112
0	"A BDCM is a cell line.\\nA BDCM is all of the following: something that is bearer of an acute myeloid leukemia, something that derives from a homo sapiens, and something that derives from a lymphatic system." []	\N	BDCM	\N	\N	EFO	"A BDCM is a cell line.\\nA BDCM is all of the following: something that is bearer of an acute myeloid leukemia, something that derives from a homo sapiens, and something that derives from a lymphatic system." []	EFO	68281	EFO:0002113	\N	BDCM	EFO:0002113
0	"" []	\N	BE2C	\N	\N	EFO	"" []	EFO	68282	EFO:0002114	\N	BE2C	EFO:0002114
0	"" []	\N	BFTC905	\N	\N	EFO	"" []	EFO	68283	EFO:0002115	\N	BFTC905	EFO:0002115
0	"" []	\N	BHT101	\N	\N	EFO	"" []	EFO	68284	EFO:0002116	\N	BHT101	EFO:0002116
0	"A BM1604 is a cell line.\\nA BM1604 is all of the following: something that is bearer of a prostate carcinoma, something that derives from a homo sapiens, and something that derives from a prostate." []	\N	BM1604	\N	\N	EFO	"A BM1604 is a cell line.\\nA BM1604 is all of the following: something that is bearer of a prostate carcinoma, something that derives from a homo sapiens, and something that derives from a prostate." []	EFO	68285	EFO:0002117	\N	BM1604	EFO:0002117
0	"" []	\N	BV173	\N	\N	EFO	"" []	EFO	68286	EFO:0002118	\N	BV173	EFO:0002118
0	"" []	\N	C32TG	\N	\N	EFO	"" []	EFO	68287	EFO:0002119	\N	C32TG	EFO:0002119
0	"" []	\N	C33A	\N	\N	EFO	"" []	EFO	68288	EFO:0002120	\N	C33A	EFO:0002120
0	"" []	\N	C3A	\N	\N	EFO	"" []	EFO	68289	EFO:0002121	\N	C3A	EFO:0002121
0	"" []	\N	C4I	\N	\N	EFO	"" []	EFO	68290	EFO:0002122	\N	C4I	EFO:0002122
0	"" []	\N	C4II	\N	\N	EFO	"" []	EFO	68291	EFO:0002123	\N	C4II	EFO:0002123
0	"" []	\N	CA46	\N	\N	EFO	"" []	EFO	68292	EFO:0002124	\N	CA46	EFO:0002124
0	"" []	\N	CAL54	\N	\N	EFO	"" []	EFO	68293	EFO:0002125	\N	CAL54	EFO:0002125
0	"" []	\N	CAL62	\N	\N	EFO	"" []	EFO	68294	EFO:0002126	\N	CAL62	EFO:0002126
0	"" []	\N	CCFSTTG1	\N	\N	EFO	"" []	EFO	68295	EFO:0002127	\N	CCFSTTG1	EFO:0002127
0	"" []	\N	CCRFCEM	\N	\N	EFO	"" []	EFO	68296	EFO:0002128	\N	CCRFCEM	EFO:0002128
0	"" []	\N	CESS	\N	\N	EFO	"" []	EFO	68297	EFO:0002130	\N	CESS	EFO:0002130
0	"" []	\N	CGTHW1	\N	\N	EFO	"" []	EFO	68298	EFO:0002131	\N	CGTHW1	EFO:0002131
0	"" []	\N	CHL1	\N	\N	EFO	"" []	EFO	68299	EFO:0002132	\N	CHL1	EFO:0002132
0	"" []	\N	CHP212	\N	\N	EFO	"" []	EFO	68300	EFO:0002133	\N	CHP212	EFO:0002133
0	"" []	\N	CMLT1	\N	\N	EFO	"" []	EFO	68301	EFO:0002134	\N	CMLT1	EFO:0002134
0	"" []	\N	COLO201	\N	\N	EFO	"" []	EFO	68302	EFO:0002135	\N	COLO201	EFO:0002135
0	"" []	\N	COLO320DM	\N	\N	EFO	"" []	EFO	68303	EFO:0002136	\N	COLO320DM	EFO:0002136
0	"" []	\N	COLO320HSR	\N	\N	EFO	"" []	EFO	68304	EFO:0002137	\N	COLO320HSR	EFO:0002137
0	"" []	\N	COLO668	\N	\N	EFO	"" []	EFO	68305	EFO:0002138	\N	COLO668	EFO:0002138
0	"" []	\N	COLO704	\N	\N	EFO	"" []	EFO	68306	EFO:0002139	\N	COLO704	EFO:0002139
0	"" []	\N	COLO829	\N	\N	EFO	"" []	EFO	68307	EFO:0002140	\N	COLO829	EFO:0002140
0	"" []	\N	CORL105	\N	\N	EFO	"" []	EFO	68308	EFO:0002141	\N	CORL105	EFO:0002141
0	"" []	\N	CORL23	\N	\N	EFO	"" []	EFO	68309	EFO:0002142	\N	CORL23	EFO:0002142
0	"" []	\N	CORL279	\N	\N	EFO	"" []	EFO	68310	EFO:0002143	\N	CORL279	EFO:0002143
0	"" []	\N	CORL88	\N	\N	EFO	"" []	EFO	68311	EFO:0002144	\N	CORL88	EFO:0002144
0	"" []	\N	CROAP2	\N	\N	EFO	"" []	EFO	68312	EFO:0002145	\N	CROAP2	EFO:0002145
0	"" []	\N	CROAP5	\N	\N	EFO	"" []	EFO	68313	EFO:0002146	\N	CROAP5	EFO:0002146
0	"" []	\N	CaHPV10	\N	\N	EFO	"" []	EFO	68314	EFO:0002147	\N	CaHPV10	EFO:0002147
0	"" []	\N	CaOv3	\N	\N	EFO	"" []	EFO	68315	EFO:0002148	\N	CaOv3	EFO:0002148
0	"" []	\N	Caki1	\N	\N	EFO	"" []	EFO	68316	EFO:0002149	\N	Caki1	EFO:0002149
0	"" []	\N	Caki2	\N	\N	EFO	"" []	EFO	68317	EFO:0002150	\N	Caki2	EFO:0002150
0	"" []	\N	Calu1	\N	\N	EFO	"" []	EFO	68318	EFO:0002151	\N	Calu1	EFO:0002151
0	"" []	\N	Calu6	\N	\N	EFO	"" []	EFO	68319	EFO:0002152	\N	Calu6	EFO:0002152
0	"" []	\N	Capan1	\N	\N	EFO	"" []	EFO	68320	EFO:0002153	\N	Capan1	EFO:0002153
0	"" []	\N	Capan2	\N	\N	EFO	"" []	EFO	68321	EFO:0002154	\N	Capan2	EFO:0002154
0	"" []	\N	ChaGoK1	\N	\N	EFO	"" []	EFO	68322	EFO:0002155	\N	ChaGoK1	EFO:0002155
0	"" []	\N	D283Med	\N	\N	EFO	"" []	EFO	68323	EFO:0002156	\N	D283Med	EFO:0002156
0	"" []	\N	D341Med	\N	\N	EFO	"" []	EFO	68324	EFO:0002157	\N	D341Med	EFO:0002157
0	"" []	\N	DB	\N	\N	EFO	"" []	EFO	68325	EFO:0002158	\N	DB	EFO:0002158
0	"" []	\N	DBTRG05MG	\N	\N	EFO	"" []	EFO	68326	EFO:0002159	\N	DBTRG05MG	EFO:0002159
0	"" []	\N	DG75	\N	\N	EFO	"" []	EFO	68327	EFO:0002160	\N	DG75	EFO:0002160
0	"" []	\N	DKMG	\N	\N	EFO	"" []	EFO	68328	EFO:0002161	\N	DKMG	EFO:0002161
0	"" []	\N	DMS114	\N	\N	EFO	"" []	EFO	68329	EFO:0002162	\N	DMS114	EFO:0002162
0	"" []	\N	DMS153	\N	\N	EFO	"" []	EFO	68330	EFO:0002163	\N	DMS153	EFO:0002163
0	"" []	\N	DMS273	\N	\N	EFO	"" []	EFO	68331	EFO:0002164	\N	DMS273	EFO:0002164
0	"" []	\N	DMS53	\N	\N	EFO	"" []	EFO	68332	EFO:0002165	\N	DMS53	EFO:0002165
0	"" []	\N	DMS79	\N	\N	EFO	"" []	EFO	68333	EFO:0002166	\N	DMS79	EFO:0002166
0	"" []	\N	DOHH2	\N	\N	EFO	"" []	EFO	68334	EFO:0002167	\N	DOHH2	EFO:0002167
0	"" []	\N	DU4475	\N	\N	EFO	"" []	EFO	68335	EFO:0002168	\N	DU4475	EFO:0002168
0	"A Daudi Burkitt's lymphoma cell line is a cell line.\\nA Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymphoma." []	\N	Daudi	\N	\N	EFO	"A Daudi Burkitt's lymphoma cell line is a cell line.\\nA Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymphoma." []	EFO	68336	EFO:0002169	\N	Daudi	EFO:0002169
0	"" []	\N	Detroit562	\N	\N	EFO	"" []	EFO	68337	EFO:0002170	\N	Detroit562	EFO:0002170
0	"" []	\N	DoTc2	\N	\N	EFO	"" []	EFO	68338	EFO:0002171	\N	DoTc2	EFO:0002171
0	"" []	\N	EB1	\N	\N	EFO	"" []	EFO	68339	EFO:0002172	\N	EB1	EFO:0002172
0	"" []	\N	EB2	\N	\N	EFO	"" []	EFO	68340	EFO:0002173	\N	EB2	EFO:0002173
0	"" []	\N	EB3	\N	\N	EFO	"" []	EFO	68341	EFO:0002174	\N	EB3	EFO:0002174
0	"" []	\N	EFM19	\N	\N	EFO	"" []	EFO	68342	EFO:0002175	\N	EFM19	EFO:0002175
0	"" []	\N	EM2	\N	\N	EFO	"" []	EFO	68343	EFO:0002176	\N	EM2	EFO:0002176
0	"" []	\N	ES2	\N	\N	EFO	"" []	EFO	68344	EFO:0002177	\N	ES2	EFO:0002177
0	"" []	\N	FaDu	\N	\N	EFO	"" []	EFO	68345	EFO:0002178	\N	FaDu	EFO:0002178
0	"A human cell line derived from a pediatric patient initially classified as Wilm's tumor, reclassified as deriving from a rhabdoid tumor of the kidney" []	\N	G401	\N	\N	EFO	"A human cell line derived from a pediatric patient initially classified as Wilm's tumor, reclassified as deriving from a rhabdoid tumor of the kidney" []	EFO	68346	EFO:0002179	\N	G401	EFO:0002179
0	"A human cell line derived from some renal leiomyeloblastoma" []	\N	G402	\N	\N	EFO	"A human cell line derived from some renal leiomyeloblastoma" []	EFO	68347	EFO:0002180	\N	G402	EFO:0002180
0	"" []	\N	GA10	\N	\N	EFO	"" []	EFO	68348	EFO:0002181	\N	GA10	EFO:0002181
0	"A Giant Cell Tumor (GCT) cell line derived from a human fibrous histiocytoma  lung metastasis" []	\N	GCT	\N	\N	EFO	"A Giant Cell Tumor (GCT) cell line derived from a human fibrous histiocytoma  lung metastasis" []	EFO	68349	EFO:0002182	\N	GCT	EFO:0002182
0	"A cell line derived from a human patient with Philadelphia chromosome negative myeloproliferative disorder, after transformation to acute myelomonoblastic leukemia.http://www.ncbi.nlm.nih.gov/pubmed/6296552" []	\N	GDM1	\N	\N	EFO	"A cell line derived from a human patient with Philadelphia chromosome negative myeloproliferative disorder, after transformation to acute myelomonoblastic leukemia.http://www.ncbi.nlm.nih.gov/pubmed/6296552" []	EFO	68350	EFO:0002183	\N	GDM1	EFO:0002183
0	"" []	\N	H4	\N	\N	EFO	"" []	EFO	68351	EFO:0002184	\N	H4	EFO:0002184
0	"" []	\N	HCC1395	\N	\N	EFO	"" []	EFO	68352	EFO:0002185	\N	HCC1395	EFO:0002185
0	"" []	\N	HCC1599	\N	\N	EFO	"" []	EFO	68353	EFO:0002186	\N	HCC1599	EFO:0002186
0	"" []	\N	HCC2218	\N	\N	EFO	"" []	EFO	68354	EFO:0002187	\N	HCC2218	EFO:0002187
0	"" []	\N	HCT15	\N	\N	EFO	"" []	EFO	68355	EFO:0002188	\N	HCT15	EFO:0002188
0	"" []	\N	HCT8	\N	\N	EFO	"" []	EFO	68356	EFO:0002189	\N	HCT8	EFO:0002189
0	"" []	\N	HDMYZ	\N	\N	EFO	"" []	EFO	68357	EFO:0002190	\N	HDMYZ	EFO:0002190
0	"" []	\N	HEC1A	\N	\N	EFO	"" []	EFO	68358	EFO:0002191	\N	HEC1A	EFO:0002191
0	"" []	\N	HEC1B	\N	\N	EFO	"" []	EFO	68359	EFO:0002192	\N	HEC1B	EFO:0002192
0	"" []	\N	HEL9217	\N	\N	EFO	"" []	EFO	68360	EFO:0002193	\N	HEL9217	EFO:0002193
0	"" []	\N	HH	\N	\N	EFO	"" []	EFO	68361	EFO:0002194	\N	HH	EFO:0002194
0	"" []	\N	HMCB	\N	\N	EFO	"" []	EFO	68362	EFO:0002195	\N	HMCB	EFO:0002195
0	"" []	\N	HOS	\N	\N	EFO	"" []	EFO	68363	EFO:0002196	\N	HOS	EFO:0002196
0	"" []	\N	HPAC	\N	\N	EFO	"" []	EFO	68364	EFO:0002197	\N	HPAC	EFO:0002197
0	"" []	\N	HPAFII	\N	\N	EFO	"" []	EFO	68365	EFO:0002198	\N	HPAFII	EFO:0002198
0	"" []	\N	HSSultan	\N	\N	EFO	"" []	EFO	68366	EFO:0002199	\N	HSSultan	EFO:0002199
0	"" []	\N	HT	\N	\N	EFO	"" []	EFO	68367	EFO:0002200	\N	HT	EFO:0002200
0	"" []	\N	HT1197	\N	\N	EFO	"" []	EFO	68368	EFO:0002202	\N	HT1197	EFO:0002202
0	"" []	\N	HT1376	\N	\N	EFO	"" []	EFO	68369	EFO:0002203	\N	HT1376	EFO:0002203
0	"" []	\N	HT3	\N	\N	EFO	"" []	EFO	68370	EFO:0002204	\N	HT3	EFO:0002204
0	"" []	\N	Hep3B	\N	\N	EFO	"" []	EFO	68371	EFO:0002205	\N	Hep3B	EFO:0002205
0	"" []	\N	HuNS1	\N	\N	EFO	"" []	EFO	68372	EFO:0002207	\N	HuNS1	EFO:0002207
0	"" []	\N	HuPT4	\N	\N	EFO	"" []	EFO	68373	EFO:0002208	\N	HuPT4	EFO:0002208
0	"" []	\N	HuT78	\N	\N	EFO	"" []	EFO	68374	EFO:0002209	\N	HuT78	EFO:0002209
0	"" []	\N	J82	\N	\N	EFO	"" []	EFO	68375	EFO:0002210	\N	J82	EFO:0002210
0	"" []	\N	JAR	\N	\N	EFO	"" []	EFO	68376	EFO:0002211	\N	JAR	EFO:0002211
0	"" []	\N	JM1	\N	\N	EFO	"" []	EFO	68377	EFO:0002212	\N	JM1	EFO:0002212
0	"" []	\N	JRT3T35	\N	\N	EFO	"" []	EFO	68378	EFO:0002213	\N	JRT3T35	EFO:0002213
0	"" []	\N	JVM3	\N	\N	EFO	"" []	EFO	68379	EFO:0002214	\N	JVM3	EFO:0002214
0	"A Jiyoye is a cell line.\\nA Jiyoye is bearer of a Burkitt's lymphoma." []	\N	Jiyoye	\N	\N	EFO	"A Jiyoye is a cell line.\\nA Jiyoye is bearer of a Burkitt's lymphoma." []	EFO	68380	EFO:0002215	\N	Jiyoye	EFO:0002215
0	"" []	\N	KATOIII	\N	\N	EFO	"" []	EFO	68381	EFO:0002217	\N	KATOIII	EFO:0002217
0	"" []	\N	KG1	\N	\N	EFO	"" []	EFO	68382	EFO:0002218	\N	KG1	EFO:0002218
0	"" []	\N	KHOS240S	\N	\N	EFO	"" []	EFO	68383	EFO:0002219	\N	KHOS240S	EFO:0002219
0	"" []	\N	KLE	\N	\N	EFO	"" []	EFO	68384	EFO:0002220	\N	KLE	EFO:0002220
0	"" []	\N	KPL1	\N	\N	EFO	"" []	EFO	68385	EFO:0002221	\N	KPL1	EFO:0002221
0	"" []	\N	KU812	\N	\N	EFO	"" []	EFO	68386	EFO:0002222	\N	KU812	EFO:0002222
0	"" []	\N	KYSE30	\N	\N	EFO	"" []	EFO	68387	EFO:0002223	\N	KYSE30	EFO:0002223
0	"" []	\N	Kasumi2	\N	\N	EFO	"" []	EFO	68388	EFO:0002224	\N	Kasumi2	EFO:0002224
0	"" []	\N	L428	\N	\N	EFO	"" []	EFO	68389	EFO:0002225	\N	L428	EFO:0002225
0	"" []	\N	LS1034	\N	\N	EFO	"" []	EFO	68390	EFO:0002226	\N	LS1034	EFO:0002226
0	"" []	\N	LS174T	\N	\N	EFO	"" []	EFO	68391	EFO:0002227	\N	LS174T	EFO:0002227
0	"" []	\N	MC116	\N	\N	EFO	"" []	EFO	68392	EFO:0002228	\N	MC116	EFO:0002228
0	"" []	\N	MCCAR	\N	\N	EFO	"" []	EFO	68393	EFO:0002229	\N	MCCAR	EFO:0002229
0	"" []	\N	MCIXC	\N	\N	EFO	"" []	EFO	68394	EFO:0002230	\N	MCIXC	EFO:0002230
0	"" []	\N	MEC1	\N	\N	EFO	"" []	EFO	68395	EFO:0002231	\N	MEC1	EFO:0002231
0	"" []	\N	MEG01	\N	\N	EFO	"" []	EFO	68396	EFO:0002232	\N	MEG01	EFO:0002232
0	"" []	\N	MESSA	\N	\N	EFO	"" []	EFO	68397	EFO:0002233	\N	MESSA	EFO:0002233
0	"" []	\N	MG63	\N	\N	EFO	"" []	EFO	68398	EFO:0002234	\N	MG63	EFO:0002234
0	"" []	\N	MHHPREB1	\N	\N	EFO	"" []	EFO	68399	EFO:0002235	\N	MHHPREB1	EFO:0002235
0	"" []	\N	MIA Paca-2	\N	\N	EFO	"" []	EFO	68400	EFO:0002236	\N	MIA Paca-2	EFO:0002236
0	"" []	\N	MJ	\N	\N	EFO	"" []	EFO	68401	EFO:0002237	\N	MJ	EFO:0002237
0	"" []	\N	ML2	\N	\N	EFO	"" []	EFO	68402	EFO:0002238	\N	ML2	EFO:0002238
0	"" []	\N	MOLT16	\N	\N	EFO	"" []	EFO	68403	EFO:0002239	\N	MOLT16	EFO:0002239
0	"" []	\N	MT3	\N	\N	EFO	"" []	EFO	68404	EFO:0002241	\N	MT3	EFO:0002241
0	"" []	\N	MV4II	\N	\N	EFO	"" []	EFO	68405	EFO:0002242	\N	MV4II	EFO:0002242
0	"" []	\N	Malme3M	\N	\N	EFO	"" []	EFO	68406	EFO:0002243	\N	Malme3M	EFO:0002243
0	"" []	\N	NALM1	\N	\N	EFO	"" []	EFO	68407	EFO:0002244	\N	NALM1	EFO:0002244
0	"" []	\N	NALM6	\N	\N	EFO	"" []	EFO	68408	EFO:0002245	\N	NALM6	EFO:0002245
0	"" []	\N	NAMALWA	\N	\N	EFO	"" []	EFO	68409	EFO:0002246	\N	NAMALWA	EFO:0002246
0	"" []	\N	NC37	\N	\N	EFO	"" []	EFO	68410	EFO:0002247	\N	NC37	EFO:0002247
0	"" []	\N	NCI-H1048	\N	\N	EFO	"" []	EFO	68411	EFO:0002248	\N	NCI-H1048	EFO:0002248
0	"" []	\N	NCI-H1092	\N	\N	EFO	"" []	EFO	68412	EFO:0002249	\N	NCI-H1092	EFO:0002249
0	"" []	\N	NCI-H1155	\N	\N	EFO	"" []	EFO	68413	EFO:0002250	\N	NCI-H1155	EFO:0002250
0	"" []	\N	NCI-H1355	\N	\N	EFO	"" []	EFO	68414	EFO:0002251	\N	NCI-H1355	EFO:0002251
0	"" []	\N	NCI-H1395	\N	\N	EFO	"" []	EFO	68415	EFO:0002252	\N	NCI-H1395	EFO:0002252
0	"" []	\N	NCI-H1436	\N	\N	EFO	"" []	EFO	68416	EFO:0002253	\N	NCI-H1436	EFO:0002253
0	"" []	\N	NCI-H1437	\N	\N	EFO	"" []	EFO	68417	EFO:0002254	\N	NCI-H1437	EFO:0002254
0	"" []	\N	NCI-H1563	\N	\N	EFO	"" []	EFO	68418	EFO:0002255	\N	NCI-H1563	EFO:0002255
0	"" []	\N	NCI-H1573	\N	\N	EFO	"" []	EFO	68419	EFO:0002256	\N	NCI-H1573	EFO:0002256
0	"" []	\N	NCI-H1581	\N	\N	EFO	"" []	EFO	68420	EFO:0002257	\N	NCI-H1581	EFO:0002257
0	"" []	\N	NCI-H1618	\N	\N	EFO	"" []	EFO	68421	EFO:0002258	\N	NCI-H1618	EFO:0002258
0	"" []	\N	NCI-H1623	\N	\N	EFO	"" []	EFO	68422	EFO:0002259	\N	NCI-H1623	EFO:0002259
0	"" []	\N	NCI-H1650	\N	\N	EFO	"" []	EFO	68423	EFO:0002260	\N	NCI-H1650	EFO:0002260
0	"" []	\N	NCI-H1651	\N	\N	EFO	"" []	EFO	68424	EFO:0002261	\N	NCI-H1651	EFO:0002261
0	"" []	\N	NCI-H1666	\N	\N	EFO	"" []	EFO	68425	EFO:0002262	\N	NCI-H1666	EFO:0002262
0	"" []	\N	NCI-H1694	\N	\N	EFO	"" []	EFO	68426	EFO:0002263	\N	NCI-H1694	EFO:0002263
0	"" []	\N	NCI-H1703	\N	\N	EFO	"" []	EFO	68427	EFO:0002264	\N	NCI-H1703	EFO:0002264
0	"" []	\N	NCI-H1770	\N	\N	EFO	"" []	EFO	68428	EFO:0002265	\N	NCI-H1770	EFO:0002265
0	"" []	\N	NCI-H1792	\N	\N	EFO	"" []	EFO	68429	EFO:0002266	\N	NCI-H1792	EFO:0002266
0	"" []	\N	NCI-H1793	\N	\N	EFO	"" []	EFO	68430	EFO:0002267	\N	NCI-H1793	EFO:0002267
0	"" []	\N	NCI-H1838	\N	\N	EFO	"" []	EFO	68431	EFO:0002268	\N	NCI-H1838	EFO:0002268
0	"" []	\N	NCI-H187	\N	\N	EFO	"" []	EFO	68432	EFO:0002269	\N	NCI-H187	EFO:0002269
0	"" []	\N	NCI-H1930	\N	\N	EFO	"" []	EFO	68433	EFO:0002270	\N	NCI-H1930	EFO:0002270
0	"" []	\N	NCI-H1975	\N	\N	EFO	"" []	EFO	68434	EFO:0002271	\N	NCI-H1975	EFO:0002271
0	"" []	\N	NCI-H1993	\N	\N	EFO	"" []	EFO	68435	EFO:0002272	\N	NCI-H1993	EFO:0002272
0	"" []	\N	NCI-H2009	\N	\N	EFO	"" []	EFO	68436	EFO:0002273	\N	NCI-H2009	EFO:0002273
0	"" []	\N	NCI-H2030	\N	\N	EFO	"" []	EFO	68437	EFO:0002274	\N	NCI-H2030	EFO:0002274
0	"" []	\N	NCI-H2052	\N	\N	EFO	"" []	EFO	68438	EFO:0002275	\N	NCI-H2052	EFO:0002275
0	"" []	\N	NCI-H2081	\N	\N	EFO	"" []	EFO	68439	EFO:0002276	\N	NCI-H2081	EFO:0002276
0	"" []	\N	NCI-H2087	\N	\N	EFO	"" []	EFO	68440	EFO:0002277	\N	NCI-H2087	EFO:0002277
0	"" []	\N	NCI-H2107	\N	\N	EFO	"" []	EFO	68441	EFO:0002278	\N	NCI-H2107	EFO:0002278
0	"" []	\N	NCI-H2122	\N	\N	EFO	"" []	EFO	68442	EFO:0002279	\N	NCI-H2122	EFO:0002279
0	"" []	\N	NCI-H2126	\N	\N	EFO	"" []	EFO	68443	EFO:0002280	\N	NCI-H2126	EFO:0002280
0	"" []	\N	NCI-H2170	\N	\N	EFO	"" []	EFO	68444	EFO:0002281	\N	NCI-H2170	EFO:0002281
0	"" []	\N	NCI-H2171	\N	\N	EFO	"" []	EFO	68445	EFO:0002282	\N	NCI-H2171	EFO:0002282
0	"" []	\N	NCI-H2195	\N	\N	EFO	"" []	EFO	68446	EFO:0002283	\N	NCI-H2195	EFO:0002283
0	"" []	\N	NCI-H2228	\N	\N	EFO	"" []	EFO	68447	EFO:0002284	\N	NCI-H2228	EFO:0002284
0	"" []	\N	NCI-H226	\N	\N	EFO	"" []	EFO	68448	EFO:0002285	\N	NCI-H226	EFO:0002285
0	"" []	\N	NCI-H23	\N	\N	EFO	"" []	EFO	68449	EFO:0002286	\N	NCI-H23	EFO:0002286
0	"" []	\N	NCI-H2347	\N	\N	EFO	"" []	EFO	68450	EFO:0002287	\N	NCI-H2347	EFO:0002287
0	"" []	\N	NCI-H2405	\N	\N	EFO	"" []	EFO	68451	EFO:0002288	\N	NCI-H2405	EFO:0002288
0	"" []	\N	NCI-H295R	\N	\N	EFO	"" []	EFO	68452	EFO:0002289	\N	NCI-H295R	EFO:0002289
0	"" []	\N	NCI-H322	\N	\N	EFO	"" []	EFO	68453	EFO:0002290	\N	NCI-H322	EFO:0002290
0	"" []	\N	NCI-H358	\N	\N	EFO	"" []	EFO	68454	EFO:0002291	\N	NCI-H358	EFO:0002291
0	"" []	\N	NCI-H441	\N	\N	EFO	"" []	EFO	68455	EFO:0002292	\N	NCI-H441	EFO:0002292
0	"" []	\N	NCI-H446	\N	\N	EFO	"" []	EFO	68456	EFO:0002293	\N	NCI-H446	EFO:0002293
0	"" []	\N	NCI-H508	\N	\N	EFO	"" []	EFO	68457	EFO:0002294	\N	NCI-H508	EFO:0002294
0	"" []	\N	NCI-H522	\N	\N	EFO	"" []	EFO	68458	EFO:0002295	\N	NCI-H522	EFO:0002295
0	"" []	\N	NCI-H524	\N	\N	EFO	"" []	EFO	68459	EFO:0002296	\N	NCI-H524	EFO:0002296
0	"" []	\N	NCI-H630	\N	\N	EFO	"" []	EFO	68460	EFO:0002297	\N	NCI-H630	EFO:0002297
0	"" []	\N	NCI-H650	\N	\N	EFO	"" []	EFO	68461	EFO:0002298	\N	NCI-H650	EFO:0002298
0	"" []	\N	NCI-H661	\N	\N	EFO	"" []	EFO	68462	EFO:0002299	\N	NCI-H661	EFO:0002299
0	"Human Caucasian lung small cell carcinoma cell line." []	\N	NCI-H69	\N	\N	EFO	"Human Caucasian lung small cell carcinoma cell line." []	EFO	68463	EFO:0002300	\N	NCI-H69	EFO:0002300
0	"" []	\N	NCI-H716	\N	\N	EFO	"" []	EFO	68464	EFO:0002301	\N	NCI-H716	EFO:0002301
0	"" []	\N	NCI-H720	\N	\N	EFO	"" []	EFO	68465	EFO:0002302	\N	NCI-H720	EFO:0002302
0	"" []	\N	NCI-H747	\N	\N	EFO	"" []	EFO	68466	EFO:0002303	\N	NCI-H747	EFO:0002303
0	"" []	\N	NCI-H748	\N	\N	EFO	"" []	EFO	68467	EFO:0002304	\N	NCI-H748	EFO:0002304
0	"" []	\N	NCI-H810	\N	\N	EFO	"" []	EFO	68468	EFO:0002305	\N	NCI-H810	EFO:0002305
0	"" []	\N	NCI-H82	\N	\N	EFO	"" []	EFO	68469	EFO:0002306	\N	NCI-H82	EFO:0002306
0	"" []	\N	NCI-H838	\N	\N	EFO	"" []	EFO	68470	EFO:0002307	\N	NCI-H838	EFO:0002307
0	"" []	\N	OE19	\N	\N	EFO	"" []	EFO	68471	EFO:0002308	\N	OE19	EFO:0002308
0	"" []	\N	OE21	\N	\N	EFO	"" []	EFO	68472	EFO:0002309	\N	OE21	EFO:0002309
0	"" []	\N	OE33	\N	\N	EFO	"" []	EFO	68473	EFO:0002310	\N	OE33	EFO:0002310
0	"" []	\N	OV90	\N	\N	EFO	"" []	EFO	68474	EFO:0002311	\N	OV90	EFO:0002311
0	"" []	\N	P3HR1	\N	\N	EFO	"" []	EFO	68475	EFO:0002312	\N	P3HR1	EFO:0002312
0	"" []	\N	PLB985	\N	\N	EFO	"" []	EFO	68476	EFO:0002313	\N	PLB985	EFO:0002313
0	"" []	\N	RCHACV	\N	\N	EFO	"" []	EFO	68477	EFO:0002314	\N	RCHACV	EFO:0002314
0	"" []	\N	RD	\N	\N	EFO	"" []	EFO	68478	EFO:0002315	\N	RD	EFO:0002315
0	"" []	\N	RDES	\N	\N	EFO	"" []	EFO	68479	EFO:0002316	\N	RDES	EFO:0002316
0	"" []	\N	REC1	\N	\N	EFO	"" []	EFO	68480	EFO:0002317	\N	REC1	EFO:0002317
0	"" []	\N	RKOE6	\N	\N	EFO	"" []	EFO	68481	EFO:0002318	\N	RKOE6	EFO:0002318
0	"" []	\N	RL	\N	\N	EFO	"" []	EFO	68482	EFO:0002319	\N	RL	EFO:0002319
0	"" []	\N	RL952	\N	\N	EFO	"" []	EFO	68483	EFO:0002320	\N	RL952	EFO:0002320
0	"" []	\N	RPMI6666	\N	\N	EFO	"" []	EFO	68484	EFO:0002321	\N	RPMI6666	EFO:0002321
0	"" []	\N	RPMI8226	\N	\N	EFO	"" []	EFO	68485	EFO:0002322	\N	RPMI8226	EFO:0002322
0	"Epithelial cells derived from the peripheral zone of a histologically normal adult human prostate were transfected with a single copy of the human papilloma virus 18 (HPV-18) to establish the RWPE-1 (ATCC CRL-11609) cell line. [PMID:9214605]." []	\N	RWPE1	\N	\N	EFO	"Epithelial cells derived from the peripheral zone of a histologically normal adult human prostate were transfected with a single copy of the human papilloma virus 18 (HPV-18) to establish the RWPE-1 (ATCC CRL-11609) cell line. [PMID:9214605]." []	EFO	68486	EFO:0002323	\N	RWPE1	EFO:0002323
0	"" []	\N	Raji	\N	\N	EFO	"" []	EFO	68487	EFO:0002324	\N	Raji	EFO:0002324
0	"" []	\N	SCaBER	\N	\N	EFO	"" []	EFO	68488	EFO:0002325	\N	SCaBER	EFO:0002325
0	"" []	\N	SEM	\N	\N	EFO	"" []	EFO	68489	EFO:0002326	\N	SEM	EFO:0002326
0	"" []	\N	SH4	\N	\N	EFO	"" []	EFO	68490	EFO:0002327	\N	SH4	EFO:0002327
0	"" []	\N	SHP77	\N	\N	EFO	"" []	EFO	68491	EFO:0002328	\N	SHP77	EFO:0002328
0	"" []	\N	SJRH30	\N	\N	EFO	"" []	EFO	68492	EFO:0002329	\N	SJRH30	EFO:0002329
0	"" []	\N	SJSA1	\N	\N	EFO	"" []	EFO	68493	EFO:0002330	\N	SJSA1	EFO:0002330
0	"" []	\N	SKLMS1	\N	\N	EFO	"" []	EFO	68494	EFO:0002331	\N	SKLMS1	EFO:0002331
0	"" []	\N	SKMEL1	\N	\N	EFO	"" []	EFO	68495	EFO:0002332	\N	SKMEL1	EFO:0002332
0	"" []	\N	SKMEL3	\N	\N	EFO	"" []	EFO	68496	EFO:0002333	\N	SKMEL3	EFO:0002333
0	"" []	\N	SKMES1	\N	\N	EFO	"" []	EFO	68497	EFO:0002334	\N	SKMES1	EFO:0002334
0	"" []	\N	SKNDZ	\N	\N	EFO	"" []	EFO	68498	EFO:0002336	\N	SKNDZ	EFO:0002336
0	"SKNEP1 is a human kidney cell line derived from a patient with Nephroblastoma." []	\N	SKNEP1	\N	\N	EFO	"SKNEP1 is a human kidney cell line derived from a patient with Nephroblastoma." []	EFO	68499	EFO:0002337	\N	SKNEP1	EFO:0002337
0	"" []	\N	SKNFI	\N	\N	EFO	"" []	EFO	68500	EFO:0002338	\N	SKNFI	EFO:0002338
0	"" []	\N	SKO007	\N	\N	EFO	"" []	EFO	68501	EFO:0002339	\N	SKO007	EFO:0002339
0	"" []	\N	SKOV3	\N	\N	EFO	"" []	EFO	68502	EFO:0002340	\N	SKOV3	EFO:0002340
0	"" []	\N	SKUT1	\N	\N	EFO	"" []	EFO	68503	EFO:0002341	\N	SKUT1	EFO:0002341
0	"" []	\N	SNB19	\N	\N	EFO	"" []	EFO	68504	EFO:0002342	\N	SNB19	EFO:0002342
0	"" []	\N	SNU1	\N	\N	EFO	"" []	EFO	68505	EFO:0002343	\N	SNU1	EFO:0002343
0	"" []	\N	SNU16	\N	\N	EFO	"" []	EFO	68506	EFO:0002344	\N	SNU16	EFO:0002344
0	"" []	\N	SNU182	\N	\N	EFO	"" []	EFO	68507	EFO:0002345	\N	SNU182	EFO:0002345
0	"" []	\N	SNU387	\N	\N	EFO	"" []	EFO	68508	EFO:0002346	\N	SNU387	EFO:0002346
0	"" []	\N	SNU398	\N	\N	EFO	"" []	EFO	68509	EFO:0002347	\N	SNU398	EFO:0002347
0	"" []	\N	SNU423	\N	\N	EFO	"" []	EFO	68510	EFO:0002348	\N	SNU423	EFO:0002348
0	"" []	\N	SNU449	\N	\N	EFO	"" []	EFO	68511	EFO:0002349	\N	SNU449	EFO:0002349
0	"" []	\N	SNU475	\N	\N	EFO	"" []	EFO	68512	EFO:0002350	\N	SNU475	EFO:0002350
0	"" []	\N	SNU5	\N	\N	EFO	"" []	EFO	68513	EFO:0002351	\N	SNU5	EFO:0002351
0	"" []	\N	SR	\N	\N	EFO	"" []	EFO	68514	EFO:0002352	\N	SR	EFO:0002352
0	"" []	\N	ST486	\N	\N	EFO	"" []	EFO	68515	EFO:0002353	\N	ST486	EFO:0002353
0	"" []	\N	SUDHL10	\N	\N	EFO	"" []	EFO	68516	EFO:0002354	\N	SUDHL10	EFO:0002354
0	"" []	\N	SUDHL16	\N	\N	EFO	"" []	EFO	68517	EFO:0002355	\N	SUDHL16	EFO:0002355
0	"" []	\N	SUDHL5	\N	\N	EFO	"" []	EFO	68518	EFO:0002356	\N	SUDHL5	EFO:0002356
0	"" []	\N	SUDHL6	\N	\N	EFO	"" []	EFO	68519	EFO:0002357	\N	SUDHL6	EFO:0002357
0	"" []	\N	SW1088	\N	\N	EFO	"" []	EFO	68520	EFO:0002358	\N	SW1088	EFO:0002358
0	"" []	\N	SW1116	\N	\N	EFO	"" []	EFO	68521	EFO:0002359	\N	SW1116	EFO:0002359
0	"" []	\N	SW1353	\N	\N	EFO	"" []	EFO	68522	EFO:0002360	\N	SW1353	EFO:0002360
0	"" []	\N	SW1417	\N	\N	EFO	"" []	EFO	68523	EFO:0002361	\N	SW1417	EFO:0002361
0	"" []	\N	SW1463	\N	\N	EFO	"" []	EFO	68524	EFO:0002362	\N	SW1463	EFO:0002362
0	"" []	\N	SW1573	\N	\N	EFO	"" []	EFO	68525	EFO:0002363	\N	SW1573	EFO:0002363
0	"" []	\N	SW1783	\N	\N	EFO	"" []	EFO	68526	EFO:0002364	\N	SW1783	EFO:0002364
0	"" []	\N	SW1990	\N	\N	EFO	"" []	EFO	68527	EFO:0002365	\N	SW1990	EFO:0002365
0	"" []	\N	SW403	\N	\N	EFO	"" []	EFO	68528	EFO:0002366	\N	SW403	EFO:0002366
0	"" []	\N	SW48	\N	\N	EFO	"" []	EFO	68529	EFO:0002367	\N	SW48	EFO:0002367
0	"" []	\N	SW620	\N	\N	EFO	"" []	EFO	68530	EFO:0002368	\N	SW620	EFO:0002368
0	"" []	\N	SW684	\N	\N	EFO	"" []	EFO	68531	EFO:0002369	\N	SW684	EFO:0002369
0	"" []	\N	SW756	\N	\N	EFO	"" []	EFO	68532	EFO:0002370	\N	SW756	EFO:0002370
0	"" []	\N	SW780	\N	\N	EFO	"" []	EFO	68533	EFO:0002371	\N	SW780	EFO:0002371
0	"" []	\N	SW837	\N	\N	EFO	"" []	EFO	68534	EFO:0002372	\N	SW837	EFO:0002372
0	"" []	\N	SW872	\N	\N	EFO	"" []	EFO	68535	EFO:0002373	\N	SW872	EFO:0002373
0	"" []	\N	SW900	\N	\N	EFO	"" []	EFO	68536	EFO:0002374	\N	SW900	EFO:0002374
0	"" []	\N	SW948	\N	\N	EFO	"" []	EFO	68537	EFO:0002375	\N	SW948	EFO:0002375
0	"" []	\N	SW954	\N	\N	EFO	"" []	EFO	68538	EFO:0002376	\N	SW954	EFO:0002376
0	"" []	\N	SW962	\N	\N	EFO	"" []	EFO	68539	EFO:0002377	\N	SW962	EFO:0002377
0	"" []	\N	SW982	\N	\N	EFO	"" []	EFO	68540	EFO:0002378	\N	SW982	EFO:0002378
0	"" []	\N	SiHa	\N	\N	EFO	"" []	EFO	68541	EFO:0002379	\N	SiHa	EFO:0002379
0	"" []	\N	TANOUE	\N	\N	EFO	"" []	EFO	68542	EFO:0002380	\N	TANOUE	EFO:0002380
0	"" []	\N	TT	\N	\N	EFO	"" []	EFO	68543	EFO:0002382	\N	TT	EFO:0002382
0	"" []	\N	Toledo	\N	\N	EFO	"" []	EFO	68544	EFO:0002383	\N	Toledo	EFO:0002383
0	"" []	\N	U266B1	\N	\N	EFO	"" []	EFO	68545	EFO:0002384	\N	U266B1	EFO:0002384
0	"" []	\N	UACC893	\N	\N	EFO	"" []	EFO	68546	EFO:0002385	\N	UACC893	EFO:0002385
0	"" []	\N	UMC11	\N	\N	EFO	"" []	EFO	68547	EFO:0002386	\N	UMC11	EFO:0002386
0	"" []	\N	UMUC3	\N	\N	EFO	"" []	EFO	68548	EFO:0002387	\N	UMUC3	EFO:0002387
0	"" []	\N	WIDR	\N	\N	EFO	"" []	EFO	68549	EFO:0002389	\N	WIDR	EFO:0002389
0	"" []	\N	WM115	\N	\N	EFO	"" []	EFO	68550	EFO:0002390	\N	WM115	EFO:0002390
0	"" []	\N	Y79	\N	\N	EFO	"" []	EFO	68551	EFO:0002392	\N	Y79	EFO:0002392
0	"" []	\N	YPAC	\N	\N	EFO	"" []	EFO	68552	EFO:0002393	\N	YPAC	EFO:0002393
0	"Cell lines derived from ovarian cancer tissue." []	\N	ovarian cancer cell lines	\N	\N	EFO	"Cell lines derived from ovarian cancer tissue." []	EFO	68553	EFO:0002394	\N	ovarian cancer cell lines	EFO:0002394
0	"" []	\N	benign neoplasm	\N	\N	EFO	"" []	EFO	68554	EFO:0002422	\N	benign neoplasm	EFO:0002422
0	"" []	\N	osteoma	\N	\N	EFO	"" []	EFO	68555	EFO:0002423	\N	osteoma	EFO:0002423
0	"" []	\N	fibroma	\N	\N	EFO	"" []	EFO	68556	EFO:0002424	\N	fibroma	EFO:0002424
0	"" []	\N	neoplasm of immature B and T cells	\N	\N	EFO	"" []	EFO	68557	EFO:0002425	\N	neoplasm of immature B and T cells	EFO:0002425
0	"" []	\N	neoplasm of mature T-cells or NK-cells	\N	\N	EFO	"" []	EFO	68558	EFO:0002426	\N	neoplasm of mature T-cells or NK-cells	EFO:0002426
0	"" []	\N	myeloid neoplasm	\N	\N	EFO	"" []	EFO	68559	EFO:0002427	\N	myeloid neoplasm	EFO:0002427
0	"" []	\N	chronic myeloproliferative disorder	\N	\N	EFO	"" []	EFO	68560	EFO:0002428	\N	chronic myeloproliferative disorder	EFO:0002428
0	"" []	\N	polycythemia vera	\N	\N	EFO	"" []	EFO	68561	EFO:0002429	\N	polycythemia vera	EFO:0002429
0	"" []	\N	primary myelofibrosis	\N	\N	EFO	"" []	EFO	68562	EFO:0002430	\N	primary myelofibrosis	EFO:0002430
0	"Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)" []	\N	tumour of cranial and spinal nerves	\N	\N	EFO	"Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)" []	EFO	68563	EFO:0002431	\N	tumour of cranial and spinal nerves	EFO:0002431
0	"" []	\N	cumulus-oocyte complex	\N	\N	EFO	"" []	EFO	68564	EFO:0002433	\N	cumulus-oocyte complex	EFO:0002433
0	"" []	\N	mesophyll cell	\N	\N	EFO	"" []	EFO	68565	EFO:0002439	\N	mesophyll cell	EFO:0002439
0	"A convenient source of human endothelial cells are those that line the large vein in the umbilical cord which is usually discarded together with the placenta after childbirth. The cells can be removed as a fairly pure suspension by mild enzymatic treatment of the vein followed by some mechanical distraction and will grow relatively easily in culture, retaining their differentiated characteristics for several passages." []	\N	HUVEC cell	\N	\N	EFO	"A convenient source of human endothelial cells are those that line the large vein in the umbilical cord which is usually discarded together with the placenta after childbirth. The cells can be removed as a fairly pure suspension by mild enzymatic treatment of the vein followed by some mechanical distraction and will grow relatively easily in culture, retaining their differentiated characteristics for several passages." []	EFO	68566	EFO:0002451	\N	HUVEC cell	EFO:0002451
0	"" []	\N	hippocampus CA1	\N	\N	EFO	"" []	EFO	68567	EFO:0002454	\N	hippocampus CA1	EFO:0002454
0	"" []	\N	hippocampus CA2	\N	\N	EFO	"" []	EFO	68568	EFO:0002455	\N	hippocampus CA2	EFO:0002455
0	"" []	\N	hippocampus CA3	\N	\N	EFO	"" []	EFO	68569	EFO:0002456	\N	hippocampus CA3	EFO:0002456
0	"" []	\N	hippocampus CA4	\N	\N	EFO	"" []	EFO	68570	EFO:0002457	\N	hippocampus CA4	EFO:0002457
0	"" []	\N	nucleus accumbens core	\N	\N	EFO	"" []	EFO	68571	EFO:0002458	\N	nucleus accumbens core	EFO:0002458
0	"" []	\N	nucleus accumbens shell	\N	\N	EFO	"" []	EFO	68572	EFO:0002459	\N	nucleus accumbens shell	EFO:0002459
0	"Hypertrophy is the increase in the volume of an organ or tissue due to the enlargement of its component cells." []	\N	hypertrophy	\N	\N	EFO	"Hypertrophy is the increase in the volume of an organ or tissue due to the enlargement of its component cells." []	EFO	68573	EFO:0002460	\N	hypertrophy	EFO:0002460
0	"Any disease which affects part of the skeletal system." []	\N	skeletal system disease	\N	\N	EFO	"Any disease which affects part of the skeletal system." []	EFO	68574	EFO:0002461	\N	skeletal system disease	EFO:0002461
0	"" []	\N	foetal structure	\N	\N	EFO	"" []	EFO	68575	EFO:0002462	\N	foetal structure	EFO:0002462
0	"" []	\N	motor cortex	\N	\N	EFO	"" []	EFO	68576	EFO:0002467	\N	motor cortex	EFO:0002467
0	"" []	\N	paraventricular nucleus	\N	\N	EFO	"" []	EFO	68577	EFO:0002469	\N	paraventricular nucleus	EFO:0002469
0	"" []	\N	periaqueductal gray	\N	\N	EFO	"" []	EFO	68578	EFO:0002470	\N	periaqueductal gray	EFO:0002470
0	"" []	\N	posterior cingulate cortex	\N	\N	EFO	"" []	EFO	68579	EFO:0002471	\N	posterior cingulate cortex	EFO:0002471
0	"" []	\N	somatomotor cortex	\N	\N	EFO	"" []	EFO	68580	EFO:0002472	\N	somatomotor cortex	EFO:0002472
0	"The area of the plant from where the stamen is shed." []	\N	stamen abscission zone	\N	\N	EFO	"The area of the plant from where the stamen is shed." []	EFO	68581	EFO:0002473	\N	stamen abscission zone	EFO:0002473
0	"" []	\N	accelerated neurological senescence	\N	\N	EFO	"" []	EFO	68582	EFO:0002495	\N	accelerated neurological senescence	EFO:0002495
0	"" []	\N	actinic keratosis	\N	\N	EFO	"" []	EFO	68583	EFO:0002496	\N	actinic keratosis	EFO:0002496
0	"" []	\N	acute hypotension	\N	\N	EFO	"" []	EFO	68584	EFO:0002497	\N	acute hypotension	EFO:0002497
0	"Insulitis is an inflammatory infiltration of the islets of Langerhans found especially in young patients with recent onset type 1 diabetes." []	\N	aggressive insulitis	\N	\N	EFO	"Insulitis is an inflammatory infiltration of the islets of Langerhans found especially in young patients with recent onset type 1 diabetes." []	EFO	68585	EFO:0002498	\N	aggressive insulitis	EFO:0002498
0	"" []	\N	anaplastic astrocytoma	\N	\N	EFO	"" []	EFO	68586	EFO:0002499	\N	anaplastic astrocytoma	EFO:0002499
0	"" []	\N	anaplastic oligoastrocytoma	\N	\N	EFO	"" []	EFO	68587	EFO:0002500	\N	anaplastic oligoastrocytoma	EFO:0002500
0	"" []	\N	anaplastic oligodendroglioma	\N	\N	EFO	"" []	EFO	68588	EFO:0002501	\N	anaplastic oligodendroglioma	EFO:0002501
0	"" []	\N	benign insulitis	\N	\N	EFO	"" []	EFO	68589	EFO:0002502	\N	benign insulitis	EFO:0002502
0	"an increase in size of the cardiac tissue, not due to increased cell number" []	\N	cardiac hypertrophy	\N	\N	EFO	"an increase in size of the cardiac tissue, not due to increased cell number" []	EFO	68590	EFO:0002503	\N	cardiac hypertrophy	EFO:0002503
0	"" []	\N	serous cystadenoma	\N	\N	EFO	"" []	EFO	68591	EFO:0002504	\N	serous cystadenoma	EFO:0002504
0	"A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans." []	\N	osteoarthritis	\N	\N	EFO	"A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans." []	EFO	68592	EFO:0002506	\N	osteoarthritis	EFO:0002506
0	"" []	\N	ovarian adenoma benign	\N	\N	EFO	"" []	EFO	68593	EFO:0002507	\N	ovarian adenoma benign	EFO:0002507
0	"A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)" []	\N	Parkinson's disease	\N	\N	EFO	"A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)" []	EFO	68594	EFO:0002508	\N	Parkinson's disease	EFO:0002508
0	"" []	\N	progressive external ophthalmoplegia	\N	\N	EFO	"" []	EFO	68595	EFO:0002509	\N	progressive external ophthalmoplegia	EFO:0002509
0	"" []	\N	serous cystadenofibroma	\N	\N	EFO	"" []	EFO	68596	EFO:0002510	\N	serous cystadenofibroma	EFO:0002510
0	"" []	\N	simple cystadenoma	\N	\N	EFO	"" []	EFO	68597	EFO:0002511	\N	simple cystadenoma	EFO:0002511
0	"" []	\N	corneal stroma	\N	\N	EFO	"" []	EFO	68598	EFO:0002514	\N	corneal stroma	EFO:0002514
0	"" []	\N	inferior ganglion of vagus nerve	\N	\N	EFO	"" []	EFO	68599	EFO:0002516	\N	inferior ganglion of vagus nerve	EFO:0002516
0	"" []	\N	pancreatic ductal adenocarcinoma	\N	\N	EFO	"" []	EFO	68600	EFO:0002517	\N	pancreatic ductal adenocarcinoma	EFO:0002517
0	"" []	\N	raphe magnus	\N	\N	EFO	"" []	EFO	68601	EFO:0002518	\N	raphe magnus	EFO:0002518
0	"" []	\N	vegetative apex	\N	\N	EFO	"" []	EFO	68602	EFO:0002519	\N	vegetative apex	EFO:0002519
0	"" []	\N	neurointermediate lobe	\N	\N	EFO	"" []	EFO	68603	EFO:0002520	\N	neurointermediate lobe	EFO:0002520
0	"" []	\N	BTBR mouse	\N	\N	EFO	"" []	EFO	68604	EFO:0002522	\N	BTBR mouse	EFO:0002522
0	"" []	\N	substantia nigra and ventral tegmental area	\N	\N	EFO	"" []	EFO	68605	EFO:0002528	\N	substantia nigra and ventral tegmental area	EFO:0002528
0	"Pancreatic beta -cell line of rat origin." []	\N	INS-1	\N	\N	EFO	"Pancreatic beta -cell line of rat origin." []	EFO	68606	EFO:0002529	\N	INS-1	EFO:0002529
0	"" []	\N	fetal blood cell	\N	\N	EFO	"" []	EFO	68607	EFO:0002534	\N	fetal blood cell	EFO:0002534
0	"" []	\N	nestin positive islet-derived progenitor cell	\N	\N	EFO	"" []	EFO	68608	EFO:0002540	\N	nestin positive islet-derived progenitor cell	EFO:0002540
0	"An Islet cell is a pancreatic cell that produces and secretes hormones such as insulin and glucagon." []	\N	islet cell	\N	\N	EFO	"An Islet cell is a pancreatic cell that produces and secretes hormones such as insulin and glucagon." []	EFO	68609	EFO:0002542	\N	islet cell	EFO:0002542
0	"" []	\N	mouse prenatal	\N	\N	EFO	"" []	EFO	68610	EFO:0002543	\N	mouse prenatal	EFO:0002543
0	"The distinct stages of the life cycle of a protozoon of the genus Plasmodium." []	\N	plasmodium parasite stage	\N	\N	EFO	"The distinct stages of the life cycle of a protozoon of the genus Plasmodium." []	EFO	68611	EFO:0002544	\N	plasmodium parasite stage	EFO:0002544
0	"" []	\N	abnormal glucose tolerance	\N	\N	EFO	"" []	EFO	68612	EFO:0002546	\N	abnormal glucose tolerance	EFO:0002546
0	"" []	\N	NOD mouse	\N	\N	EFO	"" []	EFO	68613	EFO:0002547	\N	NOD mouse	EFO:0002547
0	"" []	\N	pancreatic duct epithelium	\N	\N	EFO	"" []	EFO	68614	EFO:0002556	\N	pancreatic duct epithelium	EFO:0002556
0	"" []	\N	pancreatic mesenchyme	\N	\N	EFO	"" []	EFO	68615	EFO:0002557	\N	pancreatic mesenchyme	EFO:0002557
0	"" []	\N	gastrula 80%-epiboly	\N	\N	EFO	"" []	EFO	68616	EFO:0002560	\N	gastrula 80%-epiboly	EFO:0002560
0	"" []	\N	embryonic day 8.25	\N	\N	EFO	"" []	EFO	68617	EFO:0002561	\N	embryonic day 8.25	EFO:0002561
0	"" []	\N	embryonic day 11.5	\N	\N	EFO	"" []	EFO	68618	EFO:0002562	\N	embryonic day 11.5	EFO:0002562
0	"" []	\N	embryonic day 12.5	\N	\N	EFO	"" []	EFO	68619	EFO:0002563	\N	embryonic day 12.5	EFO:0002563
0	"" []	\N	embryonic day 13.5	\N	\N	EFO	"" []	EFO	68620	EFO:0002564	\N	embryonic day 13.5	EFO:0002564
0	"" []	\N	embryonic day 14.5	\N	\N	EFO	"" []	EFO	68621	EFO:0002565	\N	embryonic day 14.5	EFO:0002565
0	"" []	\N	embryonic day 15.5	\N	\N	EFO	"" []	EFO	68622	EFO:0002566	\N	embryonic day 15.5	EFO:0002566
0	"" []	\N	embryonic day 16.5	\N	\N	EFO	"" []	EFO	68623	EFO:0002567	\N	embryonic day 16.5	EFO:0002567
0	"" []	\N	embryonic day 17.5	\N	\N	EFO	"" []	EFO	68624	EFO:0002568	\N	embryonic day 17.5	EFO:0002568
0	"" []	\N	embryonic day 18	\N	\N	EFO	"" []	EFO	68625	EFO:0002569	\N	embryonic day 18	EFO:0002569
0	"" []	\N	embryonic day 18.5	\N	\N	EFO	"" []	EFO	68626	EFO:0002570	\N	embryonic day 18.5	EFO:0002570
0	"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects." []	\N	medical procedure	\N	\N	EFO	"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects." []	EFO	68627	EFO:0002571	\N	medical procedure	EFO:0002571
0	"" []	\N	large adipocyte	\N	\N	EFO	"" []	EFO	68628	EFO:0002572	\N	large adipocyte	EFO:0002572
0	"" []	\N	small adipocyte	\N	\N	EFO	"" []	EFO	68629	EFO:0002573	\N	small adipocyte	EFO:0002573
0	"" []	\N	esophageal endoderm	\N	\N	EFO	"" []	EFO	68630	EFO:0002575	\N	esophageal endoderm	EFO:0002575
0	"" []	\N	intestinal endoderm	\N	\N	EFO	"" []	EFO	68631	EFO:0002576	\N	intestinal endoderm	EFO:0002576
0	"" []	\N	liver endoderm	\N	\N	EFO	"" []	EFO	68632	EFO:0002577	\N	liver endoderm	EFO:0002577
0	"" []	\N	lung endoderm	\N	\N	EFO	"" []	EFO	68633	EFO:0002578	\N	lung endoderm	EFO:0002578
0	"" []	\N	pancreatic endoderm	\N	\N	EFO	"" []	EFO	68634	EFO:0002579	\N	pancreatic endoderm	EFO:0002579
0	"" []	\N	stomach endoderm	\N	\N	EFO	"" []	EFO	68635	EFO:0002580	\N	stomach endoderm	EFO:0002580
0	"Surgical removal of part or all of the pancreas." []	\N	pancreatectomy	\N	\N	EFO	"Surgical removal of part or all of the pancreas." []	EFO	68636	EFO:0002581	\N	pancreatectomy	EFO:0002581
0	"" []	\N	Theiler stage 11	\N	\N	EFO	"" []	EFO	68637	EFO:0002582	\N	Theiler stage 11	EFO:0002582
0	"" []	\N	Theiler stage 17	\N	\N	EFO	"" []	EFO	68638	EFO:0002583	\N	Theiler stage 17	EFO:0002583
0	"" []	\N	Theiler stage 21	\N	\N	EFO	"" []	EFO	68639	EFO:0002584	\N	Theiler stage 21	EFO:0002584
0	"" []	\N	Theiler stage 22	\N	\N	EFO	"" []	EFO	68640	EFO:0002585	\N	Theiler stage 22	EFO:0002585
0	"" []	\N	Theiler stage 24	\N	\N	EFO	"" []	EFO	68641	EFO:0002586	\N	Theiler stage 24	EFO:0002586
0	"" []	\N	Theiler stage 26	\N	\N	EFO	"" []	EFO	68642	EFO:0002587	\N	Theiler stage 26	EFO:0002587
0	"Theiler stage 28 is a mouse postnatal stage characterised by postnatal development after a mouse is newly born." []	\N	Theiler stage 28	\N	\N	EFO	"Theiler stage 28 is a mouse postnatal stage characterised by postnatal development after a mouse is newly born." []	EFO	68643	EFO:0002588	\N	Theiler stage 28	EFO:0002588
0	"A schizont produced in the liver of the vertebrate host." []	\N	hepatic schizont	\N	\N	EFO	"A schizont produced in the liver of the vertebrate host." []	EFO	68644	EFO:0002589	\N	hepatic schizont	EFO:0002589
0	"A developmental stage of the Plasmodium life cycle found within the erythrocyte, called such because of the shape observed." []	\N	ring stage trophozoite	\N	\N	EFO	"A developmental stage of the Plasmodium life cycle found within the erythrocyte, called such because of the shape observed." []	EFO	68645	EFO:0002590	\N	ring stage trophozoite	EFO:0002590
0	"The stage of a sporozoan cell that reproduces by schizogony, producing a varied number of daughter trophozoites or merozoites." []	\N	erythrocytic schizont	\N	\N	EFO	"The stage of a sporozoan cell that reproduces by schizogony, producing a varied number of daughter trophozoites or merozoites." []	EFO	68646	EFO:0002591	\N	erythrocytic schizont	EFO:0002591
0	"A developmental stage of the Plasmodium life cycle found within the erythrocyte." []	\N	trophozoite	\N	\N	EFO	"A developmental stage of the Plasmodium life cycle found within the erythrocyte." []	EFO	68647	EFO:0002592	\N	trophozoite	EFO:0002592
0	"" []	\N	distal renal artery	\N	\N	EFO	"" []	EFO	68648	EFO:0002593	\N	distal renal artery	EFO:0002593
0	"" []	\N	proximal renal artery	\N	\N	EFO	"" []	EFO	68649	EFO:0002594	\N	proximal renal artery	EFO:0002594
0	"" []	\N	renal branch of vagus nerve	\N	\N	EFO	"" []	EFO	68650	EFO:0002595	\N	renal branch of vagus nerve	EFO:0002595
0	"" []	\N	carotid artery endothelium	\N	\N	EFO	"" []	EFO	68651	EFO:0002596	\N	carotid artery endothelium	EFO:0002596
0	"" []	\N	distal portion of anterior interventricular branch of left coronary artery	\N	\N	EFO	"" []	EFO	68652	EFO:0002598	\N	distal portion of anterior interventricular branch of left coronary artery	EFO:0002598
0	"" []	\N	distal portion of circumflex branch of left coronary artery	\N	\N	EFO	"" []	EFO	68653	EFO:0002599	\N	distal portion of circumflex branch of left coronary artery	EFO:0002599
0	"" []	\N	distal portion of right coronary artery	\N	\N	EFO	"" []	EFO	68654	EFO:0002600	\N	distal portion of right coronary artery	EFO:0002600
0	"" []	\N	proximal portion of anterior interventricular branch of left coronary artery	\N	\N	EFO	"" []	EFO	68655	EFO:0002601	\N	proximal portion of anterior interventricular branch of left coronary artery	EFO:0002601
0	"" []	\N	proximal portion of circumflex branch of left coronary artery	\N	\N	EFO	"" []	EFO	68656	EFO:0002602	\N	proximal portion of circumflex branch of left coronary artery	EFO:0002602
0	"" []	\N	proximal portion of right coronary artery	\N	\N	EFO	"" []	EFO	68657	EFO:0002603	\N	proximal portion of right coronary artery	EFO:0002603
0	"" []	\N	gene name	\N	\N	EFO	"" []	EFO	68658	EFO:0002605	\N	gene name	EFO:0002605
0	"A HIV encephalopathy and is_a brain disease that results_in infection in adults located_in brain, has_agent Human immunodeficiency virus 1 or has_agent Human immunodeficiency virus 2. The infection has_symptom cognitive impairment, has_symptom motor dysfunction, has_symptom behavioral change, and has_symptom speech problems." []	\N	AIDS dementia	\N	\N	EFO	"A HIV encephalopathy and is_a brain disease that results_in infection in adults located_in brain, has_agent Human immunodeficiency virus 1 or has_agent Human immunodeficiency virus 2. The infection has_symptom cognitive impairment, has_symptom motor dysfunction, has_symptom behavioral change, and has_symptom speech problems." []	EFO	68659	EFO:0002608	\N	AIDS dementia	EFO:0002608
0	"" []	\N	chronic childhood arthritis	\N	\N	EFO	"" []	EFO	68660	EFO:0002609	\N	chronic childhood arthritis	EFO:0002609
0	"A drug dependence that is a psychological dependency on the regular use of cocaine." []	\N	cocaine dependence	\N	\N	EFO	"A drug dependence that is a psychological dependency on the regular use of cocaine." []	EFO	68661	EFO:0002610	\N	cocaine dependence	EFO:0002610
0	"A gammaherpesvirus that contributes to the development of Kaposi sarcoma." []	\N	human herpesvirus 8 infection	\N	\N	EFO	"A gammaherpesvirus that contributes to the development of Kaposi sarcoma." []	EFO	68662	EFO:0002612	\N	human herpesvirus 8 infection	EFO:0002612
0	"" []	\N	iatrogenic Kaposi's sarcoma	\N	\N	EFO	"" []	EFO	68663	EFO:0002613	\N	iatrogenic Kaposi's sarcoma	EFO:0002613
0	"diminished effectiveness of insulin in lowering plasma glucose levels" []	\N	insulin resistance	\N	\N	EFO	"diminished effectiveness of insulin in lowering plasma glucose levels" []	EFO	68664	EFO:0002614	\N	insulin resistance	EFO:0002614
0	"" []	\N	internal carotid artery stenosis	\N	\N	EFO	"" []	EFO	68665	EFO:0002615	\N	internal carotid artery stenosis	EFO:0002615
0	"" []	\N	macroglobulinemia	\N	\N	EFO	"" []	EFO	68666	EFO:0002616	\N	macroglobulinemia	EFO:0002616
0	"" []	\N	metastatic melanoma	\N	\N	EFO	"" []	EFO	68667	EFO:0002617	\N	metastatic melanoma	EFO:0002617
0	"Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA)." []	\N	pancreatic carcinoma	\N	\N	EFO	"Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA)." []	EFO	68668	EFO:0002618	\N	pancreatic carcinoma	EFO:0002618
0	"noninvasive prostate duct lesions that affect smaller caliber ducts" []	\N	prostate intraepithelial neoplasia	\N	\N	EFO	"noninvasive prostate duct lesions that affect smaller caliber ducts" []	EFO	68669	EFO:0002621	\N	prostate intraepithelial neoplasia	EFO:0002621
0	"A Reoviridae infectious disease that results_in inflammation located_in stomach and located_in intestine, has_agent Rotavirus, which is transmitted_by ingestion of contaminated food or water, or transmitted_by fomites. The infection has_symptom fever, has_symptom vomiting, has_symptom diarrhea, and has_symptom abdominal pain." []	\N	rotavirus infection	\N	\N	EFO	"A Reoviridae infectious disease that results_in inflammation located_in stomach and located_in intestine, has_agent Rotavirus, which is transmitted_by ingestion of contaminated food or water, or transmitted_by fomites. The infection has_symptom fever, has_symptom vomiting, has_symptom diarrhea, and has_symptom abdominal pain." []	EFO	68670	EFO:0002622	\N	rotavirus infection	EFO:0002622
0	"" []	\N	septic peritonitis	\N	\N	EFO	"" []	EFO	68671	EFO:0002623	\N	septic peritonitis	EFO:0002623
0	"presence of structurally anomalous spermatozoa in the semen; malformations include the physical bending of the sperm to produce kinks or bends" []	\N	teratozoospermia	\N	\N	EFO	"presence of structurally anomalous spermatozoa in the semen; malformations include the physical bending of the sperm to produce kinks or bends" []	EFO	68672	EFO:0002625	\N	teratozoospermia	EFO:0002625
0	"" []	\N	thymus neoplasm	\N	\N	EFO	"" []	EFO	68673	EFO:0002626	\N	thymus neoplasm	EFO:0002626
0	"" []	\N	vulvar intraepithelial neoplasia	\N	\N	EFO	"" []	EFO	68674	EFO:0002627	\N	vulvar intraepithelial neoplasia	EFO:0002627
0	"" []	\N	peripartum cardiomyopathy	\N	\N	EFO	"" []	EFO	68675	EFO:0002628	\N	peripartum cardiomyopathy	EFO:0002628
0	"" []	\N	viral cardiomyopathy	\N	\N	EFO	"" []	EFO	68676	EFO:0002629	\N	viral cardiomyopathy	EFO:0002629
0	"A type of heart disorder referring to the inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and looses its flexibility. Causes include replacement of the myocardium with scar tissue, abnormal cellular infiltration of the myocardium, or deposition of a substance (e.g., amyloid) in the myocardium." []	\N	restrictive cardiomyopathy	\N	\N	EFO	"A type of heart disorder referring to the inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and looses its flexibility. Causes include replacement of the myocardium with scar tissue, abnormal cellular infiltration of the myocardium, or deposition of a substance (e.g., amyloid) in the myocardium." []	EFO	68677	EFO:0002630	\N	restrictive cardiomyopathy	EFO:0002630
0	"" []	\N	protocol parameter	\N	\N	EFO	"" []	EFO	68678	EFO:0002658	\N	protocol parameter	EFO:0002658
0	"" []	\N	MDCC-MSB1	\N	\N	EFO	"" []	EFO	68679	EFO:0002659	\N	MDCC-MSB1	EFO:0002659
0	"A cell taken directly from a living organism, which is not immortalized." []	\N	primary cell	\N	\N	EFO	"A cell taken directly from a living organism, which is not immortalized." []	EFO	68680	EFO:0002660	\N	primary cell	EFO:0002660
0	"" []	\N	dendritic cell-derived intermediate cell	\N	\N	EFO	"" []	EFO	68681	EFO:0002661	\N	dendritic cell-derived intermediate cell	EFO:0002661
0	"" []	\N	dendritic cell-derived osteoclast	\N	\N	EFO	"" []	EFO	68682	EFO:0002662	\N	dendritic cell-derived osteoclast	EFO:0002662
0	"" []	\N	monocyte-derived intermediate cell	\N	\N	EFO	"" []	EFO	68683	EFO:0002665	\N	monocyte-derived intermediate cell	EFO:0002665
0	"" []	\N	monocyte-derived osteoclast	\N	\N	EFO	"" []	EFO	68684	EFO:0002666	\N	monocyte-derived osteoclast	EFO:0002666
0	"Etanercept (trade name Enbrel) is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Pfizer describes in a SEC filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.[1]\\nEtanercept is a fusion protein produced through expression of recombinant DNA. That is, it is a product of a DNA \\"construct\\" engineered to link the human gene for soluble TNF receptor 2 to the gene for the Fc component of human immunoglobulin G1 (IgG1). Expression of the construct produces a continuous protein \\"fusing\\" TNF receptor 2 to IgG1. Production of Etanercept is accomplished by the large-scale culturing of cells that have been \\"cloned\\" to express this recombinant DNA construct." []	\N	ENBREL	\N	\N	EFO	"Etanercept (trade name Enbrel) is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Pfizer describes in a SEC filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.[1]\\nEtanercept is a fusion protein produced through expression of recombinant DNA. That is, it is a product of a DNA \\"construct\\" engineered to link the human gene for soluble TNF receptor 2 to the gene for the Fc component of human immunoglobulin G1 (IgG1). Expression of the construct produces a continuous protein \\"fusing\\" TNF receptor 2 to IgG1. Production of Etanercept is accomplished by the large-scale culturing of cells that have been \\"cloned\\" to express this recombinant DNA construct." []	EFO	68685	EFO:0002669	\N	ENBREL	EFO:0002669
0	"CAS Number: 505-44-2\\nMolecular Weight: 163.26\\nMolecular Formula: C5H9NOS2\\nPurity: ≥97%\\nForm: Liquid\\nPhysical Appearance: Light yellow liquid\\nSMILES: CS(=O)CCCN=C=S" []	\N	iberin	\N	\N	EFO	"CAS Number: 505-44-2\\nMolecular Weight: 163.26\\nMolecular Formula: C5H9NOS2\\nPurity: ≥97%\\nForm: Liquid\\nPhysical Appearance: Light yellow liquid\\nSMILES: CS(=O)CCCN=C=S" []	EFO	68686	EFO:0002671	\N	iberin	EFO:0002671
0	"An antiprogestogen, also called an antiprogesterone or in the case of a synthetic agent, an antiprogestin, is a type of hormone antagonist in which that antagonizes or suppresses the actions of progesterone in the body, a sex hormone that plays a role in the menstrual cycle and pregnancy. Antiprogestogens may stop some cancer cells from growing and they are being studied in the treatment of breast cancer.\\nAn example of an antiprogestogen is mifepristone.[1][2" []	\N	antiprogestin	\N	\N	EFO	"An antiprogestogen, also called an antiprogesterone or in the case of a synthetic agent, an antiprogestin, is a type of hormone antagonist in which that antagonizes or suppresses the actions of progesterone in the body, a sex hormone that plays a role in the menstrual cycle and pregnancy. Antiprogestogens may stop some cancer cells from growing and they are being studied in the treatment of breast cancer.\\nAn example of an antiprogestogen is mifepristone.[1][2" []	EFO	68687	EFO:0002673	\N	antiprogestin	EFO:0002673
0	"" []	\N	ovalbumin	\N	\N	EFO	"" []	EFO	68688	EFO:0002674	\N	ovalbumin	EFO:0002674
0	"" []	\N	saline	\N	\N	EFO	"" []	EFO	68689	EFO:0002677	\N	saline	EFO:0002677
0	"4-Hydroxy-TEMPO or TEMPOL, formally 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, is a heterocyclic compound. Like the related TEMPO, it is used as a catalyst and chemical oxidant. [edit]Pharmaceutical Applications\\n\\nLikely at least partially due to its superoxide dismutase activity, TEMPOL shows radioprotective, life-prolonging properties in animal models, suggesting its potential usefulness for treatment of human diseases.[1] It is currently being studied in human subjects for prevention of radiation-induced alopecia.[2]\\nThis nitroxide antioxidant or its derivatives are also undergoing prospective clinical studies in several clinical conditions. In addition to radioprotection, these include high blood pressure[3][4] and macular degeneration[5]. A published patent[6] claims other clinical uses for TEMPOL and related compounds. These include treatment of fibrocystic disease of breast, menstrual cramps and their associated symptoms, migraine, hemorrhoids, neuropathic pain, cyclic vomiting syndrome, and peridontitis. The patent also claims treatment of the symptoms of influenza, herpes zoster and herpes simplex.\\n[edit]References" []	\N	tempol	\N	\N	EFO	"4-Hydroxy-TEMPO or TEMPOL, formally 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, is a heterocyclic compound. Like the related TEMPO, it is used as a catalyst and chemical oxidant. [edit]Pharmaceutical Applications\\n\\nLikely at least partially due to its superoxide dismutase activity, TEMPOL shows radioprotective, life-prolonging properties in animal models, suggesting its potential usefulness for treatment of human diseases.[1] It is currently being studied in human subjects for prevention of radiation-induced alopecia.[2]\\nThis nitroxide antioxidant or its derivatives are also undergoing prospective clinical studies in several clinical conditions. In addition to radioprotection, these include high blood pressure[3][4] and macular degeneration[5]. A published patent[6] claims other clinical uses for TEMPOL and related compounds. These include treatment of fibrocystic disease of breast, menstrual cramps and their associated symptoms, migraine, hemorrhoids, neuropathic pain, cyclic vomiting syndrome, and peridontitis. The patent also claims treatment of the symptoms of influenza, herpes zoster and herpes simplex.\\n[edit]References" []	EFO	68690	EFO:0002678	\N	tempol	EFO:0002678
0	"Urocortin is a protein that in humans is encoded by the UCN gene.[1][2][3] This gene is a member of the sauvagine/corticotropin-releasing factor/urotensin I family. It is structurally related to the corticotropin-releasing factor (CRF) gene and the encoded product is an endogenous ligand for CRF type 2 receptors. In the brain, it may be responsible for the effects of stress on appetite. In spite of the gene family name similarity, the product of this gene has no sequence similarity to urotensin II.[3] Urocortin is a potent anorexigenic peptide of 40 amino acids that induces fed-like motor activity when administered centrally or peripherally in fasted animals. Urocortin belongs to the corticotropin-releasing factor (CRF) family that includes CRF, urotensin I, sauvagine, urocortin II and urocortin III. Urocortin is also a potent and long-lasting hypotensive agent and increases coronary blood flow." []	\N	urocortin I	\N	\N	EFO	"Urocortin is a protein that in humans is encoded by the UCN gene.[1][2][3] This gene is a member of the sauvagine/corticotropin-releasing factor/urotensin I family. It is structurally related to the corticotropin-releasing factor (CRF) gene and the encoded product is an endogenous ligand for CRF type 2 receptors. In the brain, it may be responsible for the effects of stress on appetite. In spite of the gene family name similarity, the product of this gene has no sequence similarity to urotensin II.[3] Urocortin is a potent anorexigenic peptide of 40 amino acids that induces fed-like motor activity when administered centrally or peripherally in fasted animals. Urocortin belongs to the corticotropin-releasing factor (CRF) family that includes CRF, urotensin I, sauvagine, urocortin II and urocortin III. Urocortin is also a potent and long-lasting hypotensive agent and increases coronary blood flow." []	EFO	68691	EFO:0002679	\N	urocortin I	EFO:0002679
0	"Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family.[1] Immunohistochemistry analysis of human myocytes has shown greater immunoreactivity of Ucn2 in myocytes of the failing heart compared to those of the healthy heart. Researchers suggest this is a result of an innate mechanism in which Ucn2 acts to improve function of the failing heart [2]. The pathophysiology of heart failure is often a consequence of improper calcium handling and relaxation resulting in a lower cardiac output, decreased blood flow and overall decreased heart function [3]. Infusion of Ucn2 in healthy humans has shown a dose dependent increase in cardiac output, heart rate and left ventricle ejection fraction and a decrease in systemic vascular resistance [4]. Ucn2 has been studied as potential treatment for individuals with heart failure." []	\N	urocortin II	\N	\N	EFO	"Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family.[1] Immunohistochemistry analysis of human myocytes has shown greater immunoreactivity of Ucn2 in myocytes of the failing heart compared to those of the healthy heart. Researchers suggest this is a result of an innate mechanism in which Ucn2 acts to improve function of the failing heart [2]. The pathophysiology of heart failure is often a consequence of improper calcium handling and relaxation resulting in a lower cardiac output, decreased blood flow and overall decreased heart function [3]. Infusion of Ucn2 in healthy humans has shown a dose dependent increase in cardiac output, heart rate and left ventricle ejection fraction and a decrease in systemic vascular resistance [4]. Ucn2 has been studied as potential treatment for individuals with heart failure." []	EFO	68692	EFO:0002680	\N	urocortin II	EFO:0002680
0	"" []	\N	third instar larva stage	\N	\N	EFO	"" []	EFO	68693	EFO:0002682	\N	third instar larva stage	EFO:0002682
0	"" []	\N	floral transition	\N	\N	EFO	"" []	EFO	68694	EFO:0002683	\N	floral transition	EFO:0002683
0	"Atopy is an exaggerated IgE-mediated immune response; all atopic disorders are type I hypersensitivity disorders. Not all allergic diseases are atopic.\\nSource: Merck Manual" []	\N	atopy	\N	\N	EFO	"Atopy is an exaggerated IgE-mediated immune response; all atopic disorders are type I hypersensitivity disorders. Not all allergic diseases are atopic.\\nSource: Merck Manual" []	EFO	68695	EFO:0002686	\N	atopy	EFO:0002686
0	"" []	\N	ischemia reperfusion injury	\N	\N	EFO	"" []	EFO	68696	EFO:0002687	\N	ischemia reperfusion injury	EFO:0002687
0	"An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin)." []	\N	primary antiphospholipid syndrome	\N	\N	EFO	"An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin)." []	EFO	68697	EFO:0002689	\N	primary antiphospholipid syndrome	EFO:0002689
0	"A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow." []	\N	systemic lupus erythematosus	\N	\N	EFO	"A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow." []	EFO	68698	EFO:0002690	\N	systemic lupus erythematosus	EFO:0002690
0	"" []	\N	retinal ganglion	\N	\N	EFO	"" []	EFO	68699	EFO:0002691	\N	retinal ganglion	EFO:0002691
0	"ChIP-seq is an assay in which chromatin immunoprecipitation with high throughput sequencing is used to identify the cistrome of DNA-associated proteins." []	\N	ChIP-seq	\N	\N	EFO	"ChIP-seq is an assay in which chromatin immunoprecipitation with high throughput sequencing is used to identify the cistrome of DNA-associated proteins." []	EFO	68700	EFO:0002692	\N	ChIP-seq	EFO:0002692
0	"An assay in which -sequencing technology (e.g. Solexa/454) is used to determine NDNA sequence" []	\N	DNA-seq	\N	\N	EFO	"An assay in which -sequencing technology (e.g. Solexa/454) is used to determine NDNA sequence" []	EFO	68701	EFO:0002693	\N	DNA-seq	EFO:0002693
0	"A process performed as part of an experiment or wider study, i.e. intentionally designed." []	\N	experimental process	\N	\N	EFO	"A process performed as part of an experiment or wider study, i.e. intentionally designed." []	EFO	68702	EFO:0002694	\N	experimental process	EFO:0002694
0	"An assay which uses array based technology to determine information about nucleic acids or proteins" []	\N	array assay	\N	\N	EFO	"An assay which uses array based technology to determine information about nucleic acids or proteins" []	EFO	68703	EFO:0002696	\N	array assay	EFO:0002696
0	"An assay which uses high throughput sequencing technology to determine the sequence of nucleic acids" []	\N	high throughput sequencing assay	\N	\N	EFO	"An assay which uses high throughput sequencing technology to determine the sequence of nucleic acids" []	EFO	68704	EFO:0002697	\N	high throughput sequencing assay	EFO:0002697
0	"An instrument which consists of nucleic acid or protein molecules bound to a substrate" []	\N	array	\N	\N	EFO	"An instrument which consists of nucleic acid or protein molecules bound to a substrate" []	EFO	68705	EFO:0002698	\N	array	EFO:0002698
0	"Is an instrument is which supports massively parallel sequencing of nucleic acids" []	\N	high throughput sequencer	\N	\N	EFO	"Is an instrument is which supports massively parallel sequencing of nucleic acids" []	EFO	68706	EFO:0002699	\N	high throughput sequencer	EFO:0002699
0	"An array consisting of DNA probes bound to a substrate" []	\N	DNA array	\N	\N	EFO	"An array consisting of DNA probes bound to a substrate" []	EFO	68707	EFO:0002701	\N	DNA array	EFO:0002701
0	"A protein array is an array which provides a multiplex approach to identify protein-protein interactions, to identify the substrates of protein kinases, to identify transcription factor protein-activation, or to identify the targets of biologically active small molecules. The array is a substrate (e.g. glass) on which different molecules of protein or specific DNA binding sequences (as capture probes for the proteins) have been affixed at separate locations in an ordered manner thus forming a microscopic array. The most common protein microarray is the antibody microarray, where antibodies are spotted onto the protein chip and are used as capture molecules to detect proteins from cell lysate solutions." []	\N	protein array	\N	\N	EFO	"A protein array is an array which provides a multiplex approach to identify protein-protein interactions, to identify the substrates of protein kinases, to identify transcription factor protein-activation, or to identify the targets of biologically active small molecules. The array is a substrate (e.g. glass) on which different molecules of protein or specific DNA binding sequences (as capture probes for the proteins) have been affixed at separate locations in an ordered manner thus forming a microscopic array. The most common protein microarray is the antibody microarray, where antibodies are spotted onto the protein chip and are used as capture molecules to detect proteins from cell lysate solutions." []	EFO	68708	EFO:0002702	\N	protein array	EFO:0002702
0	"SNP array is a DNA array used to detect polymorphisms in DNA samples" []	\N	SNP array	\N	\N	EFO	"SNP array is a DNA array used to detect polymorphisms in DNA samples" []	EFO	68709	EFO:0002703	\N	SNP array	EFO:0002703
0	"A tiling array is an array which has short fragments of nucleic acid immobilized on a substrate. These are designed to cover the whole genome of the target species. Tiling arrays are used to determine genome binding in ChIP assays or to identify transcribed regions." []	\N	tiling array	\N	\N	EFO	"A tiling array is an array which has short fragments of nucleic acid immobilized on a substrate. These are designed to cover the whole genome of the target species. Tiling arrays are used to determine genome binding in ChIP assays or to identify transcribed regions." []	EFO	68710	EFO:0002704	\N	tiling array	EFO:0002704
0	"" []	\N	HPL1	\N	\N	EFO	"" []	EFO	68711	EFO:0002705	\N	HPL1	EFO:0002705
0	"" []	\N	SM1	\N	\N	EFO	"" []	EFO	68712	EFO:0002706	\N	SM1	EFO:0002706
0	"" []	\N	NT-1	\N	\N	EFO	"" []	EFO	68713	EFO:0002707	\N	NT-1	EFO:0002707
0	"A SCN2.2 is a cell line.\\nA SCN2.2 is both something that derives from a rattus norvegicus, and something that derives from a \\nsuprachiasmatic nucleus." []	\N	SCN2.2	\N	\N	EFO	"A SCN2.2 is a cell line.\\nA SCN2.2 is both something that derives from a rattus norvegicus, and something that derives from a \\nsuprachiasmatic nucleus." []	EFO	68714	EFO:0002708	\N	SCN2.2	EFO:0002708
0	"Human pancreatic adenocarcinoma cell line, established from a 61 year old human female." []	\N	BxPC-3	\N	\N	EFO	"Human pancreatic adenocarcinoma cell line, established from a 61 year old human female." []	EFO	68715	EFO:0002709	\N	BxPC-3	EFO:0002709
0	"" []	\N	COLO357	\N	\N	EFO	"" []	EFO	68716	EFO:0002710	\N	COLO357	EFO:0002710
0	"" []	\N	F13	\N	\N	EFO	"" []	EFO	68717	EFO:0002711	\N	F13	EFO:0002711
0	"A normal pancreas cell line." []	\N	KIF5	\N	\N	EFO	"A normal pancreas cell line." []	EFO	68718	EFO:0002712	\N	KIF5	EFO:0002712
0	"" []	\N	Panc1	\N	\N	EFO	"" []	EFO	68719	EFO:0002713	\N	Panc1	EFO:0002713
0	"" []	\N	Panc89	\N	\N	EFO	"" []	EFO	68720	EFO:0002714	\N	Panc89	EFO:0002714
0	"" []	\N	PancTUI	\N	\N	EFO	"" []	EFO	68721	EFO:0002715	\N	PancTUI	EFO:0002715
0	"" []	\N	Pt45P1	\N	\N	EFO	"" []	EFO	68722	EFO:0002716	\N	Pt45P1	EFO:0002716
0	"" []	\N	SH-SY5Y	\N	\N	EFO	"" []	EFO	68723	EFO:0002717	\N	SH-SY5Y	EFO:0002717
0	"" []	\N	hatching long-pec	\N	\N	EFO	"" []	EFO	68724	EFO:0002718	\N	hatching long-pec	EFO:0002718
0	"C. elegans second stage larva. At 25 Centigrade, it ranges 25.5-32.5 hours after fertilization, 11.5-18.5 hours after hatch." []	\N	L2 larva	\N	\N	EFO	"C. elegans second stage larva. At 25 Centigrade, it ranges 25.5-32.5 hours after fertilization, 11.5-18.5 hours after hatch." []	EFO	68725	EFO:0002719	\N	L2 larva	EFO:0002719
0	"C. elegans third stage larva. At 25 Centigrade, it ranges 32.5-40 hours after fertilization, 18.5-26 hours after hatch." []	\N	L3 larva	\N	\N	EFO	"C. elegans third stage larva. At 25 Centigrade, it ranges 32.5-40 hours after fertilization, 18.5-26 hours after hatch." []	EFO	68726	EFO:0002720	\N	L3 larva	EFO:0002720
0	"" []	\N	postmenopausal	\N	\N	EFO	"" []	EFO	68727	EFO:0002721	\N	postmenopausal	EFO:0002721
0	"C57Bl/10 derived non-diabetic mouse strain expressing H2g7." []	\N	B10.NOD_H2g7	\N	\N	EFO	"C57Bl/10 derived non-diabetic mouse strain expressing H2g7." []	EFO	68728	EFO:0002739	\N	B10.NOD_H2g7	EFO:0002739
0	"Nonobese diabetic (NOD) mouse strain which is homozygous for the scid mutation." []	\N	NOD.scid	\N	\N	EFO	"Nonobese diabetic (NOD) mouse strain which is homozygous for the scid mutation." []	EFO	68729	EFO:0002740	\N	NOD.scid	EFO:0002740
0	"C57Bl/10 derived non-diabetic mouse strain expressing H2g7 and Idd3" []	\N	B10.NOD_H2g7_Idd3	\N	\N	EFO	"C57Bl/10 derived non-diabetic mouse strain expressing H2g7 and Idd3" []	EFO	68730	EFO:0002741	\N	B10.NOD_H2g7_Idd3	EFO:0002741
0	"C57BL/6 congenically expressing H2g7 mouse strain." []	\N	B6.H2_g7	\N	\N	EFO	"C57BL/6 congenically expressing H2g7 mouse strain." []	EFO	68731	EFO:0002742	\N	B6.H2_g7	EFO:0002742
0	"Severe Combined Immunodeficiency (SCID) mutant in C57BL6 genetic background mouse strain." []	\N	C57BL/6-scid	\N	\N	EFO	"Severe Combined Immunodeficiency (SCID) mutant in C57BL6 genetic background mouse strain." []	EFO	68732	EFO:0002743	\N	C57BL/6-scid	EFO:0002743
0	"C57Bl/10 derived nonobese diabetic (NOD) mouse strain." []	\N	NOD.B10	\N	\N	EFO	"C57Bl/10 derived nonobese diabetic (NOD) mouse strain." []	EFO	68733	EFO:0002744	\N	NOD.B10	EFO:0002744
0	"C57Bl/6 derived nonobese diabetic (NOD) mouse strain." []	\N	NOD.B6	\N	\N	EFO	"C57Bl/6 derived nonobese diabetic (NOD) mouse strain." []	EFO	68734	EFO:0002745	\N	NOD.B6	EFO:0002745
0	"IR(lox/lox) transfection mouse strain maintained on a mixed (C57BL/6 x 129/Sv) genetic background." []	\N	IR (lox/lox)	\N	\N	EFO	"IR(lox/lox) transfection mouse strain maintained on a mixed (C57BL/6 x 129/Sv) genetic background." []	EFO	68735	EFO:0002746	\N	IR (lox/lox)	EFO:0002746
0	"Mouse strain with deficiency of the leptin gene (ObOb)." []	\N	ObOb	\N	\N	EFO	"Mouse strain with deficiency of the leptin gene (ObOb)." []	EFO	68736	EFO:0002747	\N	ObOb	EFO:0002747
0	"Athero-protected regions of aorta." []	\N	undisturbed flow regions	\N	\N	EFO	"Athero-protected regions of aorta." []	EFO	68737	EFO:0002749	\N	undisturbed flow regions	EFO:0002749
0	"Athero-susceptible regions of aorta." []	\N	disturbed flow regions	\N	\N	EFO	"Athero-susceptible regions of aorta." []	EFO	68738	EFO:0002750	\N	disturbed flow regions	EFO:0002750
0	"For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health." []	\N	benign	\N	\N	EFO	"For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health." []	EFO	68739	EFO:0002751	\N	benign	EFO:0002751
0	"" []	\N	aggressive	\N	\N	EFO	"" []	EFO	68740	EFO:0002752	\N	aggressive	EFO:0002752
0	"The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health." []	\N	diet	\N	\N	EFO	"The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health." []	EFO	68741	EFO:0002755	\N	diet	EFO:0002755
0	"Abstaining from food." []	\N	fasting	\N	\N	EFO	"Abstaining from food." []	EFO	68742	EFO:0002756	\N	fasting	EFO:0002756
0	"" []	\N	high fat diet	\N	\N	EFO	"" []	EFO	68743	EFO:0002757	\N	high fat diet	EFO:0002757
0	"" []	\N	low fat diet	\N	\N	EFO	"" []	EFO	68744	EFO:0002758	\N	low fat diet	EFO:0002758
0	"An assay in which the methylation state of DNA is determined and is compared between samples using array technology" []	\N	methylation profiling by array	\N	\N	EFO	"An assay in which the methylation state of DNA is determined and is compared between samples using array technology" []	EFO	68745	EFO:0002759	\N	methylation profiling by array	EFO:0002759
0	"An assay  where chromatin immunoprecipitation (ChIP) is used in combination with microarray technology" []	\N	ChIP-chip by array	\N	\N	EFO	"An assay  where chromatin immunoprecipitation (ChIP) is used in combination with microarray technology" []	EFO	68746	EFO:0002760	\N	ChIP-chip by array	EFO:0002760
0	"An assay in which the methylation state of DNA is determined and is compared between samples using sequencing based technology" []	\N	methylation profiling by high throughput sequencing	\N	\N	EFO	"An assay in which the methylation state of DNA is determined and is compared between samples using sequencing based technology" []	EFO	68747	EFO:0002761	\N	methylation profiling by high throughput sequencing	EFO:0002761
0	"An assay where chromatin immunoprecipitation (ChIP) is used in combination with tiling  microarray technology" []	\N	ChIP-chip by tiling array	\N	\N	EFO	"An assay where chromatin immunoprecipitation (ChIP) is used in combination with tiling  microarray technology" []	EFO	68748	EFO:0002762	\N	ChIP-chip by tiling array	EFO:0002762
0	"An assay where chromatin immunoprecipitation (ChIP) is used in combination with SNP microarray technology" []	\N	ChIP-chip by SNP array	\N	\N	EFO	"An assay where chromatin immunoprecipitation (ChIP) is used in combination with SNP microarray technology" []	EFO	68749	EFO:0002764	\N	ChIP-chip by SNP array	EFO:0002764
0	"An experiment where proteins in a sample are detected, quantified or otherwise analysed, e.g. antibody profiling using an array based technology" []	\N	proteomic profiling by array	\N	\N	EFO	"An experiment where proteins in a sample are detected, quantified or otherwise analysed, e.g. antibody profiling using an array based technology" []	EFO	68750	EFO:0002765	\N	proteomic profiling by array	EFO:0002765
0	"An assay where proteins in a sample are detected, quantified or otherwise analysed using mass spectrometry" []	\N	proteomic profiling by mass spectrometer	\N	\N	EFO	"An assay where proteins in a sample are detected, quantified or otherwise analysed using mass spectrometry" []	EFO	68751	EFO:0002766	\N	proteomic profiling by mass spectrometer	EFO:0002766
0	"An assay in which an array is used detect polymorphisms in DNA samples" []	\N	genotyping by array	\N	\N	EFO	"An assay in which an array is used detect polymorphisms in DNA samples" []	EFO	68752	EFO:0002767	\N	genotyping by array	EFO:0002767
0	"An assay in which  the transcriptome of a biological sample is analysed using array technology." []	\N	transcription profiling by array	\N	\N	EFO	"An assay in which  the transcriptome of a biological sample is analysed using array technology." []	EFO	68753	EFO:0002768	\N	transcription profiling by array	EFO:0002768
0	"An assay in which the transcriptome of a biological sample is analysed using a tiling path array." []	\N	transcription profiling by tiling array	\N	\N	EFO	"An assay in which the transcriptome of a biological sample is analysed using a tiling path array." []	EFO	68754	EFO:0002769	\N	transcription profiling by tiling array	EFO:0002769
0	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, analyse the transcibed regions of the genome, and or to quantitate transcript abundance" []	\N	transcription profiling by high throughput sequencing	\N	\N	EFO	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, analyse the transcibed regions of the genome, and or to quantitate transcript abundance" []	EFO	68755	EFO:0002770	\N	transcription profiling by high throughput sequencing	EFO:0002770
0	"An assay in which high throughput sequencing is used to determine the genotype of a DNA sample" []	\N	genotyping by high throughput sequencing	\N	\N	EFO	"An assay in which high throughput sequencing is used to determine the genotype of a DNA sample" []	EFO	68756	EFO:0002771	\N	genotyping by high throughput sequencing	EFO:0002771
0	"" []	\N	assay by molecule	\N	\N	EFO	"" []	EFO	68757	EFO:0002772	\N	assay by molecule	EFO:0002772
0	"" []	\N	assay by instrument	\N	\N	EFO	"" []	EFO	68758	EFO:0002773	\N	assay by instrument	EFO:0002773
0	"" []	\N	mass spectrometry assay	\N	\N	EFO	"" []	EFO	68759	EFO:0002774	\N	mass spectrometry assay	EFO:0002774
0	"" []	\N	aorta smooth muscle	\N	\N	EFO	"" []	EFO	68760	EFO:0002775	\N	aorta smooth muscle	EFO:0002775
0	"H0287 is a cell line derived from normal lymphoblastoid cells" []	\N	H0287	\N	\N	EFO	"H0287 is a cell line derived from normal lymphoblastoid cells" []	EFO	68761	EFO:0002776	\N	H0287	EFO:0002776
0	"NHA is a cell line derived from normal (healthy) human astrocyte cells." []	\N	Normal Human Astrocytes	\N	\N	EFO	"NHA is a cell line derived from normal (healthy) human astrocyte cells." []	EFO	68762	EFO:0002777	\N	Normal Human Astrocytes	EFO:0002777
0	"BG02ES is a cell line dervied from human embryonic stem cells." []	\N	BG02ES	\N	\N	EFO	"BG02ES is a cell line dervied from human embryonic stem cells." []	EFO	68763	EFO:0002778	\N	BG02ES	EFO:0002778
0	"" []	\N	BJ	\N	\N	EFO	"" []	EFO	68764	EFO:0002779	\N	BJ	EFO:0002779
0	"A chorion cell line is a cell line that is derived from the chorion." []	\N	chorion cell line	\N	\N	EFO	"A chorion cell line is a cell line that is derived from the chorion." []	EFO	68765	EFO:0002781	\N	chorion cell line	EFO:0002781
0	"Glioblastoma H54 is a cell line derived from" []	\N	glioblastoma H54	\N	\N	EFO	"Glioblastoma H54 is a cell line derived from" []	EFO	68766	EFO:0002782	\N	glioblastoma H54	EFO:0002782
0	"GM06990 is a cell line derived from some lymphoblastoid cells from a CEPH familiy of UTAH/MORMON ethnicity. It is supplied by Corriell under catalogue number GM06990." []	\N	GM06990	\N	\N	EFO	"GM06990 is a cell line derived from some lymphoblastoid cells from a CEPH familiy of UTAH/MORMON ethnicity. It is supplied by Corriell under catalogue number GM06990." []	EFO	68767	EFO:0002783	\N	GM06990	EFO:0002783
0	"" []	\N	GM12878	\N	\N	EFO	"" []	EFO	68768	EFO:0002784	\N	GM12878	EFO:0002784
0	"" []	\N	GM12891	\N	\N	EFO	"" []	EFO	68769	EFO:0002785	\N	GM12891	EFO:0002785
0	"A GM12892 is a cell line.\\nA GM12892 is all of the following: something that has as quality a female, something that derives from Homo sapiens, and something that derives from a b cell." []	\N	GM12892	\N	\N	EFO	"A GM12892 is a cell line.\\nA GM12892 is all of the following: something that has as quality a female, something that derives from Homo sapiens, and something that derives from a b cell." []	EFO	68770	EFO:0002786	\N	GM12892	EFO:0002786
0	"A GM18507 is a cell line.\\nA GM18507 is all of the following: something that has as quality a male, something that derives from a Homo sapiens, and something that derives from a lymphoblast." []	\N	GM18507	\N	\N	EFO	"A GM18507 is a cell line.\\nA GM18507 is all of the following: something that has as quality a male, something that derives from a Homo sapiens, and something that derives from a lymphoblast." []	EFO	68771	EFO:0002787	\N	GM18507	EFO:0002787
0	"A GM19238 is a cell line.\\nA GM19238 is all of the following: something that has as quality a female, something that derives from a Homo sapiens, and something that derives from a b cell." []	\N	GM19238	\N	\N	EFO	"A GM19238 is a cell line.\\nA GM19238 is all of the following: something that has as quality a female, something that derives from a Homo sapiens, and something that derives from a b cell." []	EFO	68772	EFO:0002788	\N	GM19238	EFO:0002788
0	"A GM19239 is a cell line.\\nA GM19239 is all of the following: something that has as quality a male, something that derives from a Homo sapiens, and something that derives from a b cell." []	\N	GM19239	\N	\N	EFO	"A GM19239 is a cell line.\\nA GM19239 is all of the following: something that has as quality a male, something that derives from a Homo sapiens, and something that derives from a b cell." []	EFO	68773	EFO:0002789	\N	GM19239	EFO:0002789
0	"A GM19240 is a cell line.\\nA GM19240 is all of the following: something that has as quality a female, something that derives from a Homo sapiens, and something that derives from a b cell." []	\N	GM19240	\N	\N	EFO	"A GM19240 is a cell line.\\nA GM19240 is all of the following: something that has as quality a female, something that derives from a Homo sapiens, and something that derives from a b cell." []	EFO	68774	EFO:0002790	\N	GM19240	EFO:0002790
0	"" []	\N	HeLa-S3	\N	\N	EFO	"" []	EFO	68775	EFO:0002791	\N	HeLa-S3	EFO:0002791
0	"A HGF is a cell line.\\nA HGF is all of the following: something that has as quality a normal, something that derives from a Homo \\nsapiens, and something that derives from a fibroblast." []	\N	HGF	\N	\N	EFO	"A HGF is a cell line.\\nA HGF is all of the following: something that has as quality a normal, something that derives from a Homo \\nsapiens, and something that derives from a fibroblast." []	EFO	68776	EFO:0002792	\N	HGF	EFO:0002792
0	"Human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976." []	\N	HL-60	\N	\N	EFO	"Human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976." []	EFO	68777	EFO:0002793	\N	HL-60	EFO:0002793
0	"" []	\N	HRE	\N	\N	EFO	"" []	EFO	68778	EFO:0002794	\N	HRE	EFO:0002794
0	"" []	\N	HUVEC cell line	\N	\N	EFO	"" []	EFO	68779	EFO:0002795	\N	HUVEC cell line	EFO:0002795
0	"Human T cell leukemia, established from the peripheral blood of a 14-year-old boy with acute lymphoblastic leukemia (ALL) at first relapse in 1976; often this cell line is called JM (JURKAT and JM are derived from the same patient and are sister clones), occasionally JM may be a subclone with somewhat divergent features." []	\N	Jurkat	\N	\N	EFO	"Human T cell leukemia, established from the peripheral blood of a 14-year-old boy with acute lymphoblastic leukemia (ALL) at first relapse in 1976; often this cell line is called JM (JURKAT and JM are derived from the same patient and are sister clones), occasionally JM may be a subclone with somewhat divergent features." []	EFO	68780	EFO:0002796	\N	Jurkat	EFO:0002796
0	"LHSR is a cell line in which human prostate epithelial cells (PrEC) were infected with amphotropic retroviruses encoding the SV40 large T antigen (L), the telomerase catalytic subunit hTERT (H), the SV40 small T antigen (S) and an oncogenic allele of H-ras (R) to create LHSR cells." []	\N	LHSR	\N	\N	EFO	"LHSR is a cell line in which human prostate epithelial cells (PrEC) were infected with amphotropic retroviruses encoding the SV40 large T antigen (L), the telomerase catalytic subunit hTERT (H), the SV40 small T antigen (S) and an oncogenic allele of H-ras (R) to create LHSR cells." []	EFO	68781	EFO:0002797	\N	LHSR	EFO:0002797
0	"" []	\N	NB4	\N	\N	EFO	"" []	EFO	68782	EFO:0002798	\N	NB4	EFO:0002798
0	"" []	\N	NHEK	\N	\N	EFO	"" []	EFO	68783	EFO:0002799	\N	NHEK	EFO:0002799
0	"SAEC is a cell line derived from Small Airway Epithelial Cells" []	\N	SAEC	\N	\N	EFO	"SAEC is a cell line derived from Small Airway Epithelial Cells" []	EFO	68784	EFO:0002800	\N	SAEC	EFO:0002800
0	"" []	\N	SKMC	\N	\N	EFO	"" []	EFO	68785	EFO:0002801	\N	SKMC	EFO:0002801
0	"neuroblastoma cell line differentiated w/ retinoic acid" []	\N	SK-N-SH_RA	\N	\N	EFO	"neuroblastoma cell line differentiated w/ retinoic acid" []	EFO	68786	EFO:0002802	\N	SK-N-SH_RA	EFO:0002802
0	"" []	\N	TH-1	\N	\N	EFO	"" []	EFO	68787	EFO:0002803	\N	TH-1	EFO:0002803
0	"" []	\N	TH-2	\N	\N	EFO	"" []	EFO	68788	EFO:0002804	\N	TH-2	EFO:0002804
0	"The retroperitoneum (or extraperitoneum) is the anatomical space in the abdominal cavity behind (retro) the peritoneum. [wikipedia: http://en.wikipedia.org/wiki/Retroperitoneum]" []	\N	retroperitoneum	\N	\N	EFO	"The retroperitoneum (or extraperitoneum) is the anatomical space in the abdominal cavity behind (retro) the peritoneum. [wikipedia: http://en.wikipedia.org/wiki/Retroperitoneum]" []	EFO	68789	EFO:0002806	\N	retroperitoneum	EFO:0002806
0	"" []	\N	4470	\N	\N	EFO	"" []	EFO	68790	EFO:0002807	\N	4470	EFO:0002807
0	"" []	\N	4475	\N	\N	EFO	"" []	EFO	68791	EFO:0002808	\N	4475	EFO:0002808
0	"" []	\N	4483	\N	\N	EFO	"" []	EFO	68792	EFO:0002809	\N	4483	EFO:0002809
0	"A 1205 lu is a cell line.\\nA 1205 lu is both something that is bearer of a melanoma, and something that derives from a homo sapiens." []	\N	1205-Lu	\N	\N	EFO	"A 1205 lu is a cell line.\\nA 1205 lu is both something that is bearer of a melanoma, and something that derives from a homo sapiens." []	EFO	68793	EFO:0002810	\N	1205-Lu	EFO:0002810
0	"Preadipocyte cell line." []	\N	3T3-F442A	\N	\N	EFO	"Preadipocyte cell line." []	EFO	68794	EFO:0002811	\N	3T3-F442A	EFO:0002811
0	"An ab2.2 is a cell line.\\nAn ab2.2 is both something that derives from a mus musculus, and something that derives from an embryonic stem cell." []	\N	AB2.2	\N	\N	EFO	"An ab2.2 is a cell line.\\nAn ab2.2 is both something that derives from a mus musculus, and something that derives from an embryonic stem cell." []	EFO	68795	EFO:0002812	\N	AB2.2	EFO:0002812
0	"" []	\N	ABC-1	\N	\N	EFO	"" []	EFO	68796	EFO:0002813	\N	ABC-1	EFO:0002813
0	"" []	\N	AZ-521	\N	\N	EFO	"" []	EFO	68797	EFO:0002814	\N	AZ-521	EFO:0002814
0	"The malignant human B-cell-line BJAB is a EBV-negative Burkitt-like lymphoma cell line." []	\N	BJAB	\N	\N	EFO	"The malignant human B-cell-line BJAB is a EBV-negative Burkitt-like lymphoma cell line." []	EFO	68798	EFO:0002815	\N	BJAB	EFO:0002815
0	"" []	\N	C3H10T1/2	\N	\N	EFO	"" []	EFO	68799	EFO:0002816	\N	C3H10T1/2	EFO:0002816
0	"" []	\N	Caco-2/TC7	\N	\N	EFO	"" []	EFO	68800	EFO:0002817	\N	Caco-2/TC7	EFO:0002817
0	"A CADO ES1 is a cell line.\\nA CADO ES1 is both something that is bearer of a 39 s sarcoma, and something that derives from Homo sapiens." []	\N	CADO ES1	\N	\N	EFO	"A CADO ES1 is a cell line.\\nA CADO ES1 is both something that is bearer of a 39 s sarcoma, and something that derives from Homo sapiens." []	EFO	68801	EFO:0002818	\N	CADO ES1	EFO:0002818
0	"" []	\N	Calu3	\N	\N	EFO	"" []	EFO	68802	EFO:0002819	\N	Calu3	EFO:0002819
0	"A CM7-1 is a cell line.\\nA CM7-1 is both something that derives from a mus musculus, and something that derives from an embryonic stem cell." []	\N	CM7-1	\N	\N	EFO	"A CM7-1 is a cell line.\\nA CM7-1 is both something that derives from a mus musculus, and something that derives from an embryonic stem cell." []	EFO	68803	EFO:0002820	\N	CM7-1	EFO:0002820
0	"Mouse, C57BL/6, T-lymphocyte cell line." []	\N	CTLL-2	\N	\N	EFO	"Mouse, C57BL/6, T-lymphocyte cell line." []	EFO	68804	EFO:0002821	\N	CTLL-2	EFO:0002821
0	"" []	\N	D10.G4.1	\N	\N	EFO	"" []	EFO	68805	EFO:0002822	\N	D10.G4.1	EFO:0002822
0	"Human colon carcinoma cell line; established from the primary colon carcinoma of an adult man." []	\N	HCT116	\N	\N	EFO	"Human colon carcinoma cell line; established from the primary colon carcinoma of an adult man." []	EFO	68806	EFO:0002824	\N	HCT116	EFO:0002824
0	"The tumorigenic KS IMM cell line derives from Kaposi's sarcoma (KS), a highly angiogenic tumor." []	\N	KS-IMM	\N	\N	EFO	"The tumorigenic KS IMM cell line derives from Kaposi's sarcoma (KS), a highly angiogenic tumor." []	EFO	68807	EFO:0002826	\N	KS-IMM	EFO:0002826
0	"A LC-1F is a cell line.\\nA LC-1F is both something that is bearer of a squamous cell lung carcinoma, and something that derives from \\na Homo sapiens." []	\N	LC-1F	\N	\N	EFO	"A LC-1F is a cell line.\\nA LC-1F is both something that is bearer of a squamous cell lung carcinoma, and something that derives from \\na Homo sapiens." []	EFO	68808	EFO:0002827	\N	LC-1F	EFO:0002827
0	"" []	\N	Lu135	\N	\N	EFO	"" []	EFO	68809	EFO:0002828	\N	Lu135	EFO:0002828
0	"The murine MIN6 cell line derived from in vivo immortalized insulin-secreting pancreatic beta cells." []	\N	MIN6	\N	\N	EFO	"The murine MIN6 cell line derived from in vivo immortalized insulin-secreting pancreatic beta cells." []	EFO	68810	EFO:0002829	\N	MIN6	EFO:0002829
0	"Human gastric adenosquamous carcinoma cell line." []	\N	MKN1	\N	\N	EFO	"Human gastric adenosquamous carcinoma cell line." []	EFO	68811	EFO:0002830	\N	MKN1	EFO:0002830
0	"Well differentiated human gastric adenocarcinoma cell line." []	\N	MKN28	\N	\N	EFO	"Well differentiated human gastric adenocarcinoma cell line." []	EFO	68812	EFO:0002831	\N	MKN28	EFO:0002831
0	"Human gastric adenocarcinoma, established from the poorly differentiated adenocarcinoma of the stomach (medullary type) of a 62-year-old woman." []	\N	MKN45	\N	\N	EFO	"Human gastric adenocarcinoma, established from the poorly differentiated adenocarcinoma of the stomach (medullary type) of a 62-year-old woman." []	EFO	68813	EFO:0002832	\N	MKN45	EFO:0002832
0	"Well differentiated human gastric adenocarcinoma cell line." []	\N	MKN74	\N	\N	EFO	"Well differentiated human gastric adenocarcinoma cell line." []	EFO	68814	EFO:0002834	\N	MKN74	EFO:0002834
0	"Homo sapiens (human) lung; fibroblast; normal cell line. The MRC-5 cell line was derived from normal lung tissue of a 14-week-old male fetus by J.P. Jacobs in September of 1966." []	\N	MRC5	\N	\N	EFO	"Homo sapiens (human) lung; fibroblast; normal cell line. The MRC-5 cell line was derived from normal lung tissue of a 14-week-old male fetus by J.P. Jacobs in September of 1966." []	EFO	68815	EFO:0002835	\N	MRC5	EFO:0002835
0	"" []	\N	MS-1	\N	\N	EFO	"" []	EFO	68816	EFO:0002836	\N	MS-1	EFO:0002836
0	"" []	\N	MS428	\N	\N	EFO	"" []	EFO	68817	EFO:0002837	\N	MS428	EFO:0002837
0	"" []	\N	MS589	\N	\N	EFO	"" []	EFO	68818	EFO:0002838	\N	MS589	EFO:0002838
0	"Human mesothelioma cell line; established from the pleural effusion of a 62-year-old Caucasian man with mesothelioma (malignant biphasic) who did not have any prior therapy." []	\N	MSTO-211H	\N	\N	EFO	"Human mesothelioma cell line; established from the pleural effusion of a 62-year-old Caucasian man with mesothelioma (malignant biphasic) who did not have any prior therapy." []	EFO	68819	EFO:0002839	\N	MSTO-211H	EFO:0002839
0	"" []	\N	N231	\N	\N	EFO	"" []	EFO	68820	EFO:0002840	\N	N231	EFO:0002840
0	"" []	\N	NCI-N87	\N	\N	EFO	"" []	EFO	68821	EFO:0002841	\N	NCI-N87	EFO:0002841
0	"" []	\N	PC-1	\N	\N	EFO	"" []	EFO	68822	EFO:0002842	\N	PC-1	EFO:0002842
0	"" []	\N	PC-10	\N	\N	EFO	"" []	EFO	68823	EFO:0002843	\N	PC-10	EFO:0002843
0	"" []	\N	PC-14	\N	\N	EFO	"" []	EFO	68824	EFO:0002844	\N	PC-14	EFO:0002844
0	"" []	\N	PC-6	\N	\N	EFO	"" []	EFO	68825	EFO:0002845	\N	PC-6	EFO:0002845
0	"" []	\N	PC-7	\N	\N	EFO	"" []	EFO	68826	EFO:0002846	\N	PC-7	EFO:0002846
0	"" []	\N	PC-9	\N	\N	EFO	"" []	EFO	68827	EFO:0002847	\N	PC-9	EFO:0002847
0	"" []	\N	QG56	\N	\N	EFO	"" []	EFO	68828	EFO:0002848	\N	QG56	EFO:0002848
0	"" []	\N	R11	\N	\N	EFO	"" []	EFO	68829	EFO:0002849	\N	R11	EFO:0002849
0	"" []	\N	RERF-LC-AI	\N	\N	EFO	"" []	EFO	68830	EFO:0002850	\N	RERF-LC-AI	EFO:0002850
0	"" []	\N	RERF-LC-KJ	\N	\N	EFO	"" []	EFO	68831	EFO:0002851	\N	RERF-LC-KJ	EFO:0002851
0	"" []	\N	RERF-LC-MS	\N	\N	EFO	"" []	EFO	68832	EFO:0002852	\N	RERF-LC-MS	EFO:0002852
0	"A RM 82 is a cell line.\\nA RM 82 is both something that is bearer of a 39 s sarcoma, and something that derives from a Homo \\nsapiens." []	\N	RM 82	\N	\N	EFO	"A RM 82 is a cell line.\\nA RM 82 is both something that is bearer of a 39 s sarcoma, and something that derives from a Homo \\nsapiens." []	EFO	68833	EFO:0002853	\N	RM 82	EFO:0002853
0	"A SBC-3 is a cell line.\\nA SBC-3 is both something that is bearer of a small cell lung carcinoma, and something that derives from a \\nHomo sapiens." []	\N	SBC-3	\N	\N	EFO	"A SBC-3 is a cell line.\\nA SBC-3 is both something that is bearer of a small cell lung carcinoma, and something that derives from a \\nHomo sapiens." []	EFO	68834	EFO:0002854	\N	SBC-3	EFO:0002854
0	"" []	\N	SBC-5	\N	\N	EFO	"" []	EFO	68835	EFO:0002855	\N	SBC-5	EFO:0002855
0	"" []	\N	SCH	\N	\N	EFO	"" []	EFO	68836	EFO:0002856	\N	SCH	EFO:0002856
0	"" []	\N	SHEP-SF	\N	\N	EFO	"" []	EFO	68837	EFO:0002857	\N	SHEP-SF	EFO:0002857
0	"" []	\N	SK-ES-1	\N	\N	EFO	"" []	EFO	68838	EFO:0002858	\N	SK-ES-1	EFO:0002858
0	"" []	\N	SK-N-AS	\N	\N	EFO	"" []	EFO	68839	EFO:0002859	\N	SK-N-AS	EFO:0002859
0	"" []	\N	SK-N-MC	\N	\N	EFO	"" []	EFO	68840	EFO:0002860	\N	SK-N-MC	EFO:0002860
0	"" []	\N	SQ-5	\N	\N	EFO	"" []	EFO	68841	EFO:0002861	\N	SQ-5	EFO:0002861
0	"" []	\N	STA-ET-1	\N	\N	EFO	"" []	EFO	68842	EFO:0002862	\N	STA-ET-1	EFO:0002862
0	"" []	\N	STA-ET-2.1	\N	\N	EFO	"" []	EFO	68843	EFO:0002863	\N	STA-ET-2.1	EFO:0002863
0	"" []	\N	T24	\N	\N	EFO	"" []	EFO	68844	EFO:0002864	\N	T24	EFO:0002864
0	"" []	\N	TC71	\N	\N	EFO	"" []	EFO	68845	EFO:0002865	\N	TC71	EFO:0002865
0	"" []	\N	TE85	\N	\N	EFO	"" []	EFO	68846	EFO:0002866	\N	TE85	EFO:0002866
0	"" []	\N	TMK1	\N	\N	EFO	"" []	EFO	68847	EFO:0002867	\N	TMK1	EFO:0002867
0	"" []	\N	TT3E	\N	\N	EFO	"" []	EFO	68848	EFO:0002868	\N	TT3E	EFO:0002868
0	"" []	\N	U2OS	\N	\N	EFO	"" []	EFO	68849	EFO:0002869	\N	U2OS	EFO:0002869
0	"" []	\N	VH-64	\N	\N	EFO	"" []	EFO	68850	EFO:0002870	\N	VH-64	EFO:0002870
0	"" []	\N	WB-F344	\N	\N	EFO	"" []	EFO	68851	EFO:0002871	\N	WB-F344	EFO:0002871
0	"" []	\N	WE-68	\N	\N	EFO	"" []	EFO	68852	EFO:0002872	\N	WE-68	EFO:0002872
0	"" []	\N	WM793	\N	\N	EFO	"" []	EFO	68853	EFO:0002873	\N	WM793	EFO:0002873
0	"" []	\N	WM793-P1N1	\N	\N	EFO	"" []	EFO	68854	EFO:0002874	\N	WM793-P1N1	EFO:0002874
0	"" []	\N	WM793-P2N1	\N	\N	EFO	"" []	EFO	68855	EFO:0002875	\N	WM793-P2N1	EFO:0002875
0	"" []	\N	YCC1	\N	\N	EFO	"" []	EFO	68856	EFO:0002876	\N	YCC1	EFO:0002876
0	"" []	\N	YCC10	\N	\N	EFO	"" []	EFO	68857	EFO:0002877	\N	YCC10	EFO:0002877
0	"" []	\N	YCC11	\N	\N	EFO	"" []	EFO	68858	EFO:0002878	\N	YCC11	EFO:0002878
0	"" []	\N	YCC16	\N	\N	EFO	"" []	EFO	68859	EFO:0002879	\N	YCC16	EFO:0002879
0	"" []	\N	YCC3	\N	\N	EFO	"" []	EFO	68860	EFO:0002880	\N	YCC3	EFO:0002880
0	"" []	\N	YCC6	\N	\N	EFO	"" []	EFO	68861	EFO:0002881	\N	YCC6	EFO:0002881
0	"" []	\N	YCC7	\N	\N	EFO	"" []	EFO	68862	EFO:0002882	\N	YCC7	EFO:0002882
0	"Cell lines that are part of the haemopoietic system." []	\N	haemopoietic system cell line	\N	\N	EFO	"Cell lines that are part of the haemopoietic system." []	EFO	68863	EFO:0002883	\N	haemopoietic system cell line	EFO:0002883
0	"" []	\N	mammary gland cell line	\N	\N	EFO	"" []	EFO	68864	EFO:0002884	\N	mammary gland cell line	EFO:0002884
0	"" []	\N	breast cancer cell line	\N	\N	EFO	"" []	EFO	68865	EFO:0002885	\N	breast cancer cell line	EFO:0002885
0	"Cell lines derived from stem cells." []	\N	stem cell derived cell line	\N	\N	EFO	"Cell lines derived from stem cells." []	EFO	68866	EFO:0002886	\N	stem cell derived cell line	EFO:0002886
0	"Cell lines derived from mice." []	\N	mouse cell line	\N	\N	EFO	"Cell lines derived from mice." []	EFO	68867	EFO:0002887	\N	mouse cell line	EFO:0002887
0	"" []	\N	Homo sapiens cell line	\N	\N	EFO	"" []	EFO	68868	EFO:0002888	\N	Homo sapiens cell line	EFO:0002888
0	"A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma." []	\N	renal carcinoma	\N	\N	EFO	"A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma." []	EFO	68869	EFO:0002890	\N	renal carcinoma	EFO:0002890
0	"Any cell line that is derived from the prostate." []	\N	prostate derived cell line	\N	\N	EFO	"Any cell line that is derived from the prostate." []	EFO	68870	EFO:0002891	\N	prostate derived cell line	EFO:0002891
0	"" []	\N	thyroid carcinoma	\N	\N	EFO	"" []	EFO	68871	EFO:0002892	\N	thyroid carcinoma	EFO:0002892
0	"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected." []	\N	choriocarcinoma	\N	\N	EFO	"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected." []	EFO	68872	EFO:0002893	\N	choriocarcinoma	EFO:0002893
0	"" []	\N	amelanotic skin melanoma	\N	\N	EFO	"" []	EFO	68873	EFO:0002894	\N	amelanotic skin melanoma	EFO:0002894
0	"Well differentiated human gastric adenocarcinoma cell line." []	\N	MKN7	\N	\N	EFO	"Well differentiated human gastric adenocarcinoma cell line." []	EFO	68874	EFO:0002895	\N	MKN7	EFO:0002895
0	"An assay in which high throughput sequencing technology is used to analyse the microRNA component of the transcriptome." []	\N	microRNA profiling by high throughput sequencing	\N	\N	EFO	"An assay in which high throughput sequencing technology is used to analyse the microRNA component of the transcriptome." []	EFO	68875	EFO:0002896	\N	microRNA profiling by high throughput sequencing	EFO:0002896
0	"" []	\N	gram per kilogram	\N	\N	EFO	"" []	EFO	68876	EFO:0002897	\N	gram per kilogram	EFO:0002897
0	"" []	\N	gram per meter squared	\N	\N	EFO	"" []	EFO	68877	EFO:0002898	\N	gram per meter squared	EFO:0002898
0	"" []	\N	microgram per kilogram	\N	\N	EFO	"" []	EFO	68878	EFO:0002899	\N	microgram per kilogram	EFO:0002899
0	"" []	\N	micromole per kilogram	\N	\N	EFO	"" []	EFO	68879	EFO:0002900	\N	micromole per kilogram	EFO:0002900
0	"" []	\N	micromole per liter	\N	\N	EFO	"" []	EFO	68880	EFO:0002901	\N	micromole per liter	EFO:0002901
0	"" []	\N	milligram per kilogram	\N	\N	EFO	"" []	EFO	68881	EFO:0002902	\N	milligram per kilogram	EFO:0002902
0	"" []	\N	weight percent	\N	\N	EFO	"" []	EFO	68882	EFO:0002904	\N	weight percent	EFO:0002904
0	"" []	\N	whole organism	\N	\N	EFO	"" []	EFO	68883	EFO:0002906	\N	whole organism	EFO:0002906
0	"A population growth assay is an assay that measures the multiplication or reproduction of cells, resulting in the rapid expansion of a cell population." []	\N	population growth assay	\N	\N	EFO	"A population growth assay is an assay that measures the multiplication or reproduction of cells, resulting in the rapid expansion of a cell population." []	EFO	68884	EFO:0002907	\N	population growth assay	EFO:0002907
0	"A motility assay is an assay which measures the controlled movement of a population of cells." []	\N	motility assay	\N	\N	EFO	"A motility assay is an assay which measures the controlled movement of a population of cells." []	EFO	68885	EFO:0002908	\N	motility assay	EFO:0002908
0	"A microscopy assay is an assay that provides images of molecules at various resolution depending on the technology used." []	\N	microscopy assay	\N	\N	EFO	"A microscopy assay is an assay that provides images of molecules at various resolution depending on the technology used." []	EFO	68886	EFO:0002909	\N	microscopy assay	EFO:0002909
0	"" []	\N	characterization of functional areas of human genome	\N	\N	EFO	"" []	EFO	68887	EFO:0002912	\N	characterization of functional areas of human genome	EFO:0002912
0	"" []	\N	Cutaneous T-cell lymphoma	\N	\N	EFO	"" []	EFO	68888	EFO:0002913	\N	Cutaneous T-cell lymphoma	EFO:0002913
0	"" []	\N	uterine sarcoma	\N	\N	EFO	"" []	EFO	68889	EFO:0002914	\N	uterine sarcoma	EFO:0002914
0	"Tumors or cancer of the ESOPHAGUS." []	\N	esophageal carcinoma	\N	\N	EFO	"Tumors or cancer of the ESOPHAGUS." []	EFO	68890	EFO:0002916	\N	esophageal carcinoma	EFO:0002916
0	"" []	\N	ovarian serous adenocarcinoma	\N	\N	EFO	"" []	EFO	68891	EFO:0002917	\N	ovarian serous adenocarcinoma	EFO:0002917
0	"" []	\N	rhabdomyosarcoma	\N	\N	EFO	"" []	EFO	68892	EFO:0002918	\N	rhabdomyosarcoma	EFO:0002918
0	"" []	\N	uterine carcinoma	\N	\N	EFO	"" []	EFO	68893	EFO:0002919	\N	uterine carcinoma	EFO:0002919
0	"" []	\N	vulva sarcoma	\N	\N	EFO	"" []	EFO	68894	EFO:0002920	\N	vulva sarcoma	EFO:0002920
0	"" []	\N	vulvar carcinoma	\N	\N	EFO	"" []	EFO	68895	EFO:0002921	\N	vulvar carcinoma	EFO:0002921
0	"" []	\N	normal cell line	\N	\N	EFO	"" []	EFO	68896	EFO:0002922	\N	normal cell line	EFO:0002922
0	"" []	\N	HapMap haplotype mapping	\N	\N	EFO	"" []	EFO	68897	EFO:0002924	\N	HapMap haplotype mapping	EFO:0002924
0	"" []	\N	ENCODE functional genome mapping	\N	\N	EFO	"" []	EFO	68898	EFO:0002925	\N	ENCODE functional genome mapping	EFO:0002925
0	"" []	\N	ENCODE cell line	\N	\N	EFO	"" []	EFO	68899	EFO:0002926	\N	ENCODE cell line	EFO:0002926
0	"" []	\N	International Unit	\N	\N	EFO	"" []	EFO	68900	EFO:0002927	\N	International Unit	EFO:0002927
0	"A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume." []	\N	International Unit per milliliter	\N	\N	EFO	"A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume." []	EFO	68901	EFO:0002928	\N	International Unit per milliliter	EFO:0002928
0	"" []	\N	microgram per kilogram per day	\N	\N	EFO	"" []	EFO	68902	EFO:0002929	\N	microgram per kilogram per day	EFO:0002929
0	"" []	\N	milligram per kilogram per day	\N	\N	EFO	"" []	EFO	68903	EFO:0002930	\N	milligram per kilogram per day	EFO:0002930
0	"" []	\N	unit per kilogram	\N	\N	EFO	"" []	EFO	68904	EFO:0002931	\N	unit per kilogram	EFO:0002931
0	"Cell lines used in experiments under the HapMap Project" []	\N	HapMap cell line	\N	\N	EFO	"Cell lines used in experiments under the HapMap Project" []	EFO	68905	EFO:0002933	\N	HapMap cell line	EFO:0002933
0	"" []	\N	lung cancer cell line	\N	\N	EFO	"" []	EFO	68906	EFO:0002934	\N	lung cancer cell line	EFO:0002934
0	"" []	\N	Drosophila melanogaster cell line	\N	\N	EFO	"" []	EFO	68907	EFO:0002935	\N	Drosophila melanogaster cell line	EFO:0002935
0	"Cell lines derived from rats." []	\N	rat cell line	\N	\N	EFO	"Cell lines derived from rats." []	EFO	68908	EFO:0002936	\N	rat cell line	EFO:0002936
0	"" []	\N	lymphoma or leukaemia cell line	\N	\N	EFO	"" []	EFO	68909	EFO:0002937	\N	lymphoma or leukaemia cell line	EFO:0002937
0	"" []	\N	hypopharyngeal carcinoma	\N	\N	EFO	"" []	EFO	68910	EFO:0002938	\N	hypopharyngeal carcinoma	EFO:0002938
0	"A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, desmoplastic medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity and advanced neuronal differentiation. (from NCI Thesuarus)" []	\N	medulloblastoma	\N	\N	EFO	"A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, desmoplastic medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity and advanced neuronal differentiation. (from NCI Thesuarus)" []	EFO	68911	EFO:0002939	\N	medulloblastoma	EFO:0002939
0	"" []	\N	zebrafish cell line	\N	\N	EFO	"" []	EFO	68912	EFO:0002940	\N	zebrafish cell line	EFO:0002940
0	"An assay in which the transcriptome of a biological sample is analysed by serial analysis of gene expression (SAGE)" []	\N	transcription profiling by SAGE	\N	\N	EFO	"An assay in which the transcriptome of a biological sample is analysed by serial analysis of gene expression (SAGE)" []	EFO	68913	EFO:0002941	\N	transcription profiling by SAGE	EFO:0002941
0	"An assay in which the transcriptome of a biological sample is analysed by Massively Parallel Signature Sequencing (MPSS)" []	\N	transcription profiling by MPSS	\N	\N	EFO	"An assay in which the transcriptome of a biological sample is analysed by Massively Parallel Signature Sequencing (MPSS)" []	EFO	68914	EFO:0002942	\N	transcription profiling by MPSS	EFO:0002942
0	"An assay in which the transcriptome of a biological sample is analysed by reverse transcription PCR (RT-PCR)" []	\N	transcription profiling by RT-PCR	\N	\N	EFO	"An assay in which the transcriptome of a biological sample is analysed by reverse transcription PCR (RT-PCR)" []	EFO	68915	EFO:0002943	\N	transcription profiling by RT-PCR	EFO:0002943
0	"A protocol description in which a material separation to recover the nucleic acid fraction of an input material is performed" []	\N	nucleic acid extraction protocol	\N	\N	EFO	"A protocol description in which a material separation to recover the nucleic acid fraction of an input material is performed" []	EFO	68916	EFO:0002944	\N	nucleic acid extraction protocol	EFO:0002944
0	"" []	\N	familial cardiomyopathy	\N	\N	EFO	"" []	EFO	68917	EFO:0002945	\N	familial cardiomyopathy	EFO:0002945
0	"The quality of an organism that has successful reproduced." []	\N	parous	\N	\N	EFO	"The quality of an organism that has successful reproduced." []	EFO	68918	EFO:0002947	\N	parous	EFO:0002947
0	"The time period after birth." []	\N	postnatal	\N	\N	EFO	"The time period after birth." []	EFO	68919	EFO:0002948	\N	postnatal	EFO:0002948
0	"The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH." []	\N	pregnancy	\N	\N	EFO	"The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH." []	EFO	68920	EFO:0002950	\N	pregnancy	EFO:0002950
0	"The quality of an organism that has never been sexually active." []	\N	virgin	\N	\N	EFO	"The quality of an organism that has never been sexually active." []	EFO	68921	EFO:0002951	\N	virgin	EFO:0002951
0	"A property of a cell which is no longer pluripotent" []	\N	differentiated	\N	\N	EFO	"A property of a cell which is no longer pluripotent" []	EFO	68922	EFO:0002954	\N	differentiated	EFO:0002954
0	"" []	\N	reproductive system cell	\N	\N	EFO	"" []	EFO	68923	EFO:0002955	\N	reproductive system cell	EFO:0002955
0	"" []	\N	musculo-skeletal system cell	\N	\N	EFO	"" []	EFO	68924	EFO:0002956	\N	musculo-skeletal system cell	EFO:0002956
0	"2102ep is an embryonal cell line" []	\N	2102Ep	\N	\N	EFO	"2102ep is an embryonal cell line" []	EFO	68925	EFO:0002957	\N	2102Ep	EFO:0002957
0	"experimental cell is a cell which is experimentally derived such as a cell line cell, or a cell differentiated in culture. Experimentally derived cells may have diffrent properties from the cell from which they originally derived, such as through gene expression changes." []	\N	experimental cell	\N	\N	EFO	"experimental cell is a cell which is experimentally derived such as a cell line cell, or a cell differentiated in culture. Experimentally derived cells may have diffrent properties from the cell from which they originally derived, such as through gene expression changes." []	EFO	68926	EFO:0002958	\N	experimental cell	EFO:0002958
0	"A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation" []	\N	NTera2	\N	\N	EFO	"A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation" []	EFO	68927	EFO:0002959	\N	NTera2	EFO:0002959
0	"A human embryonic stem cell line" []	\N	BG03	\N	\N	EFO	"A human embryonic stem cell line" []	EFO	68928	EFO:0002960	\N	BG03	EFO:0002960
0	"A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation and differentiated into neuronal like cells" []	\N	NTera2 derived dopaminergic neuronal like cells	\N	\N	EFO	"A human embryonal carcinoma (EC) stem cell line used as a model system for the study of neuronal differentiation and differentiated into neuronal like cells" []	EFO	68929	EFO:0002961	\N	NTera2 derived dopaminergic neuronal like cells	EFO:0002961
0	"" []	\N	animal reproductive system cell	\N	\N	EFO	"" []	EFO	68930	EFO:0002962	\N	animal reproductive system cell	EFO:0002962
0	"" []	\N	nervous system cell	\N	\N	EFO	"" []	EFO	68931	EFO:0002963	\N	nervous system cell	EFO:0002963
0	"" []	\N	pancreatic cell	\N	\N	EFO	"" []	EFO	68932	EFO:0002966	\N	pancreatic cell	EFO:0002966
0	"A property of a cell which is able to differentiate into into one or more differentiated cell types" []	\N	pluripotent	\N	\N	EFO	"A property of a cell which is able to differentiate into into one or more differentiated cell types" []	EFO	68933	EFO:0002967	\N	pluripotent	EFO:0002967
0	"neural stem cells experimentally derived from ES cells" []	\N	embryonic stem cell derived neuronal stem cell	\N	\N	EFO	"neural stem cells experimentally derived from ES cells" []	EFO	68934	EFO:0002968	\N	embryonic stem cell derived neuronal stem cell	EFO:0002968
0	"Myopathy is a peripheral nervous system disease consisting of any abnormal condition or disease of the muscular tissues; commonly designates a disorder involving skeletal muscle." []	\N	muscular disease	\N	\N	EFO	"Myopathy is a peripheral nervous system disease consisting of any abnormal condition or disease of the muscular tissues; commonly designates a disorder involving skeletal muscle." []	EFO	68935	EFO:0002970	\N	muscular disease	EFO:0002970
0	"The ILSXISS#/Tej recombinant inbred (RI) strains originate from crosses between ILS/IbgTejJ (009324) and ISS/IbgTejJ (009325) They may be used to study the genetics of neurogenetic, neuropharmacological and behavioral phenotypes involved in alcohol-related traits and complex or potentially complex physiologic phenotypes (including differences in longevity under ad libitum and dietary restriction conditions, aging, body temperature and body weight)." []	\N	ILSXISS#/Tej	\N	\N	EFO	"The ILSXISS#/Tej recombinant inbred (RI) strains originate from crosses between ILS/IbgTejJ (009324) and ISS/IbgTejJ (009325) They may be used to study the genetics of neurogenetic, neuropharmacological and behavioral phenotypes involved in alcohol-related traits and complex or potentially complex physiologic phenotypes (including differences in longevity under ad libitum and dietary restriction conditions, aging, body temperature and body weight)." []	EFO	68936	EFO:0002971	\N	ILSXISS#/Tej	EFO:0002971
0	"" []	\N	ILSXISS3/TejJ	\N	\N	EFO	"" []	EFO	68937	EFO:0002972	\N	ILSXISS3/TejJ	EFO:0002972
0	"" []	\N	ILSXISS7/TejJ	\N	\N	EFO	"" []	EFO	68938	EFO:0002973	\N	ILSXISS7/TejJ	EFO:0002973
0	"" []	\N	ILSXISS13/TejJ	\N	\N	EFO	"" []	EFO	68939	EFO:0002974	\N	ILSXISS13/TejJ	EFO:0002974
0	"" []	\N	ILSXISS14/TejJ	\N	\N	EFO	"" []	EFO	68940	EFO:0002975	\N	ILSXISS14/TejJ	EFO:0002975
0	"" []	\N	ILSXISS16/TejJ	\N	\N	EFO	"" []	EFO	68941	EFO:0002976	\N	ILSXISS16/TejJ	EFO:0002976
0	"" []	\N	ILSXISS19/TejJ	\N	\N	EFO	"" []	EFO	68942	EFO:0002977	\N	ILSXISS19/TejJ	EFO:0002977
0	"" []	\N	ILSXISS22/TejJ	\N	\N	EFO	"" []	EFO	68943	EFO:0002978	\N	ILSXISS22/TejJ	EFO:0002978
0	"" []	\N	ILSXISS23/TejJ	\N	\N	EFO	"" []	EFO	68944	EFO:0002979	\N	ILSXISS23/TejJ	EFO:0002979
0	"" []	\N	ILSXISS24/TejJ	\N	\N	EFO	"" []	EFO	68945	EFO:0002980	\N	ILSXISS24/TejJ	EFO:0002980
0	"" []	\N	ILSXISS25/TejJ	\N	\N	EFO	"" []	EFO	68946	EFO:0002981	\N	ILSXISS25/TejJ	EFO:0002981
0	"" []	\N	ILSXISS26/TejJ	\N	\N	EFO	"" []	EFO	68947	EFO:0002982	\N	ILSXISS26/TejJ	EFO:0002982
0	"" []	\N	ILSXISS41/TejJ	\N	\N	EFO	"" []	EFO	68948	EFO:0002983	\N	ILSXISS41/TejJ	EFO:0002983
0	"" []	\N	ILSXISS48/TejJ	\N	\N	EFO	"" []	EFO	68949	EFO:0002984	\N	ILSXISS48/TejJ	EFO:0002984
0	"" []	\N	ILSXISS49/TejJ	\N	\N	EFO	"" []	EFO	68950	EFO:0002985	\N	ILSXISS49/TejJ	EFO:0002985
0	"" []	\N	ILSXISS50/TejJ	\N	\N	EFO	"" []	EFO	68951	EFO:0002986	\N	ILSXISS50/TejJ	EFO:0002986
0	"" []	\N	ILSXISS51/TejJ	\N	\N	EFO	"" []	EFO	68952	EFO:0002987	\N	ILSXISS51/TejJ	EFO:0002987
0	"" []	\N	ILSXISS52/TejJ	\N	\N	EFO	"" []	EFO	68953	EFO:0002988	\N	ILSXISS52/TejJ	EFO:0002988
0	"" []	\N	ILSXISS56/TejJ	\N	\N	EFO	"" []	EFO	68954	EFO:0002989	\N	ILSXISS56/TejJ	EFO:0002989
0	"" []	\N	ILSXISS62/TejJ	\N	\N	EFO	"" []	EFO	68955	EFO:0002990	\N	ILSXISS62/TejJ	EFO:0002990
0	"" []	\N	ILSXISS66/TejJ	\N	\N	EFO	"" []	EFO	68956	EFO:0002991	\N	ILSXISS66/TejJ	EFO:0002991
0	"" []	\N	ILSXISS79/TejJ	\N	\N	EFO	"" []	EFO	68957	EFO:0002992	\N	ILSXISS79/TejJ	EFO:0002992
0	"" []	\N	ILSXISS80/TejJ	\N	\N	EFO	"" []	EFO	68958	EFO:0002993	\N	ILSXISS80/TejJ	EFO:0002993
0	"" []	\N	ILSXISS84/TejJ	\N	\N	EFO	"" []	EFO	68959	EFO:0002994	\N	ILSXISS84/TejJ	EFO:0002994
0	"" []	\N	ILSXISS86/TejJ	\N	\N	EFO	"" []	EFO	68960	EFO:0002995	\N	ILSXISS86/TejJ	EFO:0002995
0	"" []	\N	ILSXISS89/TejJ	\N	\N	EFO	"" []	EFO	68961	EFO:0002996	\N	ILSXISS89/TejJ	EFO:0002996
0	"" []	\N	ILSXISS90/TejJ	\N	\N	EFO	"" []	EFO	68962	EFO:0002997	\N	ILSXISS90/TejJ	EFO:0002997
0	"" []	\N	ILSXISS92/TejJ	\N	\N	EFO	"" []	EFO	68963	EFO:0002998	\N	ILSXISS92/TejJ	EFO:0002998
0	"" []	\N	ILSXISS94/TejJ	\N	\N	EFO	"" []	EFO	68964	EFO:0002999	\N	ILSXISS94/TejJ	EFO:0002999
0	"" []	\N	ILSXISS97/TejJ	\N	\N	EFO	"" []	EFO	68965	EFO:0003000	\N	ILSXISS97/TejJ	EFO:0003000
0	"" []	\N	ILSXISS98/TejJ	\N	\N	EFO	"" []	EFO	68966	EFO:0003001	\N	ILSXISS98/TejJ	EFO:0003001
0	"" []	\N	ILSXISS99/TejJ	\N	\N	EFO	"" []	EFO	68967	EFO:0003002	\N	ILSXISS99/TejJ	EFO:0003002
0	"" []	\N	ILSXISS100/TejJ	\N	\N	EFO	"" []	EFO	68968	EFO:0003003	\N	ILSXISS100/TejJ	EFO:0003003
0	"" []	\N	ILSXISS103/TejJ	\N	\N	EFO	"" []	EFO	68969	EFO:0003004	\N	ILSXISS103/TejJ	EFO:0003004
0	"" []	\N	ILSXISS107/TejJ	\N	\N	EFO	"" []	EFO	68970	EFO:0003005	\N	ILSXISS107/TejJ	EFO:0003005
0	"" []	\N	ILSXISS110/TejJ	\N	\N	EFO	"" []	EFO	68971	EFO:0003006	\N	ILSXISS110/TejJ	EFO:0003006
0	"" []	\N	ILSXISS112/TejJ	\N	\N	EFO	"" []	EFO	68972	EFO:0003007	\N	ILSXISS112/TejJ	EFO:0003007
0	"" []	\N	ILSXISS114/TejJ	\N	\N	EFO	"" []	EFO	68973	EFO:0003008	\N	ILSXISS114/TejJ	EFO:0003008
0	"" []	\N	ILSXISS115/TejJ	\N	\N	EFO	"" []	EFO	68974	EFO:0003009	\N	ILSXISS115/TejJ	EFO:0003009
0	"" []	\N	ILSXISS117/TejJ	\N	\N	EFO	"" []	EFO	68975	EFO:0003010	\N	ILSXISS117/TejJ	EFO:0003010
0	"" []	\N	ILSXISS122/TejJ	\N	\N	EFO	"" []	EFO	68976	EFO:0003011	\N	ILSXISS122/TejJ	EFO:0003011
0	"" []	\N	ILSXISS123/TejJ	\N	\N	EFO	"" []	EFO	68977	EFO:0003012	\N	ILSXISS123/TejJ	EFO:0003012
0	"" []	\N	Mus musculus subspecies	\N	\N	EFO	"" []	EFO	68978	EFO:0003013	\N	Mus musculus subspecies	EFO:0003013
0	"breast fibrocystic disease is a benign mammary displasia characterised by breast discomfort and 'lumpiness'" []	\N	breast fibrocystic disease	\N	\N	EFO	"breast fibrocystic disease is a benign mammary displasia characterised by breast discomfort and 'lumpiness'" []	EFO	68979	EFO:0003014	\N	breast fibrocystic disease	EFO:0003014
0	"Agressive behaviour is the process of engaging on hostile, affective, or retaliatory aggression and instrumental, predatory, or goal-oriented aggression towards other individuals." []	\N	aggressive behavior	\N	\N	EFO	"Agressive behaviour is the process of engaging on hostile, affective, or retaliatory aggression and instrumental, predatory, or goal-oriented aggression towards other individuals." []	EFO	68980	EFO:0003015	\N	aggressive behavior	EFO:0003015
0	"Collecting duct carcinoma is a renal cell carcinoma described as a rare and aggressive type of renal cell carcinoma. The cancerous cells form irregular tubes inside the tumor. Collecting duct carcinoma is more common among young people and unfortunately is diagnosed in most cases when the cancer has metastasized (spread inside the body)." []	\N	collecting duct carcinoma	\N	\N	EFO	"Collecting duct carcinoma is a renal cell carcinoma described as a rare and aggressive type of renal cell carcinoma. The cancerous cells form irregular tubes inside the tumor. Collecting duct carcinoma is more common among young people and unfortunately is diagnosed in most cases when the cancer has metastasized (spread inside the body)." []	EFO	68981	EFO:0003016	\N	collecting duct carcinoma	EFO:0003016
0	"" []	\N	transitional cell carcinoma of kidney	\N	\N	EFO	"" []	EFO	68982	EFO:0003017	\N	transitional cell carcinoma of kidney	EFO:0003017
0	"" []	\N	ILSXISS28/TejJ	\N	\N	EFO	"" []	EFO	68983	EFO:0003018	\N	ILSXISS28/TejJ	EFO:0003018
0	"" []	\N	ILSXISS46/TejJ	\N	\N	EFO	"" []	EFO	68984	EFO:0003019	\N	ILSXISS46/TejJ	EFO:0003019
0	"" []	\N	ILSXISS60/TejJ	\N	\N	EFO	"" []	EFO	68985	EFO:0003020	\N	ILSXISS60/TejJ	EFO:0003020
0	"" []	\N	interferon alpha	\N	\N	EFO	"" []	EFO	68986	EFO:0003021	\N	interferon alpha	EFO:0003021
0	"" []	\N	interferon alpha 2a	\N	\N	EFO	"" []	EFO	68987	EFO:0003022	\N	interferon alpha 2a	EFO:0003022
0	"" []	\N	interferon beta	\N	\N	EFO	"" []	EFO	68988	EFO:0003023	\N	interferon beta	EFO:0003023
0	"" []	\N	interferon gamma	\N	\N	EFO	"" []	EFO	68989	EFO:0003024	\N	interferon gamma	EFO:0003024
0	"" []	\N	acute megakaryoblastic leukaemia	\N	\N	EFO	"" []	EFO	68990	EFO:0003025	\N	acute megakaryoblastic leukaemia	EFO:0003025
0	"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.  The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies.  The patients present with anemia, neutropenia, and thrombocytopenia.  The prognosis is usually poor.  (WHO, 2001)" []	\N	minimally differentiated acute myeloblastic leukemia	\N	\N	EFO	"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.  The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies.  The patients present with anemia, neutropenia, and thrombocytopenia.  The prognosis is usually poor.  (WHO, 2001)" []	EFO	68991	EFO:0003026	\N	minimally differentiated acute myeloblastic leukemia	EFO:0003026
0	"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils.  The patients present with anemia, neutropenia, and thrombocytopenia.  This type of AML usually follows an aggressive clinical course.  (WHO, 2001)" []	\N	acute myeloblastic leukemia without maturation	\N	\N	EFO	"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils.  The patients present with anemia, neutropenia, and thrombocytopenia.  This type of AML usually follows an aggressive clinical course.  (WHO, 2001)" []	EFO	68992	EFO:0003027	\N	acute myeloblastic leukemia without maturation	EFO:0003027
0	"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. AML with the t(8;21) is usually AML with maturation. This type of AML frequently responds to aggressive therapy. (WHO, 2001)" []	\N	acute myeloblastic leukemia with maturation	\N	\N	EFO	"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. AML with the t(8;21) is usually AML with maturation. This type of AML frequently responds to aggressive therapy. (WHO, 2001)" []	EFO	68993	EFO:0003028	\N	acute myeloblastic leukemia with maturation	EFO:0003028
0	"An acute myeloid leukemia in which the immature cells differentiate towards basophils.  This is a rare leukemia.  The observed cases have been associated with a poor prognosis.  The term basophilic leukemia is used as a synonym for acute basophilic leukemia.  Chronic basophilic leukemia is an inappropriate term vaguely connected to the term mast cell leukemia.  (WHO, 2001)" []	\N	acute basophilic leukemia	\N	\N	EFO	"An acute myeloid leukemia in which the immature cells differentiate towards basophils.  This is a rare leukemia.  The observed cases have been associated with a poor prognosis.  The term basophilic leukemia is used as a synonym for acute basophilic leukemia.  Chronic basophilic leukemia is an inappropriate term vaguely connected to the term mast cell leukemia.  (WHO, 2001)" []	EFO	68994	EFO:0003029	\N	acute basophilic leukemia	EFO:0003029
0	"" []	\N	abscess	\N	\N	EFO	"" []	EFO	68995	EFO:0003030	\N	abscess	EFO:0003030
0	"" []	\N	anaplastic large cell lymphoma	\N	\N	EFO	"" []	EFO	68996	EFO:0003032	\N	anaplastic large cell lymphoma	EFO:0003032
0	"" []	\N	bacteriemia	\N	\N	EFO	"" []	EFO	68997	EFO:0003033	\N	bacteriemia	EFO:0003033
0	"" []	\N	cellulitis	\N	\N	EFO	"" []	EFO	68998	EFO:0003035	\N	cellulitis	EFO:0003035
0	"A cell with empty-appearing cytoplasm when viewed with a light microscope." []	\N	clear cell	\N	\N	EFO	"A cell with empty-appearing cytoplasm when viewed with a light microscope." []	EFO	68999	EFO:0003036	\N	clear cell	EFO:0003036
0	"" []	\N	CMK	\N	\N	EFO	"" []	EFO	69000	EFO:0003037	\N	CMK	EFO:0003037
0	"The EAhy 926 cell is a hybridoma line derived from human endothelium and A549/8 cells. They display stable endothelial characteristics and may provide an indication of how endothelial cells respond to photodynamic therapy." []	\N	EAhy 926 cell	\N	\N	EFO	"The EAhy 926 cell is a hybridoma line derived from human endothelium and A549/8 cells. They display stable endothelial characteristics and may provide an indication of how endothelial cells respond to photodynamic therapy." []	EFO	69001	EFO:0003039	\N	EAhy 926 cell	EFO:0003039
0	"" []	\N	embryonic cell line	\N	\N	EFO	"" []	EFO	69002	EFO:0003040	\N	embryonic cell line	EFO:0003040
0	"" []	\N	esophageal epithelium	\N	\N	EFO	"" []	EFO	69003	EFO:0003041	\N	esophageal epithelium	EFO:0003041
0	"H1 human embryonic stem cell line, usually called H1-hESC and on occasion just H1" []	\N	H1-hESC	\N	\N	EFO	"H1 human embryonic stem cell line, usually called H1-hESC and on occasion just H1" []	EFO	69004	EFO:0003042	\N	H1-hESC	EFO:0003042
0	"" []	\N	NCI-H1299	\N	\N	EFO	"" []	EFO	69005	EFO:0003043	\N	NCI-H1299	EFO:0003043
0	"" []	\N	NCI-H460	\N	\N	EFO	"" []	EFO	69006	EFO:0003044	\N	NCI-H460	EFO:0003044
0	"" []	\N	H9	\N	\N	EFO	"" []	EFO	69007	EFO:0003045	\N	H9	EFO:0003045
0	"" []	\N	heart transplant rejection	\N	\N	EFO	"" []	EFO	69008	EFO:0003046	\N	heart transplant rejection	EFO:0003046
0	"A viral hepatitis and is_a Hepacivirus infectious disease, that results_in inflammation located_in liver, has_agent Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice." []	\N	hepatitis C infection	\N	\N	EFO	"A viral hepatitis and is_a Hepacivirus infectious disease, that results_in inflammation located_in liver, has_agent Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice." []	EFO	69009	EFO:0003047	\N	hepatitis C infection	EFO:0003047
0	"" []	\N	HES2	\N	\N	EFO	"" []	EFO	69010	EFO:0003048	\N	HES2	EFO:0003048
0	"A malignant epithelial neoplasm composed of large, atypical cells." []	\N	large cell lung carcinoma	\N	\N	EFO	"A malignant epithelial neoplasm composed of large, atypical cells." []	EFO	69011	EFO:0003050	\N	large cell lung carcinoma	EFO:0003050
0	"" []	\N	calf	\N	\N	EFO	"" []	EFO	69012	EFO:0003051	\N	calf	EFO:0003051
0	"" []	\N	forearm	\N	\N	EFO	"" []	EFO	69013	EFO:0003053	\N	forearm	EFO:0003053
0	"" []	\N	LP1	\N	\N	EFO	"" []	EFO	69014	EFO:0003055	\N	LP1	EFO:0003055
0	"The human melanoma cell line M14 has been established from surgically removed melanoma metastases." []	\N	M14	\N	\N	EFO	"The human melanoma cell line M14 has been established from surgically removed melanoma metastases." []	EFO	69015	EFO:0003056	\N	M14	EFO:0003056
0	"A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy." []	\N	non-small cell lung carcinoma	\N	\N	EFO	"A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy." []	EFO	69016	EFO:0003060	\N	non-small cell lung carcinoma	EFO:0003060
0	"" []	\N	OVCAR3	\N	\N	EFO	"" []	EFO	69017	EFO:0003061	\N	OVCAR3	EFO:0003061
0	"Any one of the three (common, deep, and superficial) peroneal nerves." []	\N	peroneal nerve	\N	\N	EFO	"Any one of the three (common, deep, and superficial) peroneal nerves." []	EFO	69018	EFO:0003062	\N	peroneal nerve	EFO:0003062
0	"" []	\N	polymyositis	\N	\N	EFO	"" []	EFO	69019	EFO:0003063	\N	polymyositis	EFO:0003063
0	"" []	\N	primary cell line	\N	\N	EFO	"" []	EFO	69020	EFO:0003064	\N	primary cell line	EFO:0003064
0	"" []	\N	foot	\N	\N	EFO	"" []	EFO	69021	EFO:0003065	\N	foot	EFO:0003065
0	"" []	\N	rib	\N	\N	EFO	"" []	EFO	69022	EFO:0003066	\N	rib	EFO:0003066
0	"" []	\N	latissimus dorsi	\N	\N	EFO	"" []	EFO	69023	EFO:0003067	\N	latissimus dorsi	EFO:0003067
0	"" []	\N	buttock	\N	\N	EFO	"" []	EFO	69024	EFO:0003070	\N	buttock	EFO:0003070
0	"" []	\N	SK-N-SH	\N	\N	EFO	"" []	EFO	69025	EFO:0003072	\N	SK-N-SH	EFO:0003072
0	"A plasma cell myeloma lacking clinical manifestations and organ impairment." []	\N	asymptomatic myeloma	\N	\N	EFO	"A plasma cell myeloma lacking clinical manifestations and organ impairment." []	EFO	69026	EFO:0003073	\N	asymptomatic myeloma	EFO:0003073
0	"Mouse embryonic stem cell line" []	\N	ES cell line	\N	\N	EFO	"Mouse embryonic stem cell line" []	EFO	69027	EFO:0003074	\N	ES cell line	EFO:0003074
0	"" []	\N	xanthoma	\N	\N	EFO	"" []	EFO	69028	EFO:0003075	\N	xanthoma	EFO:0003075
0	"An epithelial cell lining the thyroid follicle." []	\N	thyrocyte	\N	\N	EFO	"An epithelial cell lining the thyroid follicle." []	EFO	69029	EFO:0003076	\N	thyrocyte	EFO:0003076
0	"A porelike structure surrounding the entire circumference of the anterior chamber through which aqueous humor circulates to the canal of Schlemm. (MeSH)" []	\N	trabecular meshwork	\N	\N	EFO	"A porelike structure surrounding the entire circumference of the anterior chamber through which aqueous humor circulates to the canal of Schlemm. (MeSH)" []	EFO	69030	EFO:0003077	\N	trabecular meshwork	EFO:0003077
0	"" []	\N	SK-MEL-28	\N	\N	EFO	"" []	EFO	69031	EFO:0003081	\N	SK-MEL-28	EFO:0003081
0	"" []	\N	COLO205	\N	\N	EFO	"" []	EFO	69032	EFO:0003082	\N	COLO205	EFO:0003082
0	"A liposarcoma with areas of pleomorphism, resembling malignant fibrous histiocytoma.  It is the rarest liposarcoma variant and usually has an aggressive clinical course." []	\N	pleomorphic liposarcoma	\N	\N	EFO	"A liposarcoma with areas of pleomorphism, resembling malignant fibrous histiocytoma.  It is the rarest liposarcoma variant and usually has an aggressive clinical course." []	EFO	69033	EFO:0003083	\N	pleomorphic liposarcoma	EFO:0003083
0	"A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma." []	\N	round cell liposarcoma	\N	\N	EFO	"A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma." []	EFO	69034	EFO:0003084	\N	round cell liposarcoma	EFO:0003084
0	"A liposarcoma of any histologic subtype mixed with a non-lipomatous, high grade sarcomatous component.  The non-lipomatous component may be present in the primary lesion or at the site of metastasis." []	\N	dedifferentiated liposarcoma	\N	\N	EFO	"A liposarcoma of any histologic subtype mixed with a non-lipomatous, high grade sarcomatous component.  The non-lipomatous component may be present in the primary lesion or at the site of metastasis." []	EFO	69035	EFO:0003085	\N	dedifferentiated liposarcoma	EFO:0003085
0	"A disease affecting the kidneys" []	\N	kidney disease	\N	\N	EFO	"A disease affecting the kidneys" []	EFO	69036	EFO:0003086	\N	kidney disease	EFO:0003086
0	"" []	\N	atrial myocardium	\N	\N	EFO	"" []	EFO	69037	EFO:0003087	\N	atrial myocardium	EFO:0003087
0	"" []	\N	ventricular myocardium	\N	\N	EFO	"" []	EFO	69038	EFO:0003088	\N	ventricular myocardium	EFO:0003088
0	"An adrenal carcinoma that forms in the outer layer of tissue of the adrenal gland." []	\N	adrenocortical carcinoma	\N	\N	EFO	"An adrenal carcinoma that forms in the outer layer of tissue of the adrenal gland." []	EFO	69039	EFO:0003093	\N	adrenocortical carcinoma	EFO:0003093
0	"" []	\N	ganglioglioma	\N	\N	EFO	"" []	EFO	69040	EFO:0003094	\N	ganglioglioma	EFO:0003094
0	"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use." []	\N	non-alcoholic fatty liver disease	\N	\N	EFO	"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use." []	EFO	69041	EFO:0003095	\N	non-alcoholic fatty liver disease	EFO:0003095
0	"A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies." []	\N	Pick disease	\N	\N	EFO	"A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies." []	EFO	69042	EFO:0003096	\N	Pick disease	EFO:0003096
0	"" []	\N	empyema	\N	\N	EFO	"" []	EFO	69043	EFO:0003097	\N	empyema	EFO:0003097
0	"Cushing syndrome is a endocrine syndrome caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland." []	\N	Cushing syndrome	\N	\N	EFO	"Cushing syndrome is a endocrine syndrome caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland." []	EFO	69044	EFO:0003099	\N	Cushing syndrome	EFO:0003099
0	"" []	\N	peripheral neuropathy	\N	\N	EFO	"" []	EFO	69045	EFO:0003100	\N	peripheral neuropathy	EFO:0003100
0	"A malignant germ cell tumor arising from the testis.  It is believed that it is derived from the sexually undifferentiated embryonic gonad.  Treatment with radiotherapy is highly successful when the tumor is diagnosed in localized stages, which represents the majority of presentations of seminoma." []	\N	testicular seminoma	\N	\N	EFO	"A malignant germ cell tumor arising from the testis.  It is believed that it is derived from the sexually undifferentiated embryonic gonad.  Treatment with radiotherapy is highly successful when the tumor is diagnosed in localized stages, which represents the majority of presentations of seminoma." []	EFO	69046	EFO:0003101	\N	testicular seminoma	EFO:0003101
0	"A bone inflammation disease that results_from infection located_in bone and located_in bone marrow." []	\N	osteomyelitis	\N	\N	EFO	"A bone inflammation disease that results_from infection located_in bone and located_in bone marrow." []	EFO	69047	EFO:0003102	\N	osteomyelitis	EFO:0003102
0	"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine." []	\N	urinary tract infection	\N	\N	EFO	"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine." []	EFO	69048	EFO:0003103	\N	urinary tract infection	EFO:0003103
0	"" []	\N	adrenocortical adenoma	\N	\N	EFO	"" []	EFO	69049	EFO:0003104	\N	adrenocortical adenoma	EFO:0003104
0	"" []	\N	spina bifida	\N	\N	EFO	"" []	EFO	69050	EFO:0003105	\N	spina bifida	EFO:0003105
0	"A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing." []	\N	pneumonia	\N	\N	EFO	"A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing." []	EFO	69051	EFO:0003106	\N	pneumonia	EFO:0003106
0	"" []	\N	essential tremor	\N	\N	EFO	"" []	EFO	69052	EFO:0003108	\N	essential tremor	EFO:0003108
0	"" []	\N	villitis	\N	\N	EFO	"" []	EFO	69053	EFO:0003110	\N	villitis	EFO:0003110
0	"" []	\N	pauciarticular juvenile rheumatoid arthritis	\N	\N	EFO	"" []	EFO	69054	EFO:0003114	\N	pauciarticular juvenile rheumatoid arthritis	EFO:0003114
0	"" []	\N	EBC-1	\N	\N	EFO	"" []	EFO	69055	EFO:0003115	\N	EBC-1	EFO:0003115
0	"" []	\N	NCI-H125	\N	\N	EFO	"" []	EFO	69056	EFO:0003116	\N	NCI-H125	EFO:0003116
0	"" []	\N	NCI-H1334	\N	\N	EFO	"" []	EFO	69057	EFO:0003117	\N	NCI-H1334	EFO:0003117
0	"" []	\N	NCI-H157	\N	\N	EFO	"" []	EFO	69058	EFO:0003118	\N	NCI-H157	EFO:0003118
0	"" []	\N	NCI-H1648	\N	\N	EFO	"" []	EFO	69059	EFO:0003119	\N	NCI-H1648	EFO:0003119
0	"" []	\N	NCI-H2279	\N	\N	EFO	"" []	EFO	69060	EFO:0003120	\N	NCI-H2279	EFO:0003120
0	"" []	\N	NCI-H2882	\N	\N	EFO	"" []	EFO	69061	EFO:0003121	\N	NCI-H2882	EFO:0003121
0	"" []	\N	NCI-H2287	\N	\N	EFO	"" []	EFO	69062	EFO:0003122	\N	NCI-H2287	EFO:0003122
0	"" []	\N	NCI-H3255	\N	\N	EFO	"" []	EFO	69063	EFO:0003123	\N	NCI-H3255	EFO:0003123
0	"" []	\N	NCI-H520	\N	\N	EFO	"" []	EFO	69064	EFO:0003124	\N	NCI-H520	EFO:0003124
0	"" []	\N	NCI-H820	\N	\N	EFO	"" []	EFO	69065	EFO:0003125	\N	NCI-H820	EFO:0003125
0	"" []	\N	HCC1171	\N	\N	EFO	"" []	EFO	69066	EFO:0003126	\N	HCC1171	EFO:0003126
0	"" []	\N	HCC1159	\N	\N	EFO	"" []	EFO	69067	EFO:0003127	\N	HCC1159	EFO:0003127
0	"" []	\N	HCC1359	\N	\N	EFO	"" []	EFO	69068	EFO:0003128	\N	HCC1359	EFO:0003128
0	"" []	\N	HCC15	\N	\N	EFO	"" []	EFO	69069	EFO:0003129	\N	HCC15	EFO:0003129
0	"" []	\N	HCC193	\N	\N	EFO	"" []	EFO	69070	EFO:0003130	\N	HCC193	EFO:0003130
0	"" []	\N	HCC366	\N	\N	EFO	"" []	EFO	69071	EFO:0003131	\N	HCC366	EFO:0003131
0	"" []	\N	HCC4006	\N	\N	EFO	"" []	EFO	69072	EFO:0003132	\N	HCC4006	EFO:0003132
0	"" []	\N	HCC44	\N	\N	EFO	"" []	EFO	69073	EFO:0003133	\N	HCC44	EFO:0003133
0	"" []	\N	HCC461	\N	\N	EFO	"" []	EFO	69074	EFO:0003134	\N	HCC461	EFO:0003134
0	"" []	\N	HCC515	\N	\N	EFO	"" []	EFO	69075	EFO:0003135	\N	HCC515	EFO:0003135
0	"" []	\N	HCC78	\N	\N	EFO	"" []	EFO	69076	EFO:0003136	\N	HCC78	EFO:0003136
0	"" []	\N	HCC827	\N	\N	EFO	"" []	EFO	69077	EFO:0003137	\N	HCC827	EFO:0003137
0	"" []	\N	HCC95	\N	\N	EFO	"" []	EFO	69078	EFO:0003138	\N	HCC95	EFO:0003138
0	"" []	\N	HCjE	\N	\N	EFO	"" []	EFO	69079	EFO:0003139	\N	HCjE	EFO:0003139
0	"" []	\N	LC2/AD	\N	\N	EFO	"" []	EFO	69080	EFO:0003140	\N	LC2/AD	EFO:0003140
0	"" []	\N	LK-2	\N	\N	EFO	"" []	EFO	69081	EFO:0003141	\N	LK-2	EFO:0003141
0	"" []	\N	Lu130	\N	\N	EFO	"" []	EFO	69082	EFO:0003142	\N	Lu130	EFO:0003142
0	"CLIP-Seq also called HITS-CLIP is a method used for finding which RNA species interact with a particular RNA-binding protein (or an RNA). It employs crosslinking between RNA and the protein, followed by immunoprecipitation with antibodies for the protein." []	\N	CLIP-seq	\N	\N	EFO	"CLIP-Seq also called HITS-CLIP is a method used for finding which RNA species interact with a particular RNA-binding protein (or an RNA). It employs crosslinking between RNA and the protein, followed by immunoprecipitation with antibodies for the protein." []	EFO	69083	EFO:0003143	\N	CLIP-seq	EFO:0003143
0	"" []	\N	heart failure	\N	\N	EFO	"" []	EFO	69084	EFO:0003144	\N	heart failure	EFO:0003144
0	"" []	\N	high output heart failure	\N	\N	EFO	"" []	EFO	69085	EFO:0003145	\N	high output heart failure	EFO:0003145
0	"" []	\N	symptomatic heart failure	\N	\N	EFO	"" []	EFO	69086	EFO:0003146	\N	symptomatic heart failure	EFO:0003146
0	"" []	\N	mild heart failure	\N	\N	EFO	"" []	EFO	69087	EFO:0003147	\N	mild heart failure	EFO:0003147
0	"" []	\N	moderate heart failure	\N	\N	EFO	"" []	EFO	69088	EFO:0003148	\N	moderate heart failure	EFO:0003148
0	"" []	\N	advanced heart failure	\N	\N	EFO	"" []	EFO	69089	EFO:0003149	\N	advanced heart failure	EFO:0003149
0	"A term used in the United States to categorize a population group comprised of persons having origins in any of the black racial groups of Africa. Includes population subgroups (e.g., Kenyan, Nigerian, Haitian). The concept refers also to individuals who classify themselves as described." []	\N	African American	\N	\N	EFO	"A term used in the United States to categorize a population group comprised of persons having origins in any of the black racial groups of Africa. Includes population subgroups (e.g., Kenyan, Nigerian, Haitian). The concept refers also to individuals who classify themselves as described." []	EFO	69090	EFO:0003150	\N	African American	EFO:0003150
0	"" []	\N	American	\N	\N	EFO	"" []	EFO	69091	EFO:0003151	\N	American	EFO:0003151
0	"Denotes a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including Cambodia, China, India, Japan, Korea, Malaysia, Mongolia, Pakistan, the Philippine Islands, Thailand, and Vietnam." []	\N	Asian	\N	\N	EFO	"Denotes a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including Cambodia, China, India, Japan, Korea, Malaysia, Mongolia, Pakistan, the Philippine Islands, Thailand, and Vietnam." []	EFO	69092	EFO:0003152	\N	Asian	EFO:0003152
0	"In North America the term is used to distinguish a person having origins in the original peoples of the Indian sub-continent from Native Americans." []	\N	Asian Indian	\N	\N	EFO	"In North America the term is used to distinguish a person having origins in the original peoples of the Indian sub-continent from Native Americans." []	EFO	69093	EFO:0003153	\N	Asian Indian	EFO:0003153
0	"Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuukese (Trukese), Fijian, Kosraean, Melanesian, Micronesian, Northern Mariana Islander, Palauan, Papua New Guinean, Pohnpeian, Polynesian, Solomon Islander, Tahitian, Tokelauan, Tongan, Yapese, or Pacific Islander, not specified." []	\N	Asian/Pacific Islander	\N	\N	EFO	"Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuukese (Trukese), Fijian, Kosraean, Melanesian, Micronesian, Northern Mariana Islander, Palauan, Papua New Guinean, Pohnpeian, Polynesian, Solomon Islander, Tahitian, Tokelauan, Tongan, Yapese, or Pacific Islander, not specified." []	EFO	69094	EFO:0003154	\N	Asian/Pacific Islander	EFO:0003154
0	"" []	\N	British	\N	\N	EFO	"" []	EFO	69095	EFO:0003155	\N	British	EFO:0003155
0	"Denotes person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White." []	\N	Caucasian	\N	\N	EFO	"Denotes person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White." []	EFO	69096	EFO:0003156	\N	Caucasian	EFO:0003156
0	"Denotes the inhabitants of China, a person from there, or their descendants elsewhere." []	\N	Chinese	\N	\N	EFO	"Denotes the inhabitants of China, a person from there, or their descendants elsewhere." []	EFO	69097	EFO:0003157	\N	Chinese	EFO:0003157
0	"" []	\N	Eastern Indian	\N	\N	EFO	"" []	EFO	69098	EFO:0003158	\N	Eastern Indian	EFO:0003158
0	"" []	\N	European-American	\N	\N	EFO	"" []	EFO	69099	EFO:0003159	\N	European-American	EFO:0003159
0	"Denotes the inhabitants of the Philippine Islands, a person from there, or their descendants elsewhere." []	\N	Filipino	\N	\N	EFO	"Denotes the inhabitants of the Philippine Islands, a person from there, or their descendants elsewhere." []	EFO	69100	EFO:0003160	\N	Filipino	EFO:0003160
0	"Han Chinese are an ethnic group native to East Asia. Han Chinese constitute about 92% of the population of the People's Republic of China (mainland China)" []	\N	Han Chinese	\N	\N	EFO	"Han Chinese are an ethnic group native to East Asia. Han Chinese constitute about 92% of the population of the People's Republic of China (mainland China)" []	EFO	69101	EFO:0003161	\N	Han Chinese	EFO:0003161
0	"Denotes the inhabitants of Iran, a person from there, or their descendants elsewhere." []	\N	Iranian	\N	\N	EFO	"Denotes the inhabitants of Iran, a person from there, or their descendants elsewhere." []	EFO	69102	EFO:0003162	\N	Iranian	EFO:0003162
0	"Denotes the inhabitants of Ireland, a person from there, or their descendants elsewhere." []	\N	Irish	\N	\N	EFO	"Denotes the inhabitants of Ireland, a person from there, or their descendants elsewhere." []	EFO	69103	EFO:0003163	\N	Irish	EFO:0003163
0	"Denotes the inhabitants of Japan, a person from there, or their descendants elsewhere." []	\N	Japanese	\N	\N	EFO	"Denotes the inhabitants of Japan, a person from there, or their descendants elsewhere." []	EFO	69104	EFO:0003164	\N	Japanese	EFO:0003164
0	"Denotes the inhabitants of Korea, a person from there, or their descendants elsewhere." []	\N	Korean	\N	\N	EFO	"Denotes the inhabitants of Korea, a person from there, or their descendants elsewhere." []	EFO	69105	EFO:0003165	\N	Korean	EFO:0003165
0	"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification." []	\N	Latino	\N	\N	EFO	"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification." []	EFO	69106	EFO:0003166	\N	Latino	EFO:0003166
0	"" []	\N	Pima Indian	\N	\N	EFO	"" []	EFO	69107	EFO:0003167	\N	Pima Indian	EFO:0003167
0	"Denotes a person having origins in any of the original peoples of Hawaii, a person from there, or their descendants elsewhere." []	\N	Hawaiian	\N	\N	EFO	"Denotes a person having origins in any of the original peoples of Hawaii, a person from there, or their descendants elsewhere." []	EFO	69108	EFO:0003168	\N	Hawaiian	EFO:0003168
0	"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification." []	\N	Hispanic	\N	\N	EFO	"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification." []	EFO	69109	EFO:0003169	\N	Hispanic	EFO:0003169
0	"Pleiotrophin (PTN) also known as heparin-binding brain mitogen (HBBM) or heparin-binding growth factor 8 (HBGF-8) or neurite growth-promoting factor 1 (NEGF1) or heparin affinity regulatory peptide (HARP) or heparin binding growth associated molecule (HB-GAM) is a protein that in humans is encoded by the PTN gene.[1] Pleiotrophin is an 18-kDa growth factor that has a high affinity for heparin. It is structurally related to midkine and retinoic acid induced heparin-binding protein." []	\N	pleiotrophin	\N	\N	EFO	"Pleiotrophin (PTN) also known as heparin-binding brain mitogen (HBBM) or heparin-binding growth factor 8 (HBGF-8) or neurite growth-promoting factor 1 (NEGF1) or heparin affinity regulatory peptide (HARP) or heparin binding growth associated molecule (HB-GAM) is a protein that in humans is encoded by the PTN gene.[1] Pleiotrophin is an 18-kDa growth factor that has a high affinity for heparin. It is structurally related to midkine and retinoic acid induced heparin-binding protein." []	EFO	69110	EFO:0003172	\N	pleiotrophin	EFO:0003172
0	"Thrombin is a \\"trypsin-like\\" serine protease protein that in humans is encoded by the F2 gene.[2][3] Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the coagulation cascade, which ultimately results in the stemming of blood loss. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions." []	\N	thrombin	\N	\N	EFO	"Thrombin is a \\"trypsin-like\\" serine protease protein that in humans is encoded by the F2 gene.[2][3] Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the coagulation cascade, which ultimately results in the stemming of blood loss. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions." []	EFO	69111	EFO:0003183	\N	thrombin	EFO:0003183
0	"" []	\N	ocimene	\N	\N	EFO	"" []	EFO	69112	EFO:0003191	\N	ocimene	EFO:0003191
0	"" []	\N	leptin	\N	\N	EFO	"" []	EFO	69113	EFO:0003199	\N	leptin	EFO:0003199
0	"" []	\N	oncostatin M	\N	\N	EFO	"" []	EFO	69114	EFO:0003200	\N	oncostatin M	EFO:0003200
0	"Erythropoietin, or its alternatives erythropoetin or erthropoyetin (/ɨˌrɪθrɵˈpɔɪ.ɨtɨn/, /ɨˌrɪθrɵˈpɔɪtən/, or /ɨˌriːθrɵ-/) or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow." []	\N	erythropoietin	\N	\N	EFO	"Erythropoietin, or its alternatives erythropoetin or erthropoyetin (/ɨˌrɪθrɵˈpɔɪ.ɨtɨn/, /ɨˌrɪθrɵˈpɔɪtən/, or /ɨˌriːθrɵ-/) or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow." []	EFO	69115	EFO:0003233	\N	erythropoietin	EFO:0003233
0	"" []	\N	follicle stimulating hormone	\N	\N	EFO	"" []	EFO	69116	EFO:0003234	\N	follicle stimulating hormone	EFO:0003234
0	"Thrombopoietin (THPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the THPO gene. Thrombopoietin is a glycoprotein hormone produced mainly by the liver and the kidney that regulates the production of platelets by the bone marrow. It stimulates the production and differentiation of megakaryocytes, the bone marrow cells that fragment into large numbers of platelets.[1]" []	\N	thrombopoietin	\N	\N	EFO	"Thrombopoietin (THPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the THPO gene. Thrombopoietin is a glycoprotein hormone produced mainly by the liver and the kidney that regulates the production of platelets by the bone marrow. It stimulates the production and differentiation of megakaryocytes, the bone marrow cells that fragment into large numbers of platelets.[1]" []	EFO	69117	EFO:0003236	\N	thrombopoietin	EFO:0003236
0	"" []	\N	chitin octamer	\N	\N	EFO	"" []	EFO	69118	EFO:0003237	\N	chitin octamer	EFO:0003237
0	"" []	\N	flagellin	\N	\N	EFO	"" []	EFO	69119	EFO:0003241	\N	flagellin	EFO:0003241
0	"Neuromedin U (or NmU) is a neuropeptide found in the brain of humans and other mammals, which has a number of diverse functions including contraction of smooth muscle, regulation of blood pressure, pain perception, appetite, bone growth, and hormone release. It was first isolated from the spinal cord in 1985, and named after its ability to cause smooth muscle contraction in the uterus." []	\N	neuromedin U	\N	\N	EFO	"Neuromedin U (or NmU) is a neuropeptide found in the brain of humans and other mammals, which has a number of diverse functions including contraction of smooth muscle, regulation of blood pressure, pain perception, appetite, bone growth, and hormone release. It was first isolated from the spinal cord in 1985, and named after its ability to cause smooth muscle contraction in the uterus." []	EFO	69120	EFO:0003266	\N	neuromedin U	EFO:0003266
0	"Tumor necrosis factor (TNF, cachexin or cachectin formerly known as tumor necrosis factor-alpha or TNF-α) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well." []	\N	tumor necrosis factor-alpha	\N	\N	EFO	"Tumor necrosis factor (TNF, cachexin or cachectin formerly known as tumor necrosis factor-alpha or TNF-α) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well." []	EFO	69121	EFO:0003271	\N	tumor necrosis factor-alpha	EFO:0003271
0	"Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Serum concentration of VEGF is high in bronchial asthma and low in diabetes mellitus. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels.\\nWhen VEGF is overexpressed, it can contribute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood supply; cancers that can express VEGF are able to grow and metastasize. Overexpression of VEGF can cause vascular disease in the retina of the eye and other parts of the body. Drugs such as bevacizumab can inhibit VEGF and control or slow those diseases.\\nVEGF is a sub-family of growth factors, to be specific, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature)." []	\N	vascular endothelial growth factor	\N	\N	EFO	"Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Serum concentration of VEGF is high in bronchial asthma and low in diabetes mellitus. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels.\\nWhen VEGF is overexpressed, it can contribute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood supply; cancers that can express VEGF are able to grow and metastasize. Overexpression of VEGF can cause vascular disease in the retina of the eye and other parts of the body. Drugs such as bevacizumab can inhibit VEGF and control or slow those diseases.\\nVEGF is a sub-family of growth factors, to be specific, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature)." []	EFO	69122	EFO:0003276	\N	vascular endothelial growth factor	EFO:0003276
0	"" []	\N	interleukin-2 (Mus musculus)	\N	\N	EFO	"" []	EFO	69123	EFO:0003292	\N	interleukin-2 (Mus musculus)	EFO:0003292
0	"" []	\N	listeriolysin	\N	\N	EFO	"" []	EFO	69124	EFO:0003294	\N	listeriolysin	EFO:0003294
0	"" []	\N	interleukin-4 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69125	EFO:0003296	\N	interleukin-4 (Homo sapiens)	EFO:0003296
0	"" []	\N	epidermal growth factor	\N	\N	EFO	"" []	EFO	69126	EFO:0003298	\N	epidermal growth factor	EFO:0003298
0	"" []	\N	hepatocyte growth factor	\N	\N	EFO	"" []	EFO	69127	EFO:0003303	\N	hepatocyte growth factor	EFO:0003303
0	"" []	\N	anti-CD28	\N	\N	EFO	"" []	EFO	69128	EFO:0003304	\N	anti-CD28	EFO:0003304
0	"Hereregulin b1 is a  signaling protein for ErbB2/ErbB4 receptor heterodimers on the cardiac muscle cells." []	\N	heregulin B1	\N	\N	EFO	"Hereregulin b1 is a  signaling protein for ErbB2/ErbB4 receptor heterodimers on the cardiac muscle cells." []	EFO	69129	EFO:0003308	\N	heregulin B1	EFO:0003308
0	"" []	\N	basic fibroblast growth factor	\N	\N	EFO	"" []	EFO	69130	EFO:0003316	\N	basic fibroblast growth factor	EFO:0003316
0	"" []	\N	anti-CD3	\N	\N	EFO	"" []	EFO	69131	EFO:0003317	\N	anti-CD3	EFO:0003317
0	"" []	\N	zebrafish component	\N	\N	EFO	"" []	EFO	69132	EFO:0003331	\N	zebrafish component	EFO:0003331
0	"" []	\N	zebrafish embryonic structure	\N	\N	EFO	"" []	EFO	69133	EFO:0003332	\N	zebrafish embryonic structure	EFO:0003332
0	"" []	\N	Drosophila developmental tissue	\N	\N	EFO	"" []	EFO	69134	EFO:0003333	\N	Drosophila developmental tissue	EFO:0003333
0	"" []	\N	Drosophila component	\N	\N	EFO	"" []	EFO	69135	EFO:0003334	\N	Drosophila component	EFO:0003334
0	"" []	\N	Drosophila embryonic structure	\N	\N	EFO	"" []	EFO	69136	EFO:0003335	\N	Drosophila embryonic structure	EFO:0003335
0	"" []	\N	mesectoderm anlage	\N	\N	EFO	"" []	EFO	69137	EFO:0003336	\N	mesectoderm anlage	EFO:0003336
0	"" []	\N	head mesoderm	\N	\N	EFO	"" []	EFO	69138	EFO:0003337	\N	head mesoderm	EFO:0003337
0	"." []	\N	embryonic optic lobe primordium	\N	\N	EFO	"." []	EFO	69139	EFO:0003338	\N	embryonic optic lobe primordium	EFO:0003338
0	"Primordium of the posterior spiracle of the larva. Originates in the posterior half of the lateral ectoderm of abdominal segment 8 during stage 12 as a group of cells that are more basophilic that those surrounding them. It forms a deep groove that fuses with the posterior arm of the tracheal primordium of A8 (tracheal metamere 10)." []	\N	posterior spiracle primordium	\N	\N	EFO	"Primordium of the posterior spiracle of the larva. Originates in the posterior half of the lateral ectoderm of abdominal segment 8 during stage 12 as a group of cells that are more basophilic that those surrounding them. It forms a deep groove that fuses with the posterior arm of the tracheal primordium of A8 (tracheal metamere 10)." []	EFO	69140	EFO:0003339	\N	posterior spiracle primordium	EFO:0003339
0	"" []	\N	posterior endoderm anlage	\N	\N	EFO	"" []	EFO	69141	EFO:0003340	\N	posterior endoderm anlage	EFO:0003340
0	"Imaginal disc that is a precursor of ventral thoracic structures of the adult." []	\N	ventral thoracic disc	\N	\N	EFO	"Imaginal disc that is a precursor of ventral thoracic structures of the adult." []	EFO	69142	EFO:0003341	\N	ventral thoracic disc	EFO:0003341
0	"" []	\N	hindgut anlage	\N	\N	EFO	"" []	EFO	69143	EFO:0003342	\N	hindgut anlage	EFO:0003342
0	"" []	\N	ventral ectoderm anlage	\N	\N	EFO	"" []	EFO	69144	EFO:0003343	\N	ventral ectoderm anlage	EFO:0003343
0	"Primordium of a single tracheal metamere of the embryonic/larval tracheal system from its appearance as a placode during stage 11 to the completion of fusion with adjacent tracheal metameres in stage 15/16. There are 10 pairs of tracheal primordia - one pair in each segment from T2 to A8. Each tracheal primordium originates as a slight depression in the lateral ectoderm during stage 10 known as a tracheal placode. During stage 11, these placodes invaginate to form tracheal pits that elongate and branch. These pits close over during stage 13. Fusion of tracheal primordia begins at stage 14 with fusion of the dorsal trunk primordia and is complete by early stage 16." []	\N	tracheal primordium	\N	\N	EFO	"Primordium of a single tracheal metamere of the embryonic/larval tracheal system from its appearance as a placode during stage 11 to the completion of fusion with adjacent tracheal metameres in stage 15/16. There are 10 pairs of tracheal primordia - one pair in each segment from T2 to A8. Each tracheal primordium originates as a slight depression in the lateral ectoderm during stage 10 known as a tracheal placode. During stage 11, these placodes invaginate to form tracheal pits that elongate and branch. These pits close over during stage 13. Fusion of tracheal primordia begins at stage 14 with fusion of the dorsal trunk primordia and is complete by early stage 16." []	EFO	69145	EFO:0003344	\N	tracheal primordium	EFO:0003344
0	"" []	\N	foregut anlage	\N	\N	EFO	"" []	EFO	69146	EFO:0003345	\N	foregut anlage	EFO:0003345
0	"" []	\N	visual anlage	\N	\N	EFO	"" []	EFO	69147	EFO:0003346	\N	visual anlage	EFO:0003346
0	"" []	\N	hypopharynx anlage	\N	\N	EFO	"" []	EFO	69148	EFO:0003347	\N	hypopharynx anlage	EFO:0003347
0	"." []	\N	pericardial cell primordium	\N	\N	EFO	"." []	EFO	69149	EFO:0003348	\N	pericardial cell primordium	EFO:0003348
0	"" []	\N	visceral muscle primordium	\N	\N	EFO	"" []	EFO	69150	EFO:0003349	\N	visceral muscle primordium	EFO:0003349
0	"" []	\N	inclusive hindgut primordium	\N	\N	EFO	"" []	EFO	69151	EFO:0003350	\N	inclusive hindgut primordium	EFO:0003350
0	"" []	\N	gnathal primordium	\N	\N	EFO	"" []	EFO	69152	EFO:0003351	\N	gnathal primordium	EFO:0003351
0	"" []	\N	foregut primordium	\N	\N	EFO	"" []	EFO	69153	EFO:0003352	\N	foregut primordium	EFO:0003352
0	"" []	\N	maxillary sensory complex primordium	\N	\N	EFO	"" []	EFO	69154	EFO:0003353	\N	maxillary sensory complex primordium	EFO:0003353
0	"" []	\N	labial sensory complex primordium	\N	\N	EFO	"" []	EFO	69155	EFO:0003354	\N	labial sensory complex primordium	EFO:0003354
0	"" []	\N	labral sensory complex primordium	\N	\N	EFO	"" []	EFO	69156	EFO:0003355	\N	labral sensory complex primordium	EFO:0003355
0	"" []	\N	head mesoderm anlage	\N	\N	EFO	"" []	EFO	69157	EFO:0003356	\N	head mesoderm anlage	EFO:0003356
0	"" []	\N	proventriculus primordium	\N	\N	EFO	"" []	EFO	69158	EFO:0003357	\N	proventriculus primordium	EFO:0003357
0	"" []	\N	sensory nervous system primordium	\N	\N	EFO	"" []	EFO	69159	EFO:0003358	\N	sensory nervous system primordium	EFO:0003358
0	"" []	\N	ventral sensory complex primordium	\N	\N	EFO	"" []	EFO	69160	EFO:0003359	\N	ventral sensory complex primordium	EFO:0003359
0	"" []	\N	ventral imaginal precursor	\N	\N	EFO	"" []	EFO	69161	EFO:0003360	\N	ventral imaginal precursor	EFO:0003360
0	"" []	\N	head visceral muscle primordium	\N	\N	EFO	"" []	EFO	69162	EFO:0003361	\N	head visceral muscle primordium	EFO:0003361
0	"" []	\N	central brain anlage	\N	\N	EFO	"" []	EFO	69163	EFO:0003362	\N	central brain anlage	EFO:0003362
0	"." []	\N	amnioserosa primordium	\N	\N	EFO	"." []	EFO	69164	EFO:0003363	\N	amnioserosa primordium	EFO:0003363
0	"Tracheal primordium that develops into the embryonic/larval the embryonic/larval visceral branch. It branches anteriorly from the dorsal portion of the transverse connective primordium during stage 12, coursing anteriorly and inwardly towards the gut." []	\N	visceral branch primordium	\N	\N	EFO	"Tracheal primordium that develops into the embryonic/larval the embryonic/larval visceral branch. It branches anteriorly from the dorsal portion of the transverse connective primordium during stage 12, coursing anteriorly and inwardly towards the gut." []	EFO	69165	EFO:0003364	\N	visceral branch primordium	EFO:0003364
0	"This primordium first becomes distinct at around stage 11 as a group of cells at the posterior tip of the visceral mesoderm (the tail end of the germ-band). During germ-band retraction these cells migrate anteriorly and split into two clusters - one on either side of the posterior midgut primordium. When these cell reach the anterior tip of the posterior midgut primordium they disperse anteriorly as two rows along the germband. Finally, during midgut closure these cells spread regularly over the underlying circular visceral muscle primordium." []	\N	longitudinal visceral muscle primordium	\N	\N	EFO	"This primordium first becomes distinct at around stage 11 as a group of cells at the posterior tip of the visceral mesoderm (the tail end of the germ-band). During germ-band retraction these cells migrate anteriorly and split into two clusters - one on either side of the posterior midgut primordium. When these cell reach the anterior tip of the posterior midgut primordium they disperse anteriorly as two rows along the germband. Finally, during midgut closure these cells spread regularly over the underlying circular visceral muscle primordium." []	EFO	69166	EFO:0003365	\N	longitudinal visceral muscle primordium	EFO:0003365
0	"Primordium that develops into a primary trachea." []	\N	primary segmental branch primordium	\N	\N	EFO	"Primordium that develops into a primary trachea." []	EFO	69167	EFO:0003366	\N	primary segmental branch primordium	EFO:0003366
0	"A 'whorl' of larval oenocyte precursors which forms transiently around each 'chordotonal precursor cell C1' during stage 11. It ceases to exist when these cells delaminate during stages 11 and 12." []	\N	oenocyte primordium	\N	\N	EFO	"A 'whorl' of larval oenocyte precursors which forms transiently around each 'chordotonal precursor cell C1' during stage 11. It ceases to exist when these cells delaminate during stages 11 and 12." []	EFO	69168	EFO:0003367	\N	oenocyte primordium	EFO:0003367
0	"" []	\N	hindgut proper primordium	\N	\N	EFO	"" []	EFO	69169	EFO:0003368	\N	hindgut proper primordium	EFO:0003368
0	"" []	\N	Malpighian tubule primordium	\N	\N	EFO	"" []	EFO	69170	EFO:0003369	\N	Malpighian tubule primordium	EFO:0003369
0	"" []	\N	posterior midgut proper primordium	\N	\N	EFO	"" []	EFO	69171	EFO:0003370	\N	posterior midgut proper primordium	EFO:0003370
0	"" []	\N	embryonic inner optic lobe primordium	\N	\N	EFO	"" []	EFO	69172	EFO:0003371	\N	embryonic inner optic lobe primordium	EFO:0003371
0	"" []	\N	visual primordium	\N	\N	EFO	"" []	EFO	69173	EFO:0003372	\N	visual primordium	EFO:0003372
0	"The fat body primordium after the gonadal sheath primordium splits from it during stage 14. During late embryogenesis, various holes and clefts form, giving the fat body its larval form. The cells of this primordium do not accumulate fat during their differentiation (this only happens in the larval fat body)." []	\N	fat body primordium	\N	\N	EFO	"The fat body primordium after the gonadal sheath primordium splits from it during stage 14. During late embryogenesis, various holes and clefts form, giving the fat body its larval form. The cells of this primordium do not accumulate fat during their differentiation (this only happens in the larval fat body)." []	EFO	69174	EFO:0003373	\N	fat body primordium	EFO:0003373
0	"" []	\N	hindgut anlage in statu nascendi	\N	\N	EFO	"" []	EFO	69175	EFO:0003374	\N	hindgut anlage in statu nascendi	EFO:0003374
0	"" []	\N	visual anlage in statu nascendi	\N	\N	EFO	"" []	EFO	69176	EFO:0003375	\N	visual anlage in statu nascendi	EFO:0003375
0	"" []	\N	Malpighian tubule main body primordium	\N	\N	EFO	"" []	EFO	69177	EFO:0003376	\N	Malpighian tubule main body primordium	EFO:0003376
0	"" []	\N	small intestine primordium	\N	\N	EFO	"" []	EFO	69178	EFO:0003377	\N	small intestine primordium	EFO:0003377
0	"" []	\N	large intestine primordium	\N	\N	EFO	"" []	EFO	69179	EFO:0003378	\N	large intestine primordium	EFO:0003378
0	"" []	\N	rectum primordium	\N	\N	EFO	"" []	EFO	69180	EFO:0003379	\N	rectum primordium	EFO:0003379
0	"" []	\N	pars intercerebralis primordium	\N	\N	EFO	"" []	EFO	69181	EFO:0003380	\N	pars intercerebralis primordium	EFO:0003380
0	"" []	\N	salivary gland body primordium	\N	\N	EFO	"" []	EFO	69182	EFO:0003381	\N	salivary gland body primordium	EFO:0003381
0	"Primordium of the embryonic/larval somatic musculature of the trunk. It arises from the outer layer of the trunk mesoderm. During germ band shortening (stage 13), it segregates into loose segmental clusters. Within these clusters, muscle formation proceeds by fusion of fusion competent myoblasts to muscle founder cells." []	\N	somatic muscle primordium	\N	\N	EFO	"Primordium of the embryonic/larval somatic musculature of the trunk. It arises from the outer layer of the trunk mesoderm. During germ band shortening (stage 13), it segregates into loose segmental clusters. Within these clusters, muscle formation proceeds by fusion of fusion competent myoblasts to muscle founder cells." []	EFO	69183	EFO:0003382	\N	somatic muscle primordium	EFO:0003382
0	"" []	\N	midline primordium	\N	\N	EFO	"" []	EFO	69184	EFO:0003383	\N	midline primordium	EFO:0003383
0	"" []	\N	ventral epidermis primordium	\N	\N	EFO	"" []	EFO	69185	EFO:0003384	\N	ventral epidermis primordium	EFO:0003384
0	"" []	\N	stomatogastric nervous system primordium	\N	\N	EFO	"" []	EFO	69186	EFO:0003385	\N	stomatogastric nervous system primordium	EFO:0003385
0	"." []	\N	central brain primordium	\N	\N	EFO	"." []	EFO	69187	EFO:0003386	\N	central brain primordium	EFO:0003386
0	"" []	\N	ventral midline neuroblast	\N	\N	EFO	"" []	EFO	69188	EFO:0003387	\N	ventral midline neuroblast	EFO:0003387
0	"" []	\N	embryonic maxillary sensory complex	\N	\N	EFO	"" []	EFO	69189	EFO:0003388	\N	embryonic maxillary sensory complex	EFO:0003388
0	"" []	\N	embryonic hindgut	\N	\N	EFO	"" []	EFO	69190	EFO:0003389	\N	embryonic hindgut	EFO:0003389
0	"" []	\N	embryonic Malpighian tubule tip cell	\N	\N	EFO	"" []	EFO	69191	EFO:0003390	\N	embryonic Malpighian tubule tip cell	EFO:0003390
0	"" []	\N	embryonic outer optic lobe primordium	\N	\N	EFO	"" []	EFO	69192	EFO:0003391	\N	embryonic outer optic lobe primordium	EFO:0003391
0	"." []	\N	hypopharynx anlage in statu nascendi	\N	\N	EFO	"." []	EFO	69193	EFO:0003392	\N	hypopharynx anlage in statu nascendi	EFO:0003392
0	"." []	\N	hypopharyngeal sense organ primordium	\N	\N	EFO	"." []	EFO	69194	EFO:0003393	\N	hypopharyngeal sense organ primordium	EFO:0003393
0	"" []	\N	embryonic stomatogastric nervous system	\N	\N	EFO	"" []	EFO	69195	EFO:0003394	\N	embryonic stomatogastric nervous system	EFO:0003394
0	"A closely associated cluster of three larval endocrine glands located anterior to the aorta and larval lymph gland. Its component glands are: the corpus cardiacum, the prothoracic gland and the corpus allatum. It is innervated by neurons of the nervus corporis cardiaci." []	\N	ring gland	\N	\N	EFO	"A closely associated cluster of three larval endocrine glands located anterior to the aorta and larval lymph gland. Its component glands are: the corpus cardiacum, the prothoracic gland and the corpus allatum. It is innervated by neurons of the nervus corporis cardiaci." []	EFO	69196	EFO:0003395	\N	ring gland	EFO:0003395
0	"A component of the embryonic/larval ring gland composed of a cluster of 10-20 cells on either side of the aorta. Ventrally, it is continuous with the corpus cardiaca, dorsally with the corpus allatum." []	\N	prothoracic gland	\N	\N	EFO	"A component of the embryonic/larval ring gland composed of a cluster of 10-20 cells on either side of the aorta. Ventrally, it is continuous with the corpus cardiaca, dorsally with the corpus allatum." []	EFO	69197	EFO:0003396	\N	prothoracic gland	EFO:0003396
0	"Multiply innervated sensillum, composed of an anterior and a posterior sensillum, located on the floor of the larval pharynx. It is innervated by 3 or 4 neurons whose axons join an anteriorly directed bundle that joins the labral nerve." []	\N	hypopharyngeal sense organ	\N	\N	EFO	"Multiply innervated sensillum, composed of an anterior and a posterior sensillum, located on the floor of the larval pharynx. It is innervated by 3 or 4 neurons whose axons join an anteriorly directed bundle that joins the labral nerve." []	EFO	69198	EFO:0003397	\N	hypopharyngeal sense organ	EFO:0003397
0	"Bulbous, distal-most segment of the haltere." []	\N	capitellum	\N	\N	EFO	"Bulbous, distal-most segment of the haltere." []	EFO	69199	EFO:0003398	\N	capitellum	EFO:0003398
0	"" []	\N	pole plasm	\N	\N	EFO	"" []	EFO	69200	EFO:0003399	\N	pole plasm	EFO:0003399
0	"" []	\N	trunk mesoderm anlage	\N	\N	EFO	"" []	EFO	69201	EFO:0003400	\N	trunk mesoderm anlage	EFO:0003400
0	"Primordium which is formed by the delamination of neuroblasts from the ventral neurogenic region. The first of five waves of delamination starts towards the end of embryonic stage 8. During stage 11, the mesectoderm loses contact with the outer surface and forms neuronal and glial precursors in the midline of this primordium." []	\N	ventral nerve cord primordium	\N	\N	EFO	"Primordium which is formed by the delamination of neuroblasts from the ventral neurogenic region. The first of five waves of delamination starts towards the end of embryonic stage 8. During stage 11, the mesectoderm loses contact with the outer surface and forms neuronal and glial precursors in the midline of this primordium." []	EFO	69202	EFO:0003401	\N	ventral nerve cord primordium	EFO:0003401
0	"" []	\N	ventral midline neuron	\N	\N	EFO	"" []	EFO	69203	EFO:0003402	\N	ventral midline neuron	EFO:0003402
0	"" []	\N	ventral midline glia	\N	\N	EFO	"" []	EFO	69204	EFO:0003403	\N	ventral midline glia	EFO:0003403
0	"" []	\N	embryonic tracheole	\N	\N	EFO	"" []	EFO	69205	EFO:0003404	\N	embryonic tracheole	EFO:0003404
0	"" []	\N	embryonic proventriculus inner layer	\N	\N	EFO	"" []	EFO	69206	EFO:0003405	\N	embryonic proventriculus inner layer	EFO:0003405
0	"" []	\N	embryonic proventriculus intermediate layer	\N	\N	EFO	"" []	EFO	69207	EFO:0003406	\N	embryonic proventriculus intermediate layer	EFO:0003406
0	"" []	\N	embryonic proventriculus outer layer	\N	\N	EFO	"" []	EFO	69208	EFO:0003407	\N	embryonic proventriculus outer layer	EFO:0003407
0	"" []	\N	larval labral segment	\N	\N	EFO	"" []	EFO	69209	EFO:0003408	\N	larval labral segment	EFO:0003408
0	"" []	\N	embryonic labial sensory complex	\N	\N	EFO	"" []	EFO	69210	EFO:0003409	\N	embryonic labial sensory complex	EFO:0003409
0	"" []	\N	embryonic midgut interstitial cell	\N	\N	EFO	"" []	EFO	69211	EFO:0003410	\N	embryonic midgut interstitial cell	EFO:0003410
0	"" []	\N	embryonic hypocerebral ganglion	\N	\N	EFO	"" []	EFO	69212	EFO:0003411	\N	embryonic hypocerebral ganglion	EFO:0003411
0	"" []	\N	lateral cord glia	\N	\N	EFO	"" []	EFO	69213	EFO:0003412	\N	lateral cord glia	EFO:0003412
0	"" []	\N	lateral cord neuron	\N	\N	EFO	"" []	EFO	69214	EFO:0003413	\N	lateral cord neuron	EFO:0003413
0	"Cell at the leading edge of the dorsal epidermis during dorsal closure." []	\N	embryonic leading edge cell	\N	\N	EFO	"Cell at the leading edge of the dorsal epidermis during dorsal closure." []	EFO	69215	EFO:0003414	\N	embryonic leading edge cell	EFO:0003414
0	"" []	\N	embryonic ventral apodeme	\N	\N	EFO	"" []	EFO	69216	EFO:0003415	\N	embryonic ventral apodeme	EFO:0003415
0	"" []	\N	lateral cord surface glia	\N	\N	EFO	"" []	EFO	69217	EFO:0003416	\N	lateral cord surface glia	EFO:0003416
0	"." []	\N	ring gland primordium	\N	\N	EFO	"." []	EFO	69218	EFO:0003417	\N	ring gland primordium	EFO:0003417
0	"." []	\N	cibarium primordium	\N	\N	EFO	"." []	EFO	69219	EFO:0003418	\N	cibarium primordium	EFO:0003418
0	"A group of cells that migrate at the leading edge of shield during gastrulation but do not involute. At the end of gastrulation, forerunner cells migrate deep into the embryo and organize to form Kupffer's vesicle." []	\N	forerunner cell group	\N	\N	EFO	"A group of cells that migrate at the leading edge of shield during gastrulation but do not involute. At the end of gastrulation, forerunner cells migrate deep into the embryo and organize to form Kupffer's vesicle." []	EFO	69220	EFO:0003419	\N	forerunner cell group	EFO:0003419
0	"The hatching gland rudiment at the time it underlies the forebrain during the early segmentation period." []	\N	polster	\N	\N	EFO	"The hatching gland rudiment at the time it underlies the forebrain during the early segmentation period." []	EFO	69221	EFO:0003422	\N	polster	EFO:0003422
0	"" []	\N	presumptive forebrain	\N	\N	EFO	"" []	EFO	69222	EFO:0003423	\N	presumptive forebrain	EFO:0003423
0	"Outermost monolayer of cells surrounding the embryo that become very flattened in the blastula and give rise to the periderm. Sometimes used synonymously with periderm." []	\N	enveloping layer	\N	\N	EFO	"Outermost monolayer of cells surrounding the embryo that become very flattened in the blastula and give rise to the periderm. Sometimes used synonymously with periderm." []	EFO	69223	EFO:0003425	\N	enveloping layer	EFO:0003425
0	"" []	\N	axial chorda mesoderm	\N	\N	EFO	"" []	EFO	69224	EFO:0003426	\N	axial chorda mesoderm	EFO:0003426
0	"" []	\N	pectoral fin bud	\N	\N	EFO	"" []	EFO	69225	EFO:0003430	\N	pectoral fin bud	EFO:0003430
0	"" []	\N	presumptive brain	\N	\N	EFO	"" []	EFO	69226	EFO:0003431	\N	presumptive brain	EFO:0003431
0	"" []	\N	presumptive dorsal mesoderm	\N	\N	EFO	"" []	EFO	69227	EFO:0003435	\N	presumptive dorsal mesoderm	EFO:0003435
0	"" []	\N	presumptive cephalic mesoderm	\N	\N	EFO	"" []	EFO	69228	EFO:0003436	\N	presumptive cephalic mesoderm	EFO:0003436
0	"" []	\N	presumptive spinal cord	\N	\N	EFO	"" []	EFO	69229	EFO:0003438	\N	presumptive spinal cord	EFO:0003438
0	"" []	\N	presumptive telencephalon	\N	\N	EFO	"" []	EFO	69230	EFO:0003441	\N	presumptive telencephalon	EFO:0003441
0	"" []	\N	presumptive diencephalon	\N	\N	EFO	"" []	EFO	69231	EFO:0003442	\N	presumptive diencephalon	EFO:0003442
0	"" []	\N	posterior lateral line placode	\N	\N	EFO	"" []	EFO	69232	EFO:0003445	\N	posterior lateral line placode	EFO:0003445
0	"Epibranchial placode that gives rise to vagal ganglion 1." []	\N	vagal placode 1	\N	\N	EFO	"Epibranchial placode that gives rise to vagal ganglion 1." []	EFO	69233	EFO:0003456	\N	vagal placode 1	EFO:0003456
0	"Epibranchial placode that gives rise to vagal ganglion 2." []	\N	vagal placode 2	\N	\N	EFO	"Epibranchial placode that gives rise to vagal ganglion 2." []	EFO	69234	EFO:0003457	\N	vagal placode 2	EFO:0003457
0	"Epibranchial placode that gives rise to vagal ganglion 3." []	\N	vagal placode 3	\N	\N	EFO	"Epibranchial placode that gives rise to vagal ganglion 3." []	EFO	69235	EFO:0003458	\N	vagal placode 3	EFO:0003458
0	"Epibranchial placode that gives rise to vagal ganglion 4." []	\N	vagal placode 4	\N	\N	EFO	"Epibranchial placode that gives rise to vagal ganglion 4." []	EFO	69236	EFO:0003459	\N	vagal placode 4	EFO:0003459
0	"" []	\N	anterior lateral line placode	\N	\N	EFO	"" []	EFO	69237	EFO:0003461	\N	anterior lateral line placode	EFO:0003461
0	"" []	\N	anterior pancreatic bud	\N	\N	EFO	"" []	EFO	69238	EFO:0003464	\N	anterior pancreatic bud	EFO:0003464
0	"" []	\N	posterior pancreatic bud	\N	\N	EFO	"" []	EFO	69239	EFO:0003465	\N	posterior pancreatic bud	EFO:0003465
0	"" []	\N	fin bud	\N	\N	EFO	"" []	EFO	69240	EFO:0003468	\N	fin bud	EFO:0003468
0	"" []	\N	pelvic fin bud	\N	\N	EFO	"" []	EFO	69241	EFO:0003469	\N	pelvic fin bud	EFO:0003469
0	"" []	\N	presumptive ventral fin fold	\N	\N	EFO	"" []	EFO	69242	EFO:0003471	\N	presumptive ventral fin fold	EFO:0003471
0	"Portion of tissue that is a patch of thickened, pseudostratified epithelium in the inner ear, consisting of regular arrays of sensory hair cells interspersed with supporting cells. The macula utricle senses linear acceleration and gravity.  The macula utricle covers most of the floor of the utricle." []	\N	macula utricle	\N	\N	EFO	"Portion of tissue that is a patch of thickened, pseudostratified epithelium in the inner ear, consisting of regular arrays of sensory hair cells interspersed with supporting cells. The macula utricle senses linear acceleration and gravity.  The macula utricle covers most of the floor of the utricle." []	EFO	69243	EFO:0003474	\N	macula utricle	EFO:0003474
0	"" []	\N	intermediate cell mass of mesoderm	\N	\N	EFO	"" []	EFO	69244	EFO:0003476	\N	intermediate cell mass of mesoderm	EFO:0003476
0	"" []	\N	median fin fold	\N	\N	EFO	"" []	EFO	69245	EFO:0003477	\N	median fin fold	EFO:0003477
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 1	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69246	EFO:0003481	\N	somite 1	EFO:0003481
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 5	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69247	EFO:0003482	\N	somite 5	EFO:0003482
0	"" []	\N	ventral mesoderm	\N	\N	EFO	"" []	EFO	69248	EFO:0003486	\N	ventral mesoderm	EFO:0003486
0	"Apical ectodermal ridge that is part of the pectoral fin bud." []	\N	apical ectodermal ridge pectoral fin bud	\N	\N	EFO	"Apical ectodermal ridge that is part of the pectoral fin bud." []	EFO	69249	EFO:0003487	\N	apical ectodermal ridge pectoral fin bud	EFO:0003487
0	"Apical ectodermal ridge that is part of the dorsal fin." []	\N	apical ectodermal ridge dorsal fin	\N	\N	EFO	"Apical ectodermal ridge that is part of the dorsal fin." []	EFO	69250	EFO:0003488	\N	apical ectodermal ridge dorsal fin	EFO:0003488
0	"" []	\N	cardinal system	\N	\N	EFO	"" []	EFO	69251	EFO:0003490	\N	cardinal system	EFO:0003490
0	"" []	\N	lateral line ganglion	\N	\N	EFO	"" []	EFO	69252	EFO:0003493	\N	lateral line ganglion	EFO:0003493
0	"Neuromast that is part of the mandibular lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	\N	mandibular lateral line neuromast	\N	\N	EFO	"Neuromast that is part of the mandibular lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	EFO	69253	EFO:0003495	\N	mandibular lateral line neuromast	EFO:0003495
0	"Neuromast that is part of the otic lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	\N	otic lateral line neuromast	\N	\N	EFO	"Neuromast that is part of the otic lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	EFO	69254	EFO:0003499	\N	otic lateral line neuromast	EFO:0003499
0	"" []	\N	tectal ventricle	\N	\N	EFO	"" []	EFO	69255	EFO:0003501	\N	tectal ventricle	EFO:0003501
0	"" []	\N	ventral mesenchyme	\N	\N	EFO	"" []	EFO	69256	EFO:0003502	\N	ventral mesenchyme	EFO:0003502
0	"Median elements that are ossified within copulae and are not assigned to a specific branchial arch number. They articulate posterolaterally with the hypobranchials." []	\N	basibranchial	\N	\N	EFO	"Median elements that are ossified within copulae and are not assigned to a specific branchial arch number. They articulate posterolaterally with the hypobranchials." []	EFO	69257	EFO:0003503	\N	basibranchial	EFO:0003503
0	"" []	\N	branchial muscle	\N	\N	EFO	"" []	EFO	69258	EFO:0003504	\N	branchial muscle	EFO:0003504
0	"Cranial nerve which enters the brain between cranial nerves VIII and IX; contains afferents and sensory efferents to the posterior lateral line ganglion and middle ganglion. Fibers from the posterior lateral line ganglion innervate the occipital dorsal lateral line and trunk lateral lines." []	\N	posterior lateral line nerve	\N	\N	EFO	"Cranial nerve which enters the brain between cranial nerves VIII and IX; contains afferents and sensory efferents to the posterior lateral line ganglion and middle ganglion. Fibers from the posterior lateral line ganglion innervate the occipital dorsal lateral line and trunk lateral lines." []	EFO	69259	EFO:0003506	\N	posterior lateral line nerve	EFO:0003506
0	"Brain structure which is paired and part of the vestibulolateralis lobe of the cerebellum and extends fibers into the cerebellar crest. From Neuroanatomy of the Zebrafish Brain." []	\N	granular eminence	\N	\N	EFO	"Brain structure which is paired and part of the vestibulolateralis lobe of the cerebellum and extends fibers into the cerebellar crest. From Neuroanatomy of the Zebrafish Brain." []	EFO	69260	EFO:0003509	\N	granular eminence	EFO:0003509
0	"Large, paired cartilage bones separating the olfactory region from the orbit. Arises from both perichondral and endochondral ossifications (Harrington 1955). Bordered by the mesethmoid anteriorly and overlain by the frontal dorsally, each lateral ethmoid extends medially to meet its fellow posteriorly along the midline. Develops from the laminae orbitonasales." []	\N	lateral ethmoid	\N	\N	EFO	"Large, paired cartilage bones separating the olfactory region from the orbit. Arises from both perichondral and endochondral ossifications (Harrington 1955). Bordered by the mesethmoid anteriorly and overlain by the frontal dorsally, each lateral ethmoid extends medially to meet its fellow posteriorly along the midline. Develops from the laminae orbitonasales." []	EFO	69261	EFO:0003510	\N	lateral ethmoid	EFO:0003510
0	"" []	\N	mandibular muscle	\N	\N	EFO	"" []	EFO	69262	EFO:0003511	\N	mandibular muscle	EFO:0003511
0	"The metapterygoid is a posterior bone that ossifies in the cartilaginous palatoquadrate arch. It first appears as a rod of bone with an anterodorsally projecting process from the middle of the dorsal surface (6.4 mm). The adult metapterygoid is roughly rectangular in shape with rounded corners and an anterodorsally projecting spine that meets the entopterygoid medially in a synostosis at its posteromedial edge. The posterior end curves dorsally to form the posteroventral surface of the orbit." []	\N	metapterygoid	\N	\N	EFO	"The metapterygoid is a posterior bone that ossifies in the cartilaginous palatoquadrate arch. It first appears as a rod of bone with an anterodorsally projecting process from the middle of the dorsal surface (6.4 mm). The adult metapterygoid is roughly rectangular in shape with rounded corners and an anterodorsally projecting spine that meets the entopterygoid medially in a synostosis at its posteromedial edge. The posterior end curves dorsally to form the posteroventral surface of the orbit." []	EFO	69263	EFO:0003512	\N	metapterygoid	EFO:0003512
0	"Dermal bone that articulates anteriorly with the hyomandibula. The opercle is paired and typically the largest bone of the opercular series." []	\N	opercle	\N	\N	EFO	"Dermal bone that articulates anteriorly with the hyomandibula. The opercle is paired and typically the largest bone of the opercular series." []	EFO	69264	EFO:0003514	\N	opercle	EFO:0003514
0	"Cartilage which is part of the pectoral fin." []	\N	pectoral fin cartilage	\N	\N	EFO	"Cartilage which is part of the pectoral fin." []	EFO	69265	EFO:0003516	\N	pectoral fin cartilage	EFO:0003516
0	"Dermal bone that is part of the opercular flap and bears the preopercular sensory canal. The preopercle is a paired bone and typically L-shaped, with the horizontal limb overlying the interopercle and the vertical limb overlying the opercle." []	\N	preopercle	\N	\N	EFO	"Dermal bone that is part of the opercular flap and bears the preopercular sensory canal. The preopercle is a paired bone and typically L-shaped, with the horizontal limb overlying the interopercle and the vertical limb overlying the opercle." []	EFO	69266	EFO:0003517	\N	preopercle	EFO:0003517
0	"Specialized neuronal receptor cells of the lateral line and acoustico-vestibular systems. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/hair_cell/hair_cell.html'>hair cells</a> by T. Whitfield.)" []	\N	hair cell posterior macula	\N	\N	EFO	"Specialized neuronal receptor cells of the lateral line and acoustico-vestibular systems. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/hair_cell/hair_cell.html'>hair cells</a> by T. Whitfield.)" []	EFO	69267	EFO:0003518	\N	hair cell posterior macula	EFO:0003518
0	"Dermal bone lying below the opercle. The subopercle is a paired bone." []	\N	subopercle	\N	\N	EFO	"Dermal bone lying below the opercle. The subopercle is a paired bone." []	EFO	69268	EFO:0003519	\N	subopercle	EFO:0003519
0	"" []	\N	medial octavolateralis nucleus	\N	\N	EFO	"" []	EFO	69269	EFO:0003520	\N	medial octavolateralis nucleus	EFO:0003520
0	"Diencephalic nucleus which is part of the caudal tuberculum. From Neuroanatomy of the Zebrafish Brain." []	\N	torus lateralis	\N	\N	EFO	"Diencephalic nucleus which is part of the caudal tuberculum. From Neuroanatomy of the Zebrafish Brain." []	EFO	69270	EFO:0003521	\N	torus lateralis	EFO:0003521
0	"Brain structure which is the ventral part of the telencephalon and is consists of periventricular nuclei surrounding the unpaired median ventricle and those which have migrated away from the ependyma. From Neuroanatomy of the Zebrafish Brain." []	\N	ventral telencephalon	\N	\N	EFO	"Brain structure which is the ventral part of the telencephalon and is consists of periventricular nuclei surrounding the unpaired median ventricle and those which have migrated away from the ependyma. From Neuroanatomy of the Zebrafish Brain." []	EFO	69271	EFO:0003522	\N	ventral telencephalon	EFO:0003522
0	"The portion of the YSL that is outside of the blastoderm margin during epiboly." []	\N	E-YSL	\N	\N	EFO	"The portion of the YSL that is outside of the blastoderm margin during epiboly." []	EFO	69272	EFO:0003523	\N	E-YSL	EFO:0003523
0	"" []	\N	cephalic musculature	\N	\N	EFO	"" []	EFO	69273	EFO:0003524	\N	cephalic musculature	EFO:0003524
0	"Paired cartilage bones, flat and hexagonal in shape that contact the orbitosphenoid anteriorly. Roofed by the frontal and bordered posteriorly by the prootic and sphenotic, the pterosphenoid bears foramina that accommodate branches of the trigeminal and facial nerves." []	\N	pterosphenoid	\N	\N	EFO	"Paired cartilage bones, flat and hexagonal in shape that contact the orbitosphenoid anteriorly. Roofed by the frontal and bordered posteriorly by the prootic and sphenotic, the pterosphenoid bears foramina that accommodate branches of the trigeminal and facial nerves." []	EFO	69274	EFO:0003527	\N	pterosphenoid	EFO:0003527
0	"The retroarticular is a cartilage bone that forms at the posteroventral tip of Meckel's cartilage where the interoperculomandibular ligament attaches (5.1 mm NL). In the adult it is basically triangular in shape. The retroarticular is ligamentously connected to the interopercle and preopercle posteriorly and abuts the ventral shelf of the dentary anteriorly." []	\N	retroarticular	\N	\N	EFO	"The retroarticular is a cartilage bone that forms at the posteroventral tip of Meckel's cartilage where the interoperculomandibular ligament attaches (5.1 mm NL). In the adult it is basically triangular in shape. The retroarticular is ligamentously connected to the interopercle and preopercle posteriorly and abuts the ventral shelf of the dentary anteriorly." []	EFO	69275	EFO:0003528	\N	retroarticular	EFO:0003528
0	"Cranial nerve which enters the brain between cranial nerves VI and VII and projects to a dorsal medullary area between cerebellum and vagal lobe. Contains afferents and sensory efferents to the anterior lateral line ganglia. From Neuroanatomy of the Zebrafish Brain." []	\N	anterior lateral line nerve	\N	\N	EFO	"Cranial nerve which enters the brain between cranial nerves VI and VII and projects to a dorsal medullary area between cerebellum and vagal lobe. Contains afferents and sensory efferents to the anterior lateral line ganglia. From Neuroanatomy of the Zebrafish Brain." []	EFO	69276	EFO:0003529	\N	anterior lateral line nerve	EFO:0003529
0	"The anguloarticular is a compound bone that results of the fusion of the dermal angular and the cartilaginous articular and forms the posterior part of the lower jaw. The dermal part ossifies initially on the posterolateral surface of Meckel's cartilage near the articulation with the quadrate (5.5 mm NL). A posterior process forms, creating a synovial joint with the quadrate." []	\N	anguloarticular	\N	\N	EFO	"The anguloarticular is a compound bone that results of the fusion of the dermal angular and the cartilaginous articular and forms the posterior part of the lower jaw. The dermal part ossifies initially on the posterolateral surface of Meckel's cartilage near the articulation with the quadrate (5.5 mm NL). A posterior process forms, creating a synovial joint with the quadrate." []	EFO	69277	EFO:0003530	\N	anguloarticular	EFO:0003530
0	"" []	\N	trunk musculature	\N	\N	EFO	"" []	EFO	69278	EFO:0003531	\N	trunk musculature	EFO:0003531
0	"Diencephalic nucleus which is located anterior to the caudal tuberal nucleus and contains tyrosine hydroxylase immunoreactive CSF contacting bipolar cells." []	\N	paraventricular organ	\N	\N	EFO	"Diencephalic nucleus which is located anterior to the caudal tuberal nucleus and contains tyrosine hydroxylase immunoreactive CSF contacting bipolar cells." []	EFO	69279	EFO:0003532	\N	paraventricular organ	EFO:0003532
0	"Diencephalic nucleus which is located posterior to the paraventricular organ." []	\N	caudal tuberal nucleus	\N	\N	EFO	"Diencephalic nucleus which is located posterior to the paraventricular organ." []	EFO	69280	EFO:0003533	\N	caudal tuberal nucleus	EFO:0003533
0	"Brain structure which is the dorsal part of the telencephalon, most of which is developmentally everted such that the ependymal lining of the unpaired median ventricle becomes located at the apparent periphery of the telencephalon. From Neuroanatomy of the Zebrafish Brain." []	\N	dorsal telencephalon	\N	\N	EFO	"Brain structure which is the dorsal part of the telencephalon, most of which is developmentally everted such that the ependymal lining of the unpaired median ventricle becomes located at the apparent periphery of the telencephalon. From Neuroanatomy of the Zebrafish Brain." []	EFO	69281	EFO:0003534	\N	dorsal telencephalon	EFO:0003534
0	"" []	\N	periventricular grey zone	\N	\N	EFO	"" []	EFO	69282	EFO:0003535	\N	periventricular grey zone	EFO:0003535
0	"Cells (incompletely cleaved before the YSL forms), located at the surface just at the rim of the blastodisc, external to the deep blastomeres." []	\N	marginal blastomere	\N	\N	EFO	"Cells (incompletely cleaved before the YSL forms), located at the surface just at the rim of the blastodisc, external to the deep blastomeres." []	EFO	69283	EFO:0003537	\N	marginal blastomere	EFO:0003537
0	"Paired fin bone that attaches the pectoral girdle to the skull via two projections contacting the epiotic and intercalar bones, and carry the main laterosensory canal." []	\N	posttemporal	\N	\N	EFO	"Paired fin bone that attaches the pectoral girdle to the skull via two projections contacting the epiotic and intercalar bones, and carry the main laterosensory canal." []	EFO	69284	EFO:0003538	\N	posttemporal	EFO:0003538
0	"" []	\N	pectoral fin musculature	\N	\N	EFO	"" []	EFO	69285	EFO:0003540	\N	pectoral fin musculature	EFO:0003540
0	"Portion of tissue that is part of the anterior neural keel and will form the optic vesicle." []	\N	optic primordium	\N	\N	EFO	"Portion of tissue that is part of the anterior neural keel and will form the optic vesicle." []	EFO	69286	EFO:0003541	\N	optic primordium	EFO:0003541
0	"Paired cartilage bone that contacts the pterosphenoid anteriorly, the sphenotic and the pterotic dorsally, and the epiotic and basioccipital posteriorly. The parasphenoid covers the ventral region of each prootic, the upper edge of which contributes to the hyomandibular facet. Bear foramina that accommodate branches of the trigeminal and facial nerves." []	\N	prootic	\N	\N	EFO	"Paired cartilage bone that contacts the pterosphenoid anteriorly, the sphenotic and the pterotic dorsally, and the epiotic and basioccipital posteriorly. The parasphenoid covers the ventral region of each prootic, the upper edge of which contributes to the hyomandibular facet. Bear foramina that accommodate branches of the trigeminal and facial nerves." []	EFO	69287	EFO:0003542	\N	prootic	EFO:0003542
0	"The sensory ganglion of the ear. (See Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/stato/stato.html'>statoacoustic ganglion</a> by T. Whitfield.)" []	\N	statoacoustic (VIII) ganglion	\N	\N	EFO	"The sensory ganglion of the ear. (See Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/stato/stato.html'>statoacoustic ganglion</a> by T. Whitfield.)" []	EFO	69288	EFO:0003543	\N	statoacoustic (VIII) ganglion	EFO:0003543
0	"Multi-tissue structure that is part of the midbrain and develops from the alar plate. The torus semicircularis is located dorsal to the lateral tegmentum where it extends into the medial tectal ventricle and receives ascending sensory octavolateralis input." []	\N	torus semicircularis	\N	\N	EFO	"Multi-tissue structure that is part of the midbrain and develops from the alar plate. The torus semicircularis is located dorsal to the lateral tegmentum where it extends into the medial tectal ventricle and receives ascending sensory octavolateralis input." []	EFO	69289	EFO:0003544	\N	torus semicircularis	EFO:0003544
0	"Brain structure which is caudally attached to the rostral medulla oblongata and extends into the tectal ventricle. The valvula cerebelli consists of a granular and a molecular layer along with aggregations of large Purkinje and eurydendroid cells and is uniquely present in ray-finned fishes. From Neuroanatomy of the Zebrafish Brain." []	\N	valvula cerebelli	\N	\N	EFO	"Brain structure which is caudally attached to the rostral medulla oblongata and extends into the tectal ventricle. The valvula cerebelli consists of a granular and a molecular layer along with aggregations of large Purkinje and eurydendroid cells and is uniquely present in ray-finned fishes. From Neuroanatomy of the Zebrafish Brain." []	EFO	69290	EFO:0003545	\N	valvula cerebelli	EFO:0003545
0	"Connective tissue partitions developing between the myotomes." []	\N	vertical myoseptum	\N	\N	EFO	"Connective tissue partitions developing between the myotomes." []	EFO	69291	EFO:0003546	\N	vertical myoseptum	EFO:0003546
0	"The quadrate is the dorsal bone in the jaw joint with the anguloarticular of the lower jaw. Ossification of the quadrate, a cartilage bone, begins as a posteriorly projecting membranous spine between the symplectic cartilage and the preopercle (5.1 mm NL). The body of the quadrate ossifies first at the ball-and-socket articulation with the anguloarticular (6.5 mm). The adult quadrate is shaped roughly like an inverted triangle with a long, posteriorly projecting spine off its posteroventral edge. The presence of a posteroventral or posterior process of the quadrate is a synapomorphy of Teleostei." []	\N	quadrate	\N	\N	EFO	"The quadrate is the dorsal bone in the jaw joint with the anguloarticular of the lower jaw. Ossification of the quadrate, a cartilage bone, begins as a posteriorly projecting membranous spine between the symplectic cartilage and the preopercle (5.1 mm NL). The body of the quadrate ossifies first at the ball-and-socket articulation with the anguloarticular (6.5 mm). The adult quadrate is shaped roughly like an inverted triangle with a long, posteriorly projecting spine off its posteroventral edge. The presence of a posteroventral or posterior process of the quadrate is a synapomorphy of Teleostei." []	EFO	69292	EFO:0003547	\N	quadrate	EFO:0003547
0	"Endochondral bone that begins ossifying on the anterior surface of the posterior end of the ceratohyal cartilage near the site of articulation with the interhyal (5.8 mm). It joins the ceratohyal in a pad of persisting cartilage." []	\N	epihyal	\N	\N	EFO	"Endochondral bone that begins ossifying on the anterior surface of the posterior end of the ceratohyal cartilage near the site of articulation with the interhyal (5.8 mm). It joins the ceratohyal in a pad of persisting cartilage." []	EFO	69293	EFO:0003548	\N	epihyal	EFO:0003548
0	"Brain structure which is part of the diencephalon and is larger than the dorsal thalamus and ventral thalamus. From Neuroanatomy of the Zebrafish Brain." []	\N	caudal tuberculum	\N	\N	EFO	"Brain structure which is part of the diencephalon and is larger than the dorsal thalamus and ventral thalamus. From Neuroanatomy of the Zebrafish Brain." []	EFO	69294	EFO:0003549	\N	caudal tuberculum	EFO:0003549
0	"" []	\N	descending octaval nucleus	\N	\N	EFO	"" []	EFO	69295	EFO:0003550	\N	descending octaval nucleus	EFO:0003550
0	"The ectopterygoid is dermal bone located at the anterior part of the palatoquadrate.  It is first visible as a very thin ossification along the anteroventral border of the palatoquadrate cartilage (6.4 mm). In adults it is a long sliver of bone that is narrow anteriorly where it meets the entopterygoid in a synostosis. It is slightly wider at its posterior synostosis with the quadrate." []	\N	ectopterygoid	\N	\N	EFO	"The ectopterygoid is dermal bone located at the anterior part of the palatoquadrate.  It is first visible as a very thin ossification along the anteroventral border of the palatoquadrate cartilage (6.4 mm). In adults it is a long sliver of bone that is narrow anteriorly where it meets the entopterygoid in a synostosis. It is slightly wider at its posterior synostosis with the quadrate." []	EFO	69296	EFO:0003552	\N	ectopterygoid	EFO:0003552
0	"The entopterygoid is a dermal bone that forms the anteroventral and ventral surface of the orbit. It develops as a long sliver of bone developing in the membrane dorsomedial to the palatoquadrate cartilage (3.8 mm NL)." []	\N	entopterygoid	\N	\N	EFO	"The entopterygoid is a dermal bone that forms the anteroventral and ventral surface of the orbit. It develops as a long sliver of bone developing in the membrane dorsomedial to the palatoquadrate cartilage (3.8 mm NL)." []	EFO	69297	EFO:0003553	\N	entopterygoid	EFO:0003553
0	"A connective tissue partition developing at the apex of the chevron-shaped myotome and separating dorsal (epaxial) and ventral (hypaxial) body wall muscle masses." []	\N	horizontal myoseptum	\N	\N	EFO	"A connective tissue partition developing at the apex of the chevron-shaped myotome and separating dorsal (epaxial) and ventral (hypaxial) body wall muscle masses." []	EFO	69298	EFO:0003555	\N	horizontal myoseptum	EFO:0003555
0	"The hyomandibula is the large, dorsal-most member of the hyoid arch.  It begins ossifying in the dorsal edge of the hyosymplectic cartilage near the hyomandibular foramen (4.6 mm NL). Ossification spreads through the cartilage, and sheets of membrane bone form off the cartilage model anteriorly and posteriorly (6.6 mm). In the adult, the hyomandibula has cartilage-capped anterior and posterior articulating heads that meet the sphenotic-prootic fossa and the pterotic fossa, respectively, in synovial joints.  A posterior knob of bone develops, also capped in cartilage, and it forms a synovial joint with the opercle." []	\N	hyomandibula	\N	\N	EFO	"The hyomandibula is the large, dorsal-most member of the hyoid arch.  It begins ossifying in the dorsal edge of the hyosymplectic cartilage near the hyomandibular foramen (4.6 mm NL). Ossification spreads through the cartilage, and sheets of membrane bone form off the cartilage model anteriorly and posteriorly (6.6 mm). In the adult, the hyomandibula has cartilage-capped anterior and posterior articulating heads that meet the sphenotic-prootic fossa and the pterotic fossa, respectively, in synovial joints.  A posterior knob of bone develops, also capped in cartilage, and it forms a synovial joint with the opercle." []	EFO	69299	EFO:0003556	\N	hyomandibula	EFO:0003556
0	"Dermal bone that is located anterior to the subopercle and lying below and slightly ventral to the horizontal limb of the preopercle. The interopercle is a paired bone." []	\N	interopercle	\N	\N	EFO	"Dermal bone that is located anterior to the subopercle and lying below and slightly ventral to the horizontal limb of the preopercle. The interopercle is a paired bone." []	EFO	69300	EFO:0003557	\N	interopercle	EFO:0003557
0	"Specialized neuronal receptor cells of the anterior macula. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/hair_cell/hair_cell.html'>hair cells</a> by T. Whitfield.)" []	\N	hair cell anterior macula	\N	\N	EFO	"Specialized neuronal receptor cells of the anterior macula. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/hair_cell/hair_cell.html'>hair cells</a> by T. Whitfield.)" []	EFO	69301	EFO:0003559	\N	hair cell anterior macula	EFO:0003559
0	"The symplectic is an irregularly rod-shaped cartilage replacement bone articulating with the hyomandibular and quadrate." []	\N	symplectic	\N	\N	EFO	"The symplectic is an irregularly rod-shaped cartilage replacement bone articulating with the hyomandibular and quadrate." []	EFO	69302	EFO:0003560	\N	symplectic	EFO:0003560
0	"" []	\N	tangential nucleus	\N	\N	EFO	"" []	EFO	69303	EFO:0003561	\N	tangential nucleus	EFO:0003561
0	"" []	\N	telencephalic ventricle	\N	\N	EFO	"" []	EFO	69304	EFO:0003562	\N	telencephalic ventricle	EFO:0003562
0	"The portion of the YSL that lies deep to the blastoderm during epiboly." []	\N	I-YSL	\N	\N	EFO	"The portion of the YSL that lies deep to the blastoderm during epiboly." []	EFO	69305	EFO:0003563	\N	I-YSL	EFO:0003563
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 14	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69306	EFO:0003564	\N	somite 14	EFO:0003564
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 2	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69307	EFO:0003565	\N	somite 2	EFO:0003565
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 3	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69308	EFO:0003566	\N	somite 3	EFO:0003566
0	"Portion of tissue that is dorsolateral to the floor plate and part of the midbrain." []	\N	basal plate midbrain region	\N	\N	EFO	"Portion of tissue that is dorsolateral to the floor plate and part of the midbrain." []	EFO	69309	EFO:0003567	\N	basal plate midbrain region	EFO:0003567
0	"Floor plate that is part of the rhombomere 2." []	\N	floor plate rhombomere 2	\N	\N	EFO	"Floor plate that is part of the rhombomere 2." []	EFO	69310	EFO:0003568	\N	floor plate rhombomere 2	EFO:0003568
0	"Floor plate that is part of the rhombomere 5." []	\N	floor plate rhombomere 5	\N	\N	EFO	"Floor plate that is part of the rhombomere 5." []	EFO	69311	EFO:0003569	\N	floor plate rhombomere 5	EFO:0003569
0	"Floor plate that is part of the rhombomere 8." []	\N	floor plate rhombomere 8	\N	\N	EFO	"Floor plate that is part of the rhombomere 8." []	EFO	69312	EFO:0003570	\N	floor plate rhombomere 8	EFO:0003570
0	"A CNS interneuron located in the spinal cord." []	\N	spinal cord interneuron	\N	\N	EFO	"A CNS interneuron located in the spinal cord." []	EFO	69313	EFO:0003571	\N	spinal cord interneuron	EFO:0003571
0	"Cranial neural crest that is part of the diencephalon." []	\N	neural crest diencephalon	\N	\N	EFO	"Cranial neural crest that is part of the diencephalon." []	EFO	69314	EFO:0003573	\N	neural crest diencephalon	EFO:0003573
0	"Cranial neural crest that is part of the telencephalon." []	\N	neural crest telencephalon	\N	\N	EFO	"Cranial neural crest that is part of the telencephalon." []	EFO	69315	EFO:0003574	\N	neural crest telencephalon	EFO:0003574
0	"Neuromast that is part of the infraorbital lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	\N	infraorbital lateral line neuromast	\N	\N	EFO	"Neuromast that is part of the infraorbital lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	EFO	69316	EFO:0003575	\N	infraorbital lateral line neuromast	EFO:0003575
0	"Neuromast that is part of the opercular lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	\N	opercular lateral line neuromast	\N	\N	EFO	"Neuromast that is part of the opercular lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	EFO	69317	EFO:0003576	\N	opercular lateral line neuromast	EFO:0003576
0	"" []	\N	nucleus of the medial longitudinal fasciculus medulla oblongata	\N	\N	EFO	"" []	EFO	69318	EFO:0003577	\N	nucleus of the medial longitudinal fasciculus medulla oblongata	EFO:0003577
0	"" []	\N	primary neuron hindbrain	\N	\N	EFO	"" []	EFO	69319	EFO:0003578	\N	primary neuron hindbrain	EFO:0003578
0	"" []	\N	slow muscle cell somite 14	\N	\N	EFO	"" []	EFO	69320	EFO:0003581	\N	slow muscle cell somite 14	EFO:0003581
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 12	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69321	EFO:0003582	\N	somite 12	EFO:0003582
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 4	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69322	EFO:0003583	\N	somite 4	EFO:0003583
0	"Floor plate that is part of the rhombomere 1." []	\N	floor plate rhombomere 1	\N	\N	EFO	"Floor plate that is part of the rhombomere 1." []	EFO	69323	EFO:0003584	\N	floor plate rhombomere 1	EFO:0003584
0	"Floor plate that is part of the neural rod." []	\N	floor plate neural rod	\N	\N	EFO	"Floor plate that is part of the neural rod." []	EFO	69324	EFO:0003585	\N	floor plate neural rod	EFO:0003585
0	"Floor plate that is part of the rhombomere 3." []	\N	floor plate rhombomere 3	\N	\N	EFO	"Floor plate that is part of the rhombomere 3." []	EFO	69325	EFO:0003586	\N	floor plate rhombomere 3	EFO:0003586
0	"Floor plate that is part of the rhombomere 6." []	\N	floor plate rhombomere 6	\N	\N	EFO	"Floor plate that is part of the rhombomere 6." []	EFO	69326	EFO:0003587	\N	floor plate rhombomere 6	EFO:0003587
0	"Floor plate that is part of the rhombomere 4." []	\N	floor plate rhombomere 4	\N	\N	EFO	"Floor plate that is part of the rhombomere 4." []	EFO	69327	EFO:0003588	\N	floor plate rhombomere 4	EFO:0003588
0	"Floor plate that is part of the rhombomere 7." []	\N	floor plate rhombomere 7	\N	\N	EFO	"Floor plate that is part of the rhombomere 7." []	EFO	69328	EFO:0003589	\N	floor plate rhombomere 7	EFO:0003589
0	"Neural crest that is part of the midbrain." []	\N	neural crest midbrain	\N	\N	EFO	"Neural crest that is part of the midbrain." []	EFO	69329	EFO:0003591	\N	neural crest midbrain	EFO:0003591
0	"Neuromast that is part of the posterior lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	\N	posterior lateral line neuromast	\N	\N	EFO	"Neuromast that is part of the posterior lateral line. (Also see Anatomical Atlas entry for <a href='http://zfin.org/zf_info/anatomy/dict/lat_line/lat_line.html'>lateral line</a> by T. Whitfield.)" []	EFO	69330	EFO:0003593	\N	posterior lateral line neuromast	EFO:0003593
0	"" []	\N	slow muscle cell somite 1	\N	\N	EFO	"" []	EFO	69331	EFO:0003598	\N	slow muscle cell somite 1	EFO:0003598
0	"" []	\N	slow muscle cell somite 4	\N	\N	EFO	"" []	EFO	69332	EFO:0003599	\N	slow muscle cell somite 4	EFO:0003599
0	"" []	\N	slow muscle cell somite 7	\N	\N	EFO	"" []	EFO	69333	EFO:0003600	\N	slow muscle cell somite 7	EFO:0003600
0	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	\N	somite 13	\N	\N	EFO	"Undifferentiated mesodermal component of early trunk or tail segment or metamere, derived from paraxial mesoderm; forms the myotome, sclerotome and perhaps dermatome." []	EFO	69334	EFO:0003601	\N	somite 13	EFO:0003601
0	"" []	\N	lateral wall spinal cord	\N	\N	EFO	"" []	EFO	69335	EFO:0003602	\N	lateral wall spinal cord	EFO:0003602
0	"" []	\N	mesenchyme derived from head mesoderm	\N	\N	EFO	"" []	EFO	69336	EFO:0003603	\N	mesenchyme derived from head mesoderm	EFO:0003603
0	"" []	\N	slow muscle cell somite 10	\N	\N	EFO	"" []	EFO	69337	EFO:0003610	\N	slow muscle cell somite 10	EFO:0003610
0	"" []	\N	caudal division of the internal carotid artery	\N	\N	EFO	"" []	EFO	69338	EFO:0003611	\N	caudal division of the internal carotid artery	EFO:0003611
0	"" []	\N	primitive internal carotid artery	\N	\N	EFO	"" []	EFO	69339	EFO:0003612	\N	primitive internal carotid artery	EFO:0003612
0	"Connect the outflow of the aortic arches to the dorsal aorta. The place where the lateral dorsal aorta fuse is called the radix of the aorta." []	\N	lateral dorsal aorta	\N	\N	EFO	"Connect the outflow of the aortic arches to the dorsal aorta. The place where the lateral dorsal aorta fuse is called the radix of the aorta." []	EFO	69340	EFO:0003613	\N	lateral dorsal aorta	EFO:0003613
0	"" []	\N	cranial division of the internal carotid artery	\N	\N	EFO	"" []	EFO	69341	EFO:0003614	\N	cranial division of the internal carotid artery	EFO:0003614
0	"" []	\N	posterior caudal vein	\N	\N	EFO	"" []	EFO	69342	EFO:0003616	\N	posterior caudal vein	EFO:0003616
0	"" []	\N	axial vasculature	\N	\N	EFO	"" []	EFO	69343	EFO:0003620	\N	axial vasculature	EFO:0003620
0	"This anteriormost portion of the intestine has the most digestive enzymes and the greatest epithelial surface area." []	\N	intestinal bulb	\N	\N	EFO	"This anteriormost portion of the intestine has the most digestive enzymes and the greatest epithelial surface area." []	EFO	69344	EFO:0003621	\N	intestinal bulb	EFO:0003621
0	"" []	\N	myoseptum	\N	\N	EFO	"" []	EFO	69345	EFO:0003625	\N	myoseptum	EFO:0003625
0	"" []	\N	pharyngeal endoderm	\N	\N	EFO	"" []	EFO	69346	EFO:0003626	\N	pharyngeal endoderm	EFO:0003626
0	"" []	\N	granulosa cell layer	\N	\N	EFO	"" []	EFO	69347	EFO:0003628	\N	granulosa cell layer	EFO:0003628
0	"" []	\N	thecal cell layer	\N	\N	EFO	"" []	EFO	69348	EFO:0003629	\N	thecal cell layer	EFO:0003629
0	"A protuberance in front of the gential pore and behind the vent. Mature females have a well developed urogenital papillae whilst in mature males it is poorly developed." []	\N	urogenital papilla	\N	\N	EFO	"A protuberance in front of the gential pore and behind the vent. Mature females have a well developed urogenital papillae whilst in mature males it is poorly developed." []	EFO	69349	EFO:0003630	\N	urogenital papilla	EFO:0003630
0	"" []	\N	pharyngeal pouches 2-6	\N	\N	EFO	"" []	EFO	69350	EFO:0003632	\N	pharyngeal pouches 2-6	EFO:0003632
0	"Ceratobranchial 5 tooth which is the posteriormost tooth in the ventral tooth row." []	\N	tooth 5V	\N	\N	EFO	"Ceratobranchial 5 tooth which is the posteriormost tooth in the ventral tooth row." []	EFO	69351	EFO:0003638	\N	tooth 5V	EFO:0003638
0	"Ceratobranchial 5 tooth which is posterior to tooth 3V and anterior to tooth 5V in the ventral tooth row." []	\N	tooth 4V	\N	\N	EFO	"Ceratobranchial 5 tooth which is posterior to tooth 3V and anterior to tooth 5V in the ventral tooth row." []	EFO	69352	EFO:0003639	\N	tooth 4V	EFO:0003639
0	"Ceratobranchial 5 tooth which is posterior to tooth 2V and anterior to tooth 4V in the ventral tooth row." []	\N	tooth 3V	\N	\N	EFO	"Ceratobranchial 5 tooth which is posterior to tooth 2V and anterior to tooth 4V in the ventral tooth row." []	EFO	69353	EFO:0003640	\N	tooth 3V	EFO:0003640
0	"A migrating group of cells originating from the posterior lateral line placode.  The primordium deposits seven to nine neuromasts and interneuromasts between them during its posterior migration to the tail." []	\N	posterior lateral line primordium	\N	\N	EFO	"A migrating group of cells originating from the posterior lateral line placode.  The primordium deposits seven to nine neuromasts and interneuromasts between them during its posterior migration to the tail." []	EFO	69354	EFO:0003641	\N	posterior lateral line primordium	EFO:0003641
0	"" []	\N	anal fin	\N	\N	EFO	"" []	EFO	69355	EFO:0003642	\N	anal fin	EFO:0003642
0	"" []	\N	non neural ectoderm	\N	\N	EFO	"" []	EFO	69356	EFO:0003643	\N	non neural ectoderm	EFO:0003643
0	"Islands of eosinic cells found on the lateroventral surface of the kidney. Function is thought to be that of the parathyroid gland in other vertebrates, which are lacking in fishes. These cells secrete hypocalcin (teleocalcin) to regulate calcium metabolism." []	\N	corpuscles of Stannius	\N	\N	EFO	"Islands of eosinic cells found on the lateroventral surface of the kidney. Function is thought to be that of the parathyroid gland in other vertebrates, which are lacking in fishes. These cells secrete hypocalcin (teleocalcin) to regulate calcium metabolism." []	EFO	69357	EFO:0003646	\N	corpuscles of Stannius	EFO:0003646
0	"Epibranchial cartilage that is bilaterally paired and appears as a separate center of chondrification (6.2 mm) posterior to the lateral tip of epibranchial 4 and immediately anterior to the upper end of ceratobranchial 5. In the adult, epibranchial 5 persists as a small, cartilaginous rod extending from the cartilaginous junction of the posterodorsal tip of the uncinate process of epibranchial 4 and tip of ceratobranchial 5, to the cartilaginous junction of ceratobranchial 4 and epibranchial 4." []	\N	epibranchial 5	\N	\N	EFO	"Epibranchial cartilage that is bilaterally paired and appears as a separate center of chondrification (6.2 mm) posterior to the lateral tip of epibranchial 4 and immediately anterior to the upper end of ceratobranchial 5. In the adult, epibranchial 5 persists as a small, cartilaginous rod extending from the cartilaginous junction of the posterodorsal tip of the uncinate process of epibranchial 4 and tip of ceratobranchial 5, to the cartilaginous junction of ceratobranchial 4 and epibranchial 4." []	EFO	69358	EFO:0003648	\N	epibranchial 5	EFO:0003648
0	"Portion of tissue that is the lateral part of the floor plate." []	\N	lateral floor plate	\N	\N	EFO	"Portion of tissue that is the lateral part of the floor plate." []	EFO	69359	EFO:0003649	\N	lateral floor plate	EFO:0003649
0	"" []	\N	ventricular system	\N	\N	EFO	"" []	EFO	69360	EFO:0003650	\N	ventricular system	EFO:0003650
0	"Stage I follicles (less than 140 microns) are primary growth stage." []	\N	ovarian follicle stage I	\N	\N	EFO	"Stage I follicles (less than 140 microns) are primary growth stage." []	EFO	69361	EFO:0003652	\N	ovarian follicle stage I	EFO:0003652
0	"Stage IV (690-730 microns) are oocyte maturation." []	\N	ovarian follicle stage IV	\N	\N	EFO	"Stage IV (690-730 microns) are oocyte maturation." []	EFO	69362	EFO:0003653	\N	ovarian follicle stage IV	EFO:0003653
0	"Stage II follicles (140-340 microns) are cortical alveolus stage." []	\N	ovarian follicle stage II	\N	\N	EFO	"Stage II follicles (140-340 microns) are cortical alveolus stage." []	EFO	69363	EFO:0003654	\N	ovarian follicle stage II	EFO:0003654
0	"Stage III (340-690 microns) are vitellogenesis." []	\N	ovarian follicle stage III	\N	\N	EFO	"Stage III (340-690 microns) are vitellogenesis." []	EFO	69364	EFO:0003655	\N	ovarian follicle stage III	EFO:0003655
0	"" []	\N	cranial vasculature	\N	\N	EFO	"" []	EFO	69365	EFO:0003656	\N	cranial vasculature	EFO:0003656
0	"" []	\N	regenerating fin	\N	\N	EFO	"" []	EFO	69366	EFO:0003657	\N	regenerating fin	EFO:0003657
0	"The ventral portion of the first pharyngeal arch, comprising the lower jaw." []	\N	ventral mandibular arch	\N	\N	EFO	"The ventral portion of the first pharyngeal arch, comprising the lower jaw." []	EFO	69367	EFO:0003660	\N	ventral mandibular arch	EFO:0003660
0	"Branchiostegal ray that is the most anterior ray which ossifies last (5.5 mm NL)." []	\N	branchiostegal ray 1	\N	\N	EFO	"Branchiostegal ray that is the most anterior ray which ossifies last (5.5 mm NL)." []	EFO	69368	EFO:0003661	\N	branchiostegal ray 1	EFO:0003661
0	"Branchiostegal ray that is the most posterior ray which ossifies first (3.4 mm NL)." []	\N	branchiostegal ray 3	\N	\N	EFO	"Branchiostegal ray that is the most posterior ray which ossifies first (3.4 mm NL)." []	EFO	69369	EFO:0003662	\N	branchiostegal ray 3	EFO:0003662
0	"Branchiostegal ray 2 is between rays 1 and 3 and ossifies second." []	\N	branchiostegal ray 2	\N	\N	EFO	"Branchiostegal ray 2 is between rays 1 and 3 and ossifies second." []	EFO	69370	EFO:0003663	\N	branchiostegal ray 2	EFO:0003663
0	"" []	\N	intersegmental vessel	\N	\N	EFO	"" []	EFO	69371	EFO:0003664	\N	intersegmental vessel	EFO:0003664
0	"" []	\N	caudal vein plexus	\N	\N	EFO	"" []	EFO	69372	EFO:0003665	\N	caudal vein plexus	EFO:0003665
0	"Renal duct that collects filtrate from the renal corpuscle and transports it to the collecting duct.  Different parts of the renal tubule reabsorb specific components of the filtrate to leave only waste." []	\N	renal tubule	\N	\N	EFO	"Renal duct that collects filtrate from the renal corpuscle and transports it to the collecting duct.  Different parts of the renal tubule reabsorb specific components of the filtrate to leave only waste." []	EFO	69373	EFO:0003666	\N	renal tubule	EFO:0003666
0	"The sensory ganglion of the facial nerve." []	\N	facial ganglion	\N	\N	EFO	"The sensory ganglion of the facial nerve." []	EFO	69374	EFO:0003669	\N	facial ganglion	EFO:0003669
0	"" []	\N	vagal ganglion 1	\N	\N	EFO	"" []	EFO	69375	EFO:0003670	\N	vagal ganglion 1	EFO:0003670
0	"" []	\N	vagal ganglion 2	\N	\N	EFO	"" []	EFO	69376	EFO:0003671	\N	vagal ganglion 2	EFO:0003671
0	"" []	\N	vagal ganglion 3	\N	\N	EFO	"" []	EFO	69377	EFO:0003672	\N	vagal ganglion 3	EFO:0003672
0	"" []	\N	vagal ganglion 4	\N	\N	EFO	"" []	EFO	69378	EFO:0003673	\N	vagal ganglion 4	EFO:0003673
0	"" []	\N	ventral anterior lateral line ganglion	\N	\N	EFO	"" []	EFO	69379	EFO:0003675	\N	ventral anterior lateral line ganglion	EFO:0003675
0	"The posterior lateral line ganglion develops from a cranial ectodermal placode and contains sensory neurons that innervate the posterior lateral line system." []	\N	posterior lateral line ganglion	\N	\N	EFO	"The posterior lateral line ganglion develops from a cranial ectodermal placode and contains sensory neurons that innervate the posterior lateral line system." []	EFO	69380	EFO:0003676	\N	posterior lateral line ganglion	EFO:0003676
0	"" []	\N	pineal complex	\N	\N	EFO	"" []	EFO	69381	EFO:0003679	\N	pineal complex	EFO:0003679
0	"" []	\N	axial hypoblast	\N	\N	EFO	"" []	EFO	69382	EFO:0003680	\N	axial hypoblast	EFO:0003680
0	"Apical ectodermal ridge that is part of the pelvic fin bud." []	\N	apical ectodermal ridge pelvic fin bud	\N	\N	EFO	"Apical ectodermal ridge that is part of the pelvic fin bud." []	EFO	69383	EFO:0003681	\N	apical ectodermal ridge pelvic fin bud	EFO:0003681
0	"" []	\N	regeneration epithelium	\N	\N	EFO	"" []	EFO	69384	EFO:0003682	\N	regeneration epithelium	EFO:0003682
0	"The anterior lateral line ganglia develops from cranial ectodermal placodes and contain sensory neurons that innervate the anterior lateral line system." []	\N	anterior lateral line ganglion	\N	\N	EFO	"The anterior lateral line ganglia develops from cranial ectodermal placodes and contain sensory neurons that innervate the anterior lateral line system." []	EFO	69385	EFO:0003683	\N	anterior lateral line ganglion	EFO:0003683
0	"" []	\N	ventral hyoid arch	\N	\N	EFO	"" []	EFO	69386	EFO:0003684	\N	ventral hyoid arch	EFO:0003684
0	"Bilaterally paired large cartilage that articulates with the chondrocranium dorsally, the opercle posteriorly, and the palatoquadrate cartilage anteriorly." []	\N	hyosymplectic cartilage	\N	\N	EFO	"Bilaterally paired large cartilage that articulates with the chondrocranium dorsally, the opercle posteriorly, and the palatoquadrate cartilage anteriorly." []	EFO	69387	EFO:0003686	\N	hyosymplectic cartilage	EFO:0003686
0	"" []	\N	primitive olfactory epithelium	\N	\N	EFO	"" []	EFO	69388	EFO:0003687	\N	primitive olfactory epithelium	EFO:0003687
0	"Floor plate that is part of the neural tube." []	\N	floor plate neural tube	\N	\N	EFO	"Floor plate that is part of the neural tube." []	EFO	69389	EFO:0003688	\N	floor plate neural tube	EFO:0003688
0	"" []	\N	chondrocranium cartilage	\N	\N	EFO	"" []	EFO	69390	EFO:0003690	\N	chondrocranium cartilage	EFO:0003690
0	"The anterior lateral line system develops from cranial ectodermal placodes, situated between the eye and the ear, that give rise to both the neuromasts and the anterior lateral line sensory nerves that innervate the neuromasts. The anterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians and are innervated by several lateral line nerves, which project to the hindbrain. The anterior lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance." []	\N	anterior lateral line system	\N	\N	EFO	"The anterior lateral line system develops from cranial ectodermal placodes, situated between the eye and the ear, that give rise to both the neuromasts and the anterior lateral line sensory nerves that innervate the neuromasts. The anterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians and are innervated by several lateral line nerves, which project to the hindbrain. The anterior lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance." []	EFO	69391	EFO:0003691	\N	anterior lateral line system	EFO:0003691
0	"The posterior lateral line system develops from cranial ectodermal placodes, situated behind the ear, that give rise to both the neuromasts and the posterior lateral line sensory nerves that innervate the neuromasts. The posterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians. The neuromasts are innervated by several lateral line nerves, which project primarily to the hindbrain. The posterior mechanosensory lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance." []	\N	posterior lateral line system	\N	\N	EFO	"The posterior lateral line system develops from cranial ectodermal placodes, situated behind the ear, that give rise to both the neuromasts and the posterior lateral line sensory nerves that innervate the neuromasts. The posterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians. The neuromasts are innervated by several lateral line nerves, which project primarily to the hindbrain. The posterior mechanosensory lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance." []	EFO	69392	EFO:0003692	\N	posterior lateral line system	EFO:0003692
0	"Cells (completely cleaved), located at the surface of the blastodisc, above the deep blastomeres." []	\N	superficial blastomere	\N	\N	EFO	"Cells (completely cleaved), located at the surface of the blastodisc, above the deep blastomeres." []	EFO	69393	EFO:0003693	\N	superficial blastomere	EFO:0003693
0	"" []	\N	pharyngeal arch 3-7	\N	\N	EFO	"" []	EFO	69394	EFO:0003694	\N	pharyngeal arch 3-7	EFO:0003694
0	"The mesencephalic veins (MsV) enter the mid cerebral veins (MCeV) at the dorsal midline. THe MCeVs originate at the dorsal midline, proceed laterally in a ventral direction to drain into the paired primordial midbrain channels (PHBC)." []	\N	mid cerebral vein	\N	\N	EFO	"The mesencephalic veins (MsV) enter the mid cerebral veins (MCeV) at the dorsal midline. THe MCeVs originate at the dorsal midline, proceed laterally in a ventral direction to drain into the paired primordial midbrain channels (PHBC)." []	EFO	69395	EFO:0003696	\N	mid cerebral vein	EFO:0003696
0	"The vessel between the anterior cerebral vein and the mid cerebral vein." []	\N	primordial midbrain channel	\N	\N	EFO	"The vessel between the anterior cerebral vein and the mid cerebral vein." []	EFO	69396	EFO:0003697	\N	primordial midbrain channel	EFO:0003697
0	"Trunk vessel that runs medially along the dorsal-most portion of the trunk and post-vent region. The DLAVs are formed by the longitudinal anastamoses of the intersegmental vessels to form a right and left pair of dorsal longitudinal anastamotic vessels. These paired vessels remodel to form a single plexiform vessel beginning at 3dpf continuing until after 7dpf.  The basilar artery connects to the DLAVs at the caudal end of the medulla oblongata.  In the early embryo (2.5-3.5 dpf) the primitive hindbrain channels also connect to the DLAV." []	\N	dorsal longitudinal anastomotic vessel	\N	\N	EFO	"Trunk vessel that runs medially along the dorsal-most portion of the trunk and post-vent region. The DLAVs are formed by the longitudinal anastamoses of the intersegmental vessels to form a right and left pair of dorsal longitudinal anastamotic vessels. These paired vessels remodel to form a single plexiform vessel beginning at 3dpf continuing until after 7dpf.  The basilar artery connects to the DLAVs at the caudal end of the medulla oblongata.  In the early embryo (2.5-3.5 dpf) the primitive hindbrain channels also connect to the DLAV." []	EFO	69397	EFO:0003698	\N	dorsal longitudinal anastomotic vessel	EFO:0003698
0	"Region where blood progenitor markers are expressed.   Probable site of definitive hematopoiesis between 36hpf and 4dpf." []	\N	ventral wall of dorsal aorta	\N	\N	EFO	"Region where blood progenitor markers are expressed.   Probable site of definitive hematopoiesis between 36hpf and 4dpf." []	EFO	69398	EFO:0003699	\N	ventral wall of dorsal aorta	EFO:0003699
0	"Hematopoietic tissue derived from the cephalic mesoderm.  Predominantly produces myeloid cells." []	\N	rostral blood island	\N	\N	EFO	"Hematopoietic tissue derived from the cephalic mesoderm.  Predominantly produces myeloid cells." []	EFO	69399	EFO:0003700	\N	rostral blood island	EFO:0003700
0	"Vessels run longitudinally along the horizontal myoseptum.  These vessels are not functional until after lumenization which occurs near 4 dpf." []	\N	parachordal vessel	\N	\N	EFO	"Vessels run longitudinally along the horizontal myoseptum.  These vessels are not functional until after lumenization which occurs near 4 dpf." []	EFO	69400	EFO:0003701	\N	parachordal vessel	EFO:0003701
0	"" []	\N	anterior lateral mesoderm	\N	\N	EFO	"" []	EFO	69401	EFO:0003702	\N	anterior lateral mesoderm	EFO:0003702
0	"" []	\N	posterior lateral mesoderm	\N	\N	EFO	"" []	EFO	69402	EFO:0003703	\N	posterior lateral mesoderm	EFO:0003703
0	"The layer of the myocardium composed of projections of contractile myocytes.   The trabecular layer is bounded internally by the endocardium.  Unlike the trabeculations of higher vertebrates, both atrial and ventricular trabeculae of the zebrafish have more strut-like character, and are more uniform without apparent regional differences." []	\N	trabecular layer	\N	\N	EFO	"The layer of the myocardium composed of projections of contractile myocytes.   The trabecular layer is bounded internally by the endocardium.  Unlike the trabeculations of higher vertebrates, both atrial and ventricular trabeculae of the zebrafish have more strut-like character, and are more uniform without apparent regional differences." []	EFO	69403	EFO:0003706	\N	trabecular layer	EFO:0003706
0	"A ring of conduction tissue that forms in the atrioventricular canal." []	\N	atrioventricular ring	\N	\N	EFO	"A ring of conduction tissue that forms in the atrioventricular canal." []	EFO	69404	EFO:0003707	\N	atrioventricular ring	EFO:0003707
0	"Is a portion of tissue that will develop into vasculature." []	\N	primordial vasculature	\N	\N	EFO	"Is a portion of tissue that will develop into vasculature." []	EFO	69405	EFO:0003708	\N	primordial vasculature	EFO:0003708
0	"A migrating group of cells originating from an anterior lateral line placode.  The primordium deposits neuromasts and interneuromasts between them during its migration." []	\N	anterior lateral line primordium	\N	\N	EFO	"A migrating group of cells originating from an anterior lateral line placode.  The primordium deposits neuromasts and interneuromasts between them during its migration." []	EFO	69406	EFO:0003710	\N	anterior lateral line primordium	EFO:0003710
0	"" []	\N	Rohon-Beard neuron	\N	\N	EFO	"" []	EFO	69407	EFO:0003711	\N	Rohon-Beard neuron	EFO:0003711
0	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, from the presumed non-coding transcibed regions of the genome, to analyse these and/or to quantitate transcript abundance" []	\N	RNA-seq of non coding RNA	\N	\N	EFO	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, from the presumed non-coding transcibed regions of the genome, to analyse these and/or to quantitate transcript abundance" []	EFO	69408	EFO:0003737	\N	RNA-seq of non coding RNA	EFO:0003737
0	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, from the presumed coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance" []	\N	RNA-seq of coding RNA	\N	\N	EFO	"An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, from the presumed coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance" []	EFO	69409	EFO:0003738	\N	RNA-seq of coding RNA	EFO:0003738
0	"" []	\N	sequencer	\N	\N	EFO	"" []	EFO	69410	EFO:0003739	\N	sequencer	EFO:0003739
0	"" []	\N	sequencing assay	\N	\N	EFO	"" []	EFO	69411	EFO:0003740	\N	sequencing assay	EFO:0003740
0	"An assay in which DNA is the input molecule derived from pooled clones (for example BACs and Fosmids) is sequenced using high throughput technology using shotgun methodology." []	\N	pooled clone sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from pooled clones (for example BACs and Fosmids) is sequenced using high throughput technology using shotgun methodology." []	EFO	69412	EFO:0003741	\N	pooled clone sequencing	EFO:0003741
0	"An assay in which DNA is the input molecule derived from clones which are mapped then sequenced in small fragments." []	\N	clone by clone sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from clones which are mapped then sequenced in small fragments." []	EFO	69413	EFO:0003742	\N	clone by clone sequencing	EFO:0003742
0	"An assay in which DNA is the input molecule derived from a clone and 5',3' or both ends of a clone are sequenced" []	\N	clone end sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from a clone and 5',3' or both ends of a clone are sequenced" []	EFO	69414	EFO:0003743	\N	clone end sequencing	EFO:0003743
0	"An assay in which DNA is the input molecule derived from fragmented whole genome preparation is sequenced" []	\N	whole genome shotgun sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from fragmented whole genome preparation is sequenced" []	EFO	69415	EFO:0003744	\N	whole genome shotgun sequencing	EFO:0003744
0	"An assay in which DNA is the input molecule derived from chromosome or other replicon is sequenced. The random part refers to the fact the sequence can not be reliably ordered within the known chromosome." []	\N	random chromosome sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from chromosome or other replicon is sequenced. The random part refers to the fact the sequence can not be reliably ordered within the known chromosome." []	EFO	69416	EFO:0003745	\N	random chromosome sequencing	EFO:0003745
0	"An assay in which DNA is the input molecule derived from exons is sequenced." []	\N	random exon sequencing	\N	\N	EFO	"An assay in which DNA is the input molecule derived from exons is sequenced." []	EFO	69417	EFO:0003746	\N	random exon sequencing	EFO:0003746
0	"An assay in which a DNA or RNA input molecule amplified by PCR is sequenced." []	\N	amplicon sequencing	\N	\N	EFO	"An assay in which a DNA or RNA input molecule amplified by PCR is sequenced." []	EFO	69418	EFO:0003747	\N	amplicon sequencing	EFO:0003747
0	"An assay in which DNA us the input molecule derived from cleavage of DNA by use of methylation sensitive restriction enzymes to fragment DNA at methylation sites before sequencing" []	\N	MRE-seq	\N	\N	EFO	"An assay in which DNA us the input molecule derived from cleavage of DNA by use of methylation sensitive restriction enzymes to fragment DNA at methylation sites before sequencing" []	EFO	69419	EFO:0003748	\N	MRE-seq	EFO:0003748
0	"An assay in which DNA is the input molecule derived from an antibody based selection process using antibodies targeting methylated DNA, which is then sequenced using high throughput sequencing technology." []	\N	MeDIP-seq	\N	\N	EFO	"An assay in which DNA is the input molecule derived from an antibody based selection process using antibodies targeting methylated DNA, which is then sequenced using high throughput sequencing technology." []	EFO	69420	EFO:0003749	\N	MeDIP-seq	EFO:0003749
0	"An assay in which DNA is the input molecule derived from a selection process using methyl binding domain protein to enrich for methylated fractions of DNA, then sequenced using high throughput sequencing." []	\N	MBD-seq	\N	\N	EFO	"An assay in which DNA is the input molecule derived from a selection process using methyl binding domain protein to enrich for methylated fractions of DNA, then sequenced using high throughput sequencing." []	EFO	69421	EFO:0003750	\N	MBD-seq	EFO:0003750
0	"An assay in which DNA is the input molecule derived from a micrococcal nuclease digestion followed by high throughput sequencing, A method that distinguishes nucleosome positioning based on the ability of nucleosomes to protect associated DNA from digestion by micrococcal nuclease. Sequenced fragments reveal nucleosome location information about the input DNA." []	\N	MNase-seq	\N	\N	EFO	"An assay in which DNA is the input molecule derived from a micrococcal nuclease digestion followed by high throughput sequencing, A method that distinguishes nucleosome positioning based on the ability of nucleosomes to protect associated DNA from digestion by micrococcal nuclease. Sequenced fragments reveal nucleosome location information about the input DNA." []	EFO	69422	EFO:0003751	\N	MNase-seq	EFO:0003751
0	"An assay in which DNA is the input molecule derived from a DNase-hypersensitivity digest of chromatin with the aim of identifying regulatory elements." []	\N	DNase-Hypersensitivity seq	\N	\N	EFO	"An assay in which DNA is the input molecule derived from a DNase-hypersensitivity digest of chromatin with the aim of identifying regulatory elements." []	EFO	69423	EFO:0003752	\N	DNase-Hypersensitivity seq	EFO:0003752
0	"An assay in which DNA is the input molecule derived from a bisulphite treatment of DNA to convert cytosine residues to uracil to determine methylation status." []	\N	Bisulfite-seq	\N	\N	EFO	"An assay in which DNA is the input molecule derived from a bisulphite treatment of DNA to convert cytosine residues to uracil to determine methylation status." []	EFO	69424	EFO:0003753	\N	Bisulfite-seq	EFO:0003753
0	"An assay in which RNA derived from an EST is sequenced" []	\N	EST sequencing	\N	\N	EFO	"An assay in which RNA derived from an EST is sequenced" []	EFO	69425	EFO:0003754	\N	EST sequencing	EFO:0003754
0	"An assay in which RNA derived from a full length cDNA template is sequenced" []	\N	FL-cDNA	\N	\N	EFO	"An assay in which RNA derived from a full length cDNA template is sequenced" []	EFO	69426	EFO:0003755	\N	FL-cDNA	EFO:0003755
0	"Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (DSM, 1994)" []	\N	autism spectrum disorder	\N	\N	EFO	"Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (DSM, 1994)" []	EFO	69427	EFO:0003756	\N	autism spectrum disorder	EFO:0003756
0	"An autism spectrum disorder that is characterized by significant difficulties in social interaction, along with restricted and repetitive patterns of behavior and interests. It differs from other autism spectrum disorders by its relative preservation of linguistic and cognitive development." []	\N	Asperger syndrome	\N	\N	EFO	"An autism spectrum disorder that is characterized by significant difficulties in social interaction, along with restricted and repetitive patterns of behavior and interests. It differs from other autism spectrum disorders by its relative preservation of linguistic and cognitive development." []	EFO	69428	EFO:0003757	\N	Asperger syndrome	EFO:0003757
0	"An autism spectrum disease that is a disorder of neural development characterized by impaired social interaction and communication, and by restricted and repetitive behavior observed in children before a child is three years old." []	\N	autism	\N	\N	EFO	"An autism spectrum disease that is a disorder of neural development characterized by impaired social interaction and communication, and by restricted and repetitive behavior observed in children before a child is three years old." []	EFO	69429	EFO:0003758	\N	autism	EFO:0003758
0	"An autism spectrum disorder that involves some autistic symptoms occuring after age 3 with an abscence of all the traits necessary for a diagnosis of autism." []	\N	pervasive developmental disorder - not otherwise specified	\N	\N	EFO	"An autism spectrum disorder that involves some autistic symptoms occuring after age 3 with an abscence of all the traits necessary for a diagnosis of autism." []	EFO	69430	EFO:0003759	\N	pervasive developmental disorder - not otherwise specified	EFO:0003759
0	"Congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement." []	\N	central nervous system cyst	\N	\N	EFO	"Congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement." []	EFO	69431	EFO:0003760	\N	central nervous system cyst	EFO:0003760
0	"Severe mental disorder with onset in MIDDLE AGE, marked by withdrawl, abnormal affect, disturbed intellectual processes, and there may be regression." []	\N	unipolar depression	\N	\N	EFO	"Severe mental disorder with onset in MIDDLE AGE, marked by withdrawl, abnormal affect, disturbed intellectual processes, and there may be regression." []	EFO	69432	EFO:0003761	\N	unipolar depression	EFO:0003761
0	"A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)" []	\N	vitamin D deficiency	\N	\N	EFO	"A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)" []	EFO	69433	EFO:0003762	\N	vitamin D deficiency	EFO:0003762
0	"A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES; or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others." []	\N	cerebrovascular disorder	\N	\N	EFO	"A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES; or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others." []	EFO	69434	EFO:0003763	\N	cerebrovascular disorder	EFO:0003763
0	"Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)" []	\N	transient ischemic attack	\N	\N	EFO	"Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)" []	EFO	69435	EFO:0003764	\N	transient ischemic attack	EFO:0003764
0	"Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)." []	\N	sign or symptom	\N	\N	EFO	"Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)." []	EFO	69436	EFO:0003765	\N	sign or symptom	EFO:0003765
0	"Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases." []	\N	pain in abdomen	\N	\N	EFO	"Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases." []	EFO	69437	EFO:0003766	\N	pain in abdomen	EFO:0003766
0	"" []	\N	inflammatory bowel disease	\N	\N	EFO	"" []	EFO	69438	EFO:0003767	\N	inflammatory bowel disease	EFO:0003767
0	"Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included." []	\N	nicotine dependence	\N	\N	EFO	"Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included." []	EFO	69439	EFO:0003768	\N	nicotine dependence	EFO:0003768
0	"Tumors or cancer of the ENDOCRINE GLANDS." []	\N	endocrine neoplasm	\N	\N	EFO	"Tumors or cancer of the ENDOCRINE GLANDS." []	EFO	69440	EFO:0003769	\N	endocrine neoplasm	EFO:0003769
0	"Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION." []	\N	diabetic retinopathy	\N	\N	EFO	"Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION." []	EFO	69441	EFO:0003770	\N	diabetic retinopathy	EFO:0003770
0	"An endocrine system component is a defined classt to caputre the partonomy of the endocrine system." []	\N	endocrine system component	\N	\N	EFO	"An endocrine system component is a defined classt to caputre the partonomy of the endocrine system." []	EFO	69442	EFO:0003773	\N	endocrine system component	EFO:0003773
0	"Conditions with excess LIPIDS in the blood." []	\N	hyperlipidemia	\N	\N	EFO	"Conditions with excess LIPIDS in the blood." []	EFO	69443	EFO:0003774	\N	hyperlipidemia	EFO:0003774
0	"Primary immunodeficiency syndrome characterized by recurrent infections and hyperimmunoglobulinemia E. Most cases are sporadic. Of the rare familial forms, the dominantly inherited subtype has additional connective tissue, dental and skeletal involvement that the recessive type does not share." []	\N	Job's syndrome	\N	\N	EFO	"Primary immunodeficiency syndrome characterized by recurrent infections and hyperimmunoglobulinemia E. Most cases are sporadic. Of the rare familial forms, the dominantly inherited subtype has additional connective tissue, dental and skeletal involvement that the recessive type does not share." []	EFO	69444	EFO:0003775	\N	Job's syndrome	EFO:0003775
0	"Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion." []	\N	coronary artery bypass	\N	\N	EFO	"Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion." []	EFO	69445	EFO:0003776	\N	coronary artery bypass	EFO:0003776
0	"Pathological conditions involving the HEART including its structural and functional abnormalities." []	\N	heart disease	\N	\N	EFO	"Pathological conditions involving the HEART including its structural and functional abnormalities." []	EFO	69446	EFO:0003777	\N	heart disease	EFO:0003777
0	"A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor." []	\N	psoriatic arthritis	\N	\N	EFO	"A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor." []	EFO	69447	EFO:0003778	\N	psoriatic arthritis	EFO:0003778
0	"Inflammatory disease of the THYROID GLAND due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-CELLS and thyroid AUTOANTIBODIES. The clinical signs can range from HYPOTHYROIDISM to THYROTOXICOSIS depending on the type of autoimmune thyroiditis." []	\N	autoimmune thyroid disease	\N	\N	EFO	"Inflammatory disease of the THYROID GLAND due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-CELLS and thyroid AUTOANTIBODIES. The clinical signs can range from HYPOTHYROIDISM to THYROTOXICOSIS depending on the type of autoimmune thyroiditis." []	EFO	69448	EFO:0003779	\N	autoimmune thyroid disease	EFO:0003779
0	"Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well." []	\N	Behcet's syndrome	\N	\N	EFO	"Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well." []	EFO	69449	EFO:0003780	\N	Behcet's syndrome	EFO:0003780
0	"Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology." []	\N	carotid artery disease	\N	\N	EFO	"Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology." []	EFO	69450	EFO:0003781	\N	carotid artery disease	EFO:0003781
0	"Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)" []	\N	motor neuron disease	\N	\N	EFO	"Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)" []	EFO	69451	EFO:0003782	\N	motor neuron disease	EFO:0003782
0	"A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900)" []	\N	progressive bulbar palsy	\N	\N	EFO	"A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900)" []	EFO	69452	EFO:0003783	\N	progressive bulbar palsy	EFO:0003783
0	"Coloration of the skin." []	\N	skin pigmentation	\N	\N	EFO	"Coloration of the skin." []	EFO	69453	EFO:0003784	\N	skin pigmentation	EFO:0003784
0	"An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods." []	\N	allergy	\N	\N	EFO	"An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods." []	EFO	69454	EFO:0003785	\N	allergy	EFO:0003785
0	"" []	\N	cytokine	\N	\N	EFO	"" []	EFO	69455	EFO:0003786	\N	cytokine	EFO:0003786
0	"" []	\N	cytokine role	\N	\N	EFO	"" []	EFO	69456	EFO:0003787	\N	cytokine role	EFO:0003787
0	"A gene expression protocol is a  protocol which is designed to be used in a gene expression experiment performed on arrays or by high throughput sequencing." []	\N	gene expression protocol	\N	\N	EFO	"A gene expression protocol is a  protocol which is designed to be used in a gene expression experiment performed on arrays or by high throughput sequencing." []	EFO	69457	EFO:0003788	\N	gene expression protocol	EFO:0003788
0	"A growth protocol is a protocol which provides instructions on the growth of a biological sample. E.g. the growth of a specific cell line or Drosophila culture" []	\N	growth protocol	\N	\N	EFO	"A growth protocol is a protocol which provides instructions on the growth of a biological sample. E.g. the growth of a specific cell line or Drosophila culture" []	EFO	69458	EFO:0003789	\N	growth protocol	EFO:0003789
0	"A hybridization protocol is the set of instructions or plan for performing a nucleic acid hybridization on an microarray such as those provided by Affymetrix" []	\N	hybridization protocol	\N	\N	EFO	"A hybridization protocol is the set of instructions or plan for performing a nucleic acid hybridization on an microarray such as those provided by Affymetrix" []	EFO	69459	EFO:0003790	\N	hybridization protocol	EFO:0003790
0	"" []	\N	interleukin (Homo sapiens)	\N	\N	EFO	"" []	EFO	69460	EFO:0003791	\N	interleukin (Homo sapiens)	EFO:0003791
0	"" []	\N	interleukin (Mus musculus)	\N	\N	EFO	"" []	EFO	69461	EFO:0003792	\N	interleukin (Mus musculus)	EFO:0003792
0	"" []	\N	interleukin (Rattus norvegicus)	\N	\N	EFO	"" []	EFO	69462	EFO:0003793	\N	interleukin (Rattus norvegicus)	EFO:0003793
0	"" []	\N	interleukin-1 beta (Homo sapiens)	\N	\N	EFO	"" []	EFO	69463	EFO:0003794	\N	interleukin-1 beta (Homo sapiens)	EFO:0003794
0	"" []	\N	interleukin-1 beta (Mus musculus)	\N	\N	EFO	"" []	EFO	69464	EFO:0003795	\N	interleukin-1 beta (Mus musculus)	EFO:0003795
0	"" []	\N	interleukin-1 beta (Rattus norvegicus)	\N	\N	EFO	"" []	EFO	69465	EFO:0003796	\N	interleukin-1 beta (Rattus norvegicus)	EFO:0003796
0	"" []	\N	interleukin-13 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69466	EFO:0003797	\N	interleukin-13 (Homo sapiens)	EFO:0003797
0	"" []	\N	interleukin-13 (Mus musculus)	\N	\N	EFO	"" []	EFO	69467	EFO:0003798	\N	interleukin-13 (Mus musculus)	EFO:0003798
0	"" []	\N	interleukin-14 (Mus musculus)	\N	\N	EFO	"" []	EFO	69468	EFO:0003799	\N	interleukin-14 (Mus musculus)	EFO:0003799
0	"" []	\N	interleukin-17 (Mus musculus)	\N	\N	EFO	"" []	EFO	69469	EFO:0003800	\N	interleukin-17 (Mus musculus)	EFO:0003800
0	"" []	\N	interleukin-19 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69470	EFO:0003801	\N	interleukin-19 (Homo sapiens)	EFO:0003801
0	"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)" []	\N	refractory anemia	\N	\N	EFO	"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)" []	EFO	69471	EFO:0003802	\N	refractory anemia	EFO:0003802
0	"" []	\N	interleukin-20 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69472	EFO:0003803	\N	interleukin-20 (Homo sapiens)	EFO:0003803
0	"" []	\N	interleukin-21 (Mus musculus)	\N	\N	EFO	"" []	EFO	69473	EFO:0003804	\N	interleukin-21 (Mus musculus)	EFO:0003804
0	"" []	\N	interleukin-24 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69474	EFO:0003805	\N	interleukin-24 (Homo sapiens)	EFO:0003805
0	"" []	\N	interleukin-26 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69475	EFO:0003806	\N	interleukin-26 (Homo sapiens)	EFO:0003806
0	"" []	\N	interleukin-33 (Rattus norvegicus)	\N	\N	EFO	"" []	EFO	69476	EFO:0003807	\N	interleukin-33 (Rattus norvegicus)	EFO:0003807
0	"A labelling protocol is a set of instructions or plan which is realised" []	\N	labelling protocol	\N	\N	EFO	"A labelling protocol is a set of instructions or plan which is realised" []	EFO	69477	EFO:0003808	\N	labelling protocol	EFO:0003808
0	"A sample treatment protocol is a protocol used in a biological experiment and defines instructions on how a sample should be treated in a given experimental scenario." []	\N	sample treatment protocol	\N	\N	EFO	"A sample treatment protocol is a protocol used in a biological experiment and defines instructions on how a sample should be treated in a given experimental scenario." []	EFO	69478	EFO:0003809	\N	sample treatment protocol	EFO:0003809
0	"" []	\N	interleukin-22 (Homo sapiens)	\N	\N	EFO	"" []	EFO	69479	EFO:0003810	\N	interleukin-22 (Homo sapiens)	EFO:0003810
0	"Refractory anemia with excess blasts I and II." []	\N	refractory anemia with excess blasts	\N	\N	EFO	"Refractory anemia with excess blasts I and II." []	EFO	69480	EFO:0003811	\N	refractory anemia with excess blasts	EFO:0003811
0	"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001)" []	\N	refractory anemia with ringed sideroblasts	\N	\N	EFO	"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001)" []	EFO	69481	EFO:0003812	\N	refractory anemia with ringed sideroblasts	EFO:0003812
0	"A protocol description in which input nucleic acid material is labeled." []	\N	nucleic acid labeling protocol	\N	\N	EFO	"A protocol description in which input nucleic acid material is labeled." []	EFO	69482	EFO:0003813	\N	nucleic acid labeling protocol	EFO:0003813
0	"A protocol describing an image acquisition process that generates an image and features extracted in numerical form from an array." []	\N	array scanning and feature extraction protocol	\N	\N	EFO	"A protocol describing an image acquisition process that generates an image and features extracted in numerical form from an array." []	EFO	69483	EFO:0003814	\N	array scanning and feature extraction protocol	EFO:0003814
0	"A protocol describing the hybridisation of the target nucleic acid sample to a fixed probe on the array." []	\N	nucleic acid hybridization to array protocol	\N	\N	EFO	"A protocol describing the hybridisation of the target nucleic acid sample to a fixed probe on the array." []	EFO	69484	EFO:0003815	\N	nucleic acid hybridization to array protocol	EFO:0003815
0	"A protocol describing a data transformation in which data transformation has the objective normalization." []	\N	normalization data transformation protocol	\N	\N	EFO	"A protocol describing a data transformation in which data transformation has the objective normalization." []	EFO	69485	EFO:0003816	\N	normalization data transformation protocol	EFO:0003816
0	"Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS." []	\N	laryngeal neoplasm	\N	\N	EFO	"Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS." []	EFO	69486	EFO:0003817	\N	laryngeal neoplasm	EFO:0003817
0	"Pathological processes involving any part of the LUNG." []	\N	lung disease	\N	\N	EFO	"Pathological processes involving any part of the LUNG." []	EFO	69487	EFO:0003818	\N	lung disease	EFO:0003818
0	"Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp. The three most prominent theories used to explain the etiology of the disease are that acids produced by bacteria lead to decalcification; that micro-organisms destroy the enamel protein; or that keratolytic micro-organisms produce chelates that lead to decalcification." []	\N	dental caries	\N	\N	EFO	"Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp. The three most prominent theories used to explain the etiology of the disease are that acids produced by bacteria lead to decalcification; that micro-organisms destroy the enamel protein; or that keratolytic micro-organisms produce chelates that lead to decalcification." []	EFO	69488	EFO:0003819	\N	dental caries	EFO:0003819
0	"Tumors or cancer located in bone tissue or specific BONES." []	\N	bone neoplasm	\N	\N	EFO	"Tumors or cancer located in bone tissue or specific BONES." []	EFO	69489	EFO:0003820	\N	bone neoplasm	EFO:0003820
0	"A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)" []	\N	migraine disorder	\N	\N	EFO	"A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)" []	EFO	69490	EFO:0003821	\N	migraine disorder	EFO:0003821
0	"The presence of an increased amount of blood in a part or organ; engorgement." []	\N	hyperemia	\N	\N	EFO	"The presence of an increased amount of blood in a part or organ; engorgement." []	EFO	69491	EFO:0003822	\N	hyperemia	EFO:0003822
0	"Tumors or cancer of the EYE." []	\N	eye neoplasm	\N	\N	EFO	"Tumors or cancer of the EYE." []	EFO	69492	EFO:0003824	\N	eye neoplasm	EFO:0003824
0	"A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)" []	\N	serous adenocarsinoma	\N	\N	EFO	"A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)" []	EFO	69493	EFO:0003825	\N	serous adenocarsinoma	EFO:0003825
0	"Tumors or cancer of the SALIVARY GLANDS." []	\N	salivary gland neoplasm	\N	\N	EFO	"Tumors or cancer of the SALIVARY GLANDS." []	EFO	69494	EFO:0003826	\N	salivary gland neoplasm	EFO:0003826
0	"Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS." []	\N	pulmonary embolism	\N	\N	EFO	"Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS." []	EFO	69495	EFO:0003827	\N	pulmonary embolism	EFO:0003827
0	"Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA." []	\N	spinal cord neoplasm	\N	\N	EFO	"Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA." []	EFO	69496	EFO:0003828	\N	spinal cord neoplasm	EFO:0003828
0	"Disorders related to or resulting from abuse or mis-use of alcohol." []	\N	alcohol dependence	\N	\N	EFO	"Disorders related to or resulting from abuse or mis-use of alcohol." []	EFO	69497	EFO:0003829	\N	alcohol dependence	EFO:0003829
0	"Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment." []	\N	prostatitis	\N	\N	EFO	"Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment." []	EFO	69498	EFO:0003830	\N	prostatitis	EFO:0003830
0	"Diseases of the GALLBLADDER. They generally involve the impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, neoplasms, or other diseases." []	\N	gall bladder disease	\N	\N	EFO	"Diseases of the GALLBLADDER. They generally involve the impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, neoplasms, or other diseases." []	EFO	69499	EFO:0003832	\N	gall bladder disease	EFO:0003832
0	"Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain." []	\N	brain neoplasm	\N	\N	EFO	"Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain." []	EFO	69500	EFO:0003833	\N	brain neoplasm	EFO:0003833
0	"A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID)." []	\N	cutaneous lupus erythematosus	\N	\N	EFO	"A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID)." []	EFO	69501	EFO:0003834	\N	cutaneous lupus erythematosus	EFO:0003834
0	"Tumors or cancer of the ANAL CANAL." []	\N	anal neoplasm	\N	\N	EFO	"Tumors or cancer of the ANAL CANAL." []	EFO	69502	EFO:0003835	\N	anal neoplasm	EFO:0003835
0	"Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes." []	\N	lipoprotein	\N	\N	EFO	"Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes." []	EFO	69503	EFO:0003836	\N	lipoprotein	EFO:0003836
0	"Process by which organic tissue becomes hardened by the physiologic deposit of calcium salts." []	\N	calcification	\N	\N	EFO	"Process by which organic tissue becomes hardened by the physiologic deposit of calcium salts." []	EFO	69504	EFO:0003837	\N	calcification	EFO:0003837
0	"Any disease or disorder of the retina." []	\N	retinopathy	\N	\N	EFO	"Any disease or disorder of the retina." []	EFO	69505	EFO:0003839	\N	retinopathy	EFO:0003839
0	"A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)" []	\N	chronic progressive multiple sclerosis	\N	\N	EFO	"A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)" []	EFO	69506	EFO:0003840	\N	chronic progressive multiple sclerosis	EFO:0003840
0	"" []	\N	thyroid neoplasm	\N	\N	EFO	"" []	EFO	69507	EFO:0003841	\N	thyroid neoplasm	EFO:0003841
0	"The bones of the upper and lower LEG. They include the PELVIC BONES." []	\N	bone of lower extremity	\N	\N	EFO	"The bones of the upper and lower LEG. They include the PELVIC BONES." []	EFO	69508	EFO:0003842	\N	bone of lower extremity	EFO:0003842
0	"An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS." []	\N	pain	\N	\N	EFO	"An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS." []	EFO	69509	EFO:0003843	\N	pain	EFO:0003843
0	"Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom." []	\N	ureteral neoplasm	\N	\N	EFO	"Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom." []	EFO	69510	EFO:0003844	\N	ureteral neoplasm	EFO:0003844
0	"Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE." []	\N	kidney stone	\N	\N	EFO	"Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE." []	EFO	69511	EFO:0003845	\N	kidney stone	EFO:0003845
0	"Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males." []	\N	urethral neoplasm	\N	\N	EFO	"Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males." []	EFO	69512	EFO:0003846	\N	urethral neoplasm	EFO:0003846
0	"Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual is mentally retarded. IQ scores between 70 and 79 are in the borderline mentally retarded range. Scores below 67 are in the retarded range. (Joynt, Clinical Neurology, 1992, Ch55, p28)" []	\N	mental retardation	\N	\N	EFO	"Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual is mentally retarded. IQ scores between 70 and 79 are in the borderline mentally retarded range. Scores below 67 are in the retarded range. (Joynt, Clinical Neurology, 1992, Ch55, p28)" []	EFO	69513	EFO:0003847	\N	mental retardation	EFO:0003847
0	"Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA." []	\N	palatal neoplasm	\N	\N	EFO	"Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA." []	EFO	69514	EFO:0003849	\N	palatal neoplasm	EFO:0003849
0	"Tumors or cancer of the ADRENAL GLANDS." []	\N	adrenal gland neoplasm	\N	\N	EFO	"Tumors or cancer of the ADRENAL GLANDS." []	EFO	69515	EFO:0003850	\N	adrenal gland neoplasm	EFO:0003850
0	"Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord." []	\N	meningeal neoplasm	\N	\N	EFO	"Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord." []	EFO	69516	EFO:0003851	\N	meningeal neoplasm	EFO:0003851
0	"Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)" []	\N	developmental disability	\N	\N	EFO	"Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)" []	EFO	69517	EFO:0003852	\N	developmental disability	EFO:0003852
0	"" []	\N	respiratory system neoplasm	\N	\N	EFO	"" []	EFO	69518	EFO:0003853	\N	respiratory system neoplasm	EFO:0003853
0	"Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency." []	\N	postmenopausal osteoporosis	\N	\N	EFO	"Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency." []	EFO	69519	EFO:0003854	\N	postmenopausal osteoporosis	EFO:0003854
0	"Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base." []	\N	intestinal polyp	\N	\N	EFO	"Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base." []	EFO	69520	EFO:0003855	\N	intestinal polyp	EFO:0003855
0	"The separation and isolation of tissues for surgical purposes, or for the analysis or study of their structures." []	\N	dissection	\N	\N	EFO	"The separation and isolation of tissues for surgical purposes, or for the analysis or study of their structures." []	EFO	69521	EFO:0003856	\N	dissection	EFO:0003856
0	"Persistent flexure or contracture of a joint. (Dorland, 27th ed)" []	\N	arthrogryposis	\N	\N	EFO	"Persistent flexure or contracture of a joint. (Dorland, 27th ed)" []	EFO	69522	EFO:0003857	\N	arthrogryposis	EFO:0003857
0	"" []	\N	skeleton structure	\N	\N	EFO	"" []	EFO	69523	EFO:0003858	\N	skeleton structure	EFO:0003858
0	"Tumors or cancer of the UTERUS." []	\N	uterine neoplasm	\N	\N	EFO	"Tumors or cancer of the UTERUS." []	EFO	69524	EFO:0003859	\N	uterine neoplasm	EFO:0003859
0	"Neoplasm located in the pancreas. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA)." []	\N	pancreatic neoplasm	\N	\N	EFO	"Neoplasm located in the pancreas. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA)." []	EFO	69525	EFO:0003860	\N	pancreatic neoplasm	EFO:0003860
0	"" []	\N	pancreactic component	\N	\N	EFO	"" []	EFO	69526	EFO:0003861	\N	pancreactic component	EFO:0003861
0	"An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness." []	\N	dementia	\N	\N	EFO	"An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness." []	EFO	69527	EFO:0003862	\N	dementia	EFO:0003862
0	"Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female." []	\N	urogenital neoplasm	\N	\N	EFO	"Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female." []	EFO	69528	EFO:0003863	\N	urogenital neoplasm	EFO:0003863
0	"Tumors or cancers of the KIDNEY." []	\N	kidney neoplasm	\N	\N	EFO	"Tumors or cancers of the KIDNEY." []	EFO	69529	EFO:0003865	\N	kidney neoplasm	EFO:0003865
0	"Tumors or cancer of the PARANASAL SINUSES." []	\N	paranasal sinus neoplasm	\N	\N	EFO	"Tumors or cancer of the PARANASAL SINUSES." []	EFO	69530	EFO:0003866	\N	paranasal sinus neoplasm	EFO:0003866
0	"Necrosis or disintegration of skeletal muscle often followed by myoglobinuria." []	\N	rhabdomyolysis	\N	\N	EFO	"Necrosis or disintegration of skeletal muscle often followed by myoglobinuria." []	EFO	69531	EFO:0003867	\N	rhabdomyolysis	EFO:0003867
0	"Tumors or cancer of the MOUTH." []	\N	mouth neoplasm	\N	\N	EFO	"Tumors or cancer of the MOUTH." []	EFO	69532	EFO:0003868	\N	mouth neoplasm	EFO:0003868
0	"Abnormal growth located in the breast or mammory gland." []	\N	breast neoplasm	\N	\N	EFO	"Abnormal growth located in the breast or mammory gland." []	EFO	69533	EFO:0003869	\N	breast neoplasm	EFO:0003869
0	"Outpouching of BASILAR ARTERY at the base of the skull. The basilar artery is the most important artery in the posterior cerebral circulation." []	\N	brain aneurysm	\N	\N	EFO	"Outpouching of BASILAR ARTERY at the base of the skull. The basilar artery is the most important artery in the posterior cerebral circulation." []	EFO	69534	EFO:0003870	\N	brain aneurysm	EFO:0003870
0	"Tumors or cancer of the TONGUE." []	\N	tongue neoplasm	\N	\N	EFO	"Tumors or cancer of the TONGUE." []	EFO	69535	EFO:0003871	\N	tongue neoplasm	EFO:0003871
0	"Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER." []	\N	colitis	\N	\N	EFO	"Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER." []	EFO	69536	EFO:0003872	\N	colitis	EFO:0003872
0	"Tumors or cancer of the PAROTID GLAND." []	\N	parotid neoplasm	\N	\N	EFO	"Tumors or cancer of the PAROTID GLAND." []	EFO	69537	EFO:0003873	\N	parotid neoplasm	EFO:0003873
0	"A condition in which one or more of the arches of the foot have flattened out." []	\N	flatfoot	\N	\N	EFO	"A condition in which one or more of the arches of the foot have flattened out." []	EFO	69538	EFO:0003874	\N	flatfoot	EFO:0003874
0	"Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART." []	\N	peripheral vascular disease	\N	\N	EFO	"Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART." []	EFO	69539	EFO:0003875	\N	peripheral vascular disease	EFO:0003875
0	"A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE." []	\N	intermittent vascular claudication	\N	\N	EFO	"A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE." []	EFO	69540	EFO:0003876	\N	intermittent vascular claudication	EFO:0003876
0	"Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types." []	\N	sleep apnea	\N	\N	EFO	"Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types." []	EFO	69541	EFO:0003877	\N	sleep apnea	EFO:0003877
0	"Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both." []	\N	urethritis	\N	\N	EFO	"Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both." []	EFO	69542	EFO:0003878	\N	urethritis	EFO:0003878
0	"Tumors or cancer of the APPENDIX." []	\N	appendiceal neoplasm	\N	\N	EFO	"Tumors or cancer of the APPENDIX." []	EFO	69543	EFO:0003880	\N	appendiceal neoplasm	EFO:0003880
0	"Excision of the uterus." []	\N	hysterectomy	\N	\N	EFO	"Excision of the uterus." []	EFO	69544	EFO:0003881	\N	hysterectomy	EFO:0003881
0	"Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis." []	\N	osteoporosis	\N	\N	EFO	"Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis." []	EFO	69545	EFO:0003882	\N	osteoporosis	EFO:0003882
0	"Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION." []	\N	brain ischemia	\N	\N	EFO	"Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION." []	EFO	69546	EFO:0003883	\N	brain ischemia	EFO:0003883
0	"The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION." []	\N	chronic kidney disease	\N	\N	EFO	"The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION." []	EFO	69547	EFO:0003884	\N	chronic kidney disease	EFO:0003884
0	"An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)" []	\N	multiple sclerosis	\N	\N	EFO	"An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)" []	EFO	69548	EFO:0003885	\N	multiple sclerosis	EFO:0003885
0	"Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg." []	\N	thrombophlebitis	\N	\N	EFO	"Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg." []	EFO	69549	EFO:0003887	\N	thrombophlebitis	EFO:0003887
0	"A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV)" []	\N	attention deficit hyperactivity disorder	\N	\N	EFO	"A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV)" []	EFO	69550	EFO:0003888	\N	attention deficit hyperactivity disorder	EFO:0003888
0	"Behavioral manifestations of cerebral dominance in which there is preferential use and superior functioning of either the left or the right side, as in the preferred use of the right hand or right foot." []	\N	functional laterality	\N	\N	EFO	"Behavioral manifestations of cerebral dominance in which there is preferential use and superior functioning of either the left or the right side, as in the preferred use of the right hand or right foot." []	EFO	69551	EFO:0003889	\N	functional laterality	EFO:0003889
0	"Disorders related to substance abuse, the side effects of a medication, or toxin exposure." []	\N	drug dependence	\N	\N	EFO	"Disorders related to substance abuse, the side effects of a medication, or toxin exposure." []	EFO	69552	EFO:0003890	\N	drug dependence	EFO:0003890
0	"Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER." []	\N	biliary tract neoplasm	\N	\N	EFO	"Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER." []	EFO	69553	EFO:0003891	\N	biliary tract neoplasm	EFO:0003891
0	"Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc." []	\N	pulmonary function measurement	\N	\N	EFO	"Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc." []	EFO	69554	EFO:0003892	\N	pulmonary function measurement	EFO:0003892
0	"Neoplasms located in the ovary that can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS." []	\N	ovarian neoplasm	\N	\N	EFO	"Neoplasms located in the ovary that can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS." []	EFO	69555	EFO:0003893	\N	ovarian neoplasm	EFO:0003893
0	"A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors." []	\N	acne	\N	\N	EFO	"A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors." []	EFO	69556	EFO:0003894	\N	acne	EFO:0003894
0	"Bleeding from the nose." []	\N	epistaxis	\N	\N	EFO	"Bleeding from the nose." []	EFO	69557	EFO:0003895	\N	epistaxis	EFO:0003895
0	"Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality." []	\N	left ventricular hypertrophy	\N	\N	EFO	"Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality." []	EFO	69558	EFO:0003896	\N	left ventricular hypertrophy	EFO:0003896
0	"Tumors or cancer of the STOMACH." []	\N	stomach neoplasm	\N	\N	EFO	"Tumors or cancer of the STOMACH." []	EFO	69559	EFO:0003897	\N	stomach neoplasm	EFO:0003897
0	"A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions." []	\N	ankylosing spondylitis	\N	\N	EFO	"A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions." []	EFO	69560	EFO:0003898	\N	ankylosing spondylitis	EFO:0003898
0	"Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint." []	\N	contracture	\N	\N	EFO	"Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint." []	EFO	69561	EFO:0003899	\N	contracture	EFO:0003899
0	"Conditions caused by abnormal CILIA movement in the body, usually causing KARTAGENER SYNDROME, chronic respiratory disorders, chronic SINUSITIS, and chronic OTITIS. Abnormal ciliary beating is likely due to defects in any of the 200 plus ciliary proteins, such as missing motor enzyme DYNEIN arms." []	\N	ciliopathy	\N	\N	EFO	"Conditions caused by abnormal CILIA movement in the body, usually causing KARTAGENER SYNDROME, chronic respiratory disorders, chronic SINUSITIS, and chronic OTITIS. Abnormal ciliary beating is likely due to defects in any of the 200 plus ciliary proteins, such as missing motor enzyme DYNEIN arms." []	EFO	69562	EFO:0003900	\N	ciliopathy	EFO:0003900
0	"Painful URINATION. It is often associated with infections of the lower URINARY TRACT." []	\N	dysuria	\N	\N	EFO	"Painful URINATION. It is often associated with infections of the lower URINARY TRACT." []	EFO	69563	EFO:0003901	\N	dysuria	EFO:0003901
0	"Broken bones in the vertebral column." []	\N	spinal fracture	\N	\N	EFO	"Broken bones in the vertebral column." []	EFO	69564	EFO:0003902	\N	spinal fracture	EFO:0003902
0	"The formation or presence of a blood clot (THROMBUS) within a vein." []	\N	venous thrombosis	\N	\N	EFO	"The formation or presence of a blood clot (THROMBUS) within a vein." []	EFO	69565	EFO:0003905	\N	venous thrombosis	EFO:0003905
0	"Surgical insertion of synthetic material to repair injured or diseased heart valves." []	\N	heart valve prosthesis	\N	\N	EFO	"Surgical insertion of synthetic material to repair injured or diseased heart valves." []	EFO	69566	EFO:0003906	\N	heart valve prosthesis	EFO:0003906
0	"The formation or presence of a blood clot (THROMBUS) within a deep vein in the lower extremity" []	\N	deep vein thrombosis	\N	\N	EFO	"The formation or presence of a blood clot (THROMBUS) within a deep vein in the lower extremity" []	EFO	69567	EFO:0003907	\N	deep vein thrombosis	EFO:0003907
0	"Deviations from the average or standard indices of refraction of the eye through its dioptric or refractive apparatus." []	\N	refractive error	\N	\N	EFO	"Deviations from the average or standard indices of refraction of the eye through its dioptric or refractive apparatus." []	EFO	69568	EFO:0003908	\N	refractive error	EFO:0003908
0	"An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart." []	\N	heart conduction system	\N	\N	EFO	"An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart." []	EFO	69569	EFO:0003909	\N	heart conduction system	EFO:0003909
0	"Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES)." []	\N	atrial flutter	\N	\N	EFO	"Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES)." []	EFO	69570	EFO:0003911	\N	atrial flutter	EFO:0003911
0	"Comparison of the BLOOD PRESSURE between the BRACHIAL ARTERY and the POSTERIOR TIBIAL ARTERY. It is a predictor of PERIPHERAL ARTERIAL DISEASE." []	\N	ankle brachial index	\N	\N	EFO	"Comparison of the BLOOD PRESSURE between the BRACHIAL ARTERY and the POSTERIOR TIBIAL ARTERY. It is a predictor of PERIPHERAL ARTERIAL DISEASE." []	EFO	69571	EFO:0003912	\N	ankle brachial index	EFO:0003912
0	"The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION." []	\N	angina pectoris	\N	\N	EFO	"The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION." []	EFO	69572	EFO:0003913	\N	angina pectoris	EFO:0003913
0	"A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA." []	\N	atherosclerosis	\N	\N	EFO	"A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA." []	EFO	69573	EFO:0003914	\N	atherosclerosis	EFO:0003914
0	"CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION)." []	\N	premature birth	\N	\N	EFO	"CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION)." []	EFO	69574	EFO:0003917	\N	premature birth	EFO:0003917
0	"A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)" []	\N	obstructive sleep apnea	\N	\N	EFO	"A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)" []	EFO	69575	EFO:0003918	\N	obstructive sleep apnea	EFO:0003918
0	"Any aspect of an individual's life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury." []	\N	risk factor	\N	\N	EFO	"Any aspect of an individual's life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury." []	EFO	69576	EFO:0003919	\N	risk factor	EFO:0003919
0	"Congenital fissure of the soft and/or hard palate, due to faulty fusion." []	\N	cleft palate	\N	\N	EFO	"Congenital fissure of the soft and/or hard palate, due to faulty fusion." []	EFO	69577	EFO:0003920	\N	cleft palate	EFO:0003920
0	"Acute INFLAMMATION in the INTESTINAL MUCOSA of the continent ileal reservoir (or pouch) in patients who have undergone ILEOSTOMY and restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE)." []	\N	pouchitis	\N	\N	EFO	"Acute INFLAMMATION in the INTESTINAL MUCOSA of the continent ileal reservoir (or pouch) in patients who have undergone ILEOSTOMY and restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE)." []	EFO	69578	EFO:0003921	\N	pouchitis	EFO:0003921
0	"The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age." []	\N	menopause	\N	\N	EFO	"The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age." []	EFO	69579	EFO:0003922	\N	menopause	EFO:0003922
0	"The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS." []	\N	bone density	\N	\N	EFO	"The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS." []	EFO	69580	EFO:0003923	\N	bone density	EFO:0003923
0	"Color of hair or fur." []	\N	hair color	\N	\N	EFO	"Color of hair or fur." []	EFO	69581	EFO:0003924	\N	hair color	EFO:0003924
0	"Intellectual or mental process whereby an organism becomes aware of or obtains knowledge." []	\N	cognition	\N	\N	EFO	"Intellectual or mental process whereby an organism becomes aware of or obtains knowledge." []	EFO	69582	EFO:0003925	\N	cognition	EFO:0003925
0	"Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury." []	\N	neuropsychological test	\N	\N	EFO	"Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury." []	EFO	69583	EFO:0003926	\N	neuropsychological test	EFO:0003926
0	"A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness." []	\N	myopia	\N	\N	EFO	"A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness." []	EFO	69584	EFO:0003927	\N	myopia	EFO:0003927
0	"ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT." []	\N	necrotizing enterocolitis	\N	\N	EFO	"ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT." []	EFO	69585	EFO:0003928	\N	necrotizing enterocolitis	EFO:0003928
0	"The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)" []	\N	relapsing-remitting multiple sclerosis	\N	\N	EFO	"The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)" []	EFO	69586	EFO:0003929	\N	relapsing-remitting multiple sclerosis	EFO:0003929
0	"The first MENSTRUAL CYCLE marked by the initiation of MENSTRUATION." []	\N	menarche	\N	\N	EFO	"The first MENSTRUAL CYCLE marked by the initiation of MENSTRUATION." []	EFO	69587	EFO:0003930	\N	menarche	EFO:0003930
0	"Breaks in bones." []	\N	bone fracture	\N	\N	EFO	"Breaks in bones." []	EFO	69588	EFO:0003931	\N	bone fracture	EFO:0003931
0	"Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli." []	\N	bacterial vaginosis	\N	\N	EFO	"Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli." []	EFO	69589	EFO:0003932	\N	bacterial vaginosis	EFO:0003932
0	"Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS." []	\N	fatty liver	\N	\N	EFO	"Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS." []	EFO	69590	EFO:0003934	\N	fatty liver	EFO:0003934
0	"The state wherein the person is well adjusted." []	\N	mental health	\N	\N	EFO	"The state wherein the person is well adjusted." []	EFO	69591	EFO:0003935	\N	mental health	EFO:0003935
0	"A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742)" []	\N	aphthous ulcer	\N	\N	EFO	"A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742)" []	EFO	69592	EFO:0003938	\N	aphthous ulcer	EFO:0003938
0	"Total number of calories taken in daily whether ingested or by parenteral routes." []	\N	energy intake	\N	\N	EFO	"Total number of calories taken in daily whether ingested or by parenteral routes." []	EFO	69593	EFO:0003939	\N	energy intake	EFO:0003939
0	"The physical activity of a human or an animal as a behavioral phenomenon." []	\N	physical activity	\N	\N	EFO	"The physical activity of a human or an animal as a behavioral phenomenon." []	EFO	69594	EFO:0003940	\N	physical activity	EFO:0003940
0	"http://en.wikipedia.org/wiki/Sex_hormone-binding_globulin" []	\N	sex hormone-binding globulin	\N	\N	EFO	"http://en.wikipedia.org/wiki/Sex_hormone-binding_globulin" []	EFO	69595	EFO:0003941	\N	sex hormone-binding globulin	EFO:0003941
0	"Transplantation between animals of different species." []	\N	heterologous transplantation	\N	\N	EFO	"Transplantation between animals of different species." []	EFO	69596	EFO:0003942	\N	heterologous transplantation	EFO:0003942
0	"" []	\N	humerus fracture	\N	\N	EFO	"" []	EFO	69597	EFO:0003943	\N	humerus fracture	EFO:0003943
0	"" []	\N	tibia fracture	\N	\N	EFO	"" []	EFO	69598	EFO:0003944	\N	tibia fracture	EFO:0003944
0	"Excessive uterine bleeding during MENSTRUATION." []	\N	menorrhagia	\N	\N	EFO	"Excessive uterine bleeding during MENSTRUATION." []	EFO	69599	EFO:0003945	\N	menorrhagia	EFO:0003945
0	"Disorder caused by loss of endothelium of the central cornea. It is characterized by hyaline endothelial outgrowths on Descemet's membrane, epithelial blisters, reduced vision, and pain." []	\N	Fuchs' endothelial dystrophy	\N	\N	EFO	"Disorder caused by loss of endothelium of the central cornea. It is characterized by hyaline endothelial outgrowths on Descemet's membrane, epithelial blisters, reduced vision, and pain." []	EFO	69600	EFO:0003946	\N	Fuchs' endothelial dystrophy	EFO:0003946
0	"Behavior-response patterns that characterize the individual." []	\N	personality	\N	\N	EFO	"Behavior-response patterns that characterize the individual." []	EFO	69601	EFO:0003947	\N	personality	EFO:0003947
0	"Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER." []	\N	gastroesophageal reflux disease	\N	\N	EFO	"Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER." []	EFO	69602	EFO:0003948	\N	gastroesophageal reflux disease	EFO:0003948
0	"Color of the iris." []	\N	eye color	\N	\N	EFO	"Color of the iris." []	EFO	69603	EFO:0003949	\N	eye color	EFO:0003949
0	"Fractures of the larger bone of the forearm." []	\N	ulna fracture	\N	\N	EFO	"Fractures of the larger bone of the forearm." []	EFO	69604	EFO:0003950	\N	ulna fracture	EFO:0003950
0	"Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply." []	\N	percutaneous transluminal coronary angioplasty	\N	\N	EFO	"Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply." []	EFO	69605	EFO:0003951	\N	percutaneous transluminal coronary angioplasty	EFO:0003951
0	"Fever in which the etiology cannot be ascertained." []	\N	fever of unknown origin	\N	\N	EFO	"Fever in which the etiology cannot be ascertained." []	EFO	69606	EFO:0003952	\N	fever of unknown origin	EFO:0003952
0	"Excision of the prepuce of the penis (FORESKIN) or part of it." []	\N	circumcision	\N	\N	EFO	"Excision of the prepuce of the penis (FORESKIN) or part of it." []	EFO	69607	EFO:0003953	\N	circumcision	EFO:0003953
0	"Bacterial diseases transmitted or propagated by sexual conduct." []	\N	bacterial sexually transmitted disease	\N	\N	EFO	"Bacterial diseases transmitted or propagated by sexual conduct." []	EFO	69608	EFO:0003955	\N	bacterial sexually transmitted disease	EFO:0003955
0	"Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS." []	\N	seasonal allergic rhinitis	\N	\N	EFO	"Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS." []	EFO	69609	EFO:0003956	\N	seasonal allergic rhinitis	EFO:0003956
0	"" []	\N	radius fracture	\N	\N	EFO	"" []	EFO	69610	EFO:0003957	\N	radius fracture	EFO:0003957
0	"An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight." []	\N	sunburn	\N	\N	EFO	"An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight." []	EFO	69611	EFO:0003958	\N	sunburn	EFO:0003958
0	"Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region." []	\N	cleft lip	\N	\N	EFO	"Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region." []	EFO	69612	EFO:0003959	\N	cleft lip	EFO:0003959
0	"A computed tomography scan (CT scan) is the output of an imaging technology which produces a 3D iimage of the subject." []	\N	computed tomography	\N	\N	EFO	"A computed tomography scan (CT scan) is the output of an imaging technology which produces a 3D iimage of the subject." []	EFO	69613	EFO:0003960	\N	computed tomography	EFO:0003960
0	"Therapeutic use of hormones to alleviate the effects of hormone deficiency." []	\N	hormone replacement therapy	\N	\N	EFO	"Therapeutic use of hormones to alleviate the effects of hormone deficiency." []	EFO	69614	EFO:0003961	\N	hormone replacement therapy	EFO:0003961
0	"Echocardiography applying the Doppler effect, with velocity detection combined with range discrimination. Short bursts of ultrasound are transmitted at regular intervals and the echoes are demodulated as they return." []	\N	pulsed doppler echocardiography	\N	\N	EFO	"Echocardiography applying the Doppler effect, with velocity detection combined with range discrimination. Short bursts of ultrasound are transmitted at regular intervals and the echoes are demodulated as they return." []	EFO	69615	EFO:0003962	\N	pulsed doppler echocardiography	EFO:0003962
0	"Disorders of increased melanin pigmentation that develop without preceding inflammatory disease." []	\N	freckles	\N	\N	EFO	"Disorders of increased melanin pigmentation that develop without preceding inflammatory disease." []	EFO	69616	EFO:0003963	\N	freckles	EFO:0003963
0	"Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES)." []	\N	hip fracture	\N	\N	EFO	"Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES)." []	EFO	69617	EFO:0003964	\N	hip fracture	EFO:0003964
0	"An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age." []	\N	very low birth weight infant	\N	\N	EFO	"An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age." []	EFO	69618	EFO:0003965	\N	very low birth weight infant	EFO:0003965
0	"" []	\N	eye disease	\N	\N	EFO	"" []	EFO	69619	EFO:0003966	\N	eye disease	EFO:0003966
0	"A sarcoma arising from vascular tissue including arteries, veins, venous sinuses, arterioles and capillaries." []	\N	vascular sarcoma	\N	\N	EFO	"A sarcoma arising from vascular tissue including arteries, veins, venous sinuses, arterioles and capillaries." []	EFO	69620	EFO:0003967	\N	vascular sarcoma	EFO:0003967
0	"A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma." []	\N	angiosarcoma	\N	\N	EFO	"A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma." []	EFO	69621	EFO:0003968	\N	angiosarcoma	EFO:0003968
0	"A protocol in which the aim is to treat a sample, collection of samples, organism or group of organisms for some experimental analysis of outcome." []	\N	treatment protocol	\N	\N	EFO	"A protocol in which the aim is to treat a sample, collection of samples, organism or group of organisms for some experimental analysis of outcome." []	EFO	69622	EFO:0003969	\N	treatment protocol	EFO:0003969
0	"" []	\N	mouse erythroleukemia cell	\N	\N	EFO	"" []	EFO	69623	EFO:0003970	\N	mouse erythroleukemia cell	EFO:0003970
0	"" []	\N	MEL cell line	\N	\N	EFO	"" []	EFO	69624	EFO:0003971	\N	MEL cell line	EFO:0003971
0	"A mouse embryonic stem cell hybrid cell line" []	\N	ESHyb	\N	\N	EFO	"A mouse embryonic stem cell hybrid cell line" []	EFO	69625	EFO:0003972	\N	ESHyb	EFO:0003972
0	"A designator of mouse strain information indicating the genetic homo or heterogenetity e.g. inbred strain" []	\N	Mus musculus strain type	\N	\N	EFO	"A designator of mouse strain information indicating the genetic homo or heterogenetity e.g. inbred strain" []	EFO	69626	EFO:0004000	\N	Mus musculus strain type	EFO:0004000
0	"A mouse strain type whereby the strain is propagated by random mating within the stock. No genes are introduced from outside the stock from generation to generation." []	\N	closed colony random bred strain	\N	\N	EFO	"A mouse strain type whereby the strain is propagated by random mating within the stock. No genes are introduced from outside the stock from generation to generation." []	EFO	69627	EFO:0004001	\N	closed colony random bred strain	EFO:0004001
0	"A coisogentic strain is a strain that differs from its progenitor inbred strain at only one locus. A coisogenic strain arises when a mutation occurs in an inbred strain." []	\N	coisogenic strain	\N	\N	EFO	"A coisogentic strain is a strain that differs from its progenitor inbred strain at only one locus. A coisogenic strain arises when a mutation occurs in an inbred strain." []	EFO	69628	EFO:0004002	\N	coisogenic strain	EFO:0004002
0	"A congenic strain is an  inbred strain that contains a small genetic region (ideally a single gene) from another strain, but which is otherwise identical to the original inbred strain. Congenic strains are derived by backcrossing to a parental inbred strain for at least ten generations while selecting for retention of a specific locus from the donor strain. For example, CBACa.C3-KitW-x/J is an inbred strain of CBA/Ca background onto which the KitW-x allele from C3H/HeJ has been placed." []	\N	congenic strain	\N	\N	EFO	"A congenic strain is an  inbred strain that contains a small genetic region (ideally a single gene) from another strain, but which is otherwise identical to the original inbred strain. Congenic strains are derived by backcrossing to a parental inbred strain for at least ten generations while selecting for retention of a specific locus from the donor strain. For example, CBACa.C3-KitW-x/J is an inbred strain of CBA/Ca background onto which the KitW-x allele from C3H/HeJ has been placed." []	EFO	69629	EFO:0004003	\N	congenic strain	EFO:0004003
0	"An inbred strain that contains a single entire chromosome from another strain. Consomic (or Chromosome Substitution Strains) are derived by backcrossing to a parental inbred strain for at least ten generations while selecting for retention of a specific whole chromosome from the donor strain. For example, C57BL/6J-Chr 4A/NaJ is a consomic strain in which the Chromosome 4 from the A/J strain has been placed on a C57BL/6J background." []	\N	consomic strain	\N	\N	EFO	"An inbred strain that contains a single entire chromosome from another strain. Consomic (or Chromosome Substitution Strains) are derived by backcrossing to a parental inbred strain for at least ten generations while selecting for retention of a specific whole chromosome from the donor strain. For example, C57BL/6J-Chr 4A/NaJ is a consomic strain in which the Chromosome 4 from the A/J strain has been placed on a C57BL/6J background." []	EFO	69630	EFO:0004004	\N	consomic strain	EFO:0004004
0	"An inbred strain carrying one or more phenotypic mutations. For example, the mutant strain C3H/H3eSn-bc3J/J carries the bouncy 3 Jackson phenotypic mutation." []	\N	inbred Mus musculus strain	\N	\N	EFO	"An inbred strain carrying one or more phenotypic mutations. For example, the mutant strain C3H/H3eSn-bc3J/J carries the bouncy 3 Jackson phenotypic mutation." []	EFO	69631	EFO:0004005	\N	inbred Mus musculus strain	EFO:0004005
0	"An inbred strain carrying one or more phenotypic mutations. For example, the mutant strain C3H/H3eSn-bc3J/J carries the bouncy 3 Jackson phenotypic mutation." []	\N	mutant strain	\N	\N	EFO	"An inbred strain carrying one or more phenotypic mutations. For example, the mutant strain C3H/H3eSn-bc3J/J carries the bouncy 3 Jackson phenotypic mutation." []	EFO	69632	EFO:0004006	\N	mutant strain	EFO:0004006
0	"Strains formed by crossing two inbred strains, followed by a few backcrosses to one of the parental strains, with subsequent inbreeding without selection." []	\N	recombinant congenic strain	\N	\N	EFO	"Strains formed by crossing two inbred strains, followed by a few backcrosses to one of the parental strains, with subsequent inbreeding without selection." []	EFO	69633	EFO:0004007	\N	recombinant congenic strain	EFO:0004007
0	"An Inbred strain created by crossing two different inbred strains, followed by brother x sister matings for at least 20 generations. A panel of recombinant inbred strains derived from a cross between the same original parental strains can be used to establish linkage between any marker that is polymorphic between the parental strains and other polymorphic markers that have been typed in each strain in the panel." []	\N	recombinant inbred strain	\N	\N	EFO	"An Inbred strain created by crossing two different inbred strains, followed by brother x sister matings for at least 20 generations. A panel of recombinant inbred strains derived from a cross between the same original parental strains can be used to establish linkage between any marker that is polymorphic between the parental strains and other polymorphic markers that have been typed in each strain in the panel." []	EFO	69634	EFO:0004008	\N	recombinant inbred strain	EFO:0004008
0	"An inbred strain that is kept in forced heterozygosity for one or more loci. For example, the SM/J strain segregates for an agouti allele and animals are either Aw/a (white bellied agouti) or a/a (black) in color." []	\N	segregating inbred strain	\N	\N	EFO	"An inbred strain that is kept in forced heterozygosity for one or more loci. For example, the SM/J strain segregates for an agouti allele and animals are either Aw/a (white bellied agouti) or a/a (black) in color." []	EFO	69635	EFO:0004009	\N	segregating inbred strain	EFO:0004009
0	"Strains formed by brother x sister matings or other inbreeding schemes from mice originally caught in the wild." []	\N	wild-derived inbred strain	\N	\N	EFO	"Strains formed by brother x sister matings or other inbreeding schemes from mice originally caught in the wild." []	EFO	69636	EFO:0004010	\N	wild-derived inbred strain	EFO:0004010
0	"A congenic strain in which the donor allele transferred to the host strain background is a major histocompatibility gene." []	\N	major histocompatibility congenic strain	\N	\N	EFO	"A congenic strain in which the donor allele transferred to the host strain background is a major histocompatibility gene." []	EFO	69637	EFO:0004011	\N	major histocompatibility congenic strain	EFO:0004011
0	"" []	\N	mating type F	\N	\N	EFO	"" []	EFO	69638	EFO:0004012	\N	mating type F	EFO:0004012
0	"A reciprocal translocation in which no genetic material is gained or lost in the resulting fusion chromosomes" []	\N	balanced reciprocal translocation	\N	\N	EFO	"A reciprocal translocation in which no genetic material is gained or lost in the resulting fusion chromosomes" []	EFO	69639	EFO:0004013	\N	balanced reciprocal translocation	EFO:0004013
0	"" []	\N	deletion	\N	\N	EFO	"" []	EFO	69640	EFO:0004014	\N	deletion	EFO:0004014
0	"A genetic modification in which part of the genome is duplicated" []	\N	duplication	\N	\N	EFO	"A genetic modification in which part of the genome is duplicated" []	EFO	69641	EFO:0004015	\N	duplication	EFO:0004015
0	"" []	\N	insertion	\N	\N	EFO	"" []	EFO	69642	EFO:0004016	\N	insertion	EFO:0004016
0	"" []	\N	inversion	\N	\N	EFO	"" []	EFO	69643	EFO:0004017	\N	inversion	EFO:0004017
0	"A genetic modification which has arisn by a spontaneous mutation in an individual" []	\N	spontaneous mutation	\N	\N	EFO	"A genetic modification which has arisn by a spontaneous mutation in an individual" []	EFO	69644	EFO:0004018	\N	spontaneous mutation	EFO:0004018
0	"A genetic modification in which a targeted mutation has been introduced into the genome of an individual" []	\N	targeted mutation	\N	\N	EFO	"A genetic modification in which a targeted mutation has been introduced into the genome of an individual" []	EFO	69645	EFO:0004019	\N	targeted mutation	EFO:0004019
0	"A genetic modification in which a transgene has been inserted into an individual" []	\N	transgenic	\N	\N	EFO	"A genetic modification in which a transgene has been inserted into an individual" []	EFO	69646	EFO:0004020	\N	transgenic	EFO:0004020
0	"A genetic modification introduced into an individual as the result of transposase activity" []	\N	transposition	\N	\N	EFO	"A genetic modification introduced into an individual as the result of transposase activity" []	EFO	69647	EFO:0004021	\N	transposition	EFO:0004021
0	"A type of chromosome rearrangement in which two nonhomologous chromosomes are each broken and then repaired in such a way that the resulting chromosomes each contain material from the other chromosome (a reciprocal translocation)." []	\N	reciprocal translocation	\N	\N	EFO	"A type of chromosome rearrangement in which two nonhomologous chromosomes are each broken and then repaired in such a way that the resulting chromosomes each contain material from the other chromosome (a reciprocal translocation)." []	EFO	69648	EFO:0004022	\N	reciprocal translocation	EFO:0004022
0	"A particular type of translocation in which the breakpoints in the two chromosomes occur at or near the centromere, followed by centric fusion such that the long arms now form a metacentric chromosome with a single centromere. Any small fragments generated in the exchange are usually lost. See also" []	\N	Roberstonian translocation	\N	\N	EFO	"A particular type of translocation in which the breakpoints in the two chromosomes occur at or near the centromere, followed by centric fusion such that the long arms now form a metacentric chromosome with a single centromere. Any small fragments generated in the exchange are usually lost. See also" []	EFO	69649	EFO:0004023	\N	Roberstonian translocation	EFO:0004023
0	"A type of chromosome rearrangement in which two nonhomologous chromosomes are each broken and then repaired" []	\N	translocation	\N	\N	EFO	"A type of chromosome rearrangement in which two nonhomologous chromosomes are each broken and then repaired" []	EFO	69650	EFO:0004024	\N	translocation	EFO:0004024
0	"C. elegans Daf-d, weak heterochronic phenotypes in seam, somatic gonad, intestine. Class III allele." []	\N	AA86	\N	\N	EFO	"C. elegans Daf-d, weak heterochronic phenotypes in seam, somatic gonad, intestine. Class III allele." []	EFO	69651	EFO:0004025	\N	AA86	EFO:0004025
0	"C. elegans Daf-c, gonadal Mig, weak heterochronic phenotypes in intestine and seam. Class VI allele." []	\N	AA87	\N	\N	EFO	"C. elegans Daf-c, gonadal Mig, weak heterochronic phenotypes in intestine and seam. Class VI allele." []	EFO	69652	EFO:0004026	\N	AA87	EFO:0004026
0	"C. elegans daf-c. Gonald Mig. Weak heterochronic phenotypes in intestine. Class VI allele." []	\N	AA89	\N	\N	EFO	"C. elegans daf-c. Gonald Mig. Weak heterochronic phenotypes in intestine. Class VI allele." []	EFO	69653	EFO:0004027	\N	AA89	EFO:0004027
0	"C. elegans wild isolate var Bristol. Generation time is about 3 days. Brood size is about 350. Also CGC reference 257. Isolated from mushroom compost near Bristol, England by L.N. Staniland. Cultured by W.L. Nicholas, identified to genus by Gunther Osche and species by Victor Nigon; subsequently cultured by C.E. Dougherty. Given to Sydney Brenner ca. 1966. Subcultured by Don Riddle in 1973. Caenorhabditis elegans wild isolate. DR subclone of CB original (Tc1 pattern I)." []	\N	N2	\N	\N	EFO	"C. elegans wild isolate var Bristol. Generation time is about 3 days. Brood size is about 350. Also CGC reference 257. Isolated from mushroom compost near Bristol, England by L.N. Staniland. Cultured by W.L. Nicholas, identified to genus by Gunther Osche and species by Victor Nigon; subsequently cultured by C.E. Dougherty. Given to Sydney Brenner ca. 1966. Subcultured by Don Riddle in 1973. Caenorhabditis elegans wild isolate. DR subclone of CB original (Tc1 pattern I)." []	EFO	69654	EFO:0004028	\N	N2	EFO:0004028
0	"Drosophila simulans isofemale line; siI haplotype; originally collected from Honolulu, Hawaii in 1998" []	\N	Drosophila simulans HW09	\N	\N	EFO	"Drosophila simulans isofemale line; siI haplotype; originally collected from Honolulu, Hawaii in 1998" []	EFO	69655	EFO:0004029	\N	Drosophila simulans HW09	EFO:0004029
0	"A genetic modification induced by insertion of a nucleic acid construct containing a reporter gene sequence downstream of a splice acceptor site that is capable of integrating into random chromosomal locations Integration of the gene trap into an intron allows the expression of a new mRNA containing one or more upstream exons followed by the reporter gene. The reporter gene is therefore expressed in the same cells and developmental stages as the gene into which the gene trap has inserted." []	\N	gene trap	\N	\N	EFO	"A genetic modification induced by insertion of a nucleic acid construct containing a reporter gene sequence downstream of a splice acceptor site that is capable of integrating into random chromosomal locations Integration of the gene trap into an intron allows the expression of a new mRNA containing one or more upstream exons followed by the reporter gene. The reporter gene is therefore expressed in the same cells and developmental stages as the gene into which the gene trap has inserted." []	EFO	69656	EFO:0004030	\N	gene trap	EFO:0004030
0	"Crosophila simulans isofemale line; siI haplotype; originally collected from Noumea, New Caledonia in 1991" []	\N	Drosophila simulans NC48	\N	\N	EFO	"Crosophila simulans isofemale line; siI haplotype; originally collected from Noumea, New Caledonia in 1991" []	EFO	69657	EFO:0004031	\N	Drosophila simulans NC48	EFO:0004031
0	"Drosophila simulans isofemale line, siII haplotype; originally collected from Ansirabe, Madagascar in 1998" []	\N	Drosophile simulans MD106	\N	\N	EFO	"Drosophila simulans isofemale line, siII haplotype; originally collected from Ansirabe, Madagascar in 1998" []	EFO	69658	EFO:0004032	\N	Drosophile simulans MD106	EFO:0004032
0	"" []	\N	experiment accession	\N	\N	EFO	"" []	EFO	69659	EFO:0004033	\N	experiment accession	EFO:0004033
0	"" []	\N	discretized differential expression	\N	\N	EFO	"" []	EFO	69660	EFO:0004034	\N	discretized differential expression	EFO:0004034
0	"" []	\N	mating type F minus	\N	\N	EFO	"" []	EFO	69661	EFO:0004035	\N	mating type F minus	EFO:0004035
0	"" []	\N	mating type h plus	\N	\N	EFO	"" []	EFO	69662	EFO:0004036	\N	mating type h plus	EFO:0004036
0	"Mouse embryonic fibroblast cell line" []	\N	MEF cell line	\N	\N	EFO	"Mouse embryonic fibroblast cell line" []	EFO	69663	EFO:0004037	\N	MEF cell line	EFO:0004037
0	"mouse embryonic stem cell" []	\N	mouse embryonic stem cell	\N	\N	EFO	"mouse embryonic stem cell" []	EFO	69664	EFO:0004038	\N	mouse embryonic stem cell	EFO:0004038
0	"" []	\N	mouse neural progenitor cell	\N	\N	EFO	"" []	EFO	69665	EFO:0004039	\N	mouse neural progenitor cell	EFO:0004039
0	"Mouse embryonic fibroblast cell" []	\N	mouse embryonic fibroblast cell	\N	\N	EFO	"Mouse embryonic fibroblast cell" []	EFO	69666	EFO:0004040	\N	mouse embryonic fibroblast cell	EFO:0004040
0	"Mouse Neural Progenitor cell line" []	\N	NPC	\N	\N	EFO	"Mouse Neural Progenitor cell line" []	EFO	69667	EFO:0004041	\N	NPC	EFO:0004041
0	"Strain of C. elegans described with phenotypes such as; increased social feeding, foraging behavior variant, carbon dioxide response variant, bordering" []	\N	AB1	\N	\N	EFO	"Strain of C. elegans described with phenotypes such as; increased social feeding, foraging behavior variant, carbon dioxide response variant, bordering" []	EFO	69668	EFO:0004042	\N	AB1	EFO:0004042
0	"Strain of C. elegans" []	\N	AB2	\N	\N	EFO	"Strain of C. elegans" []	EFO	69669	EFO:0004043	\N	AB2	EFO:0004043
0	"Strain of C. elegans described as small, recessive, abnormal bursae, males abnormal with M-MATING-NO SUCCESS." []	\N	CB30	\N	\N	EFO	"Strain of C. elegans described as small, recessive, abnormal bursae, males abnormal with M-MATING-NO SUCCESS." []	EFO	69670	EFO:0004044	\N	CB30	EFO:0004044
0	"Strain of C. elegans" []	\N	CB88	\N	\N	EFO	"Strain of C. elegans" []	EFO	69671	EFO:0004045	\N	CB88	EFO:0004045
0	"C. elegans strain described as \\"Small Dpy\\"" []	\N	CB128	\N	\N	EFO	"C. elegans strain described as \\"Small Dpy\\"" []	EFO	69672	EFO:0004046	\N	CB128	EFO:0004046
0	"Strain of C. elegans described as \\"Semi-dominant Dpy. Mapping marker standard. M-MATING++ 1-10%WT.\\"" []	\N	CB184	\N	\N	EFO	"Strain of C. elegans described as \\"Semi-dominant Dpy. Mapping marker standard. M-MATING++ 1-10%WT.\\"" []	EFO	69673	EFO:0004047	\N	CB184	EFO:0004047
0	"C. elegans strain described with phenotypes \\"Long. Abnormal bursae. Epistatic to Small. Recessive. M-MATING-NO SUCCESS.\\"" []	\N	CB185	\N	\N	EFO	"C. elegans strain described with phenotypes \\"Long. Abnormal bursae. Epistatic to Small. Recessive. M-MATING-NO SUCCESS.\\"" []	EFO	69674	EFO:0004048	\N	CB185	EFO:0004048
0	"Strain of C. elegans described with phenotypes \\"Small. Recessive. Males abnormal-abnormal spicules. M-MATING-NO SUCCESS.\\"" []	\N	CB491	\N	\N	EFO	"Strain of C. elegans described with phenotypes \\"Small. Recessive. Males abnormal-abnormal spicules. M-MATING-NO SUCCESS.\\"" []	EFO	69675	EFO:0004049	\N	CB491	EFO:0004049
0	"Strain of C. elegans described as \\"Long. Mapping marker standard. M-MATING++++ >30%WT.\\"" []	\N	CB678	\N	\N	EFO	"Strain of C. elegans described as \\"Long. Mapping marker standard. M-MATING++++ >30%WT.\\"" []	EFO	69676	EFO:0004050	\N	CB678	EFO:0004050
0	"C. elegans strain described with phenotypes; solitary feeding increased, foraging behavior variant." []	\N	CB4555	\N	\N	EFO	"C. elegans strain described with phenotypes; solitary feeding increased, foraging behavior variant." []	EFO	69677	EFO:0004051	\N	CB4555	EFO:0004051
0	"C. elegans strain with phenotypes; social feeding increased, foraging behavior variant, carbon dioxide response variant, bordering." []	\N	CB4853	\N	\N	EFO	"C. elegans strain with phenotypes; social feeding increased, foraging behavior variant, carbon dioxide response variant, bordering." []	EFO	69678	EFO:0004052	\N	CB4853	EFO:0004052
0	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering." []	\N	CB4854	\N	\N	EFO	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering." []	EFO	69679	EFO:0004053	\N	CB4854	EFO:0004053
0	"C. elegans strain with phenotypes; social feeding increased, foraging behavior variant, bordering." []	\N	CB4855	\N	\N	EFO	"C. elegans strain with phenotypes; social feeding increased, foraging behavior variant, bordering." []	EFO	69680	EFO:0004054	\N	CB4855	EFO:0004054
0	"C. elegans strain with phenotypes; social feeding increased, cryophilic, pathogen susceptibility increased (Esp), biofilm absent head (Bah), carbon dioxide response variant, pathogen load variant" []	\N	CB4856	\N	\N	EFO	"C. elegans strain with phenotypes; social feeding increased, cryophilic, pathogen susceptibility increased (Esp), biofilm absent head (Bah), carbon dioxide response variant, pathogen load variant" []	EFO	69681	EFO:0004055	\N	CB4856	EFO:0004055
0	"C. elegans strain described with phenotypes; solitary feeding increased, foraging behavior variant, bordering." []	\N	CB4857	\N	\N	EFO	"C. elegans strain described with phenotypes; solitary feeding increased, foraging behavior variant, bordering." []	EFO	69682	EFO:0004056	\N	CB4857	EFO:0004056
0	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering" []	\N	CB4932	\N	\N	EFO	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering" []	EFO	69683	EFO:0004057	\N	CB4932	EFO:0004057
0	"C. elegans strain described as \\"long\\"." []	\N	MT3847	\N	\N	EFO	"C. elegans strain described as \\"long\\"." []	EFO	69684	EFO:0004058	\N	MT3847	EFO:0004058
0	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering." []	\N	RC301	\N	\N	EFO	"C. elegans strain described with phenotypes; social feeding increased, foraging behavior variant, bordering." []	EFO	69685	EFO:0004059	\N	RC301	EFO:0004059
0	"C. elegans strain with phenotypes; solitary feeding increased, foraging behavior variant." []	\N	TR389	\N	\N	EFO	"C. elegans strain with phenotypes; solitary feeding increased, foraging behavior variant." []	EFO	69686	EFO:0004060	\N	TR389	EFO:0004060
0	"C. elegans strain with phenotypes; solitary feeding increased, foraging behavior variant." []	\N	TR403	\N	\N	EFO	"C. elegans strain with phenotypes; solitary feeding increased, foraging behavior variant." []	EFO	69687	EFO:0004061	\N	TR403	EFO:0004061
0	"C. elegans strian. Additional remarks include \\"Homozygous rrf-3 deletion allele. Increased sensitivity to RNAi when compared to WT animals. Deletion sequence (deletion in lower case letters, flanking undeleted sequence in capital letters): TGCACATATTctacagaatt ------- --------tacccgattaAATGGACAATT (from Plasterk Lab 11/05).\\"" []	\N	NL2099	\N	\N	EFO	"C. elegans strian. Additional remarks include \\"Homozygous rrf-3 deletion allele. Increased sensitivity to RNAi when compared to WT animals. Deletion sequence (deletion in lower case letters, flanking undeleted sequence in capital letters): TGCACATATTctacagaatt ------- --------tacccgattaAATGGACAATT (from Plasterk Lab 11/05).\\"" []	EFO	69688	EFO:0004062	\N	NL2099	EFO:0004062
0	"Strain of C. briggsae described with phenotypes; biofilm absent head (Bah), carbon dioxide response variant, mate finding defective" []	\N	AF16	\N	\N	EFO	"Strain of C. briggsae described with phenotypes; biofilm absent head (Bah), carbon dioxide response variant, mate finding defective" []	EFO	69689	EFO:0004063	\N	AF16	EFO:0004063
0	"Strain of C. briggsae defined as having biofilm absent head (Bah)." []	\N	VT847	\N	\N	EFO	"Strain of C. briggsae defined as having biofilm absent head (Bah)." []	EFO	69690	EFO:0004064	\N	VT847	EFO:0004064
0	"Strain of C. briggsae" []	\N	HK104	\N	\N	EFO	"Strain of C. briggsae" []	EFO	69691	EFO:0004065	\N	HK104	EFO:0004065
0	"Strain of C. remanei described as having biofilm absent head (Bah)." []	\N	EM464	\N	\N	EFO	"Strain of C. remanei described as having biofilm absent head (Bah)." []	EFO	69692	EFO:0004066	\N	EM464	EFO:0004066
0	"Strain of R. remanei" []	\N	SB146	\N	\N	EFO	"Strain of R. remanei" []	EFO	69693	EFO:0004067	\N	SB146	EFO:0004067
0	"Strain of O dolichura, collected by a Belgian expedition to the Galapagos archipelago." []	\N	DF5033	\N	\N	EFO	"Strain of O dolichura, collected by a Belgian expedition to the Galapagos archipelago." []	EFO	69694	EFO:0004068	\N	DF5033	EFO:0004068
0	"Strain of O. dolichuroides, Isolated by W. Sudhaus in April 1978 from decaying matter in a hole in a tree in Malindi, Kenya." []	\N	DF5018	\N	\N	EFO	"Strain of O. dolichuroides, Isolated by W. Sudhaus in April 1978 from decaying matter in a hole in a tree in Malindi, Kenya." []	EFO	69695	EFO:0004069	\N	DF5018	EFO:0004069
0	"Strain of O. myriophila, isolated by D. Fitch in June 1990 from soil in Scott Emmons' compost heap in the Fort Greene section of Brooklyn, NY. A second strain, DF5038, was isolated from the same location one year later from the head and ventral segments of a male pill bug (Armadillidium vulgare). Hermaphroditic. Males are easily isolated by heat shocking L4 or early adult hermaphrodites at 30C for 6-12 hrs. Grows well at 6-25C on OP50. Dauer larvae accumulate under starved or overcrowded conditions. Freezes easily using C. elegans protocols with 90% viability. Previously called Rhabditis sp. See also WBPaper00003418." []	\N	EM435	\N	\N	EFO	"Strain of O. myriophila, isolated by D. Fitch in June 1990 from soil in Scott Emmons' compost heap in the Fort Greene section of Brooklyn, NY. A second strain, DF5038, was isolated from the same location one year later from the head and ventral segments of a male pill bug (Armadillidium vulgare). Hermaphroditic. Males are easily isolated by heat shocking L4 or early adult hermaphrodites at 30C for 6-12 hrs. Grows well at 6-25C on OP50. Dauer larvae accumulate under starved or overcrowded conditions. Freezes easily using C. elegans protocols with 90% viability. Previously called Rhabditis sp. See also WBPaper00003418." []	EFO	69696	EFO:0004070	\N	EM435	EFO:0004070
0	"Strain of O. tipulae, isolated in 1991 by Carlos E. Winter in soil samples taken at the University of Sao Paulo in Brazil. Hermaphrodite strain. Adults are 1.5mm. The life cycle is a little longer than C. elegans at 22C. Each lays about 300 eggs in the three days following the moult from L4 to adult. Eggs are laid just after being fertilized resulting sometimes in plates with many eggs (much more than C. elegans). See Comp. Biochem. Physiol 103B: 189, 1992. See Nematology 2(1): 89-98, 2000. Can be grown and maintained on NGM. L1s easily frozen and stored in liquid nitrogen." []	\N	CEW1	\N	\N	EFO	"Strain of O. tipulae, isolated in 1991 by Carlos E. Winter in soil samples taken at the University of Sao Paulo in Brazil. Hermaphrodite strain. Adults are 1.5mm. The life cycle is a little longer than C. elegans at 22C. Each lays about 300 eggs in the three days following the moult from L4 to adult. Eggs are laid just after being fertilized resulting sometimes in plates with many eggs (much more than C. elegans). See Comp. Biochem. Physiol 103B: 189, 1992. See Nematology 2(1): 89-98, 2000. Can be grown and maintained on NGM. L1s easily frozen and stored in liquid nitrogen." []	EFO	69697	EFO:0004071	\N	CEW1	EFO:0004071
0	"Strain of C. elegans." []	\N	AA120	\N	\N	EFO	"Strain of C. elegans." []	EFO	69698	EFO:0004072	\N	AA120	EFO:0004072
0	"Strain of C. elegans, remarked as a \\"twitcher\\"." []	\N	CB66	\N	\N	EFO	"Strain of C. elegans, remarked as a \\"twitcher\\"." []	EFO	69699	EFO:0004073	\N	CB66	EFO:0004073
0	"Strain of C. elegans, remarked as uncoordinated and may contain a weak daf-2 mutation (sa875)." []	\N	CB120	\N	\N	EFO	"Strain of C. elegans, remarked as uncoordinated and may contain a weak daf-2 mutation (sa875)." []	EFO	69700	EFO:0004074	\N	CB120	EFO:0004074
0	"" []	\N	CB155	\N	\N	EFO	"" []	EFO	69701	EFO:0004075	\N	CB155	EFO:0004075
0	"Strain of C. elegans, remarked as Coiler Unc, severe, recessive." []	\N	CB189	\N	\N	EFO	"Strain of C. elegans, remarked as Coiler Unc, severe, recessive." []	EFO	69702	EFO:0004076	\N	CB189	EFO:0004076
0	"Strain of C. elegans, remarked as growth slow, Unc and small, revertible." []	\N	CB205	\N	\N	EFO	"Strain of C. elegans, remarked as growth slow, Unc and small, revertible." []	EFO	69703	EFO:0004077	\N	CB205	EFO:0004077
0	"Strain of C. elegans Levamisole resistant, recessive, Kinky Unc." []	\N	CB306	\N	\N	EFO	"Strain of C. elegans Levamisole resistant, recessive, Kinky Unc." []	EFO	69704	EFO:0004078	\N	CB306	EFO:0004078
0	"Strain of C. elegans, remarked as temperature sensitive dauer constitutive, maintan at 15C, 100% dauers at 25C. 15% dauer formation at 20C. Long-lived." []	\N	CB1370	\N	\N	EFO	"Strain of C. elegans, remarked as temperature sensitive dauer constitutive, maintan at 15C, 100% dauers at 25C. 15% dauer formation at 20C. Long-lived." []	EFO	69705	EFO:0004079	\N	CB1370	EFO:0004079
0	"C. elegans strain remarked as defective dauer formation. Hermaphrodites accumulate oocytes. Males mate poorly." []	\N	DR20	\N	\N	EFO	"C. elegans strain remarked as defective dauer formation. Hermaphrodites accumulate oocytes. Males mate poorly." []	EFO	69706	EFO:0004080	\N	DR20	EFO:0004080
0	"Strain of C. elegans, described as Dauer defective-leaky. Somewhat small. Suppresses daf-2." []	\N	DR26	\N	\N	EFO	"Strain of C. elegans, described as Dauer defective-leaky. Somewhat small. Suppresses daf-2." []	EFO	69707	EFO:0004081	\N	DR26	EFO:0004081
0	"C. elegans, described as temperature sensitive dauer constitutive. 100% dauers at 25C. Dauer recovery poor at 15C. Maternal effect. Egg retainer." []	\N	DR40	\N	\N	EFO	"C. elegans, described as temperature sensitive dauer constitutive. 100% dauers at 25C. Dauer recovery poor at 15C. Maternal effect. Egg retainer." []	EFO	69708	EFO:0004082	\N	DR40	EFO:0004082
0	"C. elegans strain, described as temperature sensitive, leaky at 25C. Dauers recover poorly at 15C. Dauers escape plates. Recessive. Chemotaxis defective (Na+)" []	\N	DR47	\N	\N	EFO	"C. elegans strain, described as temperature sensitive, leaky at 25C. Dauers recover poorly at 15C. Dauers escape plates. Recessive. Chemotaxis defective (Na+)" []	EFO	69709	EFO:0004083	\N	DR47	EFO:0004083
0	"C. elegans strain, described as temperature-sensitive dauer-consitutive, long-lived, intrinsically thermotolerant. Adults slightly shorter than adults of other daf-2 alleles. Up to 6% of L1s arrest at 25.5C. Makes nearly 100% dauers at 25C, 0% dauers at 15C. Good recovery of dauers at 15C." []	\N	DR1564	\N	\N	EFO	"C. elegans strain, described as temperature-sensitive dauer-consitutive, long-lived, intrinsically thermotolerant. Adults slightly shorter than adults of other daf-2 alleles. Up to 6% of L1s arrest at 25.5C. Makes nearly 100% dauers at 25C, 0% dauers at 15C. Good recovery of dauers at 15C." []	EFO	69710	EFO:0004084	\N	DR1564	EFO:0004084
0	"Strain of C. elegans, described as Class 1 allele of daf-2. Temperature sensitive Daf-c. Adults are long-lived (Age) and exhibit extrinsic thermotolerance (Itt)." []	\N	DR1567	\N	\N	EFO	"Strain of C. elegans, described as Class 1 allele of daf-2. Temperature sensitive Daf-c. Adults are long-lived (Age) and exhibit extrinsic thermotolerance (Itt)." []	EFO	69711	EFO:0004085	\N	DR1567	EFO:0004085
0	"Strain of C. elegans, described as Class 1 allele of daf-2. Temperature sensitive Daf-c. Adults are long-lived (Age) and exhibit extrinsic thermotolerance (Itt)." []	\N	DR1572	\N	\N	EFO	"Strain of C. elegans, described as Class 1 allele of daf-2. Temperature sensitive Daf-c. Adults are long-lived (Age) and exhibit extrinsic thermotolerance (Itt)." []	EFO	69712	EFO:0004086	\N	DR1572	EFO:0004086
0	"" []	\N	GR1307	\N	\N	EFO	"" []	EFO	69713	EFO:0004087	\N	GR1307	EFO:0004087
0	"C. elegans strain described as Daf-c at 27C. Weakly Egl and Clumpy." []	\N	JT709	\N	\N	EFO	"C. elegans strain described as Daf-c at 27C. Weakly Egl and Clumpy." []	EFO	69714	EFO:0004088	\N	JT709	EFO:0004088
0	"C. elegans strain. Remarks include: the embryos from homozygous mutant mothers display defects in the unequal cell divisions of P2 and P3, defects in partitioning of germ granules during these divisions, and defects in formation of the germ-line precursor cell P4. The embryos that lack P4 develop into sterile adults. These defects are incompletely expressed and sensitive to temperature. Homozygous mothers produce about 10% sterile progeny at 16C and 70% sterile progeny at 25C. The temperature sensitive period is early in embryogenesis, from fertilization to about the 28-cell stage." []	\N	SS149	\N	\N	EFO	"C. elegans strain. Remarks include: the embryos from homozygous mutant mothers display defects in the unequal cell divisions of P2 and P3, defects in partitioning of germ granules during these divisions, and defects in formation of the germ-line precursor cell P4. The embryos that lack P4 develop into sterile adults. These defects are incompletely expressed and sensitive to temperature. Homozygous mothers produce about 10% sterile progeny at 16C and 70% sterile progeny at 25C. The temperature sensitive period is early in embryogenesis, from fertilization to about the 28-cell stage." []	EFO	69715	EFO:0004089	\N	SS149	EFO:0004089
0	"C. elegans strain, described as having slow development and behavior." []	\N	MQ887	\N	\N	EFO	"C. elegans strain, described as having slow development and behavior." []	EFO	69716	EFO:0004090	\N	MQ887	EFO:0004090
0	"C. elegans strain, described as Methylviologen (paraquat) sensitive, oxygen sensitive and having a short life span." []	\N	TK22	\N	\N	EFO	"C. elegans strain, described as Methylviologen (paraquat) sensitive, oxygen sensitive and having a short life span." []	EFO	69717	EFO:0004091	\N	TK22	EFO:0004091
0	"C. elegans strain, described as Superficially wild type. This strain was provided by the C. elegans Reverse Genetics Core Facility at UBC, which is part of the International C. elegans Gene Knockout Consortium" []	\N	VC199	\N	\N	EFO	"C. elegans strain, described as Superficially wild type. This strain was provided by the C. elegans Reverse Genetics Core Facility at UBC, which is part of the International C. elegans Gene Knockout Consortium" []	EFO	69718	EFO:0004092	\N	VC199	EFO:0004092
0	"Strain of C. elegans." []	\N	CB4858	\N	\N	EFO	"Strain of C. elegans." []	EFO	69719	EFO:0004093	\N	CB4858	EFO:0004093
0	"An image prodcued as the result of a scan, such as a medical scanner or array scanner." []	\N	scanned image	\N	\N	EFO	"An image prodcued as the result of a scan, such as a medical scanner or array scanner." []	EFO	69720	EFO:0004094	\N	scanned image	EFO:0004094
0	"A file stored for use on a computer containing data." []	\N	data file	\N	\N	EFO	"A file stored for use on a computer containing data." []	EFO	69721	EFO:0004095	\N	data file	EFO:0004095
0	"A data file containing array data which has been processed in some way using a data transformation." []	\N	processed array data file	\N	\N	EFO	"A data file containing array data which has been processed in some way using a data transformation." []	EFO	69722	EFO:0004096	\N	processed array data file	EFO:0004096
0	"An array data file which has been transformed into a matrix format as defined by MAGE-TAB specification." []	\N	MAGE-TAB array data matrix file	\N	\N	EFO	"An array data file which has been transformed into a matrix format as defined by MAGE-TAB specification." []	EFO	69723	EFO:0004097	\N	MAGE-TAB array data matrix file	EFO:0004097
0	"A data file which contains data produced as the result of running an array." []	\N	array data file	\N	\N	EFO	"A data file which contains data produced as the result of running an array." []	EFO	69724	EFO:0004098	\N	array data file	EFO:0004098
0	"AMAGE-TAB array data matrix file which has been transformed using some data processing/transformation method." []	\N	derived MAGE-TAB array data matrix file	\N	\N	EFO	"AMAGE-TAB array data matrix file which has been transformed using some data processing/transformation method." []	EFO	69725	EFO:0004099	\N	derived MAGE-TAB array data matrix file	EFO:0004099
0	"An interleukin is a multifunctional cytokine produced by leukocytes for regulating immune responses." []	\N	interleukin	\N	\N	EFO	"An interleukin is a multifunctional cytokine produced by leukocytes for regulating immune responses." []	EFO	69726	EFO:0004100	\N	interleukin	EFO:0004100
0	"Type of factor that can be used in the Atlas database" []	\N	validation type	\N	\N	EFO	"Type of factor that can be used in the Atlas database" []	EFO	69727	EFO:0004101	\N	validation type	EFO:0004101
0	"Sequencing library strategy permitted in Atlas" []	\N	seq_library_strategy	\N	\N	EFO	"Sequencing library strategy permitted in Atlas" []	EFO	69728	EFO:0004102	\N	seq_library_strategy	EFO:0004102
0	"Sequencing file type permitted in Atlas" []	\N	seq file type	\N	\N	EFO	"Sequencing file type permitted in Atlas" []	EFO	69729	EFO:0004103	\N	seq file type	EFO:0004103
0	"Sequencing library source permitted in Atlas" []	\N	seq_library_source	\N	\N	EFO	"Sequencing library source permitted in Atlas" []	EFO	69730	EFO:0004104	\N	seq_library_source	EFO:0004104
0	"Sequencing library selection permitted in Atlas" []	\N	seq_library_selection	\N	\N	EFO	"Sequencing library selection permitted in Atlas" []	EFO	69731	EFO:0004105	\N	seq_library_selection	EFO:0004105
0	"Sequencing instrument model included in Atlas" []	\N	seq instrument model	\N	\N	EFO	"Sequencing instrument model included in Atlas" []	EFO	69732	EFO:0004106	\N	seq instrument model	EFO:0004106
0	"Quality control type permitted in Atlas" []	\N	Atlas Quality Control type	\N	\N	EFO	"Quality control type permitted in Atlas" []	EFO	69733	EFO:0004107	\N	Atlas Quality Control type	EFO:0004107
0	"Experiment type permitted in Atlas" []	\N	Atlas experiment type	\N	\N	EFO	"Experiment type permitted in Atlas" []	EFO	69734	EFO:0004108	\N	Atlas experiment type	EFO:0004108
0	"Flag to mark any term permitted in Atlas" []	\N	validation flag	\N	\N	EFO	"Flag to mark any term permitted in Atlas" []	EFO	69735	EFO:0004110	\N	validation flag	EFO:0004110
0	"Flag for Atlas sequencing file types" []	\N	seq file type flag	\N	\N	EFO	"Flag for Atlas sequencing file types" []	EFO	69736	EFO:0004111	\N	seq file type flag	EFO:0004111
0	"Flag for Atlas sequencing library strategies" []	\N	seq library strategy flag	\N	\N	EFO	"Flag for Atlas sequencing library strategies" []	EFO	69737	EFO:0004112	\N	seq library strategy flag	EFO:0004112
0	"Flag for Atlas sequencing library sources" []	\N	seq library source flag	\N	\N	EFO	"Flag for Atlas sequencing library sources" []	EFO	69738	EFO:0004113	\N	seq library source flag	EFO:0004113
0	"Flag for Atlas sequencing library selections" []	\N	seq library selection flag	\N	\N	EFO	"Flag for Atlas sequencing library selections" []	EFO	69739	EFO:0004114	\N	seq library selection flag	EFO:0004114
0	"Flag for Atlas sequencing instrument models" []	\N	seq instrument model flag	\N	\N	EFO	"Flag for Atlas sequencing instrument models" []	EFO	69740	EFO:0004115	\N	seq instrument model flag	EFO:0004115
0	"Flag for Atlas quality control types" []	\N	QC type flag	\N	\N	EFO	"Flag for Atlas quality control types" []	EFO	69741	EFO:0004116	\N	QC type flag	EFO:0004116
0	"Flag for Atlas experiment types" []	\N	Atlas experiment type flag	\N	\N	EFO	"Flag for Atlas experiment types" []	EFO	69742	EFO:0004117	\N	Atlas experiment type flag	EFO:0004117
0	"Flag for Atlas factor types" []	\N	factor type flag	\N	\N	EFO	"Flag for Atlas factor types" []	EFO	69743	EFO:0004118	\N	factor type flag	EFO:0004118
0	"Flag for ArrayExpres experiment types" []	\N	AE experiment type flag	\N	\N	EFO	"Flag for ArrayExpres experiment types" []	EFO	69744	EFO:0004119	\N	AE experiment type flag	EFO:0004119
0	"Experiment type permitted specifically in ArrayExpress" []	\N	ArrayExpress experiment type	\N	\N	EFO	"Experiment type permitted specifically in ArrayExpress" []	EFO	69745	EFO:0004120	\N	ArrayExpress experiment type	EFO:0004120
0	"A synostosis that results in craniosynostosis and syndactyly." []	\N	acrocephalosyndactylia	\N	\N	EFO	"A synostosis that results in craniosynostosis and syndactyly." []	EFO	69746	EFO:0004123	\N	acrocephalosyndactylia	EFO:0004123
0	"" []	\N	Darier's disease	\N	\N	EFO	"" []	EFO	69747	EFO:0004124	\N	Darier's disease	EFO:0004124
0	"" []	\N	growth hormone-secreting pituitary adenoma	\N	\N	EFO	"" []	EFO	69748	EFO:0004125	\N	growth hormone-secreting pituitary adenoma	EFO:0004125
0	"" []	\N	Adie syndrome	\N	\N	EFO	"" []	EFO	69749	EFO:0004126	\N	Adie syndrome	EFO:0004126
0	"" []	\N	hyperthyroxinemia	\N	\N	EFO	"" []	EFO	69750	EFO:0004127	\N	hyperthyroxinemia	EFO:0004127
0	"" []	\N	nephritis, hereditary	\N	\N	EFO	"" []	EFO	69751	EFO:0004128	\N	nephritis, hereditary	EFO:0004128
0	"The familial amyloid neuropathies are a rare group of autosomal dominant neuropathies of autonomic and peripheral nerves." []	\N	familial amyloid neuropathy	\N	\N	EFO	"The familial amyloid neuropathies are a rare group of autosomal dominant neuropathies of autonomic and peripheral nerves." []	EFO	69752	EFO:0004129	\N	familial amyloid neuropathy	EFO:0004129
0	"The physical size of a tumor." []	\N	tumor size	\N	\N	EFO	"The physical size of a tumor." []	EFO	69753	EFO:0004134	\N	tumor size	EFO:0004134
0	"A bundle branch block refers to a defect of the heart's electrical conduction system in which the bundle branch may cease to conduct electrical impulses appropriately. This results in altered pathways for ventricular depolarization. Since the electrical impulse can no longer use the preferred pathway across the bundle branch, it may move instead through muscle fibers in a way that both slows the electrical movement and changes the directional propagation of the impulses. As a result, there is a loss of ventricular synchrony, ventricular depolarization is prolonged, and there may be a corresponding drop in cardiac output. When heart failure is present, a specialized pacemaker may be used to resynchronize the ventricles" []	\N	bundle branch block	\N	\N	EFO	"A bundle branch block refers to a defect of the heart's electrical conduction system in which the bundle branch may cease to conduct electrical impulses appropriately. This results in altered pathways for ventricular depolarization. Since the electrical impulse can no longer use the preferred pathway across the bundle branch, it may move instead through muscle fibers in a way that both slows the electrical movement and changes the directional propagation of the impulses. As a result, there is a loss of ventricular synchrony, ventricular depolarization is prolonged, and there may be a corresponding drop in cardiac output. When heart failure is present, a specialized pacemaker may be used to resynchronize the ventricles" []	EFO	69754	EFO:0004138	\N	bundle branch block	EFO:0004138
0	"uncontrolled cell growth (neoplasia) occurring in the colon, rectum or vermiform appendix." []	\N	colorectal neoplasm	\N	\N	EFO	"uncontrolled cell growth (neoplasia) occurring in the colon, rectum or vermiform appendix." []	EFO	69755	EFO:0004142	\N	colorectal neoplasm	EFO:0004142
0	"Carpal Tunnel Syndrome (CTS) is an entrapment idiopathic median neuropathy, causing paresthesia, pain, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel." []	\N	carpal tunnel syndrome	\N	\N	EFO	"Carpal Tunnel Syndrome (CTS) is an entrapment idiopathic median neuropathy, causing paresthesia, pain, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel." []	EFO	69756	EFO:0004143	\N	carpal tunnel syndrome	EFO:0004143
0	"Acatalasia is an autosomal recessive peroxisomal disorder caused by a complete lack of catalase. The disorder is relatively benign, although it causes an increased incidence of periodontal infections, and can under rare circumstances lead to gangrene." []	\N	acatalasia	\N	\N	EFO	"Acatalasia is an autosomal recessive peroxisomal disorder caused by a complete lack of catalase. The disorder is relatively benign, although it causes an increased incidence of periodontal infections, and can under rare circumstances lead to gangrene." []	EFO	69757	EFO:0004144	\N	acatalasia	EFO:0004144
0	"A muscular disease in which the muscle fibers do not function resulting in muscular weakness." []	\N	myopathy	\N	\N	EFO	"A muscular disease in which the muscle fibers do not function resulting in muscular weakness." []	EFO	69758	EFO:0004145	\N	myopathy	EFO:0004145
0	"A nervous system disease that is located in the nervous system." []	\N	neuropathy	\N	\N	EFO	"A nervous system disease that is located in the nervous system." []	EFO	69759	EFO:0004149	\N	neuropathy	EFO:0004149
0	"Chorea is a movement disease characterized by brief, quasi-purposeful, irregular contractions that are not repetitive or rhythmic, but appear to flow from one muscle to the next." []	\N	chorea	\N	\N	EFO	"Chorea is a movement disease characterized by brief, quasi-purposeful, irregular contractions that are not repetitive or rhythmic, but appear to flow from one muscle to the next." []	EFO	69760	EFO:0004152	\N	chorea	EFO:0004152
0	"Sequence Read file forma is a generic format for DNA sequence data capable of storing data generated by any DNA sequencing technology." []	\N	Sequence Read Format (SRF)	\N	\N	EFO	"Sequence Read file forma is a generic format for DNA sequence data capable of storing data generated by any DNA sequencing technology." []	EFO	69761	EFO:0004154	\N	Sequence Read Format (SRF)	EFO:0004154
0	"FASTQ format is a text-based format for storing both a biological sequence (usually nucleotide sequence) and its corresponding quality scores." []	\N	FASTQ format	\N	\N	EFO	"FASTQ format is a text-based format for storing both a biological sequence (usually nucleotide sequence) and its corresponding quality scores." []	EFO	69762	EFO:0004155	\N	FASTQ format	EFO:0004155
0	"Standard flowgram format (SFF) is a binary file format used to encode results of pyrosequencing from the 454 Life Sciences platform for high-throughput sequencing." []	\N	Standard Flowgram Format (SFF)	\N	\N	EFO	"Standard flowgram format (SFF) is a binary file format used to encode results of pyrosequencing from the 454 Life Sciences platform for high-throughput sequencing." []	EFO	69763	EFO:0004156	\N	Standard Flowgram Format (SFF)	EFO:0004156
0	"BAM is the compressed binary version of the Sequence Alignment/Map (SAM) format" []	\N	BAM format	\N	\N	EFO	"BAM is the compressed binary version of the Sequence Alignment/Map (SAM) format" []	EFO	69764	EFO:0004157	\N	BAM format	EFO:0004157
0	"" []	\N	random RNA-Seq across whole transcriptome	\N	\N	EFO	"" []	EFO	69765	EFO:0004158	\N	random RNA-Seq across whole transcriptome	EFO:0004158
0	"" []	\N	SOLiD native csfasta format	\N	\N	EFO	"" []	EFO	69766	EFO:0004159	\N	SOLiD native csfasta format	EFO:0004159
0	"" []	\N	whole chromosome random sequencing	\N	\N	EFO	"" []	EFO	69767	EFO:0004160	\N	whole chromosome random sequencing	EFO:0004160
0	"A sequencing assay which has been used to finish the sequence of an organism or sample, i.e. to finish (close) gaps in existing coverage" []	\N	finishing sequencing assay	\N	\N	EFO	"A sequencing assay which has been used to finish the sequence of an organism or sample, i.e. to finish (close) gaps in existing coverage" []	EFO	69768	EFO:0004161	\N	finishing sequencing assay	EFO:0004161
0	"" []	\N	CTS (Concatenated Tag Sequencing)	\N	\N	EFO	"" []	EFO	69769	EFO:0004162	\N	CTS (Concatenated Tag Sequencing)	EFO:0004162
0	"" []	\N	SOLiD native qual format	\N	\N	EFO	"" []	EFO	69770	EFO:0004163	\N	SOLiD native qual format	EFO:0004163
0	"" []	\N	Illumina native qseq format	\N	\N	EFO	"" []	EFO	69771	EFO:0004164	\N	Illumina native qseq format	EFO:0004164
0	"" []	\N	Illumina native scarf format	\N	\N	EFO	"" []	EFO	69772	EFO:0004165	\N	Illumina native scarf format	EFO:0004165
0	"" []	\N	Illumina native fastq format	\N	\N	EFO	"" []	EFO	69773	EFO:0004166	\N	Illumina native fastq format	EFO:0004166
0	"RAPD is a type of PCR reaction in which the segments of DNA are amplified at random using randomly generated primers." []	\N	RAPD	\N	\N	EFO	"RAPD is a type of PCR reaction in which the segments of DNA are amplified at random using randomly generated primers." []	EFO	69774	EFO:0004167	\N	RAPD	EFO:0004167
0	"" []	\N	hypomethylated partial restriction digest	\N	\N	EFO	"" []	EFO	69775	EFO:0004168	\N	hypomethylated partial restriction digest	EFO:0004168
0	"Methyl-filtration is a cloning strategy that enriches for the coding regions of the genome" []	\N	methyl filtration	\N	\N	EFO	"Methyl-filtration is a cloning strategy that enriches for the coding regions of the genome" []	EFO	69776	EFO:0004169	\N	methyl filtration	EFO:0004169
0	"A protocol describing the processes performed and equipment used to determine the order of nucleotide bases in a nucleic acid sample" []	\N	nucleic acid sequencing protocol	\N	\N	EFO	"A protocol describing the processes performed and equipment used to determine the order of nucleotide bases in a nucleic acid sample" []	EFO	69777	EFO:0004170	\N	nucleic acid sequencing protocol	EFO:0004170
0	"A type of cot filtration in which single/low copy sequences and the repetitive sequences of a genome to be studied independently of each other." []	\N	cot filtration for single or low copy genomic DNA	\N	\N	EFO	"A type of cot filtration in which single/low copy sequences and the repetitive sequences of a genome to be studied independently of each other." []	EFO	69778	EFO:0004171	\N	cot filtration for single or low copy genomic DNA	EFO:0004171
0	"A type of cot filtration in which moderately repetitive sequences and highly repetitive sequences of a genome can be separated to be studied independently of each other." []	\N	cot filtration for moderately repetitive genomic DNA	\N	\N	EFO	"A type of cot filtration in which moderately repetitive sequences and highly repetitive sequences of a genome can be separated to be studied independently of each other." []	EFO	69779	EFO:0004172	\N	cot filtration for moderately repetitive genomic DNA	EFO:0004172
0	"" []	\N	cot filtration for highly repetitive genomic DNA	\N	\N	EFO	"" []	EFO	69780	EFO:0004173	\N	cot filtration for highly repetitive genomic DNA	EFO:0004173
0	"" []	\N	cot filtration for theoretical single copy genomic DNA	\N	\N	EFO	"" []	EFO	69781	EFO:0004174	\N	cot filtration for theoretical single copy genomic DNA	EFO:0004174
0	"Methylation-spanning linker library (MSLL) processing uses clones which span large methylated DNA blocks and thereby link unmethylated genic regions." []	\N	Methylation Spanning Linker Library (MSLL) processing	\N	\N	EFO	"Methylation-spanning linker library (MSLL) processing uses clones which span large methylated DNA blocks and thereby link unmethylated genic regions." []	EFO	69782	EFO:0004175	\N	Methylation Spanning Linker Library (MSLL) processing	EFO:0004175
0	"Chromatin Immunoprecipitation (ChIP) is an experimental process used to investigate the interaction between proteins and DNA in the cell via the immunoprecipitation of transcriptionally active chromatin from mammalian cells." []	\N	ChIP	\N	\N	EFO	"Chromatin Immunoprecipitation (ChIP) is an experimental process used to investigate the interaction between proteins and DNA in the cell via the immunoprecipitation of transcriptionally active chromatin from mammalian cells." []	EFO	69783	EFO:0004176	\N	ChIP	EFO:0004176
0	"Micrococcal Nuclease digestion is the process of using an endo-exonuclease in order to digest single-stranded and double-stranded nucleic acids and RNA." []	\N	Micrococcal Nuclease digestion	\N	\N	EFO	"Micrococcal Nuclease digestion is the process of using an endo-exonuclease in order to digest single-stranded and double-stranded nucleic acids and RNA." []	EFO	69784	EFO:0004177	\N	Micrococcal Nuclease digestion	EFO:0004177
0	"An experimental process for producing a reduced target genome often generated by restriction fragment size selection, containing a manageable number of loci to facilitate re-sampling." []	\N	reduced representation preparation	\N	\N	EFO	"An experimental process for producing a reduced target genome often generated by restriction fragment size selection, containing a manageable number of loci to facilitate re-sampling." []	EFO	69785	EFO:0004178	\N	reduced representation preparation	EFO:0004178
0	"A restriction digest is an experimental process used to prepare DNA for analysis or other processing by the use of restriction enzymes to cleave DNA at desired sites for extraction." []	\N	restriction digest	\N	\N	EFO	"A restriction digest is an experimental process used to prepare DNA for analysis or other processing by the use of restriction enzymes to cleave DNA at desired sites for extraction." []	EFO	69786	EFO:0004179	\N	restriction digest	EFO:0004179
0	"An experimental process for selecting DNA which uses 5-methylcytidine antibody." []	\N	DNA selection through 5-methylcytidine antibody	\N	\N	EFO	"An experimental process for selecting DNA which uses 5-methylcytidine antibody." []	EFO	69787	EFO:0004180	\N	DNA selection through 5-methylcytidine antibody	EFO:0004180
0	"Cap analysis gene expression (CAGE) is an experimental process which allows high-throughput identification of sequence tags corresponding to 5′ ends of mRNA at the cap sites and the identification of the transcriptional starting point (TSP)." []	\N	cap analysis gene expression	\N	\N	EFO	"Cap analysis gene expression (CAGE) is an experimental process which allows high-throughput identification of sequence tags corresponding to 5′ ends of mRNA at the cap sites and the identification of the transcriptional starting point (TSP)." []	EFO	69788	EFO:0004181	\N	cap analysis gene expression	EFO:0004181
0	"Rapid Amplification of cDNA Ends (RACE) is an experimental process used to obtain the full length sequence of an RNA transcript found within a cell. RACE produces a cDNA copy of the RNA through reverse transcription which is amplified and sequenced." []	\N	Rapid Amplification of cDNA Ends	\N	\N	EFO	"Rapid Amplification of cDNA Ends (RACE) is an experimental process used to obtain the full length sequence of an RNA transcript found within a cell. RACE produces a cDNA copy of the RNA through reverse transcription which is amplified and sequenced." []	EFO	69789	EFO:0004182	\N	Rapid Amplification of cDNA Ends	EFO:0004182
0	"Size fractionation is a process of selecting targets based on their size." []	\N	size fractionation	\N	\N	EFO	"Size fractionation is a process of selecting targets based on their size." []	EFO	69790	EFO:0004183	\N	size fractionation	EFO:0004183
0	"A protocol describing the processes performed and equipment used to prepare nucleic acid sequencing library." []	\N	nucleic acid library construction protocol	\N	\N	EFO	"A protocol describing the processes performed and equipment used to prepare nucleic acid sequencing library." []	EFO	69791	EFO:0004184	\N	nucleic acid library construction protocol	EFO:0004184
0	"The isolation and enrichment of methylated DNA by using methyl CpG binding proteins, MBD2b protein in particular.\\n\\nMethylation of cytosines located 5' to guanosine is known to have a profound effect on the expression of many eukaryotic genes. In normal cells methylation occurs predominantly in CG-poor regions, while CG-rich areas, called CpG-islands remain unmethylated. The exceptions are the extensive methylation of CpG islands associated with transcriptional inactivation of regulatory regions of imprinted genes and genes on the inactive X-chromosome of females. Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event in immortalized and transformed cells and has been associated with transcriptional inactivation of defined tumor suppressor genes in human cancers.\\n\\nTo evalute the methylation status of either a specific locus or an entire genome, the isolation and enrichment of methylated DNA can be a useful first step. A high-affinity GST-MBD protein pre-bound to a magnetic bead is used to enable this enrichement  (Fraga M.F., et al. (2003). Nuc. Acids Res, 31, 1765–1774)." []	\N	enrichment of methylated DNA	\N	\N	EFO	"The isolation and enrichment of methylated DNA by using methyl CpG binding proteins, MBD2b protein in particular.\\n\\nMethylation of cytosines located 5' to guanosine is known to have a profound effect on the expression of many eukaryotic genes. In normal cells methylation occurs predominantly in CG-poor regions, while CG-rich areas, called CpG-islands remain unmethylated. The exceptions are the extensive methylation of CpG islands associated with transcriptional inactivation of regulatory regions of imprinted genes and genes on the inactive X-chromosome of females. Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event in immortalized and transformed cells and has been associated with transcriptional inactivation of defined tumor suppressor genes in human cancers.\\n\\nTo evalute the methylation status of either a specific locus or an entire genome, the isolation and enrichment of methylated DNA can be a useful first step. A high-affinity GST-MBD protein pre-bound to a magnetic bead is used to enable this enrichement  (Fraga M.F., et al. (2003). Nuc. Acids Res, 31, 1765–1774)." []	EFO	69792	EFO:0004185	\N	enrichment of methylated DNA	EFO:0004185
0	"Deoxyribonuclease digestion is the process of using an exodeoxyribonuclease or an endodeoxyribonuclease in order to digest single-stranded and double-stranded DNA." []	\N	Deoxyribonuclease digestion	\N	\N	EFO	"Deoxyribonuclease digestion is the process of using an exodeoxyribonuclease or an endodeoxyribonuclease in order to digest single-stranded and double-stranded DNA." []	EFO	69793	EFO:0004186	\N	Deoxyribonuclease digestion	EFO:0004186
0	"cDNA library is created from a mature mRNAs from eukaryotic cells with the use of an enzyme known as reverse transcriptase." []	\N	cDNA library construction	\N	\N	EFO	"cDNA library is created from a mature mRNAs from eukaryotic cells with the use of an enzyme known as reverse transcriptase." []	EFO	69794	EFO:0004187	\N	cDNA library construction	EFO:0004187
0	"The method of preparation of sequencing templates that are enriched for targeted regions of the genome by hybridization in array or solution." []	\N	hybrid selection of targets	\N	\N	EFO	"The method of preparation of sequencing templates that are enriched for targeted regions of the genome by hybridization in array or solution." []	EFO	69795	EFO:0004188	\N	hybrid selection of targets	EFO:0004188
0	"DNA shearing is an experimental process used to prepare DNA for analysis or other processing by the use of mechanical instruments to randomly cleave DNA. DNA is sheared to the desired fragment range.\\n \\nFor instance, physical shearing can be done by probe sonication and nebulization." []	\N	DNA shearing	\N	\N	EFO	"DNA shearing is an experimental process used to prepare DNA for analysis or other processing by the use of mechanical instruments to randomly cleave DNA. DNA is sheared to the desired fragment range.\\n \\nFor instance, physical shearing can be done by probe sonication and nebulization." []	EFO	69796	EFO:0004189	\N	DNA shearing	EFO:0004189
0	"Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris." []	\N	open-angle glaucoma	\N	\N	EFO	"Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris." []	EFO	69797	EFO:0004190	\N	open-angle glaucoma	EFO:0004190
0	"" []	\N	androgenetic alopecia	\N	\N	EFO	"" []	EFO	69798	EFO:0004191	\N	androgenetic alopecia	EFO:0004191
0	"A microscopically inflammatory, usually reversible, patchy hair loss occurring in sharply defined areas and usually involving the beard or scalp. (Dorland, 27th ed)." []	\N	alopecia areata	\N	\N	EFO	"A microscopically inflammatory, usually reversible, patchy hair loss occurring in sharply defined areas and usually involving the beard or scalp. (Dorland, 27th ed)." []	EFO	69799	EFO:0004192	\N	alopecia areata	EFO:0004192
0	"A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)." []	\N	basal cell carcinoma	\N	\N	EFO	"A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)." []	EFO	69800	EFO:0004193	\N	basal cell carcinoma	EFO:0004193
0	"A chronic form of glomerulonephritis characterized by deposits of predominantly immunoglobulin A in the mesangial area (glomerular mesangium). Deposits of complement C3 and immunoglobulin G are also often found. Clinical features may progress from asymptomatic hematuria to end-stage kidney disease." []	\N	IGA glomerulonephritis	\N	\N	EFO	"A chronic form of glomerulonephritis characterized by deposits of predominantly immunoglobulin A in the mesangial area (glomerular mesangium). Deposits of complement C3 and immunoglobulin G are also often found. Clinical features may progress from asymptomatic hematuria to end-stage kidney disease." []	EFO	69801	EFO:0004194	\N	IGA glomerulonephritis	EFO:0004194
0	"Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol." []	\N	LDL cholesterol	\N	\N	EFO	"Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol." []	EFO	69802	EFO:0004195	\N	LDL cholesterol	EFO:0004195
0	"INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission ( HEPATITIS A; HEPATITIS E) or blood transfusion ( HEPATITIS B; HEPATITIS C; and HEPATITIS D)." []	\N	viral human hepatitis infection	\N	\N	EFO	"INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission ( HEPATITIS A; HEPATITIS E) or blood transfusion ( HEPATITIS B; HEPATITIS C; and HEPATITIS D)." []	EFO	69803	EFO:0004196	\N	viral human hepatitis infection	EFO:0004196
0	"INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact." []	\N	hepatitis B infection	\N	\N	EFO	"INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact." []	EFO	69804	EFO:0004197	\N	hepatitis B infection	EFO:0004197
0	"Tumors or cancer of the SKIN." []	\N	skin neoplasm	\N	\N	EFO	"Tumors or cancer of the SKIN." []	EFO	69805	EFO:0004198	\N	skin neoplasm	EFO:0004198
0	"Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)" []	\N	dysplastic nevus	\N	\N	EFO	"Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)" []	EFO	69806	EFO:0004199	\N	dysplastic nevus	EFO:0004199
0	"A DNA sequencer developed by Illumina." []	\N	Illumina Genome Analyzer	\N	\N	EFO	"A DNA sequencer developed by Illumina." []	EFO	69807	EFO:0004200	\N	Illumina Genome Analyzer	EFO:0004200
0	"A DNA sequencer developed by Illumina." []	\N	Illumina Genome Analyzer II	\N	\N	EFO	"A DNA sequencer developed by Illumina." []	EFO	69808	EFO:0004201	\N	Illumina Genome Analyzer II	EFO:0004201
0	"A DNA sequencer developed by Illumina." []	\N	Illumina Genome Analyzer IIx	\N	\N	EFO	"A DNA sequencer developed by Illumina." []	EFO	69809	EFO:0004202	\N	Illumina Genome Analyzer IIx	EFO:0004202
0	"" []	\N	Illumina HiSeq 2000	\N	\N	EFO	"" []	EFO	69810	EFO:0004203	\N	Illumina HiSeq 2000	EFO:0004203
0	"" []	\N	Illumina HiSeq 1000	\N	\N	EFO	"" []	EFO	69811	EFO:0004204	\N	Illumina HiSeq 1000	EFO:0004204
0	"" []	\N	Illumina MiSeq	\N	\N	EFO	"" []	EFO	69812	EFO:0004205	\N	Illumina MiSeq	EFO:0004205
0	"The 454 GS 20 is a GS20 high-throughput sequencing machine developed by 454 Life Sciences." []	\N	454 GS 20 sequencer	\N	\N	EFO	"The 454 GS 20 is a GS20 high-throughput sequencing machine developed by 454 Life Sciences." []	EFO	69813	EFO:0004206	\N	454 GS 20 sequencer	EFO:0004206
0	"Excessive axial myopia associated with complications (especially posterior staphyloma and CHOROIDAL NEOVASCULARIZATION) that can lead to BLINDNESS." []	\N	pathological myopia	\N	\N	EFO	"Excessive axial myopia associated with complications (especially posterior staphyloma and CHOROIDAL NEOVASCULARIZATION) that can lead to BLINDNESS." []	EFO	69814	EFO:0004207	\N	pathological myopia	EFO:0004207
0	"A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached." []	\N	Vitiligo	\N	\N	EFO	"A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached." []	EFO	69815	EFO:0004208	\N	Vitiligo	EFO:0004208
0	"Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin." []	\N	gallstones	\N	\N	EFO	"Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin." []	EFO	69816	EFO:0004210	\N	gallstones	EFO:0004210
0	"A condition of elevated levels of TRIGLYCERIDES in the blood." []	\N	Hypertriglyceridemia	\N	\N	EFO	"A condition of elevated levels of TRIGLYCERIDES in the blood." []	EFO	69817	EFO:0004211	\N	Hypertriglyceridemia	EFO:0004211
0	"A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar ( CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues." []	\N	Keloid	\N	\N	EFO	"A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar ( CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues." []	EFO	69818	EFO:0004212	\N	Keloid	EFO:0004212
0	"Formation of spongy bone in the labyrinth capsule which can progress toward the STAPES (stapedial fixation) or anteriorly toward the COCHLEA leading to conductive, sensorineural, or mixed HEARING LOSS. Several genes are associated with familial otosclerosis with varied clinical signs." []	\N	Otosclerosis	\N	\N	EFO	"Formation of spongy bone in the labyrinth capsule which can progress toward the STAPES (stapedial fixation) or anteriorly toward the COCHLEA leading to conductive, sensorineural, or mixed HEARING LOSS. Several genes are associated with familial otosclerosis with varied clinical signs." []	EFO	69819	EFO:0004213	\N	Otosclerosis	EFO:0004213
0	"An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm." []	\N	Abdominal Aortic Aneurysm	\N	\N	EFO	"An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm." []	EFO	69820	EFO:0004214	\N	Abdominal Aortic Aneurysm	EFO:0004214
0	"An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)." []	\N	anorexia nervosa	\N	\N	EFO	"An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)." []	EFO	69821	EFO:0004215	\N	anorexia nervosa	EFO:0004215
0	"A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)." []	\N	conduct disorder	\N	\N	EFO	"A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)." []	EFO	69822	EFO:0004216	\N	conduct disorder	EFO:0004216
0	"The excessive use of marijuana with associated psychological symptoms and impairment in social or occupational functioning." []	\N	marijuana dependence	\N	\N	EFO	"The excessive use of marijuana with associated psychological symptoms and impairment in social or occupational functioning." []	EFO	69823	EFO:0004218	\N	marijuana dependence	EFO:0004218
0	"A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes ( T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes." []	\N	CD8-Positive T-Lymphocytes	\N	\N	EFO	"A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes ( T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes." []	EFO	69824	EFO:0004219	\N	CD8-Positive T-Lymphocytes	EFO:0004219
0	"INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS." []	\N	Chronic Hepatitis C infection	\N	\N	EFO	"INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS." []	EFO	69825	EFO:0004220	\N	Chronic Hepatitis C infection	EFO:0004220
0	"Unequal curvature of the refractive surfaces of the eye. Thus a point source of light cannot be brought to a point focus on the retina but is spread over a more or less diffuse area. This results from the radius of curvature in one plane being longer or shorter than the radius at right angles to it. (Dorland, 27th ed)." []	\N	Astigmatism	\N	\N	EFO	"Unequal curvature of the refractive surfaces of the eye. Thus a point source of light cannot be brought to a point focus on the retina but is spread over a more or less diffuse area. This results from the radius of curvature in one plane being longer or shorter than the radius at right angles to it. (Dorland, 27th ed)." []	EFO	69826	EFO:0004222	\N	Astigmatism	EFO:0004222
0	"Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction." []	\N	Coronary Restenosis	\N	\N	EFO	"Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction." []	EFO	69827	EFO:0004224	\N	Coronary Restenosis	EFO:0004224
0	"Spasm of the large- or medium-sized coronary arteries." []	\N	Coronary Vasospasm	\N	\N	EFO	"Spasm of the large- or medium-sized coronary arteries." []	EFO	69828	EFO:0004225	\N	Coronary Vasospasm	EFO:0004225
0	"A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))." []	\N	Creutzfeldt Jacob Disease	\N	\N	EFO	"A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))." []	EFO	69829	EFO:0004226	\N	Creutzfeldt Jacob Disease	EFO:0004226
0	"A virulent form of dengue characterized by THROMBOCYTOPENIA and an increase in vascular permeability (grades I and II) and distinguished by a positive pain test (e.g., TOURNIQUET PAIN TEST). When accompanied by SHOCK (grades III and IV), it is called dengue shock syndrome." []	\N	Dengue Hemorrhagic Fever	\N	\N	EFO	"A virulent form of dengue characterized by THROMBOCYTOPENIA and an increase in vascular permeability (grades I and II) and distinguished by a positive pain test (e.g., TOURNIQUET PAIN TEST). When accompanied by SHOCK (grades III and IV), it is called dengue shock syndrome." []	EFO	69830	EFO:0004227	\N	Dengue Hemorrhagic Fever	EFO:0004227
0	"A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment." []	\N	drug-induced liver injury	\N	\N	EFO	"A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment." []	EFO	69831	EFO:0004228	\N	drug-induced liver injury	EFO:0004228
0	"A fibromatosis of the palmar fascia characterized by thickening and contracture of the fibrous bands on the palmar surfaces of the hand and fingers. It arises most commonly in men between the ages of 30 and 50." []	\N	Dupuytren Contracture	\N	\N	EFO	"A fibromatosis of the palmar fascia characterized by thickening and contracture of the fibrous bands on the palmar surfaces of the hand and fingers. It arises most commonly in men between the ages of 30 and 50." []	EFO	69832	EFO:0004229	\N	Dupuytren Contracture	EFO:0004229
0	"Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells." []	\N	endometrial neoplasm	\N	\N	EFO	"Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells." []	EFO	69833	EFO:0004230	\N	endometrial neoplasm	EFO:0004230
0	"Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens." []	\N	eosinophilic esophagitis	\N	\N	EFO	"Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens." []	EFO	69834	EFO:0004232	\N	eosinophilic esophagitis	EFO:0004232
0	"decrease in no. of leukocytes" []	\N	leukopenia	\N	\N	EFO	"decrease in no. of leukocytes" []	EFO	69835	EFO:0004233	\N	leukopenia	EFO:0004233
0	"The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction." []	\N	erectile dysfunction	\N	\N	EFO	"The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction." []	EFO	69836	EFO:0004234	\N	erectile dysfunction	EFO:0004234
0	"The deposition of flaky, translucent fibrillar material most conspicuous on the anterior lens capsule and pupillary margin but also in both surfaces of the iris, the zonules, trabecular meshwork, ciliary body, corneal endothelium, and orbital blood vessels. It sometimes forms a membrane on the anterior iris surface. Exfoliation refers to the shedding of pigment by the iris. (Newell, Ophthalmology, 7th ed, p380)" []	\N	exfoliation syndrome	\N	\N	EFO	"The deposition of flaky, translucent fibrillar material most conspicuous on the anterior lens capsule and pupillary margin but also in both surfaces of the iris, the zonules, trabecular meshwork, ciliary body, corneal endothelium, and orbital blood vessels. It sometimes forms a membrane on the anterior iris surface. Exfoliation refers to the shedding of pigment by the iris. (Newell, Ophthalmology, 7th ed, p380)" []	EFO	69837	EFO:0004235	\N	exfoliation syndrome	EFO:0004235
0	"A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE." []	\N	focal segmental glomerulosclerosis	\N	\N	EFO	"A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE." []	EFO	69838	EFO:0004236	\N	focal segmental glomerulosclerosis	EFO:0004236
0	"A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes ( GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy)." []	\N	Graves disease	\N	\N	EFO	"A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes ( GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy)." []	EFO	69839	EFO:0004237	\N	Graves disease	EFO:0004237
0	"A general term for the complete or partial loss of the ability to hear from one or both ears." []	\N	hearing loss	\N	\N	EFO	"A general term for the complete or partial loss of the ability to hear from one or both ears." []	EFO	69840	EFO:0004238	\N	hearing loss	EFO:0004238
0	"INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact." []	\N	chronic hepatitis B infection	\N	\N	EFO	"INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact." []	EFO	69841	EFO:0004239	\N	chronic hepatitis B infection	EFO:0004239
0	"Strong dependence, both physiological and emotional, upon heroin." []	\N	heroin dependence	\N	\N	EFO	"Strong dependence, both physiological and emotional, upon heroin." []	EFO	69842	EFO:0004240	\N	heroin dependence	EFO:0004240
0	"An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension." []	\N	obsessive-compulsive disorder	\N	\N	EFO	"An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension." []	EFO	69843	EFO:0004242	\N	obsessive-compulsive disorder	EFO:0004242
0	"A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182). Some carcinoid tumours are a phenotype associated with mutations in the SDHD Gene (evidence OMIM record http://www.omim.org/entry/602690)" []	\N	carcinoid tumor	\N	\N	EFO	"A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182). Some carcinoid tumours are a phenotype associated with mutations in the SDHD Gene (evidence OMIM record http://www.omim.org/entry/602690)" []	EFO	69844	EFO:0004243	\N	carcinoid tumor	EFO:0004243
0	"A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features." []	\N	interstitial lung disease	\N	\N	EFO	"A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features." []	EFO	69845	EFO:0004244	\N	interstitial lung disease	EFO:0004244
0	"An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities." []	\N	mucocutaneous lymph node syndrome	\N	\N	EFO	"An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities." []	EFO	69846	EFO:0004246	\N	mucocutaneous lymph node syndrome	EFO:0004246
0	"Those disorders that have a disturbance in mood as their predominant feature." []	\N	mood disorder	\N	\N	EFO	"Those disorders that have a disturbance in mood as their predominant feature." []	EFO	69847	EFO:0004247	\N	mood disorder	EFO:0004247
0	"The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility." []	\N	male infertility	\N	\N	EFO	"The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility." []	EFO	69848	EFO:0004248	\N	male infertility	EFO:0004248
0	"Infections with bacteria of the species NEISSERIA MENINGITIDIS." []	\N	meningococcal infection	\N	\N	EFO	"Infections with bacteria of the species NEISSERIA MENINGITIDIS." []	EFO	69849	EFO:0004249	\N	meningococcal infection	EFO:0004249
0	"Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE." []	\N	myeloproliferative disorder	\N	\N	EFO	"Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE." []	EFO	69850	EFO:0004251	\N	myeloproliferative disorder	EFO:0004251
0	"Tumors or cancer of the NASOPHARYNX." []	\N	nasopharyngeal neoplasm	\N	\N	EFO	"Tumors or cancer of the NASOPHARYNX." []	EFO	69851	EFO:0004252	\N	nasopharyngeal neoplasm	EFO:0004252
0	"Formation of stones in the KIDNEY." []	\N	nephrolithiasis	\N	\N	EFO	"Formation of stones in the KIDNEY." []	EFO	69852	EFO:0004253	\N	nephrolithiasis	EFO:0004253
0	"A type of glomerulonephritis that is characterized by the accumulation of immune deposits ( COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane." []	\N	membranous glomerulonephritis	\N	\N	EFO	"A type of glomerulonephritis that is characterized by the accumulation of immune deposits ( COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane." []	EFO	69853	EFO:0004254	\N	membranous glomerulonephritis	EFO:0004254
0	"A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction." []	\N	nephrotic syndrome	\N	\N	EFO	"A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction." []	EFO	69854	EFO:0004255	\N	nephrotic syndrome	EFO:0004255
0	"A syndrome characterized by acute OPTIC NEURITIS in combination with acute MYELITIS, TRANSVERSE. Demyelinating and/or necrotizing lesions form in one or both optic nerves and in the spinal cord. The onset of optic neuritis and myelitis may be simultaneous or separated by several months. (J Neurol Neurosurg Psychiatry 1996 Apr;60(4):382-387)." []	\N	neuromyelitis optica	\N	\N	EFO	"A syndrome characterized by acute OPTIC NEURITIS in combination with acute MYELITIS, TRANSVERSE. Demyelinating and/or necrotizing lesions form in one or both optic nerves and in the spinal cord. The onset of optic neuritis and myelitis may be simultaneous or separated by several months. (J Neurol Neurosurg Psychiatry 1996 Apr;60(4):382-387)." []	EFO	69855	EFO:0004256	\N	neuromyelitis optica	EFO:0004256
0	"Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment." []	\N	neurotic disorder	\N	\N	EFO	"Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment." []	EFO	69856	EFO:0004257	\N	neurotic disorder	EFO:0004257
0	"The 2nd cranial nerve. The optic nerve conveys visual information from the retina to the brain. The nerve carries the axons of the retinal ganglion cells which sort at the optic chiasm and continue via the optic tracts to the brain. The largest projection is to the lateral geniculate nuclei; other important targets include the superior colliculi and the suprachiasmatic nuclei. Though known as the second cranial nerve, it is considered part of the central nervous system." []	\N	optic nerve	\N	\N	EFO	"The 2nd cranial nerve. The optic nerve conveys visual information from the retina to the brain. The nerve carries the axons of the retinal ganglion cells which sort at the optic chiasm and continue via the optic tracts to the brain. The largest projection is to the lateral geniculate nuclei; other important targets include the superior colliculi and the suprachiasmatic nuclei. Though known as the second cranial nerve, it is considered part of the central nervous system." []	EFO	69857	EFO:0004258	\N	optic nerve	EFO:0004258
0	"Death of a bone or part of a bone, either atraumatic or posttraumatic." []	\N	osteonecrosis	\N	\N	EFO	"Death of a bone or part of a bone, either atraumatic or posttraumatic." []	EFO	69858	EFO:0004259	\N	osteonecrosis	EFO:0004259
0	"Diseases of BONES." []	\N	bone disease	\N	\N	EFO	"Diseases of BONES." []	EFO	69859	EFO:0004260	\N	bone disease	EFO:0004260
0	"A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry." []	\N	osteitis deformans	\N	\N	EFO	"A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry." []	EFO	69860	EFO:0004261	\N	osteitis deformans	EFO:0004261
0	"A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait." []	\N	panic disorder	\N	\N	EFO	"A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait." []	EFO	69861	EFO:0004262	\N	panic disorder	EFO:0004262
0	"Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)." []	\N	partial epilepsy	\N	\N	EFO	"Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)." []	EFO	69862	EFO:0004263	\N	partial epilepsy	EFO:0004263
0	"Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body." []	\N	vascular disease	\N	\N	EFO	"Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body." []	EFO	69863	EFO:0004264	\N	vascular disease	EFO:0004264
0	"Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less." []	\N	peripheral arterial disease	\N	\N	EFO	"Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less." []	EFO	69864	EFO:0004265	\N	peripheral arterial disease	EFO:0004265
0	"Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections." []	\N	primary ovarian insufficiency	\N	\N	EFO	"Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections." []	EFO	69865	EFO:0004266	\N	primary ovarian insufficiency	EFO:0004266
0	"FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow ( CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts ( BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes." []	\N	biliary liver cirrhosis	\N	\N	EFO	"FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow ( CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts ( BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes." []	EFO	69866	EFO:0004267	\N	biliary liver cirrhosis	EFO:0004267
0	"Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS." []	\N	sclerosing cholangitis	\N	\N	EFO	"Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS." []	EFO	69867	EFO:0004268	\N	sclerosing cholangitis	EFO:0004268
0	"Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction." []	\N	cardiac arrhythmia	\N	\N	EFO	"Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction." []	EFO	69868	EFO:0004269	\N	cardiac arrhythmia	EFO:0004269
0	"A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep. Complying with an irresistible urge to move the affected limbs brings temporary relief. Sleep may become disrupted, resulting in excessive daytime hypersomnolence. This condition may be associated with UREMIA; DIABETES MELLITUS; and rheumatoid arthritis. Restless Legs Syndrome differs from NOCTURNAL MYOCLONUS SYNDROME in that in the latter condition the individual does not report adverse sensory stimuli and it is primarily a sleep-associated movement disorder. (Adams et al., Principles of Neurology, 6th ed, p387; Schweiz Rundsch Med Prax 1997 Apr 30;86(18):732-736)." []	\N	restless legs syndrome	\N	\N	EFO	"A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep. Complying with an irresistible urge to move the affected limbs brings temporary relief. Sleep may become disrupted, resulting in excessive daytime hypersomnolence. This condition may be associated with UREMIA; DIABETES MELLITUS; and rheumatoid arthritis. Restless Legs Syndrome differs from NOCTURNAL MYOCLONUS SYNDROME in that in the latter condition the individual does not report adverse sensory stimuli and it is primarily a sleep-associated movement disorder. (Adams et al., Principles of Neurology, 6th ed, p387; Schweiz Rundsch Med Prax 1997 Apr 30;86(18):732-736)." []	EFO	69869	EFO:0004270	\N	restless legs syndrome	EFO:0004270
0	"Central retinal vein and its tributaries. It runs a short course within the optic nerve and then leaves and empties into the superior ophthalmic vein or cavernous sinus." []	\N	retinal vein	\N	\N	EFO	"Central retinal vein and its tributaries. It runs a short course within the optic nerve and then leaves and empties into the superior ophthalmic vein or cavernous sinus." []	EFO	69870	EFO:0004271	\N	retinal vein	EFO:0004271
0	"A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin." []	\N	anemia	\N	\N	EFO	"A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin." []	EFO	69871	EFO:0004272	\N	anemia	EFO:0004272
0	"An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)" []	\N	scoliosis	\N	\N	EFO	"An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)" []	EFO	69872	EFO:0004273	\N	scoliosis	EFO:0004273
0	"Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi." []	\N	gout	\N	\N	EFO	"Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi." []	EFO	69873	EFO:0004274	\N	gout	EFO:0004274
0	"A variant of bullous erythema multiforme. It ranges from mild skin and mucous membrane lesions to a severe, sometimes fatal systemic disorder. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis, and sometimes blindness. The cause of the disease is unknown." []	\N	Stevens-Johnson syndrome	\N	\N	EFO	"A variant of bullous erythema multiforme. It ranges from mild skin and mucous membrane lesions to a severe, sometimes fatal systemic disorder. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis, and sometimes blindness. The cause of the disease is unknown." []	EFO	69874	EFO:0004276	\N	Stevens-Johnson syndrome	EFO:0004276
0	"Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis." []	\N	brain infarction	\N	\N	EFO	"Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis." []	EFO	69875	EFO:0004277	\N	brain infarction	EFO:0004277
0	"Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)" []	\N	sudden cardiac arrest	\N	\N	EFO	"Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)" []	EFO	69876	EFO:0004278	\N	sudden cardiac arrest	EFO:0004278
0	"An induced skin pigment ( MELANIN) darkening after exposure to SUNLIGHT or ULTRAVIOLET RAYS. The degree of tanning depends on the intensity and duration of UV exposure, and genetic factors." []	\N	suntan	\N	\N	EFO	"An induced skin pigment ( MELANIN) darkening after exposure to SUNLIGHT or ULTRAVIOLET RAYS. The degree of tanning depends on the intensity and duration of UV exposure, and genetic factors." []	EFO	69877	EFO:0004279	\N	suntan	EFO:0004279
0	"Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions." []	\N	movement disorder	\N	\N	EFO	"Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions." []	EFO	69878	EFO:0004280	\N	movement disorder	EFO:0004280
0	"Tumors or cancer of the TESTIS. Germ cell tumors ( GERMINOMA) of the testis constitute 95% of all testicular neoplasms." []	\N	testicular neoplasm	\N	\N	EFO	"Tumors or cancer of the TESTIS. Germ cell tumors ( GERMINOMA) of the testis constitute 95% of all testicular neoplasms." []	EFO	69879	EFO:0004281	\N	testicular neoplasm	EFO:0004281
0	"An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm." []	\N	thoracic aortic aneurysm	\N	\N	EFO	"An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm." []	EFO	69880	EFO:0004282	\N	thoracic aortic aneurysm	EFO:0004282
0	"Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency ( HYPOTHYROIDISM), or hormone overproduction ( HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic ( GOITER, ENDEMIC)." []	\N	goiter	\N	\N	EFO	"Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency ( HYPOTHYROIDISM), or hormone overproduction ( HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic ( GOITER, ENDEMIC)." []	EFO	69881	EFO:0004283	\N	goiter	EFO:0004283
0	"Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)" []	\N	upper aerodigestive tract neoplasm	\N	\N	EFO	"Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)" []	EFO	69882	EFO:0004284	\N	upper aerodigestive tract neoplasm	EFO:0004284
0	"The presence of albumin in the urine, an indicator of KIDNEY DISEASES." []	\N	albuminuria	\N	\N	EFO	"The presence of albumin in the urine, an indicator of KIDNEY DISEASES." []	EFO	69883	EFO:0004285	\N	albuminuria	EFO:0004285
0	"Obstruction of a vein or VEINS (embolism) by a blood clot ( THROMBUS) in the blood stream." []	\N	venous thromboembolism	\N	\N	EFO	"Obstruction of a vein or VEINS (embolism) by a blood clot ( THROMBUS) in the blood stream." []	EFO	69884	EFO:0004286	\N	venous thromboembolism	EFO:0004286
0	"A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness ( SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST." []	\N	ventricular fibrillation	\N	\N	EFO	"A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness ( SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST." []	EFO	69885	EFO:0004287	\N	ventricular fibrillation	EFO:0004287
0	"Tumors or cancer of the COLON." []	\N	colonic neoplasm	\N	\N	EFO	"Tumors or cancer of the COLON." []	EFO	69886	EFO:0004288	\N	colonic neoplasm	EFO:0004288
0	"Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts." []	\N	lymphoid leukemia	\N	\N	EFO	"Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts." []	EFO	69887	EFO:0004289	\N	lymphoid leukemia	EFO:0004289
0	"The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT." []	\N	sneezing	\N	\N	EFO	"The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT." []	EFO	69888	EFO:0004290	\N	sneezing	EFO:0004290
0	"Orthopedic appliances used to support, align, or hold parts of the body in correct position. (Dorland, 28th ed)." []	\N	braces	\N	\N	EFO	"Orthopedic appliances used to support, align, or hold parts of the body in correct position. (Dorland, 28th ed)." []	EFO	69889	EFO:0004291	\N	braces	EFO:0004291
0	"Vaccination is: a process' that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intend to invoke a protective immune response." []	\N	vaccination	\N	\N	EFO	"Vaccination is: a process' that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intend to invoke a protective immune response." []	EFO	69890	EFO:0004292	\N	vaccination	EFO:0004292
0	"Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses." []	\N	recombination	\N	\N	EFO	"Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses." []	EFO	69891	EFO:0004293	\N	recombination	EFO:0004293
0	"The hemodynamic and electrophysiological action of the LEFT ATRIUM." []	\N	atrial function, left	\N	\N	EFO	"The hemodynamic and electrophysiological action of the LEFT ATRIUM." []	EFO	69892	EFO:0004294	\N	atrial function, left	EFO:0004294
0	"The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance." []	\N	ventricular function, left	\N	\N	EFO	"The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance." []	EFO	69893	EFO:0004295	\N	ventricular function, left	EFO:0004295
0	"Physiological activity and functions of the highly vascular thyroid gland, such as producing the thyroid hormones which are concerned in regulating the metabolic rate of the body." []	\N	thyroid function	\N	\N	EFO	"Physiological activity and functions of the highly vascular thyroid gland, such as producing the thyroid hormones which are concerned in regulating the metabolic rate of the body." []	EFO	69894	EFO:0004296	\N	thyroid function	EFO:0004296
0	"A clinical laboratory measurement is a measurement of some entity e.g. erythrocyte count which is used in the process of clinical diagnosis in human patients" []	\N	clinical laboratory measurement	\N	\N	EFO	"A clinical laboratory measurement is a measurement of some entity e.g. erythrocyte count which is used in the process of clinical diagnosis in human patients" []	EFO	69895	EFO:0004297	\N	clinical laboratory measurement	EFO:0004297
0	"A cardiovascular measurement is a measurement of some part of the cardiovascular system and is typically used  in the process of disease diagnosis in human patients." []	\N	cardiovascular measurement	\N	\N	EFO	"A cardiovascular measurement is a measurement of some part of the cardiovascular system and is typically used  in the process of disease diagnosis in human patients." []	EFO	69896	EFO:0004298	\N	cardiovascular measurement	EFO:0004298
0	"Based on known statistical data, the number of years which any person of a given age may reasonably be expected to live." []	\N	life expectancy	\N	\N	EFO	"Based on known statistical data, the number of years which any person of a given age may reasonably be expected to live." []	EFO	69897	EFO:0004299	\N	life expectancy	EFO:0004299
0	"The  length of time of an organism's life." []	\N	longevity	\N	\N	EFO	"The  length of time of an organism's life." []	EFO	69898	EFO:0004300	\N	longevity	EFO:0004300
0	"The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA andPOLYCYTHEMIA." []	\N	blood viscosity	\N	\N	EFO	"The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA andPOLYCYTHEMIA." []	EFO	69899	EFO:0004301	\N	blood viscosity	EFO:0004301
0	"Anthropometry is a measurement of the size, weight, and proportions of the human or other primate body." []	\N	anthropometry	\N	\N	EFO	"Anthropometry is a measurement of the size, weight, and proportions of the human or other primate body." []	EFO	69900	EFO:0004302	\N	anthropometry	EFO:0004302
0	"The signs of life that may be monitored or measured, namely pulse rate, respiratory rate, body temperature, and blood pressure." []	\N	vital signs	\N	\N	EFO	"The signs of life that may be monitored or measured, namely pulse rate, respiratory rate, body temperature, and blood pressure." []	EFO	69901	EFO:0004303	\N	vital signs	EFO:0004303
0	"Measurement of rate of settling of erythrocytes in anticoagulated blood." []	\N	blood sedimentation	\N	\N	EFO	"Measurement of rate of settling of erythrocytes in anticoagulated blood." []	EFO	69902	EFO:0004304	\N	blood sedimentation	EFO:0004304
0	"The number of red blood cells per unit volume in a sample of venous blood." []	\N	erythrocyte count	\N	\N	EFO	"The number of red blood cells per unit volume in a sample of venous blood." []	EFO	69903	EFO:0004305	\N	erythrocyte count	EFO:0004305
0	"ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC)." []	\N	erythrocyte indices	\N	\N	EFO	"ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC)." []	EFO	69904	EFO:0004306	\N	erythrocyte indices	EFO:0004306
0	"A test to determine the ability of an individual to maintain homeostatis of blood glucose. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg)." []	\N	glucose tolerance test	\N	\N	EFO	"A test to determine the ability of an individual to maintain homeostatis of blood glucose. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg)." []	EFO	69905	EFO:0004307	\N	glucose tolerance test	EFO:0004307
0	"The number ofÂ WHITE BLOOD CELLSÂ per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells." []	\N	leukocyte count	\N	\N	EFO	"The number ofÂ WHITE BLOOD CELLSÂ per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells." []	EFO	69906	EFO:0004308	\N	leukocyte count	EFO:0004308
0	"The number ofÂ PLATELETSÂ per unit volume in a sample of venousÂ BLOOD." []	\N	platelet count	\N	\N	EFO	"The number ofÂ PLATELETSÂ per unit volume in a sample of venousÂ BLOOD." []	EFO	69907	EFO:0004309	\N	platelet count	EFO:0004309
0	"The time required for the appearance ofÂ FIBRINÂ strands following the mixing ofÂ PLASMAÂ with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) ofÂ BLOOD COAGULATION. It is used as a screening test and to monitorÂ HEPARINÂ therapy." []	\N	partial thromboplastin time	\N	\N	EFO	"The time required for the appearance ofÂ FIBRINÂ strands following the mixing ofÂ PLASMAÂ with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) ofÂ BLOOD COAGULATION. It is used as a screening test and to monitorÂ HEPARINÂ therapy." []	EFO	69908	EFO:0004310	\N	partial thromboplastin time	EFO:0004310
0	"A heart function measurement is a measurement of some heart function or process typically used to establish normal heart function or in process of diagnosis" []	\N	heart function measurement	\N	\N	EFO	"A heart function measurement is a measurement of some heart function or process typically used to establish normal heart function or in process of diagnosis" []	EFO	69909	EFO:0004311	\N	heart function measurement	EFO:0004311
0	"The volume of air that is exhaled by a maximal expiration following a maximal inspiration." []	\N	vital capacity	\N	\N	EFO	"The volume of air that is exhaled by a maximal expiration following a maximal inspiration." []	EFO	69910	EFO:0004312	\N	vital capacity	EFO:0004312
0	"Measurement of rate of airflow over the middle half of aÂ FORCED VITAL CAPACITYÂ determination (from the 25 percent level to the 75 percent level). Common abbreviations areÂ MMFRÂ and FEF 25%-75%." []	\N	maximal midexpiratory flow rate	\N	\N	EFO	"Measurement of rate of airflow over the middle half of aÂ FORCED VITAL CAPACITYÂ determination (from the 25 percent level to the 75 percent level). Common abbreviations areÂ MMFRÂ and FEF 25%-75%." []	EFO	69911	EFO:0004313	\N	maximal midexpiratory flow rate	EFO:0004313
0	"Measure of the maximum amount of air that can be expelled in a given number of seconds during aÂ FORCED VITAL CAPACITYÂ determination . It is usually given asÂ FEVÂ followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity." []	\N	forced expiratory volume	\N	\N	EFO	"Measure of the maximum amount of air that can be expelled in a given number of seconds during aÂ FORCED VITAL CAPACITYÂ determination . It is usually given asÂ FEVÂ followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity." []	EFO	69912	EFO:0004314	\N	forced expiratory volume	EFO:0004314
0	"Behaviors associated with the ingesting of water and other liquids; includes rhythmic patterns of drinking (time intervals - onset and duration), frequency and satiety." []	\N	drinking behavior	\N	\N	EFO	"Behaviors associated with the ingesting of water and other liquids; includes rhythmic patterns of drinking (time intervals - onset and duration), frequency and satiety." []	EFO	69913	EFO:0004315	\N	drinking behavior	EFO:0004315
0	"The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity." []	\N	exploratory behavior	\N	\N	EFO	"The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity." []	EFO	69914	EFO:0004316	\N	exploratory behavior	EFO:0004316
0	"A state in which attention is largely directed outward from the self." []	\N	extraversion	\N	\N	EFO	"A state in which attention is largely directed outward from the self." []	EFO	69915	EFO:0004317	\N	extraversion	EFO:0004317
0	"Inhaling and exhaling the smoke of tobacco or something similar to tobacco." []	\N	smoking behavior	\N	\N	EFO	"Inhaling and exhaling the smoke of tobacco or something similar to tobacco." []	EFO	69916	EFO:0004318	\N	smoking behavior	EFO:0004318
0	"Discontinuation of the habit of smoking, the inhaling and exhaling of tobacco smoke." []	\N	smoking cessation	\N	\N	EFO	"Discontinuation of the habit of smoking, the inhaling and exhaling of tobacco smoke." []	EFO	69917	EFO:0004319	\N	smoking cessation	EFO:0004319
0	"A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm." []	\N	suicidal ideation	\N	\N	EFO	"A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm." []	EFO	69918	EFO:0004320	\N	suicidal ideation	EFO:0004320
0	"The unsuccessful attempt to kill oneself." []	\N	suicide, attempted	\N	\N	EFO	"The unsuccessful attempt to kill oneself." []	EFO	69919	EFO:0004321	\N	suicide, attempted	EFO:0004321
0	"Conceptual functions or thinking in all its forms." []	\N	mental process	\N	\N	EFO	"Conceptual functions or thinking in all its forms." []	EFO	69920	EFO:0004323	\N	mental process	EFO:0004323
0	"Measurements of the height, weight, length, area, etc., of the human and animal body or its parts." []	\N	body weights and measures	\N	\N	EFO	"Measurements of the height, weight, length, area, etc., of the human and animal body or its parts." []	EFO	69921	EFO:0004324	\N	body weights and measures	EFO:0004324
0	"PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS." []	\N	blood pressure	\N	\N	EFO	"PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS." []	EFO	69922	EFO:0004325	\N	blood pressure	EFO:0004325
0	"The number of times the HEART VENTRICLES contract per unit of time, usually per minute." []	\N	heart rate	\N	\N	EFO	"The number of times the HEART VENTRICLES contract per unit of time, usually per minute." []	EFO	69923	EFO:0004326	\N	heart rate	EFO:0004326
0	"Recording of the moment-to-moment electromotive forces of theÂ HEARTÂ as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is aÂ CATHODE RAY TUBE DISPLAY." []	\N	electrocardiography	\N	\N	EFO	"Recording of the moment-to-moment electromotive forces of theÂ HEARTÂ as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is aÂ CATHODE RAY TUBE DISPLAY." []	EFO	69924	EFO:0004327	\N	electrocardiography	EFO:0004327
0	"Controlled physical activity, more strenuous than at rest, which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. The intensity of exercise is often graded, using criteria such as rate of work done, oxygen consumption, and heart rate." []	\N	exercise test	\N	\N	EFO	"Controlled physical activity, more strenuous than at rest, which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. The intensity of exercise is often graded, using criteria such as rate of work done, oxygen consumption, and heart rate." []	EFO	69925	EFO:0004328	\N	exercise test	EFO:0004328
0	"Behaviors associated with the ingesting of alcoholic beverages, including social drinking." []	\N	alcohol drinking	\N	\N	EFO	"Behaviors associated with the ingesting of alcoholic beverages, including social drinking." []	EFO	69926	EFO:0004329	\N	alcohol drinking	EFO:0004329
0	"Behaviors associated with the ingesting of coffee" []	\N	coffee consumption	\N	\N	EFO	"Behaviors associated with the ingesting of coffee" []	EFO	69927	EFO:0004330	\N	coffee consumption	EFO:0004330
0	"Type of declarative memory, consisting of personal memory in contrast to general knowledge." []	\N	episodic memory	\N	\N	EFO	"Type of declarative memory, consisting of personal memory in contrast to general knowledge." []	EFO	69928	EFO:0004333	\N	episodic memory	EFO:0004333
0	"Knowing or understanding without conscious use of reasoning. (Thesaurus of ERIC Descriptors, 1994)" []	\N	intuition	\N	\N	EFO	"Knowing or understanding without conscious use of reasoning. (Thesaurus of ERIC Descriptors, 1994)" []	EFO	69929	EFO:0004334	\N	intuition	EFO:0004334
0	"Remembrance of information for a few seconds to hours." []	\N	memory, short-term	\N	\N	EFO	"Remembrance of information for a few seconds to hours." []	EFO	69930	EFO:0004335	\N	memory, short-term	EFO:0004335
0	"The process whereby an utterance is decoded into a representation in terms of linguistic units (sequences of phonetic segments which combine to form lexical and grammatical morphemes)." []	\N	speech perception	\N	\N	EFO	"The process whereby an utterance is decoded into a representation in terms of linguistic units (sequences of phonetic segments which combine to form lexical and grammatical morphemes)." []	EFO	69931	EFO:0004336	\N	speech perception	EFO:0004336
0	"The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions." []	\N	intelligence	\N	\N	EFO	"The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions." []	EFO	69932	EFO:0004337	\N	intelligence	EFO:0004337
0	"The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms." []	\N	body weight	\N	\N	EFO	"The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms." []	EFO	69933	EFO:0004338	\N	body weight	EFO:0004338
0	"The distance from the sole to the crown of the head with body standing on a flat surface and fully extended." []	\N	body height	\N	\N	EFO	"The distance from the sole to the crown of the head with body standing on a flat surface and fully extended." []	EFO	69934	EFO:0004339	\N	body height	EFO:0004339
0	"An indicator of body density as determined by the relationship ofÂ BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)" []	\N	body mass index	\N	\N	EFO	"An indicator of body density as determined by the relationship ofÂ BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)" []	EFO	69935	EFO:0004340	\N	body mass index	EFO:0004340
0	"Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks." []	\N	body fat distribution	\N	\N	EFO	"Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks." []	EFO	69936	EFO:0004341	\N	body fat distribution	EFO:0004341
0	"The measurement around the body at the level of the ABDOMEN and just above the hip bone. The measurement is usually taken immediately after exhalation." []	\N	waist circumference	\N	\N	EFO	"The measurement around the body at the level of the ABDOMEN and just above the hip bone. The measurement is usually taken immediately after exhalation." []	EFO	69937	EFO:0004342	\N	waist circumference	EFO:0004342
0	"The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered \\"at risk\\" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)" []	\N	waist-hip ratio	\N	\N	EFO	"The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered \\"at risk\\" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)" []	EFO	69938	EFO:0004343	\N	waist-hip ratio	EFO:0004343
0	"The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms." []	\N	birth weight	\N	\N	EFO	"The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms." []	EFO	69939	EFO:0004344	\N	birth weight	EFO:0004344
0	"The measurement of curvature and shape of the anterior surface of the cornea using techniques such as keratometry, keratoscopy, photokeratoscopy, profile photography, computer-assisted image processing and videokeratography. This measurement is often applied in the fitting of contact lenses and in diagnosing corneal diseases or corneal changes including keratoconus, which occur after keratotomy and keratoplasty." []	\N	corneal topography	\N	\N	EFO	"The measurement of curvature and shape of the anterior surface of the cornea using techniques such as keratometry, keratoscopy, photokeratoscopy, profile photography, computer-assisted image processing and videokeratography. This measurement is often applied in the fitting of contact lenses and in diagnosing corneal diseases or corneal changes including keratoconus, which occur after keratotomy and keratoplasty." []	EFO	69940	EFO:0004345	\N	corneal topography	EFO:0004345
0	"Non-invasive methods of visualizing and measuring the CENTRAL NERVOUS SYSTEM, especially the brain, by various imaging modalities e.g. CT scan" []	\N	neuroimaging measurement	\N	\N	EFO	"Non-invasive methods of visualizing and measuring the CENTRAL NERVOUS SYSTEM, especially the brain, by various imaging modalities e.g. CT scan" []	EFO	69941	EFO:0004346	\N	neuroimaging measurement	EFO:0004346
0	"The observable, measurable, and often pathological activity of an organism that portrays its inability to overcome a habit resulting in an insatiable craving for a substance or for performing certain acts. The addictive behavior includes the emotional and physical overdependence on the object of habit in increasing amount or frequency." []	\N	addictive behaviour	\N	\N	EFO	"The observable, measurable, and often pathological activity of an organism that portrays its inability to overcome a habit resulting in an insatiable craving for a substance or for performing certain acts. The addictive behavior includes the emotional and physical overdependence on the object of habit in increasing amount or frequency." []	EFO	69942	EFO:0004347	\N	addictive behaviour	EFO:0004347
0	"The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value." []	\N	hematocrit	\N	\N	EFO	"The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value." []	EFO	69943	EFO:0004348	\N	hematocrit	EFO:0004348
0	"Thinking that is coherent and logical." []	\N	reasoning	\N	\N	EFO	"Thinking that is coherent and logical." []	EFO	69944	EFO:0004350	\N	reasoning	EFO:0004350
0	"" []	\N	resting heart rate	\N	\N	EFO	"" []	EFO	69945	EFO:0004351	\N	resting heart rate	EFO:0004351
0	"Is the quantification of the number of deaths is a population." []	\N	mortality	\N	\N	EFO	"Is the quantification of the number of deaths is a population." []	EFO	69946	EFO:0004352	\N	mortality	EFO:0004352
0	"The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs and stimuli, hormone secretion, sleeping, and feeding." []	\N	circadian rhythm	\N	\N	EFO	"The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs and stimuli, hormone secretion, sleeping, and feeding." []	EFO	69947	EFO:0004354	\N	circadian rhythm	EFO:0004354
0	"Am electroencephalogram measurement measures the wave-like oscillations of electric potential between parts of the brain." []	\N	electroencephalogram measurement	\N	\N	EFO	"Am electroencephalogram measurement measures the wave-like oscillations of electric potential between parts of the brain." []	EFO	69948	EFO:0004357	\N	electroencephalogram measurement	EFO:0004357
0	"The measurement of wave-like oscillations of electric potential between parts of the brain recorded by EEG that are the result of a specific stimulus" []	\N	event-related brain oscillation	\N	\N	EFO	"The measurement of wave-like oscillations of electric potential between parts of the brain recorded by EEG that are the result of a specific stimulus" []	EFO	69949	EFO:0004358	\N	event-related brain oscillation	EFO:0004358
0	"A terminal section of a chromosome which has a specialized structure and which is involved in chromosomal replication and stability. Its length is believed to be a few hundred base pairs." []	\N	telomere	\N	\N	EFO	"A terminal section of a chromosome which has a specialized structure and which is involved in chromosomal replication and stability. Its length is believed to be a few hundred base pairs." []	EFO	69950	EFO:0004359	\N	telomere	EFO:0004359
0	"The coordination of a sensory or ideational (cognitive) process and a motor activity." []	\N	psychomotor performance	\N	\N	EFO	"The coordination of a sensory or ideational (cognitive) process and a motor activity." []	EFO	69951	EFO:0004362	\N	psychomotor performance	EFO:0004362
0	"" []	\N	information processing speed	\N	\N	EFO	"" []	EFO	69952	EFO:0004363	\N	information processing speed	EFO:0004363
0	"Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of skills involved in the acquisition, processing, and utilization of knowledge or information." []	\N	neurobehavioral manifestations	\N	\N	EFO	"Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of skills involved in the acquisition, processing, and utilization of knowledge or information." []	EFO	69953	EFO:0004364	\N	neurobehavioral manifestations	EFO:0004364
0	"The characteristics in behavior that a certain person has." []	\N	personality trait	\N	\N	EFO	"The characteristics in behavior that a certain person has." []	EFO	69954	EFO:0004365	\N	personality trait	EFO:0004365
0	"A personality trait rendering the individual acceptable in social or interpersonal relations. It is related to social acceptance, social approval, popularity, social status, leadership qualities, or any quality making him a socially desirable companion." []	\N	social desirability	\N	\N	EFO	"A personality trait rendering the individual acceptable in social or interpersonal relations. It is related to social acceptance, social approval, popularity, social status, leadership qualities, or any quality making him a socially desirable companion." []	EFO	69955	EFO:0004366	\N	social desirability	EFO:0004366
0	"" []	\N	induces sterile inflammation	\N	\N	EFO	"" []	EFO	69956	EFO:0004367	\N	induces sterile inflammation	EFO:0004367
0	"" []	\N	Number of molecules	\N	\N	EFO	"" []	EFO	69957	EFO:0004368	\N	Number of molecules	EFO:0004368
0	"" []	\N	microgram per square centimeter	\N	\N	EFO	"" []	EFO	69958	EFO:0004370	\N	microgram per square centimeter	EFO:0004370
0	"" []	\N	gram per kilogram per day	\N	\N	EFO	"" []	EFO	69959	EFO:0004371	\N	gram per kilogram per day	EFO:0004371
0	"" []	\N	milligram per square meter	\N	\N	EFO	"" []	EFO	69960	EFO:0004373	\N	milligram per square meter	EFO:0004373
0	"" []	\N	milligram per deciliter	\N	\N	EFO	"" []	EFO	69961	EFO:0004374	\N	milligram per deciliter	EFO:0004374
0	"" []	\N	microgram per day	\N	\N	EFO	"" []	EFO	69962	EFO:0004378	\N	microgram per day	EFO:0004378
0	"" []	\N	milli-International Unit per milliliter	\N	\N	EFO	"" []	EFO	69963	EFO:0004379	\N	milli-International Unit per milliliter	EFO:0004379
0	"" []	\N	mole per liter	\N	\N	EFO	"" []	EFO	69964	EFO:0004381	\N	mole per liter	EFO:0004381
0	"" []	\N	nanogram per liter	\N	\N	EFO	"" []	EFO	69965	EFO:0004382	\N	nanogram per liter	EFO:0004382
0	"" []	\N	nanogram per microliter	\N	\N	EFO	"" []	EFO	69966	EFO:0004383	\N	nanogram per microliter	EFO:0004383
0	"" []	\N	weight percent by volume	\N	\N	EFO	"" []	EFO	69967	EFO:0004384	\N	weight percent by volume	EFO:0004384
0	"" []	\N	picogram per milliliter	\N	\N	EFO	"" []	EFO	69968	EFO:0004385	\N	picogram per milliliter	EFO:0004385
0	"" []	\N	total particulate matter per liter	\N	\N	EFO	"" []	EFO	69969	EFO:0004386	\N	total particulate matter per liter	EFO:0004386
0	"" []	\N	inch	\N	\N	EFO	"" []	EFO	69970	EFO:0004387	\N	inch	EFO:0004387
0	"" []	\N	picomole per 10^6 cells	\N	\N	EFO	"" []	EFO	69971	EFO:0004388	\N	picomole per 10^6 cells	EFO:0004388
0	"Human chordoma cell line" []	\N	UCH-1	\N	\N	EFO	"Human chordoma cell line" []	EFO	69972	EFO:0004389	\N	UCH-1	EFO:0004389
0	"" []	\N	mouse postnatal	\N	\N	EFO	"" []	EFO	69973	EFO:0004390	\N	mouse postnatal	EFO:0004390
0	"Theiler stage 27 is a newborn mouse." []	\N	Theiler stage 27	\N	\N	EFO	"Theiler stage 27 is a newborn mouse." []	EFO	69974	EFO:0004391	\N	Theiler stage 27	EFO:0004391
0	"" []	\N	Theiler stage 1	\N	\N	EFO	"" []	EFO	69975	EFO:0004393	\N	Theiler stage 1	EFO:0004393
0	"" []	\N	Theiler stage 2	\N	\N	EFO	"" []	EFO	69976	EFO:0004394	\N	Theiler stage 2	EFO:0004394
0	"" []	\N	Theiler stage 3	\N	\N	EFO	"" []	EFO	69977	EFO:0004395	\N	Theiler stage 3	EFO:0004395
0	"" []	\N	Theiler stage 4	\N	\N	EFO	"" []	EFO	69978	EFO:0004396	\N	Theiler stage 4	EFO:0004396
0	"" []	\N	Theiler stage 5	\N	\N	EFO	"" []	EFO	69979	EFO:0004397	\N	Theiler stage 5	EFO:0004397
0	"" []	\N	Theiler stage 6	\N	\N	EFO	"" []	EFO	69980	EFO:0004398	\N	Theiler stage 6	EFO:0004398
0	"" []	\N	Theiler stage 7	\N	\N	EFO	"" []	EFO	69981	EFO:0004399	\N	Theiler stage 7	EFO:0004399
0	"" []	\N	Theiler stage 8	\N	\N	EFO	"" []	EFO	69982	EFO:0004400	\N	Theiler stage 8	EFO:0004400
0	"" []	\N	Theiler stage 9	\N	\N	EFO	"" []	EFO	69983	EFO:0004401	\N	Theiler stage 9	EFO:0004401
0	"" []	\N	Theiler stage 10	\N	\N	EFO	"" []	EFO	69984	EFO:0004402	\N	Theiler stage 10	EFO:0004402
0	"" []	\N	Theiler stage 12	\N	\N	EFO	"" []	EFO	69985	EFO:0004403	\N	Theiler stage 12	EFO:0004403
0	"" []	\N	Theiler stage 13	\N	\N	EFO	"" []	EFO	69986	EFO:0004404	\N	Theiler stage 13	EFO:0004404
0	"" []	\N	Theiler stage 14	\N	\N	EFO	"" []	EFO	69987	EFO:0004405	\N	Theiler stage 14	EFO:0004405
0	"" []	\N	Theiler stage 15	\N	\N	EFO	"" []	EFO	69988	EFO:0004406	\N	Theiler stage 15	EFO:0004406
0	"" []	\N	Theiler stage 16	\N	\N	EFO	"" []	EFO	69989	EFO:0004407	\N	Theiler stage 16	EFO:0004407
0	"" []	\N	Theiler stage 18	\N	\N	EFO	"" []	EFO	69990	EFO:0004408	\N	Theiler stage 18	EFO:0004408
0	"" []	\N	Theiler stage 19	\N	\N	EFO	"" []	EFO	69991	EFO:0004409	\N	Theiler stage 19	EFO:0004409
0	"" []	\N	Theiler stage 20	\N	\N	EFO	"" []	EFO	69992	EFO:0004410	\N	Theiler stage 20	EFO:0004410
0	"" []	\N	Theiler stage 23	\N	\N	EFO	"" []	EFO	69993	EFO:0004411	\N	Theiler stage 23	EFO:0004411
0	"" []	\N	Theiler stage 25	\N	\N	EFO	"" []	EFO	69994	EFO:0004412	\N	Theiler stage 25	EFO:0004412
0	"" []	\N	microliter per liter	\N	\N	EFO	"" []	EFO	69995	EFO:0004413	\N	microliter per liter	EFO:0004413
0	"" []	\N	joule per square meter	\N	\N	EFO	"" []	EFO	69996	EFO:0004414	\N	joule per square meter	EFO:0004414
0	"An electrically neutral ionic compound composed of cations (positively charged ions) and anions (negative ions) resulting from the neutralization reaction of an acid and a base." []	\N	ionic salt	\N	\N	EFO	"An electrically neutral ionic compound composed of cations (positively charged ions) and anions (negative ions) resulting from the neutralization reaction of an acid and a base." []	EFO	69997	EFO:0004415	\N	ionic salt	EFO:0004415
0	"" []	\N	acid	\N	\N	EFO	"" []	EFO	69998	EFO:0004416	\N	acid	EFO:0004416
0	"" []	\N	amide	\N	\N	EFO	"" []	EFO	69999	EFO:0004417	\N	amide	EFO:0004417
0	"A unit which measures substance that passes through or onto a given area per unit of time." []	\N	unit of flow rate	\N	\N	EFO	"A unit which measures substance that passes through or onto a given area per unit of time." []	EFO	70000	EFO:0004418	\N	unit of flow rate	EFO:0004418
0	"A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours." []	\N	milligram per day	\N	\N	EFO	"A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours." []	EFO	70001	EFO:0004419	\N	milligram per day	EFO:0004419
0	"A genome is the full genetic content of an organism, contained in either DNA or RNA (such as for viruses)." []	\N	genome	\N	\N	EFO	"A genome is the full genetic content of an organism, contained in either DNA or RNA (such as for viruses)." []	EFO	70002	EFO:0004420	\N	genome	EFO:0004420
0	"The transcriptome is the set of all RNA molecules, including mRNA, rRNA, tRNA, and other non-coding RNA produced in one or a population of cells." []	\N	transcriptome	\N	\N	EFO	"The transcriptome is the set of all RNA molecules, including mRNA, rRNA, tRNA, and other non-coding RNA produced in one or a population of cells." []	EFO	70003	EFO:0004421	\N	transcriptome	EFO:0004421
0	"The exome is the part of the genome formed by the complete content of exons, coding portions of genes in the genome that are expressed." []	\N	exome	\N	\N	EFO	"The exome is the part of the genome formed by the complete content of exons, coding portions of genes in the genome that are expressed." []	EFO	70004	EFO:0004422	\N	exome	EFO:0004422
0	"An exon is a nucleic acid sequence that is represented in the mature form of an RNA molecule either after portions of a precursor RNA (introns) have been removed by cis-splicing or when two or more precursor RNA molecules have been ligated by trans-splicing." []	\N	exon	\N	\N	EFO	"An exon is a nucleic acid sequence that is represented in the mature form of an RNA molecule either after portions of a precursor RNA (introns) have been removed by cis-splicing or when two or more precursor RNA molecules have been ligated by trans-splicing." []	EFO	70005	EFO:0004423	\N	exon	EFO:0004423
0	"" []	\N	family relationship	\N	\N	EFO	"" []	EFO	70006	EFO:0004424	\N	family relationship	EFO:0004424
0	"The first time point measured at the start of some process." []	\N	initial time point	\N	\N	EFO	"The first time point measured at the start of some process." []	EFO	70007	EFO:0004425	\N	initial time point	EFO:0004425
0	"A karyotype is the number and appearance of chromosomes in the nucleus of a eukaryotic cell." []	\N	karyotype	\N	\N	EFO	"A karyotype is the number and appearance of chromosomes in the nucleus of a eukaryotic cell." []	EFO	70008	EFO:0004426	\N	karyotype	EFO:0004426
0	"" []	\N	joule per square centimeter	\N	\N	EFO	"" []	EFO	70009	EFO:0004427	\N	joule per square centimeter	EFO:0004427
0	"FAIRE-Seq (Formaldehyde-Assisted Isolation of Regulatory Elements) is an assay used for determining the sequences of DNA regions associated with regulatory activity. This is enabled by the isolation of nucleosome-depleted DNA from total genomic dna to access actively transcribed dna." []	\N	FAIRE-seq	\N	\N	EFO	"FAIRE-Seq (Formaldehyde-Assisted Isolation of Regulatory Elements) is an assay used for determining the sequences of DNA regions associated with regulatory activity. This is enabled by the isolation of nucleosome-depleted DNA from total genomic dna to access actively transcribed dna." []	EFO	70010	EFO:0004428	\N	FAIRE-seq	EFO:0004428
0	"Property of an organism which indicates that the organism's parents were genetically related (potentially for several generations). Inbreeding results in closer homozygosity." []	\N	inbred	\N	\N	EFO	"Property of an organism which indicates that the organism's parents were genetically related (potentially for several generations). Inbreeding results in closer homozygosity." []	EFO	70011	EFO:0004429	\N	inbred	EFO:0004429
0	"Propety of an organism which indicates that the organism's parents are not closely related (e.g. family members)." []	\N	outbred	\N	\N	EFO	"Propety of an organism which indicates that the organism's parents are not closely related (e.g. family members)." []	EFO	70012	EFO:0004430	\N	outbred	EFO:0004430
0	"The 454 GS is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	\N	454 GS sequencer	\N	\N	EFO	"The 454 GS is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	EFO	70013	EFO:0004431	\N	454 GS sequencer	EFO:0004431
0	"" []	\N	454 GS FLX sequencer	\N	\N	EFO	"" []	EFO	70014	EFO:0004432	\N	454 GS FLX sequencer	EFO:0004432
0	"The 454 GS FLX Titanium sequencer is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	\N	454 GS FLX Titanium sequencer	\N	\N	EFO	"The 454 GS FLX Titanium sequencer is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	EFO	70015	EFO:0004433	\N	454 GS FLX Titanium sequencer	EFO:0004433
0	"The 454 GS Junior is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	\N	454 GS Junior sequencer	\N	\N	EFO	"The 454 GS Junior is a GS high-throughput sequencing machine developed by 454 Life Sciences." []	EFO	70016	EFO:0004434	\N	454 GS Junior sequencer	EFO:0004434
0	"" []	\N	AB SOLiD System	\N	\N	EFO	"" []	EFO	70017	EFO:0004435	\N	AB SOLiD System	EFO:0004435
0	"" []	\N	AB SOLiD 5500xl	\N	\N	EFO	"" []	EFO	70018	EFO:0004436	\N	AB SOLiD 5500xl	EFO:0004436
0	"" []	\N	AB SOLiD PI System	\N	\N	EFO	"" []	EFO	70019	EFO:0004437	\N	AB SOLiD PI System	EFO:0004437
0	"" []	\N	AB SOLiD 4 System	\N	\N	EFO	"" []	EFO	70020	EFO:0004438	\N	AB SOLiD 4 System	EFO:0004438
0	"" []	\N	AB SOLiD System 3.0	\N	\N	EFO	"" []	EFO	70021	EFO:0004439	\N	AB SOLiD System 3.0	EFO:0004439
0	"" []	\N	AB SOLiD 5500	\N	\N	EFO	"" []	EFO	70022	EFO:0004440	\N	AB SOLiD 5500	EFO:0004440
0	"" []	\N	AB SOLiD 4hq System	\N	\N	EFO	"" []	EFO	70023	EFO:0004441	\N	AB SOLiD 4hq System	EFO:0004441
0	"" []	\N	AB SOLiD System 2.0	\N	\N	EFO	"" []	EFO	70024	EFO:0004442	\N	AB SOLiD System 2.0	EFO:0004442
0	"An organization which has supplied material to another individual or organization, such as to be used in a biomedical investigation." []	\N	material supplier	\N	\N	EFO	"An organization which has supplied material to another individual or organization, such as to be used in a biomedical investigation." []	EFO	70025	EFO:0004443	\N	material supplier	EFO:0004443
0	"Information concerning the envinonrment a material entity has been exposed to, such as an organism from a lake." []	\N	environmental history	\N	\N	EFO	"Information concerning the envinonrment a material entity has been exposed to, such as an organism from a lake." []	EFO	70026	EFO:0004444	\N	environmental history	EFO:0004444
0	"A cohort is a collection of material entities grouped together based on some common property of interest, such as age or disease stage." []	\N	cohort	\N	\N	EFO	"A cohort is a collection of material entities grouped together based on some common property of interest, such as age or disease stage." []	EFO	70027	EFO:0004445	\N	cohort	EFO:0004445
0	"Anatomical structure which has as its parts one or more ordered aggregates of nucleotide, amino acid fatty acid or sugar molecules bonded to one another." []	\N	biological macromolecule	\N	\N	EFO	"Anatomical structure which has as its parts one or more ordered aggregates of nucleotide, amino acid fatty acid or sugar molecules bonded to one another." []	EFO	70028	EFO:0004446	\N	biological macromolecule	EFO:0004446
0	"The role of a material which has been reviewed under peer review for quality control purposes." []	\N	peer review quality control role	\N	\N	EFO	"The role of a material which has been reviewed under peer review for quality control purposes." []	EFO	70029	EFO:0004447	\N	peer review quality control role	EFO:0004447
0	"10% of flowers to be produced have opened" []	\N	Arabidopsis Growth Stage 6.10	\N	\N	EFO	"10% of flowers to be produced have opened" []	EFO	70030	EFO:0004450	\N	Arabidopsis Growth Stage 6.10	EFO:0004450
0	"30% of flowers to be produced have opened" []	\N	Arabidopsis Growth Stage 6.30	\N	\N	EFO	"30% of flowers to be produced have opened" []	EFO	70031	EFO:0004451	\N	Arabidopsis Growth Stage 6.30	EFO:0004451
0	"50% of flowers to be produced have opened" []	\N	Arabidopsis Growth Stage 6.50	\N	\N	EFO	"50% of flowers to be produced have opened" []	EFO	70032	EFO:0004452	\N	Arabidopsis Growth Stage 6.50	EFO:0004452
0	"Arabidopsis Growth Stage 6.50" []	\N	Arabidopsis Growth Stage 8.00	\N	\N	EFO	"Arabidopsis Growth Stage 6.50" []	EFO	70033	EFO:0004453	\N	Arabidopsis Growth Stage 8.00	EFO:0004453
0	"Senescence complete; ready for seed harvest." []	\N	Arabidopsis Growth Stage 9.70	\N	\N	EFO	"Senescence complete; ready for seed harvest." []	EFO	70034	EFO:0004454	\N	Arabidopsis Growth Stage 9.70	EFO:0004454
0	"Cot filtration is an experimental process that uses DNA renaturation kinetics (i.e. Cot analysis) to separate repetitive DNA sequences that dominate many eukaryotic genomes from low-copy sequences which are more gene rich." []	\N	cot filtration	\N	\N	EFO	"Cot filtration is an experimental process that uses DNA renaturation kinetics (i.e. Cot analysis) to separate repetitive DNA sequences that dominate many eukaryotic genomes from low-copy sequences which are more gene rich." []	EFO	70035	EFO:0004455	\N	cot filtration	EFO:0004455
0	"" []	\N	reduce cholesterol levels	\N	\N	EFO	"" []	EFO	70036	EFO:0004456	\N	reduce cholesterol levels	EFO:0004456
0	"Any chemical, biological or physical agents that increase the risk of neoplasms in humans or animals. Carcinogens include natural or synthesized compounds, certain viruses, and various sources of radiation. A carcinogen may directly alter the genetic material of cells (genotoxic), thereby initiating or promoting the process of malignant transformation; it also may induce cancers by mechanisms that do not involve a direct alteration of cellular genetic material (non-genotoxic). (NCI04)" []	\N	carcinogen role	\N	\N	EFO	"Any chemical, biological or physical agents that increase the risk of neoplasms in humans or animals. Carcinogens include natural or synthesized compounds, certain viruses, and various sources of radiation. A carcinogen may directly alter the genetic material of cells (genotoxic), thereby initiating or promoting the process of malignant transformation; it also may induce cancers by mechanisms that do not involve a direct alteration of cellular genetic material (non-genotoxic). (NCI04)" []	EFO	70037	EFO:0004457	\N	carcinogen role	EFO:0004457
0	"C-reactive protein (CRP) measurement is a measurement of the level of C-reactive protein in the blood.  Levels are known to rise in response to inflammation, CRP is therefore used as a clinical measure of inflammation. The measurement is used in the process of clinical diagnosis as high levels of CRP are associated with cardiovascular disease, diabetes and hypertension and in some cancers." []	\N	C-reactive protein measurement	\N	\N	EFO	"C-reactive protein (CRP) measurement is a measurement of the level of C-reactive protein in the blood.  Levels are known to rise in response to inflammation, CRP is therefore used as a clinical measure of inflammation. The measurement is used in the process of clinical diagnosis as high levels of CRP are associated with cardiovascular disease, diabetes and hypertension and in some cancers." []	EFO	70038	EFO:0004458	\N	C-reactive protein measurement	EFO:0004458
0	"A ferritin measurement a is measurement of ferritin level  in serum as an indicator of iron metabolism" []	\N	ferritin measurement	\N	\N	EFO	"A ferritin measurement a is measurement of ferritin level  in serum as an indicator of iron metabolism" []	EFO	70039	EFO:0004459	\N	ferritin measurement	EFO:0004459
0	"A soluble transferrin receptor measurement  (sTfR) is a measure of the level of the Soluble transferrin receptor protein in blood as a measure of iron metabolism." []	\N	soluble transferrin receptor measurement	\N	\N	EFO	"A soluble transferrin receptor measurement  (sTfR) is a measure of the level of the Soluble transferrin receptor protein in blood as a measure of iron metabolism." []	EFO	70040	EFO:0004460	\N	soluble transferrin receptor measurement	EFO:0004460
0	"An iron biomarker measurement is a measurement of some molecule e.g. protein or metabolite which is used as a measure of iron metabolism" []	\N	iron biomarker measurement	\N	\N	EFO	"An iron biomarker measurement is a measurement of some molecule e.g. protein or metabolite which is used as a measure of iron metabolism" []	EFO	70041	EFO:0004461	\N	iron biomarker measurement	EFO:0004461
0	"A PR interval is an  electrocardiography measurement which measures from the beginning of the P wave to the beginning of the QRS complex in the heart's electrical cycle" []	\N	PR interval	\N	\N	EFO	"A PR interval is an  electrocardiography measurement which measures from the beginning of the P wave to the beginning of the QRS complex in the heart's electrical cycle" []	EFO	70042	EFO:0004462	\N	PR interval	EFO:0004462
0	"angiotensin converting ezyme activity level" []	\N	angiotensin converting enzyme activity measurement	\N	\N	EFO	"angiotensin converting ezyme activity level" []	EFO	70043	EFO:0004463	\N	angiotensin converting enzyme activity measurement	EFO:0004463
0	"" []	\N	brain measurement	\N	\N	EFO	"" []	EFO	70044	EFO:0004464	\N	brain measurement	EFO:0004464
0	"An fasting blood glucose measurement is a measurement of glucose in the blood of a patient at some defined time point after eating." []	\N	fasting blood glucose measurement	\N	\N	EFO	"An fasting blood glucose measurement is a measurement of glucose in the blood of a patient at some defined time point after eating." []	EFO	70045	EFO:0004465	\N	fasting blood glucose measurement	EFO:0004465
0	"A fasting blood insulin measurement is a measurement of insulin in the blood at a predetermined point after the patient has fasted" []	\N	fasting blood insulin measurement	\N	\N	EFO	"A fasting blood insulin measurement is a measurement of insulin in the blood at a predetermined point after the patient has fasted" []	EFO	70046	EFO:0004466	\N	fasting blood insulin measurement	EFO:0004466
0	"An insulin measurement is a measure of insulin typically performed in the diagnosis of patients" []	\N	insulin measurement	\N	\N	EFO	"An insulin measurement is a measure of insulin typically performed in the diagnosis of patients" []	EFO	70047	EFO:0004467	\N	insulin measurement	EFO:0004467
0	"Is any quantification of glucose." []	\N	glucose measurement	\N	\N	EFO	"Is any quantification of glucose." []	EFO	70048	EFO:0004468	\N	glucose measurement	EFO:0004468
0	"The HOMA-B measurement employs the homeostatic model assessment (HOMA)  to quantify beta-cell function." []	\N	HOMA-B	\N	\N	EFO	"The HOMA-B measurement employs the homeostatic model assessment (HOMA)  to quantify beta-cell function." []	EFO	70049	EFO:0004469	\N	HOMA-B	EFO:0004469
0	"An insulin sensitivity measurement is a measurement of insulin metabolism measured using the HOMA model." []	\N	insulin sensitivity measurement	\N	\N	EFO	"An insulin sensitivity measurement is a measurement of insulin metabolism measured using the HOMA model." []	EFO	70050	EFO:0004471	\N	insulin sensitivity measurement	EFO:0004471
0	"C57BL/6 is a mouse strain as described in Jackson Laboratory strain index" []	\N	C57BL/6	\N	\N	EFO	"C57BL/6 is a mouse strain as described in Jackson Laboratory strain index" []	EFO	70051	EFO:0004472	\N	C57BL/6	EFO:0004472
0	"" []	\N	radiation induced mutation	\N	\N	EFO	"" []	EFO	70052	EFO:0004500	\N	radiation induced mutation	EFO:0004500
0	"The HOMA-IR measurement employs the homeostatic model assessment (HOMA)  to quantify insulin resistance." []	\N	HOMA-IR	\N	\N	EFO	"The HOMA-IR measurement employs the homeostatic model assessment (HOMA)  to quantify insulin resistance." []	EFO	70053	EFO:0004501	\N	HOMA-IR	EFO:0004501
0	"Adiponectin measurement is a measurement of the circulating hormone adiponectin in serum. Adiponectin regulated modulates glucose regulation and fatty acid catabolism. Adiponectin levels have been shown to beinversely correlated with with the risk of type 2 diabetes, coronary artery disease, stroke, and several metabolic traits." []	\N	adiponectin measurement	\N	\N	EFO	"Adiponectin measurement is a measurement of the circulating hormone adiponectin in serum. Adiponectin regulated modulates glucose regulation and fatty acid catabolism. Adiponectin levels have been shown to beinversely correlated with with the risk of type 2 diabetes, coronary artery disease, stroke, and several metabolic traits." []	EFO	70054	EFO:0004502	\N	adiponectin measurement	EFO:0004502
0	"A measurement quantifying some blood cell, or component." []	\N	hematological measurement	\N	\N	EFO	"A measurement quantifying some blood cell, or component." []	EFO	70055	EFO:0004503	\N	hematological measurement	EFO:0004503
0	"A serum hepcidin measurement is a measurement of the peptide hormone hepcidin. Hepcidin is secreted by the liver and regulates iron metabolism." []	\N	serum hepcidin measurement	\N	\N	EFO	"A serum hepcidin measurement is a measurement of the peptide hormone hepcidin. Hepcidin is secreted by the liver and regulates iron metabolism." []	EFO	70056	EFO:0004504	\N	serum hepcidin measurement	EFO:0004504
0	"A measurement of telomere length measures the number of TTAGGG repeats at the end of the chromosome. As cell division proceeds telomeres shorten, telomere length is measure of cellular aging." []	\N	telomere length	\N	\N	EFO	"A measurement of telomere length measures the number of TTAGGG repeats at the end of the chromosome. As cell division proceeds telomeres shorten, telomere length is measure of cellular aging." []	EFO	70057	EFO:0004505	\N	telomere length	EFO:0004505
0	"A monocyte early outgrowth colony forming unit measurement is the result of a cell culture assay in which monocytes are plated on fibronectin plates and morphology and growth assessed in an assay which correlates circulating cells and vascular function. The output of the assay is a measure of how many colonies were formed, at what point and their morphology." []	\N	monocyte early outgrowth colony forming unit	\N	\N	EFO	"A monocyte early outgrowth colony forming unit measurement is the result of a cell culture assay in which monocytes are plated on fibronectin plates and morphology and growth assessed in an assay which correlates circulating cells and vascular function. The output of the assay is a measure of how many colonies were formed, at what point and their morphology." []	EFO	70058	EFO:0004506	\N	monocyte early outgrowth colony forming unit	EFO:0004506
0	"A D dimer measurement is a quantification of a fibrinogen degradation product in blood used in the diagnosis of thrombosis." []	\N	D dimer measurement	\N	\N	EFO	"A D dimer measurement is a quantification of a fibrinogen degradation product in blood used in the diagnosis of thrombosis." []	EFO	70059	EFO:0004507	\N	D dimer measurement	EFO:0004507
0	"Spine bone size is a measurement of the dimensions of the spine." []	\N	spine bone size	\N	\N	EFO	"Spine bone size is a measurement of the dimensions of the spine." []	EFO	70060	EFO:0004508	\N	spine bone size	EFO:0004508
0	"Hemoglobin measurement is a measure of the quanity of the metallo protein hemoglobin in blood often used in the diagnosis of anaemia." []	\N	hemoglobin measurement	\N	\N	EFO	"Hemoglobin measurement is a measure of the quanity of the metallo protein hemoglobin in blood often used in the diagnosis of anaemia." []	EFO	70061	EFO:0004509	\N	hemoglobin measurement	EFO:0004509
0	"HPV seropositivity is the result of a measurement of circulating human papilloma virus specific antibodies used in the diagnosis of HPV infection." []	\N	HPV seropositivity	\N	\N	EFO	"HPV seropositivity is the result of a measurement of circulating human papilloma virus specific antibodies used in the diagnosis of HPV infection." []	EFO	70062	EFO:0004510	\N	HPV seropositivity	EFO:0004510
0	"Femoral neck bone geometry is the quantification of the dimensions of the femoral neck bone of the femur. Femoral neck bone geometry is used in determining risk of hip fracture." []	\N	femoral neck bone geometry	\N	\N	EFO	"Femoral neck bone geometry is the quantification of the dimensions of the femoral neck bone of the femur. Femoral neck bone geometry is used in determining risk of hip fracture." []	EFO	70063	EFO:0004511	\N	femoral neck bone geometry	EFO:0004511
0	"" []	\N	bone measurement	\N	\N	EFO	"" []	EFO	70064	EFO:0004512	\N	bone measurement	EFO:0004512
0	"Bone geometry is the measure of the dimensions of some bone" []	\N	bone geometry	\N	\N	EFO	"Bone geometry is the measure of the dimensions of some bone" []	EFO	70065	EFO:0004513	\N	bone geometry	EFO:0004513
0	"A bone quantitative ultrasound measurement is the output of a an ultrasound process in which bones are assayed using ultrasound and information about bone density, cortical thickness, elasticity and microarchitecture may be returned." []	\N	bone quantitative ultrasound measurement	\N	\N	EFO	"A bone quantitative ultrasound measurement is the output of a an ultrasound process in which bones are assayed using ultrasound and information about bone density, cortical thickness, elasticity and microarchitecture may be returned." []	EFO	70066	EFO:0004514	\N	bone quantitative ultrasound measurement	EFO:0004514
0	"A muscle mass measurement is the quantification of the mass of a muscle e.g. skeletal muscle for an individual." []	\N	muscle mass measurement	\N	\N	EFO	"A muscle mass measurement is the quantification of the mass of a muscle e.g. skeletal muscle for an individual." []	EFO	70067	EFO:0004515	\N	muscle mass measurement	EFO:0004515
0	"A fracture related measurement is a measure of some bone or muscular entity which collectively are used to determine the risk of bone fracture e.g. bone density, muscle mass etc." []	\N	bone fracture related measurement	\N	\N	EFO	"A fracture related measurement is a measure of some bone or muscular entity which collectively are used to determine the risk of bone fracture e.g. bone density, muscle mass etc." []	EFO	70068	EFO:0004516	\N	bone fracture related measurement	EFO:0004516
0	"An Arterial stiffness measurement is the information output of a non invasive pulse wave velocity assay. Arterial stiffness is a predictor of cardiovascular mortality" []	\N	arterial stiffness measurement	\N	\N	EFO	"An Arterial stiffness measurement is the information output of a non invasive pulse wave velocity assay. Arterial stiffness is a predictor of cardiovascular mortality" []	EFO	70069	EFO:0004517	\N	arterial stiffness measurement	EFO:0004517
0	"A serum creatinine measurement is a measure of the metabolite creatinine performed in the serum, and is used in assessment of kidney function." []	\N	serum creatinine measurement	\N	\N	EFO	"A serum creatinine measurement is a measure of the metabolite creatinine performed in the serum, and is used in assessment of kidney function." []	EFO	70070	EFO:0004518	\N	serum creatinine measurement	EFO:0004518
0	"The measurement of the soluble component of the P-selectin adhesion molecule. Soluble P-selection is associated with adverse cardiovascular events. Alternative terms include:\\nCD62 antigen-like family member P\\nGranule membrane protein 140\\nGMP-140\\nLeukocyte-endothelial cell adhesion molecule 3\\nLECAM3\\nPlatelet activation dependent granule-external membrane protein\\nPADGEM" []	\N	soluble P-selectin measurement	\N	\N	EFO	"The measurement of the soluble component of the P-selectin adhesion molecule. Soluble P-selection is associated with adverse cardiovascular events. Alternative terms include:\\nCD62 antigen-like family member P\\nGranule membrane protein 140\\nGMP-140\\nLeukocyte-endothelial cell adhesion molecule 3\\nLECAM3\\nPlatelet activation dependent granule-external membrane protein\\nPADGEM" []	EFO	70071	EFO:0004519	\N	soluble P-selectin measurement	EFO:0004519
0	"A soluble ICAM-1 measurement is the quantification of the ICAM-1 protein. ICAM-1 levels are associated with adverse cardiovascular events." []	\N	ICAM-1 measurement	\N	\N	EFO	"A soluble ICAM-1 measurement is the quantification of the ICAM-1 protein. ICAM-1 levels are associated with adverse cardiovascular events." []	EFO	70072	EFO:0004520	\N	ICAM-1 measurement	EFO:0004520
0	"A biological macromolecule that has an adhesion disposition." []	\N	adhesion factor	\N	\N	EFO	"A biological macromolecule that has an adhesion disposition." []	EFO	70073	EFO:0004521	\N	adhesion factor	EFO:0004521
0	"A soluble adhesion molecule measurement is a quantification of the soluble compoment (as opposed to membrane bound) a molecule known to participate in the process of adhesion, levels of which may be implicated in cardiovascular adverse events." []	\N	adhesion molecule measurement	\N	\N	EFO	"A soluble adhesion molecule measurement is a quantification of the soluble compoment (as opposed to membrane bound) a molecule known to participate in the process of adhesion, levels of which may be implicated in cardiovascular adverse events." []	EFO	70074	EFO:0004522	\N	adhesion molecule measurement	EFO:0004522
0	"A mean corpuscular volume is the result of calculation of the mean volume of erythrocytes in a blood sample." []	\N	mean corpuscular volume	\N	\N	EFO	"A mean corpuscular volume is the result of calculation of the mean volume of erythrocytes in a blood sample." []	EFO	70075	EFO:0004526	\N	mean corpuscular volume	EFO:0004526
0	"The MCH is  the average mass of hemoglobin per red blood cell in a sample of blood and is calculated by dividing the total mass of hemoglobin by the RBC count" []	\N	mean corpuscular hemoglobin	\N	\N	EFO	"The MCH is  the average mass of hemoglobin per red blood cell in a sample of blood and is calculated by dividing the total mass of hemoglobin by the RBC count" []	EFO	70076	EFO:0004527	\N	mean corpuscular hemoglobin	EFO:0004527
0	"The mean corpuscular gemoglobin concentration is a measure of the concentration of hemoglobin in a given volume of packed red blood cell" []	\N	mean corpuscular hemoglobin concentration	\N	\N	EFO	"The mean corpuscular gemoglobin concentration is a measure of the concentration of hemoglobin in a given volume of packed red blood cell" []	EFO	70077	EFO:0004528	\N	mean corpuscular hemoglobin concentration	EFO:0004528
0	"A measure of circulating lipid" []	\N	lipid measurement	\N	\N	EFO	"A measure of circulating lipid" []	EFO	70078	EFO:0004529	\N	lipid measurement	EFO:0004529
0	"A triglyceride  measurement is a quantification of triglycerides in some body fluid, used as a biomarker for cardiovascular disease." []	\N	triglyceride measurement	\N	\N	EFO	"A triglyceride  measurement is a quantification of triglycerides in some body fluid, used as a biomarker for cardiovascular disease." []	EFO	70079	EFO:0004530	\N	triglyceride measurement	EFO:0004530
0	"A urate measurement is the quantification of some urate in body fluid" []	\N	urate measurement	\N	\N	EFO	"A urate measurement is the quantification of some urate in body fluid" []	EFO	70080	EFO:0004531	\N	urate measurement	EFO:0004531
0	"Serum gamma-glutamyl transferase level measurement is the quantification of gamma-glutamyl transferase in blood. Gamma-glutamyl transferase is used as a marker for liver/bile duct problems and alcohol abuse." []	\N	serum gamma-glutamyl transferase measurement	\N	\N	EFO	"Serum gamma-glutamyl transferase level measurement is the quantification of gamma-glutamyl transferase in blood. Gamma-glutamyl transferase is used as a marker for liver/bile duct problems and alcohol abuse." []	EFO	70081	EFO:0004532	\N	serum gamma-glutamyl transferase measurement	EFO:0004532
0	"Alkaline phosphatase measurement is a quantification of alkaline phosphatase in blood. AP is a marker for bone and liver disease." []	\N	alkaline phosphatase measurement	\N	\N	EFO	"Alkaline phosphatase measurement is a quantification of alkaline phosphatase in blood. AP is a marker for bone and liver disease." []	EFO	70082	EFO:0004533	\N	alkaline phosphatase measurement	EFO:0004533
0	"A creatine kinase measurement is a quantification of creatine kinase in blood. Creatine kinase is a marker for tissue damage and  is assayed in blood tests as a marker of myocardial infarction (heart attack), rhabdomyolysis (severe muscle breakdown), muscular dystrophy, the autoimmune myositides and in acute renal failure." []	\N	creatine kinase measurement	\N	\N	EFO	"A creatine kinase measurement is a quantification of creatine kinase in blood. Creatine kinase is a marker for tissue damage and  is assayed in blood tests as a marker of myocardial infarction (heart attack), rhabdomyolysis (severe muscle breakdown), muscular dystrophy, the autoimmune myositides and in acute renal failure." []	EFO	70083	EFO:0004534	\N	creatine kinase measurement	EFO:0004534
0	"An albumin measurement is a quantification of albumin in blood. Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca2+, Na+, K+, fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc." []	\N	serum albumin measurement	\N	\N	EFO	"An albumin measurement is a quantification of albumin in blood. Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca2+, Na+, K+, fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc." []	EFO	70084	EFO:0004535	\N	serum albumin measurement	EFO:0004535
0	"A total blood protein measurement is a quantification of protein in a blood sample. It is used as a marker for disease and nutrition. It is performed in the liquid portion of blood and typically measures albumin and globulin." []	\N	total blood protein measurement	\N	\N	EFO	"A total blood protein measurement is a quantification of protein in a blood sample. It is used as a marker for disease and nutrition. It is performed in the liquid portion of blood and typically measures albumin and globulin." []	EFO	70085	EFO:0004536	\N	total blood protein measurement	EFO:0004536
0	"" []	\N	neonatal systemic lupus erthematosus	\N	\N	EFO	"" []	EFO	70086	EFO:0004537	\N	neonatal systemic lupus erthematosus	EFO:0004537
0	"A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)" []	\N	chronic fatigue syndrome	\N	\N	EFO	"A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)" []	EFO	70087	EFO:0004540	\N	chronic fatigue syndrome	EFO:0004540
0	"An A1C measurement is a quantification of glycated A1C hemoglobin in blood used as an index for blood glucose level over several months." []	\N	A1C measurement	\N	\N	EFO	"An A1C measurement is a quantification of glycated A1C hemoglobin in blood used as an index for blood glucose level over several months." []	EFO	70088	EFO:0004541	\N	A1C measurement	EFO:0004541
0	"A processual entity that realizes a plan which is the concretization of a plan specification." []	\N	planned process	\N	\N	EFO	"A processual entity that realizes a plan which is the concretization of a plan specification." []	EFO	70089	EFO:0004542	\N	planned process	EFO:0004542
0	"Is the quantification of amygdala response to stimulus using MRI." []	\N	amygdala reactivity measurement	\N	\N	EFO	"Is the quantification of amygdala response to stimulus using MRI." []	EFO	70090	EFO:0004550	\N	amygdala reactivity measurement	EFO:0004550
0	"Is a quantification of some aspect of the genome, e.g. copy number variation at some locus." []	\N	genomic measurement	\N	\N	EFO	"Is a quantification of some aspect of the genome, e.g. copy number variation at some locus." []	EFO	70091	EFO:0004554	\N	genomic measurement	EFO:0004554
0	"Is the quantification of some glycoprotein." []	\N	glycoprotein measurement	\N	\N	EFO	"Is the quantification of some glycoprotein." []	EFO	70092	EFO:0004555	\N	glycoprotein measurement	EFO:0004555
0	"Is the quantification of some antibody" []	\N	antibody measurement	\N	\N	EFO	"Is the quantification of some antibody" []	EFO	70093	EFO:0004556	\N	antibody measurement	EFO:0004556
0	"Is the quantification of some measureable quality of a population e.g. birth rate." []	\N	population measurement	\N	\N	EFO	"Is the quantification of some measureable quality of a population e.g. birth rate." []	EFO	70094	EFO:0004557	\N	population measurement	EFO:0004557
0	"Denotes a person with African ancestral origins who self identifies, or is identified, as African. The concept does not refer to those of other ancestry, for example, European and South Asian. In practice, the term mainly refers to people originated from forty-eight sub-Saharan Africa nations; and excudes individuals from North Africa countries, e.g. such as Algeria, Morocco, Egypt, Tunisia with Arab and Berber ethnicity." []	\N	African	\N	\N	EFO	"Denotes a person with African ancestral origins who self identifies, or is identified, as African. The concept does not refer to those of other ancestry, for example, European and South Asian. In practice, the term mainly refers to people originated from forty-eight sub-Saharan Africa nations; and excudes individuals from North Africa countries, e.g. such as Algeria, Morocco, Egypt, Tunisia with Arab and Berber ethnicity." []	EFO	70095	EFO:0004561	\N	African	EFO:0004561
0	"Cryptorchidism (derived from the Greek κρυπτός, kryptos, meaning hidden and ὄρχις, orchis, meaning testicle) is the absence of one or both testes from the scrotum. It is the most common birth defect regarding male genitalia. In unique cases, cryptorchidism can develop later in life, often as late as young adulthood. About 3% of full-term and 30% of premature infant boys are born with at least one undescended testis. However, about 80% of cryptorchid testes descend by the first year of life (the majority within three months), making the true incidence of cryptorchidism around 1% overall. Cryptorchidism is distinct from monorchism the condition of having only one testicle." []	\N	cryptorchidism	\N	\N	EFO	"Cryptorchidism (derived from the Greek κρυπτός, kryptos, meaning hidden and ὄρχις, orchis, meaning testicle) is the absence of one or both testes from the scrotum. It is the most common birth defect regarding male genitalia. In unique cases, cryptorchidism can develop later in life, often as late as young adulthood. About 3% of full-term and 30% of premature infant boys are born with at least one undescended testis. However, about 80% of cryptorchid testes descend by the first year of life (the majority within three months), making the true incidence of cryptorchidism around 1% overall. Cryptorchidism is distinct from monorchism the condition of having only one testicle." []	EFO	70096	EFO:0004562	\N	cryptorchidism	EFO:0004562
0	"A Saccharomyces cerevisiae commercially available strain used in pseudohyphal growth studies.\\nGranek and Magwene, PLoS Genet. 2010 Jan 22;6(1):e1000823, established that certain lineages of the Sigma1278B background contain a nonsense mutation in RIM15, a G-to-T transversion at position 1216 that converts a Gly codon to an opal stop codon. This rim15 mutation interacts epistatically with mutations in certain other genes to affect colony morphology." []	\N	Sigma 1278b	\N	\N	EFO	"A Saccharomyces cerevisiae commercially available strain used in pseudohyphal growth studies.\\nGranek and Magwene, PLoS Genet. 2010 Jan 22;6(1):e1000823, established that certain lineages of the Sigma1278B background contain a nonsense mutation in RIM15, a G-to-T transversion at position 1216 that converts a Gly codon to an opal stop codon. This rim15 mutation interacts epistatically with mutations in certain other genes to affect colony morphology." []	EFO	70097	EFO:0004563	\N	Sigma 1278b	EFO:0004563
0	"Pericardial fat is an adipose tissue." []	\N	pericardial fat	\N	\N	EFO	"Pericardial fat is an adipose tissue." []	EFO	70098	EFO:0004564	\N	pericardial fat	EFO:0004564
0	"A serum immunoglobulin G measurement is the measurement of the IgG antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum" []	\N	serum IgG measurement	\N	\N	EFO	"A serum immunoglobulin G measurement is the measurement of the IgG antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum" []	EFO	70099	EFO:0004565	\N	serum IgG measurement	EFO:0004565
0	"The process of increasing the mass of an organism over time." []	\N	body weight gain	\N	\N	EFO	"The process of increasing the mass of an organism over time." []	EFO	70100	EFO:0004566	\N	body weight gain	EFO:0004566
0	"The process of increasing body mass during treatment with an antipsychotic drug. http://ajp.psychiatryonline.org/article.aspx?articleid=173781" []	\N	anti-psychotic drug related weight gain	\N	\N	EFO	"The process of increasing body mass during treatment with an antipsychotic drug. http://ajp.psychiatryonline.org/article.aspx?articleid=173781" []	EFO	70101	EFO:0004567	\N	anti-psychotic drug related weight gain	EFO:0004567
0	"The measurement of the non-albumin portion of blood protein (globulin) in serum" []	\N	serum non-albumin protein measurement	\N	\N	EFO	"The measurement of the non-albumin portion of blood protein (globulin) in serum" []	EFO	70102	EFO:0004568	\N	serum non-albumin protein measurement	EFO:0004568
0	"A serotonir transported measurement is the quantification of serotonin transporter. Serotonin transporter regulates the levels of extracellular serotonin. The 5-HTT levels in brain can be measured using PET." []	\N	brain serotonin transporter measurement	\N	\N	EFO	"A serotonir transported measurement is the quantification of serotonin transporter. Serotonin transporter regulates the levels of extracellular serotonin. The 5-HTT levels in brain can be measured using PET." []	EFO	70103	EFO:0004569	\N	brain serotonin transporter measurement	EFO:0004569
0	"A bilirubin measurement is a quantification of bilirubin typically measured in serum." []	\N	bilirubin measurement	\N	\N	EFO	"A bilirubin measurement is a quantification of bilirubin typically measured in serum." []	EFO	70104	EFO:0004570	\N	bilirubin measurement	EFO:0004570
0	"A butyrylcholinesterase measurement is a quanitification of butyrylcholinesterase a non-specific cholinesterase enzyme that hydrolyses many different choline esters. It is found in liver in humans." []	\N	butyrylcholinesterase measurement	\N	\N	EFO	"A butyrylcholinesterase measurement is a quanitification of butyrylcholinesterase a non-specific cholinesterase enzyme that hydrolyses many different choline esters. It is found in liver in humans." []	EFO	70105	EFO:0004571	\N	butyrylcholinesterase measurement	EFO:0004571
0	"A C4BP measurement is the quantification of C4BP, it controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component. (Uniprot defintion)" []	\N	C4BP measurement	\N	\N	EFO	"A C4BP measurement is the quantification of C4BP, it controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component. (Uniprot defintion)" []	EFO	70106	EFO:0004572	\N	C4BP measurement	EFO:0004572
0	"A chemerin measurement is a quantification of chemerin typically in serum. Chemerin is an adipokine with important regulatory roles in adipogenesis. In humans, serum total chemerin (i.e. prochemerin plus chemerin) levels are positively associated with body mass index and metabolic syndrome (http://www.ncbi.nlm.nih.gov/pubmed/20363880)" []	\N	chemerin measurement	\N	\N	EFO	"A chemerin measurement is a quantification of chemerin typically in serum. Chemerin is an adipokine with important regulatory roles in adipogenesis. In humans, serum total chemerin (i.e. prochemerin plus chemerin) levels are positively associated with body mass index and metabolic syndrome (http://www.ncbi.nlm.nih.gov/pubmed/20363880)" []	EFO	70107	EFO:0004573	\N	chemerin measurement	EFO:0004573
0	"A total cholesterol measurement is the quantification of cholesterol in blood, total cholesterol is defined as the sum of HDL, LDL, and VLDL." []	\N	total cholesterol measurement	\N	\N	EFO	"A total cholesterol measurement is the quantification of cholesterol in blood, total cholesterol is defined as the sum of HDL, LDL, and VLDL." []	EFO	70108	EFO:0004574	\N	total cholesterol measurement	EFO:0004574
0	"An e-selectin measurement is the quantification of e-selectin typically measured in serum. E-selectin is a cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans. It is also used as a cancer biomarker." []	\N	e-selectin measurement	\N	\N	EFO	"An e-selectin measurement is the quantification of e-selectin typically measured in serum. E-selectin is a cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans. It is also used as a cancer biomarker." []	EFO	70109	EFO:0004575	\N	e-selectin measurement	EFO:0004575
0	"A fetal hemoglobin measurement is the quantification of fetal hemoglobin typically measured in the blood of children for diagnosis of congenital disease." []	\N	fetal hemoglobin measurement	\N	\N	EFO	"A fetal hemoglobin measurement is the quantification of fetal hemoglobin typically measured in the blood of children for diagnosis of congenital disease." []	EFO	70110	EFO:0004576	\N	fetal hemoglobin measurement	EFO:0004576
0	"The infant head circumference is the measurement of the diameter of the head and is a routine measure made during human development as a broad indicator of child development. It ca.n be used as a proxy for brain development" []	\N	infant head circumference	\N	\N	EFO	"The infant head circumference is the measurement of the diameter of the head and is a routine measure made during human development as a broad indicator of child development. It ca.n be used as a proxy for brain development" []	EFO	70111	EFO:0004577	\N	infant head circumference	EFO:0004577
0	"A homocysteine measurement is the quantification of homocsyteine in blood or urine and is used in the diagnosis of  B12 and/or folate deficiency, and as part of a cardiac risk assessment." []	\N	homocysteine measurement	\N	\N	EFO	"A homocysteine measurement is the quantification of homocsyteine in blood or urine and is used in the diagnosis of  B12 and/or folate deficiency, and as part of a cardiac risk assessment." []	EFO	70112	EFO:0004578	\N	homocysteine measurement	EFO:0004578
0	"A serum immunoglobulin E measurement is the measurement of the IgE antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum. IgE's main function is immunity to parasites such as parasitic worms and it plays an essential role in the allergy disorder, and is especially associated with type I hypersensitivity." []	\N	serum IgE measurement	\N	\N	EFO	"A serum immunoglobulin E measurement is the measurement of the IgE antibody isotype produced by plasma cells in response to an immunogen and which function as antibodies, measured in serum. IgE's main function is immunity to parasites such as parasitic worms and it plays an essential role in the allergy disorder, and is especially associated with type I hypersensitivity." []	EFO	70113	EFO:0004579	\N	serum IgE measurement	EFO:0004579
0	"Interleukin-18 (IL18, also known as interferon-gamma inducing factor) is a protein which in humans is encoded by the IL18 gene.[1][2] The protein encoded by this gene is a proinflammatory cytokine." []	\N	interleukin 18 (Homo sapiens)	\N	\N	EFO	"Interleukin-18 (IL18, also known as interferon-gamma inducing factor) is a protein which in humans is encoded by the IL18 gene.[1][2] The protein encoded by this gene is a proinflammatory cytokine." []	EFO	70114	EFO:0004580	\N	interleukin 18 (Homo sapiens)	EFO:0004580
0	"An IL-18 measurement is the quantification of IL-18, typically in blood." []	\N	interleukin 18 measurement	\N	\N	EFO	"An IL-18 measurement is the quantification of IL-18, typically in blood." []	EFO	70115	EFO:0004581	\N	interleukin 18 measurement	EFO:0004581
0	"A quantification of liver enzymes, typically in blood, used by clinicians to determine liver injury, disease and function." []	\N	liver enzyme measurement	\N	\N	EFO	"A quantification of liver enzymes, typically in blood, used by clinicians to determine liver injury, disease and function." []	EFO	70116	EFO:0004582	\N	liver enzyme measurement	EFO:0004582
0	"A measurement of mean platelet volume is a machine-calculated measurement of the average size of platelets found in blood" []	\N	mean platelet volume	\N	\N	EFO	"A measurement of mean platelet volume is a machine-calculated measurement of the average size of platelets found in blood" []	EFO	70117	EFO:0004584	\N	mean platelet volume	EFO:0004584
0	"A quantification of the naphthyl-keratin adduct levels. naphthyl-keratin adduct is used as a marker for exposure to the xenobiotic napthalene." []	\N	naphthyl-keratin adduct measurement	\N	\N	EFO	"A quantification of the naphthyl-keratin adduct levels. naphthyl-keratin adduct is used as a marker for exposure to the xenobiotic napthalene." []	EFO	70118	EFO:0004585	\N	naphthyl-keratin adduct measurement	EFO:0004585
0	"A complete blood cell count quantifies specific blood components." []	\N	complete blood cell count	\N	\N	EFO	"A complete blood cell count quantifies specific blood components." []	EFO	70119	EFO:0004586	\N	complete blood cell count	EFO:0004586
0	"A quantification of lymphocytes in blood." []	\N	lymphocyte count	\N	\N	EFO	"A quantification of lymphocytes in blood." []	EFO	70120	EFO:0004587	\N	lymphocyte count	EFO:0004587
0	"bachial circumference (BC) is a measurement of the diameter of the upper arm and  can be used as an indicator of muscle mass and fat tissue." []	\N	brachial circumference	\N	\N	EFO	"bachial circumference (BC) is a measurement of the diameter of the upper arm and  can be used as an indicator of muscle mass and fat tissue." []	EFO	70121	EFO:0004589	\N	brachial circumference	EFO:0004589
0	"" []	\N	childhood onset asthma	\N	\N	EFO	"" []	EFO	70122	EFO:0004591	\N	childhood onset asthma	EFO:0004591
0	"Gestational diabetes is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during third trimester). Gestational diabetes is caused when the body of a pregnant woman does not secrete enough insulin required during pregnancy, leading to increased blood sugar levels." []	\N	gestational diabetes	\N	\N	EFO	"Gestational diabetes is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during third trimester). Gestational diabetes is caused when the body of a pregnant woman does not secrete enough insulin required during pregnancy, leading to increased blood sugar levels." []	EFO	70123	EFO:0004593	\N	gestational diabetes	EFO:0004593
0	"" []	\N	childhood eosinophilic esophagitis	\N	\N	EFO	"" []	EFO	70124	EFO:0004594	\N	childhood eosinophilic esophagitis	EFO:0004594
0	"The process of transmission of HIV infection from mother to child during pregnancy, birth or breastfeeding." []	\N	HIV mother to child transmission	\N	\N	EFO	"The process of transmission of HIV infection from mother to child during pregnancy, birth or breastfeeding." []	EFO	70125	EFO:0004595	\N	HIV mother to child transmission	EFO:0004595
0	"Diabetic cataracts are thought to be caused by hyperglycemia associated with disturbed glucose metabolism" []	\N	diabetes mellitus type 2 associated cataract	\N	\N	EFO	"Diabetic cataracts are thought to be caused by hyperglycemia associated with disturbed glucose metabolism" []	EFO	70126	EFO:0004596	\N	diabetes mellitus type 2 associated cataract	EFO:0004596
0	"Variant Creutzfeldt-Jakob disease (vCJD) is a rare and fatal human neurodegenerative condition which is classified as a Transmissible Spongiform Encephalopathy (TSE) because of its ability to be transmitted and the characteristic spongy degeneration of the brain that it causes. vCJD was first described in the United Kingdom in March 1996 and has been linked with exposure to a TSE of cattle called Bovine Spongiform Encephalopathy (BSE), also known as Classical BSE1, which was first reported in the United Kingdom in 1986." []	\N	variant Creutzfeld Jacob disease	\N	\N	EFO	"Variant Creutzfeldt-Jakob disease (vCJD) is a rare and fatal human neurodegenerative condition which is classified as a Transmissible Spongiform Encephalopathy (TSE) because of its ability to be transmitted and the characteristic spongy degeneration of the brain that it causes. vCJD was first described in the United Kingdom in March 1996 and has been linked with exposure to a TSE of cattle called Bovine Spongiform Encephalopathy (BSE), also known as Classical BSE1, which was first reported in the United Kingdom in 1986." []	EFO	70127	EFO:0004597	\N	variant Creutzfeld Jacob disease	EFO:0004597
0	"Graft-versus-host disease (GVHD) is a common complication following an allogeneic tissue transplant. It is commonly associated with stem cell or bone marrow transplant but the term also applies to other forms of tissue graft." []	\N	acute graft vs. host disease	\N	\N	EFO	"Graft-versus-host disease (GVHD) is a common complication following an allogeneic tissue transplant. It is commonly associated with stem cell or bone marrow transplant but the term also applies to other forms of tissue graft." []	EFO	70128	EFO:0004599	\N	acute graft vs. host disease	EFO:0004599
0	"Genomic data is data about the genomes of an organism." []	\N	genomic data	\N	\N	EFO	"Genomic data is data about the genomes of an organism." []	EFO	70129	EFO:0004600	\N	genomic data	EFO:0004600
0	"Transcriptomic data is data about RNA transcribed by a cell, cells or organism. This includes mRNA, tRNA and cDNA." []	\N	transcriptomic data	\N	\N	EFO	"Transcriptomic data is data about RNA transcribed by a cell, cells or organism. This includes mRNA, tRNA and cDNA." []	EFO	70130	EFO:0004601	\N	transcriptomic data	EFO:0004601
0	"Metagenomic data is data about the genomes of a sample or samples containing mixed material such as from genetic material recovered directly from environmental samples." []	\N	metagenomic data	\N	\N	EFO	"Metagenomic data is data about the genomes of a sample or samples containing mixed material such as from genetic material recovered directly from environmental samples." []	EFO	70131	EFO:0004602	\N	metagenomic data	EFO:0004602
0	"Metatranscriptomic data is data about transcriptomic data from groups of organisms." []	\N	metatranscriptomic data	\N	\N	EFO	"Metatranscriptomic data is data about transcriptomic data from groups of organisms." []	EFO	70132	EFO:0004603	\N	metatranscriptomic data	EFO:0004603
0	"Synthetic DNA data is data about DNA that has been artificially created without initial template DNA such as from naturally occuring genomic sequences in an organism." []	\N	synthetic DNA data	\N	\N	EFO	"Synthetic DNA data is data about DNA that has been artificially created without initial template DNA such as from naturally occuring genomic sequences in an organism." []	EFO	70133	EFO:0004604	\N	synthetic DNA data	EFO:0004604
0	"Viral RNA data is data about a virus which stores its genetic information in RNA." []	\N	viral RNA data	\N	\N	EFO	"Viral RNA data is data about a virus which stores its genetic information in RNA." []	EFO	70134	EFO:0004605	\N	viral RNA data	EFO:0004605
0	"" []	\N	gallbladder neoplasm	\N	\N	EFO	"" []	EFO	70135	EFO:0004606	\N	gallbladder neoplasm	EFO:0004606
0	"A peptic ulcer arising in the small intestine." []	\N	duodenal ulcer	\N	\N	EFO	"A peptic ulcer arising in the small intestine." []	EFO	70136	EFO:0004607	\N	duodenal ulcer	EFO:0004607
0	"Cystic fibrosis associated meconium ileum is a thickening and congestion of the meconium in the ileum in newborns, often the first sign of cystic fibrosis. In cystic fibrosis, the meconium can form a bituminous black-green mechanical obstruction in a segment of the ileum. Beyond this there may be a few separate grey-white globular pellets. Below this level, the bowel is a narrow and empty micro-colon. Above the level of the obstruction, there are several loops of hypertrophied bowel distended with fluid. No meconium is passed, and abdominal distension and vomiting appear soon after birth. About 20% of cases of cystic fibrosis present with meconium ileus, while approximately 20% of one series of cases of meconium ileus did not have cystic fibrosis The presence of meconium ileus is not related to the severity of the cystic fibrosis." []	\N	cystic fibrosis associated meconium ileum	\N	\N	EFO	"Cystic fibrosis associated meconium ileum is a thickening and congestion of the meconium in the ileum in newborns, often the first sign of cystic fibrosis. In cystic fibrosis, the meconium can form a bituminous black-green mechanical obstruction in a segment of the ileum. Beyond this there may be a few separate grey-white globular pellets. Below this level, the bowel is a narrow and empty micro-colon. Above the level of the obstruction, there are several loops of hypertrophied bowel distended with fluid. No meconium is passed, and abdominal distension and vomiting appear soon after birth. About 20% of cases of cystic fibrosis present with meconium ileus, while approximately 20% of one series of cases of meconium ileus did not have cystic fibrosis The presence of meconium ileus is not related to the severity of the cystic fibrosis." []	EFO	70137	EFO:0004608	\N	cystic fibrosis associated meconium ileum	EFO:0004608
0	"Schizophrenia which does not respond to commonly used treatments." []	\N	treatment refractory schizophrenia	\N	\N	EFO	"Schizophrenia which does not respond to commonly used treatments." []	EFO	70138	EFO:0004609	\N	treatment refractory schizophrenia	EFO:0004609
0	"Acute lung injury (ALI) is a diffuse heterogeneous lung injury characterized by hypoxemia, non cardiogenic pulmonary edema, low lung compliance and widespread capillary leakage. ALI is caused by any stimulus of local or systemic inflammation, principally sepsis." []	\N	acute lung injury	\N	\N	EFO	"Acute lung injury (ALI) is a diffuse heterogeneous lung injury characterized by hypoxemia, non cardiogenic pulmonary edema, low lung compliance and widespread capillary leakage. ALI is caused by any stimulus of local or systemic inflammation, principally sepsis." []	EFO	70139	EFO:0004610	\N	acute lung injury	EFO:0004610
0	"The measurement of LDL cholesterol in blood used as a risk indicator for heart disease." []	\N	low density lipoprotein cholesterol measurement	\N	\N	EFO	"The measurement of LDL cholesterol in blood used as a risk indicator for heart disease." []	EFO	70140	EFO:0004611	\N	low density lipoprotein cholesterol measurement	EFO:0004611
0	"The measurement of HDL cholesterol in blood used as a risk indicator for heart disease." []	\N	high density lipoprotein cholesterol measurement	\N	\N	EFO	"The measurement of HDL cholesterol in blood used as a risk indicator for heart disease." []	EFO	70141	EFO:0004612	\N	high density lipoprotein cholesterol measurement	EFO:0004612
0	"Is a quantification of serum lipoprotein A. Apolipoprotein A-I, encoded in humans by the APOA1 gene and  is the major protein component of high density lipoprotein (HDL) in plasma.   It is is implicated as a risk factor for atherosclerotic diseases such as coronary heart disease and stroke." []	\N	apolipoprotein A 1 measurement	\N	\N	EFO	"Is a quantification of serum lipoprotein A. Apolipoprotein A-I, encoded in humans by the APOA1 gene and  is the major protein component of high density lipoprotein (HDL) in plasma.   It is is implicated as a risk factor for atherosclerotic diseases such as coronary heart disease and stroke." []	EFO	70142	EFO:0004614	\N	apolipoprotein A 1 measurement	EFO:0004614
0	"The measurement of ApoB in blood. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor, and is upregulated in response to enterovirus 71." []	\N	apolipoprotein B measurement	\N	\N	EFO	"The measurement of ApoB in blood. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor, and is upregulated in response to enterovirus 71." []	EFO	70143	EFO:0004615	\N	apolipoprotein B measurement	EFO:0004615
0	"Knee osteoarthritis is a degenerative disease of the knee joint" []	\N	osteoarthritis of the knee	\N	\N	EFO	"Knee osteoarthritis is a degenerative disease of the knee joint" []	EFO	70144	EFO:0004616	\N	osteoarthritis of the knee	EFO:0004616
0	"is a quantification of serum cystatin C C (formerly gamma trace, post-gamma-globulin or neuroendocrine basic polypeptide),[1] a protein encoded by the CST3 gene, is mainly used as a biomarker of kidney function and kidney disease." []	\N	cystatin C measurement	\N	\N	EFO	"is a quantification of serum cystatin C C (formerly gamma trace, post-gamma-globulin or neuroendocrine basic polypeptide),[1] a protein encoded by the CST3 gene, is mainly used as a biomarker of kidney function and kidney disease." []	EFO	70145	EFO:0004617	\N	cystatin C measurement	EFO:0004617
0	"is a quantification of Vitamin K or Phylloquinone, a polycyclic aromatic ketone, based on 2-methyl-1,4-naphthoquinone, with a 3-phytyl substituent. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants, particularly leaves, since it functions as an electron acceptor during photosynthesis, forming part of the electron transport chain of Photosystem I." []	\N	vitamin K measurement	\N	\N	EFO	"is a quantification of Vitamin K or Phylloquinone, a polycyclic aromatic ketone, based on 2-methyl-1,4-naphthoquinone, with a 3-phytyl substituent. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants, particularly leaves, since it functions as an electron acceptor during photosynthesis, forming part of the electron transport chain of Photosystem I." []	EFO	70146	EFO:0004618	\N	vitamin K measurement	EFO:0004618
0	"Is a quantification of factor VII in serum,  (formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class." []	\N	factor VII measurement	\N	\N	EFO	"Is a quantification of factor VII in serum,  (formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class." []	EFO	70147	EFO:0004619	\N	factor VII measurement	EFO:0004619
0	"is a quantification of Vitamin B12, vitamin B12 or vitamin B-12, is a water-solublevitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood. It is one of the eight B vitamins. It is normally involved in themetabolism of every cell of the human body, especially affecting DNA synthesis and regulation, but also fatty acid synthesis and energy production. It is the largest and most structurally complicated vitamin and can be produced industrially only through bacterial fermentation-synthesis." []	\N	vitamin B12 measurement	\N	\N	EFO	"is a quantification of Vitamin B12, vitamin B12 or vitamin B-12, is a water-solublevitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood. It is one of the eight B vitamins. It is normally involved in themetabolism of every cell of the human body, especially affecting DNA synthesis and regulation, but also fatty acid synthesis and energy production. It is the largest and most structurally complicated vitamin and can be produced industrially only through bacterial fermentation-synthesis." []	EFO	70148	EFO:0004620	\N	vitamin B12 measurement	EFO:0004620
0	"is a quantification of Vitamin B6 a water soluble vitamin" []	\N	vitamin B6 measurement	\N	\N	EFO	"is a quantification of Vitamin B6 a water soluble vitamin" []	EFO	70149	EFO:0004621	\N	vitamin B6 measurement	EFO:0004621
0	"Is a quantification of sphingolipids - molecules playing a role in signal transmission." []	\N	sphingolipid measurement	\N	\N	EFO	"Is a quantification of sphingolipids - molecules playing a role in signal transmission." []	EFO	70150	EFO:0004622	\N	sphingolipid measurement	EFO:0004622
0	"is a quantification of circulating fibrinogen  (factor I) is a soluble plasma glycoprotein, synthesised by the liver, that is converted by thrombin into fibrin during blood coagulation." []	\N	fibrinogen measurement	\N	\N	EFO	"is a quantification of circulating fibrinogen  (factor I) is a soluble plasma glycoprotein, synthesised by the liver, that is converted by thrombin into fibrin during blood coagulation." []	EFO	70151	EFO:0004623	\N	fibrinogen measurement	EFO:0004623
0	"A PSA measurement is the quantification of prostate specific antigen typically in blood used in the diagnosis of prostate cancer." []	\N	prostate specific antigen measurement	\N	\N	EFO	"A PSA measurement is the quantification of prostate specific antigen typically in blood used in the diagnosis of prostate cancer." []	EFO	70152	EFO:0004624	\N	prostate specific antigen measurement	EFO:0004624
0	"A progranulin measurement is a quantification of progranulin, typically in blood. Progranulins are secreted glycosylated peptides implicated in frontotemporal disease, and low levels of progranulin are a risk factor for frontotemporal disease" []	\N	progranulin measurement	\N	\N	EFO	"A progranulin measurement is a quantification of progranulin, typically in blood. Progranulins are secreted glycosylated peptides implicated in frontotemporal disease, and low levels of progranulin are a risk factor for frontotemporal disease" []	EFO	70153	EFO:0004625	\N	progranulin measurement	EFO:0004625
0	"Is the quantification of IGFBP-3, a member of  the insulin-like growth factor-binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. Decreased  IIGFBP3 protein levels are used as a biomarker for prostate cancer progression." []	\N	IGFBP-3 measurement	\N	\N	EFO	"Is the quantification of IGFBP-3, a member of  the insulin-like growth factor-binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. Decreased  IIGFBP3 protein levels are used as a biomarker for prostate cancer progression." []	EFO	70154	EFO:0004626	\N	IGFBP-3 measurement	EFO:0004626
0	"Is the quantification of Insulin-like growth factor 1 (IGF-1), also called somatomedin C. IGF-1 is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. Levels of IGF-1 are known to increase in some cancers." []	\N	IGF-1 measurement	\N	\N	EFO	"Is the quantification of Insulin-like growth factor 1 (IGF-1), also called somatomedin C. IGF-1 is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. Levels of IGF-1 are known to increase in some cancers." []	EFO	70155	EFO:0004627	\N	IGF-1 measurement	EFO:0004627
0	"Is a quantification of iany of the insulin like growth factors" []	\N	insulin like growth factor measurement	\N	\N	EFO	"Is a quantification of iany of the insulin like growth factors" []	EFO	70156	EFO:0004628	\N	insulin like growth factor measurement	EFO:0004628
0	"Is a quantification of von Willebrand factor (vWF) is a blood glycoprotein involved in hemostasis. It is deficient or defective in von Willebrand disease and is involved in a large number of other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic-uremic syndrome.[1] Increased plasma levels in a large number of cardiovascular, neoplastic, and connective tissue diseases are presumed to arise from adverse changes to the endothelium, and may contribute to an increased risk of thrombosis." []	\N	von Willebrand factor measurement	\N	\N	EFO	"Is a quantification of von Willebrand factor (vWF) is a blood glycoprotein involved in hemostasis. It is deficient or defective in von Willebrand disease and is involved in a large number of other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic-uremic syndrome.[1] Increased plasma levels in a large number of cardiovascular, neoplastic, and connective tissue diseases are presumed to arise from adverse changes to the endothelium, and may contribute to an increased risk of thrombosis." []	EFO	70157	EFO:0004629	\N	von Willebrand factor measurement	EFO:0004629
0	"Is a quantification of factor VIII in serum, Factor VIII (FVIII) is an essential blood clotting protein, also known as anti-hemophilic factor (AHF). In humans, Factor VIII is encoded by the F8 gene.[1][2] Defects in this gene results in hemophilia A." []	\N	factor VIII measurement	\N	\N	EFO	"Is a quantification of factor VIII in serum, Factor VIII (FVIII) is an essential blood clotting protein, also known as anti-hemophilic factor (AHF). In humans, Factor VIII is encoded by the F8 gene.[1][2] Defects in this gene results in hemophilia A." []	EFO	70158	EFO:0004630	\N	factor VIII measurement	EFO:0004630
0	"A quantification of Vitamin D levels, typically in blood. Vitamin D includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE (MeSH)" []	\N	vitamin D measurement	\N	\N	EFO	"A quantification of Vitamin D levels, typically in blood. Vitamin D includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE (MeSH)" []	EFO	70159	EFO:0004631	\N	vitamin D measurement	EFO:0004631
0	"A nevus count is the quantification of nevi on the skin." []	\N	nevus count	\N	\N	EFO	"A nevus count is the quantification of nevi on the skin." []	EFO	70160	EFO:0004632	\N	nevus count	EFO:0004632
0	"Is a quantification of Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV,] is a zymogenic (inactive) protein, the activated form of which plays an important role in regulating blood clotting, inflammation, cell death and maintaining the permeability of blood vessel walls in humans and other animals." []	\N	protein C measurement	\N	\N	EFO	"Is a quantification of Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV,] is a zymogenic (inactive) protein, the activated form of which plays an important role in regulating blood clotting, inflammation, cell death and maintaining the permeability of blood vessel walls in humans and other animals." []	EFO	70161	EFO:0004633	\N	protein C measurement	EFO:0004633
0	"A coagulation factor measurement is the quantification of any of the entities involved in the process of coagulation or regulation of coagulation. Abnormal coagulation may result in thrombosis or hemorrhage." []	\N	coagulation factor measurement	\N	\N	EFO	"A coagulation factor measurement is the quantification of any of the entities involved in the process of coagulation or regulation of coagulation. Abnormal coagulation may result in thrombosis or hemorrhage." []	EFO	70162	EFO:0004634	\N	coagulation factor measurement	EFO:0004634
0	"is a quantification of circulating soluble leptin receptor levels, these are inversely associated with diabetes risk factors, including adiposity and insulin resistance, and highly correlated with the expression levels of leptin receptor." []	\N	leptin receptor measurement	\N	\N	EFO	"is a quantification of circulating soluble leptin receptor levels, these are inversely associated with diabetes risk factors, including adiposity and insulin resistance, and highly correlated with the expression levels of leptin receptor." []	EFO	70163	EFO:0004635	\N	leptin receptor measurement	EFO:0004635
0	"is a quantification of protein S, a vitamin K-dependent plasma glycoprotein synthesized in the endothelium involved in anticoagulation and used in the diagnosis of thrombosis." []	\N	protein S measurement	\N	\N	EFO	"is a quantification of protein S, a vitamin K-dependent plasma glycoprotein synthesized in the endothelium involved in anticoagulation and used in the diagnosis of thrombosis." []	EFO	70164	EFO:0004637	\N	protein S measurement	EFO:0004637
0	"Is a quantification of phospholipids, typically in blood used as a biomarker in diet studies." []	\N	phospholipid measurement	\N	\N	EFO	"Is a quantification of phospholipids, typically in blood used as a biomarker in diet studies." []	EFO	70165	EFO:0004639	\N	phospholipid measurement	EFO:0004639
0	"" []	\N	haptoglobin measurement	\N	\N	EFO	"" []	EFO	70166	EFO:0004640	\N	haptoglobin measurement	EFO:0004640
0	"White matter integrity is a measure of brain white matter using brain imaging and quantification techniques. White matter integrity is used as a measure of CNS function." []	\N	white matter integrity	\N	\N	EFO	"White matter integrity is a measure of brain white matter using brain imaging and quantification techniques. White matter integrity is used as a measure of CNS function." []	EFO	70167	EFO:0004641	\N	white matter integrity	EFO:0004641
0	"iI a quantification of secreted cortisol, typically in the blood. Some studies report increased cortisol in depressive patients." []	\N	cortisol secretion measurement	\N	\N	EFO	"iI a quantification of secreted cortisol, typically in the blood. Some studies report increased cortisol in depressive patients." []	EFO	70168	EFO:0004642	\N	cortisol secretion measurement	EFO:0004642
0	"Is a measurement of the T-peak to T-end (TPE) interval on an electrocardiogram, is a measure of myocardial dispersion of repolarization and is associated with an increased risk of ventricular arrhythmias." []	\N	TPE interval measurement	\N	\N	EFO	"Is a measurement of the T-peak to T-end (TPE) interval on an electrocardiogram, is a measure of myocardial dispersion of repolarization and is associated with an increased risk of ventricular arrhythmias." []	EFO	70169	EFO:0004644	\N	TPE interval measurement	EFO:0004644
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vaccine. A vaccine is a preparationcontaining substances with antigenic properties administered to activate the immune system, thereby inducing an immune response." []	\N	response to vaccine	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vaccine. A vaccine is a preparationcontaining substances with antigenic properties administered to activate the immune system, thereby inducing an immune response." []	EFO	70170	EFO:0004645	\N	response to vaccine	EFO:0004645
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platinum based chemotherapy stimulus." []	\N	response to platinum based chemotherapy	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platinum based chemotherapy stimulus." []	EFO	70171	EFO:0004647	\N	response to platinum based chemotherapy	EFO:0004647
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a TNF antagonist." []	\N	response to TNF antagonist	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a TNF antagonist." []	EFO	70172	EFO:0004653	\N	response to TNF antagonist	EFO:0004653
0	"A processed genotype data file is a data file which stores information about genotypeswhich has been processed by some form of analysis method, for example normalization or noise reduction." []	\N	processed genotype data file	\N	\N	EFO	"A processed genotype data file is a data file which stores information about genotypeswhich has been processed by some form of analysis method, for example normalization or noise reduction." []	EFO	70173	EFO:0004663	\N	processed genotype data file	EFO:0004663
0	"A binding site identification design type investigates protein binding sites on nucleic acids. Non-exact synonym: ChIP, chromatin immunoprecipitation, chromatin IP." []	\N	binding site identification design	\N	\N	EFO	"A binding site identification design type investigates protein binding sites on nucleic acids. Non-exact synonym: ChIP, chromatin immunoprecipitation, chromatin IP." []	EFO	70174	EFO:0004664	\N	binding site identification design	EFO:0004664
0	"Biomolecular annotation study design types are those which are designed to investigate functions, processes, locations and identity at the molecular level e.g. genotyping." []	\N	biomolecular annotation design	\N	\N	EFO	"Biomolecular annotation study design types are those which are designed to investigate functions, processes, locations and identity at the molecular level e.g. genotyping." []	EFO	70175	EFO:0004665	\N	biomolecular annotation design	EFO:0004665
0	"A cellular modification design type is where a modification of the transcriptome, proteome (not genome) is made, for example RNAi, antibody targeting." []	\N	cellular modification design	\N	\N	EFO	"A cellular modification design type is where a modification of the transcriptome, proteome (not genome) is made, for example RNAi, antibody targeting." []	EFO	70176	EFO:0004666	\N	cellular modification design	EFO:0004666
0	"A biological variation study design type investigates differences caused by intrinsic characteristics of an organism(s) or biological system; epidemiological reasons (history of biosources); manipulation, treatment or modification of an organism(s)." []	\N	biological variation design	\N	\N	EFO	"A biological variation study design type investigates differences caused by intrinsic characteristics of an organism(s) or biological system; epidemiological reasons (history of biosources); manipulation, treatment or modification of an organism(s)." []	EFO	70177	EFO:0004667	\N	biological variation design	EFO:0004667
0	"Methodological variation study design specific for array technology" []	\N	array specific design	\N	\N	EFO	"Methodological variation study design specific for array technology" []	EFO	70178	EFO:0004668	\N	array specific design	EFO:0004668
0	"A methodological variation study design type investigates differences caused by application of protocols, hardware, software and bioassay relationships." []	\N	methodological variation design	\N	\N	EFO	"A methodological variation study design type investigates differences caused by application of protocols, hardware, software and bioassay relationships." []	EFO	70179	EFO:0004669	\N	methodological variation design	EFO:0004669
0	"Is the quantification of Beta-amyloid 1-42 in cerebrospinal fluid typically used as a biomarker for Alzheimer's Disease" []	\N	beta-amyloid 1-42 measurement	\N	\N	EFO	"Is the quantification of Beta-amyloid 1-42 in cerebrospinal fluid typically used as a biomarker for Alzheimer's Disease" []	EFO	70180	EFO:0004670	\N	beta-amyloid 1-42 measurement	EFO:0004670
0	"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle" []	\N	QT interval	\N	\N	EFO	"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle" []	EFO	70181	EFO:0004682	\N	QT interval	EFO:0004682
0	"A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision." []	\N	wet macular degeneration	\N	\N	EFO	"A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision." []	EFO	70182	EFO:0004683	\N	wet macular degeneration	EFO:0004683
0	"Is a quantification of tumor necrosis factor-alpha, a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well. The measurement is used as a biomarker for inflammation and is typically performed on a blood sample." []	\N	tumor necrosis factor-alpha measurement	\N	\N	EFO	"Is a quantification of tumor necrosis factor-alpha, a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well. The measurement is used as a biomarker for inflammation and is typically performed on a blood sample." []	EFO	70183	EFO:0004684	\N	tumor necrosis factor-alpha measurement	EFO:0004684
0	"Measurements of the hip." []	\N	hip geometry	\N	\N	EFO	"Measurements of the hip." []	EFO	70184	EFO:0004685	\N	hip geometry	EFO:0004685
0	"Left ventricular non-compaction (LVNC) is characterized by prominent left ventricular trabeculae and deep inter-trabecular recesses. The myocardial wall is often thickened with a thin, compacted epicardial layer and a thickened endocardial layer. In some patients, LVNC is associated with left ventricular dilatation and systolic dysfunction, which can be transient in neonates." []	\N	non-compaction cardiomyopathy	\N	\N	EFO	"Left ventricular non-compaction (LVNC) is characterized by prominent left ventricular trabeculae and deep inter-trabecular recesses. The myocardial wall is often thickened with a thin, compacted epicardial layer and a thickened endocardial layer. In some patients, LVNC is associated with left ventricular dilatation and systolic dysfunction, which can be transient in neonates." []	EFO	70185	EFO:0004686	\N	non-compaction cardiomyopathy	EFO:0004686
0	"Is a quantification of Factor XI, typically in blood. Factor Xi is a serine protease involved in the process of coagulation." []	\N	factor XI measurement	\N	\N	EFO	"Is a quantification of Factor XI, typically in blood. Factor Xi is a serine protease involved in the process of coagulation." []	EFO	70186	EFO:0004694	\N	factor XI measurement	EFO:0004694
0	"Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma." []	\N	intraocular pressure measurement	\N	\N	EFO	"Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma." []	EFO	70187	EFO:0004695	\N	intraocular pressure measurement	EFO:0004695
0	"Is a quantification of sex hormone binding globulin. The SHBG glycoprotein binds to circulating estradiol and testosterone, low levels of SGBG may be implicated in breast cancer etiology." []	\N	sex hormone globulin binding measurement	\N	\N	EFO	"Is a quantification of sex hormone binding globulin. The SHBG glycoprotein binds to circulating estradiol and testosterone, low levels of SGBG may be implicated in breast cancer etiology." []	EFO	70188	EFO:0004696	\N	sex hormone globulin binding measurement	EFO:0004696
0	"Is a quantification of circulating estradiol a circulating steriod sex hormone." []	\N	estradiol measurement	\N	\N	EFO	"Is a quantification of circulating estradiol a circulating steriod sex hormone." []	EFO	70189	EFO:0004697	\N	estradiol measurement	EFO:0004697
0	"Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition" []	\N	insomnia	\N	\N	EFO	"Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition" []	EFO	70190	EFO:0004698	\N	insomnia	EFO:0004698
0	"An activity distinguished primarily by an element of risk in trying to obtain a desired goal, e.g., playing a game of chance for money." []	\N	gambling behaviour	\N	\N	EFO	"An activity distinguished primarily by an element of risk in trying to obtain a desired goal, e.g., playing a game of chance for money." []	EFO	70191	EFO:0004699	\N	gambling behaviour	EFO:0004699
0	"A drug dependence that is a psychological dependency on the regular use of metamphetamine." []	\N	metamphetamine dependence	\N	\N	EFO	"A drug dependence that is a psychological dependency on the regular use of metamphetamine." []	EFO	70192	EFO:0004701	\N	metamphetamine dependence	EFO:0004701
0	"The age of onset of (human) menarche, the beginning of the first menstrual cycle in an individual" []	\N	age at menarche	\N	\N	EFO	"The age of onset of (human) menarche, the beginning of the first menstrual cycle in an individual" []	EFO	70193	EFO:0004703	\N	age at menarche	EFO:0004703
0	"The age of onset of (human) menopause, the beginning of the first menstrual cycle in an individual" []	\N	age at menopause	\N	\N	EFO	"The age of onset of (human) menopause, the beginning of the first menstrual cycle in an individual" []	EFO	70194	EFO:0004704	\N	age at menopause	EFO:0004704
0	"A deficiency of thyroid hormone." []	\N	hypothyroidism	\N	\N	EFO	"A deficiency of thyroid hormone." []	EFO	70195	EFO:0004705	\N	hypothyroidism	EFO:0004705
0	"This condition is caused by diffuse hypertrophy and hyperplasia of the smooth muscle of the antrum of the stomach and pylorus. It usually occurs in infants aged 2-8 weeks. The pyloric muscle hypertrophy results in narrowing of the pyloric canal, which can then become easily obstructed. Genetic studies have identified susceptibility loci for infantile hypertrophic pyloric stenosis (IHPS) and molecular studies have concluded that smooth muscle cells are not properly innervated in this condition." []	\N	infantile hypertrophic pyloric stenosis	\N	\N	EFO	"This condition is caused by diffuse hypertrophy and hyperplasia of the smooth muscle of the antrum of the stomach and pylorus. It usually occurs in infants aged 2-8 weeks. The pyloric muscle hypertrophy results in narrowing of the pyloric canal, which can then become easily obstructed. Genetic studies have identified susceptibility loci for infantile hypertrophic pyloric stenosis (IHPS) and molecular studies have concluded that smooth muscle cells are not properly innervated in this condition." []	EFO	70196	EFO:0004707	\N	infantile hypertrophic pyloric stenosis	EFO:0004707
0	"A distinct, highly heritable Hodgkin lymphoma subtype." []	\N	nodular sclerosis Hodgkin lymphoma	\N	\N	EFO	"A distinct, highly heritable Hodgkin lymphoma subtype." []	EFO	70197	EFO:0004708	\N	nodular sclerosis Hodgkin lymphoma	EFO:0004708
0	"Abnormal descent of a pelvic organ resulting in the protrusion of the organ beyond its normal anatomical confines." []	\N	pelvic organ prolapse	\N	\N	EFO	"Abnormal descent of a pelvic organ resulting in the protrusion of the organ beyond its normal anatomical confines." []	EFO	70198	EFO:0004710	\N	pelvic organ prolapse	EFO:0004710
0	"Elephantiasis is a  result of a complex interplay between several factors: the worm, the symbiotic Wolbachia bacteria within the worm, the host’s immune response, and the numerous opportunistic infections and disorders that arise." []	\N	elephantiasis	\N	\N	EFO	"Elephantiasis is a  result of a complex interplay between several factors: the worm, the symbiotic Wolbachia bacteria within the worm, the host’s immune response, and the numerous opportunistic infections and disorders that arise." []	EFO	70199	EFO:0004711	\N	elephantiasis	EFO:0004711
0	"A form of elephantiasis in which no parasitic infection is detected." []	\N	podoconiosis	\N	\N	EFO	"A form of elephantiasis in which no parasitic infection is detected." []	EFO	70200	EFO:0004712	\N	podoconiosis	EFO:0004712
0	"" []	\N	FEV/FEC ratio	\N	\N	EFO	"" []	EFO	70201	EFO:0004713	\N	FEV/FEC ratio	EFO:0004713
0	"Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty." []	\N	sexual dysfunction	\N	\N	EFO	"Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty." []	EFO	70202	EFO:0004714	\N	sexual dysfunction	EFO:0004714
0	"An infarct detected by MRI and not determined to be clinically significant" []	\N	MRI defined brain infarct	\N	\N	EFO	"An infarct detected by MRI and not determined to be clinically significant" []	EFO	70203	EFO:0004715	\N	MRI defined brain infarct	EFO:0004715
0	"An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)" []	\N	vasuclar dementia	\N	\N	EFO	"An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)" []	EFO	70204	EFO:0004718	\N	vasuclar dementia	EFO:0004718
0	"An autoimmune blistering disorder. It is characterized by the presence of painful blisters and erosions in the skin and mucous membranes." []	\N	pemphigus vulgaris	\N	\N	EFO	"An autoimmune blistering disorder. It is characterized by the presence of painful blisters and erosions in the skin and mucous membranes." []	EFO	70205	EFO:0004719	\N	pemphigus vulgaris	EFO:0004719
0	"A group of genetic, infectious, or sporadic degenerative human and animal nervous system disorders associated with abnormal PRIONS. These diseases are characterized by conversion of the normal prion protein to an abnormal configuration via a post-translational process. In humans, these conditions generally feature DEMENTIA; ATAXIA; and a fatal outcome. Pathologic features include a spongiform encephalopathy without evidence of inflammation. The older literature occasionally refers to these as unconventional SLOW VIRUS DISEASES. (From Proc Natl Acad Sci USA 1998 Nov 10;95(23):13363-83)" []	\N	prion disease	\N	\N	EFO	"A group of genetic, infectious, or sporadic degenerative human and animal nervous system disorders associated with abnormal PRIONS. These diseases are characterized by conversion of the normal prion protein to an abnormal configuration via a post-translational process. In humans, these conditions generally feature DEMENTIA; ATAXIA; and a fatal outcome. Pathologic features include a spongiform encephalopathy without evidence of inflammation. The older literature occasionally refers to these as unconventional SLOW VIRUS DISEASES. (From Proc Natl Acad Sci USA 1998 Nov 10;95(23):13363-83)" []	EFO	70206	EFO:0004720	\N	prion disease	EFO:0004720
0	"Calcification of the coronary artery, used as a measure of coronary atherosclerosis, a risk factor for myocardial infarction." []	\N	coronary artery calcification	\N	\N	EFO	"Calcification of the coronary artery, used as a measure of coronary atherosclerosis, a risk factor for myocardial infarction." []	EFO	70207	EFO:0004723	\N	coronary artery calcification	EFO:0004723
0	"Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events." []	\N	carotid-femoral pulse wave velocity	\N	\N	EFO	"Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events." []	EFO	70208	EFO:0004724	\N	carotid-femoral pulse wave velocity	EFO:0004724
0	"This is an annotation class for metabolite measurements where the exact metabolite measurements are unknown. Do not annotate to this class." []	\N	metabolite measurement	\N	\N	EFO	"This is an annotation class for metabolite measurements where the exact metabolite measurements are unknown. Do not annotate to this class." []	EFO	70209	EFO:0004725	\N	metabolite measurement	EFO:0004725
0	"Any intermediate or product resulting from metabolism." []	\N	metabolite	\N	\N	EFO	"Any intermediate or product resulting from metabolism." []	EFO	70210	EFO:0004727	\N	metabolite	EFO:0004727
0	"Is the quantification of serum amyloid A protein in serum and is a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs)." []	\N	serum amyloid A protein measurement	\N	\N	EFO	"Is the quantification of serum amyloid A protein in serum and is a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs)." []	EFO	70211	EFO:0004728	\N	serum amyloid A protein measurement	EFO:0004728
0	"The quantification of some vitamin, typically from a body fluid such as blood. A vitamin is an organic compound required by an organism as a vital nutrient in limited amounts. An organic chemical compound (or related set of compounds) is called a vitamin when it cannot be synthesized in sufficient quantities by an organism, and must be obtained from the diet." []	\N	vitamin measurement	\N	\N	EFO	"The quantification of some vitamin, typically from a body fluid such as blood. A vitamin is an organic compound required by an organism as a vital nutrient in limited amounts. An organic chemical compound (or related set of compounds) is called a vitamin when it cannot be synthesized in sufficient quantities by an organism, and must be obtained from the diet." []	EFO	70212	EFO:0004729	\N	vitamin measurement	EFO:0004729
0	"" []	\N	hormone measurement	\N	\N	EFO	"" []	EFO	70213	EFO:0004730	\N	hormone measurement	EFO:0004730
0	"Is a quantification of some eye structure or property of an eye structure, such as corneal thickness." []	\N	eye measurement	\N	\N	EFO	"Is a quantification of some eye structure or property of an eye structure, such as corneal thickness." []	EFO	70214	EFO:0004731	\N	eye measurement	EFO:0004731
0	"Is the quantification of some lipoprotein" []	\N	lipoprotein measurement	\N	\N	EFO	"Is the quantification of some lipoprotein" []	EFO	70215	EFO:0004732	\N	lipoprotein measurement	EFO:0004732
0	"Is a quantification of anti-cyclic citrullinated peptide antibody, these are associated with rheumatoid arthritis." []	\N	anti-cyclic citrullinated peptide antibody measurement	\N	\N	EFO	"Is a quantification of anti-cyclic citrullinated peptide antibody, these are associated with rheumatoid arthritis." []	EFO	70216	EFO:0004733	\N	anti-cyclic citrullinated peptide antibody measurement	EFO:0004733
0	"Is a quantification of serum alanine aminotransferase, most commonly found in liver, the test is used in ascertainment of liver function." []	\N	serum alanine aminotransferase measurement	\N	\N	EFO	"Is a quantification of serum alanine aminotransferase, most commonly found in liver, the test is used in ascertainment of liver function." []	EFO	70217	EFO:0004735	\N	serum alanine aminotransferase measurement	EFO:0004735
0	"Is a quantification of aspartate aminotransferase, and is commonly used as a marker for liver function." []	\N	aspartate aminotransferase measurement	\N	\N	EFO	"Is a quantification of aspartate aminotransferase, and is commonly used as a marker for liver function." []	EFO	70218	EFO:0004736	\N	aspartate aminotransferase measurement	EFO:0004736
0	"Is a of quantification some carotenoid, typically in blood. These are lipid based compounds derived from chloroplasts and chromoplasts of plants and some other photosynthetic organisms. Consumption of a diet rich in carotenoids is reported to have health benefits for human populations." []	\N	carotenoid measurement	\N	\N	EFO	"Is a of quantification some carotenoid, typically in blood. These are lipid based compounds derived from chloroplasts and chromoplasts of plants and some other photosynthetic organisms. Consumption of a diet rich in carotenoids is reported to have health benefits for human populations." []	EFO	70219	EFO:0004737	\N	carotenoid measurement	EFO:0004737
0	"Is a quantification of some tocopherol, typically in blood. Some tocopherols have Vitamin E function (note that  tocotrienols also have vitamin E function)." []	\N	tocopherol measurement	\N	\N	EFO	"Is a quantification of some tocopherol, typically in blood. Some tocopherols have Vitamin E function (note that  tocotrienols also have vitamin E function)." []	EFO	70220	EFO:0004738	\N	tocopherol measurement	EFO:0004738
0	"Is a quantification of circulating cell free DNA measured in blood used as an indicator of cell death and as an indicator of disease, for example some tumour types release this." []	\N	circulating cell free DNA measurement	\N	\N	EFO	"Is a quantification of circulating cell free DNA measured in blood used as an indicator of cell death and as an indicator of disease, for example some tumour types release this." []	EFO	70221	EFO:0004739	\N	circulating cell free DNA measurement	EFO:0004739
0	"Is a quantification of blood urea nitrogen used in the measure of renal function." []	\N	blood urea nitrogen measurement	\N	\N	EFO	"Is a quantification of blood urea nitrogen used in the measure of renal function." []	EFO	70222	EFO:0004741	\N	blood urea nitrogen measurement	EFO:0004741
0	"" []	\N	renal system measurement	\N	\N	EFO	"" []	EFO	70223	EFO:0004742	\N	renal system measurement	EFO:0004742
0	"Any measurable or observable characteristic related to the shape, structure, color or pattern of the region of the body that includes the front part of the head from the chin to the top of the forehead, where the mouth, eyes, nose, and other features are located." []	\N	facial morphology	\N	\N	EFO	"Any measurable or observable characteristic related to the shape, structure, color or pattern of the region of the body that includes the front part of the head from the chin to the top of the forehead, where the mouth, eyes, nose, and other features are located." []	EFO	70224	EFO:0004743	\N	facial morphology	EFO:0004743
0	"Is a quantification of matrix metalloproteinases, Collectively, they are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine in/activation.[3] MMPs are also thought to play a major role on cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense." []	\N	matrix metalloproteinase measurement	\N	\N	EFO	"Is a quantification of matrix metalloproteinases, Collectively, they are capable of degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine/cytokine in/activation.[3] MMPs are also thought to play a major role on cell behaviors such as cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense." []	EFO	70225	EFO:0004744	\N	matrix metalloproteinase measurement	EFO:0004744
0	"Is a quantification of NT-proBNP (N-terminal prohormone of brain natriuretic peptide) which is associated with acute congestive heart failure." []	\N	NT-proBNP measurement	\N	\N	EFO	"Is a quantification of NT-proBNP (N-terminal prohormone of brain natriuretic peptide) which is associated with acute congestive heart failure." []	EFO	70226	EFO:0004745	\N	NT-proBNP measurement	EFO:0004745
0	"Is a quantification of Lipoprotein-associated phospholipase A(2). It is involved in the process of arthrosclerosis and is a cardiovascular disease biomarker." []	\N	lipoprotein-associated phospholipase A(2) measurement	\N	\N	EFO	"Is a quantification of Lipoprotein-associated phospholipase A(2). It is involved in the process of arthrosclerosis and is a cardiovascular disease biomarker." []	EFO	70227	EFO:0004746	\N	lipoprotein-associated phospholipase A(2) measurement	EFO:0004746
0	"This is a general class for any measurement of a protein. Do not annotate to this class, request a more specific child term." []	\N	protein measurement	\N	\N	EFO	"This is a general class for any measurement of a protein. Do not annotate to this class, request a more specific child term." []	EFO	70228	EFO:0004747	\N	protein measurement	EFO:0004747
0	"Is a quantification of thyroid-stimulating hormone, a glycoprotein and hormone secreted from the pituitary which regulates the thryoid." []	\N	thyroid stimulating hormone measurement	\N	\N	EFO	"Is a quantification of thyroid-stimulating hormone, a glycoprotein and hormone secreted from the pituitary which regulates the thryoid." []	EFO	70229	EFO:0004748	\N	thyroid stimulating hormone measurement	EFO:0004748
0	"Is the quantification of Chemokine (C-C motif) ligand 2, involved in response to infection and inflammation." []	\N	CCL2 measurement	\N	\N	EFO	"Is the quantification of Chemokine (C-C motif) ligand 2, involved in response to infection and inflammation." []	EFO	70230	EFO:0004749	\N	CCL2 measurement	EFO:0004749
0	"Is a quantification of interleukin 10, typically in blood. Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells." []	\N	interleukin 10 measurement	\N	\N	EFO	"Is a quantification of interleukin 10, typically in blood. Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells." []	EFO	70231	EFO:0004750	\N	interleukin 10 measurement	EFO:0004750
0	"Is the quantification of Chemokine (C-C motif) ligand 4, involved in response to infection and inflammation,  chemoattractant for natural killer cells, monocytes and a variety of other immune cells." []	\N	CCL4 measurement	\N	\N	EFO	"Is the quantification of Chemokine (C-C motif) ligand 4, involved in response to infection and inflammation,  chemoattractant for natural killer cells, monocytes and a variety of other immune cells." []	EFO	70232	EFO:0004751	\N	CCL4 measurement	EFO:0004751
0	"Is the quantification of parathyroid hormone, typically in blood. The protein encoded by this gene is a hormone secreted by parathyroid cells. This hormone elevates blood Ca2+ level by dissolving the salts in bone and preventing their renal excretion. Defects in this gene are a cause of familial isolated hypoparathyroidism (FIH) (RefSeq)" []	\N	parathyroid hormone measurement	\N	\N	EFO	"Is the quantification of parathyroid hormone, typically in blood. The protein encoded by this gene is a hormone secreted by parathyroid cells. This hormone elevates blood Ca2+ level by dissolving the salts in bone and preventing their renal excretion. Defects in this gene are a cause of familial isolated hypoparathyroidism (FIH) (RefSeq)" []	EFO	70233	EFO:0004752	\N	parathyroid hormone measurement	EFO:0004752
0	"Is a quantification of interleukin 12. Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation." []	\N	interleukin 12 measurement	\N	\N	EFO	"Is a quantification of interleukin 12. Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation." []	EFO	70234	EFO:0004753	\N	interleukin 12 measurement	EFO:0004753
0	"Is a quantification of Interleukin 1 Receptor Antagonist (IL1-RA). Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure" []	\N	interleukin 1 receptor antagonist measurement	\N	\N	EFO	"Is a quantification of Interleukin 1 Receptor Antagonist (IL1-RA). Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure" []	EFO	70235	EFO:0004754	\N	interleukin 1 receptor antagonist measurement	EFO:0004754
0	"Is a quantification of total tau protein, a biomarker for Alzheimer's disease." []	\N	t-tau measurement	\N	\N	EFO	"Is a quantification of total tau protein, a biomarker for Alzheimer's disease." []	EFO	70236	EFO:0004760	\N	t-tau measurement	EFO:0004760
0	"Is a quantification of uric acid, typically in blood. Uric acid is associated with gout, insulin resistance and cardivascular disease." []	\N	uric acid measurement	\N	\N	EFO	"Is a quantification of uric acid, typically in blood. Uric acid is associated with gout, insulin resistance and cardivascular disease." []	EFO	70237	EFO:0004761	\N	uric acid measurement	EFO:0004761
0	"Is a quantification of VEGF, a growth factor involved in angiogenesis and a biomarker for cancer." []	\N	vascular endothelial growth factor measurement	\N	\N	EFO	"Is a quantification of VEGF, a growth factor involved in angiogenesis and a biomarker for cancer." []	EFO	70238	EFO:0004762	\N	vascular endothelial growth factor measurement	EFO:0004762
0	"Is a quantification of phosphorylated tau protein, used as a biomarker for Alzheimer's disease." []	\N	p-tau measurement	\N	\N	EFO	"Is a quantification of phosphorylated tau protein, used as a biomarker for Alzheimer's disease." []	EFO	70239	EFO:0004763	\N	p-tau measurement	EFO:0004763
0	"Is a quantification of some aspect of adipose tissue, for example used in the diagnosis and research into obesity." []	\N	adipose tissue measurement	\N	\N	EFO	"Is a quantification of some aspect of adipose tissue, for example used in the diagnosis and research into obesity." []	EFO	70240	EFO:0004764	\N	adipose tissue measurement	EFO:0004764
0	"Is a quantification of a particular location of adipose tissue." []	\N	visceral adipose tissue measurement	\N	\N	EFO	"Is a quantification of a particular location of adipose tissue." []	EFO	70241	EFO:0004765	\N	visceral adipose tissue measurement	EFO:0004765
0	"Is a quantification of a particular location of adipose tissue." []	\N	subcutaneous adipose tissue	\N	\N	EFO	"Is a quantification of a particular location of adipose tissue." []	EFO	70242	EFO:0004766	\N	subcutaneous adipose tissue	EFO:0004766
0	"Is a quantification of visceral to subcutaneous adipose tissue." []	\N	visceral:subcutaneous adipose tissue ratio	\N	\N	EFO	"Is a quantification of visceral to subcutaneous adipose tissue." []	EFO	70243	EFO:0004767	\N	visceral:subcutaneous adipose tissue ratio	EFO:0004767
0	"Is a quantification of follicle stimulating hormone. ollicle-stimulating hormone (FSH) is a hormone found in humans and other animals. It is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and luteinizing hormone (LH) act synergistically in reproduction. Specifically, an increase in FSH secretion by the anterior pituitary causes ovulation. FSH measurements are used as a biomarker of oocyte reserve." []	\N	follicle stimulating hormone measurement	\N	\N	EFO	"Is a quantification of follicle stimulating hormone. ollicle-stimulating hormone (FSH) is a hormone found in humans and other animals. It is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and luteinizing hormone (LH) act synergistically in reproduction. Specifically, an increase in FSH secretion by the anterior pituitary causes ovulation. FSH measurements are used as a biomarker of oocyte reserve." []	EFO	70244	EFO:0004768	\N	follicle stimulating hormone measurement	EFO:0004768
0	"Is a quantification of anti_Mullerian hormone, and is used as a biomarker of ovarian reserve. The AMH is  produced by the granulosa cells of the early developing antral follicles.  These  are the immature eggs that wake up from their dormant state and develop into mature eggs.  As the number of oocytes decline, the number of  small antral follicles decline in number and  the serum Anti-Mullerian hormone level falls." []	\N	anti-Mullerian hormone measurement	\N	\N	EFO	"Is a quantification of anti_Mullerian hormone, and is used as a biomarker of ovarian reserve. The AMH is  produced by the granulosa cells of the early developing antral follicles.  These  are the immature eggs that wake up from their dormant state and develop into mature eggs.  As the number of oocytes decline, the number of  small antral follicles decline in number and  the serum Anti-Mullerian hormone level falls." []	EFO	70245	EFO:0004769	\N	anti-Mullerian hormone measurement	EFO:0004769
0	"Ovarian reserve is a term that is used to determine the capacity of the ovary to provide oocytes that are capable of fertilization resulting in a healthy and successful pregnancy. Ovarian reserve is correlated with levels of FSH and anti-Mullerian hormones." []	\N	ovarian reserve	\N	\N	EFO	"Ovarian reserve is a term that is used to determine the capacity of the ovary to provide oocytes that are capable of fertilization resulting in a healthy and successful pregnancy. Ovarian reserve is correlated with levels of FSH and anti-Mullerian hormones." []	EFO	70246	EFO:0004770	\N	ovarian reserve	EFO:0004770
0	"Is a quantification of the surface area of the visual cortex, it is variable and heritable, and is correlated with visual acuity and visual perception." []	\N	visual cortical surface area measurement	\N	\N	EFO	"Is a quantification of the surface area of the visual cortex, it is variable and heritable, and is correlated with visual acuity and visual perception." []	EFO	70247	EFO:0004771	\N	visual cortical surface area measurement	EFO:0004771
0	"A form of hypertension with early onset relative to normal range for a given population." []	\N	early onset hypertension	\N	\N	EFO	"A form of hypertension with early onset relative to normal range for a given population." []	EFO	70248	EFO:0004772	\N	early onset hypertension	EFO:0004772
0	"Mastication of tobacco, correlated with an increased risk of oral cancers." []	\N	chewing tobacco behavior	\N	\N	EFO	"Mastication of tobacco, correlated with an increased risk of oral cancers." []	EFO	70249	EFO:0004774	\N	chewing tobacco behavior	EFO:0004774
0	"An exfoliative disease of skin seen primarily in adults and characterized by flaccid bullae and spreading erythema so that the skin has the appearance of being scalded. It results primarily from a toxic reaction to various drugs, but occasionally occurs as a result of infection, neoplastic conditions, or other exposure." []	\N	toxic epidermal necrolysis	\N	\N	EFO	"An exfoliative disease of skin seen primarily in adults and characterized by flaccid bullae and spreading erythema so that the skin has the appearance of being scalded. It results primarily from a toxic reaction to various drugs, but occasionally occurs as a result of infection, neoplastic conditions, or other exposure." []	EFO	70250	EFO:0004775	\N	toxic epidermal necrolysis	EFO:0004775
0	"A drug dependence that is the physiological result of being addicted to alcohol and nicotine." []	\N	alcohol and nicotine codependence	\N	\N	EFO	"A drug dependence that is the physiological result of being addicted to alcohol and nicotine." []	EFO	70251	EFO:0004776	\N	alcohol and nicotine codependence	EFO:0004776
0	"" []	\N	alcohol withdrawal	\N	\N	EFO	"" []	EFO	70252	EFO:0004777	\N	alcohol withdrawal	EFO:0004777
0	"The process of questioning an individual, usually by means of a survey to determine general health." []	\N	self rated health	\N	\N	EFO	"The process of questioning an individual, usually by means of a survey to determine general health." []	EFO	70253	EFO:0004778	\N	self rated health	EFO:0004778
0	"The CHAOS scale is a questionnaire filled out by parents that is designed to assess the level of confusion and disorganization in the child’s home environment." []	\N	CHAOS measure	\N	\N	EFO	"The CHAOS scale is a questionnaire filled out by parents that is designed to assess the level of confusion and disorganization in the child’s home environment." []	EFO	70254	EFO:0004779	\N	CHAOS measure	EFO:0004779
0	"" []	\N	DSM-IV-based social scale	\N	\N	EFO	"" []	EFO	70255	EFO:0004780	\N	DSM-IV-based social scale	EFO:0004780
0	"A measure of non social behaviour used in behavioral studies to examine autistic like traits." []	\N	DSM-IV-based  non-social scale	\N	\N	EFO	"A measure of non social behaviour used in behavioral studies to examine autistic like traits." []	EFO	70256	EFO:0004781	\N	DSM-IV-based  non-social scale	EFO:0004781
0	"Measurements used to quantify, or assess individual or population  behaviour or disorderd behaviours, e.g. by adminsistration of a questionaire." []	\N	behavior or behavioral disorder measurement	\N	\N	EFO	"Measurements used to quantify, or assess individual or population  behaviour or disorderd behaviours, e.g. by adminsistration of a questionaire." []	EFO	70257	EFO:0004782	\N	behavior or behavioral disorder measurement	EFO:0004782
0	"Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A). The TEMPS-A is designed to assess lifelong, milder aspects of bipolar symptomatology and defines five temperaments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious." []	\N	TEMPS-A questionnaire	\N	\N	EFO	"Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A). The TEMPS-A is designed to assess lifelong, milder aspects of bipolar symptomatology and defines five temperaments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious." []	EFO	70258	EFO:0004783	\N	TEMPS-A questionnaire	EFO:0004783
0	"A measure of educational progress reported using a questionnaire based approach, often used as a proxy for cognitive performance as the two are correlated." []	\N	self reported educational attainment	\N	\N	EFO	"A measure of educational progress reported using a questionnaire based approach, often used as a proxy for cognitive performance as the two are correlated." []	EFO	70259	EFO:0004784	\N	self reported educational attainment	EFO:0004784
0	"The South Texas Assessment of Neurocognition (STAN) is a 90-min primarily computerized battery of standard and experimental neuropsychological tests. The STAN combines software developed for psychological experimentation (E-Prime) and database software (Microsoft ACCESS) with a user interface developed in visual basic to provide a fully automated testing environment which logs subject information, administers tests in a pre-defined order and databases subject performance at the completion of each test." []	\N	South Texas Assessment of Neurocognition	\N	\N	EFO	"The South Texas Assessment of Neurocognition (STAN) is a 90-min primarily computerized battery of standard and experimental neuropsychological tests. The STAN combines software developed for psychological experimentation (E-Prime) and database software (Microsoft ACCESS) with a user interface developed in visual basic to provide a fully automated testing environment which logs subject information, administers tests in a pre-defined order and databases subject performance at the completion of each test." []	EFO	70260	EFO:0004785	\N	South Texas Assessment of Neurocognition	EFO:0004785
0	"The Mini-international neuropsychiatric interview is a short structured clinical interview which enables researchers to make diagnoses of psychiatric disorders according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) or ICD-10. The administration time of the interview is approximately 15 minutes and was designed for epidemiological studies and multicenter clinical trials." []	\N	Mini-International Neuropsychiatric Interview	\N	\N	EFO	"The Mini-international neuropsychiatric interview is a short structured clinical interview which enables researchers to make diagnoses of psychiatric disorders according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) or ICD-10. The administration time of the interview is approximately 15 minutes and was designed for epidemiological studies and multicenter clinical trials." []	EFO	70261	EFO:0004786	\N	Mini-International Neuropsychiatric Interview	EFO:0004786
0	"Is a quantification of the 126-amino acid C-terminal fragment of the ANP precursor, an approximately 150-amino acid polypeptide in a number of species. It is formed by the removal of the N-terminal signal sequence ANP (1-24). This prohormone contains various active ANF sequences. \\nANF  is is a powerful vasodilator, and a protein (polypeptide) hormone secreted by heart muscle cells.[1][2][3] It is involved in the homeostatic control of body water, sodium, potassium and fat (adipose tissue)." []	\N	atrial natriuretic factor measurement	\N	\N	EFO	"Is a quantification of the 126-amino acid C-terminal fragment of the ANP precursor, an approximately 150-amino acid polypeptide in a number of species. It is formed by the removal of the N-terminal signal sequence ANP (1-24). This prohormone contains various active ANF sequences. \\nANF  is is a powerful vasodilator, and a protein (polypeptide) hormone secreted by heart muscle cells.[1][2][3] It is involved in the homeostatic control of body water, sodium, potassium and fat (adipose tissue)." []	EFO	70262	EFO:0004789	\N	atrial natriuretic factor measurement	EFO:0004789
0	"Is a quantification of CD40 ligand,  primarily expressed on activated CD4+ T lymphocytes." []	\N	CD40 ligand measurement	\N	\N	EFO	"Is a quantification of CD40 ligand,  primarily expressed on activated CD4+ T lymphocytes." []	EFO	70263	EFO:0004790	\N	CD40 ligand measurement	EFO:0004790
0	"Is a quantification of tissue plasminogen activator, an enzyme which converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration." []	\N	tissue plasminogen activator measurement	\N	\N	EFO	"Is a quantification of tissue plasminogen activator, an enzyme which converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration." []	EFO	70264	EFO:0004791	\N	tissue plasminogen activator measurement	EFO:0004791
0	"Is a quantification of plasminogen activator inhibitor 1 a serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis" []	\N	plasminogen activator inhibitor 1 measurement	\N	\N	EFO	"Is a quantification of plasminogen activator inhibitor 1 a serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis" []	EFO	70265	EFO:0004792	\N	plasminogen activator inhibitor 1 measurement	EFO:0004792
0	"The response of human skin to sun exposure." []	\N	skin sensitivity to sun	\N	\N	EFO	"The response of human skin to sun exposure." []	EFO	70266	EFO:0004795	\N	skin sensitivity to sun	EFO:0004795
0	"A quantification of a genomic variation that increases or decreases the copy number of a given region." []	\N	copy number variation	\N	\N	EFO	"A quantification of a genomic variation that increases or decreases the copy number of a given region." []	EFO	70267	EFO:0004798	\N	copy number variation	EFO:0004798
0	"Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS)." []	\N	cholelithiasis	\N	\N	EFO	"Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS)." []	EFO	70268	EFO:0004799	\N	cholelithiasis	EFO:0004799
0	"Is a quantification of frontal theta event related oscillations, determined by target processing in an oddball paradigm." []	\N	frontal theta oscillation measurement	\N	\N	EFO	"Is a quantification of frontal theta event related oscillations, determined by target processing in an oddball paradigm." []	EFO	70269	EFO:0004800	\N	frontal theta oscillation measurement	EFO:0004800
0	"Is a quantification of family size, also used as a measure of male fertility." []	\N	family size	\N	\N	EFO	"Is a quantification of family size, also used as a measure of male fertility." []	EFO	70270	EFO:0004802	\N	family size	EFO:0004802
0	"A fertility quality of inhering in a male by virtue of the bearer's disposition to initiate, sustain, or support reproduction." []	\N	male fertility	\N	\N	EFO	"A fertility quality of inhering in a male by virtue of the bearer's disposition to initiate, sustain, or support reproduction." []	EFO	70271	EFO:0004803	\N	male fertility	EFO:0004803
0	"Is a quantification of birth rate, te ratio of live births in an area to the population of that area, expressed per 1000 people in the population per year. Also used as a measure of male fertility" []	\N	birth rate	\N	\N	EFO	"Is a quantification of birth rate, te ratio of live births in an area to the population of that area, expressed per 1000 people in the population per year. Also used as a measure of male fertility" []	EFO	70272	EFO:0004804	\N	birth rate	EFO:0004804
0	"Formal thought disorder (FTD), or disorganized speech, is one of the central signs of schizophrenia" []	\N	formal thought disorder	\N	\N	EFO	"Formal thought disorder (FTD), or disorganized speech, is one of the central signs of schizophrenia" []	EFO	70273	EFO:0004805	\N	formal thought disorder	EFO:0004805
0	"Is a quantification of some asbestos exposure," []	\N	asbestos exposure measurement	\N	\N	EFO	"Is a quantification of some asbestos exposure," []	EFO	70274	EFO:0004806	\N	asbestos exposure measurement	EFO:0004806
0	"Is a quantification of sleep time in humans where average sleep time was less than five hours." []	\N	short sleep	\N	\N	EFO	"Is a quantification of sleep time in humans where average sleep time was less than five hours." []	EFO	70275	EFO:0004807	\N	short sleep	EFO:0004807
0	"Is a quantification of L lactate dehydrodgenase, typically measured in serum, used as a marker of tissue breakdown as LDH is abundant in red blood cells and can function as a marker for hemolysis" []	\N	L lactate dehydrogenase measurement	\N	\N	EFO	"Is a quantification of L lactate dehydrodgenase, typically measured in serum, used as a marker of tissue breakdown as LDH is abundant in red blood cells and can function as a marker for hemolysis" []	EFO	70276	EFO:0004808	\N	L lactate dehydrogenase measurement	EFO:0004808
0	"Is a quantification of Fructose-Bisphosphate Aldolase,is an enzyme catalyzing a reversible reaction that splits the aldol, fructose 1,6-bisphosphate, into the triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (GAP)." []	\N	fructose-bisphosphate aldolase measurement	\N	\N	EFO	"Is a quantification of Fructose-Bisphosphate Aldolase,is an enzyme catalyzing a reversible reaction that splits the aldol, fructose 1,6-bisphosphate, into the triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (GAP)." []	EFO	70277	EFO:0004809	\N	fructose-bisphosphate aldolase measurement	EFO:0004809
0	"Is a quantification of interleukin-6, a  pro-inflammatory and anti-inflammatory cytokine." []	\N	interleukin-6 measurement	\N	\N	EFO	"Is a quantification of interleukin-6, a  pro-inflammatory and anti-inflammatory cytokine." []	EFO	70278	EFO:0004810	\N	interleukin-6 measurement	EFO:0004810
0	"Is a quantification of interleukin-8, is a chemokine produced by macrophages and other cell types such as epithelial cells. It is also synthesized by endothelial cells, which store IL-8 in their storage vesicles, the Weibel-Palade bodies. IL-8 is secreted and is an important mediator of the immune reaction in the innate immune system response." []	\N	interleukin-8 measurement	\N	\N	EFO	"Is a quantification of interleukin-8, is a chemokine produced by macrophages and other cell types such as epithelial cells. It is also synthesized by endothelial cells, which store IL-8 in their storage vesicles, the Weibel-Palade bodies. IL-8 is secreted and is an important mediator of the immune reaction in the innate immune system response." []	EFO	70279	EFO:0004811	\N	interleukin-8 measurement	EFO:0004811
0	"Is a quantification of interleukin-1 beta, an IL-1 cytokine family protein, secreted by macrophages and a mediator of inflammatory response." []	\N	interleukin-1 beta measurement	\N	\N	EFO	"Is a quantification of interleukin-1 beta, an IL-1 cytokine family protein, secreted by macrophages and a mediator of inflammatory response." []	EFO	70280	EFO:0004812	\N	interleukin-1 beta measurement	EFO:0004812
0	"Is a quantification of any of the alpha globulin class of proteins, typically in serum." []	\N	alpha globulin measurement	\N	\N	EFO	"Is a quantification of any of the alpha globulin class of proteins, typically in serum." []	EFO	70281	EFO:0004813	\N	alpha globulin measurement	EFO:0004813
0	"Is a quantification of the IL-6 receptor (CD126), activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis" []	\N	interleukin-6 receptor measurement	\N	\N	EFO	"Is a quantification of the IL-6 receptor (CD126), activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis" []	EFO	70282	EFO:0004814	\N	interleukin-6 receptor measurement	EFO:0004814
0	"Is a quantification of alphamacroglobulins 1 and/or 2, glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters. Chronic kidney disease can result in the leakage of alphamacroglobulins into the blood." []	\N	alpha macroglobulin measurement	\N	\N	EFO	"Is a quantification of alphamacroglobulins 1 and/or 2, glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters. Chronic kidney disease can result in the leakage of alphamacroglobulins into the blood." []	EFO	70283	EFO:0004815	\N	alpha macroglobulin measurement	EFO:0004815
0	"Is a quantification of any of the TF1b isoforms, TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis." []	\N	transforming growth factor beta measurement	\N	\N	EFO	"Is a quantification of any of the TF1b isoforms, TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis." []	EFO	70284	EFO:0004818	\N	transforming growth factor beta measurement	EFO:0004818
0	"Is a quantification of resistin, a cytokine secreted by immune and epithelial cells in human and associated with obseity and type II diabetes by some studies" []	\N	resistin measurement	\N	\N	EFO	"Is a quantification of resistin, a cytokine secreted by immune and epithelial cells in human and associated with obseity and type II diabetes by some studies" []	EFO	70285	EFO:0004819	\N	resistin measurement	EFO:0004819
0	"The ratio of males to females for live births" []	\N	sex ratio	\N	\N	EFO	"The ratio of males to females for live births" []	EFO	70286	EFO:0004820	\N	sex ratio	EFO:0004820
0	"The perception of facial expression" []	\N	perception of facial expression	\N	\N	EFO	"The perception of facial expression" []	EFO	70287	EFO:0004823	\N	perception of facial expression	EFO:0004823
0	"An inventory for personality traits devised by Cloninger et al. Traits scored include:\\nNovelty Seeking (NS)\\nHarm Avoidance (HA)\\nReward Dependence (RD)\\nPersistence (PS)\\nSelf-Directedness (SD)\\nCooperativeness (CO)\\nSelf-Transcendence (ST)" []	\N	temperament and character inventory	\N	\N	EFO	"An inventory for personality traits devised by Cloninger et al. Traits scored include:\\nNovelty Seeking (NS)\\nHarm Avoidance (HA)\\nReward Dependence (RD)\\nPersistence (PS)\\nSelf-Directedness (SD)\\nCooperativeness (CO)\\nSelf-Transcendence (ST)" []	EFO	70288	EFO:0004825	\N	temperament and character inventory	EFO:0004825
0	"Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls." []	\N	anti-neutrophil antibody associated vasculitis	\N	\N	EFO	"Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls." []	EFO	70289	EFO:0004826	\N	anti-neutrophil antibody associated vasculitis	EFO:0004826
0	"Human economic and social preferences determined by application of a survey or questionnaire." []	\N	economic and social preference	\N	\N	EFO	"Human economic and social preferences determined by application of a survey or questionnaire." []	EFO	70290	EFO:0004827	\N	economic and social preference	EFO:0004827
0	"The genetic variation of individuals in a population." []	\N	genetic variation	\N	\N	EFO	"The genetic variation of individuals in a population." []	EFO	70291	EFO:0004828	\N	genetic variation	EFO:0004828
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an irinotecan stimulus. Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin\\nts main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan." []	\N	response to irinotecan	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an irinotecan stimulus. Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin\\nts main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan." []	EFO	70292	EFO:0004829	\N	response to irinotecan	EFO:0004829
0	"The volume of the caudate nucleus, a brain structure implicated in many common neurological and psychiatric disorders" []	\N	caudate nucleus volume	\N	\N	EFO	"The volume of the caudate nucleus, a brain structure implicated in many common neurological and psychiatric disorders" []	EFO	70293	EFO:0004830	\N	caudate nucleus volume	EFO:0004830
0	"A RR interval is an  electrocardiography measurement  - R wave to R wave interval (RR interval) and is the inverse of the heart rate." []	\N	RR interval	\N	\N	EFO	"A RR interval is an  electrocardiography measurement  - R wave to R wave interval (RR interval) and is the inverse of the heart rate." []	EFO	70294	EFO:0004831	\N	RR interval	EFO:0004831
0	"optic nerve head measurement" []	\N	optic disc size measurement	\N	\N	EFO	"optic nerve head measurement" []	EFO	70295	EFO:0004832	\N	optic disc size measurement	EFO:0004832
0	"Is a quantification of neutrophils in blood." []	\N	neutrophil count	\N	\N	EFO	"Is a quantification of neutrophils in blood." []	EFO	70296	EFO:0004833	\N	neutrophil count	EFO:0004833
0	"Is a quantification of calcium, typically in serum. Calcium (Ca2+) plays a pivotal role in the physiology and biochemistry of organisms and the cell. It plays an important role in signal transduction pathways, where it acts as a second messenger, in neurotransmitter release from neurons, contraction of all muscle cell types, and fertilization. Many enzymes require calcium ions as a cofactor, those of the blood-clotting cascade being notable examples. Extracellular calcium is also important for maintaining the potential difference across excitable cell membranes, as well as proper bone formation." []	\N	calcium measurement	\N	\N	EFO	"Is a quantification of calcium, typically in serum. Calcium (Ca2+) plays a pivotal role in the physiology and biochemistry of organisms and the cell. It plays an important role in signal transduction pathways, where it acts as a second messenger, in neurotransmitter release from neurons, contraction of all muscle cell types, and fertilization. Many enzymes require calcium ions as a cofactor, those of the blood-clotting cascade being notable examples. Extracellular calcium is also important for maintaining the potential difference across excitable cell membranes, as well as proper bone formation." []	EFO	70297	EFO:0004838	\N	calcium measurement	EFO:0004838
0	"Is the ratio of CD4 vs. CD8 lymphocytes, abormal ratios may reflect an infection such as HIV." []	\N	CD4:CD8 lymphocyte ratio	\N	\N	EFO	"Is the ratio of CD4 vs. CD8 lymphocytes, abormal ratios may reflect an infection such as HIV." []	EFO	70298	EFO:0004839	\N	CD4:CD8 lymphocyte ratio	EFO:0004839
0	"Is a quantification of the thickness of brain cortex, e.g. measured by MRI, used in the diagnosis of Alzheimer's disease." []	\N	cortical thickness	\N	\N	EFO	"Is a quantification of the thickness of brain cortex, e.g. measured by MRI, used in the diagnosis of Alzheimer's disease." []	EFO	70299	EFO:0004840	\N	cortical thickness	EFO:0004840
0	"Is the ratio of 2D:4D used a a marker for prenatal androgen exposure." []	\N	digit length ratio	\N	\N	EFO	"Is the ratio of 2D:4D used a a marker for prenatal androgen exposure." []	EFO	70300	EFO:0004841	\N	digit length ratio	EFO:0004841
0	"Is a quantification of eosinphils in blood." []	\N	eosinophil count	\N	\N	EFO	"Is a quantification of eosinphils in blood." []	EFO	70301	EFO:0004842	\N	eosinophil count	EFO:0004842
0	"Is a quantification of any or all of the B vitamins" []	\N	vitamin B measurement	\N	\N	EFO	"Is a quantification of any or all of the B vitamins" []	EFO	70302	EFO:0004843	\N	vitamin B measurement	EFO:0004843
0	"Is a quantification of the size of a human hip bone." []	\N	hip bone size	\N	\N	EFO	"Is a quantification of the size of a human hip bone." []	EFO	70303	EFO:0004844	\N	hip bone size	EFO:0004844
0	"Is a quantification of magnesium in serum." []	\N	magnesium measurement	\N	\N	EFO	"Is a quantification of magnesium in serum." []	EFO	70304	EFO:0004845	\N	magnesium measurement	EFO:0004845
0	"Is the quantification of circulating serotonin (5HT), a monoamine neurotransmitter" []	\N	serotonin measurement	\N	\N	EFO	"Is the quantification of circulating serotonin (5HT), a monoamine neurotransmitter" []	EFO	70305	EFO:0004846	\N	serotonin measurement	EFO:0004846
0	"The age at which some process, or disease started in a human individual." []	\N	age at onset	\N	\N	EFO	"The age at which some process, or disease started in a human individual." []	EFO	70306	EFO:0004847	\N	age at onset	EFO:0004847
0	"Is the quantification of any vitamin A compound." []	\N	vitamin A measurement	\N	\N	EFO	"Is the quantification of any vitamin A compound." []	EFO	70307	EFO:0004857	\N	vitamin A measurement	EFO:0004857
0	"Calcification of the abdominal aortic artery, used as an indicator of sub clinical athrosclerosis" []	\N	abdominal aortic artery calcification	\N	\N	EFO	"Calcification of the abdominal aortic artery, used as an indicator of sub clinical athrosclerosis" []	EFO	70308	EFO:0004859	\N	abdominal aortic artery calcification	EFO:0004859
0	"Is a quantification of the common carotid intimal medial thickness." []	\N	common carotid intimal medial thickness	\N	\N	EFO	"Is a quantification of the common carotid intimal medial thickness." []	EFO	70309	EFO:0004860	\N	common carotid intimal medial thickness	EFO:0004860
0	"Is the quantification of serum phosphorus" []	\N	phosphorus measurement	\N	\N	EFO	"Is the quantification of serum phosphorus" []	EFO	70310	EFO:0004861	\N	phosphorus measurement	EFO:0004861
0	"Is the quantification of phytosterol, plant derived cholesterol like compounds." []	\N	phytosterol measurement	\N	\N	EFO	"Is the quantification of phytosterol, plant derived cholesterol like compounds." []	EFO	70311	EFO:0004862	\N	phytosterol measurement	EFO:0004862
0	"Is the genome wide recombination rate." []	\N	recombination rate	\N	\N	EFO	"Is the genome wide recombination rate." []	EFO	70312	EFO:0004863	\N	recombination rate	EFO:0004863
0	"Is the quantification of adipose tissue located in the renal sinus(es), correlated with chronic kidney disease and obesity." []	\N	renal sinus adipose tissue measurement	\N	\N	EFO	"Is the quantification of adipose tissue located in the renal sinus(es), correlated with chronic kidney disease and obesity." []	EFO	70313	EFO:0004864	\N	renal sinus adipose tissue measurement	EFO:0004864
0	"Is a quantification of the volume of the thyroid." []	\N	thyroid volume	\N	\N	EFO	"Is a quantification of the volume of the thyroid." []	EFO	70314	EFO:0004865	\N	thyroid volume	EFO:0004865
0	"Is a quantification of an autoantibody, an antibody produced by the immune system and directed against an individual's own protein.  e.g. anti-islet autoantibodies." []	\N	autoantibody measurement	\N	\N	EFO	"Is a quantification of an autoantibody, an antibody produced by the immune system and directed against an individual's own protein.  e.g. anti-islet autoantibodies." []	EFO	70315	EFO:0004866	\N	autoantibody measurement	EFO:0004866
0	"Is a quantification of vitamin E." []	\N	vitamin E measurement	\N	\N	EFO	"Is a quantification of vitamin E." []	EFO	70316	EFO:0004867	\N	vitamin E measurement	EFO:0004867
0	"Is a quantification of brain volume using magnetic resonance imaging." []	\N	volumetric brain MRI	\N	\N	EFO	"Is a quantification of brain volume using magnetic resonance imaging." []	EFO	70317	EFO:0004868	\N	volumetric brain MRI	EFO:0004868
0	"Is a quantification of the secreted glycoprotein YKL-40  (Chitinase-3-like protein 1) YKL-40 has been associated with asthma, inflammatory disease and cancer progression." []	\N	YKL40 measurement	\N	\N	EFO	"Is a quantification of the secreted glycoprotein YKL-40  (Chitinase-3-like protein 1) YKL-40 has been associated with asthma, inflammatory disease and cancer progression." []	EFO	70318	EFO:0004869	\N	YKL40 measurement	EFO:0004869
0	"Is a quantification of some sleep parameter." []	\N	sleep measurement	\N	\N	EFO	"Is a quantification of some sleep parameter." []	EFO	70319	EFO:0004870	\N	sleep measurement	EFO:0004870
0	"Is a quantification of any molecule involved in the process of inflammatory response." []	\N	inflammatory marker measurement	\N	\N	EFO	"Is a quantification of any molecule involved in the process of inflammatory response." []	EFO	70320	EFO:0004872	\N	inflammatory marker measurement	EFO:0004872
0	"Is a quantification of some cytokine, secreted cell signalling molecules." []	\N	cytokine measurement	\N	\N	EFO	"Is a quantification of some cytokine, secreted cell signalling molecules." []	EFO	70321	EFO:0004873	\N	cytokine measurement	EFO:0004873
0	"Is a quantification of a subject's activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. Memory performance is typically assessed by some clinical memory test and is used in the diagnosis of diseases such as Alzheimer's disease." []	\N	memory performance	\N	\N	EFO	"Is a quantification of a subject's activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. Memory performance is typically assessed by some clinical memory test and is used in the diagnosis of diseases such as Alzheimer's disease." []	EFO	70322	EFO:0004874	\N	memory performance	EFO:0004874
0	"Is the mental process necessary to acquire knowledge or skill in the measurement, properties, and relationships of quantities and sets, using numbers and symbols (mathematics)" []	\N	mathematical ability	\N	\N	EFO	"Is the mental process necessary to acquire knowledge or skill in the measurement, properties, and relationships of quantities and sets, using numbers and symbols (mathematics)" []	EFO	70323	EFO:0004875	\N	mathematical ability	EFO:0004875
0	"Is the quantification of arsenic ini urine." []	\N	urinary arsenic measurement	\N	\N	EFO	"Is the quantification of arsenic ini urine." []	EFO	70324	EFO:0004880	\N	urinary arsenic measurement	EFO:0004880
0	"Is an allergy to asaparaginase. Asparaginase is an enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity" []	\N	asparaginase hypersensitivity	\N	\N	EFO	"Is an allergy to asaparaginase. Asparaginase is an enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity" []	EFO	70325	EFO:0004881	\N	asparaginase hypersensitivity	EFO:0004881
0	"Is a quantification of some aspect of breast size" []	\N	breast size	\N	\N	EFO	"Is a quantification of some aspect of breast size" []	EFO	70326	EFO:0004884	\N	breast size	EFO:0004884
0	"Early repolarization pattern (ERP) is a common ECG variant, characterized by J point elevation manifested either as terminal QRS slurring (the transition from the QRS segment to the ST segment) or notching (a positive deflection inscribed on terminal QRS complex) associated with concave upward ST-segment elevation and prominent T waves in at least two contiguous leads." []	\N	early cardiac repolarization measurement	\N	\N	EFO	"Early repolarization pattern (ERP) is a common ECG variant, characterized by J point elevation manifested either as terminal QRS slurring (the transition from the QRS segment to the ST segment) or notching (a positive deflection inscribed on terminal QRS complex) associated with concave upward ST-segment elevation and prominent T waves in at least two contiguous leads." []	EFO	70327	EFO:0004885	\N	early cardiac repolarization measurement	EFO:0004885
0	"Is a quantification of intracranial volume." []	\N	intra cranial volume	\N	\N	EFO	"Is a quantification of intracranial volume." []	EFO	70328	EFO:0004886	\N	intra cranial volume	EFO:0004886
0	"Is the quantification of is the maximum capacity of an individual's body to transport and use oxygen during incremental exercise, and is used as an indicator of physical fitness" []	\N	maximal oxygen uptake measurement	\N	\N	EFO	"Is the quantification of is the maximum capacity of an individual's body to transport and use oxygen during incremental exercise, and is used as an indicator of physical fitness" []	EFO	70329	EFO:0004887	\N	maximal oxygen uptake measurement	EFO:0004887
0	"Emesis and queasiness occurring after anesthesia." []	\N	post operative nausea and vomiting	\N	\N	EFO	"Emesis and queasiness occurring after anesthesia." []	EFO	70330	EFO:0004888	\N	post operative nausea and vomiting	EFO:0004888
0	"Postoperative ventricular dysfunction (VnD) occurs in 9-20% of coronary artery bypass graft (CABG) surgical patients and is associated with increased postoperative morbidity and mortality." []	\N	postoperative ventricular dysfunction	\N	\N	EFO	"Postoperative ventricular dysfunction (VnD) occurs in 9-20% of coronary artery bypass graft (CABG) surgical patients and is associated with increased postoperative morbidity and mortality." []	EFO	70331	EFO:0004889	\N	postoperative ventricular dysfunction	EFO:0004889
0	"" []	\N	anti-social behavior	\N	\N	EFO	"" []	EFO	70332	EFO:0004890	\N	anti-social behavior	EFO:0004890
0	"Consistent lack of empathy" []	\N	callous character	\N	\N	EFO	"Consistent lack of empathy" []	EFO	70333	EFO:0004891	\N	callous character	EFO:0004891
0	"Sasang constitutional medicine (SCM) is a unique form of traditional Korean medicine that divides human beings into four constitutional types (Tae-Yang: TY, Tae-Eum: TE, So-Yang: SY, and So-Eum: SE), which differ in inherited characteristics, such as external appearance, personality traits, susceptibility to particular diseases, drug responses, and equilibrium among internal organ functions." []	\N	Sasang constitutional medicine	\N	\N	EFO	"Sasang constitutional medicine (SCM) is a unique form of traditional Korean medicine that divides human beings into four constitutional types (Tae-Yang: TY, Tae-Eum: TE, So-Yang: SY, and So-Eum: SE), which differ in inherited characteristics, such as external appearance, personality traits, susceptibility to particular diseases, drug responses, and equilibrium among internal organ functions." []	EFO	70334	EFO:0004892	\N	Sasang constitutional medicine	EFO:0004892
0	"A syndrome comprising  testicular germ cell cancer, cryptorchidism and some cases of hypospadias and male infertility with impaired development of the testis." []	\N	testicular dysgenesis syndrome	\N	\N	EFO	"A syndrome comprising  testicular germ cell cancer, cryptorchidism and some cases of hypospadias and male infertility with impaired development of the testis." []	EFO	70335	EFO:0004893	\N	testicular dysgenesis syndrome	EFO:0004893
0	"A combination of congenital heart defects consisting of four key features including VENTRICULAR SEPTAL DEFECTS; PULMONARY STENOSIS; RIGHT VENTRICULAR HYPERTROPHY; and a dextro-positioned AORTA. In this condition, blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into the body often causing CYANOSIS.)" []	\N	tetralogy of fallot	\N	\N	EFO	"A combination of congenital heart defects consisting of four key features including VENTRICULAR SEPTAL DEFECTS; PULMONARY STENOSIS; RIGHT VENTRICULAR HYPERTROPHY; and a dextro-positioned AORTA. In this condition, blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into the body often causing CYANOSIS.)" []	EFO	70336	EFO:0004894	\N	tetralogy of fallot	EFO:0004894
0	"A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or a general medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)" []	\N	Tourette syndrome	\N	\N	EFO	"A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or a general medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)" []	EFO	70337	EFO:0004895	\N	Tourette syndrome	EFO:0004895
0	"The Yoruba people are one of the largest ethnic groups in West Africa." []	\N	Yoruba	\N	\N	EFO	"The Yoruba people are one of the largest ethnic groups in West Africa." []	EFO	70338	EFO:0004900	\N	Yoruba	EFO:0004900
0	"Population of northern and western European ancestry." []	\N	Northern and Western European	\N	\N	EFO	"Population of northern and western European ancestry." []	EFO	70339	EFO:0004901	\N	Northern and Western European	EFO:0004901
0	"" []	\N	European HapMap cell line	\N	\N	EFO	"" []	EFO	70340	EFO:0004902	\N	European HapMap cell line	EFO:0004902
0	"The probe which is used in an assay such as an array for detecting sequence or gene expression levels." []	\N	probe design element	\N	\N	EFO	"The probe which is used in an assay such as an array for detecting sequence or gene expression levels." []	EFO	70341	EFO:0004903	\N	probe design element	EFO:0004903
0	"Induced pluripotent stem cells (iPS cells or iPSCs) are a type of pluripotent stem cell artificially derived from a non-pluripotent cell. Various methods exist to revert cells to pluripotency such as reprogramming mediated through a mature metaphase II oocyte as in somatic cell nuclear transfer." []	\N	induced pluripotent stem cell	\N	\N	EFO	"Induced pluripotent stem cells (iPS cells or iPSCs) are a type of pluripotent stem cell artificially derived from a non-pluripotent cell. Various methods exist to revert cells to pluripotency such as reprogramming mediated through a mature metaphase II oocyte as in somatic cell nuclear transfer." []	EFO	70342	EFO:0004905	\N	induced pluripotent stem cell	EFO:0004905
0	"A type of carcinoma which has spread to lymph nodes from some other primary cancer site." []	\N	metastasis to lymph node	\N	\N	EFO	"A type of carcinoma which has spread to lymph nodes from some other primary cancer site." []	EFO	70343	EFO:0004906	\N	metastasis to lymph node	EFO:0004906
0	"is a quantification of testosterone, typically in serum. Testosterone is a steroid hormone." []	\N	testosterone measurement	\N	\N	EFO	"is a quantification of testosterone, typically in serum. Testosterone is a steroid hormone." []	EFO	70344	EFO:0004908	\N	testosterone measurement	EFO:0004908
0	"is a quantification of dihydrotestosterone (DHT), typically in serum. Dihydrotestosterone is a steroid hormone, a small percentage of testosterone is reduced to DHT which has a greater affinity for  androgen receptors." []	\N	dihydrotestosterone measurement	\N	\N	EFO	"is a quantification of dihydrotestosterone (DHT), typically in serum. Dihydrotestosterone is a steroid hormone, a small percentage of testosterone is reduced to DHT which has a greater affinity for  androgen receptors." []	EFO	70345	EFO:0004909	\N	dihydrotestosterone measurement	EFO:0004909
0	"is a quantification of cytochrome P450 3A4 activity. CP4503A4 is a heme-thiolate monooxygenases induced in response to drugs, pesticides and carcinogens (Uniprot definition)." []	\N	CYP3A4 activity	\N	\N	EFO	"is a quantification of cytochrome P450 3A4 activity. CP4503A4 is a heme-thiolate monooxygenases induced in response to drugs, pesticides and carcinogens (Uniprot definition)." []	EFO	70346	EFO:0004910	\N	CYP3A4 activity	EFO:0004910
0	"Familial hypercholesterolemia is is an autosomal dominant disorder characterized by elevation of serum cholesterol bound to low density lipoprotein (OMIM)" []	\N	familial hypercholesterolemia	\N	\N	EFO	"Familial hypercholesterolemia is is an autosomal dominant disorder characterized by elevation of serum cholesterol bound to low density lipoprotein (OMIM)" []	EFO	70347	EFO:0004911	\N	familial hypercholesterolemia	EFO:0004911
0	"Is a quantification of immunoglobulin A, an antibody with a role in mucosal immunity." []	\N	serum IgA measurement	\N	\N	EFO	"Is a quantification of immunoglobulin A, an antibody with a role in mucosal immunity." []	EFO	70348	EFO:0004912	\N	serum IgA measurement	EFO:0004912
0	"Is a quantification of the lentiform nucleus (or lenticular nucleus) volume, typically by MRI." []	\N	lentiform nucleus measurement	\N	\N	EFO	"Is a quantification of the lentiform nucleus (or lenticular nucleus) volume, typically by MRI." []	EFO	70349	EFO:0004913	\N	lentiform nucleus measurement	EFO:0004913
0	"Is a quantification of the ability of humans to process different facial expressions, measured by MRI." []	\N	facial neural processing	\N	\N	EFO	"Is a quantification of the ability of humans to process different facial expressions, measured by MRI." []	EFO	70350	EFO:0004914	\N	facial neural processing	EFO:0004914
0	"Is a quantification of vaspin, commonly termed Serpin A12 (visceral adipose tissue-derived serine protease inhibitor) , typically in serum an adipokine which may modulate insulin activity in white adipose tissue (Uniprot)." []	\N	vaspin measurement	\N	\N	EFO	"Is a quantification of vaspin, commonly termed Serpin A12 (visceral adipose tissue-derived serine protease inhibitor) , typically in serum an adipokine which may modulate insulin activity in white adipose tissue (Uniprot)." []	EFO	70351	EFO:0004915	\N	vaspin measurement	EFO:0004915
0	"Is a protocol which provides instructions on the alignment of sequencing reads to reference genome" []	\N	high throughput sequence alignment protocol	\N	\N	EFO	"Is a protocol which provides instructions on the alignment of sequencing reads to reference genome" []	EFO	70352	EFO:0004917	\N	high throughput sequence alignment protocol	EFO:0004917
0	"The age, measured from some defined time point e.g. birth at which a subject (e.g. a human patient) is diagnosed with some disease e.g. breast cancer." []	\N	age at diagnosis	\N	\N	EFO	"The age, measured from some defined time point e.g. birth at which a subject (e.g. a human patient) is diagnosed with some disease e.g. breast cancer." []	EFO	70353	EFO:0004918	\N	age at diagnosis	EFO:0004918
0	"The percentage of subjects in a study who have survived without cancer spread for a defined period of time. Usually reported as time since diagnosis or treatment. Can be reported for an individual or a study population." []	\N	metastasis free survival	\N	\N	EFO	"The percentage of subjects in a study who have survived without cancer spread for a defined period of time. Usually reported as time since diagnosis or treatment. Can be reported for an individual or a study population." []	EFO	70354	EFO:0004919	\N	metastasis free survival	EFO:0004919
0	"Progression free survival is a measurement from a defined time point e.g. diagnosis and indicates that the disease did not progress i.e. tumours did not increase in size and new incidences did not occur. PFS is usually used in analyzing results of treatment for advanced disease." []	\N	progression free survival	\N	\N	EFO	"Progression free survival is a measurement from a defined time point e.g. diagnosis and indicates that the disease did not progress i.e. tumours did not increase in size and new incidences did not occur. PFS is usually used in analyzing results of treatment for advanced disease." []	EFO	70355	EFO:0004920	\N	progression free survival	EFO:0004920
0	"Apparently health human non-fetal tissue." []	\N	GM00038	\N	\N	EFO	"Apparently health human non-fetal tissue." []	EFO	70356	EFO:0004921	\N	GM00038	EFO:0004921
0	"ATAXIA-TELANGIECTASIA; AT" []	\N	GM00719	\N	\N	EFO	"ATAXIA-TELANGIECTASIA; AT" []	EFO	70357	EFO:0004922	\N	GM00719	EFO:0004922
0	"Any vein not in the chest or abdomen." []	\N	peripheral vein	\N	\N	EFO	"Any vein not in the chest or abdomen." []	EFO	70358	EFO:0004923	\N	peripheral vein	EFO:0004923
0	"Tumor stage as classified by the TNM system. T describes the size of the tumor and whether it has invaded nearby tissue, N describes regional lymph nodes that are involved, M describes distant metastasis (spread of cancer from one body part to another)." []	\N	tumor stage	\N	\N	EFO	"Tumor stage as classified by the TNM system. T describes the size of the tumor and whether it has invaded nearby tissue, N describes regional lymph nodes that are involved, M describes distant metastasis (spread of cancer from one body part to another)." []	EFO	70359	EFO:0004925	\N	tumor stage	EFO:0004925
0	"" []	\N	M stage	\N	\N	EFO	"" []	EFO	70360	EFO:0004926	\N	M stage	EFO:0004926
0	"regional lymph node stage" []	\N	N stage	\N	\N	EFO	"regional lymph node stage" []	EFO	70361	EFO:0004927	\N	N stage	EFO:0004927
0	"primary tumor staging" []	\N	T stage	\N	\N	EFO	"primary tumor staging" []	EFO	70362	EFO:0004928	\N	T stage	EFO:0004928
0	"" []	\N	M0 distant metastasis stage	\N	\N	EFO	"" []	EFO	70363	EFO:0004929	\N	M0 distant metastasis stage	EFO:0004929
0	"" []	\N	M1 distant metastasis stage	\N	\N	EFO	"" []	EFO	70364	EFO:0004930	\N	M1 distant metastasis stage	EFO:0004930
0	"" []	\N	MX distant metastasis stage	\N	\N	EFO	"" []	EFO	70365	EFO:0004931	\N	MX distant metastasis stage	EFO:0004931
0	"" []	\N	N0 lymph node stage	\N	\N	EFO	"" []	EFO	70366	EFO:0004932	\N	N0 lymph node stage	EFO:0004932
0	"" []	\N	N1 lymph node stage	\N	\N	EFO	"" []	EFO	70367	EFO:0004933	\N	N1 lymph node stage	EFO:0004933
0	"" []	\N	N2 lymph node stage	\N	\N	EFO	"" []	EFO	70368	EFO:0004934	\N	N2 lymph node stage	EFO:0004934
0	"" []	\N	N3 lymph node stage	\N	\N	EFO	"" []	EFO	70369	EFO:0004935	\N	N3 lymph node stage	EFO:0004935
0	"" []	\N	NX lymph node stage	\N	\N	EFO	"" []	EFO	70370	EFO:0004936	\N	NX lymph node stage	EFO:0004936
0	"" []	\N	T0 stage	\N	\N	EFO	"" []	EFO	70371	EFO:0004937	\N	T0 stage	EFO:0004937
0	"" []	\N	T1 tumor stage	\N	\N	EFO	"" []	EFO	70372	EFO:0004938	\N	T1 tumor stage	EFO:0004938
0	"" []	\N	T2 tumor stage	\N	\N	EFO	"" []	EFO	70373	EFO:0004939	\N	T2 tumor stage	EFO:0004939
0	"" []	\N	T3 tumor stage	\N	\N	EFO	"" []	EFO	70374	EFO:0004940	\N	T3 tumor stage	EFO:0004940
0	"" []	\N	T3a tumor stage	\N	\N	EFO	"" []	EFO	70375	EFO:0004941	\N	T3a tumor stage	EFO:0004941
0	"" []	\N	T3b tumor stage	\N	\N	EFO	"" []	EFO	70376	EFO:0004942	\N	T3b tumor stage	EFO:0004942
0	"" []	\N	T3c tumor stage	\N	\N	EFO	"" []	EFO	70377	EFO:0004943	\N	T3c tumor stage	EFO:0004943
0	"" []	\N	T4 tumor stage	\N	\N	EFO	"" []	EFO	70378	EFO:0004944	\N	T4 tumor stage	EFO:0004944
0	"" []	\N	T4a tumor stage	\N	\N	EFO	"" []	EFO	70379	EFO:0004945	\N	T4a tumor stage	EFO:0004945
0	"" []	\N	T4b tumor stage	\N	\N	EFO	"" []	EFO	70380	EFO:0004946	\N	T4b tumor stage	EFO:0004946
0	"Carcinoma in situ (CIS; abnormal cells are present but have not spread to neighboring tissue; although not cancer, CIS may become cancer and is sometimes called preinvasive cancer)" []	\N	Tis	\N	\N	EFO	"Carcinoma in situ (CIS; abnormal cells are present but have not spread to neighboring tissue; although not cancer, CIS may become cancer and is sometimes called preinvasive cancer)" []	EFO	70381	EFO:0004947	\N	Tis	EFO:0004947
0	"A stage in which the tumor cannot be evaluated" []	\N	TX	\N	\N	EFO	"A stage in which the tumor cannot be evaluated" []	EFO	70382	EFO:0004948	\N	TX	EFO:0004948
0	"A temporal measurement related to disease progression" []	\N	clinical temporal measurement	\N	\N	EFO	"A temporal measurement related to disease progression" []	EFO	70383	EFO:0004949	\N	clinical temporal measurement	EFO:0004949
0	"The point in time at which an individual was born." []	\N	date of birth	\N	\N	EFO	"The point in time at which an individual was born." []	EFO	70384	EFO:0004950	\N	date of birth	EFO:0004950
0	"A clinical temporal measurement indicating that the subject is alive at the end of the clinical investigation." []	\N	alive at endpoint	\N	\N	EFO	"A clinical temporal measurement indicating that the subject is alive at the end of the clinical investigation." []	EFO	70385	EFO:0004951	\N	alive at endpoint	EFO:0004951
0	"The recurrence of a disease after treatment" []	\N	disease recurrence	\N	\N	EFO	"The recurrence of a disease after treatment" []	EFO	70386	EFO:0004952	\N	disease recurrence	EFO:0004952
0	"The point at which a clinical diagnosis is made." []	\N	date of diagnosis	\N	\N	EFO	"The point at which a clinical diagnosis is made." []	EFO	70387	EFO:0004953	\N	date of diagnosis	EFO:0004953
0	"Staging information for melanoma." []	\N	melanoma staging	\N	\N	EFO	"Staging information for melanoma." []	EFO	70388	EFO:0004954	\N	melanoma staging	EFO:0004954
0	"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma. Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells. It is used in staging of melanoma. (NCI)" []	\N	Breslow thickness	\N	\N	EFO	"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma. Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells. It is used in staging of melanoma. (NCI)" []	EFO	70389	EFO:0004955	\N	Breslow thickness	EFO:0004955
0	"A morphologic finding indicating the cutaneous melanoma depth of invasion into the dermis and subcutaneous tissue. OR A system for describing how deep melanoma has spread into the skin. Levels I-V describe the layers of skin involved.NCI-GLOSS" []	\N	Clark level	\N	\N	EFO	"A morphologic finding indicating the cutaneous melanoma depth of invasion into the dermis and subcutaneous tissue. OR A system for describing how deep melanoma has spread into the skin. Levels I-V describe the layers of skin involved.NCI-GLOSS" []	EFO	70390	EFO:0004956	\N	Clark level	EFO:0004956
0	"A morphologic finding indicating that the cutaneous melanoma is confined to the epidermis and does not invade the dermis." []	\N	Clark level I	\N	\N	EFO	"A morphologic finding indicating that the cutaneous melanoma is confined to the epidermis and does not invade the dermis." []	EFO	70391	EFO:0004957	\N	Clark level I	EFO:0004957
0	"A morphologic finding indicating that the cutaneous melanoma has invaded part of the papillary dermis but the malignant cellular infiltrate has not reached the papillary-reticular dermis interface." []	\N	Clark level II	\N	\N	EFO	"A morphologic finding indicating that the cutaneous melanoma has invaded part of the papillary dermis but the malignant cellular infiltrate has not reached the papillary-reticular dermis interface." []	EFO	70392	EFO:0004958	\N	Clark level II	EFO:0004958
0	"A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis." []	\N	Clark level III	\N	\N	EFO	"A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis." []	EFO	70393	EFO:0004959	\N	Clark level III	EFO:0004959
0	"A morphologic finding indicating that the cutaneous melanoma has invaded the reticular dermis" []	\N	Clark level IV	\N	\N	EFO	"A morphologic finding indicating that the cutaneous melanoma has invaded the reticular dermis" []	EFO	70394	EFO:0004960	\N	Clark level IV	EFO:0004960
0	"A morphologic finding indicating that the cutaneous melanoma has invaded the subcutaneous tissue." []	\N	Clark level V	\N	\N	EFO	"A morphologic finding indicating that the cutaneous melanoma has invaded the subcutaneous tissue." []	EFO	70395	EFO:0004961	\N	Clark level V	EFO:0004961
0	"a genetic transformation that involves the insertion of a protein coding cDNA sequence at a particular locus in an organism's chromosome. Typically, this is done in mice since the technology for this process is more refined, and because mouse embryonic stem cells are easily manipulated. The difference between knock-in technology and transgenic technology is that a knock-in involves a gene inserted into a specific locus, and is a \\"targeted\\" insertion." []	\N	gene knock in	\N	\N	EFO	"a genetic transformation that involves the insertion of a protein coding cDNA sequence at a particular locus in an organism's chromosome. Typically, this is done in mice since the technology for this process is more refined, and because mouse embryonic stem cells are easily manipulated. The difference between knock-in technology and transgenic technology is that a knock-in involves a gene inserted into a specific locus, and is a \\"targeted\\" insertion." []	EFO	70396	EFO:0004963	\N	gene knock in	EFO:0004963
0	"A RNA extract that is the output of an extraction process in which total RNA from either whole cells or from specific cellular compartment(s)/organelle(s) are isolated from a specimenA RNA extract that is the output of an extraction process in which total celluar and organelle RNA molecules are isolated from a specimen." []	\N	total RNA	\N	\N	EFO	"A RNA extract that is the output of an extraction process in which total RNA from either whole cells or from specific cellular compartment(s)/organelle(s) are isolated from a specimenA RNA extract that is the output of an extraction process in which total celluar and organelle RNA molecules are isolated from a specimen." []	EFO	70397	EFO:0004964	\N	total RNA	EFO:0004964
0	"" []	\N	Alexa Fluor 647	\N	\N	EFO	"" []	EFO	70398	EFO:0004967	\N	Alexa Fluor 647	EFO:0004967
0	"" []	\N	Alexa Fluor 555	\N	\N	EFO	"" []	EFO	70399	EFO:0004968	\N	Alexa Fluor 555	EFO:0004968
0	"The total sum of the genetic information of an organism's somatic cells" []	\N	somatic genotype	\N	\N	EFO	"The total sum of the genetic information of an organism's somatic cells" []	EFO	70400	EFO:0004972	\N	somatic genotype	EFO:0004972
0	"The total sum of the genetic information of an organism's germline" []	\N	germline genotype	\N	\N	EFO	"The total sum of the genetic information of an organism's germline" []	EFO	70401	EFO:0004973	\N	germline genotype	EFO:0004973
0	"Compressive strength index (CSI) is a predictive measure for hip fracture risk that integrates multiple parameters including hip BMD, femur neck area, and weight." []	\N	comprehensive strength index	\N	\N	EFO	"Compressive strength index (CSI) is a predictive measure for hip fracture risk that integrates multiple parameters including hip BMD, femur neck area, and weight." []	EFO	70402	EFO:0004979	\N	comprehensive strength index	EFO:0004979
0	"Appendicular lean mass is a measurement of skeletal strength of lower limbs and is used as a predictive measure of hip fracture." []	\N	appendicular lean mass	\N	\N	EFO	"Appendicular lean mass is a measurement of skeletal strength of lower limbs and is used as a predictive measure of hip fracture." []	EFO	70403	EFO:0004980	\N	appendicular lean mass	EFO:0004980
0	"The peridontal microbiome is a  collection of collectivity of microorganisms isolated from human gum." []	\N	peridontal microbiome	\N	\N	EFO	"The peridontal microbiome is a  collection of collectivity of microorganisms isolated from human gum." []	EFO	70404	EFO:0004981	\N	peridontal microbiome	EFO:0004981
0	"A collection or collectivity of microorganisms." []	\N	microbiome	\N	\N	EFO	"A collection or collectivity of microorganisms." []	EFO	70405	EFO:0004982	\N	microbiome	EFO:0004982
0	"Complement C3 measurement is a quantification of the C3 glycoprotein typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes." []	\N	complement C3 measurement	\N	\N	EFO	"Complement C3 measurement is a quantification of the C3 glycoprotein typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes." []	EFO	70406	EFO:0004983	\N	complement C3 measurement	EFO:0004983
0	"Complement C4 measurement is a quantification of the C4 glycoprotein, typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes." []	\N	complement C4 measurement	\N	\N	EFO	"Complement C4 measurement is a quantification of the C4 glycoprotein, typically in serum, that is central in both the classical and the alternative pathway of complement activation . Complement activation, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes." []	EFO	70407	EFO:0004984	\N	complement C4 measurement	EFO:0004984
0	"A platelet reactivity measurement is the quantification of platelet reactivity e.g. by measuring platelet induced agglutination. High levels  of platelet reactivity are reported to be associated with cardiovascular events." []	\N	platelet reactivity measurement	\N	\N	EFO	"A platelet reactivity measurement is the quantification of platelet reactivity e.g. by measuring platelet induced agglutination. High levels  of platelet reactivity are reported to be associated with cardiovascular events." []	EFO	70408	EFO:0004985	\N	platelet reactivity measurement	EFO:0004985
0	"Embryonal carcinoma is a germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum)." []	\N	embryonal carcinoma	\N	\N	EFO	"Embryonal carcinoma is a germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum)." []	EFO	70409	EFO:0004986	\N	embryonal carcinoma	EFO:0004986
0	"A cell which bears embryonal carcinoma." []	\N	embryonal carcinoma cell	\N	\N	EFO	"A cell which bears embryonal carcinoma." []	EFO	70410	EFO:0004987	\N	embryonal carcinoma cell	EFO:0004987
0	"Embryoid bodies (EBs) are three-dimensional aggregates of pluripotent stem cells." []	\N	embryoid body	\N	\N	EFO	"Embryoid bodies (EBs) are three-dimensional aggregates of pluripotent stem cells." []	EFO	70411	EFO:0004988	\N	embryoid body	EFO:0004988
0	"J1 is an embryonic cell line." []	\N	J1	\N	\N	EFO	"J1 is an embryonic cell line." []	EFO	70412	EFO:0004990	\N	J1	EFO:0004990
0	"A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the neuromuscular junction, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)" []	\N	Myasthenia gravis	\N	\N	EFO	"A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the neuromuscular junction, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)" []	EFO	70413	EFO:0004991	\N	Myasthenia gravis	EFO:0004991
0	"An acute or chronic inflammatory process affecting the middle ear." []	\N	Otitis media	\N	\N	EFO	"An acute or chronic inflammatory process affecting the middle ear." []	EFO	70414	EFO:0004992	\N	Otitis media	EFO:0004992
0	"Is a quantification of immunoglobulin M, an antibody produced by B cells." []	\N	serum IgM measurement	\N	\N	EFO	"Is a quantification of immunoglobulin M, an antibody produced by B cells." []	EFO	70415	EFO:0004993	\N	serum IgM measurement	EFO:0004993
0	"lumbar disc degeneration is a degeneration of one or more intervertebral disc(s) of the spine." []	\N	lumbar disc degeneration	\N	\N	EFO	"lumbar disc degeneration is a degeneration of one or more intervertebral disc(s) of the spine." []	EFO	70416	EFO:0004994	\N	lumbar disc degeneration	EFO:0004994
0	"The weight of all organs and tissue in an individual less the weight of the individual's body fat." []	\N	lean body mass	\N	\N	EFO	"The weight of all organs and tissue in an individual less the weight of the individual's body fat." []	EFO	70417	EFO:0004995	\N	lean body mass	EFO:0004995
0	"Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 1 diabetes hyperglycaemia starts in the first decades of life and is usually the only recognized cause of nephropathy." []	\N	type 1 diabetes nephropathy	\N	\N	EFO	"Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 1 diabetes hyperglycaemia starts in the first decades of life and is usually the only recognized cause of nephropathy." []	EFO	70418	EFO:0004996	\N	type 1 diabetes nephropathy	EFO:0004996
0	"Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 2 diabetes hyperglycaemia starts after the forties, usually when the kidneys have already suffered the long‐term consequences of ageing and of other recognized promoters of chronic renal injury such as arterial hypertension, obesity, dyslipidaemia, and smoking." []	\N	type 2 diabetes nephropathy	\N	\N	EFO	"Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 2 diabetes hyperglycaemia starts after the forties, usually when the kidneys have already suffered the long‐term consequences of ageing and of other recognized promoters of chronic renal injury such as arterial hypertension, obesity, dyslipidaemia, and smoking." []	EFO	70419	EFO:0004997	\N	type 2 diabetes nephropathy	EFO:0004997
0	"The quantification of some carbohydrate, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	\N	carbohydrate measurement	\N	\N	EFO	"The quantification of some carbohydrate, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	EFO	70420	EFO:0004998	\N	carbohydrate measurement	EFO:0004998
0	"The quantification of N-glycans in a plasma sample." []	\N	N-glycan measurement	\N	\N	EFO	"The quantification of N-glycans in a plasma sample." []	EFO	70421	EFO:0004999	\N	N-glycan measurement	EFO:0004999
0	"" []	\N	leptin measurement	\N	\N	EFO	"" []	EFO	70422	EFO:0005000	\N	leptin measurement	EFO:0005000
0	"The quantification of some phenylalanine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	\N	phenylalanine measurement	\N	\N	EFO	"The quantification of some phenylalanine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	EFO	70423	EFO:0005001	\N	phenylalanine measurement	EFO:0005001
0	"The quantification of some lysine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	\N	lysine measurement	\N	\N	EFO	"The quantification of some lysine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	EFO	70424	EFO:0005002	\N	lysine measurement	EFO:0005002
0	"454 sequencing is a DNA sequencing using 454 technology from Roche,  which allows sequencing of a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobilized, and solutions of A, C, G, and T nucleotides are added and removed after the reaction, sequentially. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template. ssDNA template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5-prime phosphosulfate (APS) and luciferin." []	\N	454 Sequencing	\N	\N	EFO	"454 sequencing is a DNA sequencing using 454 technology from Roche,  which allows sequencing of a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobilized, and solutions of A, C, G, and T nucleotides are added and removed after the reaction, sequentially. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template. ssDNA template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5-prime phosphosulfate (APS) and luciferin." []	EFO	70425	EFO:0005016	\N	454 Sequencing	EFO:0005016
0	"A RNA extract that is the output of an extraction process in which RNA molecules without poly A tail at its 3’ end are purified." []	\N	non polyA RNA	\N	\N	EFO	"A RNA extract that is the output of an extraction process in which RNA molecules without poly A tail at its 3’ end are purified." []	EFO	70426	EFO:0005017	\N	non polyA RNA	EFO:0005017
0	"A fractionylated RNA separated on the basis of length of the RNA molecule and adenylation state, typically 'long' refers to a transcript of 200nt plus in length (Meijer et al, http://genomebiology.com/2011/12/2/R16)" []	\N	long non poly RNA	\N	\N	EFO	"A fractionylated RNA separated on the basis of length of the RNA molecule and adenylation state, typically 'long' refers to a transcript of 200nt plus in length (Meijer et al, http://genomebiology.com/2011/12/2/R16)" []	EFO	70427	EFO:0005018	\N	long non poly RNA	EFO:0005018
0	"A fraction of poly-adenylated RNA separated on the basis of length of the RNA molecule and adenylation state, typically 'long' refers to a transcript of 200nt plus in length (Meijer et al, http://genomebiology.com/2011/12/2/R16)" []	\N	long poly A RNA	\N	\N	EFO	"A fraction of poly-adenylated RNA separated on the basis of length of the RNA molecule and adenylation state, typically 'long' refers to a transcript of 200nt plus in length (Meijer et al, http://genomebiology.com/2011/12/2/R16)" []	EFO	70428	EFO:0005019	\N	long poly A RNA	EFO:0005019
0	"The latitude at which a sample was obtained. For example a sea water sample." []	\N	collection latitude	\N	\N	EFO	"The latitude at which a sample was obtained. For example a sea water sample." []	EFO	70429	EFO:0005020	\N	collection latitude	EFO:0005020
0	"The longitude at which a sample was obtained. For example a sea water sample." []	\N	collection longitude	\N	\N	EFO	"The longitude at which a sample was obtained. For example a sea water sample." []	EFO	70430	EFO:0005021	\N	collection longitude	EFO:0005021
0	"A adult mesenchymal stem cell derived from adipose tisssue" []	\N	adipose tissue derived mesenchymal stem cell	\N	\N	EFO	"A adult mesenchymal stem cell derived from adipose tisssue" []	EFO	70431	EFO:0005023	\N	adipose tissue derived mesenchymal stem cell	EFO:0005023
0	"A pericyte derived from the placenta." []	\N	placental pericyte	\N	\N	EFO	"A pericyte derived from the placenta." []	EFO	70432	EFO:0005024	\N	placental pericyte	EFO:0005024
0	"Anti-Bcl11a Antibody is used as B-cell lymphoma/leukemia 11A antibody\\nSpecies: Human, Vertebrates\\nGene: BCL11A ENSG00000119866" []	\N	anti-Bcl11a	\N	\N	EFO	"Anti-Bcl11a Antibody is used as B-cell lymphoma/leukemia 11A antibody\\nSpecies: Human, Vertebrates\\nGene: BCL11A ENSG00000119866" []	EFO	70433	EFO:0005027	\N	anti-Bcl11a	EFO:0005027
0	"Anti-trimethyl-Histone H3 (Lys27) Antibody\\nSpecies: Human, Mouse\\nGene: HIST3H3 ENSG00000168148" []	\N	anti-H3K27-3Me	\N	\N	EFO	"Anti-trimethyl-Histone H3 (Lys27) Antibody\\nSpecies: Human, Mouse\\nGene: HIST3H3 ENSG00000168148" []	EFO	70434	EFO:0005028	\N	anti-H3K27-3Me	EFO:0005028
0	"Anti-trimethyl-Histone H3 (Lys4) Antibody\\nSpecies: Human, Vertebrates\\nGene: HIST3H3 ENSG00000168148" []	\N	anti-H3k4-3Me	\N	\N	EFO	"Anti-trimethyl-Histone H3 (Lys4) Antibody\\nSpecies: Human, Vertebrates\\nGene: HIST3H3 ENSG00000168148" []	EFO	70435	EFO:0005029	\N	anti-H3k4-3Me	EFO:0005029
0	"Anti-IgG Antibody. Immunoglobulin G antibodies are available in different forms on the market. General features: activate mammalian complements, bind to protein A or protein G." []	\N	anti-IgG	\N	\N	EFO	"Anti-IgG Antibody. Immunoglobulin G antibodies are available in different forms on the market. General features: activate mammalian complements, bind to protein A or protein G." []	EFO	70436	EFO:0005030	\N	anti-IgG	EFO:0005030
0	"Label for the immunoprecipitate when control assays are used for ChIP-seq experiments.  Means that non-ChIP genomic DNA has been used to identify and adjust for sequencing biases." []	\N	input DNA	\N	\N	EFO	"Label for the immunoprecipitate when control assays are used for ChIP-seq experiments.  Means that non-ChIP genomic DNA has been used to identify and adjust for sequencing biases." []	EFO	70437	EFO:0005031	\N	input DNA	EFO:0005031
0	"IP-seq is an assay in which immunoprecipitation with high throughput sequencing is used to identify the DNA/RNA-associated proteins or protein complexes.\\nAs an immunoprecipitation it can be ChIP, RIP or another immunoprecipitation process." []	\N	IP-seq	\N	\N	EFO	"IP-seq is an assay in which immunoprecipitation with high throughput sequencing is used to identify the DNA/RNA-associated proteins or protein complexes.\\nAs an immunoprecipitation it can be ChIP, RIP or another immunoprecipitation process." []	EFO	70438	EFO:0005032	\N	IP-seq	EFO:0005032
0	"RNA Immunoprecipitation (RIP) is an experimental process used to investigate the interaction between proteins and RNA in the cell via the immunoprecipitation with an antibody that targets the protein of interest.\\nBy isolating the protein, the RNA will also be isolated as it is bound to the protein. The purified RNA-protein complexes can be separated by performing an RNA extraction and the identity of the RNA can be determined by cDNA sequencing or RT-PCR." []	\N	RIP	\N	\N	EFO	"RNA Immunoprecipitation (RIP) is an experimental process used to investigate the interaction between proteins and RNA in the cell via the immunoprecipitation with an antibody that targets the protein of interest.\\nBy isolating the protein, the RNA will also be isolated as it is bound to the protein. The purified RNA-protein complexes can be separated by performing an RNA extraction and the identity of the RNA can be determined by cDNA sequencing or RT-PCR." []	EFO	70439	EFO:0005033	\N	RIP	EFO:0005033
0	"Anti-CTCF antibody\\nSpecies: Human, Mouse, Rat, Primate, Canine (depends on vendor)\\nGene: CTCF ENSG00000102974" []	\N	anti-CTCF	\N	\N	EFO	"Anti-CTCF antibody\\nSpecies: Human, Mouse, Rat, Primate, Canine (depends on vendor)\\nGene: CTCF ENSG00000102974" []	EFO	70440	EFO:0005034	\N	anti-CTCF	EFO:0005034
0	"Measurement of the volume of the hippocampus" []	\N	hippocampal volume	\N	\N	EFO	"Measurement of the volume of the hippocampus" []	EFO	70441	EFO:0005035	\N	hippocampal volume	EFO:0005035
0	"A measurement quantifying some platelet" []	\N	platelet measurement	\N	\N	EFO	"A measurement quantifying some platelet" []	EFO	70442	EFO:0005036	\N	platelet measurement	EFO:0005036
0	"The aortic root size is the size of the part of the ascending aorta beginning at the aortic annulus and extending to the sinotubular junction" []	\N	aortic root size	\N	\N	EFO	"The aortic root size is the size of the part of the ascending aorta beginning at the aortic annulus and extending to the sinotubular junction" []	EFO	70443	EFO:0005037	\N	aortic root size	EFO:0005037
0	"Any measurable or observable characteristic related to the shape, structure, color, or pattern of the fine, keratinized filamentous growths arising from the epidermis of mammals." []	\N	hair morphology	\N	\N	EFO	"Any measurable or observable characteristic related to the shape, structure, color, or pattern of the fine, keratinized filamentous growths arising from the epidermis of mammals." []	EFO	70444	EFO:0005038	\N	hair morphology	EFO:0005038
0	"Atrophy of the hippocampus as a result of some external stress or disease" []	\N	hippocampal atrophy	\N	\N	EFO	"Atrophy of the hippocampus as a result of some external stress or disease" []	EFO	70445	EFO:0005039	\N	hippocampal atrophy	EFO:0005039
0	"Is a quatification of cardiac troponin T, typically measured in blood. Cardiac troponin T measurements are used as a marker of cardiac muscle damage and used in the diagnosis of myocardial infarction." []	\N	cardiac troponin T measurement	\N	\N	EFO	"Is a quatification of cardiac troponin T, typically measured in blood. Cardiac troponin T measurements are used as a marker of cardiac muscle damage and used in the diagnosis of myocardial infarction." []	EFO	70446	EFO:0005043	\N	cardiac troponin T measurement	EFO:0005043
0	"Leishmaniasis is a disease caused by protozoan parasites that belong to the genus Leishmania and is transmitted by the bite of certain species of sand fly (subfamily Phlebotominae)." []	\N	Leishmaniasis	\N	\N	EFO	"Leishmaniasis is a disease caused by protozoan parasites that belong to the genus Leishmania and is transmitted by the bite of certain species of sand fly (subfamily Phlebotominae)." []	EFO	70447	EFO:0005044	\N	Leishmaniasis	EFO:0005044
0	"Is a parasitic infection caused by protozoan parasites of the Leishmania genus. The parasites migrate to internal organs causing a severe form of the disease." []	\N	visceral Leishmaniasis	\N	\N	EFO	"Is a parasitic infection caused by protozoan parasites of the Leishmania genus. The parasites migrate to internal organs causing a severe form of the disease." []	EFO	70448	EFO:0005045	\N	visceral Leishmaniasis	EFO:0005045
0	"Is a parasitic infection of  the skin caused by the Leishmania protozoan parasite" []	\N	cutaneous Leishmaniasis	\N	\N	EFO	"Is a parasitic infection of  the skin caused by the Leishmania protozoan parasite" []	EFO	70449	EFO:0005046	\N	cutaneous Leishmaniasis	EFO:0005046
0	"Is a quantification of some aspect of erythrocyte function, quanity, or composition." []	\N	erythrocyte measurement	\N	\N	EFO	"Is a quantification of some aspect of erythrocyte function, quanity, or composition." []	EFO	70450	EFO:0005047	\N	erythrocyte measurement	EFO:0005047
0	"The standard protocol supplied by the manufacturer of the 454 GS 20 sequencer for nucleic acid sequencing protocol." []	\N	454 GS 20 standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the 454 GS 20 sequencer for nucleic acid sequencing protocol." []	EFO	70451	EFO:0005051	\N	454 GS 20 standard manufacturer's protocol	EFO:0005051
0	"" []	\N	nervous system measurement	\N	\N	EFO	"" []	EFO	70452	EFO:0005052	\N	nervous system measurement	EFO:0005052
0	"Is a quantification of the internal carotid intimal medial thickness." []	\N	internal carotid intimal medial thickness	\N	\N	EFO	"Is a quantification of the internal carotid intimal medial thickness." []	EFO	70453	EFO:0005053	\N	internal carotid intimal medial thickness	EFO:0005053
0	"A QRS complex is a combination of the three electrocardiographical measurements of the Q, R and S waves in the heart's electrical cycle." []	\N	QRS complex	\N	\N	EFO	"A QRS complex is a combination of the three electrocardiographical measurements of the Q, R and S waves in the heart's electrical cycle." []	EFO	70454	EFO:0005054	\N	QRS complex	EFO:0005054
0	"QRS duration is a measurement of the combined duration of the Q, R and S waves of the human heart's electric cycle" []	\N	QRS duration	\N	\N	EFO	"QRS duration is a measurement of the combined duration of the Q, R and S waves of the human heart's electric cycle" []	EFO	70455	EFO:0005055	\N	QRS duration	EFO:0005055
0	"The age at which death occurs." []	\N	age at death	\N	\N	EFO	"The age at which death occurs." []	EFO	70456	EFO:0005056	\N	age at death	EFO:0005056
0	"The determination of the amount of myoglobin present in a sample, usually blood" []	\N	myoglobin measurement	\N	\N	EFO	"The determination of the amount of myoglobin present in a sample, usually blood" []	EFO	70457	EFO:0005057	\N	myoglobin measurement	EFO:0005057
0	"The quantification of some tyrosine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	\N	tyrosine measurement	\N	\N	EFO	"The quantification of some tyrosine, typically obtained from an individual with the intention of using the measurement in some diagnostic process." []	EFO	70458	EFO:0005058	\N	tyrosine measurement	EFO:0005058
0	"The quantification of some acylcarnitine, typically obtained from the blood of an individual with the intention of using the measurement in some diagnostic process." []	\N	acylcarnitine measurement	\N	\N	EFO	"The quantification of some acylcarnitine, typically obtained from the blood of an individual with the intention of using the measurement in some diagnostic process." []	EFO	70459	EFO:0005059	\N	acylcarnitine measurement	EFO:0005059
0	"Any component which is used as part of an instrument. The part may be considered an instrument in it's own right (such as a thermometer which is part of a kiln) - instrument parts are not disjoint from instruments." []	\N	instrument part	\N	\N	EFO	"Any component which is used as part of an instrument. The part may be considered an instrument in it's own right (such as a thermometer which is part of a kiln) - instrument parts are not disjoint from instruments." []	EFO	70460	EFO:0005060	\N	instrument part	EFO:0005060
0	"A substrate is the surface on which material, such as an organism, is grown or attached." []	\N	substrate	\N	\N	EFO	"A substrate is the surface on which material, such as an organism, is grown or attached." []	EFO	70461	EFO:0005061	\N	substrate	EFO:0005061
0	"A subtrate made of glass." []	\N	glass substrate	\N	\N	EFO	"A subtrate made of glass." []	EFO	70462	EFO:0005062	\N	glass substrate	EFO:0005062
0	"A substrate made on a nylon membrane." []	\N	nylon substrate	\N	\N	EFO	"A substrate made on a nylon membrane." []	EFO	70463	EFO:0005063	\N	nylon substrate	EFO:0005063
0	"A substrate made of nitrocellulose." []	\N	nitrocellulose substrate	\N	\N	EFO	"A substrate made of nitrocellulose." []	EFO	70464	EFO:0005064	\N	nitrocellulose substrate	EFO:0005064
0	"Substrate made of silicon." []	\N	silicon substrate	\N	\N	EFO	"Substrate made of silicon." []	EFO	70465	EFO:0005065	\N	silicon substrate	EFO:0005065
0	"A grouping of some materials, including whole organisms or samples. Does not necessitate that the grouping is related in some way, so can include any arbitrary collection of materials." []	\N	collection of material	\N	\N	EFO	"A grouping of some materials, including whole organisms or samples. Does not necessitate that the grouping is related in some way, so can include any arbitrary collection of materials." []	EFO	70466	EFO:0005066	\N	collection of material	EFO:0005066
0	"A block or batch is an experimental unit arrangement into a group which is similar to one another. Typically, a blocking factor is a source of variability that is not of primary interest to the experimenter. An example of a blocking factor might be the sex of a patient; by blocking on sex, this source of variability is controlled for, thus leading to greater accuracy." []	\N	block	\N	\N	EFO	"A block or batch is an experimental unit arrangement into a group which is similar to one another. Typically, a blocking factor is a source of variability that is not of primary interest to the experimenter. An example of a blocking factor might be the sex of a patient; by blocking on sex, this source of variability is controlled for, thus leading to greater accuracy." []	EFO	70467	EFO:0005067	\N	block	EFO:0005067
0	"The surface used to coat the array substrate." []	\N	array surface coating	\N	\N	EFO	"The surface used to coat the array substrate." []	EFO	70468	EFO:0005069	\N	array surface coating	EFO:0005069
0	"An array substrate coating formed using aminosilane." []	\N	aminosilane substrate coating	\N	\N	EFO	"An array substrate coating formed using aminosilane." []	EFO	70469	EFO:0005070	\N	aminosilane substrate coating	EFO:0005070
0	"An array substrate coating formed using polylysine." []	\N	polylysine substrate coating	\N	\N	EFO	"An array substrate coating formed using polylysine." []	EFO	70470	EFO:0005071	\N	polylysine substrate coating	EFO:0005071
0	"A reporter (sometimes 'probe' or 'oligo') is material such as single stranded DNA or an antibody, usually at a particular location on an array, onto which target material of interest is hybridized and quantified." []	\N	array reporter	\N	\N	EFO	"A reporter (sometimes 'probe' or 'oligo') is material such as single stranded DNA or an antibody, usually at a particular location on an array, onto which target material of interest is hybridized and quantified." []	EFO	70471	EFO:0005072	\N	array reporter	EFO:0005072
0	"A type of reporter which is created using in situ methods." []	\N	in situ oligo	\N	\N	EFO	"A type of reporter which is created using in situ methods." []	EFO	70472	EFO:0005073	\N	in situ oligo	EFO:0005073
0	"Type of array reporter which is formed from antibodies being spotted directly on to the array surface." []	\N	spotted antibody reporter	\N	\N	EFO	"Type of array reporter which is formed from antibodies being spotted directly on to the array surface." []	EFO	70473	EFO:0005074	\N	spotted antibody reporter	EFO:0005074
0	"Type of array reporter formed from colonies (such as bacteria) are spotted directly on to the array surface." []	\N	spotted colony reporter	\N	\N	EFO	"Type of array reporter formed from colonies (such as bacteria) are spotted directly on to the array surface." []	EFO	70474	EFO:0005075	\N	spotted colony reporter	EFO:0005075
0	"An array reporter formed from directly spotting double stranded DNA on to the array surface." []	\N	spotted double stranded DNA reporter	\N	\N	EFO	"An array reporter formed from directly spotting double stranded DNA on to the array surface." []	EFO	70475	EFO:0005076	\N	spotted double stranded DNA reporter	EFO:0005076
0	"Type of array reporter which is formed from proteins being spotted directly on to the array surface." []	\N	spotted protein reporter	\N	\N	EFO	"Type of array reporter which is formed from proteins being spotted directly on to the array surface." []	EFO	70476	EFO:0005077	\N	spotted protein reporter	EFO:0005077
0	"An array reporter created by directly spotting a single stranded DNA PCR product on to the array surface." []	\N	spotted single stranded DNA PCR amplicon reporter	\N	\N	EFO	"An array reporter created by directly spotting a single stranded DNA PCR product on to the array surface." []	EFO	70477	EFO:0005078	\N	spotted single stranded DNA PCR amplicon reporter	EFO:0005078
0	"An array reporter created by directly spotting single stranded oligonucleotides on to the array surface." []	\N	spotted single stranded oligo reporter	\N	\N	EFO	"An array reporter created by directly spotting single stranded oligonucleotides on to the array surface." []	EFO	70478	EFO:0005079	\N	spotted single stranded oligo reporter	EFO:0005079
0	"quantification of the pneumoprotein CC16" []	\N	CC16 measurement	\N	\N	EFO	"quantification of the pneumoprotein CC16" []	EFO	70479	EFO:0005080	\N	CC16 measurement	EFO:0005080
0	"quantification of the pneumoprotein surfactant protein D" []	\N	surfactant protein D measurement	\N	\N	EFO	"quantification of the pneumoprotein surfactant protein D" []	EFO	70480	EFO:0005081	\N	surfactant protein D measurement	EFO:0005081
0	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer sequencer for nucleic acid sequencing protocol." []	\N	Illumina Genome Analyzer standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer sequencer for nucleic acid sequencing protocol." []	EFO	70481	EFO:0005082	\N	Illumina Genome Analyzer standard manufacturer's protocol	EFO:0005082
0	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer II sequencer for nucleic acid sequencing protocol." []	\N	Illumina Genome Analyzer II standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer II sequencer for nucleic acid sequencing protocol." []	EFO	70482	EFO:0005083	\N	Illumina Genome Analyzer II standard manufacturer's protocol	EFO:0005083
0	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer IIx sequencer for nucleic acid sequencing protocol." []	\N	Illumina Genome Analyzer IIx standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina Genome Analyzer IIx sequencer for nucleic acid sequencing protocol." []	EFO	70483	EFO:0005084	\N	Illumina Genome Analyzer IIx standard manufacturer's protocol	EFO:0005084
0	"The standard protocol supplied by the manufacturer of the Illumina HiSeq 1000 sequencer for nucleic acid sequencing protocol." []	\N	Illumina HiSeq 1000 standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina HiSeq 1000 sequencer for nucleic acid sequencing protocol." []	EFO	70484	EFO:0005085	\N	Illumina HiSeq 1000 standard manufacturer's protocol	EFO:0005085
0	"The standard protocol supplied by the manufacturer of the Illumina HiSeq 2000 sequencer for nucleic acid sequencing protocol." []	\N	Illumina HiSeq 2000 standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina HiSeq 2000 sequencer for nucleic acid sequencing protocol." []	EFO	70485	EFO:0005086	\N	Illumina HiSeq 2000 standard manufacturer's protocol	EFO:0005086
0	"The standard protocol supplied by the manufacturer of the Illumina MiSeq sequencer for nucleic acid sequencing protocol." []	\N	Illumina MiSeq standard manufacturer's protocol	\N	\N	EFO	"The standard protocol supplied by the manufacturer of the Illumina MiSeq sequencer for nucleic acid sequencing protocol." []	EFO	70486	EFO:0005087	\N	Illumina MiSeq standard manufacturer's protocol	EFO:0005087
0	"" []	\N	testicular carcinoma	\N	\N	EFO	"" []	EFO	70487	EFO:0005088	\N	testicular carcinoma	EFO:0005088
0	"quantification of the total volume of the brain" []	\N	whole-brain volume	\N	\N	EFO	"quantification of the total volume of the brain" []	EFO	70488	EFO:0005089	\N	whole-brain volume	EFO:0005089
0	"quantification of basophils in the blood" []	\N	basophil count	\N	\N	EFO	"quantification of basophils in the blood" []	EFO	70489	EFO:0005090	\N	basophil count	EFO:0005090
0	"quantification of monocytes in the blood" []	\N	monocyte count	\N	\N	EFO	"quantification of monocytes in the blood" []	EFO	70490	EFO:0005091	\N	monocyte count	EFO:0005091
0	"quantification of the volume of the entorhinal cortex" []	\N	entorhinal cortical volume	\N	\N	EFO	"quantification of the volume of the entorhinal cortex" []	EFO	70491	EFO:0005092	\N	entorhinal cortical volume	EFO:0005092
0	"circumferential measurement of the largest part of the hip" []	\N	hip circumference	\N	\N	EFO	"circumferential measurement of the largest part of the hip" []	EFO	70492	EFO:0005093	\N	hip circumference	EFO:0005093
0	"measurement of the time from start to finish of the P wave, in the electrocardiograph illustrating the initial deflection of the cardiac cycle, representing the excitation of the atria." []	\N	P wave duration	\N	\N	EFO	"measurement of the time from start to finish of the P wave, in the electrocardiograph illustrating the initial deflection of the cardiac cycle, representing the excitation of the atria." []	EFO	70493	EFO:0005094	\N	P wave duration	EFO:0005094
0	"measurement of the interval from the offset of the P wave to the onset of the QRS wave complex" []	\N	PR segment	\N	\N	EFO	"measurement of the interval from the offset of the P wave to the onset of the QRS wave complex" []	EFO	70494	EFO:0005095	\N	PR segment	EFO:0005095
0	"The abdominal wall represents the boundaries of the abdominal cavity. The abdominal wall is split into the posterior (back), lateral (sides) and anterior (front) walls. There is a common set of layers covering and forming all the walls: the deepest being the extraperitoneal fat, the parietal peritoneum, and a layer of fascia which has different names over where it covers (eg transversalis, psoas fascia). Superficial to these, but not present in the posterior wall are the three layers of muscle, the transversus abdominis (transverse abdominal muscle), the internal (obliquus internus) and the external oblique (obliquus externus)." []	\N	abdomenal wall	\N	\N	EFO	"The abdominal wall represents the boundaries of the abdominal cavity. The abdominal wall is split into the posterior (back), lateral (sides) and anterior (front) walls. There is a common set of layers covering and forming all the walls: the deepest being the extraperitoneal fat, the parietal peritoneum, and a layer of fascia which has different names over where it covers (eg transversalis, psoas fascia). Superficial to these, but not present in the posterior wall are the three layers of muscle, the transversus abdominis (transverse abdominal muscle), the internal (obliquus internus) and the external oblique (obliquus externus)." []	EFO	70495	EFO:0005096	\N	abdomenal wall	EFO:0005096
0	"the first airway branch that no longer contains cartilage; it is a branch of the bronchus[GO]." []	\N	bronchiole	\N	\N	EFO	"the first airway branch that no longer contains cartilage; it is a branch of the bronchus[GO]." []	EFO	70496	EFO:0005097	\N	bronchiole	EFO:0005097
0	"The cortical collecting duct is the portion of the collecting duct that resides in the renal cortex" []	\N	cortical collecting duct	\N	\N	EFO	"The cortical collecting duct is the portion of the collecting duct that resides in the renal cortex" []	EFO	70497	EFO:0005098	\N	cortical collecting duct	EFO:0005098
0	"A cardinal organ part that is the central column of a plant axis that consists of the primary vascular tissue and associated ground tissue." []	\N	stele	\N	\N	EFO	"A cardinal organ part that is the central column of a plant axis that consists of the primary vascular tissue and associated ground tissue." []	EFO	70498	EFO:0005099	\N	stele	EFO:0005099
0	"The last mature leaf before the inflorescence in a cereal crop plant." []	\N	flag leaf	\N	\N	EFO	"The last mature leaf before the inflorescence in a cereal crop plant." []	EFO	70499	EFO:0005100	\N	flag leaf	EFO:0005100
0	"A collective plant organ structure (PO:0025007) that is the pollen-bearing part of a stamen (PO:0009029)" []	\N	anther	\N	\N	EFO	"A collective plant organ structure (PO:0025007) that is the pollen-bearing part of a stamen (PO:0009029)" []	EFO	70500	EFO:0005101	\N	anther	EFO:0005101
0	"A stalk that is part of a stamen" []	\N	filament	\N	\N	EFO	"A stalk that is part of a stamen" []	EFO	70501	EFO:0005102	\N	filament	EFO:0005102
0	"Posterior portion of the eye-antennal disc. It gives rise to the adult antennal segments and the maxillary palp, as well as contributing to the head capsule." []	\N	antennal disc	\N	\N	EFO	"Posterior portion of the eye-antennal disc. It gives rise to the adult antennal segments and the maxillary palp, as well as contributing to the head capsule." []	EFO	70502	EFO:0005103	\N	antennal disc	EFO:0005103
0	"Anterior, bulbous portion of the eye-antennal disc that gives rise to the eye as well as contributing to the head capsule (Cohen, 1993)." []	\N	eye disc	\N	\N	EFO	"Anterior, bulbous portion of the eye-antennal disc that gives rise to the eye as well as contributing to the head capsule (Cohen, 1993)." []	EFO	70503	EFO:0005104	\N	eye disc	EFO:0005104
0	"quantification of some lipid or lipoprotein" []	\N	lipid or lipoprotein measurement	\N	\N	EFO	"quantification of some lipid or lipoprotein" []	EFO	70504	EFO:0005105	\N	lipid or lipoprotein measurement	EFO:0005105
0	"measurement of the percentages of fat, bone and muscle in human bodies" []	\N	body composition measurement	\N	\N	EFO	"measurement of the percentages of fat, bone and muscle in human bodies" []	EFO	70505	EFO:0005106	\N	body composition measurement	EFO:0005106
0	"" []	\N	collective leaf structure	\N	\N	EFO	"" []	EFO	70506	EFO:0005107	\N	collective leaf structure	EFO:0005107
0	"Distance between the tips of the longest fingers with the arms maximally outstretched laterally." []	\N	arm span	\N	\N	EFO	"Distance between the tips of the longest fingers with the arms maximally outstretched laterally." []	EFO	70507	EFO:0005108	\N	arm span	EFO:0005108
0	"" []	\N	energy expenditure	\N	\N	EFO	"" []	EFO	70508	EFO:0005109	\N	energy expenditure	EFO:0005109
0	"The determination of the amount of fatty acids present in a sample." []	\N	fatty acid measurement	\N	\N	EFO	"The determination of the amount of fatty acids present in a sample." []	EFO	70509	EFO:0005110	\N	fatty acid measurement	EFO:0005110
0	"A measurement of the folic acid in a biological sample" []	\N	folic acid measurement	\N	\N	EFO	"A measurement of the folic acid in a biological sample" []	EFO	70510	EFO:0005111	\N	folic acid measurement	EFO:0005111
0	"The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization." []	\N	gestational age	\N	\N	EFO	"The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization." []	EFO	70511	EFO:0005112	\N	gestational age	EFO:0005112
0	"A circumferential measurement of the head at the widest point, which is traditionally above the eyebrow" []	\N	head circumference	\N	\N	EFO	"A circumferential measurement of the head at the widest point, which is traditionally above the eyebrow" []	EFO	70512	EFO:0005114	\N	head circumference	EFO:0005114
0	"a quantification of metabolic rate" []	\N	metabolic rate measurement	\N	\N	EFO	"a quantification of metabolic rate" []	EFO	70513	EFO:0005115	\N	metabolic rate measurement	EFO:0005115
0	"quantification of some metabolite in urine" []	\N	urinary metabolite measurement	\N	\N	EFO	"quantification of some metabolite in urine" []	EFO	70514	EFO:0005116	\N	urinary metabolite measurement	EFO:0005116
0	"Is the quantification of Chemokine (C-C motif) ligand 5, involved in response to infection and inflammation," []	\N	CCL5 measurement	\N	\N	EFO	"Is the quantification of Chemokine (C-C motif) ligand 5, involved in response to infection and inflammation," []	EFO	70515	EFO:0005117	\N	CCL5 measurement	EFO:0005117
0	"" []	\N	IGFBP-1 measurement	\N	\N	EFO	"" []	EFO	70516	EFO:0005118	\N	IGFBP-1 measurement	EFO:0005118
0	"quantification of some antioxidant in a biological sample" []	\N	antioxidant measurement	\N	\N	EFO	"quantification of some antioxidant in a biological sample" []	EFO	70517	EFO:0005119	\N	antioxidant measurement	EFO:0005119
0	"a specimen which is the output of some freeze drying process applied with the aim of perserving the specimen" []	\N	freeze dried specimen	\N	\N	EFO	"a specimen which is the output of some freeze drying process applied with the aim of perserving the specimen" []	EFO	70518	EFO:0005121	\N	freeze dried specimen	EFO:0005121
0	"a specimen which has been treated with RNAlater, with the aim of preserving specimen RNA prior to extraction" []	\N	RNAlater specimen	\N	\N	EFO	"a specimen which has been treated with RNAlater, with the aim of preserving specimen RNA prior to extraction" []	EFO	70519	EFO:0005125	\N	RNAlater specimen	EFO:0005125
0	"quantification of the activity of enzymes from the arylesterase family" []	\N	arylesterase enzyme measurement	\N	\N	EFO	"quantification of the activity of enzymes from the arylesterase family" []	EFO	70520	EFO:0005126	\N	arylesterase enzyme measurement	EFO:0005126
0	"cancer biomarkers, such as cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein, are used as indicators for cancer screening and as predictors for therapeutic responses and prognoses in cancer patient" []	\N	cancer biomarker measurement	\N	\N	EFO	"cancer biomarkers, such as cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein, are used as indicators for cancer screening and as predictors for therapeutic responses and prognoses in cancer patient" []	EFO	70521	EFO:0005127	\N	cancer biomarker measurement	EFO:0005127
0	"quantification of the ratio of the protein albumin to globulin in the blood serum" []	\N	albumin:globulin ratio measurement	\N	\N	EFO	"quantification of the ratio of the protein albumin to globulin in the blood serum" []	EFO	70522	EFO:0005128	\N	albumin:globulin ratio measurement	EFO:0005128
0	"liver injury resulting from hepatitis C infection" []	\N	hepatitis C induced liver cirrhosis	\N	\N	EFO	"liver injury resulting from hepatitis C infection" []	EFO	70523	EFO:0005129	\N	hepatitis C induced liver cirrhosis	EFO:0005129
0	"quantification of the thyroid hormone thyroxine (T4) in the blood, usually as an indicator of thyroid function" []	\N	thyroxine measurement	\N	\N	EFO	"quantification of the thyroid hormone thyroxine (T4) in the blood, usually as an indicator of thyroid function" []	EFO	70524	EFO:0005130	\N	thyroxine measurement	EFO:0005130
0	"quantification of homovanillic acid in cerebrospinal fluid" []	\N	HVA measurement	\N	\N	EFO	"quantification of homovanillic acid in cerebrospinal fluid" []	EFO	70525	EFO:0005131	\N	HVA measurement	EFO:0005131
0	"quantification of 5-hydroxyindoleacetic acid in cerebrospinal fluid" []	\N	5-HIAA measurement	\N	\N	EFO	"quantification of 5-hydroxyindoleacetic acid in cerebrospinal fluid" []	EFO	70526	EFO:0005132	\N	5-HIAA measurement	EFO:0005132
0	"quantification of 3-methoxy-4-hydroxyphenylglycol in cerebrospinal fluid" []	\N	MHPG measurement	\N	\N	EFO	"quantification of 3-methoxy-4-hydroxyphenylglycol in cerebrospinal fluid" []	EFO	70527	EFO:0005133	\N	MHPG measurement	EFO:0005133
0	"quantification of some amino acid in a biological assay" []	\N	amino acid measurement	\N	\N	EFO	"quantification of some amino acid in a biological assay" []	EFO	70528	EFO:0005134	\N	amino acid measurement	EFO:0005134
0	"A population of organisms that is geneticaly different from others of the same species and possessing a set of defined characteristics." []	\N	strain	\N	\N	EFO	"A population of organisms that is geneticaly different from others of the same species and possessing a set of defined characteristics." []	EFO	70529	EFO:0005135	\N	strain	EFO:0005135
0	"A cultivated plant variety selected and given a name because it has desirable characteristics that distinguish it from otherwise similar plants of the same species." []	\N	cultivar	\N	\N	EFO	"A cultivated plant variety selected and given a name because it has desirable characteristics that distinguish it from otherwise similar plants of the same species." []	EFO	70530	EFO:0005136	\N	cultivar	EFO:0005136
0	"A conduction system disorder, or disease is a form of heart disease in which the electrical conduction system of the heart is disrupted, for example branch block" []	\N	conduction system disorder	\N	\N	EFO	"A conduction system disorder, or disease is a form of heart disease in which the electrical conduction system of the heart is disrupted, for example branch block" []	EFO	70531	EFO:0005137	\N	conduction system disorder	EFO:0005137
0	"A form of long QT syndrome in which malfunction of the cardiac ion channels is caused by drugs or metabolic abnormalities. Common genetic variation may influence susceptibility to acquired long QT syndrome." []	\N	acquired long QT syndrome	\N	\N	EFO	"A form of long QT syndrome in which malfunction of the cardiac ion channels is caused by drugs or metabolic abnormalities. Common genetic variation may influence susceptibility to acquired long QT syndrome." []	EFO	70532	EFO:0005138	\N	acquired long QT syndrome	EFO:0005138
0	"Quantification of some ceruloplasmin in the blood" []	\N	serum ceruloplasmin measurement	\N	\N	EFO	"Quantification of some ceruloplasmin in the blood" []	EFO	70533	EFO:0005139	\N	serum ceruloplasmin measurement	EFO:0005139
0	"Autoimmune disease or disorder is a disease characterized by an immune response of an organism against parts of itself causing pathology e.g. Graves' disease." []	\N	autoimmune disease	\N	\N	EFO	"Autoimmune disease or disorder is a disease characterized by an immune response of an organism against parts of itself causing pathology e.g. Graves' disease." []	EFO	70534	EFO:0005140	\N	autoimmune disease	EFO:0005140
0	"The Col or Columbia ecotype is an Arabidopsis thaliana ecotype, selected, by Redei, as it was a particularly fertile and vigorous plant that responded well to changes in photoperiod. The ecotype was selected from within a (nonirradiated) population of seeds named Landsberg he received from Laibach. Columbia is the ecotype sequenced in the Arabidopsis Genome Initiative." []	\N	Columbia ecotype	\N	\N	EFO	"The Col or Columbia ecotype is an Arabidopsis thaliana ecotype, selected, by Redei, as it was a particularly fertile and vigorous plant that responded well to changes in photoperiod. The ecotype was selected from within a (nonirradiated) population of seeds named Landsberg he received from Laibach. Columbia is the ecotype sequenced in the Arabidopsis Genome Initiative." []	EFO	70535	EFO:0005147	\N	Columbia ecotype	EFO:0005147
0	"Col-0 is an Arabidopsis ecotype and a direct descendant of Col-1 donated via AIS." []	\N	Col-0	\N	\N	EFO	"Col-0 is an Arabidopsis ecotype and a direct descendant of Col-1 donated via AIS." []	EFO	70536	EFO:0005148	\N	Col-0	EFO:0005148
0	"Col-1 is an Arabidopsis ecotype and the original AIS donation of Columbia (isolate 5-13) from George Redei." []	\N	Col-1	\N	\N	EFO	"Col-1 is an Arabidopsis ecotype and the original AIS donation of Columbia (isolate 5-13) from George Redei." []	EFO	70537	EFO:0005149	\N	Col-1	EFO:0005149
0	"Col-2 is an Arabidopsis ecotype and is a line that has been single seed selected from Col-1 and propagated through 5 generations of single seed descent by Shauna Somerville." []	\N	Col-2	\N	\N	EFO	"Col-2 is an Arabidopsis ecotype and is a line that has been single seed selected from Col-1 and propagated through 5 generations of single seed descent by Shauna Somerville." []	EFO	70538	EFO:0005150	\N	Col-2	EFO:0005150
0	"Col-3 is an Arabidopsis ecotype and a line that Elliot Meyerowitz used for the RFLP mapping data and has shown polymorphisms in the hands of Chris Somerville to Col-2. It is also one of the female parents used by Jim Beynon, Eric Holub and Ian Crute for the generation of their RI population (the other being glabrous Col-5)." []	\N	Col-3	\N	\N	EFO	"Col-3 is an Arabidopsis ecotype and a line that Elliot Meyerowitz used for the RFLP mapping data and has shown polymorphisms in the hands of Chris Somerville to Col-2. It is also one of the female parents used by Jim Beynon, Eric Holub and Ian Crute for the generation of their RI population (the other being glabrous Col-5)." []	EFO	70539	EFO:0005151	\N	Col-3	EFO:0005151
0	"Col-4 is an Arabidopsis ecotype and is the line used as the parental for the recombinant inbred population of Caroline Dean." []	\N	Col-4	\N	\N	EFO	"Col-4 is an Arabidopsis ecotype and is the line used as the parental for the recombinant inbred population of Caroline Dean." []	EFO	70540	EFO:0005152	\N	Col-4	EFO:0005152
0	"Col-5 is an Arabidopsis ecotype and the glabrous (gl1-1) Columbia line used by Jim Beynon, Eric Holub and Ian Crute as one of the female parents (the other being Col-3) for the generation of their RI population." []	\N	Col-5	\N	\N	EFO	"Col-5 is an Arabidopsis ecotype and the glabrous (gl1-1) Columbia line used by Jim Beynon, Eric Holub and Ian Crute as one of the female parents (the other being Col-3) for the generation of their RI population." []	EFO	70541	EFO:0005153	\N	Col-5	EFO:0005153
0	"Landsberg erecta ecotype is an Arabidopsis thaliana ecotype. It was originally selected by Rédei from within a Landsberg population on which he had performed some X-ray mutagenesis experiments." []	\N	Landsberg ecotype	\N	\N	EFO	"Landsberg erecta ecotype is an Arabidopsis thaliana ecotype. It was originally selected by Rédei from within a Landsberg population on which he had performed some X-ray mutagenesis experiments." []	EFO	70542	EFO:0005154	\N	Landsberg ecotype	EFO:0005154
0	"Ler-1 is an Arabidopsis ecotype." []	\N	Ler-1	\N	\N	EFO	"Ler-1 is an Arabidopsis ecotype." []	EFO	70543	EFO:0005155	\N	Ler-1	EFO:0005155
0	"Wassilewskija is an Arabidopsis ecotype." []	\N	Wassilewskija ecotype	\N	\N	EFO	"Wassilewskija is an Arabidopsis ecotype." []	EFO	70544	EFO:0005156	\N	Wassilewskija ecotype	EFO:0005156
0	"Ws-1 is an Arabidopsis ecotype." []	\N	Ws-1	\N	\N	EFO	"Ws-1 is an Arabidopsis ecotype." []	EFO	70545	EFO:0005157	\N	Ws-1	EFO:0005157
0	"Ws-2 is an Arabidopsis ecotype." []	\N	Ws-2	\N	\N	EFO	"Ws-2 is an Arabidopsis ecotype." []	EFO	70546	EFO:0005158	\N	Ws-2	EFO:0005158
0	"Ws-3 is an Arabidopsis ecotype." []	\N	Ws-3	\N	\N	EFO	"Ws-3 is an Arabidopsis ecotype." []	EFO	70547	EFO:0005159	\N	Ws-3	EFO:0005159
0	"Umkirch is an Arabidopsis ecotype." []	\N	Umkirch ecotype	\N	\N	EFO	"Umkirch is an Arabidopsis ecotype." []	EFO	70548	EFO:0005160	\N	Umkirch ecotype	EFO:0005160
0	"Uk-1 is an Arabidopsis ecotype." []	\N	Uk-1	\N	\N	EFO	"Uk-1 is an Arabidopsis ecotype." []	EFO	70549	EFO:0005161	\N	Uk-1	EFO:0005161
0	"Uk-2 is an Arabidopsis ecotype" []	\N	Uk-2	\N	\N	EFO	"Uk-2 is an Arabidopsis ecotype" []	EFO	70550	EFO:0005162	\N	Uk-2	EFO:0005162
0	"Uk-3 is an Arabidopsis ecotype." []	\N	Uk-3	\N	\N	EFO	"Uk-3 is an Arabidopsis ecotype." []	EFO	70551	EFO:0005163	\N	Uk-3	EFO:0005163
0	"Calver is an Arabidopsis ecotype." []	\N	Calver ecotype	\N	\N	EFO	"Calver is an Arabidopsis ecotype." []	EFO	70552	EFO:0005164	\N	Calver ecotype	EFO:0005164
0	"Cal-0 is an Arabidopsis ecotype." []	\N	Cal-0	\N	\N	EFO	"Cal-0 is an Arabidopsis ecotype." []	EFO	70553	EFO:0005165	\N	Cal-0	EFO:0005165
0	"Blanes is an Arabidopsis ecotype." []	\N	Blanes ecotype	\N	\N	EFO	"Blanes is an Arabidopsis ecotype." []	EFO	70554	EFO:0005166	\N	Blanes ecotype	EFO:0005166
0	"Bla-1 is an Arabidopsis ecotype." []	\N	Bla-1	\N	\N	EFO	"Bla-1 is an Arabidopsis ecotype." []	EFO	70555	EFO:0005167	\N	Bla-1	EFO:0005167
0	"" []	\N	wild type genotype	\N	\N	EFO	"" []	EFO	70556	EFO:0005168	\N	wild type genotype	EFO:0005168
0	"Burren is an Arabidopsis ecotype." []	\N	Burren ecotype	\N	\N	EFO	"Burren is an Arabidopsis ecotype." []	EFO	70557	EFO:0005169	\N	Burren ecotype	EFO:0005169
0	"Bur-0 is an Arabidopsis ecotype." []	\N	Bur-0	\N	\N	EFO	"Bur-0 is an Arabidopsis ecotype." []	EFO	70558	EFO:0005170	\N	Bur-0	EFO:0005170
0	"Bologna is an Arabidopsis ecotype." []	\N	Bologna ecotype	\N	\N	EFO	"Bologna is an Arabidopsis ecotype." []	EFO	70559	EFO:0005171	\N	Bologna ecotype	EFO:0005171
0	"Bl-0 is an Arabidopsis ecotype." []	\N	Bl-0	\N	\N	EFO	"Bl-0 is an Arabidopsis ecotype." []	EFO	70560	EFO:0005172	\N	Bl-0	EFO:0005172
0	"Bl-1 is an Arabidopsis ecotype." []	\N	Bl-1	\N	\N	EFO	"Bl-1 is an Arabidopsis ecotype." []	EFO	70561	EFO:0005173	\N	Bl-1	EFO:0005173
0	"Bayreuth is an Arabidopsis ecotype." []	\N	Bayreuth ecotype	\N	\N	EFO	"Bayreuth is an Arabidopsis ecotype." []	EFO	70562	EFO:0005174	\N	Bayreuth ecotype	EFO:0005174
0	"Bay-0 is an Arabidopsis ecotype." []	\N	Bay-0	\N	\N	EFO	"Bay-0 is an Arabidopsis ecotype." []	EFO	70563	EFO:0005175	\N	Bay-0	EFO:0005175
0	"Coimbra is an Arabidopsis ecotype." []	\N	Coimbra ecotype	\N	\N	EFO	"Coimbra is an Arabidopsis ecotype." []	EFO	70564	EFO:0005176	\N	Coimbra ecotype	EFO:0005176
0	"Co-1 is an Arabidopsis ecotype." []	\N	Co-1	\N	\N	EFO	"Co-1 is an Arabidopsis ecotype." []	EFO	70565	EFO:0005177	\N	Co-1	EFO:0005177
0	"San Eleno is an Arabidopsis ecotype." []	\N	San Eleno ecotype	\N	\N	EFO	"San Eleno is an Arabidopsis ecotype." []	EFO	70566	EFO:0005178	\N	San Eleno ecotype	EFO:0005178
0	"Se-0 is an Arabidopsis ecotype" []	\N	Se-0	\N	\N	EFO	"Se-0 is an Arabidopsis ecotype" []	EFO	70567	EFO:0005179	\N	Se-0	EFO:0005179
0	"The original group of Swiss mice that served as progenitors of this stock consisted of two male and seven female albino mice derived from a non-inbred stock in the laboratory of Dr. de Coulon, Centre Anticancereux Romand, Lausanne, Switzerland." []	\N	CD1 mus strain	\N	\N	EFO	"The original group of Swiss mice that served as progenitors of this stock consisted of two male and seven female albino mice derived from a non-inbred stock in the laboratory of Dr. de Coulon, Centre Anticancereux Romand, Lausanne, Switzerland." []	EFO	70568	EFO:0005180	\N	CD1 mus strain	EFO:0005180
0	"An inbred strain of mouse created in 1921 by C. C. Little at the Bussey Institute for Research in Applied Biology." []	\N	C57BL	\N	\N	EFO	"An inbred strain of mouse created in 1921 by C. C. Little at the Bussey Institute for Research in Applied Biology." []	EFO	70569	EFO:0005181	\N	C57BL	EFO:0005181
0	"N'Dama are a breed of cattle from West Africa, of the Bos taurus-type. Other names for them include Boenca or Boyenca (Guinea-Bissau), Fouta Jallon, Fouta Longhorn, Fouta Malinke, Futa, Malinke, Mandingo (Liberia), N'Dama Petite (Senegal). Originating in the Guinea highlands they are also found in southern Senegal, Guinea-Bissau, Gambia, Mali, Côte d'Ivoire, Liberia, Nigeria and Sierra Leone. They are trypanotolerant, allowing them to be kept in tsetse fly infested areas. They also show superior resistance to ticks and the diseases they carry and to Haemonchus contortus stomach worms." []	\N	N'Dama	\N	\N	EFO	"N'Dama are a breed of cattle from West Africa, of the Bos taurus-type. Other names for them include Boenca or Boyenca (Guinea-Bissau), Fouta Jallon, Fouta Longhorn, Fouta Malinke, Futa, Malinke, Mandingo (Liberia), N'Dama Petite (Senegal). Originating in the Guinea highlands they are also found in southern Senegal, Guinea-Bissau, Gambia, Mali, Côte d'Ivoire, Liberia, Nigeria and Sierra Leone. They are trypanotolerant, allowing them to be kept in tsetse fly infested areas. They also show superior resistance to ticks and the diseases they carry and to Haemonchus contortus stomach worms." []	EFO	70570	EFO:0005182	\N	N'Dama	EFO:0005182
0	"Boran cattle are a popular Zebu beef breed in eastern Africa." []	\N	Boran cattle	\N	\N	EFO	"Boran cattle are a popular Zebu beef breed in eastern Africa." []	EFO	70571	EFO:0005183	\N	Boran cattle	EFO:0005183
0	"Inbred Strain TJL Mating System: Sibling x Sibling (Female x Male) Species: laboratory mouse H2 Haplotype: d Generation: F219p (14-DEC-06) Appearance: dilute brown Related Genotype: a/a Tyrp1b/Tyrp1b Myo5ad/Myo5ad Important Note This strain is homozygous for Cdh23ahl, the age related hearing loss 1 mutation, which on this background results in progressive hearing loss that is already severe by 3 months of age. Strain Description DBA/2J is a widely used inbred strain that is valuable in a wide number of research areas including cardiovascular biology, neurobiology, and sensorineural research." []	\N	DBA/2J	\N	\N	EFO	"Inbred Strain TJL Mating System: Sibling x Sibling (Female x Male) Species: laboratory mouse H2 Haplotype: d Generation: F219p (14-DEC-06) Appearance: dilute brown Related Genotype: a/a Tyrp1b/Tyrp1b Myo5ad/Myo5ad Important Note This strain is homozygous for Cdh23ahl, the age related hearing loss 1 mutation, which on this background results in progressive hearing loss that is already severe by 3 months of age. Strain Description DBA/2J is a widely used inbred strain that is valuable in a wide number of research areas including cardiovascular biology, neurobiology, and sensorineural research." []	EFO	70572	EFO:0005184	\N	DBA/2J	EFO:0005184
0	"The terminal ileum is the most distal part of the small intestine. It connects to the cecum, the pouch between the small and the large intestine, via the ileocecal valve." []	\N	terminal ileum	\N	\N	EFO	"The terminal ileum is the most distal part of the small intestine. It connects to the cecum, the pouch between the small and the large intestine, via the ileocecal valve." []	EFO	70573	EFO:0005185	\N	terminal ileum	EFO:0005185
0	"The fundus of the uterus is the top portion, opposite from the cervix.\\nFundal height, measured from the top of the pubic bone, is routinely measured in pregnancy to determine growth rates." []	\N	uterus fundus	\N	\N	EFO	"The fundus of the uterus is the top portion, opposite from the cervix.\\nFundal height, measured from the top of the pubic bone, is routinely measured in pregnancy to determine growth rates." []	EFO	70574	EFO:0005186	\N	uterus fundus	EFO:0005186
0	"" []	\N	C-peptide measurement	\N	\N	EFO	"" []	EFO	70575	EFO:0005187	\N	C-peptide measurement	EFO:0005187
0	"" []	\N	CCL11 measurement	\N	\N	EFO	"" []	EFO	70576	EFO:0005188	\N	CCL11 measurement	EFO:0005188
0	"" []	\N	respiratory quotient	\N	\N	EFO	"" []	EFO	70577	EFO:0005189	\N	respiratory quotient	EFO:0005189
0	"" []	\N	urinary nitrogen measurement	\N	\N	EFO	"" []	EFO	70578	EFO:0005190	\N	urinary nitrogen measurement	EFO:0005190
0	"" []	\N	waist height ratio	\N	\N	EFO	"" []	EFO	70579	EFO:0005191	\N	waist height ratio	EFO:0005191
0	"measure of the variation of red blood cell (RBC) volume" []	\N	red blood cell distribution width	\N	\N	EFO	"measure of the variation of red blood cell (RBC) volume" []	EFO	70580	EFO:0005192	\N	red blood cell distribution width	EFO:0005192
0	"quantification of N-linked IgG glycans in a serum sample" []	\N	serum IgG glycosylation measurement	\N	\N	EFO	"quantification of N-linked IgG glycans in a serum sample" []	EFO	70581	EFO:0005193	\N	serum IgG glycosylation measurement	EFO:0005193
0	"quantification of the amyloid-beta, either in a sample of cerebro-spinal fluid or via PET scan, used as a biomarker for Alzheimer's disease" []	\N	amyloid-beta measurement	\N	\N	EFO	"quantification of the amyloid-beta, either in a sample of cerebro-spinal fluid or via PET scan, used as a biomarker for Alzheimer's disease" []	EFO	70582	EFO:0005194	\N	amyloid-beta measurement	EFO:0005194
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholinesterase inhbitor stimulus." []	\N	response to cholinesterase inhibitor	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholinesterase inhbitor stimulus." []	EFO	70583	EFO:0005195	\N	response to cholinesterase inhibitor	EFO:0005195
0	"quantification of some peptide with a vasodilating or vasoconstricting effect in a blood sample, usually as an indicator of cardiovascular disease" []	\N	vasoactive peptide measurement	\N	\N	EFO	"quantification of some peptide with a vasodilating or vasoconstricting effect in a blood sample, usually as an indicator of cardiovascular disease" []	EFO	70584	EFO:0005196	\N	vasoactive peptide measurement	EFO:0005196
0	"quantification of the MHC component beta-2 microglobulin, typically in a blood sample" []	\N	beta-2 microglobulin measurement	\N	\N	EFO	"quantification of the MHC component beta-2 microglobulin, typically in a blood sample" []	EFO	70585	EFO:0005197	\N	beta-2 microglobulin measurement	EFO:0005197
0	"" []	\N	transplant outcome measurement	\N	\N	EFO	"" []	EFO	70586	EFO:0005198	\N	transplant outcome measurement	EFO:0005198
0	"quantification of the outcome of a kidney transplant" []	\N	renal transplant outcome measurement	\N	\N	EFO	"quantification of the outcome of a kidney transplant" []	EFO	70587	EFO:0005199	\N	renal transplant outcome measurement	EFO:0005199
0	"Quantification of antiphospholipid antibodies in a biological sample, usually a blood sample. Antiphospholipid antibodies include anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti- β 2 glycoprotein I antibodies (anti- β 2GPI).They can be an indicator of antiphospholipid syndrome" []	\N	antiphospholipid antibody measurement	\N	\N	EFO	"Quantification of antiphospholipid antibodies in a biological sample, usually a blood sample. Antiphospholipid antibodies include anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), and anti- β 2 glycoprotein I antibodies (anti- β 2GPI).They can be an indicator of antiphospholipid syndrome" []	EFO	70588	EFO:0005200	\N	antiphospholipid antibody measurement	EFO:0005200
0	"growth is measured as the difference in body height between two time points" []	\N	height growth measurement	\N	\N	EFO	"growth is measured as the difference in body height between two time points" []	EFO	70589	EFO:0005201	\N	height growth measurement	EFO:0005201
0	"" []	\N	response to hydrochlorothiazide	\N	\N	EFO	"" []	EFO	70590	EFO:0005202	\N	response to hydrochlorothiazide	EFO:0005202
0	"A group of disorders characterized by physiological and psychological disturbances in appetite or food intake." []	\N	eating disorder	\N	\N	EFO	"A group of disorders characterized by physiological and psychological disturbances in appetite or food intake." []	EFO	70591	EFO:0005203	\N	eating disorder	EFO:0005203
0	"An eating disorder that is characterized by a cycle of binge eating (BULIMIA or bingeing) followed by inappropriate acts (purging) to avert weight gain. Purging methods often include self-induced VOMITING, use of LAXATIVES or DIURETICS, excessive exercise, and FASTING." []	\N	bulimia nervosa	\N	\N	EFO	"An eating disorder that is characterized by a cycle of binge eating (BULIMIA or bingeing) followed by inappropriate acts (purging) to avert weight gain. Purging methods often include self-induced VOMITING, use of LAXATIVES or DIURETICS, excessive exercise, and FASTING." []	EFO	70592	EFO:0005204	\N	bulimia nervosa	EFO:0005204
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of treatment with dabigatran etexilate, an anticoagulant from the class of direct thrombin inhibitors. Dabigatran is used to prevent strokes in patients with atrial fibrillations due to causes other than heart valve disease, and at least one additional risk factor for stroke,and to prevent the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee." []	\N	response to dabigatran etexilate	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of treatment with dabigatran etexilate, an anticoagulant from the class of direct thrombin inhibitors. Dabigatran is used to prevent strokes in patients with atrial fibrillations due to causes other than heart valve disease, and at least one additional risk factor for stroke,and to prevent the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee." []	EFO	70593	EFO:0005205	\N	response to dabigatran etexilate	EFO:0005205
0	"detection or quantification of bands of immunoglobulins in blood serum or cerebrospinal fluid, usually as an indicator of central nervous system disorders such as multiple sclerosis, Lyme disease, systemic lupus erythematosus or neurosarcoidosis" []	\N	oligoclonal band measurement	\N	\N	EFO	"detection or quantification of bands of immunoglobulins in blood serum or cerebrospinal fluid, usually as an indicator of central nervous system disorders such as multiple sclerosis, Lyme disease, systemic lupus erythematosus or neurosarcoidosis" []	EFO	70594	EFO:0005206	\N	oligoclonal band measurement	EFO:0005206
0	"any form of heart disease that is present at birth, including defects to the structure and function of the heart and great vessels" []	\N	congenital heart disease	\N	\N	EFO	"any form of heart disease that is present at birth, including defects to the structure and function of the heart and great vessels" []	EFO	70595	EFO:0005207	\N	congenital heart disease	EFO:0005207
0	"measurement of the flow rate of filtered fluid through the kidney, calculated either by comparative measurements of substances in the blood and urine, or estimated from a blood test" []	\N	glomerular filtration rate	\N	\N	EFO	"measurement of the flow rate of filtered fluid through the kidney, calculated either by comparative measurements of substances in the blood and urine, or estimated from a blood test" []	EFO	70596	EFO:0005208	\N	glomerular filtration rate	EFO:0005208
0	"quantification of the pattern of links between distinct units within a nervous system through neuroimaging techniques such a MRI" []	\N	brain connectivity measurement	\N	\N	EFO	"quantification of the pattern of links between distinct units within a nervous system through neuroimaging techniques such a MRI" []	EFO	70597	EFO:0005210	\N	brain connectivity measurement	EFO:0005210
0	"quantification of the rate of hydrolysis of aspirin in blood as an indicator of the therapeutic effectiveness of aspirin" []	\N	aspirin hydrolysis measurement	\N	\N	EFO	"quantification of the rate of hydrolysis of aspirin in blood as an indicator of the therapeutic effectiveness of aspirin" []	EFO	70598	EFO:0005211	\N	aspirin hydrolysis measurement	EFO:0005211
0	"The standard atmosphere is an international reference pressure defined as 101325 Pa and formerly used as a unit of pressure." []	\N	atmosphere unit	\N	\N	EFO	"The standard atmosphere is an international reference pressure defined as 101325 Pa and formerly used as a unit of pressure." []	EFO	70599	EFO:0005212	\N	atmosphere unit	EFO:0005212
0	"A measure of the corneal thickness (CCT). This can be measured by contact e.g. ultrasound, confocal microscpy or non contact methods e.g. biometry. Reduced central corneal thickness is used as an indicator for glaucoma." []	\N	central corneal thickness	\N	\N	EFO	"A measure of the corneal thickness (CCT). This can be measured by contact e.g. ultrasound, confocal microscpy or non contact methods e.g. biometry. Reduced central corneal thickness is used as an indicator for glaucoma." []	EFO	70600	EFO:0005213	\N	central corneal thickness	EFO:0005213
0	"A cell line which is a model for neuroblastoma." []	\N	neuroblastoma cell line	\N	\N	EFO	"A cell line which is a model for neuroblastoma." []	EFO	70601	EFO:0005214	\N	neuroblastoma cell line	EFO:0005214
0	"A cell line which is a model for breast adenocarcinoma." []	\N	breast adenocarcinoma cell line	\N	\N	EFO	"A cell line which is a model for breast adenocarcinoma." []	EFO	70602	EFO:0005215	\N	breast adenocarcinoma cell line	EFO:0005215
0	"A cell line used as model for hepatocellular carcinoma." []	\N	hepatoma cell line	\N	\N	EFO	"A cell line used as model for hepatocellular carcinoma." []	EFO	70603	EFO:0005216	\N	hepatoma cell line	EFO:0005216
0	"A cell line used as a model for cervical adenocarcinoma." []	\N	cervical adenocarcinoma cell line	\N	\N	EFO	"A cell line used as a model for cervical adenocarcinoma." []	EFO	70604	EFO:0005217	\N	cervical adenocarcinoma cell line	EFO:0005217
0	"A cell line which is used as a model for cervical carcinoma." []	\N	cervical carcinoma cell line	\N	\N	EFO	"A cell line which is used as a model for cervical carcinoma." []	EFO	70605	EFO:0005218	\N	cervical carcinoma cell line	EFO:0005218
0	"Tra-DIS or Transposon Directed Insertion Site Sequencing is a sequencing technology developed at the Sanger Institute. The technique involves insertingtransposons into the genome to generate large numbers of mutants." []	\N	TraDIS sequencing	\N	\N	EFO	"Tra-DIS or Transposon Directed Insertion Site Sequencing is a sequencing technology developed at the Sanger Institute. The technique involves insertingtransposons into the genome to generate large numbers of mutants." []	EFO	70606	EFO:0005219	\N	TraDIS sequencing	EFO:0005219
0	"" []	\N	pulmonary neuroendocrine tumor	\N	\N	EFO	"" []	EFO	70607	EFO:0005220	\N	pulmonary neuroendocrine tumor	EFO:0005220
0	"" []	\N	cholangiocarcinoma	\N	\N	EFO	"" []	EFO	70608	EFO:0005221	\N	cholangiocarcinoma	EFO:0005221
0	"" []	\N	avian influenza	\N	\N	EFO	"" []	EFO	70609	EFO:0005222	\N	avian influenza	EFO:0005222
0	"" []	\N	acute stress reaction	\N	\N	EFO	"" []	EFO	70610	EFO:0005223	\N	acute stress reaction	EFO:0005223
0	"" []	\N	Q fever	\N	\N	EFO	"" []	EFO	70611	EFO:0005224	\N	Q fever	EFO:0005224
0	"" []	\N	human african trypanosomiasis	\N	\N	EFO	"" []	EFO	70612	EFO:0005225	\N	human african trypanosomiasis	EFO:0005225
0	"" []	\N	swine influenza	\N	\N	EFO	"" []	EFO	70613	EFO:0005226	\N	swine influenza	EFO:0005226
0	"GRO-seq or Genomic run-on sequencing or sometimes Global run-on sequencing is a sequencing assay based on traditional nuclear run-on assays, but instead of looking at a few loci at a time, this is a high-throughput method that allows for the calculation of transcription rates of all genes across the genome. Please note that the starting materials for sequencing are RNAs, not genomic DNA because nascent transcripts are studied." []	\N	GRO-seq	\N	\N	EFO	"GRO-seq or Genomic run-on sequencing or sometimes Global run-on sequencing is a sequencing assay based on traditional nuclear run-on assays, but instead of looking at a few loci at a time, this is a high-throughput method that allows for the calculation of transcription rates of all genes across the genome. Please note that the starting materials for sequencing are RNAs, not genomic DNA because nascent transcripts are studied." []	EFO	70614	EFO:0005227	\N	GRO-seq	EFO:0005227
0	"A plant population is a grouping of plants consisting of individuals which share a particular characteristic such as inhabiting a particular region or area or ability to interbreed." []	\N	plant population	\N	\N	EFO	"A plant population is a grouping of plants consisting of individuals which share a particular characteristic such as inhabiting a particular region or area or ability to interbreed." []	EFO	70615	EFO:0005228	\N	plant population	EFO:0005228
0	"reading is the complex cognitive process of decoding symbols in order to construct or derive meaning" []	\N	reading	\N	\N	EFO	"reading is the complex cognitive process of decoding symbols in order to construct or derive meaning" []	EFO	70616	EFO:0005229	\N	reading	EFO:0005229
0	"Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus." []	\N	anxiety	\N	\N	EFO	"Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus." []	EFO	70617	EFO:0005230	\N	anxiety	EFO:0005230
0	"An established epithelial cell line derived from an adenocarcinoma of human endometrial lining." []	\N	ECC-1	\N	\N	EFO	"An established epithelial cell line derived from an adenocarcinoma of human endometrial lining." []	EFO	70618	EFO:0005231	\N	ECC-1	EFO:0005231
0	"" []	\N	endometrium adenocarcinoma	\N	\N	EFO	"" []	EFO	70619	EFO:0005232	\N	endometrium adenocarcinoma	EFO:0005232
0	"The CH12.LX B cell line derived from the murine CH12 B cell lymphoma." []	\N	CH12.LX	\N	\N	EFO	"The CH12.LX B cell line derived from the murine CH12 B cell lymphoma." []	EFO	70620	EFO:0005233	\N	CH12.LX	EFO:0005233
0	"Neuroectodermal cell line derived from a cerebral brain tumor." []	\N	PFSK-1	\N	\N	EFO	"Neuroectodermal cell line derived from a cerebral brain tumor." []	EFO	70621	EFO:0005234	\N	PFSK-1	EFO:0005234
0	"Primitive neuroectodermal tumours (PNET) are cancerous tumours that usually develop in the brain or spinal cord in children or young adults." []	\N	primitive neuroectodermal tumor	\N	\N	EFO	"Primitive neuroectodermal tumours (PNET) are cancerous tumours that usually develop in the brain or spinal cord in children or young adults." []	EFO	70622	EFO:0005235	\N	primitive neuroectodermal tumor	EFO:0005235
0	" The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line. Derived from metastatic site: lung" []	\N	NT2/D1	\N	\N	EFO	" The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line. Derived from metastatic site: lung" []	EFO	70623	EFO:0005236	\N	NT2/D1	EFO:0005236
0	"A human epithelial cell derived from subject with grade IV glioblastoma; astrocytoma." []	\N	U-87 MG	\N	\N	EFO	"A human epithelial cell derived from subject with grade IV glioblastoma; astrocytoma." []	EFO	70624	EFO:0005237	\N	U-87 MG	EFO:0005237
0	"A breed is a specific group of domestic animals or plants having homogeneous appearance, homogeneous behavior, and other characteristics that distinguish it from other animals or plants of the same species and that were arrived at through selective breeding." []	\N	breed	\N	\N	EFO	"A breed is a specific group of domestic animals or plants having homogeneous appearance, homogeneous behavior, and other characteristics that distinguish it from other animals or plants of the same species and that were arrived at through selective breeding." []	EFO	70625	EFO:0005238	\N	breed	EFO:0005238
0	"calcification of the aortic valve" []	\N	aortic valve calcification	\N	\N	EFO	"calcification of the aortic valve" []	EFO	70626	EFO:0005239	\N	aortic valve calcification	EFO:0005239
0	"A type of retinal detachment associated with a retinal tear, that is, with a break in the retina that allows fluid to pass from the vitreous space into the subretinal space between the sensory retina and the retinal pigment epithelium." []	\N	rhegmatogenous retinal detachment	\N	\N	EFO	"A type of retinal detachment associated with a retinal tear, that is, with a break in the retina that allows fluid to pass from the vitreous space into the subretinal space between the sensory retina and the retinal pigment epithelium." []	EFO	70627	EFO:0005240	\N	rhegmatogenous retinal detachment	EFO:0005240
0	"quantification of an individual's occupation, both in terms of employment vs unemployment and in terms of nature of employment, eg self-employment" []	\N	employment status	\N	\N	EFO	"quantification of an individual's occupation, both in terms of employment vs unemployment and in terms of nature of employment, eg self-employment" []	EFO	70628	EFO:0005241	\N	employment status	EFO:0005241
0	"abnormal mental state resulting from an abuse of methamphetamine" []	\N	methamphetamine-induced psychosis	\N	\N	EFO	"abnormal mental state resulting from an abuse of methamphetamine" []	EFO	70629	EFO:0005242	\N	methamphetamine-induced psychosis	EFO:0005242
0	"quantification of the enzyme myeloperoxidase in the blood, for example as an indicator of coronary artery disease" []	\N	myeloperoxidase measurement	\N	\N	EFO	"quantification of the enzyme myeloperoxidase in the blood, for example as an indicator of coronary artery disease" []	EFO	70630	EFO:0005243	\N	myeloperoxidase measurement	EFO:0005243
0	"any of a group of similar operations that first divides the stomach into a small upper pouch and a much larger lower \\"remnant\\" pouch and then re-arranges the small intestine to connect to bot" []	\N	gastric bypass	\N	\N	EFO	"any of a group of similar operations that first divides the stomach into a small upper pouch and a much larger lower \\"remnant\\" pouch and then re-arranges the small intestine to connect to bot" []	EFO	70631	EFO:0005244	\N	gastric bypass	EFO:0005244
0	"the process of decreasing the mass of an organsim over time" []	\N	body weight loss	\N	\N	EFO	"the process of decreasing the mass of an organsim over time" []	EFO	70632	EFO:0005245	\N	body weight loss	EFO:0005245
0	"a large group of disorders characterized by excessive daytime sleepiness" []	\N	hypersomnia	\N	\N	EFO	"a large group of disorders characterized by excessive daytime sleepiness" []	EFO	70633	EFO:0005246	\N	hypersomnia	EFO:0005246
0	"measurement of the IgG antibody isotype produced by plasma cells in response to a Heliobacter pylori infection" []	\N	anti-Heliobacter pylori serum IgG measurement	\N	\N	EFO	"measurement of the IgG antibody isotype produced by plasma cells in response to a Heliobacter pylori infection" []	EFO	70634	EFO:0005247	\N	anti-Heliobacter pylori serum IgG measurement	EFO:0005247
0	"" []	\N	occupation-related stress disorder	\N	\N	EFO	"" []	EFO	70635	EFO:0005250	\N	occupation-related stress disorder	EFO:0005250
0	"Blood pressure that is abnormally low." []	\N	hypotension	\N	\N	EFO	"Blood pressure that is abnormally low." []	EFO	70636	EFO:0005251	\N	hypotension	EFO:0005251
0	"Sudden fall of the blood pressure of at least 20/10 mm Hg when a person stands up." []	\N	orthostatic hypotension	\N	\N	EFO	"Sudden fall of the blood pressure of at least 20/10 mm Hg when a person stands up." []	EFO	70637	EFO:0005252	\N	orthostatic hypotension	EFO:0005252
0	"drastic decline in blood pressure which happens after eating a meal and most likely due to insufficient compensation in cardiac output by the autonomic nervous sytem for the diversion of blood to the intestines " []	\N	postprandial hypotension	\N	\N	EFO	"drastic decline in blood pressure which happens after eating a meal and most likely due to insufficient compensation in cardiac output by the autonomic nervous sytem for the diversion of blood to the intestines " []	EFO	70638	EFO:0005253	\N	postprandial hypotension	EFO:0005253
0	"Neurally mediated hypotension is a sudden drop in blood pressure while an individual stands up. It occurs when there is an abnormal reflex interaction between the heart and the brain, both of which usually are structurally normal" []	\N	neurally mediated hypotension	\N	\N	EFO	"Neurally mediated hypotension is a sudden drop in blood pressure while an individual stands up. It occurs when there is an abnormal reflex interaction between the heart and the brain, both of which usually are structurally normal" []	EFO	70639	EFO:0005254	\N	neurally mediated hypotension	EFO:0005254
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anthracycline-based chemotherapy stimulus." []	\N	response to anthracycline-based chemotherapy	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anthracycline-based chemotherapy stimulus." []	EFO	70640	EFO:0005257	\N	response to anthracycline-based chemotherapy	EFO:0005257
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antimicrotubule agent stimulus." []	\N	response to antimicrotubule agent	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antimicrotubule agent stimulus." []	EFO	70641	EFO:0005260	\N	response to antimicrotubule agent	EFO:0005260
0	"degenerative calcification of the mitral valve ring, often used as a marker of severe coronary artery disease " []	\N	mitral annular calcification	\N	\N	EFO	"degenerative calcification of the mitral valve ring, often used as a marker of severe coronary artery disease " []	EFO	70642	EFO:0005262	\N	mitral annular calcification	EFO:0005262
0	"TOV-112D is a human epithelial cell line initiated in October of 1992 from a patient with early onset ovarian cancer. The patient was of French-Canadian descent with an unknown family history of ovarian cancer." []	\N	TOV-112D	\N	\N	EFO	"TOV-112D is a human epithelial cell line initiated in October of 1992 from a patient with early onset ovarian cancer. The patient was of French-Canadian descent with an unknown family history of ovarian cancer." []	EFO	70643	EFO:0005263	\N	TOV-112D	EFO:0005263
0	"The ectocervical Ect1/E6E7 (ATCC CRL-2614) and endocervical End1/E6E7 (ATCC CRL-2615) cell lines were established in 1996 from normal epithelial tissue taken from a premenopausal woman undergoing hysterectomy for endometriosis." []	\N	Ect1	\N	\N	EFO	"The ectocervical Ect1/E6E7 (ATCC CRL-2614) and endocervical End1/E6E7 (ATCC CRL-2615) cell lines were established in 1996 from normal epithelial tissue taken from a premenopausal woman undergoing hysterectomy for endometriosis." []	EFO	70644	EFO:0005264	\N	Ect1	EFO:0005264
0	"MOLT-3 is a male human malignant T-lymphoblastic cell line." []	\N	MOLT-3	\N	\N	EFO	"MOLT-3 is a male human malignant T-lymphoblastic cell line." []	EFO	70645	EFO:0005265	\N	MOLT-3	EFO:0005265
0	"quantification of selenium in blood" []	\N	serum selenium measurement	\N	\N	EFO	"quantification of selenium in blood" []	EFO	70646	EFO:0005266	\N	serum selenium measurement	EFO:0005266
0	"quantification of copper in blood" []	\N	serum copper measurement	\N	\N	EFO	"quantification of copper in blood" []	EFO	70647	EFO:0005267	\N	serum copper measurement	EFO:0005267
0	"quantification of zinc in blood" []	\N	serum zinc measurement	\N	\N	EFO	"quantification of zinc in blood" []	EFO	70648	EFO:0005268	\N	serum zinc measurement	EFO:0005268
0	"any structural anomly of the heart that is present from birth" []	\N	congenital heart malformation	\N	\N	EFO	"any structural anomly of the heart that is present from birth" []	EFO	70649	EFO:0005269	\N	congenital heart malformation	EFO:0005269
0	"duration of sleep, measured either via a self-reporting questionnaire, interview or through obversation in a sleep lab" []	\N	sleep duration	\N	\N	EFO	"duration of sleep, measured either via a self-reporting questionnaire, interview or through obversation in a sleep lab" []	EFO	70650	EFO:0005271	\N	sleep duration	EFO:0005271
0	"self-reported quality of sleeping" []	\N	sleep quality	\N	\N	EFO	"self-reported quality of sleeping" []	EFO	70651	EFO:0005272	\N	sleep quality	EFO:0005272
0	"self-reported assessment of how difficult an individual is to wake" []	\N	sleep depth	\N	\N	EFO	"self-reported assessment of how difficult an individual is to wake" []	EFO	70652	EFO:0005273	\N	sleep depth	EFO:0005273
0	"measurement of the time at which sleep begins" []	\N	sleep time	\N	\N	EFO	"measurement of the time at which sleep begins" []	EFO	70653	EFO:0005274	\N	sleep time	EFO:0005274
0	"the quantification of dihydroxy docosatrienoic acid, a metabolite significantly associated with increased risk of heart failure" []	\N	dihydroxy docosatrienoic acid measurement	\N	\N	EFO	"the quantification of dihydroxy docosatrienoic acid, a metabolite significantly associated with increased risk of heart failure" []	EFO	70654	EFO:0005275	\N	dihydroxy docosatrienoic acid measurement	EFO:0005275
0	"the quantification of hydroxy-leucine, a metabolite significantly associated with increased risk of heart failure" []	\N	hydroxy-leucine measurement	\N	\N	EFO	"the quantification of hydroxy-leucine, a metabolite significantly associated with increased risk of heart failure" []	EFO	70655	EFO:0005276	\N	hydroxy-leucine measurement	EFO:0005276
0	"cardiovascular disease biomarkers, such as ST2 cardiac biomarker and C-reactive protein, are used as indicators for cardiovascular disease and as predictors for therapeutic responses" []	\N	cardiovascular disease biomarker measurement	\N	\N	EFO	"cardiovascular disease biomarkers, such as ST2 cardiac biomarker and C-reactive protein, are used as indicators for cardiovascular disease and as predictors for therapeutic responses" []	EFO	70656	EFO:0005278	\N	cardiovascular disease biomarker measurement	EFO:0005278
0	"A variety of conditions affecting the anatomic and functional characteristics of the temporomandibular joint. Factors contributing to the complexity of temporomandibular diseases are its relation to dentition and mastication and the symptomatic effects in other areas which account for referred pain to the joint and the difficulties in applying traditional diagnostic procedures to temporomandibular joint pathology where tissue is rarely obtained and x-rays are often inadequate or nonspecific. Common diseases are developmental abnormalities, trauma, subluxation, luxation, arthritis, and neoplasia." []	\N	temporomandibular joint disorder	\N	\N	EFO	"A variety of conditions affecting the anatomic and functional characteristics of the temporomandibular joint. Factors contributing to the complexity of temporomandibular diseases are its relation to dentition and mastication and the symptomatic effects in other areas which account for referred pain to the joint and the difficulties in applying traditional diagnostic procedures to temporomandibular joint pathology where tissue is rarely obtained and x-rays are often inadequate or nonspecific. Common diseases are developmental abnormalities, trauma, subluxation, luxation, arthritis, and neoplasia." []	EFO	70657	EFO:0005279	\N	temporomandibular joint disorder	EFO:0005279
0	"amount of time, usually recorded in minutes, between going to bed and falling asleep" []	\N	sleep latency	\N	\N	EFO	"amount of time, usually recorded in minutes, between going to bed and falling asleep" []	EFO	70658	EFO:0005280	\N	sleep latency	EFO:0005280
0	"Established from human bone marrow stromal cells transformed by HPV-16 E6/E7." []	\N	HS-5	\N	\N	EFO	"Established from human bone marrow stromal cells transformed by HPV-16 E6/E7." []	EFO	70659	EFO:0005282	\N	HS-5	EFO:0005282
0	"Established from human bone marrow stromal cells transformed by HPV-16 E6/E7." []	\N	HS-27A	\N	\N	EFO	"Established from human bone marrow stromal cells transformed by HPV-16 E6/E7." []	EFO	70660	EFO:0005283	\N	HS-27A	EFO:0005283
0	"Mouse lymphocytic leukemia established from the methylcholanthrene-induced tumor in a DBA strain mouse (subline 212, 8-month-old female) in 1949; the cells were propagated by heterotransplantation into DBA/2 mice; an in-vitro suspension culture was first reported in 1966; cells are used for cytotoxicity studies.[BTO:0000702]" []	\N	L-1210	\N	\N	EFO	"Mouse lymphocytic leukemia established from the methylcholanthrene-induced tumor in a DBA strain mouse (subline 212, 8-month-old female) in 1949; the cells were propagated by heterotransplantation into DBA/2 mice; an in-vitro suspension culture was first reported in 1966; cells are used for cytotoxicity studies.[BTO:0000702]" []	EFO	70661	EFO:0005284	\N	L-1210	EFO:0005284
0	"Murine B-lymphoma cell line. PMID: 14738152 [BTO:0001930]" []	\N	A20	\N	\N	EFO	"Murine B-lymphoma cell line. PMID: 14738152 [BTO:0001930]" []	EFO	70662	EFO:0005285	\N	A20	EFO:0005285
0	"Albino inbred mus musculus strain." []	\N	BALB/cAnN	\N	\N	EFO	"Albino inbred mus musculus strain." []	EFO	70663	EFO:0005286	\N	BALB/cAnN	EFO:0005286
0	"A malignant tumor in the reticulum connective tissue." []	\N	reticulum cell sarcoma	\N	\N	EFO	"A malignant tumor in the reticulum connective tissue." []	EFO	70664	EFO:0005287	\N	reticulum cell sarcoma	EFO:0005287
0	"Type of epithelial lung cancer arising from glandular origin." []	\N	non-small cell lung adenocarcinoma	\N	\N	EFO	"Type of epithelial lung cancer arising from glandular origin." []	EFO	70665	EFO:0005288	\N	non-small cell lung adenocarcinoma	EFO:0005288
0	"The mural granulosa cells form during antral folliculogenesis, process in which a single antral cavity is formed, separating two functionally distinct granulosa cell populations. The mural granulosa cells line the wall of the follicle and are critical for steroidogenesis and ovulation." []	\N	mural granulosa cell	\N	\N	EFO	"The mural granulosa cells form during antral folliculogenesis, process in which a single antral cavity is formed, separating two functionally distinct granulosa cell populations. The mural granulosa cells line the wall of the follicle and are critical for steroidogenesis and ovulation." []	EFO	70666	EFO:0005289	\N	mural granulosa cell	EFO:0005289
0	"" []	\N	Brown Norway	\N	\N	EFO	"" []	EFO	70667	EFO:0005290	\N	Brown Norway	EFO:0005290
0	"" []	\N	Dark agouti	\N	\N	EFO	"" []	EFO	70668	EFO:0005291	\N	Dark agouti	EFO:0005291
0	"" []	\N	lymphoblastoid cell line	\N	\N	EFO	"" []	EFO	70669	EFO:0005292	\N	lymphoblastoid cell line	EFO:0005292
0	"" []	\N	B-lymphoblast	\N	\N	EFO	"" []	EFO	70670	EFO:0005293	\N	B-lymphoblast	EFO:0005293
0	"" []	\N	chronic myelogenous leukemia cell line	\N	\N	EFO	"" []	EFO	70671	EFO:0005294	\N	chronic myelogenous leukemia cell line	EFO:0005294
0	"A type of `migraine` in which there is an aura characterized by focal neurological phenomena that usually proceed, but may accompany or occur in the absence of, the headache. The symptoms of an aura may include fully reversible visual, sensory, and speech symptoms but not motor weakness. Visual symptoms may include flickering lights, spots and lines and/or loss of vision and/or unilateral sensory symptoms such as paresthesias or numbness. At least one of the symptoms of an aura develops gradually over 5 or more minutes and/or different symptoms occur in succession." []	\N	migraine with aura	\N	\N	EFO	"A type of `migraine` in which there is an aura characterized by focal neurological phenomena that usually proceed, but may accompany or occur in the absence of, the headache. The symptoms of an aura may include fully reversible visual, sensory, and speech symptoms but not motor weakness. Visual symptoms may include flickering lights, spots and lines and/or loss of vision and/or unilateral sensory symptoms such as paresthesias or numbness. At least one of the symptoms of an aura develops gradually over 5 or more minutes and/or different symptoms occur in succession." []	EFO	70672	EFO:0005295	\N	migraine with aura	EFO:0005295
0	"Repeated headache attacks lasting 4-72 h fulfilling at least two of the following criteria: 1) unilateral location, 2) pulsating quality, 3) moderate or severe pain intensity, and 4) aggravation by or causing avoidance of routine physical activity such as climbing stairs. Headache attacks are commonly accompanied by nausea, vomiting, photophobia, or phonophobia. The definition of this term is based on the definition in the International Classification of Headache Disorders by the International Headache Society (pmid:15304572), which additionally stipulate that such headaches must have occurred at least five times and not other secondary cause must be apparent in order to make the diagnosis." []	\N	migraine without aura	\N	\N	EFO	"Repeated headache attacks lasting 4-72 h fulfilling at least two of the following criteria: 1) unilateral location, 2) pulsating quality, 3) moderate or severe pain intensity, and 4) aggravation by or causing avoidance of routine physical activity such as climbing stairs. Headache attacks are commonly accompanied by nausea, vomiting, photophobia, or phonophobia. The definition of this term is based on the definition in the International Classification of Headache Disorders by the International Headache Society (pmid:15304572), which additionally stipulate that such headaches must have occurred at least five times and not other secondary cause must be apparent in order to make the diagnosis." []	EFO	70673	EFO:0005296	\N	migraine without aura	EFO:0005296
0	"A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis." []	\N	Wegener's granulomatosis	\N	\N	EFO	"A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis." []	EFO	70674	EFO:0005297	\N	Wegener's granulomatosis	EFO:0005297
0	"quantification of allergic sensitization status, for example through measurement of allergen-specific IgE in the blood or skin reaction after puncture of skin through a droplet of allergen extract (skin prick test)" []	\N	allergic sensitization measurement	\N	\N	EFO	"quantification of allergic sensitization status, for example through measurement of allergen-specific IgE in the blood or skin reaction after puncture of skin through a droplet of allergen extract (skin prick test)" []	EFO	70675	EFO:0005298	\N	allergic sensitization measurement	EFO:0005298
0	"non-word reading is the complex cognitive process of decoding symbols in order to derive that they do not form meaningful words" []	\N	non-word reading	\N	\N	EFO	"non-word reading is the complex cognitive process of decoding symbols in order to derive that they do not form meaningful words" []	EFO	70676	EFO:0005299	\N	non-word reading	EFO:0005299
0	"word reading is the complex cognitive process of decoding symbols in order to construct or derive meaningful words" []	\N	word reading	\N	\N	EFO	"word reading is the complex cognitive process of decoding symbols in order to construct or derive meaningful words" []	EFO	70677	EFO:0005300	\N	word reading	EFO:0005300
0	"reading and spelling ability refers to the complex cognitive processes involved in assembling and decoding symbols in order to construct or derive words" []	\N	reading and spelling ability	\N	\N	EFO	"reading and spelling ability refers to the complex cognitive processes involved in assembling and decoding symbols in order to construct or derive words" []	EFO	70678	EFO:0005301	\N	reading and spelling ability	EFO:0005301
0	"ChIP-exo is a chromatin immunoprecipitation based method for mapping the locations at which a protein of interest (transcription factor) binds to the genome. It is a modification of the ChIP-seq protocol, improving the resolution of binding sites from hundreds of base pairs to less than one base pair." []	\N	ChIP-exo	\N	\N	EFO	"ChIP-exo is a chromatin immunoprecipitation based method for mapping the locations at which a protein of interest (transcription factor) binds to the genome. It is a modification of the ChIP-seq protocol, improving the resolution of binding sites from hundreds of base pairs to less than one base pair." []	EFO	70679	EFO:0005302	\N	ChIP-exo	EFO:0005302
0	"Unexpected death in infancy which remains unexplained following autopsy, review of the medical history, and investigation of the death circumstances and death scene." []	\N	sudden infant death syndrome	\N	\N	EFO	"Unexpected death in infancy which remains unexplained following autopsy, review of the medical history, and investigation of the death circumstances and death scene." []	EFO	70680	EFO:0005303	\N	sudden infant death syndrome	EFO:0005303
0	"atrial conduction disorder is a form of heart disease in which the conduction of the cardiac atrium is disrupted" []	\N	atrial conduction disease	\N	\N	EFO	"atrial conduction disorder is a form of heart disease in which the conduction of the cardiac atrium is disrupted" []	EFO	70681	EFO:0005304	\N	atrial conduction disease	EFO:0005304
0	"atrioventricular node disease is a form of heart disease in which the conduction of the atrioventricular nodes is disrupted" []	\N	atrioventricular node disease	\N	\N	EFO	"atrioventricular node disease is a form of heart disease in which the conduction of the atrioventricular nodes is disrupted" []	EFO	70682	EFO:0005305	\N	atrioventricular node disease	EFO:0005305
0	"A disorder characterized by an electrocardiographic finding of three or more consecutive complexes of ventricular origin with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)" []	\N	ventricular tachycardia	\N	\N	EFO	"A disorder characterized by an electrocardiographic finding of three or more consecutive complexes of ventricular origin with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)" []	EFO	70683	EFO:0005306	\N	ventricular tachycardia	EFO:0005306
0	"A type of ventricular tachycardia characterized by polymorphioc QRS complexes that change in amplitue and cycle length, and thus have the appearance of oscillating around the baseline in the EKG." []	\N	torsades de pointes	\N	\N	EFO	"A type of ventricular tachycardia characterized by polymorphioc QRS complexes that change in amplitue and cycle length, and thus have the appearance of oscillating around the baseline in the EKG." []	EFO	70684	EFO:0005307	\N	torsades de pointes	EFO:0005307
0	"A disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate between 101 and 240 beats per minute. The P wave morphology must be distinct from the sinus P wave morphology. (CDISC)" []	\N	atrial tachycardia	\N	\N	EFO	"A disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate between 101 and 240 beats per minute. The P wave morphology must be distinct from the sinus P wave morphology. (CDISC)" []	EFO	70685	EFO:0005308	\N	atrial tachycardia	EFO:0005308
0	"Ta stage is a bladder carcinoma stage characterised by non-invasive papillary carcinoma, sometimes called superficial bladder carcinoma. These are early stage cancers that are found only in the lining of the innermost layer of bladder and are considered one of the more treatable forms of bladder cancer." []	\N	Ta stage	\N	\N	EFO	"Ta stage is a bladder carcinoma stage characterised by non-invasive papillary carcinoma, sometimes called superficial bladder carcinoma. These are early stage cancers that are found only in the lining of the innermost layer of bladder and are considered one of the more treatable forms of bladder cancer." []	EFO	70686	EFO:0005309	\N	Ta stage	EFO:0005309
0	"A method used for finding which RNA species interact with a particular RNA-binding protein. It involves immunoprecipitation with antibodies for the protein and then isolation of the RNAs associated with the protein. Unlike CLIP-seq, no cross-linking of RNAs and proteins is carried out prior to immunoprecipitation." []	\N	RIP-seq	\N	\N	EFO	"A method used for finding which RNA species interact with a particular RNA-binding protein. It involves immunoprecipitation with antibodies for the protein and then isolation of the RNAs associated with the protein. Unlike CLIP-seq, no cross-linking of RNAs and proteins is carried out prior to immunoprecipitation." []	EFO	70687	EFO:0005310	\N	RIP-seq	EFO:0005310
0	"" []	\N	picomole per microliter	\N	\N	EFO	"" []	EFO	70688	EFO:0005313	\N	picomole per microliter	EFO:0005313
0	"" []	\N	femtomole per nanogram	\N	\N	EFO	"" []	EFO	70689	EFO:0005314	\N	femtomole per nanogram	EFO:0005314
0	"A genetic transformation that the modification of the genetic material (either coding or non-coding) of an organism is caused by mutagenic compounds or irradiation" []	\N	induced mutation	\N	\N	EFO	"A genetic transformation that the modification of the genetic material (either coding or non-coding) of an organism is caused by mutagenic compounds or irradiation" []	EFO	70690	EFO:0005315	\N	induced mutation	EFO:0005315
0	"Physical combination of several instances of like material, eg RNA extracted from samples or dishes of cell cultures into one big aliquot of cells." []	\N	sample pooling	\N	\N	EFO	"Physical combination of several instances of like material, eg RNA extracted from samples or dishes of cell cultures into one big aliquot of cells." []	EFO	70691	EFO:0005316	\N	sample pooling	EFO:0005316
0	"quantification of the distance between the anterior surface of the cornea and the fovea, usually measured by A-scan ultrasonography or optical coherence biometry" []	\N	axial length measurement	\N	\N	EFO	"quantification of the distance between the anterior surface of the cornea and the fovea, usually measured by A-scan ultrasonography or optical coherence biometry" []	EFO	70692	EFO:0005318	\N	axial length measurement	EFO:0005318
0	"a type of skin inflammation (dermatitis) that results from exposure to allergens (allergic contact dermatitis) or irritants (irritant contact dermatitis)" []	\N	contact dermatitis	\N	\N	EFO	"a type of skin inflammation (dermatitis) that results from exposure to allergens (allergic contact dermatitis) or irritants (irritant contact dermatitis)" []	EFO	70693	EFO:0005319	\N	contact dermatitis	EFO:0005319
0	"a form of allergic contact dermatitis that results from exposure to nickel" []	\N	contact dermatitis due to nickel	\N	\N	EFO	"a form of allergic contact dermatitis that results from exposure to nickel" []	EFO	70694	EFO:0005320	\N	contact dermatitis due to nickel	EFO:0005320
0	"a hypomineralisation of systemic origin of one to four permanent first molars frequently associated with affected incisors" []	\N	molar-incisor hypomineralization	\N	\N	EFO	"a hypomineralisation of systemic origin of one to four permanent first molars frequently associated with affected incisors" []	EFO	70695	EFO:0005321	\N	molar-incisor hypomineralization	EFO:0005321
0	"bavioural manifestation including low levels of empathy, absence of guilt and emotional unresponsiveness" []	\N	callous-unemotional behaviour	\N	\N	EFO	"bavioural manifestation including low levels of empathy, absence of guilt and emotional unresponsiveness" []	EFO	70696	EFO:0005322	\N	callous-unemotional behaviour	EFO:0005322
0	"clinical manifestation that occurs as a result of a surgical intervention" []	\N	post-operative sign or symptom	\N	\N	EFO	"clinical manifestation that occurs as a result of a surgical intervention" []	EFO	70697	EFO:0005323	\N	post-operative sign or symptom	EFO:0005323
0	"sensory disturbance, such as hypoesthesia or dysesthesia, that occurs as a result of a surgical intervention, possibly but not necessarily due to a nerve injury" []	\N	post-operative sensory disturbance	\N	\N	EFO	"sensory disturbance, such as hypoesthesia or dysesthesia, that occurs as a result of a surgical intervention, possibly but not necessarily due to a nerve injury" []	EFO	70698	EFO:0005324	\N	post-operative sensory disturbance	EFO:0005324
0	"" []	\N	response to angiotensin-converting enzyme inhibitor	\N	\N	EFO	"" []	EFO	70699	EFO:0005325	\N	response to angiotensin-converting enzyme inhibitor	EFO:0005325
0	"" []	\N	GM18505	\N	\N	EFO	"" []	EFO	70700	EFO:0005332	\N	GM18505	EFO:0005332
0	"" []	\N	GM08714	\N	\N	EFO	"" []	EFO	70701	EFO:0005333	\N	GM08714	EFO:0005333
0	"" []	\N	GM10248	\N	\N	EFO	"" []	EFO	70702	EFO:0005334	\N	GM10248	EFO:0005334
0	"" []	\N	GM10266	\N	\N	EFO	"" []	EFO	70703	EFO:0005335	\N	GM10266	EFO:0005335
0	"" []	\N	GM10847	\N	\N	EFO	"" []	EFO	70704	EFO:0005336	\N	GM10847	EFO:0005336
0	"" []	\N	GM12864	\N	\N	EFO	"" []	EFO	70705	EFO:0005337	\N	GM12864	EFO:0005337
0	"" []	\N	GM12865	\N	\N	EFO	"" []	EFO	70706	EFO:0005338	\N	GM12865	EFO:0005338
0	"" []	\N	GM12866	\N	\N	EFO	"" []	EFO	70707	EFO:0005339	\N	GM12866	EFO:0005339
0	"" []	\N	GM12867	\N	\N	EFO	"" []	EFO	70708	EFO:0005340	\N	GM12867	EFO:0005340
0	"" []	\N	GM12868	\N	\N	EFO	"" []	EFO	70709	EFO:0005341	\N	GM12868	EFO:0005341
0	"" []	\N	GM12869	\N	\N	EFO	"" []	EFO	70710	EFO:0005342	\N	GM12869	EFO:0005342
0	"" []	\N	GM12870	\N	\N	EFO	"" []	EFO	70711	EFO:0005343	\N	GM12870	EFO:0005343
0	"" []	\N	GM12871	\N	\N	EFO	"" []	EFO	70712	EFO:0005344	\N	GM12871	EFO:0005344
0	"" []	\N	GM13976	\N	\N	EFO	"" []	EFO	70713	EFO:0005345	\N	GM13976	EFO:0005345
0	"" []	\N	GM13977	\N	\N	EFO	"" []	EFO	70714	EFO:0005346	\N	GM13977	EFO:0005346
0	"" []	\N	GM15510	\N	\N	EFO	"" []	EFO	70715	EFO:0005347	\N	GM15510	EFO:0005347
0	"" []	\N	GM18526	\N	\N	EFO	"" []	EFO	70716	EFO:0005348	\N	GM18526	EFO:0005348
0	"" []	\N	GM18951	\N	\N	EFO	"" []	EFO	70717	EFO:0005349	\N	GM18951	EFO:0005349
0	"" []	\N	GM19099	\N	\N	EFO	"" []	EFO	70718	EFO:0005350	\N	GM19099	EFO:0005350
0	"" []	\N	GM19193	\N	\N	EFO	"" []	EFO	70719	EFO:0005351	\N	GM19193	EFO:0005351
0	"" []	\N	GM20000	\N	\N	EFO	"" []	EFO	70720	EFO:0005352	\N	GM20000	EFO:0005352
0	"" []	\N	GM12801	\N	\N	EFO	"" []	EFO	70721	EFO:0005353	\N	GM12801	EFO:0005353
0	"" []	\N	milligram per kilogram body weight	\N	\N	EFO	"" []	EFO	70722	EFO:0005354	\N	milligram per kilogram body weight	EFO:0005354
0	"A human embryonic stem cell line" []	\N	HUES1	\N	\N	EFO	"A human embryonic stem cell line" []	EFO	70723	EFO:0005355	\N	HUES1	EFO:0005355
0	"" []	\N	CAL120	\N	\N	EFO	"" []	EFO	70724	EFO:0005356	\N	CAL120	EFO:0005356
0	"" []	\N	CAL148	\N	\N	EFO	"" []	EFO	70725	EFO:0005357	\N	CAL148	EFO:0005357
0	"" []	\N	CAL51	\N	\N	EFO	"" []	EFO	70726	EFO:0005358	\N	CAL51	EFO:0005358
0	"" []	\N	CAL851	\N	\N	EFO	"" []	EFO	70727	EFO:0005359	\N	CAL851	EFO:0005359
0	"" []	\N	CCD-11Lu	\N	\N	EFO	"" []	EFO	70728	EFO:0005360	\N	CCD-11Lu	EFO:0005360
0	"" []	\N	CCD-13Lu	\N	\N	EFO	"" []	EFO	70729	EFO:0005361	\N	CCD-13Lu	EFO:0005361
0	"" []	\N	CCD-16Lu	\N	\N	EFO	"" []	EFO	70730	EFO:0005362	\N	CCD-16Lu	EFO:0005362
0	"" []	\N	CCD-19Lu	\N	\N	EFO	"" []	EFO	70731	EFO:0005363	\N	CCD-19Lu	EFO:0005363
0	"" []	\N	CCD-25Lu	\N	\N	EFO	"" []	EFO	70732	EFO:0005364	\N	CCD-25Lu	EFO:0005364
0	"" []	\N	CCD-29Lu	\N	\N	EFO	"" []	EFO	70733	EFO:0005365	\N	CCD-29Lu	EFO:0005365
0	"" []	\N	CCD-33Lu	\N	\N	EFO	"" []	EFO	70734	EFO:0005366	\N	CCD-33Lu	EFO:0005366
0	"" []	\N	CCD-8Lu	\N	\N	EFO	"" []	EFO	70735	EFO:0005367	\N	CCD-8Lu	EFO:0005367
0	"" []	\N	HFL1	\N	\N	EFO	"" []	EFO	70736	EFO:0005368	\N	HFL1	EFO:0005368
0	"" []	\N	Granta-519	\N	\N	EFO	"" []	EFO	70737	EFO:0005369	\N	Granta-519	EFO:0005369
0	"" []	\N	HCC2998	\N	\N	EFO	"" []	EFO	70738	EFO:0005370	\N	HCC2998	EFO:0005370
0	"" []	\N	HCC1195	\N	\N	EFO	"" []	EFO	70739	EFO:0005371	\N	HCC1195	EFO:0005371
0	"" []	\N	HCC1419	\N	\N	EFO	"" []	EFO	70740	EFO:0005372	\N	HCC1419	EFO:0005372
0	"" []	\N	HCC1806	\N	\N	EFO	"" []	EFO	70741	EFO:0005373	\N	HCC1806	EFO:0005373
0	"" []	\N	HCC227	\N	\N	EFO	"" []	EFO	70742	EFO:0005374	\N	HCC227	EFO:0005374
0	"" []	\N	HCC2935	\N	\N	EFO	"" []	EFO	70743	EFO:0005375	\N	HCC2935	EFO:0005375
0	"" []	\N	UACC-257	\N	\N	EFO	"" []	EFO	70744	EFO:0005376	\N	UACC-257	EFO:0005376
0	"" []	\N	UACC-62	\N	\N	EFO	"" []	EFO	70745	EFO:0005377	\N	UACC-62	EFO:0005377
0	"" []	\N	HepG3	\N	\N	EFO	"" []	EFO	70746	EFO:0005382	\N	HepG3	EFO:0005382
0	"" []	\N	HMEC1	\N	\N	EFO	"" []	EFO	70747	EFO:0005383	\N	HMEC1	EFO:0005383
0	"HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers." []	\N	HuH-7	\N	\N	EFO	"HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers." []	EFO	70748	EFO:0005384	\N	HuH-7	EFO:0005384
0	"" []	\N	IGROV-1	\N	\N	EFO	"" []	EFO	70749	EFO:0005385	\N	IGROV-1	EFO:0005385
0	"" []	\N	INA-6	\N	\N	EFO	"" []	EFO	70750	EFO:0005386	\N	INA-6	EFO:0005386
0	"" []	\N	JeKo-1	\N	\N	EFO	"" []	EFO	70751	EFO:0005387	\N	JeKo-1	EFO:0005387
0	"" []	\N	JIMT-1	\N	\N	EFO	"" []	EFO	70752	EFO:0005388	\N	JIMT-1	EFO:0005388
0	"" []	\N	KARPAS 231	\N	\N	EFO	"" []	EFO	70753	EFO:0005389	\N	KARPAS 231	EFO:0005389
0	"" []	\N	KARPAS 299	\N	\N	EFO	"" []	EFO	70754	EFO:0005390	\N	KARPAS 299	EFO:0005390
0	"" []	\N	LA-N-1	\N	\N	EFO	"" []	EFO	70755	EFO:0005391	\N	LA-N-1	EFO:0005391
0	"" []	\N	LAPC-4	\N	\N	EFO	"" []	EFO	70756	EFO:0005392	\N	LAPC-4	EFO:0005392
0	"" []	\N	LAPC-9	\N	\N	EFO	"" []	EFO	70757	EFO:0005393	\N	LAPC-9	EFO:0005393
0	"" []	\N	MLO-Y4	\N	\N	EFO	"" []	EFO	70758	EFO:0005394	\N	MLO-Y4	EFO:0005394
0	"" []	\N	MUTZ-3	\N	\N	EFO	"" []	EFO	70759	EFO:0005395	\N	MUTZ-3	EFO:0005395
0	"Transcription profiling sequencing process in which targeted exome regions of the genome are sequenced." []	\N	exome sequencing	\N	\N	EFO	"Transcription profiling sequencing process in which targeted exome regions of the genome are sequenced." []	EFO	70760	EFO:0005396	\N	exome sequencing	EFO:0005396
0	"An image analysis technique combining automated microscopy, robotic handling, and quantitative image analysis for the large scale study of cells." []	\N	high content analysis of cells	\N	\N	EFO	"An image analysis technique combining automated microscopy, robotic handling, and quantitative image analysis for the large scale study of cells." []	EFO	70761	EFO:0005397	\N	high content analysis of cells	EFO:0005397
0	"An image analysis technique to characterise the molecular content of cells by combining automated microscopy, robotic handling, and quantitative image analysis." []	\N	high content analysis of cells by molecular content	\N	\N	EFO	"An image analysis technique to characterise the molecular content of cells by combining automated microscopy, robotic handling, and quantitative image analysis." []	EFO	70762	EFO:0005398	\N	high content analysis of cells by molecular content	EFO:0005398
0	"An image analysis technique to characterise the morphological and physical  properties of cells by combining automated microscopy, robotic handling, and quantitative image analysis." []	\N	high content analysis of cells by morphological and physical properties	\N	\N	EFO	"An image analysis technique to characterise the morphological and physical  properties of cells by combining automated microscopy, robotic handling, and quantitative image analysis." []	EFO	70763	EFO:0005399	\N	high content analysis of cells by morphological and physical properties	EFO:0005399
0	"hair loss as a result of chemotherapy treatment" []	\N	chemotherapy-induced alopecia	\N	\N	EFO	"hair loss as a result of chemotherapy treatment" []	EFO	70764	EFO:0005400	\N	chemotherapy-induced alopecia	EFO:0005400
0	"physiological response of an organism, eg in terms of blood pressure, to being fed a diet high in sodium" []	\N	response to high sodium diet	\N	\N	EFO	"physiological response of an organism, eg in terms of blood pressure, to being fed a diet high in sodium" []	EFO	70765	EFO:0005401	\N	response to high sodium diet	EFO:0005401
0	"physiological response of an organism, eg in terms of blood pressure, to being fed a diet low in sodium" []	\N	response to low sodium diet	\N	\N	EFO	"physiological response of an organism, eg in terms of blood pressure, to being fed a diet low in sodium" []	EFO	70766	EFO:0005402	\N	response to low sodium diet	EFO:0005402
0	"physiological response of an organism to being given potassium as a dietary supplement" []	\N	response to dietary potassium supplementation	\N	\N	EFO	"physiological response of an organism to being given potassium as a dietary supplement" []	EFO	70767	EFO:0005403	\N	response to dietary potassium supplementation	EFO:0005403
0	"physiological response, in terms of blood pressure, heart rate or pain, to a cardiovascular test performed by immersing the hand into ice water, usually for one minute " []	\N	response to cold pressor test	\N	\N	EFO	"physiological response, in terms of blood pressure, heart rate or pain, to a cardiovascular test performed by immersing the hand into ice water, usually for one minute " []	EFO	70768	EFO:0005404	\N	response to cold pressor test	EFO:0005404
0	"" []	\N	response to antihypertensive drug	\N	\N	EFO	"" []	EFO	70769	EFO:0005405	\N	response to antihypertensive drug	EFO:0005405
0	"An adenoma that arises from the colon or rectum. The group of colorectal adenomas includes tubular, villous, and tubulovillous adenomas, traditional serrated adenomas, sessile serrated adenomas/polyps, and familial adenomatous polyposis." []	\N	colorectal adenoma	\N	\N	EFO	"An adenoma that arises from the colon or rectum. The group of colorectal adenomas includes tubular, villous, and tubulovillous adenomas, traditional serrated adenomas, sessile serrated adenomas/polyps, and familial adenomatous polyposis." []	EFO	70770	EFO:0005406	\N	colorectal adenoma	EFO:0005406
0	"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor." []	\N	psychosis	\N	\N	EFO	"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor." []	EFO	70771	EFO:0005407	\N	psychosis	EFO:0005407
0	"the quantification of pyroglutamine, a metabolite significantly associated with increased risk of heart failure" []	\N	pyroglutamine measurement	\N	\N	EFO	"the quantification of pyroglutamine, a metabolite significantly associated with increased risk of heart failure" []	EFO	70772	EFO:0005408	\N	pyroglutamine measurement	EFO:0005408
0	"The weight of the individual's body fat." []	\N	fat body mass	\N	\N	EFO	"The weight of the individual's body fat." []	EFO	70773	EFO:0005409	\N	fat body mass	EFO:0005409
0	"Failure of some or all of an individual's teeth to develop.It occurs most often in the third molar (wisdom tooth)." []	\N	tooth agenesis	\N	\N	EFO	"Failure of some or all of an individual's teeth to develop.It occurs most often in the third molar (wisdom tooth)." []	EFO	70774	EFO:0005410	\N	tooth agenesis	EFO:0005410
0	"A disorder in which the individual suffers from both symptoms that qualify as schizophrenia and symptoms that qualify as a mood disorder (e.g., depression or bipolar disorder) for a substantial portion (but not all) of the active period of the illness; for the remainder of the active period of the illness, the individual suffers from delusions or hallucinations in the absence of prominent mood symptoms." []	\N	schizoaffective disorder	\N	\N	EFO	"A disorder in which the individual suffers from both symptoms that qualify as schizophrenia and symptoms that qualify as a mood disorder (e.g., depression or bipolar disorder) for a substantial portion (but not all) of the active period of the illness; for the remainder of the active period of the illness, the individual suffers from delusions or hallucinations in the absence of prominent mood symptoms." []	EFO	70775	EFO:0005411	\N	schizoaffective disorder	EFO:0005411
0	"quantification of the effect of persistent interference in daily life activities and role performance by psychiatric conditions or related symptoms, usually established through a combination of medical assessments and questionnaires " []	\N	functional impairment measurement	\N	\N	EFO	"quantification of the effect of persistent interference in daily life activities and role performance by psychiatric conditions or related symptoms, usually established through a combination of medical assessments and questionnaires " []	EFO	70776	EFO:0005412	\N	functional impairment measurement	EFO:0005412
0	"quantification of the level of joint damage, eg through radiological analysis" []	\N	joint damage measurement	\N	\N	EFO	"quantification of the level of joint damage, eg through radiological analysis" []	EFO	70777	EFO:0005413	\N	joint damage measurement	EFO:0005413
0	"one of the primary characteristics of asthma, characterised by easily triggered increased airway smooth muscle contractility" []	\N	airway hyperresponsiveness	\N	\N	EFO	"one of the primary characteristics of asthma, characterised by easily triggered increased airway smooth muscle contractility" []	EFO	70778	EFO:0005414	\N	airway hyperresponsiveness	EFO:0005414
0	"quantification of the protease inhibitor alpha-1-antitrypsin in the blood" []	\N	serum alpha-1-antitrypsin measurement	\N	\N	EFO	"quantification of the protease inhibitor alpha-1-antitrypsin in the blood" []	EFO	70779	EFO:0005415	\N	serum alpha-1-antitrypsin measurement	EFO:0005415
0	"A soluble ST2 measurement is the quantification of the ST2 protein. ST2 levels are associated with adverse cardiovascular events." []	\N	serum ST2 measurement	\N	\N	EFO	"A soluble ST2 measurement is the quantification of the ST2 protein. ST2 levels are associated with adverse cardiovascular events." []	EFO	70780	EFO:0005416	\N	serum ST2 measurement	EFO:0005416
0	"response to treatment with an inhibitor of mTOR (mammalian Target Of Rapamycin), such as everolimus or rapamycin" []	\N	response to mTOR inhibitor	\N	\N	EFO	"response to treatment with an inhibitor of mTOR (mammalian Target Of Rapamycin), such as everolimus or rapamycin" []	EFO	70781	EFO:0005417	\N	response to mTOR inhibitor	EFO:0005417
0	"quantification of symmetric or asymmetric dimethylarginine in the blood" []	\N	serum dimethylarginine measurement	\N	\N	EFO	"quantification of symmetric or asymmetric dimethylarginine in the blood" []	EFO	70782	EFO:0005418	\N	serum dimethylarginine measurement	EFO:0005418
0	"quantificiation of ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease." []	\N	contrast sensitivity measurement	\N	\N	EFO	"quantificiation of ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease." []	EFO	70783	EFO:0005419	\N	contrast sensitivity measurement	EFO:0005419
0	"quantification of the volume of grey matter in the brain, usuallly through an MRI scan" []	\N	grey matter volume measurement	\N	\N	EFO	"quantification of the volume of grey matter in the brain, usuallly through an MRI scan" []	EFO	70784	EFO:0005420	\N	grey matter volume measurement	EFO:0005420
0	"quantification of the amino acid derivate homoarginine in the blood" []	\N	serum homoarginine measurement	\N	\N	EFO	"quantification of the amino acid derivate homoarginine in the blood" []	EFO	70785	EFO:0005421	\N	serum homoarginine measurement	EFO:0005421
0	"" []	\N	skin aging	\N	\N	EFO	"" []	EFO	70786	EFO:0005422	\N	skin aging	EFO:0005422
0	"" []	\N	adolescent idiopathic scoliosis	\N	\N	EFO	"" []	EFO	70787	EFO:0005423	\N	adolescent idiopathic scoliosis	EFO:0005423
0	"" []	\N	dyslexia	\N	\N	EFO	"" []	EFO	70788	EFO:0005424	\N	dyslexia	EFO:0005424
0	"" []	\N	language impairment	\N	\N	EFO	"" []	EFO	70789	EFO:0005425	\N	language impairment	EFO:0005425
0	"" []	\N	autism spectrum disorder symptom	\N	\N	EFO	"" []	EFO	70790	EFO:0005426	\N	autism spectrum disorder symptom	EFO:0005426
0	"" []	\N	social communication impairment	\N	\N	EFO	"" []	EFO	70791	EFO:0005427	\N	social communication impairment	EFO:0005427
0	"" []	\N	borderline personality disorder symptom	\N	\N	EFO	"" []	EFO	70792	EFO:0005429	\N	borderline personality disorder symptom	EFO:0005429
0	"" []	\N	nicotine use	\N	\N	EFO	"" []	EFO	70793	EFO:0005430	\N	nicotine use	EFO:0005430
0	"" []	\N	illegal drug consumption	\N	\N	EFO	"" []	EFO	70794	EFO:0005431	\N	illegal drug consumption	EFO:0005431
0	"" []	\N	non-substance related disinhibited behaviour	\N	\N	EFO	"" []	EFO	70795	EFO:0005432	\N	non-substance related disinhibited behaviour	EFO:0005432
0	"An array design in which a reporter on an array associated with a BioSequence that has a context dependent predicted signal. e.g. a yeast reporter on a human array, is a control biosequence expected to be of low signal if no spikes are used. If spikes are used, the signal is expected to be high." []	\N	array control biosequence\\n	\N	\N	EFO	"An array design in which a reporter on an array associated with a BioSequence that has a context dependent predicted signal. e.g. a yeast reporter on a human array, is a control biosequence expected to be of low signal if no spikes are used. If spikes are used, the signal is expected to be high." []	EFO	70796	EFO:0005433	\N	array control biosequence\\n	EFO:0005433
0	"An array design in which an array contains a reporter where only buffer was deposited on the array, acting as a control." []	\N	array control buffer	\N	\N	EFO	"An array design in which an array contains a reporter where only buffer was deposited on the array, acting as a control." []	EFO	70797	EFO:0005434	\N	array control buffer	EFO:0005434
0	"An array design in which a reporter on an array has no material or buffer was deposited on the array." []	\N	array control empty	\N	\N	EFO	"An array design in which a reporter on an array has no material or buffer was deposited on the array." []	EFO	70798	EFO:0005435	\N	array control empty	EFO:0005435
0	"An array design in which a reporter has genomic DNA deposited on it; the genomic DNA may be fragmented, e.g. salmon sperm DNA, Cot1DNA." []	\N	array control genomic DNA	\N	\N	EFO	"An array design in which a reporter has genomic DNA deposited on it; the genomic DNA may be fragmented, e.g. salmon sperm DNA, Cot1DNA." []	EFO	70799	EFO:0005436	\N	array control genomic DNA	EFO:0005436
0	"An array design in which a reporter is included that could be used to determine the quality and general performance of the labeled extract. An example is a pool of BioSequences representing widely-expressed genes (i.e., housekeeping genes)." []	\N	array control hybridization quality	\N	\N	EFO	"An array design in which a reporter is included that could be used to determine the quality and general performance of the labeled extract. An example is a pool of BioSequences representing widely-expressed genes (i.e., housekeeping genes)." []	EFO	70800	EFO:0005437	\N	array control hybridization quality	EFO:0005437
0	"An array design in which a reporter is used as a control where some label has been deposited. This includes fluor and radioactively labeled oligos and fluors alone." []	\N	array control label	\N	\N	EFO	"An array design in which a reporter is used as a control where some label has been deposited. This includes fluor and radioactively labeled oligos and fluors alone." []	EFO	70801	EFO:0005438	\N	array control label	EFO:0005438
0	"An array design in which a Reporter is included on an array of whose BioSequence is of known length used as a methodological control for hybridization efficiency.\\n" []	\N	array control reporter size	\N	\N	EFO	"An array design in which a Reporter is included on an array of whose BioSequence is of known length used as a methodological control for hybridization efficiency.\\n" []	EFO	70802	EFO:0005439	\N	array control reporter size	EFO:0005439
0	"An array design in which a reporter is used a control for reasons such as quality or result verifcation. " []	\N	array control design	\N	\N	EFO	"An array design in which a reporter is used a control for reasons such as quality or result verifcation. " []	EFO	70803	EFO:0005440	\N	array control design	EFO:0005440
0	"" []	\N	DU 145	\N	\N	EFO	"" []	EFO	70804	EFO:0005441	\N	DU 145	EFO:0005441
0	"" []	\N	OVCAR4	\N	\N	EFO	"" []	EFO	70805	EFO:0005442	\N	OVCAR4	EFO:0005442
0	"" []	\N	OVCAR5	\N	\N	EFO	"" []	EFO	70806	EFO:0005443	\N	OVCAR5	EFO:0005443
0	"" []	\N	OVCAR8	\N	\N	EFO	"" []	EFO	70807	EFO:0005444	\N	OVCAR8	EFO:0005444
0	"" []	\N	PEO1	\N	\N	EFO	"" []	EFO	70808	EFO:0005445	\N	PEO1	EFO:0005445
0	"" []	\N	PEO14	\N	\N	EFO	"" []	EFO	70809	EFO:0005446	\N	PEO14	EFO:0005446
0	"" []	\N	PEO23	\N	\N	EFO	"" []	EFO	70810	EFO:0005447	\N	PEO23	EFO:0005447
0	"" []	\N	PEO4	\N	\N	EFO	"" []	EFO	70811	EFO:0005448	\N	PEO4	EFO:0005448
0	"" []	\N	PEO6	\N	\N	EFO	"" []	EFO	70812	EFO:0005449	\N	PEO6	EFO:0005449
0	"" []	\N	SF126	\N	\N	EFO	"" []	EFO	70813	EFO:0005450	\N	SF126	EFO:0005450
0	"" []	\N	SF268	\N	\N	EFO	"" []	EFO	70814	EFO:0005451	\N	SF268	EFO:0005451
0	"" []	\N	SF295	\N	\N	EFO	"" []	EFO	70815	EFO:0005452	\N	SF295	EFO:0005452
0	"" []	\N	SF539	\N	\N	EFO	"" []	EFO	70816	EFO:0005453	\N	SF539	EFO:0005453
0	"" []	\N	SHEF-1	\N	\N	EFO	"" []	EFO	70817	EFO:0005454	\N	SHEF-1	EFO:0005454
0	"" []	\N	SHEF-3	\N	\N	EFO	"" []	EFO	70818	EFO:0005455	\N	SHEF-3	EFO:0005455
0	"" []	\N	SHEP-2	\N	\N	EFO	"" []	EFO	70819	EFO:0005456	\N	SHEP-2	EFO:0005456
0	"" []	\N	SK-MM-1	\N	\N	EFO	"" []	EFO	70820	EFO:0005457	\N	SK-MM-1	EFO:0005457
0	"" []	\N	SK-MM-2	\N	\N	EFO	"" []	EFO	70821	EFO:0005458	\N	SK-MM-2	EFO:0005458
0	"" []	\N	SKI-DCLC	\N	\N	EFO	"" []	EFO	70822	EFO:0005460	\N	SKI-DCLC	EFO:0005460
0	"" []	\N	SUDHL1	\N	\N	EFO	"" []	EFO	70823	EFO:0005461	\N	SUDHL1	EFO:0005461
0	"" []	\N	SW527	\N	\N	EFO	"" []	EFO	70824	EFO:0005462	\N	SW527	EFO:0005462
0	"" []	\N	BL-2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"" []	EFO	70825	EFO:0005475	\N	BL-2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005475
0	"" []	\N	JVM-2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"" []	EFO	70826	EFO:0005476	\N	JVM-2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005476
0	"" []	\N	U-266 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"" []	EFO	70827	EFO:0005478	\N	U-266 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005478
0	"" []	\N	Z-138 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"" []	EFO	70828	EFO:0005479	\N	Z-138 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005479
0	"This is a mouse suspension cell line derived from MEL cells by stable transfection with a GATA-1-ER fusion protein construct as described by Choe et al., 2003 (Cancer Res 63, 6363–6369, 2003).  These cells can be terminally differentiated into mature erythroid cells with β-estradiol treatment, while GATA-1 alone can induce MEL cells to differentiate and to lose their tumorigenic properties. [PMID: 14559825]" []	\N	MEL-GATA-1-ER {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"This is a mouse suspension cell line derived from MEL cells by stable transfection with a GATA-1-ER fusion protein construct as described by Choe et al., 2003 (Cancer Res 63, 6363–6369, 2003).  These cells can be terminally differentiated into mature erythroid cells with β-estradiol treatment, while GATA-1 alone can induce MEL cells to differentiate and to lose their tumorigenic properties. [PMID: 14559825]" []	EFO	70829	EFO:0005480	\N	MEL-GATA-1-ER {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005480
0	"Mouse Embryonic Kidney Fibroblast.  As described in Lingenfelter et al., 1998 (Nat Genet. 1998 18:212-3) and Yang et al., 2010 (Genome Res. 2010 20:614-22), PATSKI is a female interspecific mouse fibroblast that was derived from the embryonic kidney of an M.spretus x C57BL/6J hybrid mouse such that the C57Bl/6J X chromosome (maternal) is always the inactive X. This is an adherent cell line." []	\N	Patski {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"Mouse Embryonic Kidney Fibroblast.  As described in Lingenfelter et al., 1998 (Nat Genet. 1998 18:212-3) and Yang et al., 2010 (Genome Res. 2010 20:614-22), PATSKI is a female interspecific mouse fibroblast that was derived from the embryonic kidney of an M.spretus x C57BL/6J hybrid mouse such that the C57Bl/6J X chromosome (maternal) is always the inactive X. This is an adherent cell line." []	EFO	70830	EFO:0005481	\N	Patski {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005481
0	"Mouse hematopoietic suspension cell line positive for CD34.  The cells have a diploid complement of chromosomes, are non-tumorigenic and bipotential (can be induced to differentiate in vivo into two distinct haematopoietic lineages), and which in appropriate circumstances protect mice from potentially lethal radiation. [PMID: 763330]" []	\N	416B {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"Mouse hematopoietic suspension cell line positive for CD34.  The cells have a diploid complement of chromosomes, are non-tumorigenic and bipotential (can be induced to differentiate in vivo into two distinct haematopoietic lineages), and which in appropriate circumstances protect mice from potentially lethal radiation. [PMID: 763330]" []	EFO	70831	EFO:0005482	\N	416B {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005482
0	"An embryonic cell line isolated from C57BL/6 mouse strain.  Injection of Bruce4 cells into C57BL/6 blastocysts will produce agouti chimeras." []	\N	ES-Bruce4 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"An embryonic cell line isolated from C57BL/6 mouse strain.  Injection of Bruce4 cells into C57BL/6 blastocysts will produce agouti chimeras." []	EFO	70832	EFO:0005483	\N	ES-Bruce4 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005483
0	"46C is an embryonic cell line, constructed in the laboratory of Austin Smith, in which a drug resistance gene is placed under the control of a Sox1 promoter.  Cells were isolated from the 129a mouse strain. [PMID: 12524553]" []	\N	46C {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"46C is an embryonic cell line, constructed in the laboratory of Austin Smith, in which a drug resistance gene is placed under the control of a Sox1 promoter.  Cells were isolated from the 129a mouse strain. [PMID: 12524553]" []	EFO	70833	EFO:0005484	\N	46C {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005484
0	"ES-cells isolated from C57BL/6xCBA" []	\N	TT2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"ES-cells isolated from C57BL/6xCBA" []	EFO	70834	EFO:0005485	\N	TT2 {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005485
0	"Fetal myoblast Desmin+" []	\N	J185a {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	\N	\N	EFO	"Fetal myoblast Desmin+" []	EFO	70835	EFO:0005486	\N	J185a {http://www.co-ode.org/patterns#createdBy="http://e-lico.eu/populous#OPPL_pattern"}	EFO:0005486
0	"" []	\N	DZ685	\N	\N	EFO	"" []	EFO	70836	EFO:0005487	\N	DZ685	EFO:0005487
0	"" []	\N	NW1229	\N	\N	EFO	"" []	EFO	70837	EFO:0005488	\N	NW1229	EFO:0005488
0	"" []	\N	LX837	\N	\N	EFO	"" []	EFO	70838	EFO:0005489	\N	LX837	EFO:0005489
0	"" []	\N	BA671	\N	\N	EFO	"" []	EFO	70839	EFO:0005490	\N	BA671	EFO:0005490
0	"" []	\N	CB1489	\N	\N	EFO	"" []	EFO	70840	EFO:0005491	\N	CB1489	EFO:0005491
0	"" []	\N	JK1107	\N	\N	EFO	"" []	EFO	70841	EFO:0005492	\N	JK1107	EFO:0005492
0	"" []	\N	MT10430	\N	\N	EFO	"" []	EFO	70842	EFO:0005493	\N	MT10430	EFO:0005493
0	"organ producing either sperm or ova" []	\N	gonad	\N	\N	EFO	"organ producing either sperm or ova" []	EFO	70843	EFO:0005494	\N	gonad	EFO:0005494
0	"Neuron class of two pharyngeal neurosecretory-motor neurons." []	\N	NSM	\N	\N	EFO	"Neuron class of two pharyngeal neurosecretory-motor neurons." []	EFO	70844	EFO:0005495	\N	NSM	EFO:0005495
0	"" []	\N	Caenorhabditis component	\N	\N	EFO	"" []	EFO	70845	EFO:0005496	\N	Caenorhabditis component	EFO:0005496
0	"type of cells that make up muscle layers in the pharynx in worms such as C. elegans" []	\N	pharyngeal muscle cell	\N	\N	EFO	"type of cells that make up muscle layers in the pharynx in worms such as C. elegans" []	EFO	70846	EFO:0005497	\N	pharyngeal muscle cell	EFO:0005497
0	"C. elegans at 20 Centigrade: 0-24 hours after L4-adult molt" []	\N	newly molted young adult hermaphrodite	\N	\N	EFO	"C. elegans at 20 Centigrade: 0-24 hours after L4-adult molt" []	EFO	70847	EFO:0005498	\N	newly molted young adult hermaphrodite	EFO:0005498
0	"C. elegans 520-620min after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. The shape of embryo is elongated and tripple fold. A stage between 2-fold embryo and fully-elongated embryo. Also called pretzel embryo or pretzel stage. " []	\N	3-fold embryo	\N	\N	EFO	"C. elegans 520-620min after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. The shape of embryo is elongated and tripple fold. A stage between 2-fold embryo and fully-elongated embryo. Also called pretzel embryo or pretzel stage. " []	EFO	70848	EFO:0005499	\N	3-fold embryo	EFO:0005499
0	"C. elegans 20-40min after first cleavage at 20 Centigrade. Contains 4 cells." []	\N	4-cell embryo	\N	\N	EFO	"C. elegans 20-40min after first cleavage at 20 Centigrade. Contains 4 cells." []	EFO	70849	EFO:0005500	\N	4-cell embryo	EFO:0005500
0	"C. elegans 0-350min after first cleavage at 20 Centigrade. Proliferate from 1 cell to 560 cells. From start of first cleavage till cleavage is over." []	\N	proliferating embryo	\N	\N	EFO	"C. elegans 0-350min after first cleavage at 20 Centigrade. Proliferate from 1 cell to 560 cells. From start of first cleavage till cleavage is over." []	EFO	70850	EFO:0005501	\N	proliferating embryo	EFO:0005501
0	"C. elegans 210-350min after first cleavage at 20 Centigrade. Proliferate from 421 cells to 560 cells. The stage before the fast cleavage of cells finishes." []	\N	late cleavage stage embryo	\N	\N	EFO	"C. elegans 210-350min after first cleavage at 20 Centigrade. Proliferate from 421 cells to 560 cells. The stage before the fast cleavage of cells finishes." []	EFO	70851	EFO:0005502	\N	late cleavage stage embryo	EFO:0005502
0	"C. elegans 100-290min after first cleavage at 20 Centigrade. Proliferate from 28 cells to 421 cells. Referring to the whole period of gastrulation." []	\N	gastrulating embryo	\N	\N	EFO	"C. elegans 100-290min after first cleavage at 20 Centigrade. Proliferate from 28 cells to 421 cells. Referring to the whole period of gastrulation." []	EFO	70852	EFO:0005503	\N	gastrulating embryo	EFO:0005503
0	"C. elegans 620-800min(hatch) after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. A stage after elongation is over. The last stage of embryogenesis. Also called pre-hatched embryo, late embryo or morphogenetic embryo." []	\N	fully-elongated embryo	\N	\N	EFO	"C. elegans 620-800min(hatch) after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. A stage after elongation is over. The last stage of embryogenesis. Also called pre-hatched embryo, late embryo or morphogenetic embryo." []	EFO	70853	EFO:0005504	\N	fully-elongated embryo	EFO:0005504
0	"C. elegans 290-350min after first cleavage at 20 Centigrade. Proliferate from 421 cells to 560 cells. The stage when embryo just finished gastulation and is enclosing." []	\N	enclosing embryo	\N	\N	EFO	"C. elegans 290-350min after first cleavage at 20 Centigrade. Proliferate from 421 cells to 560 cells. The stage when embryo just finished gastulation and is enclosing." []	EFO	70854	EFO:0005505	\N	enclosing embryo	EFO:0005505
0	"C. elegans 350-620min after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. The stage that embryo starts elongation till elongation is over." []	\N	elongating embryo	\N	\N	EFO	"C. elegans 350-620min after first cleavage at 20 Centigrade. Cell number remains at ~560 cells, with some new cells generated and some cells go through programmed cell death. The stage that embryo starts elongation till elongation is over." []	EFO	70855	EFO:0005506	\N	elongating embryo	EFO:0005506
0	"C. elegans third stage larva specialized for dispersal and long term survival." []	\N	dauer larva	\N	\N	EFO	"C. elegans third stage larva specialized for dispersal and long term survival." []	EFO	70856	EFO:0005507	\N	dauer larva	EFO:0005507
0	"C. elegans first stage larva. At 25 Centigrade, it ranges 14-25.5 hours after fertilization, 0-11.5 hours after hatch." []	\N	L1 larva	\N	\N	EFO	"C. elegans first stage larva. At 25 Centigrade, it ranges 14-25.5 hours after fertilization, 0-11.5 hours after hatch." []	EFO	70857	EFO:0005508	\N	L1 larva	EFO:0005508
0	"C. elegans fourth stage larva. At 25 Centigrade, it ranges 40-49.5 hours after fertilization, 26-35.5 hours after hatch." []	\N	L4 larva	\N	\N	EFO	"C. elegans fourth stage larva. At 25 Centigrade, it ranges 40-49.5 hours after fertilization, 26-35.5 hours after hatch." []	EFO	70858	EFO:0005509	\N	L4 larva	EFO:0005509
0	"C. elegans stage when the larval shifts from L2d larva to dauer larva. It includes the synthesis of new cuticle, cease of phrayngeal pumping during a lethargus stage, and the shed off of old cuticle. " []	\N	L2d-dauer molt	\N	\N	EFO	"C. elegans stage when the larval shifts from L2d larva to dauer larva. It includes the synthesis of new cuticle, cease of phrayngeal pumping during a lethargus stage, and the shed off of old cuticle. " []	EFO	70859	EFO:0005510	\N	L2d-dauer molt	EFO:0005510
0	"C. elegans stage right after a larva recovered from dauer but has not started transformation to L4 larva yet." []	\N	post dauer stage	\N	\N	EFO	"C. elegans stage right after a larva recovered from dauer but has not started transformation to L4 larva yet." []	EFO	70860	EFO:0005511	\N	post dauer stage	EFO:0005511
0	"quantification of the level of estrogen receptors in a tumor" []	\N	estrogen receptor status	\N	\N	EFO	"quantification of the level of estrogen receptors in a tumor" []	EFO	70861	EFO:0005512	\N	estrogen receptor status	EFO:0005512
0	"quantification of the level of progesterone receptors in a tumor" []	\N	progesterone receptor status	\N	\N	EFO	"quantification of the level of progesterone receptors in a tumor" []	EFO	70862	EFO:0005513	\N	progesterone receptor status	EFO:0005513
0	"quantification of the level of human epidermal growth factor receptor 2 (HER2) in a tumor" []	\N	HER2 status	\N	\N	EFO	"quantification of the level of human epidermal growth factor receptor 2 (HER2) in a tumor" []	EFO	70863	EFO:0005514	\N	HER2 status	EFO:0005514
0	"RIP-Chip refers to the immunoprecipitation of RNPs from cell extracts and the subsequent microarray analysis of associated RNA molecules." []	\N	RIP-Chip by array	\N	\N	EFO	"RIP-Chip refers to the immunoprecipitation of RNPs from cell extracts and the subsequent microarray analysis of associated RNA molecules." []	EFO	70864	EFO:0005517	\N	RIP-Chip by array	EFO:0005517
0	"Describes the procedure whereby biological samples for an experiment are sourced." []	\N	sample collection protocol	\N	\N	EFO	"Describes the procedure whereby biological samples for an experiment are sourced." []	EFO	70865	EFO:0005518	\N	sample collection protocol	EFO:0005518
0	"Describes the procedure which dissects biological materials into anatomical sub-components, e.g. specific organs or tissues." []	\N	dissection protocol	\N	\N	EFO	"Describes the procedure which dissects biological materials into anatomical sub-components, e.g. specific organs or tissues." []	EFO	70866	EFO:0005519	\N	dissection protocol	EFO:0005519
0	"Describes the conversion of samples (e.g. RNA samples) to another form (e.g. complementary DNA) with no prior dedicated extraction step of the former form, and no labeling of the converted product with chemical tags or dyes during the process. Other examples of such conversions are bisulphite conversion for DNA methylation analysis, various RNA modifications prior to immunoprecipitation." []	\N	conversion protocol	\N	\N	EFO	"Describes the conversion of samples (e.g. RNA samples) to another form (e.g. complementary DNA) with no prior dedicated extraction step of the former form, and no labeling of the converted product with chemical tags or dyes during the process. Other examples of such conversions are bisulphite conversion for DNA methylation analysis, various RNA modifications prior to immunoprecipitation." []	EFO	70867	EFO:0005520	\N	conversion protocol	EFO:0005520
0	"The technology type or platform of the reporters on the array." []	\N	technology type	\N	\N	EFO	"The technology type or platform of the reporters on the array." []	EFO	70868	EFO:0005521	\N	technology type	EFO:0005521
0	"Controlled terms for descriptors of types of array substrates." []	\N	substrate type	\N	\N	EFO	"Controlled terms for descriptors of types of array substrates." []	EFO	70869	EFO:0005522	\N	substrate type	EFO:0005522
0	"Controlled terms for descriptors for coating of the substrate." []	\N	surface type	\N	\N	EFO	"Controlled terms for descriptors for coating of the substrate." []	EFO	70870	EFO:0005523	\N	surface type	EFO:0005523
0	"stroke caused by the blockage of blood flow in one of the large arteries feeding the brain" []	\N	large artery stroke	\N	\N	EFO	"stroke caused by the blockage of blood flow in one of the large arteries feeding the brain" []	EFO	70871	EFO:0005524	\N	large artery stroke	EFO:0005524
0	"physiological response of an organism, eg in terms of flushing, to consuming alcohol" []	\N	response to alcohol	\N	\N	EFO	"physiological response of an organism, eg in terms of flushing, to consuming alcohol" []	EFO	70872	EFO:0005526	\N	response to alcohol	EFO:0005526
0	"quantification of the volumetric fraction of blood pumped out of the left and right ventricle with each heartbeat or cardiac cycle" []	\N	ejection fraction measurement	\N	\N	EFO	"quantification of the volumetric fraction of blood pumped out of the left and right ventricle with each heartbeat or cardiac cycle" []	EFO	70873	EFO:0005527	\N	ejection fraction measurement	EFO:0005527
0	"quantification of the content of parasites in the blood, used as a measurement of parasite load in the organism and an indication of the degree of an active parasitic infection" []	\N	parasitemia measurement	\N	\N	EFO	"quantification of the content of parasites in the blood, used as a measurement of parasite load in the organism and an indication of the degree of an active parasitic infection" []	EFO	70874	EFO:0005528	\N	parasitemia measurement	EFO:0005528
0	"a form of cardiomyopathy that develops as a result of Chagas disease, an infection with the protozoan parasite Trypanosoma Cruzi" []	\N	Chagas cardiomyopathy	\N	\N	EFO	"a form of cardiomyopathy that develops as a result of Chagas disease, an infection with the protozoan parasite Trypanosoma Cruzi" []	EFO	70875	EFO:0005529	\N	Chagas cardiomyopathy	EFO:0005529
0	"Trypanosoma cruzi seropositivity is the result of a measurement of circulating T. cruzi specific antibodies " []	\N	Trypanosoma cruzi seropositivity	\N	\N	EFO	"Trypanosoma cruzi seropositivity is the result of a measurement of circulating T. cruzi specific antibodies " []	EFO	70876	EFO:0005530	\N	Trypanosoma cruzi seropositivity	EFO:0005530
0	"Urticaria is a kind of skin rash notable for pale red, raised, itchy bumps that might also cause a burning or stinging sensation. It is often but not necessarily caused by an allergic reaction." []	\N	urticaria	\N	\N	EFO	"Urticaria is a kind of skin rash notable for pale red, raised, itchy bumps that might also cause a burning or stinging sensation. It is often but not necessarily caused by an allergic reaction." []	EFO	70877	EFO:0005531	\N	urticaria	EFO:0005531
0	"condition similar to urticarai but with swelling occuring in a lower layer of the dermis as well as in the subcutis" []	\N	angioedema	\N	\N	EFO	"condition similar to urticarai but with swelling occuring in a lower layer of the dermis as well as in the subcutis" []	EFO	70878	EFO:0005532	\N	angioedema	EFO:0005532
0	"" []	\N	response to non-steroidal anti-inflammatory	\N	\N	EFO	"" []	EFO	70879	EFO:0005533	\N	response to non-steroidal anti-inflammatory	EFO:0005533
0	"anoxic encephalopathy resulting from acute CO intoxication, developing within 2-6 weeks of the poisoning event" []	\N	delayed encephalopathy after acute carbon monoxide poisoning	\N	\N	EFO	"anoxic encephalopathy resulting from acute CO intoxication, developing within 2-6 weeks of the poisoning event" []	EFO	70880	EFO:0005534	\N	delayed encephalopathy after acute carbon monoxide poisoning	EFO:0005534
0	"A vial is a unique aliquot of biological material e.g. iPSC " []	\N	specimen vial	\N	\N	EFO	"A vial is a unique aliquot of biological material e.g. iPSC " []	EFO	70881	EFO:0005535	\N	specimen vial	EFO:0005535
0	"Quantification of the fraction of nitric oxide in the total exhalation volume, used as a non-invasive biomarker of eosinophilic airway inflammation. Higher Feno values are associated with childhood asthma symptoms, exacerbations, physician-diagnosed asthma and atopy." []	\N	nitric oxide exhalation measurement	\N	\N	EFO	"Quantification of the fraction of nitric oxide in the total exhalation volume, used as a non-invasive biomarker of eosinophilic airway inflammation. Higher Feno values are associated with childhood asthma symptoms, exacerbations, physician-diagnosed asthma and atopy." []	EFO	70882	EFO:0005536	\N	nitric oxide exhalation measurement	EFO:0005536
0	"an aggressive subtype of breast cancer that is estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative" []	\N	triple-negative breast cancer	\N	\N	EFO	"an aggressive subtype of breast cancer that is estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative" []	EFO	70883	EFO:0005537	\N	triple-negative breast cancer	EFO:0005537
0	"quantification of the capacity of a given individual to generate thrombin, measured in plasma and shown to associate with thrombotic disorders" []	\N	thrombin generation potential measurement	\N	\N	EFO	"quantification of the capacity of a given individual to generate thrombin, measured in plasma and shown to associate with thrombotic disorders" []	EFO	70884	EFO:0005538	\N	thrombin generation potential measurement	EFO:0005538
0	"An endocrine system disease that is located_in the adrenal gland." []	\N	adrenal gland disease	\N	\N	EFO	"An endocrine system disease that is located_in the adrenal gland." []	EFO	70885	EFO:0005539	\N	adrenal gland disease	EFO:0005539
0	"A carcinoma that starts in the bile duct." []	\N	bile duct carcinoma	\N	\N	EFO	"A carcinoma that starts in the bile duct." []	EFO	70886	EFO:0005540	\N	bile duct carcinoma	EFO:0005540
0	"A bone disease that results_in abnormal growth and development located_in bone or located_in cartilage." []	\N	bone development disease	\N	\N	EFO	"A bone disease that results_in abnormal growth and development located_in bone or located_in cartilage." []	EFO	70887	EFO:0005541	\N	bone development disease	EFO:0005541
0	"A primary bacterial infectious disease that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F) located_in neuromuscular junction, resulting in descending muscle paralysis, has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F." []	\N	botulism	\N	\N	EFO	"A primary bacterial infectious disease that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F) located_in neuromuscular junction, resulting in descending muscle paralysis, has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F." []	EFO	70888	EFO:0005542	\N	botulism	EFO:0005542
0	"" []	\N	brain glioma	\N	\N	EFO	"" []	EFO	70889	EFO:0005543	\N	brain glioma	EFO:0005543
0	"A congenital disorder of glycosylation involve disrupted synthesis of the lipid-linked oligosaccharide precursor." []	\N	congenital disorder of glycosylation type I	\N	\N	EFO	"A congenital disorder of glycosylation involve disrupted synthesis of the lipid-linked oligosaccharide precursor." []	EFO	70890	EFO:0005545	\N	congenital disorder of glycosylation type I	EFO:0005545
0	"A congenital disorder of glycosylation that involves malfunctioning trimming/processing of the protein-bound oligosaccharide chain." []	\N	congenital disorder of glycosylation type II	\N	\N	EFO	"A congenital disorder of glycosylation that involves malfunctioning trimming/processing of the protein-bound oligosaccharide chain." []	EFO	70891	EFO:0005546	\N	congenital disorder of glycosylation type II	EFO:0005546
0	"A viral infectious disease that results_in infection, has_material_basis_in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has_symptom fever, has_symptom severe headache, has_symptom severe pain behind the eyes, has_symptom joint pain, has_symptom muscle and bone pain, has_symptom rash, and has_symptom mild bleeding." []	\N	dengue disease	\N	\N	EFO	"A viral infectious disease that results_in infection, has_material_basis_in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has_symptom fever, has_symptom severe headache, has_symptom severe pain behind the eyes, has_symptom joint pain, has_symptom muscle and bone pain, has_symptom rash, and has_symptom mild bleeding." []	EFO	70892	EFO:0005547	\N	dengue disease	EFO:0005547
0	"A disease of mental health that occur during a child's developmental period between birth and age 18 resulting in retarding of the child's psycholotgical or physical development." []	\N	developmental disorder of mental health	\N	\N	EFO	"A disease of mental health that occur during a child's developmental period between birth and age 18 resulting in retarding of the child's psycholotgical or physical development." []	EFO	70893	EFO:0005548	\N	developmental disorder of mental health	EFO:0005548
0	"A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys." []	\N	diphtheria	\N	\N	EFO	"A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys." []	EFO	70894	EFO:0005549	\N	diphtheria	EFO:0005549
0	"" []	\N	dysembryoplastic neuroepithelial tumor	\N	\N	EFO	"" []	EFO	70895	EFO:0005551	\N	dysembryoplastic neuroepithelial tumor	EFO:0005551
0	"" []	\N	eccrine sweat gland cancer	\N	\N	EFO	"" []	EFO	70896	EFO:0005553	\N	eccrine sweat gland cancer	EFO:0005553
0	"A severe combined immunodeficiency that is a X-linked SCID caused by mutations in genes encoding common gamma chain proteins shared by the interleukin (IL-2,4,7,9,16 and21) receptors resulting in a non-functional gamma chain, defective interleukin signalling, minimal or ascent T- and NK cells and non-functional B-cells." []	\N	gamma chain deficiency	\N	\N	EFO	"A severe combined immunodeficiency that is a X-linked SCID caused by mutations in genes encoding common gamma chain proteins shared by the interleukin (IL-2,4,7,9,16 and21) receptors resulting in a non-functional gamma chain, defective interleukin signalling, minimal or ascent T- and NK cells and non-functional B-cells." []	EFO	70897	EFO:0005555	\N	gamma chain deficiency	EFO:0005555
0	"A bilirubin metabolic disorder that involves elevated levels of unconjugated bilirubin as bilirubin is not being conjugated as a result of reduced glucuronyltransferase activity." []	\N	Gilbert syndrome	\N	\N	EFO	"A bilirubin metabolic disorder that involves elevated levels of unconjugated bilirubin as bilirubin is not being conjugated as a result of reduced glucuronyltransferase activity." []	EFO	70898	EFO:0005556	\N	Gilbert syndrome	EFO:0005556
0	"" []	\N	gum cancer	\N	\N	EFO	"" []	EFO	70899	EFO:0005557	\N	gum cancer	EFO:0005557
0	"" []	\N	hemolytic anemia	\N	\N	EFO	"" []	EFO	70900	EFO:0005558	\N	hemolytic anemia	EFO:0005558
0	"An exostosis that has_material_basis_in a mutation on the genes EXT1, EXT2 and EXT3 which results_in multiple bony spurs throughout a child's growth." []	\N	hereditary multiple exostoses	\N	\N	EFO	"An exostosis that has_material_basis_in a mutation on the genes EXT1, EXT2 and EXT3 which results_in multiple bony spurs throughout a child's growth." []	EFO	70901	EFO:0005560	\N	hereditary multiple exostoses	EFO:0005560
0	"A neoplasm consisting of histiocytes. Forms include BENIGN FIBROUS HISTIOCYTOMA; and MALIGNANT FIBROUS HISTIOCYTOMA (MeSH)" []	\N	histiocytoma	\N	\N	EFO	"A neoplasm consisting of histiocytes. Forms include BENIGN FIBROUS HISTIOCYTOMA; and MALIGNANT FIBROUS HISTIOCYTOMA (MeSH)" []	EFO	70902	EFO:0005561	\N	histiocytoma	EFO:0005561
0	"" []	\N	hydronephrosis	\N	\N	EFO	"" []	EFO	70903	EFO:0005562	\N	hydronephrosis	EFO:0005562
0	"" []	\N	hypercalcemia	\N	\N	EFO	"" []	EFO	70904	EFO:0005563	\N	hypercalcemia	EFO:0005563
0	"" []	\N	janus kinase-3 deficiency	\N	\N	EFO	"" []	EFO	70905	EFO:0005565	\N	janus kinase-3 deficiency	EFO:0005565
0	"" []	\N	malignant peritoneal mesothelioma	\N	\N	EFO	"" []	EFO	70906	EFO:0005567	\N	malignant peritoneal mesothelioma	EFO:0005567
0	"" []	\N	methylmalonic aciduria and homocystinuria type cblE	\N	\N	EFO	"" []	EFO	70907	EFO:0005568	\N	methylmalonic aciduria and homocystinuria type cblE	EFO:0005568
0	"" []	\N	microphthalmia	\N	\N	EFO	"" []	EFO	70908	EFO:0005569	\N	microphthalmia	EFO:0005569
0	"A gastrointestinal system cancer that is located_in the oral cavity." []	\N	oral cavity cancer	\N	\N	EFO	"A gastrointestinal system cancer that is located_in the oral cavity." []	EFO	70909	EFO:0005570	\N	oral cavity cancer	EFO:0005570
0	"A bone development disease that results_in defective development of cartilage or bone." []	\N	osteochondrodysplasia	\N	\N	EFO	"A bone development disease that results_in defective development of cartilage or bone." []	EFO	70910	EFO:0005571	\N	osteochondrodysplasia	EFO:0005571
0	"A penile cancer that is located_in the skin or tissues of the penis." []	\N	penis carcinoma	\N	\N	EFO	"A penile cancer that is located_in the skin or tissues of the penis." []	EFO	70911	EFO:0005575	\N	penis carcinoma	EFO:0005575
0	"" []	\N	pernicious anemia	\N	\N	EFO	"" []	EFO	70912	EFO:0005576	\N	pernicious anemia	EFO:0005576
0	"A gastrointestinal system cancer that is located_in the pharynx." []	\N	pharynx cancer	\N	\N	EFO	"A gastrointestinal system cancer that is located_in the pharynx." []	EFO	70913	EFO:0005577	\N	pharynx cancer	EFO:0005577
0	"An endocrine gland cancer located_in the pituitary gland located at the base of the brain." []	\N	pituitary cancer	\N	\N	EFO	"An endocrine gland cancer located_in the pituitary gland located at the base of the brain." []	EFO	70914	EFO:0005578	\N	pituitary cancer	EFO:0005578
0	"" []	\N	pseudohermaphroditism	\N	\N	EFO	"" []	EFO	70915	EFO:0005579	\N	pseudohermaphroditism	EFO:0005579
0	"" []	\N	red color blindness	\N	\N	EFO	"" []	EFO	70916	EFO:0005580	\N	red color blindness	EFO:0005580
0	"" []	\N	red-green color blindness	\N	\N	EFO	"" []	EFO	70917	EFO:0005581	\N	red-green color blindness	EFO:0005581
0	"" []	\N	renal pelvis carcinoma	\N	\N	EFO	"" []	EFO	70918	EFO:0005582	\N	renal pelvis carcinoma	EFO:0005582
0	"A bone remodeling disease that has_material_basis_in a vitamin D deficiency in children which results_in softening and deformity located_in bone." []	\N	rickets	\N	\N	EFO	"A bone remodeling disease that has_material_basis_in a vitamin D deficiency in children which results_in softening and deformity located_in bone." []	EFO	70919	EFO:0005583	\N	rickets	EFO:0005583
0	"" []	\N	seborrheic keratosis	\N	\N	EFO	"" []	EFO	70920	EFO:0005584	\N	seborrheic keratosis	EFO:0005584
0	"A primary bacterial infectious disease that results_in infection located_in epithelium of colon, has_material_basis_in Shigella boydii, has_material_basis_in Shigella dysenteriae, has_material_basis_in Shigella flexneri, or has_material_basis_in Shigella sonnei, which produce toxins that can attack the lining of the large intestine, causing swelling, ulcers on the intestinal wall, and bloody diarrhea. The bacteria are transmitted_by ingestion of food and water contaminated with feces." []	\N	shigellosis	\N	\N	EFO	"A primary bacterial infectious disease that results_in infection located_in epithelium of colon, has_material_basis_in Shigella boydii, has_material_basis_in Shigella dysenteriae, has_material_basis_in Shigella flexneri, or has_material_basis_in Shigella sonnei, which produce toxins that can attack the lining of the large intestine, causing swelling, ulcers on the intestinal wall, and bloody diarrhea. The bacteria are transmitted_by ingestion of food and water contaminated with feces." []	EFO	70921	EFO:0005585	\N	shigellosis	EFO:0005585
0	"A small intestine cancer that develops from epithelial cells and is located_in the small intestine." []	\N	small intestine carcinoma	\N	\N	EFO	"A small intestine cancer that develops from epithelial cells and is located_in the small intestine." []	EFO	70922	EFO:0005588	\N	small intestine carcinoma	EFO:0005588
0	"A lipid metabolism disorder that involves defects in steroid metabolism." []	\N	steroid inherited metabolic disorder	\N	\N	EFO	"A lipid metabolism disorder that involves defects in steroid metabolism." []	EFO	70923	EFO:0005590	\N	steroid inherited metabolic disorder	EFO:0005590
0	"" []	\N	sweat gland carcinoma	\N	\N	EFO	"" []	EFO	70924	EFO:0005591	\N	sweat gland carcinoma	EFO:0005591
0	"" []	\N	T-cell leukemia	\N	\N	EFO	"" []	EFO	70925	EFO:0005592	\N	T-cell leukemia	EFO:0005592
0	"A primary bacterial infectious disease that results_in prolonged contraction of skeletal muscle fibers, has_material_basis_in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli." []	\N	tetanus	\N	\N	EFO	"A primary bacterial infectious disease that results_in prolonged contraction of skeletal muscle fibers, has_material_basis_in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli." []	EFO	70926	EFO:0005593	\N	tetanus	EFO:0005593
0	"" []	\N	toxic encephalopathy	\N	\N	EFO	"" []	EFO	70927	EFO:0005595	\N	toxic encephalopathy	EFO:0005595
0	"An inherited metabolic disorder resulting from a deficiency in vitamin or vitamin cofactor transport or metabolism." []	\N	vitamin metabolic disorder	\N	\N	EFO	"An inherited metabolic disorder resulting from a deficiency in vitamin or vitamin cofactor transport or metabolism." []	EFO	70928	EFO:0005596	\N	vitamin metabolic disorder	EFO:0005596
0	"" []	\N	methylmalonic aciduria and homocystinuria type cblG	\N	\N	EFO	"" []	EFO	70929	EFO:0005597	\N	methylmalonic aciduria and homocystinuria type cblG	EFO:0005597
0	"A fatty streak is the first grossly visible (visible to the naked eye) lesion in the development of atherosclerosis. It appears as an irregular yellow-white discoloration on the luminal surface of an artery. It consists of aggregates of foam cells, which are lipoprotein-loaded macrophages located beneath[ambiguous] the inner, endothelial layer of an artery. Fatty streaks may also include T cells, aggregated platelets, and smooth muscle cells. It is the precursor lesion of atheromas that may become atheromatous plaques" []	\N	abdominal aortic fatty streak	\N	\N	EFO	"A fatty streak is the first grossly visible (visible to the naked eye) lesion in the development of atherosclerosis. It appears as an irregular yellow-white discoloration on the luminal surface of an artery. It consists of aggregates of foam cells, which are lipoprotein-loaded macrophages located beneath[ambiguous] the inner, endothelial layer of an artery. Fatty streaks may also include T cells, aggregated platelets, and smooth muscle cells. It is the precursor lesion of atheromas that may become atheromatous plaques" []	EFO	70930	EFO:0005600	\N	abdominal aortic fatty streak	EFO:0005600
0	"An atherosclerotic abnormality of the abdominal aorta used as a container term for fibrous plaques, complicated lesions, and calcified lesions." []	\N	abdominal aortic raised atherosclerotic lesion	\N	\N	EFO	"An atherosclerotic abnormality of the abdominal aorta used as a container term for fibrous plaques, complicated lesions, and calcified lesions." []	EFO	70931	EFO:0005601	\N	abdominal aortic raised atherosclerotic lesion	EFO:0005601
0	"" []	\N	age at alcohol diagnosis	\N	\N	EFO	"" []	EFO	70932	EFO:0005602	\N	age at alcohol diagnosis	EFO:0005602
0	"" []	\N	age at breast cancer diagnosis	\N	\N	EFO	"" []	EFO	70933	EFO:0005603	\N	age at breast cancer diagnosis	EFO:0005603
0	"A reported family history of breast cancer in one or more family members." []	\N	family history of breast cancer	\N	\N	EFO	"A reported family history of breast cancer in one or more family members." []	EFO	70934	EFO:0005606	\N	family history of breast cancer	EFO:0005606
0	"A staging of breast cancer for example by the American Joint Committee on Cancer, stage 7, or other coding system." []	\N	breast cancer stage	\N	\N	EFO	"A staging of breast cancer for example by the American Joint Committee on Cancer, stage 7, or other coding system." []	EFO	70935	EFO:0005607	\N	breast cancer stage	EFO:0005607
0	"A measure of cortical opacity used in the diagnosis of cataract." []	\N	cortical opacity measurement	\N	\N	EFO	"A measure of cortical opacity used in the diagnosis of cataract." []	EFO	70936	EFO:0005608	\N	cortical opacity measurement	EFO:0005608
0	"Strong dependence, both physiological and emotional, upon opiates." []	\N	opiate dependence	\N	\N	EFO	"Strong dependence, both physiological and emotional, upon opiates." []	EFO	70937	EFO:0005611	\N	opiate dependence	EFO:0005611
0	"Strong dependence, both physiological and emotional, upon morphine." []	\N	morphine dependence	\N	\N	EFO	"Strong dependence, both physiological and emotional, upon morphine." []	EFO	70938	EFO:0005612	\N	morphine dependence	EFO:0005612
0	"A classification of prostate cancer stage e.g. Gleason grade finding" []	\N	prostate cancer staging	\N	\N	EFO	"A classification of prostate cancer stage e.g. Gleason grade finding" []	EFO	70939	EFO:0005615	\N	prostate cancer staging	EFO:0005615
0	"coronary artery raised lesion" []	\N	coronary artery raised atherosclerotic lesion	\N	\N	EFO	"coronary artery raised lesion" []	EFO	70940	EFO:0005616	\N	coronary artery raised atherosclerotic lesion	EFO:0005616
0	"A fatty streak is the first grossly visible (visible to the naked eye) lesion in the development of atherosclerosis. It appears as an irregular yellow-white discoloration on the luminal surface of an artery. It consists of aggregates of foam cells, which are lipoprotein-loaded macrophages located beneath[ambiguous] the inner, endothelial layer of an artery. Fatty streaks may also include T cells, aggregated platelets, and smooth muscle cells. It is the precursor lesion of atheromas that may become atheromatous plaques" []	\N	thoracic aortic fatty streak	\N	\N	EFO	"A fatty streak is the first grossly visible (visible to the naked eye) lesion in the development of atherosclerosis. It appears as an irregular yellow-white discoloration on the luminal surface of an artery. It consists of aggregates of foam cells, which are lipoprotein-loaded macrophages located beneath[ambiguous] the inner, endothelial layer of an artery. Fatty streaks may also include T cells, aggregated platelets, and smooth muscle cells. It is the precursor lesion of atheromas that may become atheromatous plaques" []	EFO	70941	EFO:0005617	\N	thoracic aortic fatty streak	EFO:0005617
0	"An atherosclerotic abnormality of the thoracic aorta used as a container term for fibrous plaques, complicated lesions, and calcified lesions." []	\N	'thoracic aortic raised atherosclerotic lesion'	\N	\N	EFO	"An atherosclerotic abnormality of the thoracic aorta used as a container term for fibrous plaques, complicated lesions, and calcified lesions." []	EFO	70942	EFO:0005618	\N	'thoracic aortic raised atherosclerotic lesion'	EFO:0005618
0	"" []	\N	lung adenocarcinoma grade	\N	\N	EFO	"" []	EFO	70943	EFO:0005620	\N	lung adenocarcinoma grade	EFO:0005620
0	"Crohn's colitis is a type of Crohn's disease that affects the large intestine." []	\N	Crohn's colitis	\N	\N	EFO	"Crohn's colitis is a type of Crohn's disease that affects the large intestine." []	EFO	70944	EFO:0005622	\N	Crohn's colitis	EFO:0005622
0	"" []	\N	distal colitis	\N	\N	EFO	"" []	EFO	70945	EFO:0005623	\N	distal colitis	EFO:0005623
0	"Ileocolitis or ileal Crohn's is the most common type of Crohn's disease. It affects both the ileum (small intestine) and the colon. " []	\N	ileocolitis	\N	\N	EFO	"Ileocolitis or ileal Crohn's is the most common type of Crohn's disease. It affects both the ileum (small intestine) and the colon. " []	EFO	70946	EFO:0005624	\N	ileocolitis	EFO:0005624
0	"Crohn's disease affecting the mouth." []	\N	oral Crohn's disease	\N	\N	EFO	"Crohn's disease affecting the mouth." []	EFO	70947	EFO:0005625	\N	oral Crohn's disease	EFO:0005625
0	"Pancolitis is a severe form of ulcerative colitis." []	\N	pancolitis	\N	\N	EFO	"Pancolitis is a severe form of ulcerative colitis." []	EFO	70948	EFO:0005626	\N	pancolitis	EFO:0005626
0	"Perianal Crohn's disease is a type of Crohn's disease affecting the anus." []	\N	perianal Crohn's disease	\N	\N	EFO	"Perianal Crohn's disease is a type of Crohn's disease affecting the anus." []	EFO	70949	EFO:0005627	\N	perianal Crohn's disease	EFO:0005627
0	"Proctitis is an inflammation of the rectum." []	\N	proctitis	\N	\N	EFO	"Proctitis is an inflammation of the rectum." []	EFO	70950	EFO:0005628	\N	proctitis	EFO:0005628
0	"Small bowel Crohn's disease is a chronic inflammatory bowel disease affecting the small instestine." []	\N	small bowel Crohn's disease	\N	\N	EFO	"Small bowel Crohn's disease is a chronic inflammatory bowel disease affecting the small instestine." []	EFO	70951	EFO:0005629	\N	small bowel Crohn's disease	EFO:0005629
0	"CEL data file format describes the format used in a CEL file for storing the results of the intensity calculations on the pixel values of a DAT file. This includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm and a user defined flag indicating the feature should be excluded from future analysis. The file stores the previously stated data for each feature on the probe array." []	\N	CEL data file format	\N	\N	EFO	"CEL data file format describes the format used in a CEL file for storing the results of the intensity calculations on the pixel values of a DAT file. This includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm and a user defined flag indicating the feature should be excluded from future analysis. The file stores the previously stated data for each feature on the probe array." []	EFO	70952	EFO:0005630	\N	CEL data file format	EFO:0005630
0	"An adenocarcinoma of the rectum. " []	\N	rectal adenocarcinoma	\N	\N	EFO	"An adenocarcinoma of the rectum. " []	EFO	70953	EFO:0005631	\N	rectal adenocarcinoma	EFO:0005631
0	"The presence of necrosis affecting the intestine." []	\N	intestinal necrosis	\N	\N	EFO	"The presence of necrosis affecting the intestine." []	EFO	70954	EFO:0005632	\N	intestinal necrosis	EFO:0005632
0	"" []	\N	ATC Code A Alimentary code and metabolism	\N	\N	EFO	"" []	EFO	70955	EFO:0005633	\N	ATC Code A Alimentary code and metabolism	EFO:0005633
0	"The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of active ingredients of drugs according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. It is controlled by the World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC), and was first published in 1976." []	\N	ATC Classification System	\N	\N	EFO	"The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of active ingredients of drugs according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. It is controlled by the World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC), and was first published in 1976." []	EFO	70956	EFO:0005634	\N	ATC Classification System	EFO:0005634
0	"" []	\N	ATC Code B Blood and blood forming organs	\N	\N	EFO	"" []	EFO	70957	EFO:0005635	\N	ATC Code B Blood and blood forming organs	EFO:0005635
0	"" []	\N	ATC Code C Cardiovascular system	\N	\N	EFO	"" []	EFO	70958	EFO:0005636	\N	ATC Code C Cardiovascular system	EFO:0005636
0	"" []	\N	ATC Code D Dermatologicals	\N	\N	EFO	"" []	EFO	70959	EFO:0005637	\N	ATC Code D Dermatologicals	EFO:0005637
0	"" []	\N	ATC Code G Genito-urinary system and sex hormones	\N	\N	EFO	"" []	EFO	70960	EFO:0005638	\N	ATC Code G Genito-urinary system and sex hormones	EFO:0005638
0	"" []	\N	ATC Code H Systemic hormonal preparations, excluding sex hormones and insulins	\N	\N	EFO	"" []	EFO	70961	EFO:0005639	\N	ATC Code H Systemic hormonal preparations, excluding sex hormones and insulins	EFO:0005639
0	"" []	\N	ATC Code J Antiinfectives for systemic use	\N	\N	EFO	"" []	EFO	70962	EFO:0005640	\N	ATC Code J Antiinfectives for systemic use	EFO:0005640
0	"" []	\N	ATC Code L Antineoplastic and immunomodulating agents	\N	\N	EFO	"" []	EFO	70963	EFO:0005641	\N	ATC Code L Antineoplastic and immunomodulating agents	EFO:0005641
0	"" []	\N	ATC Code M Musculo-skeletal system	\N	\N	EFO	"" []	EFO	70964	EFO:0005642	\N	ATC Code M Musculo-skeletal system	EFO:0005642
0	"" []	\N	ATC Code N Nervous system	\N	\N	EFO	"" []	EFO	70965	EFO:0005643	\N	ATC Code N Nervous system	EFO:0005643
0	"" []	\N	ATC Code P Antiparasitic products, insecticides and repellents	\N	\N	EFO	"" []	EFO	70966	EFO:0005644	\N	ATC Code P Antiparasitic products, insecticides and repellents	EFO:0005644
0	"" []	\N	ATC Code R Respiratory system	\N	\N	EFO	"" []	EFO	70967	EFO:0005645	\N	ATC Code R Respiratory system	EFO:0005645
0	"" []	\N	ATC Code S Sensory organs	\N	\N	EFO	"" []	EFO	70968	EFO:0005646	\N	ATC Code S Sensory organs	EFO:0005646
0	"" []	\N	ATC Code V Various	\N	\N	EFO	"" []	EFO	70969	EFO:0005647	\N	ATC Code V Various	EFO:0005647
0	"This line was haploid when it was established. Like other lines, it may go back in forth in ploidy (by factors of two), depending on the growth conditions and the general health of the cells." []	\N	1182-4H	\N	\N	EFO	"This line was haploid when it was established. Like other lines, it may go back in forth in ploidy (by factors of two), depending on the growth conditions and the general health of the cells." []	EFO	70970	EFO:0005648	\N	1182-4H	EFO:0005648
0	"A bone structure disease that involves a defect in the lumbar vertebral column." []	\N	spondylolysis	\N	\N	EFO	"A bone structure disease that involves a defect in the lumbar vertebral column." []	EFO	70971	EFO:0005649	\N	spondylolysis	EFO:0005649
0	"Cells are from the ventral leg imaginal disc of the third instar larval stage. Transcriptome analysis suggests similarity to cells in the tibia or femur region of a leg disc (Cherbas et al., 2011)." []	\N	CME-L1	\N	\N	EFO	"Cells are from the ventral leg imaginal disc of the third instar larval stage. Transcriptome analysis suggests similarity to cells in the tibia or femur region of a leg disc (Cherbas et al., 2011)." []	EFO	70972	EFO:0005650	\N	CME-L1	EFO:0005650
0	"" []	\N	drosophila developmental stage	\N	\N	EFO	"" []	EFO	70973	EFO:0005651	\N	drosophila developmental stage	EFO:0005651
0	"quantification of some metabolite in serum" []	\N	serum metabolite measurement	\N	\N	EFO	"quantification of some metabolite in serum" []	EFO	70974	EFO:0005653	\N	serum metabolite measurement	EFO:0005653
0	"quantification of the speed at which sound travels through bone as an indicator of the physical and structural properties of the bone" []	\N	velocity of sound measurement	\N	\N	EFO	"quantification of the speed at which sound travels through bone as an indicator of the physical and structural properties of the bone" []	EFO	70975	EFO:0005654	\N	velocity of sound measurement	EFO:0005654
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytosine arabinoside stimulus. Cytosine arabinoside is a cytidine analogue used as a drug in the treatment of various carcinomas." []	\N	response to cytosine arabinoside	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytosine arabinoside stimulus. Cytosine arabinoside is a cytidine analogue used as a drug in the treatment of various carcinomas." []	EFO	70976	EFO:0005655	\N	response to cytosine arabinoside	EFO:0005655
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a protease inhibitor, a class of antiviral drugs" []	\N	response to protease inhibitor	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a protease inhibitor, a class of antiviral drugs" []	EFO	70977	EFO:0005657	\N	response to protease inhibitor	EFO:0005657
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a selective serotonin reuptake inhibitor stimulus, a mood-stimulating drug." []	\N	response to selective serotonin reuptake inhibitor	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a selective serotonin reuptake inhibitor stimulus, a mood-stimulating drug." []	EFO	70978	EFO:0005658	\N	response to selective serotonin reuptake inhibitor	EFO:0005658
0	"Is the quantification of Beta-amyloid 1-40 in plasma, typically used as a biomarker for Alzheimer's Disease" []	\N	plasma beta-amyloid 1-40 measurement	\N	\N	EFO	"Is the quantification of Beta-amyloid 1-40 in plasma, typically used as a biomarker for Alzheimer's Disease" []	EFO	70979	EFO:0005659	\N	plasma beta-amyloid 1-40 measurement	EFO:0005659
0	"Is the quantification of Beta-amyloid 1-42 in plasma, typically used as a biomarker for Alzheimer's Disease" []	\N	plasma beta-amyloid 1-42 measurement	\N	\N	EFO	"Is the quantification of Beta-amyloid 1-42 in plasma, typically used as a biomarker for Alzheimer's Disease" []	EFO	70980	EFO:0005660	\N	plasma beta-amyloid 1-42 measurement	EFO:0005660
0	"The CBCL is a widely used checklist of between 100 and 120 questions (depending on target age group) for identifying problem behaviour in children." []	\N	Child Behaviour Checklist assessment	\N	\N	EFO	"The CBCL is a widely used checklist of between 100 and 120 questions (depending on target age group) for identifying problem behaviour in children." []	EFO	70981	EFO:0005661	\N	Child Behaviour Checklist assessment	EFO:0005661
0	"quantification of the glycoprotein uromodulin in urine" []	\N	urinary uromodulin measurement	\N	\N	EFO	"quantification of the glycoprotein uromodulin in urine" []	EFO	70982	EFO:0005663	\N	urinary uromodulin measurement	EFO:0005663
0	"quantification of some metabolite in blood" []	\N	blood metabolite measurement	\N	\N	EFO	"quantification of some metabolite in blood" []	EFO	70983	EFO:0005664	\N	blood metabolite measurement	EFO:0005664
0	"quantification of white matter hyperintensity, usually measured by MRI" []	\N	white matter hyperintensity measurement	\N	\N	EFO	"quantification of white matter hyperintensity, usually measured by MRI" []	EFO	70984	EFO:0005665	\N	white matter hyperintensity measurement	EFO:0005665
0	"quantification of the antibodies to the enzyme thyroid peroxidase in blood, usually as an indicator for autoimmune thyroid disease" []	\N	thyroid peroxidase antibody measurement	\N	\N	EFO	"quantification of the antibodies to the enzyme thyroid peroxidase in blood, usually as an indicator for autoimmune thyroid disease" []	EFO	70985	EFO:0005666	\N	thyroid peroxidase antibody measurement	EFO:0005666
0	"quantification of the amount of albumin excreted in urine, measured as an indicator for kidney malfunctions such as diabetic nephropathy" []	\N	urinary albumin excretion rate	\N	\N	EFO	"quantification of the amount of albumin excreted in urine, measured as an indicator for kidney malfunctions such as diabetic nephropathy" []	EFO	70986	EFO:0005667	\N	urinary albumin excretion rate	EFO:0005667
0	"quantification of the depth of the anterior chamber of the eye as an indicator for eye disease such as primary angle closure glaucoma" []	\N	anterior chamber depth measurement	\N	\N	EFO	"quantification of the depth of the anterior chamber of the eye as an indicator for eye disease such as primary angle closure glaucoma" []	EFO	70987	EFO:0005668	\N	anterior chamber depth measurement	EFO:0005668
0	"stroke subtype classified by the rupture of blood vessels in the lobar or nonlobar regions of the brain" []	\N	intracerebral hemorrhage	\N	\N	EFO	"stroke subtype classified by the rupture of blood vessels in the lobar or nonlobar regions of the brain" []	EFO	70988	EFO:0005669	\N	intracerebral hemorrhage	EFO:0005669
0	"initation of the habit of smoking, the inhaling and exhaling of tobacco smoke." []	\N	smoking initiation	\N	\N	EFO	"initation of the habit of smoking, the inhaling and exhaling of tobacco smoke." []	EFO	70989	EFO:0005670	\N	smoking initiation	EFO:0005670
0	"the quantification of some smoking or smoking-related behaviour, usually self-reported via a questionnaire" []	\N	smoking behaviour measurement	\N	\N	EFO	"the quantification of some smoking or smoking-related behaviour, usually self-reported via a questionnaire" []	EFO	70990	EFO:0005671	\N	smoking behaviour measurement	EFO:0005671
0	"A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction." []	\N	acute coronary syndrome	\N	\N	EFO	"A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction." []	EFO	70991	EFO:0005672	\N	acute coronary syndrome	EFO:0005672
0	"" []	\N	chronic mucus hypersecretion	\N	\N	EFO	"" []	EFO	70992	EFO:0005673	\N	chronic mucus hypersecretion	EFO:0005673
0	"quantification of the microstructre of the white matter of the brain" []	\N	white matter microstructure measurement	\N	\N	EFO	"quantification of the microstructre of the white matter of the brain" []	EFO	70993	EFO:0005674	\N	white matter microstructure measurement	EFO:0005674
0	"the quantification of vitamin D-binding protein in blood as a biomarker for vitamin D-related diseases such as osteoporosis, arthritis, cardiovascular disease and cancer" []	\N	vitamin D-binding protein measurement	\N	\N	EFO	"the quantification of vitamin D-binding protein in blood as a biomarker for vitamin D-related diseases such as osteoporosis, arthritis, cardiovascular disease and cancer" []	EFO	70994	EFO:0005675	\N	vitamin D-binding protein measurement	EFO:0005675
0	"Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma." []	\N	autoimmune hepatits type 1	\N	\N	EFO	"Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma." []	EFO	70995	EFO:0005676	\N	autoimmune hepatits type 1	EFO:0005676
0	"quantification of the onset of puberty in human males and females through a series of proxy measurements such as genital enlargement (males) or breast development (females). These characteristics are assessed based on pre-defined scales either through self-reporting or through assessment by a medical professional." []	\N	puberty onset measurement	\N	\N	EFO	"quantification of the onset of puberty in human males and females through a series of proxy measurements such as genital enlargement (males) or breast development (females). These characteristics are assessed based on pre-defined scales either through self-reporting or through assessment by a medical professional." []	EFO	70996	EFO:0005677	\N	puberty onset measurement	EFO:0005677
0	"age-related neuropathological condition with severe neuronal cell loss and gliosis in the hippocampus" []	\N	hippocampal sclerosis of aging	\N	\N	EFO	"age-related neuropathological condition with severe neuronal cell loss and gliosis in the hippocampus" []	EFO	70997	EFO:0005678	\N	hippocampal sclerosis of aging	EFO:0005678
0	"conotruncal and related malformations account for around a third of all congential heart defects and include a range of conditions including but not limited to tetralogy of Fallot, D-transposition of the great arteries, ventricular septal defects (conoventricular, posterior malalignment and conoseptal hypoplasia), double outlet right ventricle, aortic arch anomalies, truncus arteriosus, and interrupted aortic arch." []	\N	conotruncal heart defect	\N	\N	EFO	"conotruncal and related malformations account for around a third of all congential heart defects and include a range of conditions including but not limited to tetralogy of Fallot, D-transposition of the great arteries, ventricular septal defects (conoventricular, posterior malalignment and conoseptal hypoplasia), double outlet right ventricle, aortic arch anomalies, truncus arteriosus, and interrupted aortic arch." []	EFO	70998	EFO:0005679	\N	conotruncal heart defect	EFO:0005679
0	"The determination of the amount of omega-6 polyunsaturated fatty acids present in a sample." []	\N	omega-6 polyunsaturated fatty acid measurement	\N	\N	EFO	"The determination of the amount of omega-6 polyunsaturated fatty acids present in a sample." []	EFO	70999	EFO:0005680	\N	omega-6 polyunsaturated fatty acid measurement	EFO:0005680
0	"Staphylococcus aureus infection is a bacterial disease caused by infection from the Staphylococcus aureus bacteria." []	\N	Staphylococcus aureus infection	\N	\N	EFO	"Staphylococcus aureus infection is a bacterial disease caused by infection from the Staphylococcus aureus bacteria." []	EFO	71000	EFO:0005681	\N	Staphylococcus aureus infection	EFO:0005681
0	"quantification of the relative amount of oxygen that is dissolved or carried in a given medium" []	\N	oxygen saturation measurement	\N	\N	EFO	"quantification of the relative amount of oxygen that is dissolved or carried in a given medium" []	EFO	71001	EFO:0005682	\N	oxygen saturation measurement	EFO:0005682
0	"A portion of plant tissue that consists of mass of undifferentiated plant cells. Consists primarily of parenchyma cells but may contain other cell types as the callus begins to differentiate. May be formed as a result of wounding or may develop in culture." []	\N	plant callus	\N	\N	EFO	"A portion of plant tissue that consists of mass of undifferentiated plant cells. Consists primarily of parenchyma cells but may contain other cell types as the callus begins to differentiate. May be formed as a result of wounding or may develop in culture." []	EFO	71002	EFO:0005683	\N	plant callus	EFO:0005683
0	"An assay in which sequencing technology (e.g. Illumina) is used to generate RNA sequence, from the presumed coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance in individual cells instead of a population of cells." []	\N	RNA-seq of coding RNA from single cells	\N	\N	EFO	"An assay in which sequencing technology (e.g. Illumina) is used to generate RNA sequence, from the presumed coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance in individual cells instead of a population of cells." []	EFO	71003	EFO:0005684	\N	RNA-seq of coding RNA from single cells	EFO:0005684
0	"An assay in which sequencing technology (e.g. Illumina) is used to generate RNA sequence, from the presumed non-coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance in individual cells instead of a population of cells." []	\N	RNA-seq of non coding RNA from single cells	\N	\N	EFO	"An assay in which sequencing technology (e.g. Illumina) is used to generate RNA sequence, from the presumed non-coding transcibed regions of the genome, or analyse these or to quantitate transcript abundance in individual cells instead of a population of cells." []	EFO	71004	EFO:0005685	\N	RNA-seq of non coding RNA from single cells	EFO:0005685
0	"Receptive language means the ability to understand or comprehend language heard or read" []	\N	receptive language perception	\N	\N	EFO	"Receptive language means the ability to understand or comprehend language heard or read" []	EFO	71005	EFO:0005686	\N	receptive language perception	EFO:0005686
0	"A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation." []	\N	fibromyalgia	\N	\N	EFO	"A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation." []	EFO	71006	EFO:0005687	\N	fibromyalgia	EFO:0005687
0	"non-high-density lipoprotein cholesterol (NHDL), calculated by subtracting the amount of cholesterol in the HDL fraction from total cholesterol, quantifies almost all potentially atherogenic apolipoprotein B containing lipoproteins encompassing cholesterol bound to low-density lipoproteins (LDL), very low-density lipoproteins, intermediate-density lipoproteins, lipoprotein(a), chylomicrons, and chylomicron remnants" []	\N	NHDL cholesterol	\N	\N	EFO	"non-high-density lipoprotein cholesterol (NHDL), calculated by subtracting the amount of cholesterol in the HDL fraction from total cholesterol, quantifies almost all potentially atherogenic apolipoprotein B containing lipoproteins encompassing cholesterol bound to low-density lipoproteins (LDL), very low-density lipoproteins, intermediate-density lipoproteins, lipoprotein(a), chylomicrons, and chylomicron remnants" []	EFO	71007	EFO:0005688	\N	NHDL cholesterol	EFO:0005688
0	"The quantification of NHDL cholesterol in blood, calculated by subtracting the amount of cholesterol in the HDL fraction from total cholesterol and used as an indicator for cardiovascular disease risk" []	\N	non-high density lipoprotein cholesterol measurement	\N	\N	EFO	"The quantification of NHDL cholesterol in blood, calculated by subtracting the amount of cholesterol in the HDL fraction from total cholesterol and used as an indicator for cardiovascular disease risk" []	EFO	71008	EFO:0005689	\N	non-high density lipoprotein cholesterol measurement	EFO:0005689
0	"" []	\N	musical aptitude	\N	\N	EFO	"" []	EFO	71009	EFO:0005690	\N	musical aptitude	EFO:0005690
0	"The quantification in blood of trimethylamine N-oxide, a product of gut microbiome and hepatic-mediated metabolism of dietary choline and L-carnitine" []	\N	plasma trimethylamine N-oxide measurement	\N	\N	EFO	"The quantification in blood of trimethylamine N-oxide, a product of gut microbiome and hepatic-mediated metabolism of dietary choline and L-carnitine" []	EFO	71010	EFO:0005691	\N	plasma trimethylamine N-oxide measurement	EFO:0005691
0	"transposable element identification design type aims to discover non-reference transposable element (TE) insertions from whole genome sequencing data." []	\N	transposable element identification design	\N	\N	EFO	"transposable element identification design type aims to discover non-reference transposable element (TE) insertions from whole genome sequencing data." []	EFO	71011	EFO:0005692	\N	transposable element identification design	EFO:0005692
0	"mobile element identification design type aims to discover the mobile element (ME) insertions from whole genome sequencing data. The methodology may include the translation of read-pair and split-read mapping signals to detect ME insertions (MEIs)." []	\N	mobile element identification design	\N	\N	EFO	"mobile element identification design type aims to discover the mobile element (ME) insertions from whole genome sequencing data. The methodology may include the translation of read-pair and split-read mapping signals to detect ME insertions (MEIs)." []	EFO	71012	EFO:0005693	\N	mobile element identification design	EFO:0005693
0	"KMS-11 cell line was derived from four patients with multiple myeloma. These cells represent a later stage of B-cell differentiation, and shows characteristics of plasma cells by secreting surface kappa chain immunoglobulins." []	\N	KMS-11	\N	\N	EFO	"KMS-11 cell line was derived from four patients with multiple myeloma. These cells represent a later stage of B-cell differentiation, and shows characteristics of plasma cells by secreting surface kappa chain immunoglobulins." []	EFO	71013	EFO:0005694	\N	KMS-11	EFO:0005694
0	"Medulloblastoma (aka D721), surgical resection from a patient with medulloblastoma as described by Darrell Bigner (1997)" []	\N	D721Med	\N	\N	EFO	"Medulloblastoma (aka D721), surgical resection from a patient with medulloblastoma as described by Darrell Bigner (1997)" []	EFO	71014	EFO:0005696	\N	D721Med	EFO:0005696
0	"M059J cells were isolated from a tumor specimen taken from a 33 year old male with untreated malignant glioblastoma. The cells were isolated concurrently from the same tumor specimen as M059K (see CRL-2365)." []	\N	M059J	\N	\N	EFO	"M059J cells were isolated from a tumor specimen taken from a 33 year old male with untreated malignant glioblastoma. The cells were isolated concurrently from the same tumor specimen as M059K (see CRL-2365)." []	EFO	71015	EFO:0005697	\N	M059J	EFO:0005697
0	"The Daoy cell line was established in 1985 by P. F Jacobsen of the Royal Perth Hospital in Western Australia. The line was derived from biopsy material taken from a tumor in the posterior fossa of a 4 year old boy." []	\N	Daoy	\N	\N	EFO	"The Daoy cell line was established in 1985 by P. F Jacobsen of the Royal Perth Hospital in Western Australia. The line was derived from biopsy material taken from a tumor in the posterior fossa of a 4 year old boy." []	EFO	71016	EFO:0005698	\N	Daoy	EFO:0005698
0	"The desmoplastic variant of medulloblastoma is a highly malignant primary brain tumor and is typically seen in adolescents or young adults and tends to favor one of the cerebellar hemispheres." []	\N	desmoplastic medulloblastoma	\N	\N	EFO	"The desmoplastic variant of medulloblastoma is a highly malignant primary brain tumor and is typically seen in adolescents or young adults and tends to favor one of the cerebellar hemispheres." []	EFO	71017	EFO:0005699	\N	desmoplastic medulloblastoma	EFO:0005699
0	"This is an adherent cell line derived from a hepatic rhabdoid tumor. Hepatic rhabdoid tumors are extremely rare. This cell line has a large deletion on 22q, which indicates numerous genes in addition to SNF5 are deleted." []	\N	TTC549	\N	\N	EFO	"This is an adherent cell line derived from a hepatic rhabdoid tumor. Hepatic rhabdoid tumors are extremely rare. This cell line has a large deletion on 22q, which indicates numerous genes in addition to SNF5 are deleted." []	EFO	71018	EFO:0005700	\N	TTC549	EFO:0005700
0	"Malignant rhabdoid tumour (MRT) is a very aggressive form of tumour originally described as a variant of Wilms tumour, which is primarily a kidney tumour that occurs mainly in children." []	\N	malignant rhabdoid tumour	\N	\N	EFO	"Malignant rhabdoid tumour (MRT) is a very aggressive form of tumour originally described as a variant of Wilms tumour, which is primarily a kidney tumour that occurs mainly in children." []	EFO	71019	EFO:0005701	\N	malignant rhabdoid tumour	EFO:0005701
0	"A malignant rhabdoid tumor diploid cell population cloned from the A204 ATCC cell line. [PMID: 16897758]" []	\N	A204.1	\N	\N	EFO	"A malignant rhabdoid tumor diploid cell population cloned from the A204 ATCC cell line. [PMID: 16897758]" []	EFO	71020	EFO:0005702	\N	A204.1	EFO:0005702
0	"This is an adherent cell line that represents the prototypical renal rhabdoid tumor [PMID: 16897758]. G401.6 is a diploid, 6-thioguanine-resistant clonal variant of the G401 cell line isolated by Weissman et al., Science, 236:175-180 (1986). The parental cell line, G401, can be ordered from the ATCC (CRL1441)." []	\N	G401.6	\N	\N	EFO	"This is an adherent cell line that represents the prototypical renal rhabdoid tumor [PMID: 16897758]. G401.6 is a diploid, 6-thioguanine-resistant clonal variant of the G401 cell line isolated by Weissman et al., Science, 236:175-180 (1986). The parental cell line, G401, can be ordered from the ATCC (CRL1441)." []	EFO	71021	EFO:0005703	\N	G401.6	EFO:0005703
0	"HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers. HuH7.5 developed from HuH7." []	\N	HuH-7.5	\N	\N	EFO	"HuH-7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was originally taken from a liver tumor in a 57-year-old Japanese male in 1982. The line was established by Nakabayshi, H. and Sato, J. HuH-7 is an immortal cell line of epithelial-like tumorigenic cells. It usually grow in 2D monolayers. HuH7.5 developed from HuH7." []	EFO	71022	EFO:0005704	\N	HuH-7.5	EFO:0005704
0	"Nasal biopsies were collected from volunteer donors as an outpatient procedure as described (Feron et al., 1998). This was done by a registered otolaryngologist via an endoscopic procedure to ensure biopsy samples were taken from the superior, posterior region of the nasal septum close to the cribriform plate. Pieces of olfactory mucosa were obtained which contain stem cells in the olfactory epithelium. The stem cell population derived from human olfactory mucosa has been described as ecto-mesenchymal (Delorme et al., 2010) because it has characteristics of both neural and mesenchymal stem cells, suggesting a neural crest origin." []	\N	olfactory neurosphere cell line	\N	\N	EFO	"Nasal biopsies were collected from volunteer donors as an outpatient procedure as described (Feron et al., 1998). This was done by a registered otolaryngologist via an endoscopic procedure to ensure biopsy samples were taken from the superior, posterior region of the nasal septum close to the cribriform plate. Pieces of olfactory mucosa were obtained which contain stem cells in the olfactory epithelium. The stem cell population derived from human olfactory mucosa has been described as ecto-mesenchymal (Delorme et al., 2010) because it has characteristics of both neural and mesenchymal stem cells, suggesting a neural crest origin." []	EFO	71023	EFO:0005705	\N	olfactory neurosphere cell line	EFO:0005705
0	"This cell line was from a melanoma metastasis tumor taken from the subcutaneous shoulder of an individual. Cell line was derived by Dr. Yardena Samuels (samuelsy" []	\N	Mel-2183	\N	\N	EFO	"This cell line was from a melanoma metastasis tumor taken from the subcutaneous shoulder of an individual. Cell line was derived by Dr. Yardena Samuels (samuelsy" []	EFO	71024	EFO:0005706	\N	Mel-2183	EFO:0005706
0	"This line was derived from a primary clear cell adenocarcinoma. The karyotype is hypertriploid; Y was present in 60% the cells examined. The cells display both microvilli and desmosomes, and can be grown in soft agar. The cells produce a PTH like peptides that is identical to peptides produced by breast and lung tumors." []	\N	786-0	\N	\N	EFO	"This line was derived from a primary clear cell adenocarcinoma. The karyotype is hypertriploid; Y was present in 60% the cells examined. The cells display both microvilli and desmosomes, and can be grown in soft agar. The cells produce a PTH like peptides that is identical to peptides produced by breast and lung tumors." []	EFO	71025	EFO:0005707	\N	786-0	EFO:0005707
0	"" []	\N	renal cell adenocarcinoma	\N	\N	EFO	"" []	EFO	71026	EFO:0005708	\N	renal cell adenocarcinoma	EFO:0005708
0	"First trimester human trophoblast cells established by immortalizing a physiologic extravillous trophoblast cell via transfection with a plasmid containing the simian virus 40 large T antigen (SV40) (see Graham et al., 1993). Cells are a thin layer of ectoderm that forms the wall of many mammalian blastulas and functions in the nutrition and implantation of the embryo." []	\N	HTR8/SVneo	\N	\N	EFO	"First trimester human trophoblast cells established by immortalizing a physiologic extravillous trophoblast cell via transfection with a plasmid containing the simian virus 40 large T antigen (SV40) (see Graham et al., 1993). Cells are a thin layer of ectoderm that forms the wall of many mammalian blastulas and functions in the nutrition and implantation of the embryo." []	EFO	71027	EFO:0005709	\N	HTR8/SVneo	EFO:0005709
0	"This is an adherent cell line. HFF-Myc are human foreskin fibroblasts containing a virally integrated vector expressing the canine cMyc gene. Cells were received from Dr. Beverly Torok-Storb, Fred Hutchison Cancer Research Center, Seattle, WA." []	\N	HFF-Myc	\N	\N	EFO	"This is an adherent cell line. HFF-Myc are human foreskin fibroblasts containing a virally integrated vector expressing the canine cMyc gene. Cells were received from Dr. Beverly Torok-Storb, Fred Hutchison Cancer Research Center, Seattle, WA." []	EFO	71028	EFO:0005710	\N	HFF-Myc	EFO:0005710
0	"Normal benign adult human pancreatic duct cells immortalized with E6E7 gene of HPV-16. HPDE6-E6E7 cells demonstrated a near normal genotype and phenotype of pancreatic duct epithelial cells. [PMC1861644]" []	\N	HPDE6-E6E7	\N	\N	EFO	"Normal benign adult human pancreatic duct cells immortalized with E6E7 gene of HPV-16. HPDE6-E6E7 cells demonstrated a near normal genotype and phenotype of pancreatic duct epithelial cells. [PMC1861644]" []	EFO	71029	EFO:0005711	\N	HPDE6-E6E7	EFO:0005711
0	"Human skin malignant melanoma cells that can be ordered from ATCC. This is a hyperdiploid human cell line with the modal chromosome number of 49, occurring in 24% of cells. Polyploid cells occurred at 22%, which is high. Cells are adherent, and were first harvested in 1971 from a metastatic site in a lymph node." []	\N	RPMI-7951	\N	\N	EFO	"Human skin malignant melanoma cells that can be ordered from ATCC. This is a hyperdiploid human cell line with the modal chromosome number of 49, occurring in 24% of cells. Polyploid cells occurred at 22%, which is high. Cells are adherent, and were first harvested in 1971 from a metastatic site in a lymph node." []	EFO	71030	EFO:0005712	\N	RPMI-7951	EFO:0005712
0	"Human pancreas adenocarcinoma (PA-TU-8988T), \\"established in 1985 from the liver metastasis of a primary pancreatic adenocarcinoma from a 64-year-old woman; sister cell line of PA-TU-8988S\\" - DSMZ." []	\N	8988T	\N	\N	EFO	"Human pancreas adenocarcinoma (PA-TU-8988T), \\"established in 1985 from the liver metastasis of a primary pancreatic adenocarcinoma from a 64-year-old woman; sister cell line of PA-TU-8988S\\" - DSMZ." []	EFO	71031	EFO:0005713	\N	8988T	EFO:0005713
0	"Skeletal myoblasts derived from satellite cells from the pectoralis major muscle of a 41 year old caucasian heart transplant donor, immortalized with lox-hygro-hTERT (LH), and Cdk4-neo (CN), Zhu et al. (2007) in Aging Cell, vol. 6, pp 515-523. M2 is an extremely well-differentiating subclone of LHCN (thus \\"LHCN-M2\\")." []	\N	LHCN-M2	\N	\N	EFO	"Skeletal myoblasts derived from satellite cells from the pectoralis major muscle of a 41 year old caucasian heart transplant donor, immortalized with lox-hygro-hTERT (LH), and Cdk4-neo (CN), Zhu et al. (2007) in Aging Cell, vol. 6, pp 515-523. M2 is an extremely well-differentiating subclone of LHCN (thus \\"LHCN-M2\\")." []	EFO	71032	EFO:0005714	\N	LHCN-M2	EFO:0005714
0	"The WERI-Rb-1 line is one of two human retinoblastoma cell lines established in 1974 by R.M. McFall and T.W. Sery. This is a near diploid line. The modal chromosome number is 47 occurring at 38%, and the rate of polyploidy is 9%. Cells are grape-like clusters of round cells in suspension." []	\N	WERI-Rb-1	\N	\N	EFO	"The WERI-Rb-1 line is one of two human retinoblastoma cell lines established in 1974 by R.M. McFall and T.W. Sery. This is a near diploid line. The modal chromosome number is 47 occurring at 38%, and the rate of polyploidy is 9%. Cells are grape-like clusters of round cells in suspension." []	EFO	71033	EFO:0005715	\N	WERI-Rb-1	EFO:0005715
0	"Malignant neoplasm of retina." []	\N	retinal cancer	\N	\N	EFO	"Malignant neoplasm of retina." []	EFO	71034	EFO:0005716	\N	retinal cancer	EFO:0005716
0	"A retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives_from the tissues of the retina. OMIM mapping confirmed by DO. [LS]." []	\N	retinoblastoma (nonhereditary)	\N	\N	EFO	"A retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives_from the tissues of the retina. OMIM mapping confirmed by DO. [LS]." []	EFO	71035	EFO:0005717	\N	retinoblastoma (nonhereditary)	EFO:0005717
0	"\\"The cell line Ishikawa was established from an endometrial adenocarcinoma of a 39 year old woman. Cells can be commercially obtained from Sigma (99040201-1VL). However, it should be noted that the original source of these cells (M. Nashide, Japan) can spontaneously lose the progesterone and \\nestrogen receptor. For details, see Nishida M., The Ishikawa cells from birth to the \\npresent. Hum Cell. 2002 Sep;15(3):104-17.\\"" []	\N	Ishikawa	\N	\N	EFO	"\\"The cell line Ishikawa was established from an endometrial adenocarcinoma of a 39 year old woman. Cells can be commercially obtained from Sigma (99040201-1VL). However, it should be noted that the original source of these cells (M. Nashide, Japan) can spontaneously lose the progesterone and \\nestrogen receptor. For details, see Nishida M., The Ishikawa cells from birth to the \\npresent. Hum Cell. 2002 Sep;15(3):104-17.\\"" []	EFO	71036	EFO:0005718	\N	Ishikawa	EFO:0005718
0	"Established from a pleural effusion of 73 year-old woman diagnosed with B-cell non-Hodgkin lymphoma (intra-abdominal, diffuse large cell lymphoma, refractory, terminal). Cells are available from Dr Abraham Karpas, Department of Haematology, University of Cambridge, and are round and polygonal, growing in suspension. [PMID: 2297573]" []	\N	Karpas 422	\N	\N	EFO	"Established from a pleural effusion of 73 year-old woman diagnosed with B-cell non-Hodgkin lymphoma (intra-abdominal, diffuse large cell lymphoma, refractory, terminal). Cells are available from Dr Abraham Karpas, Department of Haematology, University of Cambridge, and are round and polygonal, growing in suspension. [PMID: 2297573]" []	EFO	71037	EFO:0005719	\N	Karpas 422	EFO:0005719
0	"This melanoma cell line was derived from a metastatic axillary node of the skin of a 24 year old female. It is a hyperpentaploid human cell line with the modal chromosome number of 120, occurring in 9% of cells. [PMID: 1067619]" []	\N	SK-MEL-5	\N	\N	EFO	"This melanoma cell line was derived from a metastatic axillary node of the skin of a 24 year old female. It is a hyperpentaploid human cell line with the modal chromosome number of 120, occurring in 9% of cells. [PMID: 1067619]" []	EFO	71038	EFO:0005720	\N	SK-MEL-5	EFO:0005720
0	"SK-N-DZ is a neuroblastoma cell line derived in 1978 from a bone marrow metastasis from a child with poorly differentiated embryonal neuroblastoma." []	\N	SK-N-DZ	\N	\N	EFO	"SK-N-DZ is a neuroblastoma cell line derived in 1978 from a bone marrow metastasis from a child with poorly differentiated embryonal neuroblastoma." []	EFO	71039	EFO:0005721	\N	SK-N-DZ	EFO:0005721
0	"The line was established from cells from the bone marrow of a child with rhabdomyosarcoma. Derived from a metastatic site of the bone marrow. The cells show ultrastructural elements of primitive skeletal muscle differentiation." []	\N	SJCRH30	\N	\N	EFO	"The line was established from cells from the bone marrow of a child with rhabdomyosarcoma. Derived from a metastatic site of the bone marrow. The cells show ultrastructural elements of primitive skeletal muscle differentiation." []	EFO	71040	EFO:0005722	\N	SJCRH30	EFO:0005722
0	"Fibroblasts taken from a skin punch of the arm" []	\N	GM23248	\N	\N	EFO	"Fibroblasts taken from a skin punch of the arm" []	EFO	71041	EFO:0005723	\N	GM23248	EFO:0005723
0	"MM.1S is a B lymphoblast cell line derived in 1986. The parent cell line, MM.1, was established from peripheral blood of a multiple myeloma patient who had become resistant to steroid-based therapy. provide critical information about disease progression and the development of drug resistance. This cell line represents a valuable tool for elucidating the mechanisms of action of glucocorticoids and the development of new therapeutics. [PMID: 2926241]" []	\N	MM.1S	\N	\N	EFO	"MM.1S is a B lymphoblast cell line derived in 1986. The parent cell line, MM.1, was established from peripheral blood of a multiple myeloma patient who had become resistant to steroid-based therapy. provide critical information about disease progression and the development of drug resistance. This cell line represents a valuable tool for elucidating the mechanisms of action of glucocorticoids and the development of new therapeutics. [PMID: 2926241]" []	EFO	71042	EFO:0005724	\N	MM.1S	EFO:0005724
0	"BE(2)-C is a clone of the SK-N-BE(2) neuroblastoma cell line (ATCC CRL-2271) that was established in November of 1972 from a bone marrow biopsy taken from child with disseminated neuroblastoma after repeated courses of chemotherapy and radiotherapy. The cells grow as clusters of flattened neuroblastic cells with occasional fine cell processes (neurites). Unlike the parent line, they generally do not detach and float." []	\N	BE(2)-C	\N	\N	EFO	"BE(2)-C is a clone of the SK-N-BE(2) neuroblastoma cell line (ATCC CRL-2271) that was established in November of 1972 from a bone marrow biopsy taken from child with disseminated neuroblastoma after repeated courses of chemotherapy and radiotherapy. The cells grow as clusters of flattened neuroblastic cells with occasional fine cell processes (neurites). Unlike the parent line, they generally do not detach and float." []	EFO	71043	EFO:0005725	\N	BE(2)-C	EFO:0005725
0	"LNCaP clone FGC was isolated in 1977 by J.S. Horoszewicz, et al., from a needle aspiration biopsy of the left supraclavicular lymph node of a 50-year-old Caucasian male (blood type B+) with confirmed diagnosis of metastatic prostate carcinoma. This is a hypotetraploid human cell line. The modal chromosome number was 84, occurring in 22% of cells. However, cells with chromosome counts of 86 (20%) and 87 (18%) also occurred at high frequencies. These cells are responsive to 5-alpha-dihydrotestosterone (growth modulation and acid phosphatase production)." []	\N	LNCaP clone FGC	\N	\N	EFO	"LNCaP clone FGC was isolated in 1977 by J.S. Horoszewicz, et al., from a needle aspiration biopsy of the left supraclavicular lymph node of a 50-year-old Caucasian male (blood type B+) with confirmed diagnosis of metastatic prostate carcinoma. This is a hypotetraploid human cell line. The modal chromosome number was 84, occurring in 22% of cells. However, cells with chromosome counts of 86 (20%) and 87 (18%) also occurred at high frequencies. These cells are responsive to 5-alpha-dihydrotestosterone (growth modulation and acid phosphatase production)." []	EFO	71044	EFO:0005726	\N	LNCaP clone FGC	EFO:0005726
0	"A bronchial epithelial cell derived cell line is defined as something that derives from an airway epithelial cell\\n" []	\N	bronchial epithelial cell derived cell line\\n	\N	\N	EFO	"A bronchial epithelial cell derived cell line is defined as something that derives from an airway epithelial cell\\n" []	EFO	71045	EFO:0005728	\N	bronchial epithelial cell derived cell line\\n	EFO:0005728
0	"An endothelial cell derived cell line is defined as something that derives from an endothelial cell." []	\N	endothelial cell line derived cell line	\N	\N	EFO	"An endothelial cell derived cell line is defined as something that derives from an endothelial cell." []	EFO	71046	EFO:0005730	\N	endothelial cell line derived cell line	EFO:0005730
0	"A cardiac myocyte cell derived cell line is defined as something that derives from cardiac myocyte cell" []	\N	cardiac myocyte cell derived cell line	\N	\N	EFO	"A cardiac myocyte cell derived cell line is defined as something that derives from cardiac myocyte cell" []	EFO	71047	EFO:0005731	\N	cardiac myocyte cell derived cell line	EFO:0005731
0	"A plant environment involving the application of an abiotic or biotic treatment." []	\N	plant treatment	\N	\N	EFO	"A plant environment involving the application of an abiotic or biotic treatment." []	EFO	71048	EO:0001001	\N	plant treatment	EO:0001001
0	"Imaginal disc of the ventral prothoracic segment. Precursor of structures of the adult ventral prothorax including the prothoracic (1st) leg." []	\N	prothoracic leg disc	\N	\N	EFO	"Imaginal disc of the ventral prothoracic segment. Precursor of structures of the adult ventral prothorax including the prothoracic (1st) leg." []	EFO	71049	FBbt:00001781	\N	prothoracic leg disc	FBbt:00001781
0	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an etoposide stimulus." []	\N	response to etoposide	\N	\N	EFO	"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an etoposide stimulus." []	EFO	71050	GO:190252	\N	response to etoposide	GO:190252
0	"The pattern in which a particular genetic trait or disorder is passed from one generation to the next." []	\N	mode of inheritance	\N	\N	EFO	"The pattern in which a particular genetic trait or disorder is passed from one generation to the next." []	EFO	71051	HP:0000005	\N	mode of inheritance	HP:0000005
0	"An abnormality of the skeletal system." []	\N	abnormality of the skeletal system	\N	\N	EFO	"An abnormality of the skeletal system." []	EFO	71052	HP:0000924	\N	abnormality of the skeletal system	HP:0000924
0	"Osteopenia refers to a reduction in bone mineral density (BMD) below normal peak BMD but not low enough to be classified as osteoporosis. According to the WHO, osteopenia is characterized by a value of BMD more than 1 standard deviation below the young adult mean, but less than 2 standard deviations below this value." []	\N	osteopenia	\N	\N	EFO	"Osteopenia refers to a reduction in bone mineral density (BMD) below normal peak BMD but not low enough to be classified as osteoporosis. According to the WHO, osteopenia is characterized by a value of BMD more than 1 standard deviation below the young adult mean, but less than 2 standard deviations below this value." []	EFO	71053	HP:0000938	\N	osteopenia	HP:0000938
0	"An abnormality of the skin." []	\N	abnormality of the skin	\N	\N	EFO	"An abnormality of the skin." []	EFO	71054	HP:0000951	\N	abnormality of the skin	HP:0000951
0	"Any manifestation of a skin disease associated with the production of pus." []	\N	pyoderma	\N	\N	EFO	"Any manifestation of a skin disease associated with the production of pus." []	EFO	71055	HP:0000999	\N	pyoderma	HP:0000999
0	"Loss of previously present mental abilities, generally in adults." []	\N	cognitive decline	\N	\N	EFO	"Loss of previously present mental abilities, generally in adults." []	EFO	71056	HP:0001268	\N	cognitive decline	HP:0001268
0	"" []	\N	heterogeneous	\N	\N	EFO	"" []	EFO	71057	HP:0001425	\N	heterogeneous	HP:0001425
0	"Abnormality of the abdomen ('belly'), that is, the part of the body between the pelvis and the thorax." []	\N	abnormality of the abdomen	\N	\N	EFO	"Abnormality of the abdomen ('belly'), that is, the part of the body between the pelvis and the thorax." []	EFO	71058	HP:0001438	\N	abnormality of the abdomen	HP:0001438
0	"Abnormality of growth." []	\N	growth abnormality	\N	\N	EFO	"Abnormality of growth." []	EFO	71059	HP:0001507	\N	growth abnormality	HP:0001507
0	"A deficiency or slowing down of growth pre- and postnatally. Poor or abnormally slow gains in weight or height in a child." []	\N	growth delay	\N	\N	EFO	"A deficiency or slowing down of growth pre- and postnatally. Poor or abnormally slow gains in weight or height in a child." []	EFO	71060	HP:0001510	\N	growth delay	HP:0001510
0	"Accumulation of fluid in the peritoneal cavity. Ascites is commonly associated with liver disease that has resulted in portal hypertension and low serum albumin levels." []	\N	ascites	\N	\N	EFO	"Accumulation of fluid in the peritoneal cavity. Ascites is commonly associated with liver disease that has resulted in portal hypertension and low serum albumin levels." []	EFO	71061	HP:0001541	\N	ascites	HP:0001541
0	"Excessive postnatal growth which may comprise increased weight, increased length, and/or increased head circumference." []	\N	overgrowth	\N	\N	EFO	"Excessive postnatal growth which may comprise increased weight, increased length, and/or increased head circumference." []	EFO	71062	HP:0001548	\N	overgrowth	HP:0001548
0	"An abnormality of the integument, which consists of the skin and the superficial fascia." []	\N	abnormality of the integument	\N	\N	EFO	"An abnormality of the integument, which consists of the skin and the superficial fascia." []	EFO	71063	HP:0001574	\N	abnormality of the integument	HP:0001574
0	"Any abnormality of the `cardiovascular system` (FMA:7161)." []	\N	abnormal phenotype of the cardiovascular system	\N	\N	EFO	"Any abnormality of the `cardiovascular system` (FMA:7161)." []	EFO	71064	HP:0001626	\N	abnormal phenotype of the cardiovascular system	HP:0001626
0	"Increased time between the start of the Q wave and the end of the T wave as measured by the electrocardiogram (EKG)." []	\N	prolonged QT interval	\N	\N	EFO	"Increased time between the start of the Q wave and the end of the T wave as measured by the electrocardiogram (EKG)." []	EFO	71065	HP:0001657	\N	prolonged QT interval	HP:0001657
0	"An abnormality of the `aorta` (FMA:3734)." []	\N	phenotypic abnormality of the aorta	\N	\N	EFO	"An abnormality of the `aorta` (FMA:3734)." []	EFO	71066	HP:0001679	\N	phenotypic abnormality of the aorta	HP:0001679
0	"Reduction in existing body weight." []	\N	weight loss	\N	\N	EFO	"Reduction in existing body weight." []	EFO	71067	HP:0001824	\N	weight loss	HP:0001824
0	"An abnormality of the hematopoietic system." []	\N	abnormality of blood and blood-forming tissues	\N	\N	EFO	"An abnormality of the hematopoietic system." []	EFO	71068	HP:0001871	\N	abnormality of blood and blood-forming tissues	HP:0001871
0	"" []	\N	iron deficiency anemia	\N	\N	EFO	"" []	EFO	71069	HP:0001891	\N	iron deficiency anemia	HP:0001891
0	"" []	\N	abnormality of metabolism/homeostasis	\N	\N	EFO	"" []	EFO	71070	HP:0001939	\N	abnormality of metabolism/homeostasis	HP:0001939
0	"Elevated body temperature due to failed thermoregulation." []	\N	fever	\N	\N	EFO	"Elevated body temperature due to failed thermoregulation." []	EFO	71071	HP:0001945	\N	fever	HP:0001945
0	"Abnormally increased frequency of loose or watery bowel movements." []	\N	diarrhea	\N	\N	EFO	"Abnormally increased frequency of loose or watery bowel movements." []	EFO	71072	HP:0002014	\N	diarrhea	HP:0002014
0	"Infrequent or difficult evacuation of feces." []	\N	constipation	\N	\N	EFO	"Infrequent or difficult evacuation of feces." []	EFO	71073	HP:0002019	\N	constipation	HP:0002019
0	"Pain perceived to originate in the abdomen." []	\N	abdominal pain	\N	\N	EFO	"Pain perceived to originate in the abdomen." []	EFO	71074	HP:0002027	\N	abdominal pain	HP:0002027
0	"Protrusion of the rectal mucous membrane through the anus." []	\N	rectal prolapse	\N	\N	EFO	"Protrusion of the rectal mucous membrane through the anus." []	EFO	71075	HP:0002035	\N	rectal prolapse	HP:0002035
0	"Hemorrhage affecting the gastrointestinal tract." []	\N	gastrointestinal hemorrhage	\N	\N	EFO	"Hemorrhage affecting the gastrointestinal tract." []	EFO	71076	HP:0002239	\N	gastrointestinal hemorrhage	HP:0002239
0	"An abnormality resulting from a lack of intestinal ganglion cells (i.e., an aganglionic section of bowel) that results in bowel obstruction with enlargement of the colon." []	\N	megacolon	\N	\N	EFO	"An abnormality resulting from a lack of intestinal ganglion cells (i.e., an aganglionic section of bowel) that results in bowel obstruction with enlargement of the colon." []	EFO	71077	HP:0002251	\N	megacolon	HP:0002251
0	"The passage of fresh (red) blood per anus, usually in or with stools. Most rectal bleeding comes from the colon, rectum, or anus." []	\N	rectal bleeding	\N	\N	EFO	"The passage of fresh (red) blood per anus, usually in or with stools. Most rectal bleeding comes from the colon, rectum, or anus." []	EFO	71078	HP:0002573	\N	rectal bleeding	HP:0002573
0	"" []	\N	intussusception	\N	\N	EFO	"" []	EFO	71079	HP:0002576	\N	intussusception	HP:0002576
0	"An abnormality of the immune system. The immune system is composed of organs and interdependent cell types that collectively protect the body from infections and from the growth of tumor cells. The organs of the immune system comprise the bone marrow, the spleen, the thymus,the lymph nodes, and the cell types comprise B cells, T cells, natural killer cells, granulocytes,dendritic cells, and macrophages." []	\N	abnormality of the immune system	\N	\N	EFO	"An abnormality of the immune system. The immune system is composed of organs and interdependent cell types that collectively protect the body from infections and from the growth of tumor cells. The organs of the immune system comprise the bone marrow, the spleen, the thymus,the lymph nodes, and the cell types comprise B cells, T cells, natural killer cells, granulocytes,dendritic cells, and macrophages." []	EFO	71080	HP:0002715	\N	abnormality of the immune system	HP:0002715
0	"Increased susceptibility to microbial infections, as manifested by recurrent episodes of infection." []	\N	recurrent infection	\N	\N	EFO	"Increased susceptibility to microbial infections, as manifested by recurrent episodes of infection." []	EFO	71081	HP:0002719	\N	recurrent infection	HP:0002719
0	"Joint pain." []	\N	arthralgia	\N	\N	EFO	"Joint pain." []	EFO	71082	HP:0002829	\N	arthralgia	HP:0002829
0	"Inflammation of a lymph node." []	\N	lymphadenitis	\N	\N	EFO	"Inflammation of a lymph node." []	EFO	71083	HP:0002840	\N	lymphadenitis	HP:0002840
0	"Reduction in the concentration of albumin in the blood." []	\N	hypoalbuminemia	\N	\N	EFO	"Reduction in the concentration of albumin in the blood." []	EFO	71084	HP:0003073	\N	hypoalbuminemia	HP:0003073
0	"Abdominal distention can be a secondary feature associated with a number of conditions such as bowel obstruction." []	\N	abdominal distention	\N	\N	EFO	"Abdominal distention can be a secondary feature associated with a number of conditions such as bowel obstruction." []	EFO	71085	HP:0003270	\N	abdominal distention	HP:0003270
0	"An abnormal increase or decrease of weight or an abnormal distribution of mass in the body." []	\N	abnormality of body weight	\N	\N	EFO	"An abnormal increase or decrease of weight or an abnormal distribution of mass in the body." []	EFO	71086	HP:0004323	\N	abnormality of body weight	HP:0004323
0	"Severe weight loss, wasting of muscle, loss of appetite, and general debility related to a chronic disease." []	\N	cachexia	\N	\N	EFO	"Severe weight loss, wasting of muscle, loss of appetite, and general debility related to a chronic disease." []	EFO	71087	HP:0004326	\N	cachexia	HP:0004326
0	"An abnormality of temperature homeostasis." []	\N	abnormality of temperature regulation	\N	\N	EFO	"An abnormality of temperature homeostasis." []	EFO	71088	HP:0004370	\N	abnormality of temperature regulation	HP:0004370
0	"Inflammation of the gastrointestinal tract." []	\N	gastrointestinal inflammation	\N	\N	EFO	"Inflammation of the gastrointestinal tract." []	EFO	71089	HP:0004386	\N	gastrointestinal inflammation	HP:0004386
0	"" []	\N	chronic bronchitis	\N	\N	EFO	"" []	EFO	71090	HP:0004469	\N	chronic bronchitis	HP:0004469
0	"Obstruction of the gastrointestinal tract." []	\N	gastrointestinal obstruction	\N	\N	EFO	"Obstruction of the gastrointestinal tract." []	EFO	71091	HP:0004796	\N	gastrointestinal obstruction	HP:0004796
0	"Disseminated intravascular coagulation is characterized by the widespread activation of coagulation, which results in the intravascular formation of fibrin and ultimately thrombotic occlusion of small and midsize vessels. DIC is a complex syndrome in which there is pathological generation of thrombin and diffuse intravascular clot formation. DIC may occur as acute decompensated or chronic compensated form. In acute decompensated DIC, there is a sudden massive exposure of tissue factor over a brief time period; Intravascular coagulation can also compromise the blood supply to organs and, in conjunction with hemodynamic and metabolic derangements, may contribute to the failure of multiple organs. At the same time, the use and subsequent depletion of platelets and coagulation proteins resulting from the ongoing coagulation may induce severe bleeding. Chronic DIC, also known as compensated DIC, results from a persistent weak or intermittent activating stimulus. Under such conditions, destruction and production of coagulation factors and platelets are balanced." []	\N	disseminated intravascular coagulation	\N	\N	EFO	"Disseminated intravascular coagulation is characterized by the widespread activation of coagulation, which results in the intravascular formation of fibrin and ultimately thrombotic occlusion of small and midsize vessels. DIC is a complex syndrome in which there is pathological generation of thrombin and diffuse intravascular clot formation. DIC may occur as acute decompensated or chronic compensated form. In acute decompensated DIC, there is a sudden massive exposure of tissue factor over a brief time period; Intravascular coagulation can also compromise the blood supply to organs and, in conjunction with hemodynamic and metabolic derangements, may contribute to the failure of multiple organs. At the same time, the use and subsequent depletion of platelets and coagulation proteins resulting from the ongoing coagulation may induce severe bleeding. Chronic DIC, also known as compensated DIC, results from a persistent weak or intermittent activating stimulus. Under such conditions, destruction and production of coagulation factors and platelets are balanced." []	EFO	71092	HP:0005521	\N	disseminated intravascular coagulation	HP:0005521
0	"Cutaneous skin tags also known as acrochorda or fibroepithelial polyps are small benign tumours that may either form secondarily over time primarily in areas where the skin forms creases, such as the neck, armpit or groin or may also be present at birth, in which case they usually occur in the periauricular region." []	\N	skin tags	\N	\N	EFO	"Cutaneous skin tags also known as acrochorda or fibroepithelial polyps are small benign tumours that may either form secondarily over time primarily in areas where the skin forms creases, such as the neck, armpit or groin or may also be present at birth, in which case they usually occur in the periauricular region." []	EFO	71093	HP:0010609	\N	skin tags	HP:0010609
0	"The age group in which disease manifestations appear." []	\N	age of onset	\N	\N	EFO	"The age group in which disease manifestations appear." []	EFO	71094	HP:0011007	\N	age of onset	HP:0011007
0	"Sudden appearance of disease manifestations over a short period of time." []	\N	acute	\N	\N	EFO	"Sudden appearance of disease manifestations over a short period of time." []	EFO	71095	HP:0011009	\N	acute	HP:0011009
0	"Slow, creeping onset, slow progress and long continuance of disease manifestations. According to the U.S. National Center for Health Statistics, a chronic condition is one lasting 3 months or more." []	\N	chronic	\N	\N	EFO	"Slow, creeping onset, slow progress and long continuance of disease manifestations. According to the U.S. National Center for Health Statistics, a chronic condition is one lasting 3 months or more." []	EFO	71096	HP:0011010	\N	chronic	HP:0011010
0	"An abnormality of the gastrointestinal tract." []	\N	abnormality of the gastrointestinal tract	\N	\N	EFO	"An abnormality of the gastrointestinal tract." []	EFO	71097	HP:0011024	\N	abnormality of the gastrointestinal tract	HP:0011024
0	"Aspirin induced asthma is caused by an anomaly in the arachidonic acid cascade, which causes increased production of cysteinyl leukotrienes, a series of chemicals involved in the body's inflammatory response. When medications like NSAIDs or aspirin block the COX-1 enzyme, prostaglandin and thromboxane production is decreased, which causes the overproduction of leukotrienes and produces the severe asthma and allergy-like effects. Although the underlying cause is not fully understood, the attachment of platelets to certain leukocytes in the blood may contribute to the overproduction of leukotrienes" []	\N	aspirin induced asthma	\N	\N	EFO	"Aspirin induced asthma is caused by an anomaly in the arachidonic acid cascade, which causes increased production of cysteinyl leukotrienes, a series of chemicals involved in the body's inflammatory response. When medications like NSAIDs or aspirin block the COX-1 enzyme, prostaglandin and thromboxane production is decreased, which causes the overproduction of leukotrienes and produces the severe asthma and allergy-like effects. Although the underlying cause is not fully understood, the attachment of platelets to certain leukocytes in the blood may contribute to the overproduction of leukotrienes" []	EFO	71098	HP:0012042	\N	aspirin induced asthma	HP:0012042
0	"This subontology is designed to provide terms to characterize and specify the phenotypic abnormalities defined in the Phenotypic abnormality subontology, with respect to severity, laterality, age of onset, and other aspects." []	\N	clinical modifier	\N	\N	EFO	"This subontology is designed to provide terms to characterize and specify the phenotypic abnormalities defined in the Phenotypic abnormality subontology, with respect to severity, laterality, age of onset, and other aspects." []	EFO	71099	HP:0012823	\N	clinical modifier	HP:0012823
0	"An anomaly of the lymphatic system, a network of lymphatic vessels that carry a clear fluid called lymph unidirectionally towards either the right lymphatic duct or the thoracic duct, which in turn drain into the right and left subclavian veins respectively." []	\N	abnormality of the lymphatic system	\N	\N	EFO	"An anomaly of the lymphatic system, a network of lymphatic vessels that carry a clear fluid called lymph unidirectionally towards either the right lymphatic duct or the thoracic duct, which in turn drain into the right and left subclavian veins respectively." []	EFO	71100	HP:0100763	\N	abnormality of the lymphatic system	HP:0100763
0	"A label is a symbol that is part of some other datum and is used to either partially define the denotation of that datum or to provide a means for identifying the datum as a member of the set of data with the same label." []	\N	label	\N	\N	EFO	"A label is a symbol that is part of some other datum and is used to either partially define the denotation of that datum or to provide a means for identifying the datum as a member of the set of data with the same label." []	EFO	71101	IAO:0000009	\N	label	IAO:0000009
